<?xml version="1.0" encoding="utf-8"?>
<feed xmlns="http://www.w3.org/2005/Atom">
    <id>https://macwaneric.github.io/cancer.rss.feed/index.html</id>
    <title>CancerFeed</title>
    <updated>2024-02-13T00:50:40.595Z</updated>
    <generator>osmosfeed 1.15.1</generator>
    <link rel="alternate" href="https://macwaneric.github.io/cancer.rss.feed/index.html"/>
    <link rel="self" href="https://macwaneric.github.io/cancer.rss.feed/feed.atom"/>
    <entry>
        <title type="html"><![CDATA[Minimal residual disease monitoring in acute myeloid leukemia: Focus on MFC-MRD and treatment guidance for elderly patients]]></title>
        <id>pubmed:38342613</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38342613/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240212195038&amp;v=2.18.0"/>
        <updated>2024-02-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) is distinguished by clonal growth of myeloid precursor cells, which impairs normal hematopoiesis. Minimal residual disease (MRD) refers to the residual leukemia cells that persist after chemotherapy. Patients who test positive for MRD have a higher likelihood of experiencing a recurrence, regardless of the specific chemotherapy approach used. Multi-parameter flow cytometry (MFC), polymerase chain reaction (PCR), and next-generation sequencing (NGS) are commonly...]]></summary>
        <author>
            <name>Yue Sun</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune-driven clonal cell selection at the intersection among cancer, infections, autoimmunity and senescence]]></title>
        <id>pubmed:38341340</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38341340/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240212195038&amp;v=2.18.0"/>
        <updated>2024-02-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Immune surveillance mechanisms play a crucial role in maintaining lifelong immune homeostasis in response to pathologic stimuli and aberrant cell states. However, their persistence, especially in the context of chronic antigenic exposure, can create a fertile ground for immune evasion. These escaping cell phenotypes, harboring a variety of genomic and transcriptomic aberrances, chiefly in human leukocyte antigen (HLA) and antigen presentation machinery genes, may survive and proliferate,...]]></summary>
        <author>
            <name>Simona Pagliuca</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements]]></title>
        <id>pubmed:38339265</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38339265/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240212195038&amp;v=2.18.0"/>
        <updated>2024-02-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelofibrosis (MF) is an essential element of primary myelofibrosis, whereas secondary MF may develop in the advanced stages of other myeloid neoplasms, especially polycythemia vera and essential thrombocythemia. Over the last two decades, advances in molecular diagnostic techniques, particularly the integration of next-generation sequencing in clinical laboratories, have revolutionized the diagnosis, classification, and clinical decision making of myelofibrosis. Driver mutations involving JAK2,...]]></summary>
        <author>
            <name>Tanvi Verma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring the Molecular Aspects of Myeloproliferative Neoplasms Associated with Unusual Site Vein Thrombosis: Review of the Literature and Latest Insights]]></title>
        <id>pubmed:38338802</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38338802/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240212195038&amp;v=2.18.0"/>
        <updated>2024-02-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are the leading causes of unusual site thrombosis, affecting nearly 40% of individuals with conditions like Budd-Chiari syndrome or portal vein thrombosis. Diagnosing MPNs in these cases is challenging because common indicators, such as spleen enlargement and elevated blood cell counts, can be obscured by portal hypertension or bleeding issues. Recent advancements in diagnostic tools have enhanced the accuracy of MPN diagnosis and classification. While bone...]]></summary>
        <author>
            <name>Erika Morsia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune-driven clonal cell selection at the intersection among cancer, infections, autoimmunity and senescence]]></title>
        <id>pubmed:38341340</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38341340/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240211195044&amp;v=2.18.0"/>
        <updated>2024-02-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Immune surveillance mechanisms play a crucial role in maintaining lifelong immune homeostasis in response to pathologic stimuli and aberrant cell states. However, their persistence, especially in the context of chronic antigenic exposure, can create a fertile ground for immune evasion. These escaping cell phenotypes, harboring a variety of genomic and transcriptomic aberrances, chiefly in human leukocyte antigen (HLA) and antigen presentation machinery genes, may survive and proliferate,...]]></summary>
        <author>
            <name>Simona Pagliuca</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements]]></title>
        <id>pubmed:38339265</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38339265/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240211195044&amp;v=2.18.0"/>
        <updated>2024-02-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelofibrosis (MF) is an essential element of primary myelofibrosis, whereas secondary MF may develop in the advanced stages of other myeloid neoplasms, especially polycythemia vera and essential thrombocythemia. Over the last two decades, advances in molecular diagnostic techniques, particularly the integration of next-generation sequencing in clinical laboratories, have revolutionized the diagnosis, classification, and clinical decision making of myelofibrosis. Driver mutations involving JAK2,...]]></summary>
        <author>
            <name>Tanvi Verma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring the Molecular Aspects of Myeloproliferative Neoplasms Associated with Unusual Site Vein Thrombosis: Review of the Literature and Latest Insights]]></title>
        <id>pubmed:38338802</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38338802/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240211195044&amp;v=2.18.0"/>
        <updated>2024-02-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are the leading causes of unusual site thrombosis, affecting nearly 40% of individuals with conditions like Budd-Chiari syndrome or portal vein thrombosis. Diagnosing MPNs in these cases is challenging because common indicators, such as spleen enlargement and elevated blood cell counts, can be obscured by portal hypertension or bleeding issues. Recent advancements in diagnostic tools have enhanced the accuracy of MPN diagnosis and classification. While bone...]]></summary>
        <author>
            <name>Erika Morsia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements]]></title>
        <id>pubmed:38339265</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38339265/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240210195415&amp;v=2.18.0"/>
        <updated>2024-02-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelofibrosis (MF) is an essential element of primary myelofibrosis, whereas secondary MF may develop in the advanced stages of other myeloid neoplasms, especially polycythemia vera and essential thrombocythemia. Over the last two decades, advances in molecular diagnostic techniques, particularly the integration of next-generation sequencing in clinical laboratories, have revolutionized the diagnosis, classification, and clinical decision making of myelofibrosis. Driver mutations involving JAK2,...]]></summary>
        <author>
            <name>Tanvi Verma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring the Molecular Aspects of Myeloproliferative Neoplasms Associated with Unusual Site Vein Thrombosis: Review of the Literature and Latest Insights]]></title>
        <id>pubmed:38338802</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38338802/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240210195415&amp;v=2.18.0"/>
        <updated>2024-02-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are the leading causes of unusual site thrombosis, affecting nearly 40% of individuals with conditions like Budd-Chiari syndrome or portal vein thrombosis. Diagnosing MPNs in these cases is challenging because common indicators, such as spleen enlargement and elevated blood cell counts, can be obscured by portal hypertension or bleeding issues. Recent advancements in diagnostic tools have enhanced the accuracy of MPN diagnosis and classification. While bone...]]></summary>
        <author>
            <name>Erika Morsia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Macromutations Yielding Karyotype Alterations (and the Process(es) behind Them) Are the Favored Route of Carcinogenesis and Speciation]]></title>
        <id>pubmed:38339305</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38339305/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240212195038&amp;v=2.18.0"/>
        <updated>2024-02-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[It is argued that carcinogenesis and speciation are evolutionary events which are based on changes in the 'karyotypic code' through a phase of 'genome instability', followed by a bottleneck of selection for the viability and adaptability of the initial cells. Genomic (i.e., chromosomal) instability is caused by (massive) DNA breakage and the subsequent mis-repair of DNA double-strand breaks (DSBs) resulting in various chromosome rearrangements. Potential tumor cells are selected for rapid...]]></summary>
        <author>
            <name>Ingo Schubert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements]]></title>
        <id>pubmed:38339265</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38339265/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240212195038&amp;v=2.18.0"/>
        <updated>2024-02-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelofibrosis (MF) is an essential element of primary myelofibrosis, whereas secondary MF may develop in the advanced stages of other myeloid neoplasms, especially polycythemia vera and essential thrombocythemia. Over the last two decades, advances in molecular diagnostic techniques, particularly the integration of next-generation sequencing in clinical laboratories, have revolutionized the diagnosis, classification, and clinical decision making of myelofibrosis. Driver mutations involving JAK2,...]]></summary>
        <author>
            <name>Tanvi Verma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Novel Insights into the Initiation, Evolution, and Progression of Multiple Myeloma by Multi-Omics Investigation]]></title>
        <id>pubmed:38339250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38339250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240212195038&amp;v=2.18.0"/>
        <updated>2024-02-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The evolutionary history of multiple myeloma (MM) includes malignant transformation, followed by progression to pre-malignant stages and overt malignancy, ultimately leading to more aggressive and resistant forms. Over the past decade, large effort has been made to identify the potential therapeutic targets in MM. However, MM remains largely incurable. Most patients experience multiple relapses and inevitably become refractory to treatment. Tumor-initiating cell populations are the postulated...]]></summary>
        <author>
            <name>Lixin Gong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Macromutations Yielding Karyotype Alterations (and the Process(es) behind Them) Are the Favored Route of Carcinogenesis and Speciation]]></title>
        <id>pubmed:38339305</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38339305/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240211195044&amp;v=2.18.0"/>
        <updated>2024-02-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[It is argued that carcinogenesis and speciation are evolutionary events which are based on changes in the 'karyotypic code' through a phase of 'genome instability', followed by a bottleneck of selection for the viability and adaptability of the initial cells. Genomic (i.e., chromosomal) instability is caused by (massive) DNA breakage and the subsequent mis-repair of DNA double-strand breaks (DSBs) resulting in various chromosome rearrangements. Potential tumor cells are selected for rapid...]]></summary>
        <author>
            <name>Ingo Schubert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements]]></title>
        <id>pubmed:38339265</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38339265/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240211195044&amp;v=2.18.0"/>
        <updated>2024-02-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelofibrosis (MF) is an essential element of primary myelofibrosis, whereas secondary MF may develop in the advanced stages of other myeloid neoplasms, especially polycythemia vera and essential thrombocythemia. Over the last two decades, advances in molecular diagnostic techniques, particularly the integration of next-generation sequencing in clinical laboratories, have revolutionized the diagnosis, classification, and clinical decision making of myelofibrosis. Driver mutations involving JAK2,...]]></summary>
        <author>
            <name>Tanvi Verma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Novel Insights into the Initiation, Evolution, and Progression of Multiple Myeloma by Multi-Omics Investigation]]></title>
        <id>pubmed:38339250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38339250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240211195044&amp;v=2.18.0"/>
        <updated>2024-02-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The evolutionary history of multiple myeloma (MM) includes malignant transformation, followed by progression to pre-malignant stages and overt malignancy, ultimately leading to more aggressive and resistant forms. Over the past decade, large effort has been made to identify the potential therapeutic targets in MM. However, MM remains largely incurable. Most patients experience multiple relapses and inevitably become refractory to treatment. Tumor-initiating cell populations are the postulated...]]></summary>
        <author>
            <name>Lixin Gong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Macromutations Yielding Karyotype Alterations (and the Process(es) behind Them) Are the Favored Route of Carcinogenesis and Speciation]]></title>
        <id>pubmed:38339305</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38339305/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240210195415&amp;v=2.18.0"/>
        <updated>2024-02-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[It is argued that carcinogenesis and speciation are evolutionary events which are based on changes in the 'karyotypic code' through a phase of 'genome instability', followed by a bottleneck of selection for the viability and adaptability of the initial cells. Genomic (i.e., chromosomal) instability is caused by (massive) DNA breakage and the subsequent mis-repair of DNA double-strand breaks (DSBs) resulting in various chromosome rearrangements. Potential tumor cells are selected for rapid...]]></summary>
        <author>
            <name>Ingo Schubert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements]]></title>
        <id>pubmed:38339265</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38339265/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240210195415&amp;v=2.18.0"/>
        <updated>2024-02-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelofibrosis (MF) is an essential element of primary myelofibrosis, whereas secondary MF may develop in the advanced stages of other myeloid neoplasms, especially polycythemia vera and essential thrombocythemia. Over the last two decades, advances in molecular diagnostic techniques, particularly the integration of next-generation sequencing in clinical laboratories, have revolutionized the diagnosis, classification, and clinical decision making of myelofibrosis. Driver mutations involving JAK2,...]]></summary>
        <author>
            <name>Tanvi Verma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Novel Insights into the Initiation, Evolution, and Progression of Multiple Myeloma by Multi-Omics Investigation]]></title>
        <id>pubmed:38339250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38339250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240210195415&amp;v=2.18.0"/>
        <updated>2024-02-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The evolutionary history of multiple myeloma (MM) includes malignant transformation, followed by progression to pre-malignant stages and overt malignancy, ultimately leading to more aggressive and resistant forms. Over the past decade, large effort has been made to identify the potential therapeutic targets in MM. However, MM remains largely incurable. Most patients experience multiple relapses and inevitably become refractory to treatment. Tumor-initiating cell populations are the postulated...]]></summary>
        <author>
            <name>Lixin Gong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case report: Cytopenias in VEXAS syndrome - a WHO 2022 based approach in a single-center cohort]]></title>
        <id>pubmed:38333211</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38333211/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240212195038&amp;v=2.18.0"/>
        <updated>2024-02-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[VEXAS syndrome is an acquired autoinflammatory disease characterized in most cases by cytopenias and macrocytic anemia. Dyshematopoiesis is a frequent finding in chronic inflammatory conditions and therefore, cytopenias are not easily classified in VEXAS patients. Here we report a series of 7 patients affected by VEXAS associated cytopenias, treated at our center. The use of NGS, together with morphological assays, integrated with the WHO 2022 criteria, allowed to identify three subsets of VEXAS...]]></summary>
        <author>
            <name>Elisa Diral</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case report: Cytopenias in VEXAS syndrome - a WHO 2022 based approach in a single-center cohort]]></title>
        <id>pubmed:38333211</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38333211/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240211195044&amp;v=2.18.0"/>
        <updated>2024-02-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[VEXAS syndrome is an acquired autoinflammatory disease characterized in most cases by cytopenias and macrocytic anemia. Dyshematopoiesis is a frequent finding in chronic inflammatory conditions and therefore, cytopenias are not easily classified in VEXAS patients. Here we report a series of 7 patients affected by VEXAS associated cytopenias, treated at our center. The use of NGS, together with morphological assays, integrated with the WHO 2022 criteria, allowed to identify three subsets of VEXAS...]]></summary>
        <author>
            <name>Elisa Diral</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case report: Cytopenias in VEXAS syndrome - a WHO 2022 based approach in a single-center cohort]]></title>
        <id>pubmed:38333211</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38333211/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240210195415&amp;v=2.18.0"/>
        <updated>2024-02-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[VEXAS syndrome is an acquired autoinflammatory disease characterized in most cases by cytopenias and macrocytic anemia. Dyshematopoiesis is a frequent finding in chronic inflammatory conditions and therefore, cytopenias are not easily classified in VEXAS patients. Here we report a series of 7 patients affected by VEXAS associated cytopenias, treated at our center. The use of NGS, together with morphological assays, integrated with the WHO 2022 criteria, allowed to identify three subsets of VEXAS...]]></summary>
        <author>
            <name>Elisa Diral</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case report: Cytopenias in VEXAS syndrome - a WHO 2022 based approach in a single-center cohort]]></title>
        <id>pubmed:38333211</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38333211/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240209194815&amp;v=2.18.0"/>
        <updated>2024-02-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[VEXAS syndrome is an acquired autoinflammatory disease characterized in most cases by cytopenias and macrocytic anemia. Dyshematopoiesis is a frequent finding in chronic inflammatory conditions and therefore, cytopenias are not easily classified in VEXAS patients. Here we report a series of 7 patients affected by VEXAS associated cytopenias, treated at our center. The use of NGS, together with morphological assays, integrated with the WHO 2022 criteria, allowed to identify three subsets of VEXAS...]]></summary>
        <author>
            <name>Elisa Diral</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Oxford Nanopore Technology and its Application in Liquid Biopsies]]></title>
        <id>pubmed:38327653</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38327653/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240212195038&amp;v=2.18.0"/>
        <updated>2024-02-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Advanced medical technologies are transforming the future of healthcare, in particular, the screening and detection of molecular-genetic changes in patients suspected of having a neoplasm. They are based on the assumption that neoplasms release small amounts of various neoplasm-specific molecules, such as tumor DNA, called circulating DNA (cirDNA), into the extracellular space and subsequently into the blood. The detection of tumor-specific molecules and specific molecular changes in body fluids...]]></summary>
        <author>
            <name>Mariya Levkova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Oxford Nanopore Technology and its Application in Liquid Biopsies]]></title>
        <id>pubmed:38327653</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38327653/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240211195044&amp;v=2.18.0"/>
        <updated>2024-02-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Advanced medical technologies are transforming the future of healthcare, in particular, the screening and detection of molecular-genetic changes in patients suspected of having a neoplasm. They are based on the assumption that neoplasms release small amounts of various neoplasm-specific molecules, such as tumor DNA, called circulating DNA (cirDNA), into the extracellular space and subsequently into the blood. The detection of tumor-specific molecules and specific molecular changes in body fluids...]]></summary>
        <author>
            <name>Mariya Levkova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Oxford Nanopore Technology and its Application in Liquid Biopsies]]></title>
        <id>pubmed:38327653</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38327653/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240210195415&amp;v=2.18.0"/>
        <updated>2024-02-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Advanced medical technologies are transforming the future of healthcare, in particular, the screening and detection of molecular-genetic changes in patients suspected of having a neoplasm. They are based on the assumption that neoplasms release small amounts of various neoplasm-specific molecules, such as tumor DNA, called circulating DNA (cirDNA), into the extracellular space and subsequently into the blood. The detection of tumor-specific molecules and specific molecular changes in body fluids...]]></summary>
        <author>
            <name>Mariya Levkova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Oxford Nanopore Technology and its Application in Liquid Biopsies]]></title>
        <id>pubmed:38327653</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38327653/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240209194815&amp;v=2.18.0"/>
        <updated>2024-02-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Advanced medical technologies are transforming the future of healthcare, in particular, the screening and detection of molecular-genetic changes in patients suspected of having a neoplasm. They are based on the assumption that neoplasms release small amounts of various neoplasm-specific molecules, such as tumor DNA, called circulating DNA (cirDNA), into the extracellular space and subsequently into the blood. The detection of tumor-specific molecules and specific molecular changes in body fluids...]]></summary>
        <author>
            <name>Mariya Levkova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Oxford Nanopore Technology and its Application in Liquid Biopsies]]></title>
        <id>pubmed:38327653</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38327653/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240208194923&amp;v=2.18.0"/>
        <updated>2024-02-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Advanced medical technologies are transforming the future of healthcare, in particular, the screening and detection of molecular-genetic changes in patients suspected of having a neoplasm. They are based on the assumption that neoplasms release small amounts of various neoplasm-specific molecules, such as tumor DNA, called circulating DNA (cirDNA), into the extracellular space and subsequently into the blood. The detection of tumor-specific molecules and specific molecular changes in body fluids...]]></summary>
        <author>
            <name>Mariya Levkova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic evolutional analysis of surgical resected specimen to assess osimertinib as a first-line therapy in two patients with lung cancer harboring EGFR mutation: Case series]]></title>
        <id>pubmed:38323355</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38323355/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240212195038&amp;v=2.18.0"/>
        <updated>2024-02-07T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is crucial for patients with lung cancer harboring EGFR mutations. However, almost all patients experience disease progression, regardless of their response to the targeted therapy, necessitating the development of additional treatment options. Two patients with lung cancer harboring EGFR-L858R mutations in exon 21 were treated by surgical resection during successful osimertinib treatment. Because the pathological diagnosis...]]></summary>
        <author>
            <name>Hayato Koba</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic evolutional analysis of surgical resected specimen to assess osimertinib as a first-line therapy in two patients with lung cancer harboring EGFR mutation: Case series]]></title>
        <id>pubmed:38323355</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38323355/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240211195044&amp;v=2.18.0"/>
        <updated>2024-02-07T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is crucial for patients with lung cancer harboring EGFR mutations. However, almost all patients experience disease progression, regardless of their response to the targeted therapy, necessitating the development of additional treatment options. Two patients with lung cancer harboring EGFR-L858R mutations in exon 21 were treated by surgical resection during successful osimertinib treatment. Because the pathological diagnosis...]]></summary>
        <author>
            <name>Hayato Koba</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic evolutional analysis of surgical resected specimen to assess osimertinib as a first-line therapy in two patients with lung cancer harboring EGFR mutation: Case series]]></title>
        <id>pubmed:38323355</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38323355/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240210195415&amp;v=2.18.0"/>
        <updated>2024-02-07T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is crucial for patients with lung cancer harboring EGFR mutations. However, almost all patients experience disease progression, regardless of their response to the targeted therapy, necessitating the development of additional treatment options. Two patients with lung cancer harboring EGFR-L858R mutations in exon 21 were treated by surgical resection during successful osimertinib treatment. Because the pathological diagnosis...]]></summary>
        <author>
            <name>Hayato Koba</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic evolutional analysis of surgical resected specimen to assess osimertinib as a first-line therapy in two patients with lung cancer harboring EGFR mutation: Case series]]></title>
        <id>pubmed:38323355</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38323355/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240209194815&amp;v=2.18.0"/>
        <updated>2024-02-07T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is crucial for patients with lung cancer harboring EGFR mutations. However, almost all patients experience disease progression, regardless of their response to the targeted therapy, necessitating the development of additional treatment options. Two patients with lung cancer harboring EGFR-L858R mutations in exon 21 were treated by surgical resection during successful osimertinib treatment. Because the pathological diagnosis...]]></summary>
        <author>
            <name>Hayato Koba</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic evolutional analysis of surgical resected specimen to assess osimertinib as a first-line therapy in two patients with lung cancer harboring EGFR mutation: Case series]]></title>
        <id>pubmed:38323355</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38323355/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240208194923&amp;v=2.18.0"/>
        <updated>2024-02-07T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is crucial for patients with lung cancer harboring EGFR mutations. However, almost all patients experience disease progression, regardless of their response to the targeted therapy, necessitating the development of additional treatment options. Two patients with lung cancer harboring EGFR-L858R mutations in exon 21 were treated by surgical resection during successful osimertinib treatment. Because the pathological diagnosis...]]></summary>
        <author>
            <name>Hayato Koba</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic evolutional analysis of surgical resected specimen to assess osimertinib as a first-line therapy in two patients with lung cancer harboring EGFR mutation: Case series]]></title>
        <id>pubmed:38323355</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38323355/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240207194932&amp;v=2.18.0"/>
        <updated>2024-02-07T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is crucial for patients with lung cancer harboring EGFR mutations. However, almost all patients experience disease progression, regardless of their response to the targeted therapy, necessitating the development of additional treatment options. Two patients with lung cancer harboring EGFR-L858R mutations in exon 21 were treated by surgical resection during successful osimertinib treatment. Because the pathological diagnosis...]]></summary>
        <author>
            <name>Hayato Koba</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential is associated with current smoking status and history of exacerbation in patients with COPD]]></title>
        <id>pubmed:38320547</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38320547/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240212195038&amp;v=2.18.0"/>
        <updated>2024-02-06T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Given that CHIP in specific genes was significantly associated with current smoking status and acute exacerbation, CHIP can be considered as a candidate biomarker for COPD patients.]]></summary>
        <author>
            <name>Jung-Kyu Lee</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[How Great Is the Threat of Clonal Hematopoiesis? Let This New Risk Score Be Your Guide]]></title>
        <id>pubmed:38320009</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38320009/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240212195038&amp;v=2.18.0"/>
        <updated>2024-02-06T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The recent expanding compendium of sequencing analysis has offered insight into the pathobiology of myeloid neoplasms. This molecular evidence of clonal hematopoiesis provides information to allow earlier identification of predisposition states to myeloid neoplasms, such as clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of unknown significance (CCUS). The ability to risk-stratify cases of clonal hematopoiesis that may evolve to frank myeloid neoplasms is essential to...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential is associated with current smoking status and history of exacerbation in patients with COPD]]></title>
        <id>pubmed:38320547</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38320547/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240211195044&amp;v=2.18.0"/>
        <updated>2024-02-06T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Given that CHIP in specific genes was significantly associated with current smoking status and acute exacerbation, CHIP can be considered as a candidate biomarker for COPD patients.]]></summary>
        <author>
            <name>Jung-Kyu Lee</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[How Great Is the Threat of Clonal Hematopoiesis? Let This New Risk Score Be Your Guide]]></title>
        <id>pubmed:38320009</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38320009/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240211195044&amp;v=2.18.0"/>
        <updated>2024-02-06T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The recent expanding compendium of sequencing analysis has offered insight into the pathobiology of myeloid neoplasms. This molecular evidence of clonal hematopoiesis provides information to allow earlier identification of predisposition states to myeloid neoplasms, such as clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of unknown significance (CCUS). The ability to risk-stratify cases of clonal hematopoiesis that may evolve to frank myeloid neoplasms is essential to...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential is associated with current smoking status and history of exacerbation in patients with COPD]]></title>
        <id>pubmed:38320547</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38320547/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240210195415&amp;v=2.18.0"/>
        <updated>2024-02-06T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Given that CHIP in specific genes was significantly associated with current smoking status and acute exacerbation, CHIP can be considered as a candidate biomarker for COPD patients.]]></summary>
        <author>
            <name>Jung-Kyu Lee</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[How Great Is the Threat of Clonal Hematopoiesis? Let This New Risk Score Be Your Guide]]></title>
        <id>pubmed:38320009</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38320009/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240210195415&amp;v=2.18.0"/>
        <updated>2024-02-06T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The recent expanding compendium of sequencing analysis has offered insight into the pathobiology of myeloid neoplasms. This molecular evidence of clonal hematopoiesis provides information to allow earlier identification of predisposition states to myeloid neoplasms, such as clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of unknown significance (CCUS). The ability to risk-stratify cases of clonal hematopoiesis that may evolve to frank myeloid neoplasms is essential to...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential is associated with current smoking status and history of exacerbation in patients with COPD]]></title>
        <id>pubmed:38320547</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38320547/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240209194815&amp;v=2.18.0"/>
        <updated>2024-02-06T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Given that CHIP in specific genes was significantly associated with current smoking status and acute exacerbation, CHIP can be considered as a candidate biomarker for COPD patients.]]></summary>
        <author>
            <name>Jung-Kyu Lee</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[How Great Is the Threat of Clonal Hematopoiesis? Let This New Risk Score Be Your Guide]]></title>
        <id>pubmed:38320009</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38320009/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240209194815&amp;v=2.18.0"/>
        <updated>2024-02-06T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The recent expanding compendium of sequencing analysis has offered insight into the pathobiology of myeloid neoplasms. This molecular evidence of clonal hematopoiesis provides information to allow earlier identification of predisposition states to myeloid neoplasms, such as clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of unknown significance (CCUS). The ability to risk-stratify cases of clonal hematopoiesis that may evolve to frank myeloid neoplasms is essential to...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential is associated with current smoking status and history of exacerbation in patients with COPD]]></title>
        <id>pubmed:38320547</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38320547/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240208194923&amp;v=2.18.0"/>
        <updated>2024-02-06T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Given that CHIP in specific genes was significantly associated with current smoking status and acute exacerbation, CHIP can be considered as a candidate biomarker for COPD patients.]]></summary>
        <author>
            <name>Jung-Kyu Lee</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[How Great Is the Threat of Clonal Hematopoiesis? Let This New Risk Score Be Your Guide]]></title>
        <id>pubmed:38320009</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38320009/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240208194923&amp;v=2.18.0"/>
        <updated>2024-02-06T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The recent expanding compendium of sequencing analysis has offered insight into the pathobiology of myeloid neoplasms. This molecular evidence of clonal hematopoiesis provides information to allow earlier identification of predisposition states to myeloid neoplasms, such as clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of unknown significance (CCUS). The ability to risk-stratify cases of clonal hematopoiesis that may evolve to frank myeloid neoplasms is essential to...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential is associated with current smoking status and history of exacerbation in patients with COPD]]></title>
        <id>pubmed:38320547</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38320547/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240207194932&amp;v=2.18.0"/>
        <updated>2024-02-06T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Given that CHIP in specific genes was significantly associated with current smoking status and acute exacerbation, CHIP can be considered as a candidate biomarker for COPD patients.]]></summary>
        <author>
            <name>Jung-Kyu Lee</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[How Great Is the Threat of Clonal Hematopoiesis? Let This New Risk Score Be Your Guide]]></title>
        <id>pubmed:38320009</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38320009/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240207194932&amp;v=2.18.0"/>
        <updated>2024-02-06T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The recent expanding compendium of sequencing analysis has offered insight into the pathobiology of myeloid neoplasms. This molecular evidence of clonal hematopoiesis provides information to allow earlier identification of predisposition states to myeloid neoplasms, such as clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of unknown significance (CCUS). The ability to risk-stratify cases of clonal hematopoiesis that may evolve to frank myeloid neoplasms is essential to...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[How Great Is the Threat of Clonal Hematopoiesis? Let This New Risk Score Be Your Guide]]></title>
        <id>pubmed:38320009</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38320009/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240206194820&amp;v=2.18.0"/>
        <updated>2024-02-06T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The recent expanding compendium of sequencing analysis has offered insight into the pathobiology of myeloid neoplasms. This molecular evidence of clonal hematopoiesis provides information to allow earlier identification of predisposition states to myeloid neoplasms, such as clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of unknown significance (CCUS). The ability to risk-stratify cases of clonal hematopoiesis that may evolve to frank myeloid neoplasms is essential to...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Rare subclonal sequencing of breast cancers indicates putative metastatic driver mutations are predominately acquired after dissemination]]></title>
        <id>pubmed:38321573</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38321573/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240212195038&amp;v=2.18.0"/>
        <updated>2024-02-06T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our results strongly suggest that metastatic driver mutations are sequentially acquired and selected within the same clonal lineage both before, but more commonly after, dissemination from the primary tumor, and that these mutations are biologically consequential. Despite inherent limitations in sampling archival primary tumors, our findings indicate that tumor cells in most patients continue to undergo clinically relevant genomic evolution after their dissemination from the primary...]]></summary>
        <author>
            <name>Matthew R Lawrence-Paul</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[How Great Is the Threat of Clonal Hematopoiesis? Let This New Risk Score Be Your Guide]]></title>
        <id>pubmed:38320009</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38320009/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240212195038&amp;v=2.18.0"/>
        <updated>2024-02-06T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The recent expanding compendium of sequencing analysis has offered insight into the pathobiology of myeloid neoplasms. This molecular evidence of clonal hematopoiesis provides information to allow earlier identification of predisposition states to myeloid neoplasms, such as clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of unknown significance (CCUS). The ability to risk-stratify cases of clonal hematopoiesis that may evolve to frank myeloid neoplasms is essential to...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Resolving the heterogeneous tumour microenvironment in cardiac myxoma through single-cell and spatial transcriptomics]]></title>
        <id>pubmed:38318640</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38318640/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240212195038&amp;v=2.18.0"/>
        <updated>2024-02-06T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our study presents the first comprehensive characterisation of the TME in CM at both single-cell and spatial resolution. Our study provides novel insight into the differentiation of myxoma tumour cells and advance our understanding of the TME in CM. Given the rarity of cardiac tumours, our study provides invaluable datasets and promotes the development of medical therapies for CM.]]></summary>
        <author>
            <name>Xuanyu Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Rare subclonal sequencing of breast cancers indicates putative metastatic driver mutations are predominately acquired after dissemination]]></title>
        <id>pubmed:38321573</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38321573/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240211195044&amp;v=2.18.0"/>
        <updated>2024-02-06T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our results strongly suggest that metastatic driver mutations are sequentially acquired and selected within the same clonal lineage both before, but more commonly after, dissemination from the primary tumor, and that these mutations are biologically consequential. Despite inherent limitations in sampling archival primary tumors, our findings indicate that tumor cells in most patients continue to undergo clinically relevant genomic evolution after their dissemination from the primary...]]></summary>
        <author>
            <name>Matthew R Lawrence-Paul</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[How Great Is the Threat of Clonal Hematopoiesis? Let This New Risk Score Be Your Guide]]></title>
        <id>pubmed:38320009</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38320009/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240211195044&amp;v=2.18.0"/>
        <updated>2024-02-06T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The recent expanding compendium of sequencing analysis has offered insight into the pathobiology of myeloid neoplasms. This molecular evidence of clonal hematopoiesis provides information to allow earlier identification of predisposition states to myeloid neoplasms, such as clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of unknown significance (CCUS). The ability to risk-stratify cases of clonal hematopoiesis that may evolve to frank myeloid neoplasms is essential to...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Resolving the heterogeneous tumour microenvironment in cardiac myxoma through single-cell and spatial transcriptomics]]></title>
        <id>pubmed:38318640</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38318640/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240211195044&amp;v=2.18.0"/>
        <updated>2024-02-06T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our study presents the first comprehensive characterisation of the TME in CM at both single-cell and spatial resolution. Our study provides novel insight into the differentiation of myxoma tumour cells and advance our understanding of the TME in CM. Given the rarity of cardiac tumours, our study provides invaluable datasets and promotes the development of medical therapies for CM.]]></summary>
        <author>
            <name>Xuanyu Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Rare subclonal sequencing of breast cancers indicates putative metastatic driver mutations are predominately acquired after dissemination]]></title>
        <id>pubmed:38321573</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38321573/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240210195415&amp;v=2.18.0"/>
        <updated>2024-02-06T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our results strongly suggest that metastatic driver mutations are sequentially acquired and selected within the same clonal lineage both before, but more commonly after, dissemination from the primary tumor, and that these mutations are biologically consequential. Despite inherent limitations in sampling archival primary tumors, our findings indicate that tumor cells in most patients continue to undergo clinically relevant genomic evolution after their dissemination from the primary...]]></summary>
        <author>
            <name>Matthew R Lawrence-Paul</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[How Great Is the Threat of Clonal Hematopoiesis? Let This New Risk Score Be Your Guide]]></title>
        <id>pubmed:38320009</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38320009/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240210195415&amp;v=2.18.0"/>
        <updated>2024-02-06T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The recent expanding compendium of sequencing analysis has offered insight into the pathobiology of myeloid neoplasms. This molecular evidence of clonal hematopoiesis provides information to allow earlier identification of predisposition states to myeloid neoplasms, such as clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of unknown significance (CCUS). The ability to risk-stratify cases of clonal hematopoiesis that may evolve to frank myeloid neoplasms is essential to...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Resolving the heterogeneous tumour microenvironment in cardiac myxoma through single-cell and spatial transcriptomics]]></title>
        <id>pubmed:38318640</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38318640/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240210195415&amp;v=2.18.0"/>
        <updated>2024-02-06T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our study presents the first comprehensive characterisation of the TME in CM at both single-cell and spatial resolution. Our study provides novel insight into the differentiation of myxoma tumour cells and advance our understanding of the TME in CM. Given the rarity of cardiac tumours, our study provides invaluable datasets and promotes the development of medical therapies for CM.]]></summary>
        <author>
            <name>Xuanyu Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Rare subclonal sequencing of breast cancers indicates putative metastatic driver mutations are predominately acquired after dissemination]]></title>
        <id>pubmed:38321573</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38321573/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240209194815&amp;v=2.18.0"/>
        <updated>2024-02-06T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our results strongly suggest that metastatic driver mutations are sequentially acquired and selected within the same clonal lineage both before, but more commonly after, dissemination from the primary tumor, and that these mutations are biologically consequential. Despite inherent limitations in sampling archival primary tumors, our findings indicate that tumor cells in most patients continue to undergo clinically relevant genomic evolution after their dissemination from the primary...]]></summary>
        <author>
            <name>Matthew R Lawrence-Paul</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[How Great Is the Threat of Clonal Hematopoiesis? Let This New Risk Score Be Your Guide]]></title>
        <id>pubmed:38320009</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38320009/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240209194815&amp;v=2.18.0"/>
        <updated>2024-02-06T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The recent expanding compendium of sequencing analysis has offered insight into the pathobiology of myeloid neoplasms. This molecular evidence of clonal hematopoiesis provides information to allow earlier identification of predisposition states to myeloid neoplasms, such as clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of unknown significance (CCUS). The ability to risk-stratify cases of clonal hematopoiesis that may evolve to frank myeloid neoplasms is essential to...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Resolving the heterogeneous tumour microenvironment in cardiac myxoma through single-cell and spatial transcriptomics]]></title>
        <id>pubmed:38318640</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38318640/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240209194815&amp;v=2.18.0"/>
        <updated>2024-02-06T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our study presents the first comprehensive characterisation of the TME in CM at both single-cell and spatial resolution. Our study provides novel insight into the differentiation of myxoma tumour cells and advance our understanding of the TME in CM. Given the rarity of cardiac tumours, our study provides invaluable datasets and promotes the development of medical therapies for CM.]]></summary>
        <author>
            <name>Xuanyu Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Rare subclonal sequencing of breast cancers indicates putative metastatic driver mutations are predominately acquired after dissemination]]></title>
        <id>pubmed:38321573</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38321573/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240208194923&amp;v=2.18.0"/>
        <updated>2024-02-06T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our results strongly suggest that metastatic driver mutations are sequentially acquired and selected within the same clonal lineage both before, but more commonly after, dissemination from the primary tumor, and that these mutations are biologically consequential. Despite inherent limitations in sampling archival primary tumors, our findings indicate that tumor cells in most patients continue to undergo clinically relevant genomic evolution after their dissemination from the primary...]]></summary>
        <author>
            <name>Matthew R Lawrence-Paul</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[How Great Is the Threat of Clonal Hematopoiesis? Let This New Risk Score Be Your Guide]]></title>
        <id>pubmed:38320009</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38320009/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240208194923&amp;v=2.18.0"/>
        <updated>2024-02-06T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The recent expanding compendium of sequencing analysis has offered insight into the pathobiology of myeloid neoplasms. This molecular evidence of clonal hematopoiesis provides information to allow earlier identification of predisposition states to myeloid neoplasms, such as clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of unknown significance (CCUS). The ability to risk-stratify cases of clonal hematopoiesis that may evolve to frank myeloid neoplasms is essential to...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Resolving the heterogeneous tumour microenvironment in cardiac myxoma through single-cell and spatial transcriptomics]]></title>
        <id>pubmed:38318640</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38318640/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240208194923&amp;v=2.18.0"/>
        <updated>2024-02-06T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our study presents the first comprehensive characterisation of the TME in CM at both single-cell and spatial resolution. Our study provides novel insight into the differentiation of myxoma tumour cells and advance our understanding of the TME in CM. Given the rarity of cardiac tumours, our study provides invaluable datasets and promotes the development of medical therapies for CM.]]></summary>
        <author>
            <name>Xuanyu Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Rare subclonal sequencing of breast cancers indicates putative metastatic driver mutations are predominately acquired after dissemination]]></title>
        <id>pubmed:38321573</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38321573/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240207194932&amp;v=2.18.0"/>
        <updated>2024-02-06T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our results strongly suggest that metastatic driver mutations are sequentially acquired and selected within the same clonal lineage both before, but more commonly after, dissemination from the primary tumor, and that these mutations are biologically consequential. Despite inherent limitations in sampling archival primary tumors, our findings indicate that tumor cells in most patients continue to undergo clinically relevant genomic evolution after their dissemination from the primary...]]></summary>
        <author>
            <name>Matthew R Lawrence-Paul</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Resolving the heterogeneous tumour microenvironment in cardiac myxoma through single-cell and spatial transcriptomics]]></title>
        <id>pubmed:38318640</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38318640/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240207194932&amp;v=2.18.0"/>
        <updated>2024-02-06T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our study presents the first comprehensive characterisation of the TME in CM at both single-cell and spatial resolution. Our study provides novel insight into the differentiation of myxoma tumour cells and advance our understanding of the TME in CM. Given the rarity of cardiac tumours, our study provides invaluable datasets and promotes the development of medical therapies for CM.]]></summary>
        <author>
            <name>Xuanyu Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Natural history of germline BRCA1 mutated and BRCA wild-type triple-negative breast cancer]]></title>
        <id>pubmed:38315150</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38315150/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240212195038&amp;v=2.18.0"/>
        <updated>2024-02-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[We report a deep next-generation sequencing (NGS) analysis of 13 sequentially sampled tumours, eight sequentially sampled circulating tumour DNA (ctDNA) and three germline DNA samples over the life history of three triple-negative breast cancer (TNBC) patients, two of whom had germline pathogenic BRCA1 mutation, to unravel tumour evolution. Tumour tissue from all timepoints and germline DNA was subjected to whole exome sequencing (WES), custom amplicon deep sequencing (30,000X) of a WES-derived...]]></summary>
        <author>
            <name>Nilesh Laxman Gardi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Natural history of germline BRCA1 mutated and BRCA wild-type triple-negative breast cancer]]></title>
        <id>pubmed:38315150</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38315150/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240211195044&amp;v=2.18.0"/>
        <updated>2024-02-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[We report a deep next-generation sequencing (NGS) analysis of 13 sequentially sampled tumours, eight sequentially sampled circulating tumour DNA (ctDNA) and three germline DNA samples over the life history of three triple-negative breast cancer (TNBC) patients, two of whom had germline pathogenic BRCA1 mutation, to unravel tumour evolution. Tumour tissue from all timepoints and germline DNA was subjected to whole exome sequencing (WES), custom amplicon deep sequencing (30,000X) of a WES-derived...]]></summary>
        <author>
            <name>Nilesh Laxman Gardi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Natural history of germline BRCA1 mutated and BRCA wild-type triple-negative breast cancer]]></title>
        <id>pubmed:38315150</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38315150/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240210195415&amp;v=2.18.0"/>
        <updated>2024-02-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[We report a deep next-generation sequencing (NGS) analysis of 13 sequentially sampled tumours, eight sequentially sampled circulating tumour DNA (ctDNA) and three germline DNA samples over the life history of three triple-negative breast cancer (TNBC) patients, two of whom had germline pathogenic BRCA1 mutation, to unravel tumour evolution. Tumour tissue from all timepoints and germline DNA was subjected to whole exome sequencing (WES), custom amplicon deep sequencing (30,000X) of a WES-derived...]]></summary>
        <author>
            <name>Nilesh Laxman Gardi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Natural history of germline BRCA1 mutated and BRCA wild-type triple-negative breast cancer]]></title>
        <id>pubmed:38315150</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38315150/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240209194815&amp;v=2.18.0"/>
        <updated>2024-02-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[We report a deep next-generation sequencing (NGS) analysis of 13 sequentially sampled tumours, eight sequentially sampled circulating tumour DNA (ctDNA) and three germline DNA samples over the life history of three triple-negative breast cancer (TNBC) patients, two of whom had germline pathogenic BRCA1 mutation, to unravel tumour evolution. Tumour tissue from all timepoints and germline DNA was subjected to whole exome sequencing (WES), custom amplicon deep sequencing (30,000X) of a WES-derived...]]></summary>
        <author>
            <name>Nilesh Laxman Gardi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Natural history of germline BRCA1 mutated and BRCA wild-type triple-negative breast cancer]]></title>
        <id>pubmed:38315150</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38315150/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240208194923&amp;v=2.18.0"/>
        <updated>2024-02-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[We report a deep next-generation sequencing (NGS) analysis of 13 sequentially sampled tumours, eight sequentially sampled circulating tumour DNA (ctDNA) and three germline DNA samples over the life history of three triple-negative breast cancer (TNBC) patients, two of whom had germline pathogenic BRCA1 mutation, to unravel tumour evolution. Tumour tissue from all timepoints and germline DNA was subjected to whole exome sequencing (WES), custom amplicon deep sequencing (30,000X) of a WES-derived...]]></summary>
        <author>
            <name>Nilesh Laxman Gardi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Natural history of germline BRCA1 mutated and BRCA wild-type triple-negative breast cancer]]></title>
        <id>pubmed:38315150</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38315150/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240207194932&amp;v=2.18.0"/>
        <updated>2024-02-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[We report a deep next-generation sequencing (NGS) analysis of 13 sequentially sampled tumours, eight sequentially sampled circulating tumour DNA (ctDNA) and three germline DNA samples over the life history of three triple-negative breast cancer (TNBC) patients, two of whom had germline pathogenic BRCA1 mutation, to unravel tumour evolution. Tumour tissue from all timepoints and germline DNA was subjected to whole exome sequencing (WES), custom amplicon deep sequencing (30,000X) of a WES-derived...]]></summary>
        <author>
            <name>Nilesh Laxman Gardi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Natural history of germline BRCA1 mutated and BRCA wild-type triple-negative breast cancer]]></title>
        <id>pubmed:38315150</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38315150/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240206194820&amp;v=2.18.0"/>
        <updated>2024-02-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[We report a deep next-generation sequencing (NGS) analysis of 13 sequentially sampled tumours, eight sequentially sampled circulating tumour DNA (ctDNA) and three germline DNA samples over the life history of three triple-negative breast cancer (TNBC) patients, two of whom had germline pathogenic BRCA1 mutation, to unravel tumour evolution. Tumour tissue from all timepoints and germline DNA was subjected to whole exome sequencing (WES), custom amplicon deep sequencing (30,000X) of a WES-derived...]]></summary>
        <author>
            <name>Nilesh Laxman Gardi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Natural history of germline BRCA1 mutated and BRCA wild-type triple-negative breast cancer]]></title>
        <id>pubmed:38315150</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38315150/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240205194943&amp;v=2.18.0"/>
        <updated>2024-02-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[We report a deep next-generation sequencing (NGS) analysis of 13 sequentially sampled tumours, eight sequentially sampled circulating tumour DNA (ctDNA) and three germline DNA samples over the life history of three triple-negative breast cancer (TNBC) patients, two of whom had germline pathogenic BRCA1 mutation, to unravel tumour evolution. Tumour tissue from all timepoints and germline DNA was subjected to whole exome sequencing (WES), custom amplicon deep sequencing (30,000X) of a WES-derived...]]></summary>
        <author>
            <name>Nilesh Laxman Gardi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in children with predisposing conditions]]></title>
        <id>pubmed:38311515</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38311515/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240212195038&amp;v=2.18.0"/>
        <updated>2024-02-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis in children and young adults differs from that occuring in the older adult population. A variety of stressors drive this phenomenon, sometimes independent of age-related processes. For the purposes of this review, we adopt the term clonal hematopoiesis in predisposed individuals (CHIPI) to differentiate it from classical, age-related clonal hematopoiesis of indeterminate potential (CHIP). Stress-induced CHIPI selection can be extrinsic, such as following immunologic,...]]></summary>
        <author>
            <name>Enrico Attardi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline predisposition for clonal hematopoiesis]]></title>
        <id>pubmed:38311514</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38311514/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240212195038&amp;v=2.18.0"/>
        <updated>2024-02-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is an entity hallmarked by skewed hematopoiesis with persistent overrepresentation of cells from a common stem/progenitor lineage harboring single-nucleotide variants and/or insertions/deletions. CH is a common and age-related phenomenon that is associated with an increased risk of hematological malignancies, cardiovascular disease, and all-cause mortality. While CH is a term of the hematological aspect, there exists a complex interaction with other organ systems,...]]></summary>
        <author>
            <name>Yasuo Kubota</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Detecting Multiple Driver Mutations in a Patient with Essential Thrombocythemia]]></title>
        <id>pubmed:38310350</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38310350/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240212195038&amp;v=2.18.0"/>
        <updated>2024-02-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND Three driver mutations have been identified in patients with essential thrombocythemia - JAK2 V617F, CALR, and MPL. Out of these, JAK2 V617F is mostly common. These mutations are thought to be mutually exclusive; therefore, the initial workup may not include the identification of all mutations separately. CASE REPORT We present a case of a 55-year-old woman who was referred to the hematology clinic for an elevated platelet count noted when she was hospitalized for a renal stone. The...]]></summary>
        <author>
            <name>Shivani Sharma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in children with predisposing conditions]]></title>
        <id>pubmed:38311515</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38311515/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240211195044&amp;v=2.18.0"/>
        <updated>2024-02-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis in children and young adults differs from that occuring in the older adult population. A variety of stressors drive this phenomenon, sometimes independent of age-related processes. For the purposes of this review, we adopt the term clonal hematopoiesis in predisposed individuals (CHIPI) to differentiate it from classical, age-related clonal hematopoiesis of indeterminate potential (CHIP). Stress-induced CHIPI selection can be extrinsic, such as following immunologic,...]]></summary>
        <author>
            <name>Enrico Attardi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline predisposition for clonal hematopoiesis]]></title>
        <id>pubmed:38311514</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38311514/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240211195044&amp;v=2.18.0"/>
        <updated>2024-02-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is an entity hallmarked by skewed hematopoiesis with persistent overrepresentation of cells from a common stem/progenitor lineage harboring single-nucleotide variants and/or insertions/deletions. CH is a common and age-related phenomenon that is associated with an increased risk of hematological malignancies, cardiovascular disease, and all-cause mortality. While CH is a term of the hematological aspect, there exists a complex interaction with other organ systems,...]]></summary>
        <author>
            <name>Yasuo Kubota</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Detecting Multiple Driver Mutations in a Patient with Essential Thrombocythemia]]></title>
        <id>pubmed:38310350</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38310350/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240211195044&amp;v=2.18.0"/>
        <updated>2024-02-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND Three driver mutations have been identified in patients with essential thrombocythemia - JAK2 V617F, CALR, and MPL. Out of these, JAK2 V617F is mostly common. These mutations are thought to be mutually exclusive; therefore, the initial workup may not include the identification of all mutations separately. CASE REPORT We present a case of a 55-year-old woman who was referred to the hematology clinic for an elevated platelet count noted when she was hospitalized for a renal stone. The...]]></summary>
        <author>
            <name>Shivani Sharma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in children with predisposing conditions]]></title>
        <id>pubmed:38311515</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38311515/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240210195415&amp;v=2.18.0"/>
        <updated>2024-02-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis in children and young adults differs from that occuring in the older adult population. A variety of stressors drive this phenomenon, sometimes independent of age-related processes. For the purposes of this review, we adopt the term clonal hematopoiesis in predisposed individuals (CHIPI) to differentiate it from classical, age-related clonal hematopoiesis of indeterminate potential (CHIP). Stress-induced CHIPI selection can be extrinsic, such as following immunologic,...]]></summary>
        <author>
            <name>Enrico Attardi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline predisposition for clonal hematopoiesis]]></title>
        <id>pubmed:38311514</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38311514/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240210195415&amp;v=2.18.0"/>
        <updated>2024-02-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is an entity hallmarked by skewed hematopoiesis with persistent overrepresentation of cells from a common stem/progenitor lineage harboring single-nucleotide variants and/or insertions/deletions. CH is a common and age-related phenomenon that is associated with an increased risk of hematological malignancies, cardiovascular disease, and all-cause mortality. While CH is a term of the hematological aspect, there exists a complex interaction with other organ systems,...]]></summary>
        <author>
            <name>Yasuo Kubota</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Detecting Multiple Driver Mutations in a Patient with Essential Thrombocythemia]]></title>
        <id>pubmed:38310350</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38310350/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240210195415&amp;v=2.18.0"/>
        <updated>2024-02-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND Three driver mutations have been identified in patients with essential thrombocythemia - JAK2 V617F, CALR, and MPL. Out of these, JAK2 V617F is mostly common. These mutations are thought to be mutually exclusive; therefore, the initial workup may not include the identification of all mutations separately. CASE REPORT We present a case of a 55-year-old woman who was referred to the hematology clinic for an elevated platelet count noted when she was hospitalized for a renal stone. The...]]></summary>
        <author>
            <name>Shivani Sharma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in children with predisposing conditions]]></title>
        <id>pubmed:38311515</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38311515/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240209194815&amp;v=2.18.0"/>
        <updated>2024-02-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis in children and young adults differs from that occuring in the older adult population. A variety of stressors drive this phenomenon, sometimes independent of age-related processes. For the purposes of this review, we adopt the term clonal hematopoiesis in predisposed individuals (CHIPI) to differentiate it from classical, age-related clonal hematopoiesis of indeterminate potential (CHIP). Stress-induced CHIPI selection can be extrinsic, such as following immunologic,...]]></summary>
        <author>
            <name>Enrico Attardi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline predisposition for clonal hematopoiesis]]></title>
        <id>pubmed:38311514</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38311514/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240209194815&amp;v=2.18.0"/>
        <updated>2024-02-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is an entity hallmarked by skewed hematopoiesis with persistent overrepresentation of cells from a common stem/progenitor lineage harboring single-nucleotide variants and/or insertions/deletions. CH is a common and age-related phenomenon that is associated with an increased risk of hematological malignancies, cardiovascular disease, and all-cause mortality. While CH is a term of the hematological aspect, there exists a complex interaction with other organ systems,...]]></summary>
        <author>
            <name>Yasuo Kubota</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Detecting Multiple Driver Mutations in a Patient with Essential Thrombocythemia]]></title>
        <id>pubmed:38310350</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38310350/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240209194815&amp;v=2.18.0"/>
        <updated>2024-02-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND Three driver mutations have been identified in patients with essential thrombocythemia - JAK2 V617F, CALR, and MPL. Out of these, JAK2 V617F is mostly common. These mutations are thought to be mutually exclusive; therefore, the initial workup may not include the identification of all mutations separately. CASE REPORT We present a case of a 55-year-old woman who was referred to the hematology clinic for an elevated platelet count noted when she was hospitalized for a renal stone. The...]]></summary>
        <author>
            <name>Shivani Sharma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in children with predisposing conditions]]></title>
        <id>pubmed:38311515</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38311515/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240208194923&amp;v=2.18.0"/>
        <updated>2024-02-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis in children and young adults differs from that occuring in the older adult population. A variety of stressors drive this phenomenon, sometimes independent of age-related processes. For the purposes of this review, we adopt the term clonal hematopoiesis in predisposed individuals (CHIPI) to differentiate it from classical, age-related clonal hematopoiesis of indeterminate potential (CHIP). Stress-induced CHIPI selection can be extrinsic, such as following immunologic,...]]></summary>
        <author>
            <name>Enrico Attardi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline predisposition for clonal hematopoiesis]]></title>
        <id>pubmed:38311514</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38311514/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240208194923&amp;v=2.18.0"/>
        <updated>2024-02-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is an entity hallmarked by skewed hematopoiesis with persistent overrepresentation of cells from a common stem/progenitor lineage harboring single-nucleotide variants and/or insertions/deletions. CH is a common and age-related phenomenon that is associated with an increased risk of hematological malignancies, cardiovascular disease, and all-cause mortality. While CH is a term of the hematological aspect, there exists a complex interaction with other organ systems,...]]></summary>
        <author>
            <name>Yasuo Kubota</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Detecting Multiple Driver Mutations in a Patient with Essential Thrombocythemia]]></title>
        <id>pubmed:38310350</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38310350/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240208194923&amp;v=2.18.0"/>
        <updated>2024-02-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND Three driver mutations have been identified in patients with essential thrombocythemia - JAK2 V617F, CALR, and MPL. Out of these, JAK2 V617F is mostly common. These mutations are thought to be mutually exclusive; therefore, the initial workup may not include the identification of all mutations separately. CASE REPORT We present a case of a 55-year-old woman who was referred to the hematology clinic for an elevated platelet count noted when she was hospitalized for a renal stone. The...]]></summary>
        <author>
            <name>Shivani Sharma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in children with predisposing conditions]]></title>
        <id>pubmed:38311515</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38311515/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240207194932&amp;v=2.18.0"/>
        <updated>2024-02-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis in children and young adults differs from that occuring in the older adult population. A variety of stressors drive this phenomenon, sometimes independent of age-related processes. For the purposes of this review, we adopt the term clonal hematopoiesis in predisposed individuals (CHIPI) to differentiate it from classical, age-related clonal hematopoiesis of indeterminate potential (CHIP). Stress-induced CHIPI selection can be extrinsic, such as following immunologic,...]]></summary>
        <author>
            <name>Enrico Attardi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline predisposition for clonal hematopoiesis]]></title>
        <id>pubmed:38311514</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38311514/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240207194932&amp;v=2.18.0"/>
        <updated>2024-02-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is an entity hallmarked by skewed hematopoiesis with persistent overrepresentation of cells from a common stem/progenitor lineage harboring single-nucleotide variants and/or insertions/deletions. CH is a common and age-related phenomenon that is associated with an increased risk of hematological malignancies, cardiovascular disease, and all-cause mortality. While CH is a term of the hematological aspect, there exists a complex interaction with other organ systems,...]]></summary>
        <author>
            <name>Yasuo Kubota</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Detecting Multiple Driver Mutations in a Patient with Essential Thrombocythemia]]></title>
        <id>pubmed:38310350</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38310350/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240207194932&amp;v=2.18.0"/>
        <updated>2024-02-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND Three driver mutations have been identified in patients with essential thrombocythemia - JAK2 V617F, CALR, and MPL. Out of these, JAK2 V617F is mostly common. These mutations are thought to be mutually exclusive; therefore, the initial workup may not include the identification of all mutations separately. CASE REPORT We present a case of a 55-year-old woman who was referred to the hematology clinic for an elevated platelet count noted when she was hospitalized for a renal stone. The...]]></summary>
        <author>
            <name>Shivani Sharma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in children with predisposing conditions]]></title>
        <id>pubmed:38311515</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38311515/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240206194820&amp;v=2.18.0"/>
        <updated>2024-02-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis in children and young adults differs from that occuring in the older adult population. A variety of stressors drive this phenomenon, sometimes independent of age-related processes. For the purposes of this review, we adopt the term clonal hematopoiesis in predisposed individuals (CHIPI) to differentiate it from classical, age-related clonal hematopoiesis of indeterminate potential (CHIP). Stress-induced CHIPI selection can be extrinsic, such as following immunologic,...]]></summary>
        <author>
            <name>Enrico Attardi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline predisposition for clonal hematopoiesis]]></title>
        <id>pubmed:38311514</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38311514/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240206194820&amp;v=2.18.0"/>
        <updated>2024-02-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is an entity hallmarked by skewed hematopoiesis with persistent overrepresentation of cells from a common stem/progenitor lineage harboring single-nucleotide variants and/or insertions/deletions. CH is a common and age-related phenomenon that is associated with an increased risk of hematological malignancies, cardiovascular disease, and all-cause mortality. While CH is a term of the hematological aspect, there exists a complex interaction with other organ systems,...]]></summary>
        <author>
            <name>Yasuo Kubota</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Detecting Multiple Driver Mutations in a Patient with Essential Thrombocythemia]]></title>
        <id>pubmed:38310350</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38310350/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240206194820&amp;v=2.18.0"/>
        <updated>2024-02-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND Three driver mutations have been identified in patients with essential thrombocythemia - JAK2 V617F, CALR, and MPL. Out of these, JAK2 V617F is mostly common. These mutations are thought to be mutually exclusive; therefore, the initial workup may not include the identification of all mutations separately. CASE REPORT We present a case of a 55-year-old woman who was referred to the hematology clinic for an elevated platelet count noted when she was hospitalized for a renal stone. The...]]></summary>
        <author>
            <name>Shivani Sharma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis in children with predisposing conditions]]></title>
        <id>pubmed:38311515</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38311515/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240205194943&amp;v=2.18.0"/>
        <updated>2024-02-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis in children and young adults differs from that occuring in the older adult population. A variety of stressors drive this phenomenon, sometimes independent of age-related processes. For the purposes of this review, we adopt the term clonal hematopoiesis in predisposed individuals (CHIPI) to differentiate it from classical, age-related clonal hematopoiesis of indeterminate potential (CHIP). Stress-induced CHIPI selection can be extrinsic, such as following immunologic,...]]></summary>
        <author>
            <name>Enrico Attardi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline predisposition for clonal hematopoiesis]]></title>
        <id>pubmed:38311514</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38311514/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240205194943&amp;v=2.18.0"/>
        <updated>2024-02-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is an entity hallmarked by skewed hematopoiesis with persistent overrepresentation of cells from a common stem/progenitor lineage harboring single-nucleotide variants and/or insertions/deletions. CH is a common and age-related phenomenon that is associated with an increased risk of hematological malignancies, cardiovascular disease, and all-cause mortality. While CH is a term of the hematological aspect, there exists a complex interaction with other organ systems,...]]></summary>
        <author>
            <name>Yasuo Kubota</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Detecting Multiple Driver Mutations in a Patient with Essential Thrombocythemia]]></title>
        <id>pubmed:38310350</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38310350/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240205194943&amp;v=2.18.0"/>
        <updated>2024-02-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND Three driver mutations have been identified in patients with essential thrombocythemia - JAK2 V617F, CALR, and MPL. Out of these, JAK2 V617F is mostly common. These mutations are thought to be mutually exclusive; therefore, the initial workup may not include the identification of all mutations separately. CASE REPORT We present a case of a 55-year-old woman who was referred to the hematology clinic for an elevated platelet count noted when she was hospitalized for a renal stone. The...]]></summary>
        <author>
            <name>Shivani Sharma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Detecting Multiple Driver Mutations in a Patient with Essential Thrombocythemia]]></title>
        <id>pubmed:38310350</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38310350/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240204195148&amp;v=2.18.0"/>
        <updated>2024-02-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND Three driver mutations have been identified in patients with essential thrombocythemia - JAK2 V617F, CALR, and MPL. Out of these, JAK2 V617F is mostly common. These mutations are thought to be mutually exclusive; therefore, the initial workup may not include the identification of all mutations separately. CASE REPORT We present a case of a 55-year-old woman who was referred to the hematology clinic for an elevated platelet count noted when she was hospitalized for a renal stone. The...]]></summary>
        <author>
            <name>Shivani Sharma</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic neoplasms evolving from inherited bone marrow failure syndromes / germline predisposition syndromes: Back under the microscope]]></title>
        <id>pubmed:38301422</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38301422/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240212195038&amp;v=2.18.0"/>
        <updated>2024-02-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Inherited bone marrow failure syndromes and germline predisposition syndromes (IBMFS/GPS) are associated with increased risk for hematologic malignancies, particularly myeloid neoplasms, such as myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML). The diagnosis of MDS in these syndromes poses difficulty due to frequent bone marrow hypocellularity and the presence of some degree of dysplastic features related to the underlying germline defect causing abnormal maturation of one or...]]></summary>
        <author>
            <name>M Tarek Elghetany</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic neoplasms evolving from inherited bone marrow failure syndromes / germline predisposition syndromes: Back under the microscope]]></title>
        <id>pubmed:38301422</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38301422/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240211195044&amp;v=2.18.0"/>
        <updated>2024-02-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Inherited bone marrow failure syndromes and germline predisposition syndromes (IBMFS/GPS) are associated with increased risk for hematologic malignancies, particularly myeloid neoplasms, such as myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML). The diagnosis of MDS in these syndromes poses difficulty due to frequent bone marrow hypocellularity and the presence of some degree of dysplastic features related to the underlying germline defect causing abnormal maturation of one or...]]></summary>
        <author>
            <name>M Tarek Elghetany</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic neoplasms evolving from inherited bone marrow failure syndromes / germline predisposition syndromes: Back under the microscope]]></title>
        <id>pubmed:38301422</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38301422/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240210195415&amp;v=2.18.0"/>
        <updated>2024-02-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Inherited bone marrow failure syndromes and germline predisposition syndromes (IBMFS/GPS) are associated with increased risk for hematologic malignancies, particularly myeloid neoplasms, such as myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML). The diagnosis of MDS in these syndromes poses difficulty due to frequent bone marrow hypocellularity and the presence of some degree of dysplastic features related to the underlying germline defect causing abnormal maturation of one or...]]></summary>
        <author>
            <name>M Tarek Elghetany</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic neoplasms evolving from inherited bone marrow failure syndromes / germline predisposition syndromes: Back under the microscope]]></title>
        <id>pubmed:38301422</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38301422/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240209194815&amp;v=2.18.0"/>
        <updated>2024-02-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Inherited bone marrow failure syndromes and germline predisposition syndromes (IBMFS/GPS) are associated with increased risk for hematologic malignancies, particularly myeloid neoplasms, such as myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML). The diagnosis of MDS in these syndromes poses difficulty due to frequent bone marrow hypocellularity and the presence of some degree of dysplastic features related to the underlying germline defect causing abnormal maturation of one or...]]></summary>
        <author>
            <name>M Tarek Elghetany</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic neoplasms evolving from inherited bone marrow failure syndromes / germline predisposition syndromes: Back under the microscope]]></title>
        <id>pubmed:38301422</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38301422/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240208194923&amp;v=2.18.0"/>
        <updated>2024-02-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Inherited bone marrow failure syndromes and germline predisposition syndromes (IBMFS/GPS) are associated with increased risk for hematologic malignancies, particularly myeloid neoplasms, such as myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML). The diagnosis of MDS in these syndromes poses difficulty due to frequent bone marrow hypocellularity and the presence of some degree of dysplastic features related to the underlying germline defect causing abnormal maturation of one or...]]></summary>
        <author>
            <name>M Tarek Elghetany</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic neoplasms evolving from inherited bone marrow failure syndromes / germline predisposition syndromes: Back under the microscope]]></title>
        <id>pubmed:38301422</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38301422/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240207194932&amp;v=2.18.0"/>
        <updated>2024-02-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Inherited bone marrow failure syndromes and germline predisposition syndromes (IBMFS/GPS) are associated with increased risk for hematologic malignancies, particularly myeloid neoplasms, such as myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML). The diagnosis of MDS in these syndromes poses difficulty due to frequent bone marrow hypocellularity and the presence of some degree of dysplastic features related to the underlying germline defect causing abnormal maturation of one or...]]></summary>
        <author>
            <name>M Tarek Elghetany</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic neoplasms evolving from inherited bone marrow failure syndromes / germline predisposition syndromes: Back under the microscope]]></title>
        <id>pubmed:38301422</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38301422/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240206194820&amp;v=2.18.0"/>
        <updated>2024-02-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Inherited bone marrow failure syndromes and germline predisposition syndromes (IBMFS/GPS) are associated with increased risk for hematologic malignancies, particularly myeloid neoplasms, such as myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML). The diagnosis of MDS in these syndromes poses difficulty due to frequent bone marrow hypocellularity and the presence of some degree of dysplastic features related to the underlying germline defect causing abnormal maturation of one or...]]></summary>
        <author>
            <name>M Tarek Elghetany</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic neoplasms evolving from inherited bone marrow failure syndromes / germline predisposition syndromes: Back under the microscope]]></title>
        <id>pubmed:38301422</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38301422/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240205194943&amp;v=2.18.0"/>
        <updated>2024-02-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Inherited bone marrow failure syndromes and germline predisposition syndromes (IBMFS/GPS) are associated with increased risk for hematologic malignancies, particularly myeloid neoplasms, such as myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML). The diagnosis of MDS in these syndromes poses difficulty due to frequent bone marrow hypocellularity and the presence of some degree of dysplastic features related to the underlying germline defect causing abnormal maturation of one or...]]></summary>
        <author>
            <name>M Tarek Elghetany</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic neoplasms evolving from inherited bone marrow failure syndromes / germline predisposition syndromes: Back under the microscope]]></title>
        <id>pubmed:38301422</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38301422/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240204195148&amp;v=2.18.0"/>
        <updated>2024-02-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Inherited bone marrow failure syndromes and germline predisposition syndromes (IBMFS/GPS) are associated with increased risk for hematologic malignancies, particularly myeloid neoplasms, such as myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML). The diagnosis of MDS in these syndromes poses difficulty due to frequent bone marrow hypocellularity and the presence of some degree of dysplastic features related to the underlying germline defect causing abnormal maturation of one or...]]></summary>
        <author>
            <name>M Tarek Elghetany</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic neoplasms evolving from inherited bone marrow failure syndromes / germline predisposition syndromes: Back under the microscope]]></title>
        <id>pubmed:38301422</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38301422/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240203195418&amp;v=2.18.0"/>
        <updated>2024-02-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Inherited bone marrow failure syndromes and germline predisposition syndromes (IBMFS/GPS) are associated with increased risk for hematologic malignancies, particularly myeloid neoplasms, such as myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML). The diagnosis of MDS in these syndromes poses difficulty due to frequent bone marrow hypocellularity and the presence of some degree of dysplastic features related to the underlying germline defect causing abnormal maturation of one or...]]></summary>
        <author>
            <name>M Tarek Elghetany</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic neoplasms evolving from inherited bone marrow failure syndromes / germline predisposition syndromes: Back under the microscope]]></title>
        <id>pubmed:38301422</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38301422/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240202194939&amp;v=2.18.0"/>
        <updated>2024-02-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Inherited bone marrow failure syndromes and germline predisposition syndromes (IBMFS/GPS) are associated with increased risk for hematologic malignancies, particularly myeloid neoplasms, such as myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML). The diagnosis of MDS in these syndromes poses difficulty due to frequent bone marrow hypocellularity and the presence of some degree of dysplastic features related to the underlying germline defect causing abnormal maturation of one or...]]></summary>
        <author>
            <name>M Tarek Elghetany</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential-associated non-small cell lung cancer risk is potentiated by small particulate matter air pollution among non-smokers: a novel somatic variant-environment interaction]]></title>
        <id>pubmed:38293139</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38293139/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240212195038&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Small particulate matter air pollution (PM (2.5) ) is a recognized driver of non-small cell lung cancer (NSCLC) among non-smoking individuals. Inhaled PM (2.5) recruits pro-inflammatory macrophages to the air-lung interface, which promotes malignant lung epithelial cell growth and progression to overt cancer. We sought to determine whether clonal hematopoiesis of indeterminate potential (CHIP), a common age-related condition characterized by hyperinflammatory macrophages, exacerbates PM (2.5)...]]></summary>
        <author>
            <name>Caitlyn Vlasschaert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential-associated non-small cell lung cancer risk is potentiated by small particulate matter air pollution among non-smokers: a novel somatic variant-environment interaction]]></title>
        <id>pubmed:38293139</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38293139/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240211195044&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Small particulate matter air pollution (PM (2.5) ) is a recognized driver of non-small cell lung cancer (NSCLC) among non-smoking individuals. Inhaled PM (2.5) recruits pro-inflammatory macrophages to the air-lung interface, which promotes malignant lung epithelial cell growth and progression to overt cancer. We sought to determine whether clonal hematopoiesis of indeterminate potential (CHIP), a common age-related condition characterized by hyperinflammatory macrophages, exacerbates PM (2.5)...]]></summary>
        <author>
            <name>Caitlyn Vlasschaert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential-associated non-small cell lung cancer risk is potentiated by small particulate matter air pollution among non-smokers: a novel somatic variant-environment interaction]]></title>
        <id>pubmed:38293139</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38293139/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240210195415&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Small particulate matter air pollution (PM (2.5) ) is a recognized driver of non-small cell lung cancer (NSCLC) among non-smoking individuals. Inhaled PM (2.5) recruits pro-inflammatory macrophages to the air-lung interface, which promotes malignant lung epithelial cell growth and progression to overt cancer. We sought to determine whether clonal hematopoiesis of indeterminate potential (CHIP), a common age-related condition characterized by hyperinflammatory macrophages, exacerbates PM (2.5)...]]></summary>
        <author>
            <name>Caitlyn Vlasschaert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential-associated non-small cell lung cancer risk is potentiated by small particulate matter air pollution among non-smokers: a novel somatic variant-environment interaction]]></title>
        <id>pubmed:38293139</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38293139/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240209194815&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Small particulate matter air pollution (PM (2.5) ) is a recognized driver of non-small cell lung cancer (NSCLC) among non-smoking individuals. Inhaled PM (2.5) recruits pro-inflammatory macrophages to the air-lung interface, which promotes malignant lung epithelial cell growth and progression to overt cancer. We sought to determine whether clonal hematopoiesis of indeterminate potential (CHIP), a common age-related condition characterized by hyperinflammatory macrophages, exacerbates PM (2.5)...]]></summary>
        <author>
            <name>Caitlyn Vlasschaert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential-associated non-small cell lung cancer risk is potentiated by small particulate matter air pollution among non-smokers: a novel somatic variant-environment interaction]]></title>
        <id>pubmed:38293139</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38293139/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240208194923&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Small particulate matter air pollution (PM (2.5) ) is a recognized driver of non-small cell lung cancer (NSCLC) among non-smoking individuals. Inhaled PM (2.5) recruits pro-inflammatory macrophages to the air-lung interface, which promotes malignant lung epithelial cell growth and progression to overt cancer. We sought to determine whether clonal hematopoiesis of indeterminate potential (CHIP), a common age-related condition characterized by hyperinflammatory macrophages, exacerbates PM (2.5)...]]></summary>
        <author>
            <name>Caitlyn Vlasschaert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential-associated non-small cell lung cancer risk is potentiated by small particulate matter air pollution among non-smokers: a novel somatic variant-environment interaction]]></title>
        <id>pubmed:38293139</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38293139/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240207194932&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Small particulate matter air pollution (PM (2.5) ) is a recognized driver of non-small cell lung cancer (NSCLC) among non-smoking individuals. Inhaled PM (2.5) recruits pro-inflammatory macrophages to the air-lung interface, which promotes malignant lung epithelial cell growth and progression to overt cancer. We sought to determine whether clonal hematopoiesis of indeterminate potential (CHIP), a common age-related condition characterized by hyperinflammatory macrophages, exacerbates PM (2.5)...]]></summary>
        <author>
            <name>Caitlyn Vlasschaert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential-associated non-small cell lung cancer risk is potentiated by small particulate matter air pollution among non-smokers: a novel somatic variant-environment interaction]]></title>
        <id>pubmed:38293139</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38293139/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240206194820&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Small particulate matter air pollution (PM (2.5) ) is a recognized driver of non-small cell lung cancer (NSCLC) among non-smoking individuals. Inhaled PM (2.5) recruits pro-inflammatory macrophages to the air-lung interface, which promotes malignant lung epithelial cell growth and progression to overt cancer. We sought to determine whether clonal hematopoiesis of indeterminate potential (CHIP), a common age-related condition characterized by hyperinflammatory macrophages, exacerbates PM (2.5)...]]></summary>
        <author>
            <name>Caitlyn Vlasschaert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential-associated non-small cell lung cancer risk is potentiated by small particulate matter air pollution among non-smokers: a novel somatic variant-environment interaction]]></title>
        <id>pubmed:38293139</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38293139/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240205194943&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Small particulate matter air pollution (PM (2.5) ) is a recognized driver of non-small cell lung cancer (NSCLC) among non-smoking individuals. Inhaled PM (2.5) recruits pro-inflammatory macrophages to the air-lung interface, which promotes malignant lung epithelial cell growth and progression to overt cancer. We sought to determine whether clonal hematopoiesis of indeterminate potential (CHIP), a common age-related condition characterized by hyperinflammatory macrophages, exacerbates PM (2.5)...]]></summary>
        <author>
            <name>Caitlyn Vlasschaert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential-associated non-small cell lung cancer risk is potentiated by small particulate matter air pollution among non-smokers: a novel somatic variant-environment interaction]]></title>
        <id>pubmed:38293139</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38293139/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240204195148&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Small particulate matter air pollution (PM (2.5) ) is a recognized driver of non-small cell lung cancer (NSCLC) among non-smoking individuals. Inhaled PM (2.5) recruits pro-inflammatory macrophages to the air-lung interface, which promotes malignant lung epithelial cell growth and progression to overt cancer. We sought to determine whether clonal hematopoiesis of indeterminate potential (CHIP), a common age-related condition characterized by hyperinflammatory macrophages, exacerbates PM (2.5)...]]></summary>
        <author>
            <name>Caitlyn Vlasschaert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential-associated non-small cell lung cancer risk is potentiated by small particulate matter air pollution among non-smokers: a novel somatic variant-environment interaction]]></title>
        <id>pubmed:38293139</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38293139/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240203195418&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Small particulate matter air pollution (PM (2.5) ) is a recognized driver of non-small cell lung cancer (NSCLC) among non-smoking individuals. Inhaled PM (2.5) recruits pro-inflammatory macrophages to the air-lung interface, which promotes malignant lung epithelial cell growth and progression to overt cancer. We sought to determine whether clonal hematopoiesis of indeterminate potential (CHIP), a common age-related condition characterized by hyperinflammatory macrophages, exacerbates PM (2.5)...]]></summary>
        <author>
            <name>Caitlyn Vlasschaert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential-associated non-small cell lung cancer risk is potentiated by small particulate matter air pollution among non-smokers: a novel somatic variant-environment interaction]]></title>
        <id>pubmed:38293139</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38293139/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240202194939&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Small particulate matter air pollution (PM (2.5) ) is a recognized driver of non-small cell lung cancer (NSCLC) among non-smoking individuals. Inhaled PM (2.5) recruits pro-inflammatory macrophages to the air-lung interface, which promotes malignant lung epithelial cell growth and progression to overt cancer. We sought to determine whether clonal hematopoiesis of indeterminate potential (CHIP), a common age-related condition characterized by hyperinflammatory macrophages, exacerbates PM (2.5)...]]></summary>
        <author>
            <name>Caitlyn Vlasschaert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential-associated non-small cell lung cancer risk is potentiated by small particulate matter air pollution among non-smokers: a novel somatic variant-environment interaction]]></title>
        <id>pubmed:38293139</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38293139/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240201195024&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Small particulate matter air pollution (PM (2.5) ) is a recognized driver of non-small cell lung cancer (NSCLC) among non-smoking individuals. Inhaled PM (2.5) recruits pro-inflammatory macrophages to the air-lung interface, which promotes malignant lung epithelial cell growth and progression to overt cancer. We sought to determine whether clonal hematopoiesis of indeterminate potential (CHIP), a common age-related condition characterized by hyperinflammatory macrophages, exacerbates PM (2.5)...]]></summary>
        <author>
            <name>Caitlyn Vlasschaert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential-associated non-small cell lung cancer risk is potentiated by small particulate matter air pollution among non-smokers: a novel somatic variant-environment interaction]]></title>
        <id>pubmed:38293139</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38293139/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240131195240&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Small particulate matter air pollution (PM (2.5) ) is a recognized driver of non-small cell lung cancer (NSCLC) among non-smoking individuals. Inhaled PM (2.5) recruits pro-inflammatory macrophages to the air-lung interface, which promotes malignant lung epithelial cell growth and progression to overt cancer. We sought to determine whether clonal hematopoiesis of indeterminate potential (CHIP), a common age-related condition characterized by hyperinflammatory macrophages, exacerbates PM (2.5)...]]></summary>
        <author>
            <name>Caitlyn Vlasschaert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Computational validation of clonal and subclonal copy number alterations from bulk tumor sequencing using CNAqc]]></title>
        <id>pubmed:38297376</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38297376/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240212195038&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Copy number alterations (CNAs) are among the most important genetic events in cancer, but their detection from sequencing data is challenging because of unknown sample purity, tumor ploidy, and general intra-tumor heterogeneity. Here, we present CNAqc, an evolution-inspired method to perform the computational validation of clonal and subclonal CNAs detected from bulk DNA sequencing. CNAqc is validated using single-cell data and simulations, is applied to over 4000 TCGA and PCAWG samples, and is...]]></summary>
        <author>
            <name>Alice Antonello</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Adaptive Control of Tumor Growth]]></title>
        <id>pubmed:38294947</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38294947/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240212195038&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer treatment optimizations select the most optimum combinations of drugs, sequencing schedules, and appropriate doses that would limit toxicity and yield an improved patient quality of life. However, these optimizations often lack an adequate consideration of cancer's near-infinite potential for evolutionary adaptation to therapeutic interventions. Adapting cancer therapy based on monitored tumor burden and clonal composition is an intuitively sound approach to the treatment of cancer as an...]]></summary>
        <author>
            <name>Youcef Derbal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single cell RNA-sequencing of Ewing sarcoma tumors demonstrates transcriptional heterogeneity and clonal evolution]]></title>
        <id>pubmed:38293103</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38293103/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240212195038&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ewing sarcoma is the second most common bone cancer in children, accounting for 2% of pediatric cancer diagnoses. Patients who present with metastatic disease at the time of diagnosis have a dismal prognosis, compared to the >70% 5-year survival of those with localized disease. Here, we utilized single cell RNA-sequencing to characterize the transcriptional landscape of primary Ewing sarcoma tumors and surrounding tumor microenvironment (TME). Copy-number analysis identified subclonal evolution...]]></summary>
        <author>
            <name>Andrew Goodspeed</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TGF- and BMP signaling are associated with the transformation of glioblastoma to gliosarcoma and then osteosarcoma]]></title>
        <id>pubmed:38292240</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38292240/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240212195038&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This unusual clinical case provided an opportunity to explore the modulators of longitudinal sarcomatous transformation, potentially uncovering markers indicating predisposition to this change and identification of novel therapeutic targets.]]></summary>
        <author>
            <name>Aiguo Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Computational validation of clonal and subclonal copy number alterations from bulk tumor sequencing using CNAqc]]></title>
        <id>pubmed:38297376</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38297376/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240211195044&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Copy number alterations (CNAs) are among the most important genetic events in cancer, but their detection from sequencing data is challenging because of unknown sample purity, tumor ploidy, and general intra-tumor heterogeneity. Here, we present CNAqc, an evolution-inspired method to perform the computational validation of clonal and subclonal CNAs detected from bulk DNA sequencing. CNAqc is validated using single-cell data and simulations, is applied to over 4000 TCGA and PCAWG samples, and is...]]></summary>
        <author>
            <name>Alice Antonello</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Adaptive Control of Tumor Growth]]></title>
        <id>pubmed:38294947</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38294947/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240211195044&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer treatment optimizations select the most optimum combinations of drugs, sequencing schedules, and appropriate doses that would limit toxicity and yield an improved patient quality of life. However, these optimizations often lack an adequate consideration of cancer's near-infinite potential for evolutionary adaptation to therapeutic interventions. Adapting cancer therapy based on monitored tumor burden and clonal composition is an intuitively sound approach to the treatment of cancer as an...]]></summary>
        <author>
            <name>Youcef Derbal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single cell RNA-sequencing of Ewing sarcoma tumors demonstrates transcriptional heterogeneity and clonal evolution]]></title>
        <id>pubmed:38293103</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38293103/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240211195044&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ewing sarcoma is the second most common bone cancer in children, accounting for 2% of pediatric cancer diagnoses. Patients who present with metastatic disease at the time of diagnosis have a dismal prognosis, compared to the >70% 5-year survival of those with localized disease. Here, we utilized single cell RNA-sequencing to characterize the transcriptional landscape of primary Ewing sarcoma tumors and surrounding tumor microenvironment (TME). Copy-number analysis identified subclonal evolution...]]></summary>
        <author>
            <name>Andrew Goodspeed</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TGF- and BMP signaling are associated with the transformation of glioblastoma to gliosarcoma and then osteosarcoma]]></title>
        <id>pubmed:38292240</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38292240/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240211195044&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This unusual clinical case provided an opportunity to explore the modulators of longitudinal sarcomatous transformation, potentially uncovering markers indicating predisposition to this change and identification of novel therapeutic targets.]]></summary>
        <author>
            <name>Aiguo Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Computational validation of clonal and subclonal copy number alterations from bulk tumor sequencing using CNAqc]]></title>
        <id>pubmed:38297376</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38297376/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240210195415&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Copy number alterations (CNAs) are among the most important genetic events in cancer, but their detection from sequencing data is challenging because of unknown sample purity, tumor ploidy, and general intra-tumor heterogeneity. Here, we present CNAqc, an evolution-inspired method to perform the computational validation of clonal and subclonal CNAs detected from bulk DNA sequencing. CNAqc is validated using single-cell data and simulations, is applied to over 4000 TCGA and PCAWG samples, and is...]]></summary>
        <author>
            <name>Alice Antonello</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Adaptive Control of Tumor Growth]]></title>
        <id>pubmed:38294947</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38294947/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240210195415&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer treatment optimizations select the most optimum combinations of drugs, sequencing schedules, and appropriate doses that would limit toxicity and yield an improved patient quality of life. However, these optimizations often lack an adequate consideration of cancer's near-infinite potential for evolutionary adaptation to therapeutic interventions. Adapting cancer therapy based on monitored tumor burden and clonal composition is an intuitively sound approach to the treatment of cancer as an...]]></summary>
        <author>
            <name>Youcef Derbal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single cell RNA-sequencing of Ewing sarcoma tumors demonstrates transcriptional heterogeneity and clonal evolution]]></title>
        <id>pubmed:38293103</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38293103/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240210195415&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ewing sarcoma is the second most common bone cancer in children, accounting for 2% of pediatric cancer diagnoses. Patients who present with metastatic disease at the time of diagnosis have a dismal prognosis, compared to the >70% 5-year survival of those with localized disease. Here, we utilized single cell RNA-sequencing to characterize the transcriptional landscape of primary Ewing sarcoma tumors and surrounding tumor microenvironment (TME). Copy-number analysis identified subclonal evolution...]]></summary>
        <author>
            <name>Andrew Goodspeed</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TGF- and BMP signaling are associated with the transformation of glioblastoma to gliosarcoma and then osteosarcoma]]></title>
        <id>pubmed:38292240</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38292240/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240210195415&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This unusual clinical case provided an opportunity to explore the modulators of longitudinal sarcomatous transformation, potentially uncovering markers indicating predisposition to this change and identification of novel therapeutic targets.]]></summary>
        <author>
            <name>Aiguo Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Computational validation of clonal and subclonal copy number alterations from bulk tumor sequencing using CNAqc]]></title>
        <id>pubmed:38297376</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38297376/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240209194815&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Copy number alterations (CNAs) are among the most important genetic events in cancer, but their detection from sequencing data is challenging because of unknown sample purity, tumor ploidy, and general intra-tumor heterogeneity. Here, we present CNAqc, an evolution-inspired method to perform the computational validation of clonal and subclonal CNAs detected from bulk DNA sequencing. CNAqc is validated using single-cell data and simulations, is applied to over 4000 TCGA and PCAWG samples, and is...]]></summary>
        <author>
            <name>Alice Antonello</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Adaptive Control of Tumor Growth]]></title>
        <id>pubmed:38294947</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38294947/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240209194815&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer treatment optimizations select the most optimum combinations of drugs, sequencing schedules, and appropriate doses that would limit toxicity and yield an improved patient quality of life. However, these optimizations often lack an adequate consideration of cancer's near-infinite potential for evolutionary adaptation to therapeutic interventions. Adapting cancer therapy based on monitored tumor burden and clonal composition is an intuitively sound approach to the treatment of cancer as an...]]></summary>
        <author>
            <name>Youcef Derbal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single cell RNA-sequencing of Ewing sarcoma tumors demonstrates transcriptional heterogeneity and clonal evolution]]></title>
        <id>pubmed:38293103</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38293103/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240209194815&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ewing sarcoma is the second most common bone cancer in children, accounting for 2% of pediatric cancer diagnoses. Patients who present with metastatic disease at the time of diagnosis have a dismal prognosis, compared to the >70% 5-year survival of those with localized disease. Here, we utilized single cell RNA-sequencing to characterize the transcriptional landscape of primary Ewing sarcoma tumors and surrounding tumor microenvironment (TME). Copy-number analysis identified subclonal evolution...]]></summary>
        <author>
            <name>Andrew Goodspeed</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TGF- and BMP signaling are associated with the transformation of glioblastoma to gliosarcoma and then osteosarcoma]]></title>
        <id>pubmed:38292240</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38292240/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240209194815&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This unusual clinical case provided an opportunity to explore the modulators of longitudinal sarcomatous transformation, potentially uncovering markers indicating predisposition to this change and identification of novel therapeutic targets.]]></summary>
        <author>
            <name>Aiguo Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Computational validation of clonal and subclonal copy number alterations from bulk tumor sequencing using CNAqc]]></title>
        <id>pubmed:38297376</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38297376/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240208194923&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Copy number alterations (CNAs) are among the most important genetic events in cancer, but their detection from sequencing data is challenging because of unknown sample purity, tumor ploidy, and general intra-tumor heterogeneity. Here, we present CNAqc, an evolution-inspired method to perform the computational validation of clonal and subclonal CNAs detected from bulk DNA sequencing. CNAqc is validated using single-cell data and simulations, is applied to over 4000 TCGA and PCAWG samples, and is...]]></summary>
        <author>
            <name>Alice Antonello</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Adaptive Control of Tumor Growth]]></title>
        <id>pubmed:38294947</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38294947/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240208194923&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer treatment optimizations select the most optimum combinations of drugs, sequencing schedules, and appropriate doses that would limit toxicity and yield an improved patient quality of life. However, these optimizations often lack an adequate consideration of cancer's near-infinite potential for evolutionary adaptation to therapeutic interventions. Adapting cancer therapy based on monitored tumor burden and clonal composition is an intuitively sound approach to the treatment of cancer as an...]]></summary>
        <author>
            <name>Youcef Derbal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single cell RNA-sequencing of Ewing sarcoma tumors demonstrates transcriptional heterogeneity and clonal evolution]]></title>
        <id>pubmed:38293103</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38293103/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240208194923&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ewing sarcoma is the second most common bone cancer in children, accounting for 2% of pediatric cancer diagnoses. Patients who present with metastatic disease at the time of diagnosis have a dismal prognosis, compared to the >70% 5-year survival of those with localized disease. Here, we utilized single cell RNA-sequencing to characterize the transcriptional landscape of primary Ewing sarcoma tumors and surrounding tumor microenvironment (TME). Copy-number analysis identified subclonal evolution...]]></summary>
        <author>
            <name>Andrew Goodspeed</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TGF- and BMP signaling are associated with the transformation of glioblastoma to gliosarcoma and then osteosarcoma]]></title>
        <id>pubmed:38292240</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38292240/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240208194923&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This unusual clinical case provided an opportunity to explore the modulators of longitudinal sarcomatous transformation, potentially uncovering markers indicating predisposition to this change and identification of novel therapeutic targets.]]></summary>
        <author>
            <name>Aiguo Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Computational validation of clonal and subclonal copy number alterations from bulk tumor sequencing using CNAqc]]></title>
        <id>pubmed:38297376</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38297376/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240207194932&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Copy number alterations (CNAs) are among the most important genetic events in cancer, but their detection from sequencing data is challenging because of unknown sample purity, tumor ploidy, and general intra-tumor heterogeneity. Here, we present CNAqc, an evolution-inspired method to perform the computational validation of clonal and subclonal CNAs detected from bulk DNA sequencing. CNAqc is validated using single-cell data and simulations, is applied to over 4000 TCGA and PCAWG samples, and is...]]></summary>
        <author>
            <name>Alice Antonello</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Adaptive Control of Tumor Growth]]></title>
        <id>pubmed:38294947</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38294947/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240207194932&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer treatment optimizations select the most optimum combinations of drugs, sequencing schedules, and appropriate doses that would limit toxicity and yield an improved patient quality of life. However, these optimizations often lack an adequate consideration of cancer's near-infinite potential for evolutionary adaptation to therapeutic interventions. Adapting cancer therapy based on monitored tumor burden and clonal composition is an intuitively sound approach to the treatment of cancer as an...]]></summary>
        <author>
            <name>Youcef Derbal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single cell RNA-sequencing of Ewing sarcoma tumors demonstrates transcriptional heterogeneity and clonal evolution]]></title>
        <id>pubmed:38293103</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38293103/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240207194932&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ewing sarcoma is the second most common bone cancer in children, accounting for 2% of pediatric cancer diagnoses. Patients who present with metastatic disease at the time of diagnosis have a dismal prognosis, compared to the >70% 5-year survival of those with localized disease. Here, we utilized single cell RNA-sequencing to characterize the transcriptional landscape of primary Ewing sarcoma tumors and surrounding tumor microenvironment (TME). Copy-number analysis identified subclonal evolution...]]></summary>
        <author>
            <name>Andrew Goodspeed</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TGF- and BMP signaling are associated with the transformation of glioblastoma to gliosarcoma and then osteosarcoma]]></title>
        <id>pubmed:38292240</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38292240/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240207194932&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This unusual clinical case provided an opportunity to explore the modulators of longitudinal sarcomatous transformation, potentially uncovering markers indicating predisposition to this change and identification of novel therapeutic targets.]]></summary>
        <author>
            <name>Aiguo Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Computational validation of clonal and subclonal copy number alterations from bulk tumor sequencing using CNAqc]]></title>
        <id>pubmed:38297376</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38297376/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240206194820&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Copy number alterations (CNAs) are among the most important genetic events in cancer, but their detection from sequencing data is challenging because of unknown sample purity, tumor ploidy, and general intra-tumor heterogeneity. Here, we present CNAqc, an evolution-inspired method to perform the computational validation of clonal and subclonal CNAs detected from bulk DNA sequencing. CNAqc is validated using single-cell data and simulations, is applied to over 4000 TCGA and PCAWG samples, and is...]]></summary>
        <author>
            <name>Alice Antonello</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Adaptive Control of Tumor Growth]]></title>
        <id>pubmed:38294947</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38294947/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240206194820&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer treatment optimizations select the most optimum combinations of drugs, sequencing schedules, and appropriate doses that would limit toxicity and yield an improved patient quality of life. However, these optimizations often lack an adequate consideration of cancer's near-infinite potential for evolutionary adaptation to therapeutic interventions. Adapting cancer therapy based on monitored tumor burden and clonal composition is an intuitively sound approach to the treatment of cancer as an...]]></summary>
        <author>
            <name>Youcef Derbal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single cell RNA-sequencing of Ewing sarcoma tumors demonstrates transcriptional heterogeneity and clonal evolution]]></title>
        <id>pubmed:38293103</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38293103/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240206194820&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ewing sarcoma is the second most common bone cancer in children, accounting for 2% of pediatric cancer diagnoses. Patients who present with metastatic disease at the time of diagnosis have a dismal prognosis, compared to the >70% 5-year survival of those with localized disease. Here, we utilized single cell RNA-sequencing to characterize the transcriptional landscape of primary Ewing sarcoma tumors and surrounding tumor microenvironment (TME). Copy-number analysis identified subclonal evolution...]]></summary>
        <author>
            <name>Andrew Goodspeed</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TGF- and BMP signaling are associated with the transformation of glioblastoma to gliosarcoma and then osteosarcoma]]></title>
        <id>pubmed:38292240</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38292240/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240206194820&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This unusual clinical case provided an opportunity to explore the modulators of longitudinal sarcomatous transformation, potentially uncovering markers indicating predisposition to this change and identification of novel therapeutic targets.]]></summary>
        <author>
            <name>Aiguo Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Computational validation of clonal and subclonal copy number alterations from bulk tumor sequencing using CNAqc]]></title>
        <id>pubmed:38297376</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38297376/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240205194943&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Copy number alterations (CNAs) are among the most important genetic events in cancer, but their detection from sequencing data is challenging because of unknown sample purity, tumor ploidy, and general intra-tumor heterogeneity. Here, we present CNAqc, an evolution-inspired method to perform the computational validation of clonal and subclonal CNAs detected from bulk DNA sequencing. CNAqc is validated using single-cell data and simulations, is applied to over 4000 TCGA and PCAWG samples, and is...]]></summary>
        <author>
            <name>Alice Antonello</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Adaptive Control of Tumor Growth]]></title>
        <id>pubmed:38294947</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38294947/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240205194943&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer treatment optimizations select the most optimum combinations of drugs, sequencing schedules, and appropriate doses that would limit toxicity and yield an improved patient quality of life. However, these optimizations often lack an adequate consideration of cancer's near-infinite potential for evolutionary adaptation to therapeutic interventions. Adapting cancer therapy based on monitored tumor burden and clonal composition is an intuitively sound approach to the treatment of cancer as an...]]></summary>
        <author>
            <name>Youcef Derbal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single cell RNA-sequencing of Ewing sarcoma tumors demonstrates transcriptional heterogeneity and clonal evolution]]></title>
        <id>pubmed:38293103</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38293103/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240205194943&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ewing sarcoma is the second most common bone cancer in children, accounting for 2% of pediatric cancer diagnoses. Patients who present with metastatic disease at the time of diagnosis have a dismal prognosis, compared to the >70% 5-year survival of those with localized disease. Here, we utilized single cell RNA-sequencing to characterize the transcriptional landscape of primary Ewing sarcoma tumors and surrounding tumor microenvironment (TME). Copy-number analysis identified subclonal evolution...]]></summary>
        <author>
            <name>Andrew Goodspeed</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TGF- and BMP signaling are associated with the transformation of glioblastoma to gliosarcoma and then osteosarcoma]]></title>
        <id>pubmed:38292240</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38292240/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240205194943&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This unusual clinical case provided an opportunity to explore the modulators of longitudinal sarcomatous transformation, potentially uncovering markers indicating predisposition to this change and identification of novel therapeutic targets.]]></summary>
        <author>
            <name>Aiguo Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Computational validation of clonal and subclonal copy number alterations from bulk tumor sequencing using CNAqc]]></title>
        <id>pubmed:38297376</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38297376/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240204195148&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Copy number alterations (CNAs) are among the most important genetic events in cancer, but their detection from sequencing data is challenging because of unknown sample purity, tumor ploidy, and general intra-tumor heterogeneity. Here, we present CNAqc, an evolution-inspired method to perform the computational validation of clonal and subclonal CNAs detected from bulk DNA sequencing. CNAqc is validated using single-cell data and simulations, is applied to over 4000 TCGA and PCAWG samples, and is...]]></summary>
        <author>
            <name>Alice Antonello</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Adaptive Control of Tumor Growth]]></title>
        <id>pubmed:38294947</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38294947/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240204195148&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer treatment optimizations select the most optimum combinations of drugs, sequencing schedules, and appropriate doses that would limit toxicity and yield an improved patient quality of life. However, these optimizations often lack an adequate consideration of cancer's near-infinite potential for evolutionary adaptation to therapeutic interventions. Adapting cancer therapy based on monitored tumor burden and clonal composition is an intuitively sound approach to the treatment of cancer as an...]]></summary>
        <author>
            <name>Youcef Derbal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single cell RNA-sequencing of Ewing sarcoma tumors demonstrates transcriptional heterogeneity and clonal evolution]]></title>
        <id>pubmed:38293103</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38293103/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240204195148&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ewing sarcoma is the second most common bone cancer in children, accounting for 2% of pediatric cancer diagnoses. Patients who present with metastatic disease at the time of diagnosis have a dismal prognosis, compared to the >70% 5-year survival of those with localized disease. Here, we utilized single cell RNA-sequencing to characterize the transcriptional landscape of primary Ewing sarcoma tumors and surrounding tumor microenvironment (TME). Copy-number analysis identified subclonal evolution...]]></summary>
        <author>
            <name>Andrew Goodspeed</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TGF- and BMP signaling are associated with the transformation of glioblastoma to gliosarcoma and then osteosarcoma]]></title>
        <id>pubmed:38292240</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38292240/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240204195148&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This unusual clinical case provided an opportunity to explore the modulators of longitudinal sarcomatous transformation, potentially uncovering markers indicating predisposition to this change and identification of novel therapeutic targets.]]></summary>
        <author>
            <name>Aiguo Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Computational validation of clonal and subclonal copy number alterations from bulk tumor sequencing using CNAqc]]></title>
        <id>pubmed:38297376</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38297376/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240203195418&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Copy number alterations (CNAs) are among the most important genetic events in cancer, but their detection from sequencing data is challenging because of unknown sample purity, tumor ploidy, and general intra-tumor heterogeneity. Here, we present CNAqc, an evolution-inspired method to perform the computational validation of clonal and subclonal CNAs detected from bulk DNA sequencing. CNAqc is validated using single-cell data and simulations, is applied to over 4000 TCGA and PCAWG samples, and is...]]></summary>
        <author>
            <name>Alice Antonello</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Adaptive Control of Tumor Growth]]></title>
        <id>pubmed:38294947</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38294947/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240203195418&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer treatment optimizations select the most optimum combinations of drugs, sequencing schedules, and appropriate doses that would limit toxicity and yield an improved patient quality of life. However, these optimizations often lack an adequate consideration of cancer's near-infinite potential for evolutionary adaptation to therapeutic interventions. Adapting cancer therapy based on monitored tumor burden and clonal composition is an intuitively sound approach to the treatment of cancer as an...]]></summary>
        <author>
            <name>Youcef Derbal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single cell RNA-sequencing of Ewing sarcoma tumors demonstrates transcriptional heterogeneity and clonal evolution]]></title>
        <id>pubmed:38293103</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38293103/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240203195418&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ewing sarcoma is the second most common bone cancer in children, accounting for 2% of pediatric cancer diagnoses. Patients who present with metastatic disease at the time of diagnosis have a dismal prognosis, compared to the >70% 5-year survival of those with localized disease. Here, we utilized single cell RNA-sequencing to characterize the transcriptional landscape of primary Ewing sarcoma tumors and surrounding tumor microenvironment (TME). Copy-number analysis identified subclonal evolution...]]></summary>
        <author>
            <name>Andrew Goodspeed</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TGF- and BMP signaling are associated with the transformation of glioblastoma to gliosarcoma and then osteosarcoma]]></title>
        <id>pubmed:38292240</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38292240/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240203195418&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This unusual clinical case provided an opportunity to explore the modulators of longitudinal sarcomatous transformation, potentially uncovering markers indicating predisposition to this change and identification of novel therapeutic targets.]]></summary>
        <author>
            <name>Aiguo Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Computational validation of clonal and subclonal copy number alterations from bulk tumor sequencing using CNAqc]]></title>
        <id>pubmed:38297376</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38297376/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240202194939&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Copy number alterations (CNAs) are among the most important genetic events in cancer, but their detection from sequencing data is challenging because of unknown sample purity, tumor ploidy, and general intra-tumor heterogeneity. Here, we present CNAqc, an evolution-inspired method to perform the computational validation of clonal and subclonal CNAs detected from bulk DNA sequencing. CNAqc is validated using single-cell data and simulations, is applied to over 4000 TCGA and PCAWG samples, and is...]]></summary>
        <author>
            <name>Alice Antonello</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Adaptive Control of Tumor Growth]]></title>
        <id>pubmed:38294947</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38294947/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240202194939&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer treatment optimizations select the most optimum combinations of drugs, sequencing schedules, and appropriate doses that would limit toxicity and yield an improved patient quality of life. However, these optimizations often lack an adequate consideration of cancer's near-infinite potential for evolutionary adaptation to therapeutic interventions. Adapting cancer therapy based on monitored tumor burden and clonal composition is an intuitively sound approach to the treatment of cancer as an...]]></summary>
        <author>
            <name>Youcef Derbal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single cell RNA-sequencing of Ewing sarcoma tumors demonstrates transcriptional heterogeneity and clonal evolution]]></title>
        <id>pubmed:38293103</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38293103/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240202194939&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ewing sarcoma is the second most common bone cancer in children, accounting for 2% of pediatric cancer diagnoses. Patients who present with metastatic disease at the time of diagnosis have a dismal prognosis, compared to the >70% 5-year survival of those with localized disease. Here, we utilized single cell RNA-sequencing to characterize the transcriptional landscape of primary Ewing sarcoma tumors and surrounding tumor microenvironment (TME). Copy-number analysis identified subclonal evolution...]]></summary>
        <author>
            <name>Andrew Goodspeed</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TGF- and BMP signaling are associated with the transformation of glioblastoma to gliosarcoma and then osteosarcoma]]></title>
        <id>pubmed:38292240</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38292240/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240202194939&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This unusual clinical case provided an opportunity to explore the modulators of longitudinal sarcomatous transformation, potentially uncovering markers indicating predisposition to this change and identification of novel therapeutic targets.]]></summary>
        <author>
            <name>Aiguo Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Computational validation of clonal and subclonal copy number alterations from bulk tumor sequencing using CNAqc]]></title>
        <id>pubmed:38297376</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38297376/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240201195024&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Copy number alterations (CNAs) are among the most important genetic events in cancer, but their detection from sequencing data is challenging because of unknown sample purity, tumor ploidy, and general intra-tumor heterogeneity. Here, we present CNAqc, an evolution-inspired method to perform the computational validation of clonal and subclonal CNAs detected from bulk DNA sequencing. CNAqc is validated using single-cell data and simulations, is applied to over 4000 TCGA and PCAWG samples, and is...]]></summary>
        <author>
            <name>Alice Antonello</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single cell RNA-sequencing of Ewing sarcoma tumors demonstrates transcriptional heterogeneity and clonal evolution]]></title>
        <id>pubmed:38293103</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38293103/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240201195024&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ewing sarcoma is the second most common bone cancer in children, accounting for 2% of pediatric cancer diagnoses. Patients who present with metastatic disease at the time of diagnosis have a dismal prognosis, compared to the >70% 5-year survival of those with localized disease. Here, we utilized single cell RNA-sequencing to characterize the transcriptional landscape of primary Ewing sarcoma tumors and surrounding tumor microenvironment (TME). Copy-number analysis identified subclonal evolution...]]></summary>
        <author>
            <name>Andrew Goodspeed</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TGF- and BMP signaling are associated with the transformation of glioblastoma to gliosarcoma and then osteosarcoma]]></title>
        <id>pubmed:38292240</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38292240/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240201195024&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This unusual clinical case provided an opportunity to explore the modulators of longitudinal sarcomatous transformation, potentially uncovering markers indicating predisposition to this change and identification of novel therapeutic targets.]]></summary>
        <author>
            <name>Aiguo Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single cell RNA-sequencing of Ewing sarcoma tumors demonstrates transcriptional heterogeneity and clonal evolution]]></title>
        <id>pubmed:38293103</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38293103/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240131195240&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ewing sarcoma is the second most common bone cancer in children, accounting for 2% of pediatric cancer diagnoses. Patients who present with metastatic disease at the time of diagnosis have a dismal prognosis, compared to the >70% 5-year survival of those with localized disease. Here, we utilized single cell RNA-sequencing to characterize the transcriptional landscape of primary Ewing sarcoma tumors and surrounding tumor microenvironment (TME). Copy-number analysis identified subclonal evolution...]]></summary>
        <author>
            <name>Andrew Goodspeed</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TGF- and BMP signaling are associated with the transformation of glioblastoma to gliosarcoma and then osteosarcoma]]></title>
        <id>pubmed:38292240</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38292240/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240131195240&amp;v=2.18.0"/>
        <updated>2024-01-31T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This unusual clinical case provided an opportunity to explore the modulators of longitudinal sarcomatous transformation, potentially uncovering markers indicating predisposition to this change and identification of novel therapeutic targets.]]></summary>
        <author>
            <name>Aiguo Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Engineered T cells from induced pluripotent stem cells: from research towards clinical implementation]]></title>
        <id>pubmed:38283344</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38283344/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240212195038&amp;v=2.18.0"/>
        <updated>2024-01-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Induced pluripotent stem cell (iPSC)-derived T (iT) cells represent a groundbreaking frontier in adoptive cell therapies with engineered T cells, poised to overcome pivotal limitations associated with conventional manufacturing methods. iPSCs offer an off-the-shelf source of therapeutic T cells with the potential for infinite expansion and straightforward genetic manipulation to ensure hypo-immunogenicity and introduce specific therapeutic functions, such as antigen specificity through a...]]></summary>
        <author>
            <name>Ratchapong Netsrithong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Engineered T cells from induced pluripotent stem cells: from research towards clinical implementation]]></title>
        <id>pubmed:38283344</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38283344/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240211195044&amp;v=2.18.0"/>
        <updated>2024-01-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Induced pluripotent stem cell (iPSC)-derived T (iT) cells represent a groundbreaking frontier in adoptive cell therapies with engineered T cells, poised to overcome pivotal limitations associated with conventional manufacturing methods. iPSCs offer an off-the-shelf source of therapeutic T cells with the potential for infinite expansion and straightforward genetic manipulation to ensure hypo-immunogenicity and introduce specific therapeutic functions, such as antigen specificity through a...]]></summary>
        <author>
            <name>Ratchapong Netsrithong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Engineered T cells from induced pluripotent stem cells: from research towards clinical implementation]]></title>
        <id>pubmed:38283344</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38283344/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240210195415&amp;v=2.18.0"/>
        <updated>2024-01-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Induced pluripotent stem cell (iPSC)-derived T (iT) cells represent a groundbreaking frontier in adoptive cell therapies with engineered T cells, poised to overcome pivotal limitations associated with conventional manufacturing methods. iPSCs offer an off-the-shelf source of therapeutic T cells with the potential for infinite expansion and straightforward genetic manipulation to ensure hypo-immunogenicity and introduce specific therapeutic functions, such as antigen specificity through a...]]></summary>
        <author>
            <name>Ratchapong Netsrithong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Engineered T cells from induced pluripotent stem cells: from research towards clinical implementation]]></title>
        <id>pubmed:38283344</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38283344/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240209194815&amp;v=2.18.0"/>
        <updated>2024-01-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Induced pluripotent stem cell (iPSC)-derived T (iT) cells represent a groundbreaking frontier in adoptive cell therapies with engineered T cells, poised to overcome pivotal limitations associated with conventional manufacturing methods. iPSCs offer an off-the-shelf source of therapeutic T cells with the potential for infinite expansion and straightforward genetic manipulation to ensure hypo-immunogenicity and introduce specific therapeutic functions, such as antigen specificity through a...]]></summary>
        <author>
            <name>Ratchapong Netsrithong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Engineered T cells from induced pluripotent stem cells: from research towards clinical implementation]]></title>
        <id>pubmed:38283344</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38283344/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240208194923&amp;v=2.18.0"/>
        <updated>2024-01-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Induced pluripotent stem cell (iPSC)-derived T (iT) cells represent a groundbreaking frontier in adoptive cell therapies with engineered T cells, poised to overcome pivotal limitations associated with conventional manufacturing methods. iPSCs offer an off-the-shelf source of therapeutic T cells with the potential for infinite expansion and straightforward genetic manipulation to ensure hypo-immunogenicity and introduce specific therapeutic functions, such as antigen specificity through a...]]></summary>
        <author>
            <name>Ratchapong Netsrithong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Engineered T cells from induced pluripotent stem cells: from research towards clinical implementation]]></title>
        <id>pubmed:38283344</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38283344/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240207194932&amp;v=2.18.0"/>
        <updated>2024-01-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Induced pluripotent stem cell (iPSC)-derived T (iT) cells represent a groundbreaking frontier in adoptive cell therapies with engineered T cells, poised to overcome pivotal limitations associated with conventional manufacturing methods. iPSCs offer an off-the-shelf source of therapeutic T cells with the potential for infinite expansion and straightforward genetic manipulation to ensure hypo-immunogenicity and introduce specific therapeutic functions, such as antigen specificity through a...]]></summary>
        <author>
            <name>Ratchapong Netsrithong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Engineered T cells from induced pluripotent stem cells: from research towards clinical implementation]]></title>
        <id>pubmed:38283344</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38283344/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240206194820&amp;v=2.18.0"/>
        <updated>2024-01-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Induced pluripotent stem cell (iPSC)-derived T (iT) cells represent a groundbreaking frontier in adoptive cell therapies with engineered T cells, poised to overcome pivotal limitations associated with conventional manufacturing methods. iPSCs offer an off-the-shelf source of therapeutic T cells with the potential for infinite expansion and straightforward genetic manipulation to ensure hypo-immunogenicity and introduce specific therapeutic functions, such as antigen specificity through a...]]></summary>
        <author>
            <name>Ratchapong Netsrithong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Engineered T cells from induced pluripotent stem cells: from research towards clinical implementation]]></title>
        <id>pubmed:38283344</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38283344/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240205194943&amp;v=2.18.0"/>
        <updated>2024-01-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Induced pluripotent stem cell (iPSC)-derived T (iT) cells represent a groundbreaking frontier in adoptive cell therapies with engineered T cells, poised to overcome pivotal limitations associated with conventional manufacturing methods. iPSCs offer an off-the-shelf source of therapeutic T cells with the potential for infinite expansion and straightforward genetic manipulation to ensure hypo-immunogenicity and introduce specific therapeutic functions, such as antigen specificity through a...]]></summary>
        <author>
            <name>Ratchapong Netsrithong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Engineered T cells from induced pluripotent stem cells: from research towards clinical implementation]]></title>
        <id>pubmed:38283344</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38283344/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240204195148&amp;v=2.18.0"/>
        <updated>2024-01-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Induced pluripotent stem cell (iPSC)-derived T (iT) cells represent a groundbreaking frontier in adoptive cell therapies with engineered T cells, poised to overcome pivotal limitations associated with conventional manufacturing methods. iPSCs offer an off-the-shelf source of therapeutic T cells with the potential for infinite expansion and straightforward genetic manipulation to ensure hypo-immunogenicity and introduce specific therapeutic functions, such as antigen specificity through a...]]></summary>
        <author>
            <name>Ratchapong Netsrithong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Engineered T cells from induced pluripotent stem cells: from research towards clinical implementation]]></title>
        <id>pubmed:38283344</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38283344/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240203195418&amp;v=2.18.0"/>
        <updated>2024-01-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Induced pluripotent stem cell (iPSC)-derived T (iT) cells represent a groundbreaking frontier in adoptive cell therapies with engineered T cells, poised to overcome pivotal limitations associated with conventional manufacturing methods. iPSCs offer an off-the-shelf source of therapeutic T cells with the potential for infinite expansion and straightforward genetic manipulation to ensure hypo-immunogenicity and introduce specific therapeutic functions, such as antigen specificity through a...]]></summary>
        <author>
            <name>Ratchapong Netsrithong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Engineered T cells from induced pluripotent stem cells: from research towards clinical implementation]]></title>
        <id>pubmed:38283344</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38283344/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240202194939&amp;v=2.18.0"/>
        <updated>2024-01-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Induced pluripotent stem cell (iPSC)-derived T (iT) cells represent a groundbreaking frontier in adoptive cell therapies with engineered T cells, poised to overcome pivotal limitations associated with conventional manufacturing methods. iPSCs offer an off-the-shelf source of therapeutic T cells with the potential for infinite expansion and straightforward genetic manipulation to ensure hypo-immunogenicity and introduce specific therapeutic functions, such as antigen specificity through a...]]></summary>
        <author>
            <name>Ratchapong Netsrithong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Engineered T cells from induced pluripotent stem cells: from research towards clinical implementation]]></title>
        <id>pubmed:38283344</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38283344/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240201195024&amp;v=2.18.0"/>
        <updated>2024-01-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Induced pluripotent stem cell (iPSC)-derived T (iT) cells represent a groundbreaking frontier in adoptive cell therapies with engineered T cells, poised to overcome pivotal limitations associated with conventional manufacturing methods. iPSCs offer an off-the-shelf source of therapeutic T cells with the potential for infinite expansion and straightforward genetic manipulation to ensure hypo-immunogenicity and introduce specific therapeutic functions, such as antigen specificity through a...]]></summary>
        <author>
            <name>Ratchapong Netsrithong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Engineered T cells from induced pluripotent stem cells: from research towards clinical implementation]]></title>
        <id>pubmed:38283344</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38283344/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240131195240&amp;v=2.18.0"/>
        <updated>2024-01-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Induced pluripotent stem cell (iPSC)-derived T (iT) cells represent a groundbreaking frontier in adoptive cell therapies with engineered T cells, poised to overcome pivotal limitations associated with conventional manufacturing methods. iPSCs offer an off-the-shelf source of therapeutic T cells with the potential for infinite expansion and straightforward genetic manipulation to ensure hypo-immunogenicity and introduce specific therapeutic functions, such as antigen specificity through a...]]></summary>
        <author>
            <name>Ratchapong Netsrithong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Engineered T cells from induced pluripotent stem cells: from research towards clinical implementation]]></title>
        <id>pubmed:38283344</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38283344/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240130195039&amp;v=2.18.0"/>
        <updated>2024-01-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Induced pluripotent stem cell (iPSC)-derived T (iT) cells represent a groundbreaking frontier in adoptive cell therapies with engineered T cells, poised to overcome pivotal limitations associated with conventional manufacturing methods. iPSCs offer an off-the-shelf source of therapeutic T cells with the potential for infinite expansion and straightforward genetic manipulation to ensure hypo-immunogenicity and introduce specific therapeutic functions, such as antigen specificity through a...]]></summary>
        <author>
            <name>Ratchapong Netsrithong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Engineered T cells from induced pluripotent stem cells: from research towards clinical implementation]]></title>
        <id>pubmed:38283344</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38283344/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240129195013&amp;v=2.18.0"/>
        <updated>2024-01-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Induced pluripotent stem cell (iPSC)-derived T (iT) cells represent a groundbreaking frontier in adoptive cell therapies with engineered T cells, poised to overcome pivotal limitations associated with conventional manufacturing methods. iPSCs offer an off-the-shelf source of therapeutic T cells with the potential for infinite expansion and straightforward genetic manipulation to ensure hypo-immunogenicity and introduce specific therapeutic functions, such as antigen specificity through a...]]></summary>
        <author>
            <name>Ratchapong Netsrithong</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Chorea and Cognitive Impairment in JAK2V617F-Positive Myeloproliferative Disorders: A Case Report and Literature Review]]></title>
        <id>pubmed:38276052</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38276052/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240212195038&amp;v=2.18.0"/>
        <updated>2024-01-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chorea is a hyperkinetic movement disorder, accompanied by dystonia, myoclonus, tics, stereotypies, and tremors. It is characterized by excessive, purposeless movements that are distressing, irregularly timed, and randomly distributed. Chorea can be present in many diseases, such as hereditary, metabolic disturbance, drug-induced, and functional disorders, and, rarely, genetic, autoimmune, and infectious diseases. Primary myelofibrosis (PMF) is a myeloproliferative neoplasm that leads to...]]></summary>
        <author>
            <name>Ioana Butnariu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Chorea and Cognitive Impairment in JAK2V617F-Positive Myeloproliferative Disorders: A Case Report and Literature Review]]></title>
        <id>pubmed:38276052</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38276052/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240211195044&amp;v=2.18.0"/>
        <updated>2024-01-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chorea is a hyperkinetic movement disorder, accompanied by dystonia, myoclonus, tics, stereotypies, and tremors. It is characterized by excessive, purposeless movements that are distressing, irregularly timed, and randomly distributed. Chorea can be present in many diseases, such as hereditary, metabolic disturbance, drug-induced, and functional disorders, and, rarely, genetic, autoimmune, and infectious diseases. Primary myelofibrosis (PMF) is a myeloproliferative neoplasm that leads to...]]></summary>
        <author>
            <name>Ioana Butnariu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Chorea and Cognitive Impairment in JAK2V617F-Positive Myeloproliferative Disorders: A Case Report and Literature Review]]></title>
        <id>pubmed:38276052</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38276052/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240210195415&amp;v=2.18.0"/>
        <updated>2024-01-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chorea is a hyperkinetic movement disorder, accompanied by dystonia, myoclonus, tics, stereotypies, and tremors. It is characterized by excessive, purposeless movements that are distressing, irregularly timed, and randomly distributed. Chorea can be present in many diseases, such as hereditary, metabolic disturbance, drug-induced, and functional disorders, and, rarely, genetic, autoimmune, and infectious diseases. Primary myelofibrosis (PMF) is a myeloproliferative neoplasm that leads to...]]></summary>
        <author>
            <name>Ioana Butnariu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Chorea and Cognitive Impairment in JAK2V617F-Positive Myeloproliferative Disorders: A Case Report and Literature Review]]></title>
        <id>pubmed:38276052</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38276052/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240209194815&amp;v=2.18.0"/>
        <updated>2024-01-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chorea is a hyperkinetic movement disorder, accompanied by dystonia, myoclonus, tics, stereotypies, and tremors. It is characterized by excessive, purposeless movements that are distressing, irregularly timed, and randomly distributed. Chorea can be present in many diseases, such as hereditary, metabolic disturbance, drug-induced, and functional disorders, and, rarely, genetic, autoimmune, and infectious diseases. Primary myelofibrosis (PMF) is a myeloproliferative neoplasm that leads to...]]></summary>
        <author>
            <name>Ioana Butnariu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Chorea and Cognitive Impairment in JAK2V617F-Positive Myeloproliferative Disorders: A Case Report and Literature Review]]></title>
        <id>pubmed:38276052</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38276052/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240208194923&amp;v=2.18.0"/>
        <updated>2024-01-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chorea is a hyperkinetic movement disorder, accompanied by dystonia, myoclonus, tics, stereotypies, and tremors. It is characterized by excessive, purposeless movements that are distressing, irregularly timed, and randomly distributed. Chorea can be present in many diseases, such as hereditary, metabolic disturbance, drug-induced, and functional disorders, and, rarely, genetic, autoimmune, and infectious diseases. Primary myelofibrosis (PMF) is a myeloproliferative neoplasm that leads to...]]></summary>
        <author>
            <name>Ioana Butnariu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Chorea and Cognitive Impairment in JAK2V617F-Positive Myeloproliferative Disorders: A Case Report and Literature Review]]></title>
        <id>pubmed:38276052</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38276052/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240207194932&amp;v=2.18.0"/>
        <updated>2024-01-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chorea is a hyperkinetic movement disorder, accompanied by dystonia, myoclonus, tics, stereotypies, and tremors. It is characterized by excessive, purposeless movements that are distressing, irregularly timed, and randomly distributed. Chorea can be present in many diseases, such as hereditary, metabolic disturbance, drug-induced, and functional disorders, and, rarely, genetic, autoimmune, and infectious diseases. Primary myelofibrosis (PMF) is a myeloproliferative neoplasm that leads to...]]></summary>
        <author>
            <name>Ioana Butnariu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Chorea and Cognitive Impairment in JAK2V617F-Positive Myeloproliferative Disorders: A Case Report and Literature Review]]></title>
        <id>pubmed:38276052</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38276052/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240206194820&amp;v=2.18.0"/>
        <updated>2024-01-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chorea is a hyperkinetic movement disorder, accompanied by dystonia, myoclonus, tics, stereotypies, and tremors. It is characterized by excessive, purposeless movements that are distressing, irregularly timed, and randomly distributed. Chorea can be present in many diseases, such as hereditary, metabolic disturbance, drug-induced, and functional disorders, and, rarely, genetic, autoimmune, and infectious diseases. Primary myelofibrosis (PMF) is a myeloproliferative neoplasm that leads to...]]></summary>
        <author>
            <name>Ioana Butnariu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Chorea and Cognitive Impairment in JAK2V617F-Positive Myeloproliferative Disorders: A Case Report and Literature Review]]></title>
        <id>pubmed:38276052</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38276052/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240205194943&amp;v=2.18.0"/>
        <updated>2024-01-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chorea is a hyperkinetic movement disorder, accompanied by dystonia, myoclonus, tics, stereotypies, and tremors. It is characterized by excessive, purposeless movements that are distressing, irregularly timed, and randomly distributed. Chorea can be present in many diseases, such as hereditary, metabolic disturbance, drug-induced, and functional disorders, and, rarely, genetic, autoimmune, and infectious diseases. Primary myelofibrosis (PMF) is a myeloproliferative neoplasm that leads to...]]></summary>
        <author>
            <name>Ioana Butnariu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Chorea and Cognitive Impairment in JAK2V617F-Positive Myeloproliferative Disorders: A Case Report and Literature Review]]></title>
        <id>pubmed:38276052</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38276052/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240204195148&amp;v=2.18.0"/>
        <updated>2024-01-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chorea is a hyperkinetic movement disorder, accompanied by dystonia, myoclonus, tics, stereotypies, and tremors. It is characterized by excessive, purposeless movements that are distressing, irregularly timed, and randomly distributed. Chorea can be present in many diseases, such as hereditary, metabolic disturbance, drug-induced, and functional disorders, and, rarely, genetic, autoimmune, and infectious diseases. Primary myelofibrosis (PMF) is a myeloproliferative neoplasm that leads to...]]></summary>
        <author>
            <name>Ioana Butnariu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Chorea and Cognitive Impairment in JAK2V617F-Positive Myeloproliferative Disorders: A Case Report and Literature Review]]></title>
        <id>pubmed:38276052</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38276052/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240203195418&amp;v=2.18.0"/>
        <updated>2024-01-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chorea is a hyperkinetic movement disorder, accompanied by dystonia, myoclonus, tics, stereotypies, and tremors. It is characterized by excessive, purposeless movements that are distressing, irregularly timed, and randomly distributed. Chorea can be present in many diseases, such as hereditary, metabolic disturbance, drug-induced, and functional disorders, and, rarely, genetic, autoimmune, and infectious diseases. Primary myelofibrosis (PMF) is a myeloproliferative neoplasm that leads to...]]></summary>
        <author>
            <name>Ioana Butnariu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Chorea and Cognitive Impairment in JAK2V617F-Positive Myeloproliferative Disorders: A Case Report and Literature Review]]></title>
        <id>pubmed:38276052</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38276052/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240202194939&amp;v=2.18.0"/>
        <updated>2024-01-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chorea is a hyperkinetic movement disorder, accompanied by dystonia, myoclonus, tics, stereotypies, and tremors. It is characterized by excessive, purposeless movements that are distressing, irregularly timed, and randomly distributed. Chorea can be present in many diseases, such as hereditary, metabolic disturbance, drug-induced, and functional disorders, and, rarely, genetic, autoimmune, and infectious diseases. Primary myelofibrosis (PMF) is a myeloproliferative neoplasm that leads to...]]></summary>
        <author>
            <name>Ioana Butnariu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Chorea and Cognitive Impairment in JAK2V617F-Positive Myeloproliferative Disorders: A Case Report and Literature Review]]></title>
        <id>pubmed:38276052</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38276052/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240201195024&amp;v=2.18.0"/>
        <updated>2024-01-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chorea is a hyperkinetic movement disorder, accompanied by dystonia, myoclonus, tics, stereotypies, and tremors. It is characterized by excessive, purposeless movements that are distressing, irregularly timed, and randomly distributed. Chorea can be present in many diseases, such as hereditary, metabolic disturbance, drug-induced, and functional disorders, and, rarely, genetic, autoimmune, and infectious diseases. Primary myelofibrosis (PMF) is a myeloproliferative neoplasm that leads to...]]></summary>
        <author>
            <name>Ioana Butnariu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Chorea and Cognitive Impairment in JAK2V617F-Positive Myeloproliferative Disorders: A Case Report and Literature Review]]></title>
        <id>pubmed:38276052</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38276052/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240131195240&amp;v=2.18.0"/>
        <updated>2024-01-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chorea is a hyperkinetic movement disorder, accompanied by dystonia, myoclonus, tics, stereotypies, and tremors. It is characterized by excessive, purposeless movements that are distressing, irregularly timed, and randomly distributed. Chorea can be present in many diseases, such as hereditary, metabolic disturbance, drug-induced, and functional disorders, and, rarely, genetic, autoimmune, and infectious diseases. Primary myelofibrosis (PMF) is a myeloproliferative neoplasm that leads to...]]></summary>
        <author>
            <name>Ioana Butnariu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Chorea and Cognitive Impairment in JAK2V617F-Positive Myeloproliferative Disorders: A Case Report and Literature Review]]></title>
        <id>pubmed:38276052</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38276052/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240130195039&amp;v=2.18.0"/>
        <updated>2024-01-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chorea is a hyperkinetic movement disorder, accompanied by dystonia, myoclonus, tics, stereotypies, and tremors. It is characterized by excessive, purposeless movements that are distressing, irregularly timed, and randomly distributed. Chorea can be present in many diseases, such as hereditary, metabolic disturbance, drug-induced, and functional disorders, and, rarely, genetic, autoimmune, and infectious diseases. Primary myelofibrosis (PMF) is a myeloproliferative neoplasm that leads to...]]></summary>
        <author>
            <name>Ioana Butnariu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Chorea and Cognitive Impairment in JAK2V617F-Positive Myeloproliferative Disorders: A Case Report and Literature Review]]></title>
        <id>pubmed:38276052</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38276052/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240129195013&amp;v=2.18.0"/>
        <updated>2024-01-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chorea is a hyperkinetic movement disorder, accompanied by dystonia, myoclonus, tics, stereotypies, and tremors. It is characterized by excessive, purposeless movements that are distressing, irregularly timed, and randomly distributed. Chorea can be present in many diseases, such as hereditary, metabolic disturbance, drug-induced, and functional disorders, and, rarely, genetic, autoimmune, and infectious diseases. Primary myelofibrosis (PMF) is a myeloproliferative neoplasm that leads to...]]></summary>
        <author>
            <name>Ioana Butnariu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Chorea and Cognitive Impairment in JAK2V617F-Positive Myeloproliferative Disorders: A Case Report and Literature Review]]></title>
        <id>pubmed:38276052</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38276052/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240128195055&amp;v=2.18.0"/>
        <updated>2024-01-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chorea is a hyperkinetic movement disorder, accompanied by dystonia, myoclonus, tics, stereotypies, and tremors. It is characterized by excessive, purposeless movements that are distressing, irregularly timed, and randomly distributed. Chorea can be present in many diseases, such as hereditary, metabolic disturbance, drug-induced, and functional disorders, and, rarely, genetic, autoimmune, and infectious diseases. Primary myelofibrosis (PMF) is a myeloproliferative neoplasm that leads to...]]></summary>
        <author>
            <name>Ioana Butnariu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Chorea and Cognitive Impairment in JAK2V617F-Positive Myeloproliferative Disorders: A Case Report and Literature Review]]></title>
        <id>pubmed:38276052</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38276052/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240127195322&amp;v=2.18.0"/>
        <updated>2024-01-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chorea is a hyperkinetic movement disorder, accompanied by dystonia, myoclonus, tics, stereotypies, and tremors. It is characterized by excessive, purposeless movements that are distressing, irregularly timed, and randomly distributed. Chorea can be present in many diseases, such as hereditary, metabolic disturbance, drug-induced, and functional disorders, and, rarely, genetic, autoimmune, and infectious diseases. Primary myelofibrosis (PMF) is a myeloproliferative neoplasm that leads to...]]></summary>
        <author>
            <name>Ioana Butnariu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Chorea and Cognitive Impairment in JAK2V617F-Positive Myeloproliferative Disorders: A Case Report and Literature Review]]></title>
        <id>pubmed:38276052</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38276052/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240126194954&amp;v=2.18.0"/>
        <updated>2024-01-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chorea is a hyperkinetic movement disorder, accompanied by dystonia, myoclonus, tics, stereotypies, and tremors. It is characterized by excessive, purposeless movements that are distressing, irregularly timed, and randomly distributed. Chorea can be present in many diseases, such as hereditary, metabolic disturbance, drug-induced, and functional disorders, and, rarely, genetic, autoimmune, and infectious diseases. Primary myelofibrosis (PMF) is a myeloproliferative neoplasm that leads to...]]></summary>
        <author>
            <name>Ioana Butnariu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Incident Heart Failure With Preserved Ejection Fraction]]></title>
        <id>pubmed:38270950</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38270950/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240212195038&amp;v=2.18.0"/>
        <updated>2024-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: In this cohort study, TET2 CHIP was an independent risk factor associated with incident HFpEF. This finding may have implications for the prevention and management of HFpEF, including development of targeted therapies.]]></summary>
        <author>
            <name>Art Schuermans</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Nonpreferential but Detrimental Accumulation of Macrophages With Clonal Hematopoiesis-Driver Mutations in Cardiovascular Tissues]]></title>
        <id>pubmed:38269586</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38269586/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240212195038&amp;v=2.18.0"/>
        <updated>2024-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Quantitatively, CHIP-mutated myeloid cells did not preferentially accumulate in cardiovascular tissues, but qualitatively, they expressed a more disease-prone phenotype.]]></summary>
        <author>
            <name>Tsai-Sang Dederichs</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Incident Heart Failure With Preserved Ejection Fraction]]></title>
        <id>pubmed:38270950</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38270950/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240211195044&amp;v=2.18.0"/>
        <updated>2024-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: In this cohort study, TET2 CHIP was an independent risk factor associated with incident HFpEF. This finding may have implications for the prevention and management of HFpEF, including development of targeted therapies.]]></summary>
        <author>
            <name>Art Schuermans</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Nonpreferential but Detrimental Accumulation of Macrophages With Clonal Hematopoiesis-Driver Mutations in Cardiovascular Tissues]]></title>
        <id>pubmed:38269586</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38269586/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240211195044&amp;v=2.18.0"/>
        <updated>2024-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Quantitatively, CHIP-mutated myeloid cells did not preferentially accumulate in cardiovascular tissues, but qualitatively, they expressed a more disease-prone phenotype.]]></summary>
        <author>
            <name>Tsai-Sang Dederichs</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Incident Heart Failure With Preserved Ejection Fraction]]></title>
        <id>pubmed:38270950</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38270950/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240210195415&amp;v=2.18.0"/>
        <updated>2024-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: In this cohort study, TET2 CHIP was an independent risk factor associated with incident HFpEF. This finding may have implications for the prevention and management of HFpEF, including development of targeted therapies.]]></summary>
        <author>
            <name>Art Schuermans</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Nonpreferential but Detrimental Accumulation of Macrophages With Clonal Hematopoiesis-Driver Mutations in Cardiovascular Tissues]]></title>
        <id>pubmed:38269586</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38269586/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240210195415&amp;v=2.18.0"/>
        <updated>2024-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Quantitatively, CHIP-mutated myeloid cells did not preferentially accumulate in cardiovascular tissues, but qualitatively, they expressed a more disease-prone phenotype.]]></summary>
        <author>
            <name>Tsai-Sang Dederichs</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Incident Heart Failure With Preserved Ejection Fraction]]></title>
        <id>pubmed:38270950</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38270950/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240209194815&amp;v=2.18.0"/>
        <updated>2024-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: In this cohort study, TET2 CHIP was an independent risk factor associated with incident HFpEF. This finding may have implications for the prevention and management of HFpEF, including development of targeted therapies.]]></summary>
        <author>
            <name>Art Schuermans</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Nonpreferential but Detrimental Accumulation of Macrophages With Clonal Hematopoiesis-Driver Mutations in Cardiovascular Tissues]]></title>
        <id>pubmed:38269586</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38269586/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240209194815&amp;v=2.18.0"/>
        <updated>2024-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Quantitatively, CHIP-mutated myeloid cells did not preferentially accumulate in cardiovascular tissues, but qualitatively, they expressed a more disease-prone phenotype.]]></summary>
        <author>
            <name>Tsai-Sang Dederichs</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Incident Heart Failure With Preserved Ejection Fraction]]></title>
        <id>pubmed:38270950</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38270950/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240208194923&amp;v=2.18.0"/>
        <updated>2024-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: In this cohort study, TET2 CHIP was an independent risk factor associated with incident HFpEF. This finding may have implications for the prevention and management of HFpEF, including development of targeted therapies.]]></summary>
        <author>
            <name>Art Schuermans</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Nonpreferential but Detrimental Accumulation of Macrophages With Clonal Hematopoiesis-Driver Mutations in Cardiovascular Tissues]]></title>
        <id>pubmed:38269586</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38269586/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240208194923&amp;v=2.18.0"/>
        <updated>2024-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Quantitatively, CHIP-mutated myeloid cells did not preferentially accumulate in cardiovascular tissues, but qualitatively, they expressed a more disease-prone phenotype.]]></summary>
        <author>
            <name>Tsai-Sang Dederichs</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Incident Heart Failure With Preserved Ejection Fraction]]></title>
        <id>pubmed:38270950</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38270950/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240207194932&amp;v=2.18.0"/>
        <updated>2024-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: In this cohort study, TET2 CHIP was an independent risk factor associated with incident HFpEF. This finding may have implications for the prevention and management of HFpEF, including development of targeted therapies.]]></summary>
        <author>
            <name>Art Schuermans</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Nonpreferential but Detrimental Accumulation of Macrophages With Clonal Hematopoiesis-Driver Mutations in Cardiovascular Tissues]]></title>
        <id>pubmed:38269586</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38269586/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240207194932&amp;v=2.18.0"/>
        <updated>2024-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Quantitatively, CHIP-mutated myeloid cells did not preferentially accumulate in cardiovascular tissues, but qualitatively, they expressed a more disease-prone phenotype.]]></summary>
        <author>
            <name>Tsai-Sang Dederichs</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Incident Heart Failure With Preserved Ejection Fraction]]></title>
        <id>pubmed:38270950</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38270950/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240206194820&amp;v=2.18.0"/>
        <updated>2024-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: In this cohort study, TET2 CHIP was an independent risk factor associated with incident HFpEF. This finding may have implications for the prevention and management of HFpEF, including development of targeted therapies.]]></summary>
        <author>
            <name>Art Schuermans</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Nonpreferential but Detrimental Accumulation of Macrophages With Clonal Hematopoiesis-Driver Mutations in Cardiovascular Tissues]]></title>
        <id>pubmed:38269586</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38269586/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240206194820&amp;v=2.18.0"/>
        <updated>2024-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Quantitatively, CHIP-mutated myeloid cells did not preferentially accumulate in cardiovascular tissues, but qualitatively, they expressed a more disease-prone phenotype.]]></summary>
        <author>
            <name>Tsai-Sang Dederichs</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Incident Heart Failure With Preserved Ejection Fraction]]></title>
        <id>pubmed:38270950</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38270950/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240205194943&amp;v=2.18.0"/>
        <updated>2024-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: In this cohort study, TET2 CHIP was an independent risk factor associated with incident HFpEF. This finding may have implications for the prevention and management of HFpEF, including development of targeted therapies.]]></summary>
        <author>
            <name>Art Schuermans</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Nonpreferential but Detrimental Accumulation of Macrophages With Clonal Hematopoiesis-Driver Mutations in Cardiovascular Tissues]]></title>
        <id>pubmed:38269586</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38269586/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240205194943&amp;v=2.18.0"/>
        <updated>2024-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Quantitatively, CHIP-mutated myeloid cells did not preferentially accumulate in cardiovascular tissues, but qualitatively, they expressed a more disease-prone phenotype.]]></summary>
        <author>
            <name>Tsai-Sang Dederichs</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Incident Heart Failure With Preserved Ejection Fraction]]></title>
        <id>pubmed:38270950</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38270950/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240204195148&amp;v=2.18.0"/>
        <updated>2024-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: In this cohort study, TET2 CHIP was an independent risk factor associated with incident HFpEF. This finding may have implications for the prevention and management of HFpEF, including development of targeted therapies.]]></summary>
        <author>
            <name>Art Schuermans</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Nonpreferential but Detrimental Accumulation of Macrophages With Clonal Hematopoiesis-Driver Mutations in Cardiovascular Tissues]]></title>
        <id>pubmed:38269586</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38269586/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240204195148&amp;v=2.18.0"/>
        <updated>2024-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Quantitatively, CHIP-mutated myeloid cells did not preferentially accumulate in cardiovascular tissues, but qualitatively, they expressed a more disease-prone phenotype.]]></summary>
        <author>
            <name>Tsai-Sang Dederichs</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Incident Heart Failure With Preserved Ejection Fraction]]></title>
        <id>pubmed:38270950</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38270950/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240203195418&amp;v=2.18.0"/>
        <updated>2024-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: In this cohort study, TET2 CHIP was an independent risk factor associated with incident HFpEF. This finding may have implications for the prevention and management of HFpEF, including development of targeted therapies.]]></summary>
        <author>
            <name>Art Schuermans</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Nonpreferential but Detrimental Accumulation of Macrophages With Clonal Hematopoiesis-Driver Mutations in Cardiovascular Tissues]]></title>
        <id>pubmed:38269586</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38269586/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240203195418&amp;v=2.18.0"/>
        <updated>2024-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Quantitatively, CHIP-mutated myeloid cells did not preferentially accumulate in cardiovascular tissues, but qualitatively, they expressed a more disease-prone phenotype.]]></summary>
        <author>
            <name>Tsai-Sang Dederichs</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Incident Heart Failure With Preserved Ejection Fraction]]></title>
        <id>pubmed:38270950</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38270950/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240202194939&amp;v=2.18.0"/>
        <updated>2024-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: In this cohort study, TET2 CHIP was an independent risk factor associated with incident HFpEF. This finding may have implications for the prevention and management of HFpEF, including development of targeted therapies.]]></summary>
        <author>
            <name>Art Schuermans</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Nonpreferential but Detrimental Accumulation of Macrophages With Clonal Hematopoiesis-Driver Mutations in Cardiovascular Tissues]]></title>
        <id>pubmed:38269586</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38269586/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240202194939&amp;v=2.18.0"/>
        <updated>2024-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Quantitatively, CHIP-mutated myeloid cells did not preferentially accumulate in cardiovascular tissues, but qualitatively, they expressed a more disease-prone phenotype.]]></summary>
        <author>
            <name>Tsai-Sang Dederichs</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Incident Heart Failure With Preserved Ejection Fraction]]></title>
        <id>pubmed:38270950</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38270950/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240201195024&amp;v=2.18.0"/>
        <updated>2024-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: In this cohort study, TET2 CHIP was an independent risk factor associated with incident HFpEF. This finding may have implications for the prevention and management of HFpEF, including development of targeted therapies.]]></summary>
        <author>
            <name>Art Schuermans</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Nonpreferential but Detrimental Accumulation of Macrophages With Clonal Hematopoiesis-Driver Mutations in Cardiovascular Tissues]]></title>
        <id>pubmed:38269586</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38269586/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240201195024&amp;v=2.18.0"/>
        <updated>2024-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Quantitatively, CHIP-mutated myeloid cells did not preferentially accumulate in cardiovascular tissues, but qualitatively, they expressed a more disease-prone phenotype.]]></summary>
        <author>
            <name>Tsai-Sang Dederichs</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Incident Heart Failure With Preserved Ejection Fraction]]></title>
        <id>pubmed:38270950</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38270950/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240131195240&amp;v=2.18.0"/>
        <updated>2024-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: In this cohort study, TET2 CHIP was an independent risk factor associated with incident HFpEF. This finding may have implications for the prevention and management of HFpEF, including development of targeted therapies.]]></summary>
        <author>
            <name>Art Schuermans</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Nonpreferential but Detrimental Accumulation of Macrophages With Clonal Hematopoiesis-Driver Mutations in Cardiovascular Tissues]]></title>
        <id>pubmed:38269586</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38269586/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240131195240&amp;v=2.18.0"/>
        <updated>2024-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Quantitatively, CHIP-mutated myeloid cells did not preferentially accumulate in cardiovascular tissues, but qualitatively, they expressed a more disease-prone phenotype.]]></summary>
        <author>
            <name>Tsai-Sang Dederichs</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Incident Heart Failure With Preserved Ejection Fraction]]></title>
        <id>pubmed:38270950</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38270950/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240130195039&amp;v=2.18.0"/>
        <updated>2024-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: In this cohort study, TET2 CHIP was an independent risk factor associated with incident HFpEF. This finding may have implications for the prevention and management of HFpEF, including development of targeted therapies.]]></summary>
        <author>
            <name>Art Schuermans</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Nonpreferential but Detrimental Accumulation of Macrophages With Clonal Hematopoiesis-Driver Mutations in Cardiovascular Tissues]]></title>
        <id>pubmed:38269586</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38269586/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240130195039&amp;v=2.18.0"/>
        <updated>2024-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Quantitatively, CHIP-mutated myeloid cells did not preferentially accumulate in cardiovascular tissues, but qualitatively, they expressed a more disease-prone phenotype.]]></summary>
        <author>
            <name>Tsai-Sang Dederichs</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Incident Heart Failure With Preserved Ejection Fraction]]></title>
        <id>pubmed:38270950</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38270950/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240129195013&amp;v=2.18.0"/>
        <updated>2024-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: In this cohort study, TET2 CHIP was an independent risk factor associated with incident HFpEF. This finding may have implications for the prevention and management of HFpEF, including development of targeted therapies.]]></summary>
        <author>
            <name>Art Schuermans</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Nonpreferential but Detrimental Accumulation of Macrophages With Clonal Hematopoiesis-Driver Mutations in Cardiovascular Tissues]]></title>
        <id>pubmed:38269586</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38269586/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240129195013&amp;v=2.18.0"/>
        <updated>2024-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Quantitatively, CHIP-mutated myeloid cells did not preferentially accumulate in cardiovascular tissues, but qualitatively, they expressed a more disease-prone phenotype.]]></summary>
        <author>
            <name>Tsai-Sang Dederichs</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Incident Heart Failure With Preserved Ejection Fraction]]></title>
        <id>pubmed:38270950</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38270950/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240128195055&amp;v=2.18.0"/>
        <updated>2024-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: In this cohort study, TET2 CHIP was an independent risk factor associated with incident HFpEF. This finding may have implications for the prevention and management of HFpEF, including development of targeted therapies.]]></summary>
        <author>
            <name>Art Schuermans</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Nonpreferential but Detrimental Accumulation of Macrophages With Clonal Hematopoiesis-Driver Mutations in Cardiovascular Tissues]]></title>
        <id>pubmed:38269586</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38269586/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240128195055&amp;v=2.18.0"/>
        <updated>2024-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Quantitatively, CHIP-mutated myeloid cells did not preferentially accumulate in cardiovascular tissues, but qualitatively, they expressed a more disease-prone phenotype.]]></summary>
        <author>
            <name>Tsai-Sang Dederichs</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Incident Heart Failure With Preserved Ejection Fraction]]></title>
        <id>pubmed:38270950</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38270950/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240127195322&amp;v=2.18.0"/>
        <updated>2024-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: In this cohort study, TET2 CHIP was an independent risk factor associated with incident HFpEF. This finding may have implications for the prevention and management of HFpEF, including development of targeted therapies.]]></summary>
        <author>
            <name>Art Schuermans</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Nonpreferential but Detrimental Accumulation of Macrophages With Clonal Hematopoiesis-Driver Mutations in Cardiovascular Tissues]]></title>
        <id>pubmed:38269586</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38269586/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240127195322&amp;v=2.18.0"/>
        <updated>2024-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Quantitatively, CHIP-mutated myeloid cells did not preferentially accumulate in cardiovascular tissues, but qualitatively, they expressed a more disease-prone phenotype.]]></summary>
        <author>
            <name>Tsai-Sang Dederichs</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Incident Heart Failure With Preserved Ejection Fraction]]></title>
        <id>pubmed:38270950</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38270950/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240126194954&amp;v=2.18.0"/>
        <updated>2024-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: In this cohort study, TET2 CHIP was an independent risk factor associated with incident HFpEF. This finding may have implications for the prevention and management of HFpEF, including development of targeted therapies.]]></summary>
        <author>
            <name>Art Schuermans</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Nonpreferential but Detrimental Accumulation of Macrophages With Clonal Hematopoiesis-Driver Mutations in Cardiovascular Tissues]]></title>
        <id>pubmed:38269586</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38269586/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240126194954&amp;v=2.18.0"/>
        <updated>2024-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Quantitatively, CHIP-mutated myeloid cells did not preferentially accumulate in cardiovascular tissues, but qualitatively, they expressed a more disease-prone phenotype.]]></summary>
        <author>
            <name>Tsai-Sang Dederichs</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Incident Heart Failure With Preserved Ejection Fraction]]></title>
        <id>pubmed:38270950</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38270950/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240125195050&amp;v=2.18.0"/>
        <updated>2024-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: In this cohort study, TET2 CHIP was an independent risk factor associated with incident HFpEF. This finding may have implications for the prevention and management of HFpEF, including development of targeted therapies.]]></summary>
        <author>
            <name>Art Schuermans</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Nonpreferential but Detrimental Accumulation of Macrophages With Clonal Hematopoiesis-Driver Mutations in Cardiovascular Tissues]]></title>
        <id>pubmed:38269586</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38269586/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240125195050&amp;v=2.18.0"/>
        <updated>2024-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Quantitatively, CHIP-mutated myeloid cells did not preferentially accumulate in cardiovascular tissues, but qualitatively, they expressed a more disease-prone phenotype.]]></summary>
        <author>
            <name>Tsai-Sang Dederichs</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclonal Cancer Driver Mutations are Prevalent in the Unresected Peritumoral Edema of Adult Diffuse Gliomas]]></title>
        <id>pubmed:38270917</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38270917/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240212195038&amp;v=2.18.0"/>
        <updated>2024-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Adult diffuse gliomas commonly recur regardless of therapy. As recurrence typically arises from the peritumoral edema adjacent to the resected bulk tumor, the profiling of somatic mutations from infiltrative malignant cells within this critical, unresected region could provide important insights into residual disease. A key obstacle has been the inability to distinguish between next-generation sequencing (NGS) noise and the true but weak signal from tumor cells hidden among the noncancerous...]]></summary>
        <author>
            <name>Hunter R Underhill</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclonal Cancer Driver Mutations are Prevalent in the Unresected Peritumoral Edema of Adult Diffuse Gliomas]]></title>
        <id>pubmed:38270917</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38270917/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240211195044&amp;v=2.18.0"/>
        <updated>2024-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Adult diffuse gliomas commonly recur regardless of therapy. As recurrence typically arises from the peritumoral edema adjacent to the resected bulk tumor, the profiling of somatic mutations from infiltrative malignant cells within this critical, unresected region could provide important insights into residual disease. A key obstacle has been the inability to distinguish between next-generation sequencing (NGS) noise and the true but weak signal from tumor cells hidden among the noncancerous...]]></summary>
        <author>
            <name>Hunter R Underhill</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclonal Cancer Driver Mutations are Prevalent in the Unresected Peritumoral Edema of Adult Diffuse Gliomas]]></title>
        <id>pubmed:38270917</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38270917/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240210195415&amp;v=2.18.0"/>
        <updated>2024-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Adult diffuse gliomas commonly recur regardless of therapy. As recurrence typically arises from the peritumoral edema adjacent to the resected bulk tumor, the profiling of somatic mutations from infiltrative malignant cells within this critical, unresected region could provide important insights into residual disease. A key obstacle has been the inability to distinguish between next-generation sequencing (NGS) noise and the true but weak signal from tumor cells hidden among the noncancerous...]]></summary>
        <author>
            <name>Hunter R Underhill</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclonal Cancer Driver Mutations are Prevalent in the Unresected Peritumoral Edema of Adult Diffuse Gliomas]]></title>
        <id>pubmed:38270917</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38270917/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240209194815&amp;v=2.18.0"/>
        <updated>2024-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Adult diffuse gliomas commonly recur regardless of therapy. As recurrence typically arises from the peritumoral edema adjacent to the resected bulk tumor, the profiling of somatic mutations from infiltrative malignant cells within this critical, unresected region could provide important insights into residual disease. A key obstacle has been the inability to distinguish between next-generation sequencing (NGS) noise and the true but weak signal from tumor cells hidden among the noncancerous...]]></summary>
        <author>
            <name>Hunter R Underhill</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclonal Cancer Driver Mutations are Prevalent in the Unresected Peritumoral Edema of Adult Diffuse Gliomas]]></title>
        <id>pubmed:38270917</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38270917/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240208194923&amp;v=2.18.0"/>
        <updated>2024-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Adult diffuse gliomas commonly recur regardless of therapy. As recurrence typically arises from the peritumoral edema adjacent to the resected bulk tumor, the profiling of somatic mutations from infiltrative malignant cells within this critical, unresected region could provide important insights into residual disease. A key obstacle has been the inability to distinguish between next-generation sequencing (NGS) noise and the true but weak signal from tumor cells hidden among the noncancerous...]]></summary>
        <author>
            <name>Hunter R Underhill</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclonal Cancer Driver Mutations are Prevalent in the Unresected Peritumoral Edema of Adult Diffuse Gliomas]]></title>
        <id>pubmed:38270917</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38270917/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240207194932&amp;v=2.18.0"/>
        <updated>2024-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Adult diffuse gliomas commonly recur regardless of therapy. As recurrence typically arises from the peritumoral edema adjacent to the resected bulk tumor, the profiling of somatic mutations from infiltrative malignant cells within this critical, unresected region could provide important insights into residual disease. A key obstacle has been the inability to distinguish between next-generation sequencing (NGS) noise and the true but weak signal from tumor cells hidden among the noncancerous...]]></summary>
        <author>
            <name>Hunter R Underhill</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclonal Cancer Driver Mutations are Prevalent in the Unresected Peritumoral Edema of Adult Diffuse Gliomas]]></title>
        <id>pubmed:38270917</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38270917/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240206194820&amp;v=2.18.0"/>
        <updated>2024-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Adult diffuse gliomas commonly recur regardless of therapy. As recurrence typically arises from the peritumoral edema adjacent to the resected bulk tumor, the profiling of somatic mutations from infiltrative malignant cells within this critical, unresected region could provide important insights into residual disease. A key obstacle has been the inability to distinguish between next-generation sequencing (NGS) noise and the true but weak signal from tumor cells hidden among the noncancerous...]]></summary>
        <author>
            <name>Hunter R Underhill</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclonal Cancer Driver Mutations are Prevalent in the Unresected Peritumoral Edema of Adult Diffuse Gliomas]]></title>
        <id>pubmed:38270917</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38270917/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240205194943&amp;v=2.18.0"/>
        <updated>2024-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Adult diffuse gliomas commonly recur regardless of therapy. As recurrence typically arises from the peritumoral edema adjacent to the resected bulk tumor, the profiling of somatic mutations from infiltrative malignant cells within this critical, unresected region could provide important insights into residual disease. A key obstacle has been the inability to distinguish between next-generation sequencing (NGS) noise and the true but weak signal from tumor cells hidden among the noncancerous...]]></summary>
        <author>
            <name>Hunter R Underhill</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclonal Cancer Driver Mutations are Prevalent in the Unresected Peritumoral Edema of Adult Diffuse Gliomas]]></title>
        <id>pubmed:38270917</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38270917/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240204195148&amp;v=2.18.0"/>
        <updated>2024-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Adult diffuse gliomas commonly recur regardless of therapy. As recurrence typically arises from the peritumoral edema adjacent to the resected bulk tumor, the profiling of somatic mutations from infiltrative malignant cells within this critical, unresected region could provide important insights into residual disease. A key obstacle has been the inability to distinguish between next-generation sequencing (NGS) noise and the true but weak signal from tumor cells hidden among the noncancerous...]]></summary>
        <author>
            <name>Hunter R Underhill</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclonal Cancer Driver Mutations are Prevalent in the Unresected Peritumoral Edema of Adult Diffuse Gliomas]]></title>
        <id>pubmed:38270917</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38270917/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240203195418&amp;v=2.18.0"/>
        <updated>2024-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Adult diffuse gliomas commonly recur regardless of therapy. As recurrence typically arises from the peritumoral edema adjacent to the resected bulk tumor, the profiling of somatic mutations from infiltrative malignant cells within this critical, unresected region could provide important insights into residual disease. A key obstacle has been the inability to distinguish between next-generation sequencing (NGS) noise and the true but weak signal from tumor cells hidden among the noncancerous...]]></summary>
        <author>
            <name>Hunter R Underhill</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclonal Cancer Driver Mutations are Prevalent in the Unresected Peritumoral Edema of Adult Diffuse Gliomas]]></title>
        <id>pubmed:38270917</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38270917/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240202194939&amp;v=2.18.0"/>
        <updated>2024-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Adult diffuse gliomas commonly recur regardless of therapy. As recurrence typically arises from the peritumoral edema adjacent to the resected bulk tumor, the profiling of somatic mutations from infiltrative malignant cells within this critical, unresected region could provide important insights into residual disease. A key obstacle has been the inability to distinguish between next-generation sequencing (NGS) noise and the true but weak signal from tumor cells hidden among the noncancerous...]]></summary>
        <author>
            <name>Hunter R Underhill</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclonal Cancer Driver Mutations are Prevalent in the Unresected Peritumoral Edema of Adult Diffuse Gliomas]]></title>
        <id>pubmed:38270917</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38270917/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240201195024&amp;v=2.18.0"/>
        <updated>2024-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Adult diffuse gliomas commonly recur regardless of therapy. As recurrence typically arises from the peritumoral edema adjacent to the resected bulk tumor, the profiling of somatic mutations from infiltrative malignant cells within this critical, unresected region could provide important insights into residual disease. A key obstacle has been the inability to distinguish between next-generation sequencing (NGS) noise and the true but weak signal from tumor cells hidden among the noncancerous...]]></summary>
        <author>
            <name>Hunter R Underhill</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclonal Cancer Driver Mutations are Prevalent in the Unresected Peritumoral Edema of Adult Diffuse Gliomas]]></title>
        <id>pubmed:38270917</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38270917/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240131195240&amp;v=2.18.0"/>
        <updated>2024-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Adult diffuse gliomas commonly recur regardless of therapy. As recurrence typically arises from the peritumoral edema adjacent to the resected bulk tumor, the profiling of somatic mutations from infiltrative malignant cells within this critical, unresected region could provide important insights into residual disease. A key obstacle has been the inability to distinguish between next-generation sequencing (NGS) noise and the true but weak signal from tumor cells hidden among the noncancerous...]]></summary>
        <author>
            <name>Hunter R Underhill</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclonal Cancer Driver Mutations are Prevalent in the Unresected Peritumoral Edema of Adult Diffuse Gliomas]]></title>
        <id>pubmed:38270917</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38270917/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240130195039&amp;v=2.18.0"/>
        <updated>2024-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Adult diffuse gliomas commonly recur regardless of therapy. As recurrence typically arises from the peritumoral edema adjacent to the resected bulk tumor, the profiling of somatic mutations from infiltrative malignant cells within this critical, unresected region could provide important insights into residual disease. A key obstacle has been the inability to distinguish between next-generation sequencing (NGS) noise and the true but weak signal from tumor cells hidden among the noncancerous...]]></summary>
        <author>
            <name>Hunter R Underhill</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclonal Cancer Driver Mutations are Prevalent in the Unresected Peritumoral Edema of Adult Diffuse Gliomas]]></title>
        <id>pubmed:38270917</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38270917/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240129195013&amp;v=2.18.0"/>
        <updated>2024-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Adult diffuse gliomas commonly recur regardless of therapy. As recurrence typically arises from the peritumoral edema adjacent to the resected bulk tumor, the profiling of somatic mutations from infiltrative malignant cells within this critical, unresected region could provide important insights into residual disease. A key obstacle has been the inability to distinguish between next-generation sequencing (NGS) noise and the true but weak signal from tumor cells hidden among the noncancerous...]]></summary>
        <author>
            <name>Hunter R Underhill</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclonal Cancer Driver Mutations are Prevalent in the Unresected Peritumoral Edema of Adult Diffuse Gliomas]]></title>
        <id>pubmed:38270917</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38270917/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240128195055&amp;v=2.18.0"/>
        <updated>2024-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Adult diffuse gliomas commonly recur regardless of therapy. As recurrence typically arises from the peritumoral edema adjacent to the resected bulk tumor, the profiling of somatic mutations from infiltrative malignant cells within this critical, unresected region could provide important insights into residual disease. A key obstacle has been the inability to distinguish between next-generation sequencing (NGS) noise and the true but weak signal from tumor cells hidden among the noncancerous...]]></summary>
        <author>
            <name>Hunter R Underhill</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclonal Cancer Driver Mutations are Prevalent in the Unresected Peritumoral Edema of Adult Diffuse Gliomas]]></title>
        <id>pubmed:38270917</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38270917/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240127195322&amp;v=2.18.0"/>
        <updated>2024-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Adult diffuse gliomas commonly recur regardless of therapy. As recurrence typically arises from the peritumoral edema adjacent to the resected bulk tumor, the profiling of somatic mutations from infiltrative malignant cells within this critical, unresected region could provide important insights into residual disease. A key obstacle has been the inability to distinguish between next-generation sequencing (NGS) noise and the true but weak signal from tumor cells hidden among the noncancerous...]]></summary>
        <author>
            <name>Hunter R Underhill</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclonal Cancer Driver Mutations are Prevalent in the Unresected Peritumoral Edema of Adult Diffuse Gliomas]]></title>
        <id>pubmed:38270917</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38270917/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240126194954&amp;v=2.18.0"/>
        <updated>2024-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Adult diffuse gliomas commonly recur regardless of therapy. As recurrence typically arises from the peritumoral edema adjacent to the resected bulk tumor, the profiling of somatic mutations from infiltrative malignant cells within this critical, unresected region could provide important insights into residual disease. A key obstacle has been the inability to distinguish between next-generation sequencing (NGS) noise and the true but weak signal from tumor cells hidden among the noncancerous...]]></summary>
        <author>
            <name>Hunter R Underhill</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclonal Cancer Driver Mutations are Prevalent in the Unresected Peritumoral Edema of Adult Diffuse Gliomas]]></title>
        <id>pubmed:38270917</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38270917/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240125195050&amp;v=2.18.0"/>
        <updated>2024-01-25T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Adult diffuse gliomas commonly recur regardless of therapy. As recurrence typically arises from the peritumoral edema adjacent to the resected bulk tumor, the profiling of somatic mutations from infiltrative malignant cells within this critical, unresected region could provide important insights into residual disease. A key obstacle has been the inability to distinguish between next-generation sequencing (NGS) noise and the true but weak signal from tumor cells hidden among the noncancerous...]]></summary>
        <author>
            <name>Hunter R Underhill</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between periodontitis and inflammatory comorbidities: The common role of innate immune cells, underlying mechanisms and therapeutic targets]]></title>
        <id>pubmed:38266446</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38266446/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240211195044&amp;v=2.18.0"/>
        <updated>2024-01-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Periodontitis, which is related to various systemic diseases, is a chronic inflammatory disease caused by periodontal dysbiosis of the microbiota. Multiple factors can influence the interaction of periodontitis and associated inflammatory disorders, among which host immunity is an important contributor to this interaction. Innate immunity can be activated aberrantly because of the systemic inflammation induced by periodontitis. This aberrant activation not only exacerbates periodontal tissue...]]></summary>
        <author>
            <name>Qibing Wu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between periodontitis and inflammatory comorbidities: The common role of innate immune cells, underlying mechanisms and therapeutic targets]]></title>
        <id>pubmed:38266446</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38266446/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240210195415&amp;v=2.18.0"/>
        <updated>2024-01-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Periodontitis, which is related to various systemic diseases, is a chronic inflammatory disease caused by periodontal dysbiosis of the microbiota. Multiple factors can influence the interaction of periodontitis and associated inflammatory disorders, among which host immunity is an important contributor to this interaction. Innate immunity can be activated aberrantly because of the systemic inflammation induced by periodontitis. This aberrant activation not only exacerbates periodontal tissue...]]></summary>
        <author>
            <name>Qibing Wu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between periodontitis and inflammatory comorbidities: The common role of innate immune cells, underlying mechanisms and therapeutic targets]]></title>
        <id>pubmed:38266446</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38266446/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240209194815&amp;v=2.18.0"/>
        <updated>2024-01-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Periodontitis, which is related to various systemic diseases, is a chronic inflammatory disease caused by periodontal dysbiosis of the microbiota. Multiple factors can influence the interaction of periodontitis and associated inflammatory disorders, among which host immunity is an important contributor to this interaction. Innate immunity can be activated aberrantly because of the systemic inflammation induced by periodontitis. This aberrant activation not only exacerbates periodontal tissue...]]></summary>
        <author>
            <name>Qibing Wu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between periodontitis and inflammatory comorbidities: The common role of innate immune cells, underlying mechanisms and therapeutic targets]]></title>
        <id>pubmed:38266446</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38266446/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240208194923&amp;v=2.18.0"/>
        <updated>2024-01-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Periodontitis, which is related to various systemic diseases, is a chronic inflammatory disease caused by periodontal dysbiosis of the microbiota. Multiple factors can influence the interaction of periodontitis and associated inflammatory disorders, among which host immunity is an important contributor to this interaction. Innate immunity can be activated aberrantly because of the systemic inflammation induced by periodontitis. This aberrant activation not only exacerbates periodontal tissue...]]></summary>
        <author>
            <name>Qibing Wu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between periodontitis and inflammatory comorbidities: The common role of innate immune cells, underlying mechanisms and therapeutic targets]]></title>
        <id>pubmed:38266446</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38266446/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240207194932&amp;v=2.18.0"/>
        <updated>2024-01-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Periodontitis, which is related to various systemic diseases, is a chronic inflammatory disease caused by periodontal dysbiosis of the microbiota. Multiple factors can influence the interaction of periodontitis and associated inflammatory disorders, among which host immunity is an important contributor to this interaction. Innate immunity can be activated aberrantly because of the systemic inflammation induced by periodontitis. This aberrant activation not only exacerbates periodontal tissue...]]></summary>
        <author>
            <name>Qibing Wu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between periodontitis and inflammatory comorbidities: The common role of innate immune cells, underlying mechanisms and therapeutic targets]]></title>
        <id>pubmed:38266446</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38266446/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240206194820&amp;v=2.18.0"/>
        <updated>2024-01-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Periodontitis, which is related to various systemic diseases, is a chronic inflammatory disease caused by periodontal dysbiosis of the microbiota. Multiple factors can influence the interaction of periodontitis and associated inflammatory disorders, among which host immunity is an important contributor to this interaction. Innate immunity can be activated aberrantly because of the systemic inflammation induced by periodontitis. This aberrant activation not only exacerbates periodontal tissue...]]></summary>
        <author>
            <name>Qibing Wu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between periodontitis and inflammatory comorbidities: The common role of innate immune cells, underlying mechanisms and therapeutic targets]]></title>
        <id>pubmed:38266446</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38266446/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240205194943&amp;v=2.18.0"/>
        <updated>2024-01-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Periodontitis, which is related to various systemic diseases, is a chronic inflammatory disease caused by periodontal dysbiosis of the microbiota. Multiple factors can influence the interaction of periodontitis and associated inflammatory disorders, among which host immunity is an important contributor to this interaction. Innate immunity can be activated aberrantly because of the systemic inflammation induced by periodontitis. This aberrant activation not only exacerbates periodontal tissue...]]></summary>
        <author>
            <name>Qibing Wu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between periodontitis and inflammatory comorbidities: The common role of innate immune cells, underlying mechanisms and therapeutic targets]]></title>
        <id>pubmed:38266446</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38266446/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240204195148&amp;v=2.18.0"/>
        <updated>2024-01-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Periodontitis, which is related to various systemic diseases, is a chronic inflammatory disease caused by periodontal dysbiosis of the microbiota. Multiple factors can influence the interaction of periodontitis and associated inflammatory disorders, among which host immunity is an important contributor to this interaction. Innate immunity can be activated aberrantly because of the systemic inflammation induced by periodontitis. This aberrant activation not only exacerbates periodontal tissue...]]></summary>
        <author>
            <name>Qibing Wu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between periodontitis and inflammatory comorbidities: The common role of innate immune cells, underlying mechanisms and therapeutic targets]]></title>
        <id>pubmed:38266446</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38266446/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240203195418&amp;v=2.18.0"/>
        <updated>2024-01-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Periodontitis, which is related to various systemic diseases, is a chronic inflammatory disease caused by periodontal dysbiosis of the microbiota. Multiple factors can influence the interaction of periodontitis and associated inflammatory disorders, among which host immunity is an important contributor to this interaction. Innate immunity can be activated aberrantly because of the systemic inflammation induced by periodontitis. This aberrant activation not only exacerbates periodontal tissue...]]></summary>
        <author>
            <name>Qibing Wu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between periodontitis and inflammatory comorbidities: The common role of innate immune cells, underlying mechanisms and therapeutic targets]]></title>
        <id>pubmed:38266446</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38266446/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240202194939&amp;v=2.18.0"/>
        <updated>2024-01-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Periodontitis, which is related to various systemic diseases, is a chronic inflammatory disease caused by periodontal dysbiosis of the microbiota. Multiple factors can influence the interaction of periodontitis and associated inflammatory disorders, among which host immunity is an important contributor to this interaction. Innate immunity can be activated aberrantly because of the systemic inflammation induced by periodontitis. This aberrant activation not only exacerbates periodontal tissue...]]></summary>
        <author>
            <name>Qibing Wu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between periodontitis and inflammatory comorbidities: The common role of innate immune cells, underlying mechanisms and therapeutic targets]]></title>
        <id>pubmed:38266446</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38266446/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240201195024&amp;v=2.18.0"/>
        <updated>2024-01-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Periodontitis, which is related to various systemic diseases, is a chronic inflammatory disease caused by periodontal dysbiosis of the microbiota. Multiple factors can influence the interaction of periodontitis and associated inflammatory disorders, among which host immunity is an important contributor to this interaction. Innate immunity can be activated aberrantly because of the systemic inflammation induced by periodontitis. This aberrant activation not only exacerbates periodontal tissue...]]></summary>
        <author>
            <name>Qibing Wu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between periodontitis and inflammatory comorbidities: The common role of innate immune cells, underlying mechanisms and therapeutic targets]]></title>
        <id>pubmed:38266446</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38266446/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240131195240&amp;v=2.18.0"/>
        <updated>2024-01-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Periodontitis, which is related to various systemic diseases, is a chronic inflammatory disease caused by periodontal dysbiosis of the microbiota. Multiple factors can influence the interaction of periodontitis and associated inflammatory disorders, among which host immunity is an important contributor to this interaction. Innate immunity can be activated aberrantly because of the systemic inflammation induced by periodontitis. This aberrant activation not only exacerbates periodontal tissue...]]></summary>
        <author>
            <name>Qibing Wu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between periodontitis and inflammatory comorbidities: The common role of innate immune cells, underlying mechanisms and therapeutic targets]]></title>
        <id>pubmed:38266446</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38266446/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240130195039&amp;v=2.18.0"/>
        <updated>2024-01-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Periodontitis, which is related to various systemic diseases, is a chronic inflammatory disease caused by periodontal dysbiosis of the microbiota. Multiple factors can influence the interaction of periodontitis and associated inflammatory disorders, among which host immunity is an important contributor to this interaction. Innate immunity can be activated aberrantly because of the systemic inflammation induced by periodontitis. This aberrant activation not only exacerbates periodontal tissue...]]></summary>
        <author>
            <name>Qibing Wu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between periodontitis and inflammatory comorbidities: The common role of innate immune cells, underlying mechanisms and therapeutic targets]]></title>
        <id>pubmed:38266446</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38266446/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240129195013&amp;v=2.18.0"/>
        <updated>2024-01-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Periodontitis, which is related to various systemic diseases, is a chronic inflammatory disease caused by periodontal dysbiosis of the microbiota. Multiple factors can influence the interaction of periodontitis and associated inflammatory disorders, among which host immunity is an important contributor to this interaction. Innate immunity can be activated aberrantly because of the systemic inflammation induced by periodontitis. This aberrant activation not only exacerbates periodontal tissue...]]></summary>
        <author>
            <name>Qibing Wu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between periodontitis and inflammatory comorbidities: The common role of innate immune cells, underlying mechanisms and therapeutic targets]]></title>
        <id>pubmed:38266446</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38266446/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240128195055&amp;v=2.18.0"/>
        <updated>2024-01-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Periodontitis, which is related to various systemic diseases, is a chronic inflammatory disease caused by periodontal dysbiosis of the microbiota. Multiple factors can influence the interaction of periodontitis and associated inflammatory disorders, among which host immunity is an important contributor to this interaction. Innate immunity can be activated aberrantly because of the systemic inflammation induced by periodontitis. This aberrant activation not only exacerbates periodontal tissue...]]></summary>
        <author>
            <name>Qibing Wu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between periodontitis and inflammatory comorbidities: The common role of innate immune cells, underlying mechanisms and therapeutic targets]]></title>
        <id>pubmed:38266446</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38266446/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240127195322&amp;v=2.18.0"/>
        <updated>2024-01-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Periodontitis, which is related to various systemic diseases, is a chronic inflammatory disease caused by periodontal dysbiosis of the microbiota. Multiple factors can influence the interaction of periodontitis and associated inflammatory disorders, among which host immunity is an important contributor to this interaction. Innate immunity can be activated aberrantly because of the systemic inflammation induced by periodontitis. This aberrant activation not only exacerbates periodontal tissue...]]></summary>
        <author>
            <name>Qibing Wu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between periodontitis and inflammatory comorbidities: The common role of innate immune cells, underlying mechanisms and therapeutic targets]]></title>
        <id>pubmed:38266446</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38266446/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240126194954&amp;v=2.18.0"/>
        <updated>2024-01-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Periodontitis, which is related to various systemic diseases, is a chronic inflammatory disease caused by periodontal dysbiosis of the microbiota. Multiple factors can influence the interaction of periodontitis and associated inflammatory disorders, among which host immunity is an important contributor to this interaction. Innate immunity can be activated aberrantly because of the systemic inflammation induced by periodontitis. This aberrant activation not only exacerbates periodontal tissue...]]></summary>
        <author>
            <name>Qibing Wu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between periodontitis and inflammatory comorbidities: The common role of innate immune cells, underlying mechanisms and therapeutic targets]]></title>
        <id>pubmed:38266446</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38266446/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240125195050&amp;v=2.18.0"/>
        <updated>2024-01-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Periodontitis, which is related to various systemic diseases, is a chronic inflammatory disease caused by periodontal dysbiosis of the microbiota. Multiple factors can influence the interaction of periodontitis and associated inflammatory disorders, among which host immunity is an important contributor to this interaction. Innate immunity can be activated aberrantly because of the systemic inflammation induced by periodontitis. This aberrant activation not only exacerbates periodontal tissue...]]></summary>
        <author>
            <name>Qibing Wu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[IDH1-Mutant Preleukemic Hematopoietic Stem Cells Can Be Eliminated by Inhibition of Oxidative Phosphorylation]]></title>
        <id>pubmed:38261864</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38261864/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240210195415&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Rare preleukemic hematopoietic stem cells (pHSC) harboring only the initiating mutations can be detected at the time of acute myeloid leukemia (AML) diagnosis. pHSCs are the origin of leukemia and a potential reservoir for relapse. Using primary human samples and gene editing to model isocitrate dehydrogenase 1 (IDH1) mutant pHSCs, we show epigenetic, transcriptional, and metabolic differences between pHSCs and healthy hematopoietic stem cells (HSC). We confirm that IDH1-driven clonal...]]></summary>
        <author>
            <name>Niklas Landberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[IDH1-Mutant Preleukemic Hematopoietic Stem Cells Can Be Eliminated by Inhibition of Oxidative Phosphorylation]]></title>
        <id>pubmed:38261864</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38261864/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240209194815&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Rare preleukemic hematopoietic stem cells (pHSC) harboring only the initiating mutations can be detected at the time of acute myeloid leukemia (AML) diagnosis. pHSCs are the origin of leukemia and a potential reservoir for relapse. Using primary human samples and gene editing to model isocitrate dehydrogenase 1 (IDH1) mutant pHSCs, we show epigenetic, transcriptional, and metabolic differences between pHSCs and healthy hematopoietic stem cells (HSC). We confirm that IDH1-driven clonal...]]></summary>
        <author>
            <name>Niklas Landberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Somatic cancer driver mutations are enriched and associated with inflammatory states in Alzheimer's disease microglia]]></title>
        <id>pubmed:38260600</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38260600/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240209194815&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Alzheimer's disease (AD) is an age-associated neurodegenerative disorder characterized by progressive neuronal loss and pathological accumulation of the misfolded proteins amyloid- and tau^(1,2). Neuroinflammation mediated by microglia and brain-resident macrophages plays a crucial role in AD pathogenesis^(1-5), though the mechanisms by which age, genes, and other risk factors interact remain largely unknown. Somatic mutations accumulate with age and lead to clonal expansion of many cell types,...]]></summary>
        <author>
            <name>August Yue Huang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gemtuzumab Ozogamicin in Acute Myeloid Leukemia: Efficacy, Toxicity, and Resistance Mechanisms-A Systematic Review]]></title>
        <id>pubmed:38255313</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38255313/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240209194815&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) is a diverse group of leukemias characterized by the uncontrolled proliferation of clonal neoplastic hematopoietic precursor cells with chromosomal rearrangements and multiple gene mutations and the impairment of normal hematopoiesis. Current efforts to improve AML outcomes have focused on developing targeted therapies that may allow for improved antileukemic effects while reducing toxicity significantly. Gemtuzumab ozogamicin (GO) is one of the most thoroughly...]]></summary>
        <author>
            <name>Aurelia Collados-Ros</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[IDH1-Mutant Preleukemic Hematopoietic Stem Cells Can Be Eliminated by Inhibition of Oxidative Phosphorylation]]></title>
        <id>pubmed:38261864</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38261864/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240208194923&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Rare preleukemic hematopoietic stem cells (pHSC) harboring only the initiating mutations can be detected at the time of acute myeloid leukemia (AML) diagnosis. pHSCs are the origin of leukemia and a potential reservoir for relapse. Using primary human samples and gene editing to model isocitrate dehydrogenase 1 (IDH1) mutant pHSCs, we show epigenetic, transcriptional, and metabolic differences between pHSCs and healthy hematopoietic stem cells (HSC). We confirm that IDH1-driven clonal...]]></summary>
        <author>
            <name>Niklas Landberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Somatic cancer driver mutations are enriched and associated with inflammatory states in Alzheimer's disease microglia]]></title>
        <id>pubmed:38260600</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38260600/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240208194923&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Alzheimer's disease (AD) is an age-associated neurodegenerative disorder characterized by progressive neuronal loss and pathological accumulation of the misfolded proteins amyloid- and tau^(1,2). Neuroinflammation mediated by microglia and brain-resident macrophages plays a crucial role in AD pathogenesis^(1-5), though the mechanisms by which age, genes, and other risk factors interact remain largely unknown. Somatic mutations accumulate with age and lead to clonal expansion of many cell types,...]]></summary>
        <author>
            <name>August Yue Huang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gemtuzumab Ozogamicin in Acute Myeloid Leukemia: Efficacy, Toxicity, and Resistance Mechanisms-A Systematic Review]]></title>
        <id>pubmed:38255313</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38255313/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240208194923&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) is a diverse group of leukemias characterized by the uncontrolled proliferation of clonal neoplastic hematopoietic precursor cells with chromosomal rearrangements and multiple gene mutations and the impairment of normal hematopoiesis. Current efforts to improve AML outcomes have focused on developing targeted therapies that may allow for improved antileukemic effects while reducing toxicity significantly. Gemtuzumab ozogamicin (GO) is one of the most thoroughly...]]></summary>
        <author>
            <name>Aurelia Collados-Ros</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[IDH1-Mutant Preleukemic Hematopoietic Stem Cells Can Be Eliminated by Inhibition of Oxidative Phosphorylation]]></title>
        <id>pubmed:38261864</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38261864/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240207194932&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Rare preleukemic hematopoietic stem cells (pHSC) harboring only the initiating mutations can be detected at the time of acute myeloid leukemia (AML) diagnosis. pHSCs are the origin of leukemia and a potential reservoir for relapse. Using primary human samples and gene editing to model isocitrate dehydrogenase 1 (IDH1) mutant pHSCs, we show epigenetic, transcriptional, and metabolic differences between pHSCs and healthy hematopoietic stem cells (HSC). We confirm that IDH1-driven clonal...]]></summary>
        <author>
            <name>Niklas Landberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Somatic cancer driver mutations are enriched and associated with inflammatory states in Alzheimer's disease microglia]]></title>
        <id>pubmed:38260600</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38260600/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240207194932&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Alzheimer's disease (AD) is an age-associated neurodegenerative disorder characterized by progressive neuronal loss and pathological accumulation of the misfolded proteins amyloid- and tau^(1,2). Neuroinflammation mediated by microglia and brain-resident macrophages plays a crucial role in AD pathogenesis^(1-5), though the mechanisms by which age, genes, and other risk factors interact remain largely unknown. Somatic mutations accumulate with age and lead to clonal expansion of many cell types,...]]></summary>
        <author>
            <name>August Yue Huang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gemtuzumab Ozogamicin in Acute Myeloid Leukemia: Efficacy, Toxicity, and Resistance Mechanisms-A Systematic Review]]></title>
        <id>pubmed:38255313</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38255313/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240207194932&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) is a diverse group of leukemias characterized by the uncontrolled proliferation of clonal neoplastic hematopoietic precursor cells with chromosomal rearrangements and multiple gene mutations and the impairment of normal hematopoiesis. Current efforts to improve AML outcomes have focused on developing targeted therapies that may allow for improved antileukemic effects while reducing toxicity significantly. Gemtuzumab ozogamicin (GO) is one of the most thoroughly...]]></summary>
        <author>
            <name>Aurelia Collados-Ros</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[IDH1-Mutant Preleukemic Hematopoietic Stem Cells Can Be Eliminated by Inhibition of Oxidative Phosphorylation]]></title>
        <id>pubmed:38261864</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38261864/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240206194820&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Rare preleukemic hematopoietic stem cells (pHSC) harboring only the initiating mutations can be detected at the time of acute myeloid leukemia (AML) diagnosis. pHSCs are the origin of leukemia and a potential reservoir for relapse. Using primary human samples and gene editing to model isocitrate dehydrogenase 1 (IDH1) mutant pHSCs, we show epigenetic, transcriptional, and metabolic differences between pHSCs and healthy hematopoietic stem cells (HSC). We confirm that IDH1-driven clonal...]]></summary>
        <author>
            <name>Niklas Landberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Somatic cancer driver mutations are enriched and associated with inflammatory states in Alzheimer's disease microglia]]></title>
        <id>pubmed:38260600</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38260600/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240206194820&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Alzheimer's disease (AD) is an age-associated neurodegenerative disorder characterized by progressive neuronal loss and pathological accumulation of the misfolded proteins amyloid- and tau^(1,2). Neuroinflammation mediated by microglia and brain-resident macrophages plays a crucial role in AD pathogenesis^(1-5), though the mechanisms by which age, genes, and other risk factors interact remain largely unknown. Somatic mutations accumulate with age and lead to clonal expansion of many cell types,...]]></summary>
        <author>
            <name>August Yue Huang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gemtuzumab Ozogamicin in Acute Myeloid Leukemia: Efficacy, Toxicity, and Resistance Mechanisms-A Systematic Review]]></title>
        <id>pubmed:38255313</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38255313/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240206194820&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) is a diverse group of leukemias characterized by the uncontrolled proliferation of clonal neoplastic hematopoietic precursor cells with chromosomal rearrangements and multiple gene mutations and the impairment of normal hematopoiesis. Current efforts to improve AML outcomes have focused on developing targeted therapies that may allow for improved antileukemic effects while reducing toxicity significantly. Gemtuzumab ozogamicin (GO) is one of the most thoroughly...]]></summary>
        <author>
            <name>Aurelia Collados-Ros</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[IDH1-Mutant Preleukemic Hematopoietic Stem Cells Can Be Eliminated by Inhibition of Oxidative Phosphorylation]]></title>
        <id>pubmed:38261864</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38261864/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240205194943&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Rare preleukemic hematopoietic stem cells (pHSC) harboring only the initiating mutations can be detected at the time of acute myeloid leukemia (AML) diagnosis. pHSCs are the origin of leukemia and a potential reservoir for relapse. Using primary human samples and gene editing to model isocitrate dehydrogenase 1 (IDH1) mutant pHSCs, we show epigenetic, transcriptional, and metabolic differences between pHSCs and healthy hematopoietic stem cells (HSC). We confirm that IDH1-driven clonal...]]></summary>
        <author>
            <name>Niklas Landberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Somatic cancer driver mutations are enriched and associated with inflammatory states in Alzheimer's disease microglia]]></title>
        <id>pubmed:38260600</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38260600/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240205194943&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Alzheimer's disease (AD) is an age-associated neurodegenerative disorder characterized by progressive neuronal loss and pathological accumulation of the misfolded proteins amyloid- and tau^(1,2). Neuroinflammation mediated by microglia and brain-resident macrophages plays a crucial role in AD pathogenesis^(1-5), though the mechanisms by which age, genes, and other risk factors interact remain largely unknown. Somatic mutations accumulate with age and lead to clonal expansion of many cell types,...]]></summary>
        <author>
            <name>August Yue Huang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gemtuzumab Ozogamicin in Acute Myeloid Leukemia: Efficacy, Toxicity, and Resistance Mechanisms-A Systematic Review]]></title>
        <id>pubmed:38255313</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38255313/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240205194943&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) is a diverse group of leukemias characterized by the uncontrolled proliferation of clonal neoplastic hematopoietic precursor cells with chromosomal rearrangements and multiple gene mutations and the impairment of normal hematopoiesis. Current efforts to improve AML outcomes have focused on developing targeted therapies that may allow for improved antileukemic effects while reducing toxicity significantly. Gemtuzumab ozogamicin (GO) is one of the most thoroughly...]]></summary>
        <author>
            <name>Aurelia Collados-Ros</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[IDH1-Mutant Preleukemic Hematopoietic Stem Cells Can Be Eliminated by Inhibition of Oxidative Phosphorylation]]></title>
        <id>pubmed:38261864</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38261864/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240204195148&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Rare preleukemic hematopoietic stem cells (pHSC) harboring only the initiating mutations can be detected at the time of acute myeloid leukemia (AML) diagnosis. pHSCs are the origin of leukemia and a potential reservoir for relapse. Using primary human samples and gene editing to model isocitrate dehydrogenase 1 (IDH1) mutant pHSCs, we show epigenetic, transcriptional, and metabolic differences between pHSCs and healthy hematopoietic stem cells (HSC). We confirm that IDH1-driven clonal...]]></summary>
        <author>
            <name>Niklas Landberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Somatic cancer driver mutations are enriched and associated with inflammatory states in Alzheimer's disease microglia]]></title>
        <id>pubmed:38260600</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38260600/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240204195148&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Alzheimer's disease (AD) is an age-associated neurodegenerative disorder characterized by progressive neuronal loss and pathological accumulation of the misfolded proteins amyloid- and tau ^(1,2) . Neuroinflammation mediated by microglia and brain-resident macrophages plays a crucial role in AD pathogenesis ^(1-5) , though the mechanisms by which age, genes, and other risk factors interact remain largely unknown. Somatic mutations accumulate with age and lead to clonal expansion of many cell...]]></summary>
        <author>
            <name>August Yue Huang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gemtuzumab Ozogamicin in Acute Myeloid Leukemia: Efficacy, Toxicity, and Resistance Mechanisms-A Systematic Review]]></title>
        <id>pubmed:38255313</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38255313/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240204195148&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) is a diverse group of leukemias characterized by the uncontrolled proliferation of clonal neoplastic hematopoietic precursor cells with chromosomal rearrangements and multiple gene mutations and the impairment of normal hematopoiesis. Current efforts to improve AML outcomes have focused on developing targeted therapies that may allow for improved antileukemic effects while reducing toxicity significantly. Gemtuzumab ozogamicin (GO) is one of the most thoroughly...]]></summary>
        <author>
            <name>Aurelia Collados-Ros</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[IDH1-Mutant Preleukemic Hematopoietic Stem Cells Can Be Eliminated by Inhibition of Oxidative Phosphorylation]]></title>
        <id>pubmed:38261864</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38261864/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240203195418&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Rare preleukemic hematopoietic stem cells (pHSC) harboring only the initiating mutations can be detected at the time of acute myeloid leukemia (AML) diagnosis. pHSCs are the origin of leukemia and a potential reservoir for relapse. Using primary human samples and gene editing to model isocitrate dehydrogenase 1 (IDH1) mutant pHSCs, we show epigenetic, transcriptional, and metabolic differences between pHSCs and healthy hematopoietic stem cells (HSC). We confirm that IDH1-driven clonal...]]></summary>
        <author>
            <name>Niklas Landberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Somatic cancer driver mutations are enriched and associated with inflammatory states in Alzheimer's disease microglia]]></title>
        <id>pubmed:38260600</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38260600/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240203195418&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Alzheimer's disease (AD) is an age-associated neurodegenerative disorder characterized by progressive neuronal loss and pathological accumulation of the misfolded proteins amyloid- and tau ^(1,2) . Neuroinflammation mediated by microglia and brain-resident macrophages plays a crucial role in AD pathogenesis ^(1-5) , though the mechanisms by which age, genes, and other risk factors interact remain largely unknown. Somatic mutations accumulate with age and lead to clonal expansion of many cell...]]></summary>
        <author>
            <name>August Yue Huang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gemtuzumab Ozogamicin in Acute Myeloid Leukemia: Efficacy, Toxicity, and Resistance Mechanisms-A Systematic Review]]></title>
        <id>pubmed:38255313</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38255313/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240203195418&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) is a diverse group of leukemias characterized by the uncontrolled proliferation of clonal neoplastic hematopoietic precursor cells with chromosomal rearrangements and multiple gene mutations and the impairment of normal hematopoiesis. Current efforts to improve AML outcomes have focused on developing targeted therapies that may allow for improved antileukemic effects while reducing toxicity significantly. Gemtuzumab ozogamicin (GO) is one of the most thoroughly...]]></summary>
        <author>
            <name>Aurelia Collados-Ros</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[IDH1-Mutant Preleukemic Hematopoietic Stem Cells Can Be Eliminated by Inhibition of Oxidative Phosphorylation]]></title>
        <id>pubmed:38261864</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38261864/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240202194939&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Rare preleukemic hematopoietic stem cells (pHSC) harboring only the initiating mutations can be detected at the time of acute myeloid leukemia (AML) diagnosis. pHSCs are the origin of leukemia and a potential reservoir for relapse. Using primary human samples and gene editing to model isocitrate dehydrogenase 1 (IDH1) mutant pHSCs, we show epigenetic, transcriptional, and metabolic differences between pHSCs and healthy hematopoietic stem cells (HSC). We confirm that IDH1-driven clonal...]]></summary>
        <author>
            <name>Niklas Landberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Somatic cancer driver mutations are enriched and associated with inflammatory states in Alzheimer's disease microglia]]></title>
        <id>pubmed:38260600</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38260600/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240202194939&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Alzheimer's disease (AD) is an age-associated neurodegenerative disorder characterized by progressive neuronal loss and pathological accumulation of the misfolded proteins amyloid- and tau ^(1,2) . Neuroinflammation mediated by microglia and brain-resident macrophages plays a crucial role in AD pathogenesis ^(1-5) , though the mechanisms by which age, genes, and other risk factors interact remain largely unknown. Somatic mutations accumulate with age and lead to clonal expansion of many cell...]]></summary>
        <author>
            <name>August Yue Huang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gemtuzumab Ozogamicin in Acute Myeloid Leukemia: Efficacy, Toxicity, and Resistance Mechanisms-A Systematic Review]]></title>
        <id>pubmed:38255313</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38255313/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240202194939&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) is a diverse group of leukemias characterized by the uncontrolled proliferation of clonal neoplastic hematopoietic precursor cells with chromosomal rearrangements and multiple gene mutations and the impairment of normal hematopoiesis. Current efforts to improve AML outcomes have focused on developing targeted therapies that may allow for improved antileukemic effects while reducing toxicity significantly. Gemtuzumab ozogamicin (GO) is one of the most thoroughly...]]></summary>
        <author>
            <name>Aurelia Collados-Ros</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[IDH1-Mutant Preleukemic Hematopoietic Stem Cells Can Be Eliminated by Inhibition of Oxidative Phosphorylation]]></title>
        <id>pubmed:38261864</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38261864/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240201195024&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Rare preleukemic hematopoietic stem cells (pHSC) harboring only the initiating mutations can be detected at the time of acute myeloid leukemia (AML) diagnosis. pHSCs are the origin of leukemia and a potential reservoir for relapse. Using primary human samples and gene editing to model isocitrate dehydrogenase 1 (IDH1) mutant pHSCs, we show epigenetic, transcriptional, and metabolic differences between pHSCs and healthy hematopoietic stem cells (HSC). We confirm that IDH1-driven clonal...]]></summary>
        <author>
            <name>Niklas Landberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Somatic cancer driver mutations are enriched and associated with inflammatory states in Alzheimer's disease microglia]]></title>
        <id>pubmed:38260600</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38260600/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240201195024&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Alzheimer's disease (AD) is an age-associated neurodegenerative disorder characterized by progressive neuronal loss and pathological accumulation of the misfolded proteins amyloid- and tau ^(1,2) . Neuroinflammation mediated by microglia and brain-resident macrophages plays a crucial role in AD pathogenesis ^(1-5) , though the mechanisms by which age, genes, and other risk factors interact remain largely unknown. Somatic mutations accumulate with age and lead to clonal expansion of many cell...]]></summary>
        <author>
            <name>August Yue Huang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gemtuzumab Ozogamicin in Acute Myeloid Leukemia: Efficacy, Toxicity, and Resistance Mechanisms-A Systematic Review]]></title>
        <id>pubmed:38255313</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38255313/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240201195024&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) is a diverse group of leukemias characterized by the uncontrolled proliferation of clonal neoplastic hematopoietic precursor cells with chromosomal rearrangements and multiple gene mutations and the impairment of normal hematopoiesis. Current efforts to improve AML outcomes have focused on developing targeted therapies that may allow for improved antileukemic effects while reducing toxicity significantly. Gemtuzumab ozogamicin (GO) is one of the most thoroughly...]]></summary>
        <author>
            <name>Aurelia Collados-Ros</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[IDH1-Mutant Preleukemic Hematopoietic Stem Cells Can Be Eliminated by Inhibition of Oxidative Phosphorylation]]></title>
        <id>pubmed:38261864</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38261864/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240131195240&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Rare preleukemic hematopoietic stem cells (pHSC) harboring only the initiating mutations can be detected at the time of acute myeloid leukemia (AML) diagnosis. pHSCs are the origin of leukemia and a potential reservoir for relapse. Using primary human samples and gene editing to model isocitrate dehydrogenase 1 (IDH1) mutant pHSCs, we show epigenetic, transcriptional, and metabolic differences between pHSCs and healthy hematopoietic stem cells (HSC). We confirm that IDH1-driven clonal...]]></summary>
        <author>
            <name>Niklas Landberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Somatic cancer driver mutations are enriched and associated with inflammatory states in Alzheimer's disease microglia]]></title>
        <id>pubmed:38260600</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38260600/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240131195240&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Alzheimer's disease (AD) is an age-associated neurodegenerative disorder characterized by progressive neuronal loss and pathological accumulation of the misfolded proteins amyloid- and tau ^(1,2) . Neuroinflammation mediated by microglia and brain-resident macrophages plays a crucial role in AD pathogenesis ^(1-5) , though the mechanisms by which age, genes, and other risk factors interact remain largely unknown. Somatic mutations accumulate with age and lead to clonal expansion of many cell...]]></summary>
        <author>
            <name>August Yue Huang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gemtuzumab Ozogamicin in Acute Myeloid Leukemia: Efficacy, Toxicity, and Resistance Mechanisms-A Systematic Review]]></title>
        <id>pubmed:38255313</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38255313/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240131195240&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) is a diverse group of leukemias characterized by the uncontrolled proliferation of clonal neoplastic hematopoietic precursor cells with chromosomal rearrangements and multiple gene mutations and the impairment of normal hematopoiesis. Current efforts to improve AML outcomes have focused on developing targeted therapies that may allow for improved antileukemic effects while reducing toxicity significantly. Gemtuzumab ozogamicin (GO) is one of the most thoroughly...]]></summary>
        <author>
            <name>Aurelia Collados-Ros</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[IDH1-Mutant Preleukemic Hematopoietic Stem Cells Can Be Eliminated by Inhibition of Oxidative Phosphorylation]]></title>
        <id>pubmed:38261864</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38261864/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240130195039&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Rare preleukemic hematopoietic stem cells (pHSC) harboring only the initiating mutations can be detected at the time of acute myeloid leukemia (AML) diagnosis. pHSCs are the origin of leukemia and a potential reservoir for relapse. Using primary human samples and gene editing to model isocitrate dehydrogenase 1 (IDH1) mutant pHSCs, we show epigenetic, transcriptional, and metabolic differences between pHSCs and healthy hematopoietic stem cells (HSC). We confirm that IDH1-driven clonal...]]></summary>
        <author>
            <name>Niklas Landberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Somatic cancer driver mutations are enriched and associated with inflammatory states in Alzheimer's disease microglia]]></title>
        <id>pubmed:38260600</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38260600/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240130195039&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Alzheimer's disease (AD) is an age-associated neurodegenerative disorder characterized by progressive neuronal loss and pathological accumulation of the misfolded proteins amyloid- and tau ^(1,2) . Neuroinflammation mediated by microglia and brain-resident macrophages plays a crucial role in AD pathogenesis ^(1-5) , though the mechanisms by which age, genes, and other risk factors interact remain largely unknown. Somatic mutations accumulate with age and lead to clonal expansion of many cell...]]></summary>
        <author>
            <name>August Yue Huang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gemtuzumab Ozogamicin in Acute Myeloid Leukemia: Efficacy, Toxicity, and Resistance Mechanisms-A Systematic Review]]></title>
        <id>pubmed:38255313</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38255313/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240130195039&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) is a diverse group of leukemias characterized by the uncontrolled proliferation of clonal neoplastic hematopoietic precursor cells with chromosomal rearrangements and multiple gene mutations and the impairment of normal hematopoiesis. Current efforts to improve AML outcomes have focused on developing targeted therapies that may allow for improved antileukemic effects while reducing toxicity significantly. Gemtuzumab ozogamicin (GO) is one of the most thoroughly...]]></summary>
        <author>
            <name>Aurelia Collados-Ros</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[IDH1-Mutant Preleukemic Hematopoietic Stem Cells Can Be Eliminated by Inhibition of Oxidative Phosphorylation]]></title>
        <id>pubmed:38261864</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38261864/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240129195013&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Rare preleukemic hematopoietic stem cells (pHSC) harboring only the initiating mutations can be detected at the time of acute myeloid leukemia (AML) diagnosis. pHSCs are the origin of leukemia and a potential reservoir for relapse. Using primary human samples and gene editing to model isocitrate dehydrogenase 1 (IDH1) mutant pHSCs, we show epigenetic, transcriptional, and metabolic differences between pHSCs and healthy hematopoietic stem cells (HSC). We confirm that IDH1-driven clonal...]]></summary>
        <author>
            <name>Niklas Landberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Somatic cancer driver mutations are enriched and associated with inflammatory states in Alzheimer's disease microglia]]></title>
        <id>pubmed:38260600</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38260600/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240129195013&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Alzheimer's disease (AD) is an age-associated neurodegenerative disorder characterized by progressive neuronal loss and pathological accumulation of the misfolded proteins amyloid- and tau ^(1,2) . Neuroinflammation mediated by microglia and brain-resident macrophages plays a crucial role in AD pathogenesis ^(1-5) , though the mechanisms by which age, genes, and other risk factors interact remain largely unknown. Somatic mutations accumulate with age and lead to clonal expansion of many cell...]]></summary>
        <author>
            <name>August Yue Huang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gemtuzumab Ozogamicin in Acute Myeloid Leukemia: Efficacy, Toxicity, and Resistance Mechanisms-A Systematic Review]]></title>
        <id>pubmed:38255313</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38255313/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240129195013&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) is a diverse group of leukemias characterized by the uncontrolled proliferation of clonal neoplastic hematopoietic precursor cells with chromosomal rearrangements and multiple gene mutations and the impairment of normal hematopoiesis. Current efforts to improve AML outcomes have focused on developing targeted therapies that may allow for improved antileukemic effects while reducing toxicity significantly. Gemtuzumab ozogamicin (GO) is one of the most thoroughly...]]></summary>
        <author>
            <name>Aurelia Collados-Ros</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[IDH1-Mutant Preleukemic Hematopoietic Stem Cells Can Be Eliminated by Inhibition of Oxidative Phosphorylation]]></title>
        <id>pubmed:38261864</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38261864/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240128195055&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Rare preleukemic hematopoietic stem cells (pHSC) harboring only the initiating mutations can be detected at the time of acute myeloid leukemia (AML) diagnosis. pHSCs are the origin of leukemia and a potential reservoir for relapse. Using primary human samples and gene editing to model isocitrate dehydrogenase 1 (IDH1) mutant pHSCs, we show epigenetic, transcriptional, and metabolic differences between pHSCs and healthy hematopoietic stem cells (HSC). We confirm that IDH1-driven clonal...]]></summary>
        <author>
            <name>Niklas Landberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Somatic cancer driver mutations are enriched and associated with inflammatory states in Alzheimer's disease microglia]]></title>
        <id>pubmed:38260600</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38260600/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240128195055&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Alzheimer's disease (AD) is an age-associated neurodegenerative disorder characterized by progressive neuronal loss and pathological accumulation of the misfolded proteins amyloid- and tau ^(1,2) . Neuroinflammation mediated by microglia and brain-resident macrophages plays a crucial role in AD pathogenesis ^(1-5) , though the mechanisms by which age, genes, and other risk factors interact remain largely unknown. Somatic mutations accumulate with age and lead to clonal expansion of many cell...]]></summary>
        <author>
            <name>August Yue Huang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gemtuzumab Ozogamicin in Acute Myeloid Leukemia: Efficacy, Toxicity, and Resistance Mechanisms-A Systematic Review]]></title>
        <id>pubmed:38255313</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38255313/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240128195055&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) is a diverse group of leukemias characterized by the uncontrolled proliferation of clonal neoplastic hematopoietic precursor cells with chromosomal rearrangements and multiple gene mutations and the impairment of normal hematopoiesis. Current efforts to improve AML outcomes have focused on developing targeted therapies that may allow for improved antileukemic effects while reducing toxicity significantly. Gemtuzumab ozogamicin (GO) is one of the most thoroughly...]]></summary>
        <author>
            <name>Aurelia Collados-Ros</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[IDH1-Mutant Preleukemic Hematopoietic Stem Cells Can Be Eliminated by Inhibition of Oxidative Phosphorylation]]></title>
        <id>pubmed:38261864</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38261864/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240127195322&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Rare preleukemic hematopoietic stem cells (pHSC) harboring only the initiating mutations can be detected at the time of acute myeloid leukemia (AML) diagnosis. pHSCs are the origin of leukemia and a potential reservoir for relapse. Using primary human samples and gene editing to model isocitrate dehydrogenase 1 (IDH1) mutant pHSCs, we show epigenetic, transcriptional, and metabolic differences between pHSCs and healthy hematopoietic stem cells (HSC). We confirm that IDH1-driven clonal...]]></summary>
        <author>
            <name>Niklas Landberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Somatic cancer driver mutations are enriched and associated with inflammatory states in Alzheimer's disease microglia]]></title>
        <id>pubmed:38260600</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38260600/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240127195322&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Alzheimer's disease (AD) is an age-associated neurodegenerative disorder characterized by progressive neuronal loss and pathological accumulation of the misfolded proteins amyloid- and tau ^(1,2) . Neuroinflammation mediated by microglia and brain-resident macrophages plays a crucial role in AD pathogenesis ^(1-5) , though the mechanisms by which age, genes, and other risk factors interact remain largely unknown. Somatic mutations accumulate with age and lead to clonal expansion of many cell...]]></summary>
        <author>
            <name>August Yue Huang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gemtuzumab Ozogamicin in Acute Myeloid Leukemia: Efficacy, Toxicity, and Resistance Mechanisms-A Systematic Review]]></title>
        <id>pubmed:38255313</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38255313/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240127195322&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) is a diverse group of leukemias characterized by the uncontrolled proliferation of clonal neoplastic hematopoietic precursor cells with chromosomal rearrangements and multiple gene mutations and the impairment of normal hematopoiesis. Current efforts to improve AML outcomes have focused on developing targeted therapies that may allow for improved antileukemic effects while reducing toxicity significantly. Gemtuzumab ozogamicin (GO) is one of the most thoroughly...]]></summary>
        <author>
            <name>Aurelia Collados-Ros</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[IDH1-Mutant Preleukemic Hematopoietic Stem Cells Can Be Eliminated by Inhibition of Oxidative Phosphorylation]]></title>
        <id>pubmed:38261864</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38261864/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240126194954&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Rare preleukemic hematopoietic stem cells (pHSC) harboring only the initiating mutations can be detected at the time of acute myeloid leukemia (AML) diagnosis. pHSCs are the origin of leukemia and a potential reservoir for relapse. Using primary human samples and gene editing to model isocitrate dehydrogenase 1 (IDH1) mutant pHSCs, we show epigenetic, transcriptional, and metabolic differences between pHSCs and healthy hematopoietic stem cells (HSC). We confirm that IDH1-driven clonal...]]></summary>
        <author>
            <name>Niklas Landberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Somatic cancer driver mutations are enriched and associated with inflammatory states in Alzheimer's disease microglia]]></title>
        <id>pubmed:38260600</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38260600/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240126194954&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Alzheimer's disease (AD) is an age-associated neurodegenerative disorder characterized by progressive neuronal loss and pathological accumulation of the misfolded proteins amyloid- and tau ^(1,2) . Neuroinflammation mediated by microglia and brain-resident macrophages plays a crucial role in AD pathogenesis ^(1-5) , though the mechanisms by which age, genes, and other risk factors interact remain largely unknown. Somatic mutations accumulate with age and lead to clonal expansion of many cell...]]></summary>
        <author>
            <name>August Yue Huang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gemtuzumab Ozogamicin in Acute Myeloid Leukemia: Efficacy, Toxicity, and Resistance Mechanisms-A Systematic Review]]></title>
        <id>pubmed:38255313</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38255313/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240126194954&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) is a diverse group of leukemias characterized by the uncontrolled proliferation of clonal neoplastic hematopoietic precursor cells with chromosomal rearrangements and multiple gene mutations and the impairment of normal hematopoiesis. Current efforts to improve AML outcomes have focused on developing targeted therapies that may allow for improved antileukemic effects while reducing toxicity significantly. Gemtuzumab ozogamicin (GO) is one of the most thoroughly...]]></summary>
        <author>
            <name>Aurelia Collados-Ros</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[IDH1-Mutant Preleukemic Hematopoietic Stem Cells Can Be Eliminated by Inhibition of Oxidative Phosphorylation]]></title>
        <id>pubmed:38261864</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38261864/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240125195050&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Rare preleukemic hematopoietic stem cells (pHSC) harboring only the initiating mutations can be detected at the time of acute myeloid leukemia (AML) diagnosis. pHSCs are the origin of leukemia and a potential reservoir for relapse. Using primary human samples and gene editing to model isocitrate dehydrogenase 1 (IDH1) mutant pHSCs, we show epigenetic, transcriptional, and metabolic differences between pHSCs and healthy hematopoietic stem cells (HSC). We confirm that IDH1-driven clonal...]]></summary>
        <author>
            <name>Niklas Landberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Somatic cancer driver mutations are enriched and associated with inflammatory states in Alzheimer's disease microglia]]></title>
        <id>pubmed:38260600</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38260600/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240125195050&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Alzheimer's disease (AD) is an age-associated neurodegenerative disorder characterized by progressive neuronal loss and pathological accumulation of the misfolded proteins amyloid- and tau ^(1,2) . Neuroinflammation mediated by microglia and brain-resident macrophages plays a crucial role in AD pathogenesis ^(1-5) , though the mechanisms by which age, genes, and other risk factors interact remain largely unknown. Somatic mutations accumulate with age and lead to clonal expansion of many cell...]]></summary>
        <author>
            <name>August Yue Huang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gemtuzumab Ozogamicin in Acute Myeloid Leukemia: Efficacy, Toxicity, and Resistance Mechanisms-A Systematic Review]]></title>
        <id>pubmed:38255313</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38255313/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240125195050&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) is a diverse group of leukemias characterized by the uncontrolled proliferation of clonal neoplastic hematopoietic precursor cells with chromosomal rearrangements and multiple gene mutations and the impairment of normal hematopoiesis. Current efforts to improve AML outcomes have focused on developing targeted therapies that may allow for improved antileukemic effects while reducing toxicity significantly. Gemtuzumab ozogamicin (GO) is one of the most thoroughly...]]></summary>
        <author>
            <name>Aurelia Collados-Ros</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[IDH1-Mutant Preleukemic Hematopoietic Stem Cells Can Be Eliminated by Inhibition of Oxidative Phosphorylation]]></title>
        <id>pubmed:38261864</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38261864/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240124195506&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Rare preleukemic hematopoietic stem cells (pHSC) harboring only the initiating mutations can be detected at the time of acute myeloid leukemia (AML) diagnosis. pHSCs are the origin of leukemia and a potential reservoir for relapse. Using primary human samples and gene editing to model isocitrate dehydrogenase 1 (IDH1) mutant pHSCs, we show epigenetic, transcriptional, and metabolic differences between pHSCs and healthy hematopoietic stem cells (HSC). We confirm that IDH1-driven clonal...]]></summary>
        <author>
            <name>Niklas Landberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Somatic cancer driver mutations are enriched and associated with inflammatory states in Alzheimer's disease microglia]]></title>
        <id>pubmed:38260600</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38260600/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240124195506&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Alzheimer's disease (AD) is an age-associated neurodegenerative disorder characterized by progressive neuronal loss and pathological accumulation of the misfolded proteins amyloid- and tau ^(1,2) . Neuroinflammation mediated by microglia and brain-resident macrophages plays a crucial role in AD pathogenesis ^(1-5) , though the mechanisms by which age, genes, and other risk factors interact remain largely unknown. Somatic mutations accumulate with age and lead to clonal expansion of many cell...]]></summary>
        <author>
            <name>August Yue Huang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gemtuzumab Ozogamicin in Acute Myeloid Leukemia: Efficacy, Toxicity, and Resistance Mechanisms-A Systematic Review]]></title>
        <id>pubmed:38255313</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38255313/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240124195506&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) is a diverse group of leukemias characterized by the uncontrolled proliferation of clonal neoplastic hematopoietic precursor cells with chromosomal rearrangements and multiple gene mutations and the impairment of normal hematopoiesis. Current efforts to improve AML outcomes have focused on developing targeted therapies that may allow for improved antileukemic effects while reducing toxicity significantly. Gemtuzumab ozogamicin (GO) is one of the most thoroughly...]]></summary>
        <author>
            <name>Aurelia Collados-Ros</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[IDH1-Mutant Preleukemic Hematopoietic Stem Cells Can Be Eliminated by Inhibition of Oxidative Phosphorylation]]></title>
        <id>pubmed:38261864</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38261864/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240123195503&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Rare preleukemic hematopoietic stem cells (pHSC) harboring only the initiating mutations can be detected at the time of acute myeloid leukemia (AML) diagnosis. pHSCs are the origin of leukemia and a potential reservoir for relapse. Using primary human samples and gene editing to model isocitrate dehydrogenase 1 (IDH1) mutant pHSCs, we show epigenetic, transcriptional, and metabolic differences between pHSCs and healthy hematopoietic stem cells (HSC). We confirm that IDH1-driven clonal...]]></summary>
        <author>
            <name>Niklas Landberg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Somatic cancer driver mutations are enriched and associated with inflammatory states in Alzheimer's disease microglia]]></title>
        <id>pubmed:38260600</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38260600/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240123195503&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Alzheimer's disease (AD) is an age-associated neurodegenerative disorder characterized by progressive neuronal loss and pathological accumulation of the misfolded proteins amyloid- and tau ^(1,2) . Neuroinflammation mediated by microglia and brain-resident macrophages plays a crucial role in AD pathogenesis ^(1-5) , though the mechanisms by which age, genes, and other risk factors interact remain largely unknown. Somatic mutations accumulate with age and lead to clonal expansion of many cell...]]></summary>
        <author>
            <name>August Yue Huang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Gemtuzumab Ozogamicin in Acute Myeloid Leukemia: Efficacy, Toxicity, and Resistance Mechanisms-A Systematic Review]]></title>
        <id>pubmed:38255313</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38255313/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240123195503&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) is a diverse group of leukemias characterized by the uncontrolled proliferation of clonal neoplastic hematopoietic precursor cells with chromosomal rearrangements and multiple gene mutations and the impairment of normal hematopoiesis. Current efforts to improve AML outcomes have focused on developing targeted therapies that may allow for improved antileukemic effects while reducing toxicity significantly. Gemtuzumab ozogamicin (GO) is one of the most thoroughly...]]></summary>
        <author>
            <name>Aurelia Collados-Ros</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A mass cytometry approach to track the evolution of T cell responses during infection and immunotherapy by paired T cell receptor repertoire and T cell differentiation state analysis]]></title>
        <id>pubmed:38260336</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38260336/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240209194815&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[T cell receptor (TCR) recognition followed by clonal expansion is a fundamental feature of adaptive immune responses. Here, we developed a mass cytometric (CyTOF) approach combining antibodies specific for different TCR V- and V-chains with antibodies against T cell activation and differentiation proteins to identify antigen-specific expansions of T cell subsets and assess aspects of cellular function. This strategy allowed for the identification of expansions of specific V and V chain...]]></summary>
        <author>
            <name>Jesse Garcia Castillo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell DNA Sequencing and Immunophenotypic Profiling to Track Clonal Evolution in an Acute Myeloid Leukemia Patient]]></title>
        <id>pubmed:38255173</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38255173/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240209194815&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell DNA sequencing can address the sequence of somatic genetic events during myeloid transformation in relapsed acute myeloid leukemia (AML). We present an NPM1-mutated AML patient with an initial low ratio of FLT3-ITD (low-risk ELN-2017), treated with midostaurin combined with standard chemotherapy as front-line treatment, and with salvage therapy plus gilteritinib following allogenic stem cell transplantation after relapse. Simultaneous single-cell DNA sequencing and cell-surface...]]></summary>
        <author>
            <name>Mara Garca-lvarez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A mass cytometry approach to track the evolution of T cell responses during infection and immunotherapy by paired T cell receptor repertoire and T cell differentiation state analysis]]></title>
        <id>pubmed:38260336</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38260336/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240208194923&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[T cell receptor (TCR) recognition followed by clonal expansion is a fundamental feature of adaptive immune responses. Here, we developed a mass cytometric (CyTOF) approach combining antibodies specific for different TCR V- and V-chains with antibodies against T cell activation and differentiation proteins to identify antigen-specific expansions of T cell subsets and assess aspects of cellular function. This strategy allowed for the identification of expansions of specific V and V chain...]]></summary>
        <author>
            <name>Jesse Garcia Castillo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell DNA Sequencing and Immunophenotypic Profiling to Track Clonal Evolution in an Acute Myeloid Leukemia Patient]]></title>
        <id>pubmed:38255173</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38255173/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240208194923&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell DNA sequencing can address the sequence of somatic genetic events during myeloid transformation in relapsed acute myeloid leukemia (AML). We present an NPM1-mutated AML patient with an initial low ratio of FLT3-ITD (low-risk ELN-2017), treated with midostaurin combined with standard chemotherapy as front-line treatment, and with salvage therapy plus gilteritinib following allogenic stem cell transplantation after relapse. Simultaneous single-cell DNA sequencing and cell-surface...]]></summary>
        <author>
            <name>Mara Garca-lvarez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A mass cytometry approach to track the evolution of T cell responses during infection and immunotherapy by paired T cell receptor repertoire and T cell differentiation state analysis]]></title>
        <id>pubmed:38260336</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38260336/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240207194932&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[T cell receptor (TCR) recognition followed by clonal expansion is a fundamental feature of adaptive immune responses. Here, we developed a mass cytometric (CyTOF) approach combining antibodies specific for different TCR V- and V-chains with antibodies against T cell activation and differentiation proteins to identify antigen-specific expansions of T cell subsets and assess aspects of cellular function. This strategy allowed for the identification of expansions of specific V and V chain...]]></summary>
        <author>
            <name>Jesse Garcia Castillo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell DNA Sequencing and Immunophenotypic Profiling to Track Clonal Evolution in an Acute Myeloid Leukemia Patient]]></title>
        <id>pubmed:38255173</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38255173/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240207194932&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell DNA sequencing can address the sequence of somatic genetic events during myeloid transformation in relapsed acute myeloid leukemia (AML). We present an NPM1-mutated AML patient with an initial low ratio of FLT3-ITD (low-risk ELN-2017), treated with midostaurin combined with standard chemotherapy as front-line treatment, and with salvage therapy plus gilteritinib following allogenic stem cell transplantation after relapse. Simultaneous single-cell DNA sequencing and cell-surface...]]></summary>
        <author>
            <name>Mara Garca-lvarez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A mass cytometry approach to track the evolution of T cell responses during infection and immunotherapy by paired T cell receptor repertoire and T cell differentiation state analysis]]></title>
        <id>pubmed:38260336</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38260336/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240206194820&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[T cell receptor (TCR) recognition followed by clonal expansion is a fundamental feature of adaptive immune responses. Here, we developed a mass cytometric (CyTOF) approach combining antibodies specific for different TCR V- and V-chains with antibodies against T cell activation and differentiation proteins to identify antigen-specific expansions of T cell subsets and assess aspects of cellular function. This strategy allowed for the identification of expansions of specific V and V chain...]]></summary>
        <author>
            <name>Jesse Garcia Castillo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell DNA Sequencing and Immunophenotypic Profiling to Track Clonal Evolution in an Acute Myeloid Leukemia Patient]]></title>
        <id>pubmed:38255173</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38255173/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240206194820&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell DNA sequencing can address the sequence of somatic genetic events during myeloid transformation in relapsed acute myeloid leukemia (AML). We present an NPM1-mutated AML patient with an initial low ratio of FLT3-ITD (low-risk ELN-2017), treated with midostaurin combined with standard chemotherapy as front-line treatment, and with salvage therapy plus gilteritinib following allogenic stem cell transplantation after relapse. Simultaneous single-cell DNA sequencing and cell-surface...]]></summary>
        <author>
            <name>Mara Garca-lvarez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A mass cytometry approach to track the evolution of T cell responses during infection and immunotherapy by paired T cell receptor repertoire and T cell differentiation state analysis]]></title>
        <id>pubmed:38260336</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38260336/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240205194943&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[T cell receptor (TCR) recognition followed by clonal expansion is a fundamental feature of adaptive immune responses. Here, we developed a mass cytometric (CyTOF) approach combining antibodies specific for different TCR V- and V-chains with antibodies against T cell activation and differentiation proteins to identify antigen-specific expansions of T cell subsets and assess aspects of cellular function. This strategy allowed for the identification of expansions of specific V and V chain...]]></summary>
        <author>
            <name>Jesse Garcia Castillo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell DNA Sequencing and Immunophenotypic Profiling to Track Clonal Evolution in an Acute Myeloid Leukemia Patient]]></title>
        <id>pubmed:38255173</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38255173/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240205194943&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell DNA sequencing can address the sequence of somatic genetic events during myeloid transformation in relapsed acute myeloid leukemia (AML). We present an NPM1-mutated AML patient with an initial low ratio of FLT3-ITD (low-risk ELN-2017), treated with midostaurin combined with standard chemotherapy as front-line treatment, and with salvage therapy plus gilteritinib following allogenic stem cell transplantation after relapse. Simultaneous single-cell DNA sequencing and cell-surface...]]></summary>
        <author>
            <name>Mara Garca-lvarez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A mass cytometry approach to track the evolution of T cell responses during infection and immunotherapy by paired T cell receptor repertoire and T cell differentiation state analysis]]></title>
        <id>pubmed:38260336</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38260336/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240204195148&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[T cell receptor (TCR) recognition followed by clonal expansion is a fundamental feature of adaptive immune responses. Here, we developed a mass cytometric (CyTOF) approach combining antibodies specific for different TCR V- and V-chains with antibodies against T cell activation and differentiation proteins to identify antigen-specific expansions of T cell subsets and assess aspects of cellular function. This strategy allowed for the identification of expansions of specific V and V chain...]]></summary>
        <author>
            <name>Jesse Garcia Castillo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell DNA Sequencing and Immunophenotypic Profiling to Track Clonal Evolution in an Acute Myeloid Leukemia Patient]]></title>
        <id>pubmed:38255173</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38255173/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240204195148&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell DNA sequencing can address the sequence of somatic genetic events during myeloid transformation in relapsed acute myeloid leukemia (AML). We present an NPM1-mutated AML patient with an initial low ratio of FLT3-ITD (low-risk ELN-2017), treated with midostaurin combined with standard chemotherapy as front-line treatment, and with salvage therapy plus gilteritinib following allogenic stem cell transplantation after relapse. Simultaneous single-cell DNA sequencing and cell-surface...]]></summary>
        <author>
            <name>Mara Garca-lvarez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A mass cytometry approach to track the evolution of T cell responses during infection and immunotherapy by paired T cell receptor repertoire and T cell differentiation state analysis]]></title>
        <id>pubmed:38260336</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38260336/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240203195418&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[T cell receptor (TCR) recognition followed by clonal expansion is a fundamental feature of adaptive immune responses. Here, we developed a mass cytometric (CyTOF) approach combining antibodies specific for different TCR V- and V-chains with antibodies against T cell activation and differentiation proteins to identify antigen-specific expansions of T cell subsets and assess aspects of cellular function. This strategy allowed for the identification of expansions of specific V and V chain...]]></summary>
        <author>
            <name>Jesse Garcia Castillo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell DNA Sequencing and Immunophenotypic Profiling to Track Clonal Evolution in an Acute Myeloid Leukemia Patient]]></title>
        <id>pubmed:38255173</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38255173/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240203195418&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell DNA sequencing can address the sequence of somatic genetic events during myeloid transformation in relapsed acute myeloid leukemia (AML). We present an NPM1-mutated AML patient with an initial low ratio of FLT3-ITD (low-risk ELN-2017), treated with midostaurin combined with standard chemotherapy as front-line treatment, and with salvage therapy plus gilteritinib following allogenic stem cell transplantation after relapse. Simultaneous single-cell DNA sequencing and cell-surface...]]></summary>
        <author>
            <name>Mara Garca-lvarez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A mass cytometry approach to track the evolution of T cell responses during infection and immunotherapy by paired T cell receptor repertoire and T cell differentiation state analysis]]></title>
        <id>pubmed:38260336</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38260336/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240202194939&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[T cell receptor (TCR) recognition followed by clonal expansion is a fundamental feature of adaptive immune responses. Here, we developed a mass cytometric (CyTOF) approach combining antibodies specific for different TCR V- and V-chains with antibodies against T cell activation and differentiation proteins to identify antigen-specific expansions of T cell subsets and assess aspects of cellular function. This strategy allowed for the identification of expansions of specific V and V chain...]]></summary>
        <author>
            <name>Jesse Garcia Castillo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell DNA Sequencing and Immunophenotypic Profiling to Track Clonal Evolution in an Acute Myeloid Leukemia Patient]]></title>
        <id>pubmed:38255173</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38255173/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240202194939&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell DNA sequencing can address the sequence of somatic genetic events during myeloid transformation in relapsed acute myeloid leukemia (AML). We present an NPM1-mutated AML patient with an initial low ratio of FLT3-ITD (low-risk ELN-2017), treated with midostaurin combined with standard chemotherapy as front-line treatment, and with salvage therapy plus gilteritinib following allogenic stem cell transplantation after relapse. Simultaneous single-cell DNA sequencing and cell-surface...]]></summary>
        <author>
            <name>Mara Garca-lvarez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A mass cytometry approach to track the evolution of T cell responses during infection and immunotherapy by paired T cell receptor repertoire and T cell differentiation state analysis]]></title>
        <id>pubmed:38260336</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38260336/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240201195024&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[T cell receptor (TCR) recognition followed by clonal expansion is a fundamental feature of adaptive immune responses. Here, we developed a mass cytometric (CyTOF) approach combining antibodies specific for different TCR V- and V-chains with antibodies against T cell activation and differentiation proteins to identify antigen-specific expansions of T cell subsets and assess aspects of cellular function. This strategy allowed for the identification of expansions of specific V and V chain...]]></summary>
        <author>
            <name>Jesse Garcia Castillo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell DNA Sequencing and Immunophenotypic Profiling to Track Clonal Evolution in an Acute Myeloid Leukemia Patient]]></title>
        <id>pubmed:38255173</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38255173/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240201195024&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell DNA sequencing can address the sequence of somatic genetic events during myeloid transformation in relapsed acute myeloid leukemia (AML). We present an NPM1-mutated AML patient with an initial low ratio of FLT3-ITD (low-risk ELN-2017), treated with midostaurin combined with standard chemotherapy as front-line treatment, and with salvage therapy plus gilteritinib following allogenic stem cell transplantation after relapse. Simultaneous single-cell DNA sequencing and cell-surface...]]></summary>
        <author>
            <name>Mara Garca-lvarez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A mass cytometry approach to track the evolution of T cell responses during infection and immunotherapy by paired T cell receptor repertoire and T cell differentiation state analysis]]></title>
        <id>pubmed:38260336</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38260336/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240131195240&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[T cell receptor (TCR) recognition followed by clonal expansion is a fundamental feature of adaptive immune responses. Here, we developed a mass cytometric (CyTOF) approach combining antibodies specific for different TCR V- and V-chains with antibodies against T cell activation and differentiation proteins to identify antigen-specific expansions of T cell subsets and assess aspects of cellular function. This strategy allowed for the identification of expansions of specific V and V chain...]]></summary>
        <author>
            <name>Jesse Garcia Castillo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell DNA Sequencing and Immunophenotypic Profiling to Track Clonal Evolution in an Acute Myeloid Leukemia Patient]]></title>
        <id>pubmed:38255173</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38255173/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240131195240&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell DNA sequencing can address the sequence of somatic genetic events during myeloid transformation in relapsed acute myeloid leukemia (AML). We present an NPM1-mutated AML patient with an initial low ratio of FLT3-ITD (low-risk ELN-2017), treated with midostaurin combined with standard chemotherapy as front-line treatment, and with salvage therapy plus gilteritinib following allogenic stem cell transplantation after relapse. Simultaneous single-cell DNA sequencing and cell-surface...]]></summary>
        <author>
            <name>Mara Garca-lvarez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A mass cytometry approach to track the evolution of T cell responses during infection and immunotherapy by paired T cell receptor repertoire and T cell differentiation state analysis]]></title>
        <id>pubmed:38260336</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38260336/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240130195039&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[T cell receptor (TCR) recognition followed by clonal expansion is a fundamental feature of adaptive immune responses. Here, we developed a mass cytometric (CyTOF) approach combining antibodies specific for different TCR V- and V-chains with antibodies against T cell activation and differentiation proteins to identify antigen-specific expansions of T cell subsets and assess aspects of cellular function. This strategy allowed for the identification of expansions of specific V and V chain...]]></summary>
        <author>
            <name>Jesse Garcia Castillo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell DNA Sequencing and Immunophenotypic Profiling to Track Clonal Evolution in an Acute Myeloid Leukemia Patient]]></title>
        <id>pubmed:38255173</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38255173/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240130195039&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell DNA sequencing can address the sequence of somatic genetic events during myeloid transformation in relapsed acute myeloid leukemia (AML). We present an NPM1-mutated AML patient with an initial low ratio of FLT3-ITD (low-risk ELN-2017), treated with midostaurin combined with standard chemotherapy as front-line treatment, and with salvage therapy plus gilteritinib following allogenic stem cell transplantation after relapse. Simultaneous single-cell DNA sequencing and cell-surface...]]></summary>
        <author>
            <name>Mara Garca-lvarez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A mass cytometry approach to track the evolution of T cell responses during infection and immunotherapy by paired T cell receptor repertoire and T cell differentiation state analysis]]></title>
        <id>pubmed:38260336</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38260336/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240129195013&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[T cell receptor (TCR) recognition followed by clonal expansion is a fundamental feature of adaptive immune responses. Here, we developed a mass cytometric (CyTOF) approach combining antibodies specific for different TCR V- and V-chains with antibodies against T cell activation and differentiation proteins to identify antigen-specific expansions of T cell subsets and assess aspects of cellular function. This strategy allowed for the identification of expansions of specific V and V chain...]]></summary>
        <author>
            <name>Jesse Garcia Castillo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell DNA Sequencing and Immunophenotypic Profiling to Track Clonal Evolution in an Acute Myeloid Leukemia Patient]]></title>
        <id>pubmed:38255173</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38255173/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240129195013&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell DNA sequencing can address the sequence of somatic genetic events during myeloid transformation in relapsed acute myeloid leukemia (AML). We present an NPM1-mutated AML patient with an initial low ratio of FLT3-ITD (low-risk ELN-2017), treated with midostaurin combined with standard chemotherapy as front-line treatment, and with salvage therapy plus gilteritinib following allogenic stem cell transplantation after relapse. Simultaneous single-cell DNA sequencing and cell-surface...]]></summary>
        <author>
            <name>Mara Garca-lvarez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell DNA Sequencing and Immunophenotypic Profiling to Track Clonal Evolution in an Acute Myeloid Leukemia Patient]]></title>
        <id>pubmed:38255173</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38255173/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240128195055&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell DNA sequencing can address the sequence of somatic genetic events during myeloid transformation in relapsed acute myeloid leukemia (AML). We present an NPM1-mutated AML patient with an initial low ratio of FLT3-ITD (low-risk ELN-2017), treated with midostaurin combined with standard chemotherapy as front-line treatment, and with salvage therapy plus gilteritinib following allogenic stem cell transplantation after relapse. Simultaneous single-cell DNA sequencing and cell-surface...]]></summary>
        <author>
            <name>Mara Garca-lvarez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell DNA Sequencing and Immunophenotypic Profiling to Track Clonal Evolution in an Acute Myeloid Leukemia Patient]]></title>
        <id>pubmed:38255173</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38255173/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240127195322&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell DNA sequencing can address the sequence of somatic genetic events during myeloid transformation in relapsed acute myeloid leukemia (AML). We present an NPM1-mutated AML patient with an initial low ratio of FLT3-ITD (low-risk ELN-2017), treated with midostaurin combined with standard chemotherapy as front-line treatment, and with salvage therapy plus gilteritinib following allogenic stem cell transplantation after relapse. Simultaneous single-cell DNA sequencing and cell-surface...]]></summary>
        <author>
            <name>Mara Garca-lvarez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell DNA Sequencing and Immunophenotypic Profiling to Track Clonal Evolution in an Acute Myeloid Leukemia Patient]]></title>
        <id>pubmed:38255173</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38255173/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240126194954&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell DNA sequencing can address the sequence of somatic genetic events during myeloid transformation in relapsed acute myeloid leukemia (AML). We present an NPM1-mutated AML patient with an initial low ratio of FLT3-ITD (low-risk ELN-2017), treated with midostaurin combined with standard chemotherapy as front-line treatment, and with salvage therapy plus gilteritinib following allogenic stem cell transplantation after relapse. Simultaneous single-cell DNA sequencing and cell-surface...]]></summary>
        <author>
            <name>Mara Garca-lvarez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell DNA Sequencing and Immunophenotypic Profiling to Track Clonal Evolution in an Acute Myeloid Leukemia Patient]]></title>
        <id>pubmed:38255173</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38255173/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240125195050&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell DNA sequencing can address the sequence of somatic genetic events during myeloid transformation in relapsed acute myeloid leukemia (AML). We present an NPM1-mutated AML patient with an initial low ratio of FLT3-ITD (low-risk ELN-2017), treated with midostaurin combined with standard chemotherapy as front-line treatment, and with salvage therapy plus gilteritinib following allogenic stem cell transplantation after relapse. Simultaneous single-cell DNA sequencing and cell-surface...]]></summary>
        <author>
            <name>Mara Garca-lvarez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell DNA Sequencing and Immunophenotypic Profiling to Track Clonal Evolution in an Acute Myeloid Leukemia Patient]]></title>
        <id>pubmed:38255173</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38255173/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240124195506&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell DNA sequencing can address the sequence of somatic genetic events during myeloid transformation in relapsed acute myeloid leukemia (AML). We present an NPM1-mutated AML patient with an initial low ratio of FLT3-ITD (low-risk ELN-2017), treated with midostaurin combined with standard chemotherapy as front-line treatment, and with salvage therapy plus gilteritinib following allogenic stem cell transplantation after relapse. Simultaneous single-cell DNA sequencing and cell-surface...]]></summary>
        <author>
            <name>Mara Garca-lvarez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell DNA Sequencing and Immunophenotypic Profiling to Track Clonal Evolution in an Acute Myeloid Leukemia Patient]]></title>
        <id>pubmed:38255173</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38255173/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240123195503&amp;v=2.18.0"/>
        <updated>2024-01-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell DNA sequencing can address the sequence of somatic genetic events during myeloid transformation in relapsed acute myeloid leukemia (AML). We present an NPM1-mutated AML patient with an initial low ratio of FLT3-ITD (low-risk ELN-2017), treated with midostaurin combined with standard chemotherapy as front-line treatment, and with salvage therapy plus gilteritinib following allogenic stem cell transplantation after relapse. Simultaneous single-cell DNA sequencing and cell-surface...]]></summary>
        <author>
            <name>Mara Garca-lvarez</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deciphering cell states and genealogies of human hematopoiesis]]></title>
        <id>pubmed:38253266</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38253266/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240207194932&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The human blood system is maintained through the differentiation and massive amplification of a limited number of long-lived hematopoietic stem cells (HSCs). Perturbations to this process underlie diverse diseases, but the clonal contributions to human hematopoiesis and how this changes with age remain incompletely understood. While recent insights have emerged from barcoding studies in model systems^(4,5,16,17), simultaneous detection of cell states and phylogenies from natural barcodes in...]]></summary>
        <author>
            <name>Chen Weng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deciphering cell states and genealogies of human hematopoiesis]]></title>
        <id>pubmed:38253266</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38253266/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240206194820&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The human blood system is maintained through the differentiation and massive amplification of a limited number of long-lived hematopoietic stem cells (HSCs). Perturbations to this process underlie diverse diseases, but the clonal contributions to human hematopoiesis and how this changes with age remain incompletely understood. While recent insights have emerged from barcoding studies in model systems^(4,5,16,17), simultaneous detection of cell states and phylogenies from natural barcodes in...]]></summary>
        <author>
            <name>Chen Weng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deciphering cell states and genealogies of human hematopoiesis]]></title>
        <id>pubmed:38253266</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38253266/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240205194943&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The human blood system is maintained through the differentiation and massive amplification of a limited number of long-lived hematopoietic stem cells (HSCs). Perturbations to this process underlie diverse diseases, but the clonal contributions to human hematopoiesis and how this changes with age remain incompletely understood. While recent insights have emerged from barcoding studies in model systems^(4,5,16,17), simultaneous detection of cell states and phylogenies from natural barcodes in...]]></summary>
        <author>
            <name>Chen Weng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deciphering cell states and genealogies of human hematopoiesis]]></title>
        <id>pubmed:38253266</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38253266/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240204195148&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The human blood system is maintained through the differentiation and massive amplification of a limited number of long-lived hematopoietic stem cells (HSCs). Perturbations to this process underlie diverse diseases, but the clonal contributions to human hematopoiesis and how this changes with age remain incompletely understood. While recent insights have emerged from barcoding studies in model systems^(4,5,16,17), simultaneous detection of cell states and phylogenies from natural barcodes in...]]></summary>
        <author>
            <name>Chen Weng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deciphering cell states and genealogies of human hematopoiesis]]></title>
        <id>pubmed:38253266</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38253266/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240203195418&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The human blood system is maintained through the differentiation and massive amplification of a limited number of long-lived hematopoietic stem cells (HSCs). Perturbations to this process underlie diverse diseases, but the clonal contributions to human hematopoiesis and how this changes with age remain incompletely understood. While recent insights have emerged from barcoding studies in model systems^(4,5,16,17), simultaneous detection of cell states and phylogenies from natural barcodes in...]]></summary>
        <author>
            <name>Chen Weng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deciphering cell states and genealogies of human hematopoiesis]]></title>
        <id>pubmed:38253266</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38253266/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240202194939&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The human blood system is maintained through the differentiation and massive amplification of a limited number of long-lived hematopoietic stem cells (HSCs). Perturbations to this process underlie diverse diseases, but the clonal contributions to human hematopoiesis and how this changes with age remain incompletely understood. While recent insights have emerged from barcoding studies in model systems^(4,5,16,17), simultaneous detection of cell states and phylogenies from natural barcodes in...]]></summary>
        <author>
            <name>Chen Weng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deciphering cell states and genealogies of human hematopoiesis]]></title>
        <id>pubmed:38253266</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38253266/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240201195024&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The human blood system is maintained through the differentiation and massive amplification of a limited number of long-lived hematopoietic stem cells (HSCs). Perturbations to this process underlie diverse diseases, but the clonal contributions to human hematopoiesis and how this changes with age remain incompletely understood. While recent insights have emerged from barcoding studies in model systems^(4,5,16,17), simultaneous detection of cell states and phylogenies from natural barcodes in...]]></summary>
        <author>
            <name>Chen Weng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deciphering cell states and genealogies of human hematopoiesis]]></title>
        <id>pubmed:38253266</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38253266/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240131195240&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The human blood system is maintained through the differentiation and massive amplification of a limited number of long-lived hematopoietic stem cells (HSCs). Perturbations to this process underlie diverse diseases, but the clonal contributions to human hematopoiesis and how this changes with age remain incompletely understood. While recent insights have emerged from barcoding studies in model systems^(4,5,16,17), simultaneous detection of cell states and phylogenies from natural barcodes in...]]></summary>
        <author>
            <name>Chen Weng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deciphering cell states and genealogies of human hematopoiesis]]></title>
        <id>pubmed:38253266</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38253266/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240130195039&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The human blood system is maintained through the differentiation and massive amplification of a limited number of long-lived hematopoietic stem cells (HSCs). Perturbations to this process underlie diverse diseases, but the clonal contributions to human hematopoiesis and how this changes with age remain incompletely understood. While recent insights have emerged from barcoding studies in model systems^(4,5,16,17), simultaneous detection of cell states and phylogenies from natural barcodes in...]]></summary>
        <author>
            <name>Chen Weng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deciphering cell states and genealogies of human hematopoiesis]]></title>
        <id>pubmed:38253266</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38253266/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240129195013&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The human blood system is maintained through the differentiation and massive amplification of a limited number of long-lived hematopoietic stem cells (HSCs). Perturbations to this process underlie diverse diseases, but the clonal contributions to human hematopoiesis and how this changes with age remain incompletely understood. While recent insights have emerged from barcoding studies in model systems^(4,5,16,17), simultaneous detection of cell states and phylogenies from natural barcodes in...]]></summary>
        <author>
            <name>Chen Weng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deciphering cell states and genealogies of human hematopoiesis]]></title>
        <id>pubmed:38253266</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38253266/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240128195055&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The human blood system is maintained through the differentiation and massive amplification of a limited number of long-lived hematopoietic stem cells (HSCs). Perturbations to this process underlie diverse diseases, but the clonal contributions to human hematopoiesis and how this changes with age remain incompletely understood. While recent insights have emerged from barcoding studies in model systems^(4,5,16,17), simultaneous detection of cell states and phylogenies from natural barcodes in...]]></summary>
        <author>
            <name>Chen Weng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deciphering cell states and genealogies of human hematopoiesis]]></title>
        <id>pubmed:38253266</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38253266/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240127195322&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The human blood system is maintained through the differentiation and massive amplification of a limited number of long-lived hematopoietic stem cells (HSCs). Perturbations to this process underlie diverse diseases, but the clonal contributions to human hematopoiesis and how this changes with age remain incompletely understood. While recent insights have emerged from barcoding studies in model systems^(4,5,16,17), simultaneous detection of cell states and phylogenies from natural barcodes in...]]></summary>
        <author>
            <name>Chen Weng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deciphering cell states and genealogies of human hematopoiesis]]></title>
        <id>pubmed:38253266</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38253266/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240126194954&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The human blood system is maintained through the differentiation and massive amplification of a limited number of long-lived hematopoietic stem cells (HSCs). Perturbations to this process underlie diverse diseases, but the clonal contributions to human hematopoiesis and how this changes with age remain incompletely understood. While recent insights have emerged from barcoding studies in model systems^(4,5,16,17), simultaneous detection of cell states and phylogenies from natural barcodes in...]]></summary>
        <author>
            <name>Chen Weng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deciphering cell states and genealogies of human hematopoiesis]]></title>
        <id>pubmed:38253266</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38253266/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240125195050&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The human blood system is maintained through the differentiation and massive amplification of a limited number of long-lived hematopoietic stem cells (HSCs). Perturbations to this process underlie diverse diseases, but the clonal contributions to human hematopoiesis and how this changes with age remain incompletely understood. While recent insights have emerged from barcoding studies in model systems^(4,5,16,17), simultaneous detection of cell states and phylogenies from natural barcodes in...]]></summary>
        <author>
            <name>Chen Weng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deciphering cell states and genealogies of human hematopoiesis]]></title>
        <id>pubmed:38253266</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38253266/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240124195506&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The human blood system is maintained through the differentiation and massive amplification of a limited number of long-lived hematopoietic stem cells (HSCs). Perturbations to this process underlie diverse diseases, but the clonal contributions to human hematopoiesis and how this changes with age remain incompletely understood. While recent insights have emerged from barcoding studies in model systems^(4,5,16,17), simultaneous detection of cell states and phylogenies from natural barcodes in...]]></summary>
        <author>
            <name>Chen Weng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deciphering cell states and genealogies of human hematopoiesis]]></title>
        <id>pubmed:38253266</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38253266/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240123195503&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The human blood system is maintained through the differentiation and massive amplification of a limited number of long-lived hematopoietic stem cells (HSCs). Perturbations to this process underlie diverse diseases, but the clonal contributions to human hematopoiesis and how this changes with age remain incompletely understood. While recent insights have emerged from barcoding studies in model systems^(4,5,16,17), simultaneous detection of cell states and phylogenies from natural barcodes in...]]></summary>
        <author>
            <name>Chen Weng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Divergent immune microenvironments in two tumor nodules from a patient with mismatch repair-deficient prostate cancer]]></title>
        <id>pubmed:38253539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38253539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240209194815&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients with prostate cancer (PC) generally do not respond favorably to immune checkpoint inhibitors, which may be due to a low abundance of tumor-infiltrating lymphocytes even when mutational load is high. Here, we identified a patient who presented with high-grade primary prostate cancer with two adjacent tumor nodules. While both nodules were mismatch repair-deficient (MMRd), exhibited pathogenic MSH2 and MSH6 alterations, had a high tumor mutational burden (TMB), and demonstrated high...]]></summary>
        <author>
            <name>Hannah E Bergom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Divergent immune microenvironments in two tumor nodules from a patient with mismatch repair-deficient prostate cancer]]></title>
        <id>pubmed:38253539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38253539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240208194923&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients with prostate cancer (PC) generally do not respond favorably to immune checkpoint inhibitors, which may be due to a low abundance of tumor-infiltrating lymphocytes even when mutational load is high. Here, we identified a patient who presented with high-grade primary prostate cancer with two adjacent tumor nodules. While both nodules were mismatch repair-deficient (MMRd), exhibited pathogenic MSH2 and MSH6 alterations, had a high tumor mutational burden (TMB), and demonstrated high...]]></summary>
        <author>
            <name>Hannah E Bergom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical utility of plasma cell-free DNA in pancreatic neuroendocrine neoplasms]]></title>
        <id>pubmed:38252063</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38252063/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240208194923&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[In advanced pancreatic neuroendocrine neoplasms (PanNEN), there is little data detailing the frequency of genetic alterations identified in cell free DNA (cfDNA), plasma-tissue concordance of detected alterations, and clinical utility of cfDNA. Patients with metastatic PanNENs underwent cfDNA collection in routine practice. Next-generation sequencing (NGS) of cfDNA and matched tissue when available was performed. Clinical actionability of variants was annotated by OncoKB. Thirty-two cfDNA...]]></summary>
        <author>
            <name>Darren Cowzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Divergent immune microenvironments in two tumor nodules from a patient with mismatch repair-deficient prostate cancer]]></title>
        <id>pubmed:38253539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38253539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240207194932&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients with prostate cancer (PC) generally do not respond favorably to immune checkpoint inhibitors, which may be due to a low abundance of tumor-infiltrating lymphocytes even when mutational load is high. Here, we identified a patient who presented with high-grade primary prostate cancer with two adjacent tumor nodules. While both nodules were mismatch repair-deficient (MMRd), exhibited pathogenic MSH2 and MSH6 alterations, had a high tumor mutational burden (TMB), and demonstrated high...]]></summary>
        <author>
            <name>Hannah E Bergom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical utility of plasma cell-free DNA in pancreatic neuroendocrine neoplasms]]></title>
        <id>pubmed:38252063</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38252063/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240207194932&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[In advanced pancreatic neuroendocrine neoplasms (PanNEN), there is little data detailing the frequency of genetic alterations identified in cell free DNA (cfDNA), plasma-tissue concordance of detected alterations, and clinical utility of cfDNA. Patients with metastatic PanNENs underwent cfDNA collection in routine practice. Next-generation sequencing (NGS) of cfDNA and matched tissue when available was performed. Clinical actionability of variants was annotated by OncoKB. Thirty-two cfDNA...]]></summary>
        <author>
            <name>Darren Cowzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal genetically detectable minimal residual disease by fluorescence <em>in situ</em> hybridization confers a poor prognosis in myeloma]]></title>
        <id>pubmed:38249329</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38249329/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240207194932&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: These findings highlighted the prognostic value of genetic testing in residual tumor cells, which may provide a deep understanding of clonal evolution and guide clinical therapeutic strategies.]]></summary>
        <author>
            <name>Jian Cui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Divergent immune microenvironments in two tumor nodules from a patient with mismatch repair-deficient prostate cancer]]></title>
        <id>pubmed:38253539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38253539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240206194820&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients with prostate cancer (PC) generally do not respond favorably to immune checkpoint inhibitors, which may be due to a low abundance of tumor-infiltrating lymphocytes even when mutational load is high. Here, we identified a patient who presented with high-grade primary prostate cancer with two adjacent tumor nodules. While both nodules were mismatch repair-deficient (MMRd), exhibited pathogenic MSH2 and MSH6 alterations, had a high tumor mutational burden (TMB), and demonstrated high...]]></summary>
        <author>
            <name>Hannah E Bergom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical utility of plasma cell-free DNA in pancreatic neuroendocrine neoplasms]]></title>
        <id>pubmed:38252063</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38252063/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240206194820&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[In advanced pancreatic neuroendocrine neoplasms (PanNEN), there is little data detailing the frequency of genetic alterations identified in cell free DNA (cfDNA), plasma-tissue concordance of detected alterations, and clinical utility of cfDNA. Patients with metastatic PanNENs underwent cfDNA collection in routine practice. Next-generation sequencing (NGS) of cfDNA and matched tissue when available was performed. Clinical actionability of variants was annotated by OncoKB. Thirty-two cfDNA...]]></summary>
        <author>
            <name>Darren Cowzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal genetically detectable minimal residual disease by fluorescence <em>in situ</em> hybridization confers a poor prognosis in myeloma]]></title>
        <id>pubmed:38249329</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38249329/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240206194820&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: These findings highlighted the prognostic value of genetic testing in residual tumor cells, which may provide a deep understanding of clonal evolution and guide clinical therapeutic strategies.]]></summary>
        <author>
            <name>Jian Cui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Divergent immune microenvironments in two tumor nodules from a patient with mismatch repair-deficient prostate cancer]]></title>
        <id>pubmed:38253539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38253539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240205194943&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients with prostate cancer (PC) generally do not respond favorably to immune checkpoint inhibitors, which may be due to a low abundance of tumor-infiltrating lymphocytes even when mutational load is high. Here, we identified a patient who presented with high-grade primary prostate cancer with two adjacent tumor nodules. While both nodules were mismatch repair-deficient (MMRd), exhibited pathogenic MSH2 and MSH6 alterations, had a high tumor mutational burden (TMB), and demonstrated high...]]></summary>
        <author>
            <name>Hannah E Bergom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical utility of plasma cell-free DNA in pancreatic neuroendocrine neoplasms]]></title>
        <id>pubmed:38252063</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38252063/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240205194943&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[In advanced pancreatic neuroendocrine neoplasms (PanNEN), there is little data detailing the frequency of genetic alterations identified in cell free DNA (cfDNA), plasma-tissue concordance of detected alterations, and clinical utility of cfDNA. Patients with metastatic PanNENs underwent cfDNA collection in routine practice. Next-generation sequencing (NGS) of cfDNA and matched tissue when available was performed. Clinical actionability of variants was annotated by OncoKB. Thirty-two cfDNA...]]></summary>
        <author>
            <name>Darren Cowzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal genetically detectable minimal residual disease by fluorescence <em>in situ</em> hybridization confers a poor prognosis in myeloma]]></title>
        <id>pubmed:38249329</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38249329/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240205194943&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: These findings highlighted the prognostic value of genetic testing in residual tumor cells, which may provide a deep understanding of clonal evolution and guide clinical therapeutic strategies.]]></summary>
        <author>
            <name>Jian Cui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Divergent immune microenvironments in two tumor nodules from a patient with mismatch repair-deficient prostate cancer]]></title>
        <id>pubmed:38253539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38253539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240204195148&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients with prostate cancer (PC) generally do not respond favorably to immune checkpoint inhibitors, which may be due to a low abundance of tumor-infiltrating lymphocytes even when mutational load is high. Here, we identified a patient who presented with high-grade primary prostate cancer with two adjacent tumor nodules. While both nodules were mismatch repair-deficient (MMRd), exhibited pathogenic MSH2 and MSH6 alterations, had a high tumor mutational burden (TMB), and demonstrated high...]]></summary>
        <author>
            <name>Hannah E Bergom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical utility of plasma cell-free DNA in pancreatic neuroendocrine neoplasms]]></title>
        <id>pubmed:38252063</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38252063/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240204195148&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[In advanced pancreatic neuroendocrine neoplasms (PanNEN), there is little data detailing the frequency of genetic alterations identified in cell free DNA (cfDNA), plasma-tissue concordance of detected alterations, and clinical utility of cfDNA. Patients with metastatic PanNENs underwent cfDNA collection in routine practice. Next-generation sequencing (NGS) of cfDNA and matched tissue when available was performed. Clinical actionability of variants was annotated by OncoKB. Thirty-two cfDNA...]]></summary>
        <author>
            <name>Darren Cowzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal genetically detectable minimal residual disease by fluorescence <em>in situ</em> hybridization confers a poor prognosis in myeloma]]></title>
        <id>pubmed:38249329</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38249329/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240204195148&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: These findings highlighted the prognostic value of genetic testing in residual tumor cells, which may provide a deep understanding of clonal evolution and guide clinical therapeutic strategies.]]></summary>
        <author>
            <name>Jian Cui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Divergent immune microenvironments in two tumor nodules from a patient with mismatch repair-deficient prostate cancer]]></title>
        <id>pubmed:38253539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38253539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240203195418&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients with prostate cancer (PC) generally do not respond favorably to immune checkpoint inhibitors, which may be due to a low abundance of tumor-infiltrating lymphocytes even when mutational load is high. Here, we identified a patient who presented with high-grade primary prostate cancer with two adjacent tumor nodules. While both nodules were mismatch repair-deficient (MMRd), exhibited pathogenic MSH2 and MSH6 alterations, had a high tumor mutational burden (TMB), and demonstrated high...]]></summary>
        <author>
            <name>Hannah E Bergom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical utility of plasma cell-free DNA in pancreatic neuroendocrine neoplasms]]></title>
        <id>pubmed:38252063</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38252063/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240203195418&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[In advanced pancreatic neuroendocrine neoplasms (PanNEN), there is little data detailing the frequency of genetic alterations identified in cell free DNA (cfDNA), plasma-tissue concordance of detected alterations, and clinical utility of cfDNA. Patients with metastatic PanNENs underwent cfDNA collection in routine practice. Next-generation sequencing (NGS) of cfDNA and matched tissue when available was performed. Clinical actionability of variants was annotated by OncoKB. Thirty-two cfDNA...]]></summary>
        <author>
            <name>Darren Cowzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal genetically detectable minimal residual disease by fluorescence <em>in situ</em> hybridization confers a poor prognosis in myeloma]]></title>
        <id>pubmed:38249329</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38249329/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240203195418&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: These findings highlighted the prognostic value of genetic testing in residual tumor cells, which may provide a deep understanding of clonal evolution and guide clinical therapeutic strategies.]]></summary>
        <author>
            <name>Jian Cui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Divergent immune microenvironments in two tumor nodules from a patient with mismatch repair-deficient prostate cancer]]></title>
        <id>pubmed:38253539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38253539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240202194939&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients with prostate cancer (PC) generally do not respond favorably to immune checkpoint inhibitors, which may be due to a low abundance of tumor-infiltrating lymphocytes even when mutational load is high. Here, we identified a patient who presented with high-grade primary prostate cancer with two adjacent tumor nodules. While both nodules were mismatch repair-deficient (MMRd), exhibited pathogenic MSH2 and MSH6 alterations, had a high tumor mutational burden (TMB), and demonstrated high...]]></summary>
        <author>
            <name>Hannah E Bergom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical utility of plasma cell-free DNA in pancreatic neuroendocrine neoplasms]]></title>
        <id>pubmed:38252063</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38252063/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240202194939&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[In advanced pancreatic neuroendocrine neoplasms (PanNEN), there is little data detailing the frequency of genetic alterations identified in cell free DNA (cfDNA), plasma-tissue concordance of detected alterations, and clinical utility of cfDNA. Patients with metastatic PanNENs underwent cfDNA collection in routine practice. Next-generation sequencing (NGS) of cfDNA and matched tissue when available was performed. Clinical actionability of variants was annotated by OncoKB. Thirty-two cfDNA...]]></summary>
        <author>
            <name>Darren Cowzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal genetically detectable minimal residual disease by fluorescence <em>in situ</em> hybridization confers a poor prognosis in myeloma]]></title>
        <id>pubmed:38249329</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38249329/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240202194939&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: These findings highlighted the prognostic value of genetic testing in residual tumor cells, which may provide a deep understanding of clonal evolution and guide clinical therapeutic strategies.]]></summary>
        <author>
            <name>Jian Cui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Divergent immune microenvironments in two tumor nodules from a patient with mismatch repair-deficient prostate cancer]]></title>
        <id>pubmed:38253539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38253539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240201195024&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients with prostate cancer (PC) generally do not respond favorably to immune checkpoint inhibitors, which may be due to a low abundance of tumor-infiltrating lymphocytes even when mutational load is high. Here, we identified a patient who presented with high-grade primary prostate cancer with two adjacent tumor nodules. While both nodules were mismatch repair-deficient (MMRd), exhibited pathogenic MSH2 and MSH6 alterations, had a high tumor mutational burden (TMB), and demonstrated high...]]></summary>
        <author>
            <name>Hannah E Bergom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical utility of plasma cell-free DNA in pancreatic neuroendocrine neoplasms]]></title>
        <id>pubmed:38252063</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38252063/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240201195024&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[In advanced pancreatic neuroendocrine neoplasms (PanNEN), there is little data detailing the frequency of genetic alterations identified in cell free DNA (cfDNA), plasma-tissue concordance of detected alterations, and clinical utility of cfDNA. Patients with metastatic PanNENs underwent cfDNA collection in routine practice. Next-generation sequencing (NGS) of cfDNA and matched tissue when available was performed. Clinical actionability of variants was annotated by OncoKB. Thirty-two cfDNA...]]></summary>
        <author>
            <name>Darren Cowzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal genetically detectable minimal residual disease by fluorescence <em>in situ</em> hybridization confers a poor prognosis in myeloma]]></title>
        <id>pubmed:38249329</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38249329/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240201195024&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: These findings highlighted the prognostic value of genetic testing in residual tumor cells, which may provide a deep understanding of clonal evolution and guide clinical therapeutic strategies.]]></summary>
        <author>
            <name>Jian Cui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Divergent immune microenvironments in two tumor nodules from a patient with mismatch repair-deficient prostate cancer]]></title>
        <id>pubmed:38253539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38253539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240131195240&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients with prostate cancer (PC) generally do not respond favorably to immune checkpoint inhibitors, which may be due to a low abundance of tumor-infiltrating lymphocytes even when mutational load is high. Here, we identified a patient who presented with high-grade primary prostate cancer with two adjacent tumor nodules. While both nodules were mismatch repair-deficient (MMRd), exhibited pathogenic MSH2 and MSH6 alterations, had a high tumor mutational burden (TMB), and demonstrated high...]]></summary>
        <author>
            <name>Hannah E Bergom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical utility of plasma cell-free DNA in pancreatic neuroendocrine neoplasms]]></title>
        <id>pubmed:38252063</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38252063/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240131195240&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[In advanced pancreatic neuroendocrine neoplasms (PanNEN), there is little data detailing the frequency of genetic alterations identified in cell free DNA (cfDNA), plasma-tissue concordance of detected alterations, and clinical utility of cfDNA. Patients with metastatic PanNENs underwent cfDNA collection in routine practice. Next-generation sequencing (NGS) of cfDNA and matched tissue when available was performed. Clinical actionability of variants was annotated by OncoKB. Thirty-two cfDNA...]]></summary>
        <author>
            <name>Darren Cowzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal genetically detectable minimal residual disease by fluorescence <em>in situ</em> hybridization confers a poor prognosis in myeloma]]></title>
        <id>pubmed:38249329</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38249329/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240131195240&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: These findings highlighted the prognostic value of genetic testing in residual tumor cells, which may provide a deep understanding of clonal evolution and guide clinical therapeutic strategies.]]></summary>
        <author>
            <name>Jian Cui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Divergent immune microenvironments in two tumor nodules from a patient with mismatch repair-deficient prostate cancer]]></title>
        <id>pubmed:38253539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38253539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240130195039&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients with prostate cancer (PC) generally do not respond favorably to immune checkpoint inhibitors, which may be due to a low abundance of tumor-infiltrating lymphocytes even when mutational load is high. Here, we identified a patient who presented with high-grade primary prostate cancer with two adjacent tumor nodules. While both nodules were mismatch repair-deficient (MMRd), exhibited pathogenic MSH2 and MSH6 alterations, had a high tumor mutational burden (TMB), and demonstrated high...]]></summary>
        <author>
            <name>Hannah E Bergom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical utility of plasma cell-free DNA in pancreatic neuroendocrine neoplasms]]></title>
        <id>pubmed:38252063</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38252063/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240130195039&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[In advanced pancreatic neuroendocrine neoplasms (PanNEN), there is little data detailing the frequency of genetic alterations identified in cell free DNA (cfDNA), plasma-tissue concordance of detected alterations, and clinical utility of cfDNA. Patients with metastatic PanNENs underwent cfDNA collection in routine practice. Next-generation sequencing (NGS) of cfDNA and matched tissue when available was performed. Clinical actionability of variants was annotated by OncoKB. Thirty-two cfDNA...]]></summary>
        <author>
            <name>Darren Cowzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal genetically detectable minimal residual disease by fluorescence <em>in situ</em> hybridization confers a poor prognosis in myeloma]]></title>
        <id>pubmed:38249329</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38249329/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240130195039&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: These findings highlighted the prognostic value of genetic testing in residual tumor cells, which may provide a deep understanding of clonal evolution and guide clinical therapeutic strategies.]]></summary>
        <author>
            <name>Jian Cui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Divergent immune microenvironments in two tumor nodules from a patient with mismatch repair-deficient prostate cancer]]></title>
        <id>pubmed:38253539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38253539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240129195013&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients with prostate cancer (PC) generally do not respond favorably to immune checkpoint inhibitors, which may be due to a low abundance of tumor-infiltrating lymphocytes even when mutational load is high. Here, we identified a patient who presented with high-grade primary prostate cancer with two adjacent tumor nodules. While both nodules were mismatch repair-deficient (MMRd), exhibited pathogenic MSH2 and MSH6 alterations, had a high tumor mutational burden (TMB), and demonstrated high...]]></summary>
        <author>
            <name>Hannah E Bergom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical utility of plasma cell-free DNA in pancreatic neuroendocrine neoplasms]]></title>
        <id>pubmed:38252063</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38252063/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240129195013&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[In advanced pancreatic neuroendocrine neoplasms (PanNEN), there is little data detailing the frequency of genetic alterations identified in cell free DNA (cfDNA), plasma-tissue concordance of detected alterations, and clinical utility of cfDNA. Patients with metastatic PanNENs underwent cfDNA collection in routine practice. Next-generation sequencing (NGS) of cfDNA and matched tissue when available was performed. Clinical actionability of variants was annotated by OncoKB. Thirty-two cfDNA...]]></summary>
        <author>
            <name>Darren Cowzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal genetically detectable minimal residual disease by fluorescence <em>in situ</em> hybridization confers a poor prognosis in myeloma]]></title>
        <id>pubmed:38249329</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38249329/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240129195013&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: These findings highlighted the prognostic value of genetic testing in residual tumor cells, which may provide a deep understanding of clonal evolution and guide clinical therapeutic strategies.]]></summary>
        <author>
            <name>Jian Cui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Divergent immune microenvironments in two tumor nodules from a patient with mismatch repair-deficient prostate cancer]]></title>
        <id>pubmed:38253539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38253539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240128195055&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients with prostate cancer (PC) generally do not respond favorably to immune checkpoint inhibitors, which may be due to a low abundance of tumor-infiltrating lymphocytes even when mutational load is high. Here, we identified a patient who presented with high-grade primary prostate cancer with two adjacent tumor nodules. While both nodules were mismatch repair-deficient (MMRd), exhibited pathogenic MSH2 and MSH6 alterations, had a high tumor mutational burden (TMB), and demonstrated high...]]></summary>
        <author>
            <name>Hannah E Bergom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical utility of plasma cell-free DNA in pancreatic neuroendocrine neoplasms]]></title>
        <id>pubmed:38252063</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38252063/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240128195055&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[In advanced pancreatic neuroendocrine neoplasms (PanNEN), there is little data detailing the frequency of genetic alterations identified in cell free DNA (cfDNA), plasma-tissue concordance of detected alterations, and clinical utility of cfDNA. Patients with metastatic PanNENs underwent cfDNA collection in routine practice. Next-generation sequencing (NGS) of cfDNA and matched tissue when available was performed. Clinical actionability of variants was annotated by OncoKB. Thirty-two cfDNA...]]></summary>
        <author>
            <name>Darren Cowzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal genetically detectable minimal residual disease by fluorescence <em>in situ</em> hybridization confers a poor prognosis in myeloma]]></title>
        <id>pubmed:38249329</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38249329/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240128195055&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: These findings highlighted the prognostic value of genetic testing in residual tumor cells, which may provide a deep understanding of clonal evolution and guide clinical therapeutic strategies.]]></summary>
        <author>
            <name>Jian Cui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Divergent immune microenvironments in two tumor nodules from a patient with mismatch repair-deficient prostate cancer]]></title>
        <id>pubmed:38253539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38253539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240127195322&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients with prostate cancer (PC) generally do not respond favorably to immune checkpoint inhibitors, which may be due to a low abundance of tumor-infiltrating lymphocytes even when mutational load is high. Here, we identified a patient who presented with high-grade primary prostate cancer with two adjacent tumor nodules. While both nodules were mismatch repair-deficient (MMRd), exhibited pathogenic MSH2 and MSH6 alterations, had a high tumor mutational burden (TMB), and demonstrated high...]]></summary>
        <author>
            <name>Hannah E Bergom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical utility of plasma cell-free DNA in pancreatic neuroendocrine neoplasms]]></title>
        <id>pubmed:38252063</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38252063/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240127195322&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[In advanced pancreatic neuroendocrine neoplasms (PanNEN), there is little data detailing the frequency of genetic alterations identified in cell free DNA (cfDNA), plasma-tissue concordance of detected alterations, and clinical utility of cfDNA. Patients with metastatic PanNENs underwent cfDNA collection in routine practice. Next-generation sequencing (NGS) of cfDNA and matched tissue when available was performed. Clinical actionability of variants was annotated by OncoKB. Thirty-two cfDNA...]]></summary>
        <author>
            <name>Darren Cowzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal genetically detectable minimal residual disease by fluorescence <em>in situ</em> hybridization confers a poor prognosis in myeloma]]></title>
        <id>pubmed:38249329</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38249329/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240127195322&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: These findings highlighted the prognostic value of genetic testing in residual tumor cells, which may provide a deep understanding of clonal evolution and guide clinical therapeutic strategies.]]></summary>
        <author>
            <name>Jian Cui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Divergent immune microenvironments in two tumor nodules from a patient with mismatch repair-deficient prostate cancer]]></title>
        <id>pubmed:38253539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38253539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240126194954&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients with prostate cancer (PC) generally do not respond favorably to immune checkpoint inhibitors, which may be due to a low abundance of tumor-infiltrating lymphocytes even when mutational load is high. Here, we identified a patient who presented with high-grade primary prostate cancer with two adjacent tumor nodules. While both nodules were mismatch repair-deficient (MMRd), exhibited pathogenic MSH2 and MSH6 alterations, had a high tumor mutational burden (TMB), and demonstrated high...]]></summary>
        <author>
            <name>Hannah E Bergom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical utility of plasma cell-free DNA in pancreatic neuroendocrine neoplasms]]></title>
        <id>pubmed:38252063</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38252063/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240126194954&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[In advanced pancreatic neuroendocrine neoplasms (PanNEN), there is little data detailing the frequency of genetic alterations identified in cell free DNA (cfDNA), plasma-tissue concordance of detected alterations, and clinical utility of cfDNA. Patients with metastatic PanNENs underwent cfDNA collection in routine practice. Next-generation sequencing (NGS) of cfDNA and matched tissue when available was performed. Clinical actionability of variants was annotated by OncoKB. Thirty-two cfDNA...]]></summary>
        <author>
            <name>Darren Cowzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal genetically detectable minimal residual disease by fluorescence <em>in situ</em> hybridization confers a poor prognosis in myeloma]]></title>
        <id>pubmed:38249329</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38249329/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240126194954&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: These findings highlighted the prognostic value of genetic testing in residual tumor cells, which may provide a deep understanding of clonal evolution and guide clinical therapeutic strategies.]]></summary>
        <author>
            <name>Jian Cui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Divergent immune microenvironments in two tumor nodules from a patient with mismatch repair-deficient prostate cancer]]></title>
        <id>pubmed:38253539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38253539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240125195050&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients with prostate cancer (PC) generally do not respond favorably to immune checkpoint inhibitors, which may be due to a low abundance of tumor-infiltrating lymphocytes even when mutational load is high. Here, we identified a patient who presented with high-grade primary prostate cancer with two adjacent tumor nodules. While both nodules were mismatch repair-deficient (MMRd), exhibited pathogenic MSH2 and MSH6 alterations, had a high tumor mutational burden (TMB), and demonstrated high...]]></summary>
        <author>
            <name>Hannah E Bergom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical utility of plasma cell-free DNA in pancreatic neuroendocrine neoplasms]]></title>
        <id>pubmed:38252063</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38252063/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240125195050&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[In advanced pancreatic neuroendocrine neoplasms (PanNEN), there is little data detailing the frequency of genetic alterations identified in cell free DNA (cfDNA), plasma-tissue concordance of detected alterations, and clinical utility of cfDNA. Patients with metastatic PanNENs underwent cfDNA collection in routine practice. Next-generation sequencing (NGS) of cfDNA and matched tissue when available was performed. Clinical actionability of variants was annotated by OncoKB. Thirty-two cfDNA...]]></summary>
        <author>
            <name>Darren Cowzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal genetically detectable minimal residual disease by fluorescence <em>in situ</em> hybridization confers a poor prognosis in myeloma]]></title>
        <id>pubmed:38249329</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38249329/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240125195050&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: These findings highlighted the prognostic value of genetic testing in residual tumor cells, which may provide a deep understanding of clonal evolution and guide clinical therapeutic strategies.]]></summary>
        <author>
            <name>Jian Cui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Divergent immune microenvironments in two tumor nodules from a patient with mismatch repair-deficient prostate cancer]]></title>
        <id>pubmed:38253539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38253539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240124195506&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients with prostate cancer (PC) generally do not respond favorably to immune checkpoint inhibitors, which may be due to a low abundance of tumor-infiltrating lymphocytes even when mutational load is high. Here, we identified a patient who presented with high-grade primary prostate cancer with two adjacent tumor nodules. While both nodules were mismatch repair-deficient (MMRd), exhibited pathogenic MSH2 and MSH6 alterations, had a high tumor mutational burden (TMB), and demonstrated high...]]></summary>
        <author>
            <name>Hannah E Bergom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical utility of plasma cell-free DNA in pancreatic neuroendocrine neoplasms]]></title>
        <id>pubmed:38252063</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38252063/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240124195506&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[In advanced pancreatic neuroendocrine neoplasms (PanNEN), there is little data detailing the frequency of genetic alterations identified in cell free DNA (cfDNA), plasma-tissue concordance of detected alterations, and clinical utility of cfDNA. Patients with metastatic PanNENs underwent cfDNA collection in routine practice. Next-generation sequencing (NGS) of cfDNA and matched tissue when available was performed. Clinical actionability of variants was annotated by OncoKB. Thirty-two cfDNA...]]></summary>
        <author>
            <name>Darren Cowzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal genetically detectable minimal residual disease by fluorescence <em>in situ</em> hybridization confers a poor prognosis in myeloma]]></title>
        <id>pubmed:38249329</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38249329/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240124195506&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: These findings highlighted the prognostic value of genetic testing in residual tumor cells, which may provide a deep understanding of clonal evolution and guide clinical therapeutic strategies.]]></summary>
        <author>
            <name>Jian Cui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Divergent immune microenvironments in two tumor nodules from a patient with mismatch repair-deficient prostate cancer]]></title>
        <id>pubmed:38253539</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38253539/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240123195503&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients with prostate cancer (PC) generally do not respond favorably to immune checkpoint inhibitors, which may be due to a low abundance of tumor-infiltrating lymphocytes even when mutational load is high. Here, we identified a patient who presented with high-grade primary prostate cancer with two adjacent tumor nodules. While both nodules were mismatch repair-deficient (MMRd), exhibited pathogenic MSH2 and MSH6 alterations, had a high tumor mutational burden (TMB), and demonstrated high...]]></summary>
        <author>
            <name>Hannah E Bergom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical utility of plasma cell-free DNA in pancreatic neuroendocrine neoplasms]]></title>
        <id>pubmed:38252063</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38252063/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240123195503&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[In advanced pancreatic neuroendocrine neoplasms (PanNEN), there is little data detailing the frequency of genetic alterations identified in cell free DNA (cfDNA), plasma-tissue concordance of detected alterations, and clinical utility of cfDNA. Patients with metastatic PanNENs underwent cfDNA collection in routine practice. Next-generation sequencing (NGS) of cfDNA and matched tissue when available was performed. Clinical actionability of variants was annotated by OncoKB. Thirty-two cfDNA...]]></summary>
        <author>
            <name>Darren Cowzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal genetically detectable minimal residual disease by fluorescence <em>in situ</em> hybridization confers a poor prognosis in myeloma]]></title>
        <id>pubmed:38249329</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38249329/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240123195503&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: These findings highlighted the prognostic value of genetic testing in residual tumor cells, which may provide a deep understanding of clonal evolution and guide clinical therapeutic strategies.]]></summary>
        <author>
            <name>Jian Cui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical utility of plasma cell-free DNA in pancreatic neuroendocrine neoplasms]]></title>
        <id>pubmed:38252063</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38252063/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240122195511&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[In advanced pancreatic neuroendocrine neoplasms (PanNEN), there is little data detailing the frequency of genetic alterations identified in cell free DNA (cfDNA), plasma-tissue concordance of detected alterations, and clinical utility of cfDNA. Patients with metastatic PanNENs underwent cfDNA collection in routine practice. Next-generation sequencing (NGS) of cfDNA and matched tissue when available was performed. Clinical actionability of variants was annotated by OncoKB. Thirty-two cfDNA...]]></summary>
        <author>
            <name>Darren Cowzer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal genetically detectable minimal residual disease by fluorescence <em>in situ</em> hybridization confers a poor prognosis in myeloma]]></title>
        <id>pubmed:38249329</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38249329/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240122195511&amp;v=2.18.0"/>
        <updated>2024-01-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: These findings highlighted the prognostic value of genetic testing in residual tumor cells, which may provide a deep understanding of clonal evolution and guide clinical therapeutic strategies.]]></summary>
        <author>
            <name>Jian Cui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Idiopathic erythrocytosis: a germline disease?]]></title>
        <id>pubmed:38244120</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38244120/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240206194820&amp;v=2.18.0"/>
        <updated>2024-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Polycythemia Vera (PV) is typically caused by V617F or exon 12 JAK2 mutations. Little is known about Polycythemia cases where no JAK2 variants can be detected, and no other causes identified. This condition is defined as idiopathic erythrocytosis (IE). We evaluated clinical-laboratory parameters of a cohort of 56 IE patients and we determined their molecular profile at diagnosis with paired blood/buccal-DNA exome-sequencing coupled with a high-depth targeted OncoPanel to identify a possible...]]></summary>
        <author>
            <name>E M Elli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Idiopathic erythrocytosis: a germline disease?]]></title>
        <id>pubmed:38244120</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38244120/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240205194943&amp;v=2.18.0"/>
        <updated>2024-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Polycythemia Vera (PV) is typically caused by V617F or exon 12 JAK2 mutations. Little is known about Polycythemia cases where no JAK2 variants can be detected, and no other causes identified. This condition is defined as idiopathic erythrocytosis (IE). We evaluated clinical-laboratory parameters of a cohort of 56 IE patients and we determined their molecular profile at diagnosis with paired blood/buccal-DNA exome-sequencing coupled with a high-depth targeted OncoPanel to identify a possible...]]></summary>
        <author>
            <name>E M Elli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Idiopathic erythrocytosis: a germline disease?]]></title>
        <id>pubmed:38244120</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38244120/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240204195148&amp;v=2.18.0"/>
        <updated>2024-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Polycythemia Vera (PV) is typically caused by V617F or exon 12 JAK2 mutations. Little is known about Polycythemia cases where no JAK2 variants can be detected, and no other causes identified. This condition is defined as idiopathic erythrocytosis (IE). We evaluated clinical-laboratory parameters of a cohort of 56 IE patients and we determined their molecular profile at diagnosis with paired blood/buccal-DNA exome-sequencing coupled with a high-depth targeted OncoPanel to identify a possible...]]></summary>
        <author>
            <name>E M Elli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Idiopathic erythrocytosis: a germline disease?]]></title>
        <id>pubmed:38244120</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38244120/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240203195418&amp;v=2.18.0"/>
        <updated>2024-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Polycythemia Vera (PV) is typically caused by V617F or exon 12 JAK2 mutations. Little is known about Polycythemia cases where no JAK2 variants can be detected, and no other causes identified. This condition is defined as idiopathic erythrocytosis (IE). We evaluated clinical-laboratory parameters of a cohort of 56 IE patients and we determined their molecular profile at diagnosis with paired blood/buccal-DNA exome-sequencing coupled with a high-depth targeted OncoPanel to identify a possible...]]></summary>
        <author>
            <name>E M Elli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Idiopathic erythrocytosis: a germline disease?]]></title>
        <id>pubmed:38244120</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38244120/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240202194939&amp;v=2.18.0"/>
        <updated>2024-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Polycythemia Vera (PV) is typically caused by V617F or exon 12 JAK2 mutations. Little is known about Polycythemia cases where no JAK2 variants can be detected, and no other causes identified. This condition is defined as idiopathic erythrocytosis (IE). We evaluated clinical-laboratory parameters of a cohort of 56 IE patients and we determined their molecular profile at diagnosis with paired blood/buccal-DNA exome-sequencing coupled with a high-depth targeted OncoPanel to identify a possible...]]></summary>
        <author>
            <name>E M Elli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Idiopathic erythrocytosis: a germline disease?]]></title>
        <id>pubmed:38244120</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38244120/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240201195024&amp;v=2.18.0"/>
        <updated>2024-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Polycythemia Vera (PV) is typically caused by V617F or exon 12 JAK2 mutations. Little is known about Polycythemia cases where no JAK2 variants can be detected, and no other causes identified. This condition is defined as idiopathic erythrocytosis (IE). We evaluated clinical-laboratory parameters of a cohort of 56 IE patients and we determined their molecular profile at diagnosis with paired blood/buccal-DNA exome-sequencing coupled with a high-depth targeted OncoPanel to identify a possible...]]></summary>
        <author>
            <name>E M Elli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Idiopathic erythrocytosis: a germline disease?]]></title>
        <id>pubmed:38244120</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38244120/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240131195240&amp;v=2.18.0"/>
        <updated>2024-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Polycythemia Vera (PV) is typically caused by V617F or exon 12 JAK2 mutations. Little is known about Polycythemia cases where no JAK2 variants can be detected, and no other causes identified. This condition is defined as idiopathic erythrocytosis (IE). We evaluated clinical-laboratory parameters of a cohort of 56 IE patients and we determined their molecular profile at diagnosis with paired blood/buccal-DNA exome-sequencing coupled with a high-depth targeted OncoPanel to identify a possible...]]></summary>
        <author>
            <name>E M Elli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Idiopathic erythrocytosis: a germline disease?]]></title>
        <id>pubmed:38244120</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38244120/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240130195039&amp;v=2.18.0"/>
        <updated>2024-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Polycythemia Vera (PV) is typically caused by V617F or exon 12 JAK2 mutations. Little is known about Polycythemia cases where no JAK2 variants can be detected, and no other causes identified. This condition is defined as idiopathic erythrocytosis (IE). We evaluated clinical-laboratory parameters of a cohort of 56 IE patients and we determined their molecular profile at diagnosis with paired blood/buccal-DNA exome-sequencing coupled with a high-depth targeted OncoPanel to identify a possible...]]></summary>
        <author>
            <name>E M Elli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Idiopathic erythrocytosis: a germline disease?]]></title>
        <id>pubmed:38244120</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38244120/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240129195013&amp;v=2.18.0"/>
        <updated>2024-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Polycythemia Vera (PV) is typically caused by V617F or exon 12 JAK2 mutations. Little is known about Polycythemia cases where no JAK2 variants can be detected, and no other causes identified. This condition is defined as idiopathic erythrocytosis (IE). We evaluated clinical-laboratory parameters of a cohort of 56 IE patients and we determined their molecular profile at diagnosis with paired blood/buccal-DNA exome-sequencing coupled with a high-depth targeted OncoPanel to identify a possible...]]></summary>
        <author>
            <name>E M Elli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Idiopathic erythrocytosis: a germline disease?]]></title>
        <id>pubmed:38244120</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38244120/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240128195055&amp;v=2.18.0"/>
        <updated>2024-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Polycythemia Vera (PV) is typically caused by V617F or exon 12 JAK2 mutations. Little is known about Polycythemia cases where no JAK2 variants can be detected, and no other causes identified. This condition is defined as idiopathic erythrocytosis (IE). We evaluated clinical-laboratory parameters of a cohort of 56 IE patients and we determined their molecular profile at diagnosis with paired blood/buccal-DNA exome-sequencing coupled with a high-depth targeted OncoPanel to identify a possible...]]></summary>
        <author>
            <name>E M Elli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Idiopathic erythrocytosis: a germline disease?]]></title>
        <id>pubmed:38244120</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38244120/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240127195322&amp;v=2.18.0"/>
        <updated>2024-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Polycythemia Vera (PV) is typically caused by V617F or exon 12 JAK2 mutations. Little is known about Polycythemia cases where no JAK2 variants can be detected, and no other causes identified. This condition is defined as idiopathic erythrocytosis (IE). We evaluated clinical-laboratory parameters of a cohort of 56 IE patients and we determined their molecular profile at diagnosis with paired blood/buccal-DNA exome-sequencing coupled with a high-depth targeted OncoPanel to identify a possible...]]></summary>
        <author>
            <name>E M Elli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Idiopathic erythrocytosis: a germline disease?]]></title>
        <id>pubmed:38244120</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38244120/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240126194954&amp;v=2.18.0"/>
        <updated>2024-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Polycythemia Vera (PV) is typically caused by V617F or exon 12 JAK2 mutations. Little is known about Polycythemia cases where no JAK2 variants can be detected, and no other causes identified. This condition is defined as idiopathic erythrocytosis (IE). We evaluated clinical-laboratory parameters of a cohort of 56 IE patients and we determined their molecular profile at diagnosis with paired blood/buccal-DNA exome-sequencing coupled with a high-depth targeted OncoPanel to identify a possible...]]></summary>
        <author>
            <name>E M Elli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Idiopathic erythrocytosis: a germline disease?]]></title>
        <id>pubmed:38244120</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38244120/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240125195050&amp;v=2.18.0"/>
        <updated>2024-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Polycythemia Vera (PV) is typically caused by V617F or exon 12 JAK2 mutations. Little is known about Polycythemia cases where no JAK2 variants can be detected, and no other causes identified. This condition is defined as idiopathic erythrocytosis (IE). We evaluated clinical-laboratory parameters of a cohort of 56 IE patients and we determined their molecular profile at diagnosis with paired blood/buccal-DNA exome-sequencing coupled with a high-depth targeted OncoPanel to identify a possible...]]></summary>
        <author>
            <name>E M Elli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Idiopathic erythrocytosis: a germline disease?]]></title>
        <id>pubmed:38244120</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38244120/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240124195506&amp;v=2.18.0"/>
        <updated>2024-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Polycythemia Vera (PV) is typically caused by V617F or exon 12 JAK2 mutations. Little is known about Polycythemia cases where no JAK2 variants can be detected, and no other causes identified. This condition is defined as idiopathic erythrocytosis (IE). We evaluated clinical-laboratory parameters of a cohort of 56 IE patients and we determined their molecular profile at diagnosis with paired blood/buccal-DNA exome-sequencing coupled with a high-depth targeted OncoPanel to identify a possible...]]></summary>
        <author>
            <name>E M Elli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Idiopathic erythrocytosis: a germline disease?]]></title>
        <id>pubmed:38244120</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38244120/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240123195503&amp;v=2.18.0"/>
        <updated>2024-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Polycythemia Vera (PV) is typically caused by V617F or exon 12 JAK2 mutations. Little is known about Polycythemia cases where no JAK2 variants can be detected, and no other causes identified. This condition is defined as idiopathic erythrocytosis (IE). We evaluated clinical-laboratory parameters of a cohort of 56 IE patients and we determined their molecular profile at diagnosis with paired blood/buccal-DNA exome-sequencing coupled with a high-depth targeted OncoPanel to identify a possible...]]></summary>
        <author>
            <name>E M Elli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Idiopathic erythrocytosis: a germline disease?]]></title>
        <id>pubmed:38244120</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38244120/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240122195511&amp;v=2.18.0"/>
        <updated>2024-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Polycythemia Vera (PV) is typically caused by V617F or exon 12 JAK2 mutations. Little is known about Polycythemia cases where no JAK2 variants can be detected, and no other causes identified. This condition is defined as idiopathic erythrocytosis (IE). We evaluated clinical-laboratory parameters of a cohort of 56 IE patients and we determined their molecular profile at diagnosis with paired blood/buccal-DNA exome-sequencing coupled with a high-depth targeted OncoPanel to identify a possible...]]></summary>
        <author>
            <name>E M Elli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Idiopathic erythrocytosis: a germline disease?]]></title>
        <id>pubmed:38244120</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38244120/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240121195630&amp;v=2.18.0"/>
        <updated>2024-01-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Polycythemia Vera (PV) is typically caused by V617F or exon 12 JAK2 mutations. Little is known about Polycythemia cases where no JAK2 variants can be detected, and no other causes identified. This condition is defined as idiopathic erythrocytosis (IE). We evaluated clinical-laboratory parameters of a cohort of 56 IE patients and we determined their molecular profile at diagnosis with paired blood/buccal-DNA exome-sequencing coupled with a high-depth targeted OncoPanel to identify a possible...]]></summary>
        <author>
            <name>E M Elli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[DNMT3A clonal hematopoiesis-driver mutations induce cardiac fibrosis by paracrine activation of fibroblasts]]></title>
        <id>pubmed:38242884</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38242884/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240205194943&amp;v=2.18.0"/>
        <updated>2024-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic mutations in epigenetic regulators like DNA methyltransferase 3 alpha (DNMT3A), play a pivotal role in driving clonal hematopoiesis of indeterminate potential (CHIP), and are associated with unfavorable outcomes in patients suffering from heart failure (HF). However, the precise interactions between CHIP-mutated cells and other cardiac cell types remain unknown. Here, we identify fibroblasts as potential partners in interactions with CHIP-mutated monocytes. We used combined...]]></summary>
        <author>
            <name>Mariana Shumliakivska</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[DNMT3A clonal hematopoiesis-driver mutations induce cardiac fibrosis by paracrine activation of fibroblasts]]></title>
        <id>pubmed:38242884</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38242884/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240204195148&amp;v=2.18.0"/>
        <updated>2024-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic mutations in epigenetic regulators like DNA methyltransferase 3 alpha (DNMT3A), play a pivotal role in driving clonal hematopoiesis of indeterminate potential (CHIP), and are associated with unfavorable outcomes in patients suffering from heart failure (HF). However, the precise interactions between CHIP-mutated cells and other cardiac cell types remain unknown. Here, we identify fibroblasts as potential partners in interactions with CHIP-mutated monocytes. We used combined...]]></summary>
        <author>
            <name>Mariana Shumliakivska</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[DNMT3A clonal hematopoiesis-driver mutations induce cardiac fibrosis by paracrine activation of fibroblasts]]></title>
        <id>pubmed:38242884</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38242884/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240203195418&amp;v=2.18.0"/>
        <updated>2024-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic mutations in epigenetic regulators like DNA methyltransferase 3 alpha (DNMT3A), play a pivotal role in driving clonal hematopoiesis of indeterminate potential (CHIP), and are associated with unfavorable outcomes in patients suffering from heart failure (HF). However, the precise interactions between CHIP-mutated cells and other cardiac cell types remain unknown. Here, we identify fibroblasts as potential partners in interactions with CHIP-mutated monocytes. We used combined...]]></summary>
        <author>
            <name>Mariana Shumliakivska</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[DNMT3A clonal hematopoiesis-driver mutations induce cardiac fibrosis by paracrine activation of fibroblasts]]></title>
        <id>pubmed:38242884</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38242884/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240202194939&amp;v=2.18.0"/>
        <updated>2024-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic mutations in epigenetic regulators like DNA methyltransferase 3 alpha (DNMT3A), play a pivotal role in driving clonal hematopoiesis of indeterminate potential (CHIP), and are associated with unfavorable outcomes in patients suffering from heart failure (HF). However, the precise interactions between CHIP-mutated cells and other cardiac cell types remain unknown. Here, we identify fibroblasts as potential partners in interactions with CHIP-mutated monocytes. We used combined...]]></summary>
        <author>
            <name>Mariana Shumliakivska</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[DNMT3A clonal hematopoiesis-driver mutations induce cardiac fibrosis by paracrine activation of fibroblasts]]></title>
        <id>pubmed:38242884</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38242884/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240201195024&amp;v=2.18.0"/>
        <updated>2024-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic mutations in epigenetic regulators like DNA methyltransferase 3 alpha (DNMT3A), play a pivotal role in driving clonal hematopoiesis of indeterminate potential (CHIP), and are associated with unfavorable outcomes in patients suffering from heart failure (HF). However, the precise interactions between CHIP-mutated cells and other cardiac cell types remain unknown. Here, we identify fibroblasts as potential partners in interactions with CHIP-mutated monocytes. We used combined...]]></summary>
        <author>
            <name>Mariana Shumliakivska</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[DNMT3A clonal hematopoiesis-driver mutations induce cardiac fibrosis by paracrine activation of fibroblasts]]></title>
        <id>pubmed:38242884</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38242884/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240131195240&amp;v=2.18.0"/>
        <updated>2024-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic mutations in epigenetic regulators like DNA methyltransferase 3 alpha (DNMT3A), play a pivotal role in driving clonal hematopoiesis of indeterminate potential (CHIP), and are associated with unfavorable outcomes in patients suffering from heart failure (HF). However, the precise interactions between CHIP-mutated cells and other cardiac cell types remain unknown. Here, we identify fibroblasts as potential partners in interactions with CHIP-mutated monocytes. We used combined...]]></summary>
        <author>
            <name>Mariana Shumliakivska</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[DNMT3A clonal hematopoiesis-driver mutations induce cardiac fibrosis by paracrine activation of fibroblasts]]></title>
        <id>pubmed:38242884</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38242884/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240130195039&amp;v=2.18.0"/>
        <updated>2024-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic mutations in epigenetic regulators like DNA methyltransferase 3 alpha (DNMT3A), play a pivotal role in driving clonal hematopoiesis of indeterminate potential (CHIP), and are associated with unfavorable outcomes in patients suffering from heart failure (HF). However, the precise interactions between CHIP-mutated cells and other cardiac cell types remain unknown. Here, we identify fibroblasts as potential partners in interactions with CHIP-mutated monocytes. We used combined...]]></summary>
        <author>
            <name>Mariana Shumliakivska</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[DNMT3A clonal hematopoiesis-driver mutations induce cardiac fibrosis by paracrine activation of fibroblasts]]></title>
        <id>pubmed:38242884</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38242884/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240129195013&amp;v=2.18.0"/>
        <updated>2024-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic mutations in epigenetic regulators like DNA methyltransferase 3 alpha (DNMT3A), play a pivotal role in driving clonal hematopoiesis of indeterminate potential (CHIP), and are associated with unfavorable outcomes in patients suffering from heart failure (HF). However, the precise interactions between CHIP-mutated cells and other cardiac cell types remain unknown. Here, we identify fibroblasts as potential partners in interactions with CHIP-mutated monocytes. We used combined...]]></summary>
        <author>
            <name>Mariana Shumliakivska</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[DNMT3A clonal hematopoiesis-driver mutations induce cardiac fibrosis by paracrine activation of fibroblasts]]></title>
        <id>pubmed:38242884</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38242884/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240128195055&amp;v=2.18.0"/>
        <updated>2024-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic mutations in epigenetic regulators like DNA methyltransferase 3 alpha (DNMT3A), play a pivotal role in driving clonal hematopoiesis of indeterminate potential (CHIP), and are associated with unfavorable outcomes in patients suffering from heart failure (HF). However, the precise interactions between CHIP-mutated cells and other cardiac cell types remain unknown. Here, we identify fibroblasts as potential partners in interactions with CHIP-mutated monocytes. We used combined...]]></summary>
        <author>
            <name>Mariana Shumliakivska</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[DNMT3A clonal hematopoiesis-driver mutations induce cardiac fibrosis by paracrine activation of fibroblasts]]></title>
        <id>pubmed:38242884</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38242884/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240127195322&amp;v=2.18.0"/>
        <updated>2024-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic mutations in epigenetic regulators like DNA methyltransferase 3 alpha (DNMT3A), play a pivotal role in driving clonal hematopoiesis of indeterminate potential (CHIP), and are associated with unfavorable outcomes in patients suffering from heart failure (HF). However, the precise interactions between CHIP-mutated cells and other cardiac cell types remain unknown. Here, we identify fibroblasts as potential partners in interactions with CHIP-mutated monocytes. We used combined...]]></summary>
        <author>
            <name>Mariana Shumliakivska</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[DNMT3A clonal hematopoiesis-driver mutations induce cardiac fibrosis by paracrine activation of fibroblasts]]></title>
        <id>pubmed:38242884</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38242884/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240126194954&amp;v=2.18.0"/>
        <updated>2024-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic mutations in epigenetic regulators like DNA methyltransferase 3 alpha (DNMT3A), play a pivotal role in driving clonal hematopoiesis of indeterminate potential (CHIP), and are associated with unfavorable outcomes in patients suffering from heart failure (HF). However, the precise interactions between CHIP-mutated cells and other cardiac cell types remain unknown. Here, we identify fibroblasts as potential partners in interactions with CHIP-mutated monocytes. We used combined...]]></summary>
        <author>
            <name>Mariana Shumliakivska</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[DNMT3A clonal hematopoiesis-driver mutations induce cardiac fibrosis by paracrine activation of fibroblasts]]></title>
        <id>pubmed:38242884</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38242884/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240125195050&amp;v=2.18.0"/>
        <updated>2024-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic mutations in epigenetic regulators like DNA methyltransferase 3 alpha (DNMT3A), play a pivotal role in driving clonal hematopoiesis of indeterminate potential (CHIP), and are associated with unfavorable outcomes in patients suffering from heart failure (HF). However, the precise interactions between CHIP-mutated cells and other cardiac cell types remain unknown. Here, we identify fibroblasts as potential partners in interactions with CHIP-mutated monocytes. We used combined...]]></summary>
        <author>
            <name>Mariana Shumliakivska</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[DNMT3A clonal hematopoiesis-driver mutations induce cardiac fibrosis by paracrine activation of fibroblasts]]></title>
        <id>pubmed:38242884</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38242884/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240124195506&amp;v=2.18.0"/>
        <updated>2024-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic mutations in epigenetic regulators like DNA methyltransferase 3 alpha (DNMT3A), play a pivotal role in driving clonal hematopoiesis of indeterminate potential (CHIP), and are associated with unfavorable outcomes in patients suffering from heart failure (HF). However, the precise interactions between CHIP-mutated cells and other cardiac cell types remain unknown. Here, we identify fibroblasts as potential partners in interactions with CHIP-mutated monocytes. We used combined...]]></summary>
        <author>
            <name>Mariana Shumliakivska</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[DNMT3A clonal hematopoiesis-driver mutations induce cardiac fibrosis by paracrine activation of fibroblasts]]></title>
        <id>pubmed:38242884</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38242884/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240123195503&amp;v=2.18.0"/>
        <updated>2024-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic mutations in epigenetic regulators like DNA methyltransferase 3 alpha (DNMT3A), play a pivotal role in driving clonal hematopoiesis of indeterminate potential (CHIP), and are associated with unfavorable outcomes in patients suffering from heart failure (HF). However, the precise interactions between CHIP-mutated cells and other cardiac cell types remain unknown. Here, we identify fibroblasts as potential partners in interactions with CHIP-mutated monocytes. We used combined...]]></summary>
        <author>
            <name>Mariana Shumliakivska</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[DNMT3A clonal hematopoiesis-driver mutations induce cardiac fibrosis by paracrine activation of fibroblasts]]></title>
        <id>pubmed:38242884</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38242884/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240122195511&amp;v=2.18.0"/>
        <updated>2024-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic mutations in epigenetic regulators like DNA methyltransferase 3 alpha (DNMT3A), play a pivotal role in driving clonal hematopoiesis of indeterminate potential (CHIP), and are associated with unfavorable outcomes in patients suffering from heart failure (HF). However, the precise interactions between CHIP-mutated cells and other cardiac cell types remain unknown. Here, we identify fibroblasts as potential partners in interactions with CHIP-mutated monocytes. We used combined...]]></summary>
        <author>
            <name>Mariana Shumliakivska</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[DNMT3A clonal hematopoiesis-driver mutations induce cardiac fibrosis by paracrine activation of fibroblasts]]></title>
        <id>pubmed:38242884</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38242884/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240121195630&amp;v=2.18.0"/>
        <updated>2024-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic mutations in epigenetic regulators like DNA methyltransferase 3 alpha (DNMT3A), play a pivotal role in driving clonal hematopoiesis of indeterminate potential (CHIP), and are associated with unfavorable outcomes in patients suffering from heart failure (HF). However, the precise interactions between CHIP-mutated cells and other cardiac cell types remain unknown. Here, we identify fibroblasts as potential partners in interactions with CHIP-mutated monocytes. We used combined...]]></summary>
        <author>
            <name>Mariana Shumliakivska</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[DNMT3A clonal hematopoiesis-driver mutations induce cardiac fibrosis by paracrine activation of fibroblasts]]></title>
        <id>pubmed:38242884</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38242884/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240120195815&amp;v=2.18.0"/>
        <updated>2024-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic mutations in epigenetic regulators like DNA methyltransferase 3 alpha (DNMT3A), play a pivotal role in driving clonal hematopoiesis of indeterminate potential (CHIP), and are associated with unfavorable outcomes in patients suffering from heart failure (HF). However, the precise interactions between CHIP-mutated cells and other cardiac cell types remain unknown. Here, we identify fibroblasts as potential partners in interactions with CHIP-mutated monocytes. We used combined...]]></summary>
        <author>
            <name>Mariana Shumliakivska</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immunogram defines four cancer-immunity cycle phenotypes with distinct clonal selection patterns across solid tumors]]></title>
        <id>pubmed:38243238</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38243238/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240206194820&amp;v=2.18.0"/>
        <updated>2024-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our findings provide new insight into the interaction between immunity and cancer evolution, which may contribute to optimizing immunotherapy strategies.]]></summary>
        <author>
            <name>Ying Hu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immunogram defines four cancer-immunity cycle phenotypes with distinct clonal selection patterns across solid tumors]]></title>
        <id>pubmed:38243238</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38243238/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240205194943&amp;v=2.18.0"/>
        <updated>2024-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our findings provide new insight into the interaction between immunity and cancer evolution, which may contribute to optimizing immunotherapy strategies.]]></summary>
        <author>
            <name>Ying Hu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immunogram defines four cancer-immunity cycle phenotypes with distinct clonal selection patterns across solid tumors]]></title>
        <id>pubmed:38243238</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38243238/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240204195148&amp;v=2.18.0"/>
        <updated>2024-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our findings provide new insight into the interaction between immunity and cancer evolution, which may contribute to optimizing immunotherapy strategies.]]></summary>
        <author>
            <name>Ying Hu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immunogram defines four cancer-immunity cycle phenotypes with distinct clonal selection patterns across solid tumors]]></title>
        <id>pubmed:38243238</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38243238/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240203195418&amp;v=2.18.0"/>
        <updated>2024-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our findings provide new insight into the interaction between immunity and cancer evolution, which may contribute to optimizing immunotherapy strategies.]]></summary>
        <author>
            <name>Ying Hu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immunogram defines four cancer-immunity cycle phenotypes with distinct clonal selection patterns across solid tumors]]></title>
        <id>pubmed:38243238</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38243238/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240202194939&amp;v=2.18.0"/>
        <updated>2024-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our findings provide new insight into the interaction between immunity and cancer evolution, which may contribute to optimizing immunotherapy strategies.]]></summary>
        <author>
            <name>Ying Hu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immunogram defines four cancer-immunity cycle phenotypes with distinct clonal selection patterns across solid tumors]]></title>
        <id>pubmed:38243238</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38243238/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240201195024&amp;v=2.18.0"/>
        <updated>2024-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our findings provide new insight into the interaction between immunity and cancer evolution, which may contribute to optimizing immunotherapy strategies.]]></summary>
        <author>
            <name>Ying Hu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immunogram defines four cancer-immunity cycle phenotypes with distinct clonal selection patterns across solid tumors]]></title>
        <id>pubmed:38243238</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38243238/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240131195240&amp;v=2.18.0"/>
        <updated>2024-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our findings provide new insight into the interaction between immunity and cancer evolution, which may contribute to optimizing immunotherapy strategies.]]></summary>
        <author>
            <name>Ying Hu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immunogram defines four cancer-immunity cycle phenotypes with distinct clonal selection patterns across solid tumors]]></title>
        <id>pubmed:38243238</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38243238/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240130195039&amp;v=2.18.0"/>
        <updated>2024-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our findings provide new insight into the interaction between immunity and cancer evolution, which may contribute to optimizing immunotherapy strategies.]]></summary>
        <author>
            <name>Ying Hu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immunogram defines four cancer-immunity cycle phenotypes with distinct clonal selection patterns across solid tumors]]></title>
        <id>pubmed:38243238</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38243238/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240129195013&amp;v=2.18.0"/>
        <updated>2024-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our findings provide new insight into the interaction between immunity and cancer evolution, which may contribute to optimizing immunotherapy strategies.]]></summary>
        <author>
            <name>Ying Hu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immunogram defines four cancer-immunity cycle phenotypes with distinct clonal selection patterns across solid tumors]]></title>
        <id>pubmed:38243238</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38243238/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240128195055&amp;v=2.18.0"/>
        <updated>2024-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our findings provide new insight into the interaction between immunity and cancer evolution, which may contribute to optimizing immunotherapy strategies.]]></summary>
        <author>
            <name>Ying Hu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immunogram defines four cancer-immunity cycle phenotypes with distinct clonal selection patterns across solid tumors]]></title>
        <id>pubmed:38243238</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38243238/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240127195322&amp;v=2.18.0"/>
        <updated>2024-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our findings provide new insight into the interaction between immunity and cancer evolution, which may contribute to optimizing immunotherapy strategies.]]></summary>
        <author>
            <name>Ying Hu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immunogram defines four cancer-immunity cycle phenotypes with distinct clonal selection patterns across solid tumors]]></title>
        <id>pubmed:38243238</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38243238/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240126194954&amp;v=2.18.0"/>
        <updated>2024-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our findings provide new insight into the interaction between immunity and cancer evolution, which may contribute to optimizing immunotherapy strategies.]]></summary>
        <author>
            <name>Ying Hu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immunogram defines four cancer-immunity cycle phenotypes with distinct clonal selection patterns across solid tumors]]></title>
        <id>pubmed:38243238</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38243238/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240125195050&amp;v=2.18.0"/>
        <updated>2024-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our findings provide new insight into the interaction between immunity and cancer evolution, which may contribute to optimizing immunotherapy strategies.]]></summary>
        <author>
            <name>Ying Hu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immunogram defines four cancer-immunity cycle phenotypes with distinct clonal selection patterns across solid tumors]]></title>
        <id>pubmed:38243238</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38243238/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240124195506&amp;v=2.18.0"/>
        <updated>2024-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our findings provide new insight into the interaction between immunity and cancer evolution, which may contribute to optimizing immunotherapy strategies.]]></summary>
        <author>
            <name>Ying Hu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immunogram defines four cancer-immunity cycle phenotypes with distinct clonal selection patterns across solid tumors]]></title>
        <id>pubmed:38243238</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38243238/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240123195503&amp;v=2.18.0"/>
        <updated>2024-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our findings provide new insight into the interaction between immunity and cancer evolution, which may contribute to optimizing immunotherapy strategies.]]></summary>
        <author>
            <name>Ying Hu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immunogram defines four cancer-immunity cycle phenotypes with distinct clonal selection patterns across solid tumors]]></title>
        <id>pubmed:38243238</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38243238/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240122195511&amp;v=2.18.0"/>
        <updated>2024-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our findings provide new insight into the interaction between immunity and cancer evolution, which may contribute to optimizing immunotherapy strategies.]]></summary>
        <author>
            <name>Ying Hu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immunogram defines four cancer-immunity cycle phenotypes with distinct clonal selection patterns across solid tumors]]></title>
        <id>pubmed:38243238</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38243238/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240121195630&amp;v=2.18.0"/>
        <updated>2024-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our findings provide new insight into the interaction between immunity and cancer evolution, which may contribute to optimizing immunotherapy strategies.]]></summary>
        <author>
            <name>Ying Hu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immunogram defines four cancer-immunity cycle phenotypes with distinct clonal selection patterns across solid tumors]]></title>
        <id>pubmed:38243238</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38243238/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240120195815&amp;v=2.18.0"/>
        <updated>2024-01-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our findings provide new insight into the interaction between immunity and cancer evolution, which may contribute to optimizing immunotherapy strategies.]]></summary>
        <author>
            <name>Ying Hu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline and Somatic Mutations in DNA Methyltransferase 3A <em>(DNMT3A)</em> Predispose to Pulmonary Arterial Hypertension (PAH) in Humans and Mice: <em>Implications for Associated PAH</em>]]></title>
        <id>pubmed:38234783</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38234783/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240204195148&amp;v=2.18.0"/>
        <updated>2024-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Germline and acquired DNMT3A variants predispose to PAH in humans. DNMT3A mRNA expression is reduced in human PAH PBMCs. Hematopoietic depletion of Dnmt3a causes inflammatory PAH in mice. DNMT3A is a novel APAH gene and may be a biomarker and therapeutic target.]]></summary>
        <author>
            <name>Ruaa Al-Qazazi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline and Somatic Mutations in DNA Methyltransferase 3A <em>(DNMT3A)</em> Predispose to Pulmonary Arterial Hypertension (PAH) in Humans and Mice: <em>Implications for Associated PAH</em>]]></title>
        <id>pubmed:38234783</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38234783/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240203195418&amp;v=2.18.0"/>
        <updated>2024-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Germline and acquired DNMT3A variants predispose to PAH in humans. DNMT3A mRNA expression is reduced in human PAH PBMCs. Hematopoietic depletion of Dnmt3a causes inflammatory PAH in mice. DNMT3A is a novel APAH gene and may be a biomarker and therapeutic target.]]></summary>
        <author>
            <name>Ruaa Al-Qazazi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline and Somatic Mutations in DNA Methyltransferase 3A <em>(DNMT3A)</em> Predispose to Pulmonary Arterial Hypertension (PAH) in Humans and Mice: <em>Implications for Associated PAH</em>]]></title>
        <id>pubmed:38234783</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38234783/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240202194939&amp;v=2.18.0"/>
        <updated>2024-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Germline and acquired DNMT3A variants predispose to PAH in humans. DNMT3A mRNA expression is reduced in human PAH PBMCs. Hematopoietic depletion of Dnmt3a causes inflammatory PAH in mice. DNMT3A is a novel APAH gene and may be a biomarker and therapeutic target.]]></summary>
        <author>
            <name>Ruaa Al-Qazazi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline and Somatic Mutations in DNA Methyltransferase 3A <em>(DNMT3A)</em> Predispose to Pulmonary Arterial Hypertension (PAH) in Humans and Mice: <em>Implications for Associated PAH</em>]]></title>
        <id>pubmed:38234783</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38234783/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240201195024&amp;v=2.18.0"/>
        <updated>2024-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Germline and acquired DNMT3A variants predispose to PAH in humans. DNMT3A mRNA expression is reduced in human PAH PBMCs. Hematopoietic depletion of Dnmt3a causes inflammatory PAH in mice. DNMT3A is a novel APAH gene and may be a biomarker and therapeutic target.]]></summary>
        <author>
            <name>Ruaa Al-Qazazi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline and Somatic Mutations in DNA Methyltransferase 3A <em>(DNMT3A)</em> Predispose to Pulmonary Arterial Hypertension (PAH) in Humans and Mice: <em>Implications for Associated PAH</em>]]></title>
        <id>pubmed:38234783</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38234783/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240131195240&amp;v=2.18.0"/>
        <updated>2024-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Germline and acquired DNMT3A variants predispose to PAH in humans. DNMT3A mRNA expression is reduced in human PAH PBMCs. Hematopoietic depletion of Dnmt3a causes inflammatory PAH in mice. DNMT3A is a novel APAH gene and may be a biomarker and therapeutic target.]]></summary>
        <author>
            <name>Ruaa Al-Qazazi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline and Somatic Mutations in DNA Methyltransferase 3A <em>(DNMT3A)</em> Predispose to Pulmonary Arterial Hypertension (PAH) in Humans and Mice: <em>Implications for Associated PAH</em>]]></title>
        <id>pubmed:38234783</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38234783/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240130195039&amp;v=2.18.0"/>
        <updated>2024-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Germline and acquired DNMT3A variants predispose to PAH in humans. DNMT3A mRNA expression is reduced in human PAH PBMCs. Hematopoietic depletion of Dnmt3a causes inflammatory PAH in mice. DNMT3A is a novel APAH gene and may be a biomarker and therapeutic target.]]></summary>
        <author>
            <name>Ruaa Al-Qazazi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline and Somatic Mutations in DNA Methyltransferase 3A <em>(DNMT3A)</em> Predispose to Pulmonary Arterial Hypertension (PAH) in Humans and Mice: <em>Implications for Associated PAH</em>]]></title>
        <id>pubmed:38234783</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38234783/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240129195013&amp;v=2.18.0"/>
        <updated>2024-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Germline and acquired DNMT3A variants predispose to PAH in humans. DNMT3A mRNA expression is reduced in human PAH PBMCs. Hematopoietic depletion of Dnmt3a causes inflammatory PAH in mice. DNMT3A is a novel APAH gene and may be a biomarker and therapeutic target.]]></summary>
        <author>
            <name>Ruaa Al-Qazazi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline and Somatic Mutations in DNA Methyltransferase 3A <em>(DNMT3A)</em> Predispose to Pulmonary Arterial Hypertension (PAH) in Humans and Mice: <em>Implications for Associated PAH</em>]]></title>
        <id>pubmed:38234783</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38234783/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240128195055&amp;v=2.18.0"/>
        <updated>2024-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Germline and acquired DNMT3A variants predispose to PAH in humans. DNMT3A mRNA expression is reduced in human PAH PBMCs. Hematopoietic depletion of Dnmt3a causes inflammatory PAH in mice. DNMT3A is a novel APAH gene and may be a biomarker and therapeutic target.]]></summary>
        <author>
            <name>Ruaa Al-Qazazi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline and Somatic Mutations in DNA Methyltransferase 3A <em>(DNMT3A)</em> Predispose to Pulmonary Arterial Hypertension (PAH) in Humans and Mice: <em>Implications for Associated PAH</em>]]></title>
        <id>pubmed:38234783</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38234783/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240127195322&amp;v=2.18.0"/>
        <updated>2024-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Germline and acquired DNMT3A variants predispose to PAH in humans. DNMT3A mRNA expression is reduced in human PAH PBMCs. Hematopoietic depletion of Dnmt3a causes inflammatory PAH in mice. DNMT3A is a novel APAH gene and may be a biomarker and therapeutic target.]]></summary>
        <author>
            <name>Ruaa Al-Qazazi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline and Somatic Mutations in DNA Methyltransferase 3A <em>(DNMT3A)</em> Predispose to Pulmonary Arterial Hypertension (PAH) in Humans and Mice: <em>Implications for Associated PAH</em>]]></title>
        <id>pubmed:38234783</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38234783/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240126194954&amp;v=2.18.0"/>
        <updated>2024-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Germline and acquired DNMT3A variants predispose to PAH in humans. DNMT3A mRNA expression is reduced in human PAH PBMCs. Hematopoietic depletion of Dnmt3a causes inflammatory PAH in mice. DNMT3A is a novel APAH gene and may be a biomarker and therapeutic target.]]></summary>
        <author>
            <name>Ruaa Al-Qazazi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline and Somatic Mutations in DNA Methyltransferase 3A <em>(DNMT3A)</em> Predispose to Pulmonary Arterial Hypertension (PAH) in Humans and Mice: <em>Implications for Associated PAH</em>]]></title>
        <id>pubmed:38234783</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38234783/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240125195050&amp;v=2.18.0"/>
        <updated>2024-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Germline and acquired DNMT3A variants predispose to PAH in humans. DNMT3A mRNA expression is reduced in human PAH PBMCs. Hematopoietic depletion of Dnmt3a causes inflammatory PAH in mice. DNMT3A is a novel APAH gene and may be a biomarker and therapeutic target.]]></summary>
        <author>
            <name>Ruaa Al-Qazazi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline and Somatic Mutations in DNA Methyltransferase 3A <em>(DNMT3A)</em> Predispose to Pulmonary Arterial Hypertension (PAH) in Humans and Mice: <em>Implications for Associated PAH</em>]]></title>
        <id>pubmed:38234783</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38234783/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240124195506&amp;v=2.18.0"/>
        <updated>2024-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Germline and acquired DNMT3A variants predispose to PAH in humans. DNMT3A mRNA expression is reduced in human PAH PBMCs. Hematopoietic depletion of Dnmt3a causes inflammatory PAH in mice. DNMT3A is a novel APAH gene and may be a biomarker and therapeutic target.]]></summary>
        <author>
            <name>Ruaa Al-Qazazi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline and Somatic Mutations in DNA Methyltransferase 3A <em>(DNMT3A)</em> Predispose to Pulmonary Arterial Hypertension (PAH) in Humans and Mice: <em>Implications for Associated PAH</em>]]></title>
        <id>pubmed:38234783</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38234783/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240123195503&amp;v=2.18.0"/>
        <updated>2024-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Germline and acquired DNMT3A variants predispose to PAH in humans. DNMT3A mRNA expression is reduced in human PAH PBMCs. Hematopoietic depletion of Dnmt3a causes inflammatory PAH in mice. DNMT3A is a novel APAH gene and may be a biomarker and therapeutic target.]]></summary>
        <author>
            <name>Ruaa Al-Qazazi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline and Somatic Mutations in DNA Methyltransferase 3A <em>(DNMT3A)</em> Predispose to Pulmonary Arterial Hypertension (PAH) in Humans and Mice: <em>Implications for Associated PAH</em>]]></title>
        <id>pubmed:38234783</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38234783/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240122195511&amp;v=2.18.0"/>
        <updated>2024-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Germline and acquired DNMT3A variants predispose to PAH in humans. DNMT3A mRNA expression is reduced in human PAH PBMCs. Hematopoietic depletion of Dnmt3a causes inflammatory PAH in mice. DNMT3A is a novel APAH gene and may be a biomarker and therapeutic target.]]></summary>
        <author>
            <name>Ruaa Al-Qazazi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline and Somatic Mutations in DNA Methyltransferase 3A <em>(DNMT3A)</em> Predispose to Pulmonary Arterial Hypertension (PAH) in Humans and Mice: <em>Implications for Associated PAH</em>]]></title>
        <id>pubmed:38234783</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38234783/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240121195630&amp;v=2.18.0"/>
        <updated>2024-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Germline and acquired DNMT3A variants predispose to PAH in humans. DNMT3A mRNA expression is reduced in human PAH PBMCs. Hematopoietic depletion of Dnmt3a causes inflammatory PAH in mice. DNMT3A is a novel APAH gene and may be a biomarker and therapeutic target.]]></summary>
        <author>
            <name>Ruaa Al-Qazazi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline and Somatic Mutations in DNA Methyltransferase 3A <em>(DNMT3A)</em> Predispose to Pulmonary Arterial Hypertension (PAH) in Humans and Mice: <em>Implications for Associated PAH</em>]]></title>
        <id>pubmed:38234783</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38234783/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240120195815&amp;v=2.18.0"/>
        <updated>2024-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Germline and acquired DNMT3A variants predispose to PAH in humans. DNMT3A mRNA expression is reduced in human PAH PBMCs. Hematopoietic depletion of Dnmt3a causes inflammatory PAH in mice. DNMT3A is a novel APAH gene and may be a biomarker and therapeutic target.]]></summary>
        <author>
            <name>Ruaa Al-Qazazi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline and Somatic Mutations in DNA Methyltransferase 3A <em>(DNMT3A)</em> Predispose to Pulmonary Arterial Hypertension (PAH) in Humans and Mice: <em>Implications for Associated PAH</em>]]></title>
        <id>pubmed:38234783</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38234783/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240119195313&amp;v=2.18.0"/>
        <updated>2024-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Germline and acquired DNMT3A variants predispose to PAH in humans. DNMT3A mRNA expression is reduced in human PAH PBMCs. Hematopoietic depletion of Dnmt3a causes inflammatory PAH in mice. DNMT3A is a novel APAH gene and may be a biomarker and therapeutic target.]]></summary>
        <author>
            <name>Ruaa Al-Qazazi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline and Somatic Mutations in DNA Methyltransferase 3A <em>(DNMT3A)</em> Predispose to Pulmonary Arterial Hypertension (PAH) in Humans and Mice: <em>Implications for Associated PAH</em>]]></title>
        <id>pubmed:38234783</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38234783/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240118195421&amp;v=2.18.0"/>
        <updated>2024-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Germline and acquired DNMT3A variants predispose to PAH in humans. DNMT3A mRNA expression is reduced in human PAH PBMCs. Hematopoietic depletion of Dnmt3a causes inflammatory PAH in mice. DNMT3A is a novel APAH gene and may be a biomarker and therapeutic target.]]></summary>
        <author>
            <name>Ruaa Al-Qazazi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical application of tumour-in-normal contamination assessment from whole genome sequencing]]></title>
        <id>pubmed:38238294</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38238294/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240206194820&amp;v=2.18.0"/>
        <updated>2024-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The unexpected contamination of normal samples with tumour cells reduces variant detection sensitivity, compromising downstream analyses in canonical tumour-normal analyses. Leveraging whole-genome sequencing data available at Genomics England, we develop a tool for normal sample contamination assessment, which we validate in silico and against minimal residual disease testing. From a systematic review of [Formula: see text] patients with haematological malignancies and sarcomas, we find...]]></summary>
        <author>
            <name>Jonathan Mitchell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical application of tumour-in-normal contamination assessment from whole genome sequencing]]></title>
        <id>pubmed:38238294</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38238294/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240205194943&amp;v=2.18.0"/>
        <updated>2024-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The unexpected contamination of normal samples with tumour cells reduces variant detection sensitivity, compromising downstream analyses in canonical tumour-normal analyses. Leveraging whole-genome sequencing data available at Genomics England, we develop a tool for normal sample contamination assessment, which we validate in silico and against minimal residual disease testing. From a systematic review of [Formula: see text] patients with haematological malignancies and sarcomas, we find...]]></summary>
        <author>
            <name>Jonathan Mitchell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical application of tumour-in-normal contamination assessment from whole genome sequencing]]></title>
        <id>pubmed:38238294</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38238294/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240204195148&amp;v=2.18.0"/>
        <updated>2024-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The unexpected contamination of normal samples with tumour cells reduces variant detection sensitivity, compromising downstream analyses in canonical tumour-normal analyses. Leveraging whole-genome sequencing data available at Genomics England, we develop a tool for normal sample contamination assessment, which we validate in silico and against minimal residual disease testing. From a systematic review of [Formula: see text] patients with haematological malignancies and sarcomas, we find...]]></summary>
        <author>
            <name>Jonathan Mitchell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical application of tumour-in-normal contamination assessment from whole genome sequencing]]></title>
        <id>pubmed:38238294</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38238294/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240203195418&amp;v=2.18.0"/>
        <updated>2024-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The unexpected contamination of normal samples with tumour cells reduces variant detection sensitivity, compromising downstream analyses in canonical tumour-normal analyses. Leveraging whole-genome sequencing data available at Genomics England, we develop a tool for normal sample contamination assessment, which we validate in silico and against minimal residual disease testing. From a systematic review of [Formula: see text] patients with haematological malignancies and sarcomas, we find...]]></summary>
        <author>
            <name>Jonathan Mitchell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical application of tumour-in-normal contamination assessment from whole genome sequencing]]></title>
        <id>pubmed:38238294</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38238294/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240202194939&amp;v=2.18.0"/>
        <updated>2024-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The unexpected contamination of normal samples with tumour cells reduces variant detection sensitivity, compromising downstream analyses in canonical tumour-normal analyses. Leveraging whole-genome sequencing data available at Genomics England, we develop a tool for normal sample contamination assessment, which we validate in silico and against minimal residual disease testing. From a systematic review of [Formula: see text] patients with haematological malignancies and sarcomas, we find...]]></summary>
        <author>
            <name>Jonathan Mitchell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical application of tumour-in-normal contamination assessment from whole genome sequencing]]></title>
        <id>pubmed:38238294</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38238294/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240201195024&amp;v=2.18.0"/>
        <updated>2024-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The unexpected contamination of normal samples with tumour cells reduces variant detection sensitivity, compromising downstream analyses in canonical tumour-normal analyses. Leveraging whole-genome sequencing data available at Genomics England, we develop a tool for normal sample contamination assessment, which we validate in silico and against minimal residual disease testing. From a systematic review of [Formula: see text] patients with haematological malignancies and sarcomas, we find...]]></summary>
        <author>
            <name>Jonathan Mitchell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical application of tumour-in-normal contamination assessment from whole genome sequencing]]></title>
        <id>pubmed:38238294</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38238294/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240131195240&amp;v=2.18.0"/>
        <updated>2024-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The unexpected contamination of normal samples with tumour cells reduces variant detection sensitivity, compromising downstream analyses in canonical tumour-normal analyses. Leveraging whole-genome sequencing data available at Genomics England, we develop a tool for normal sample contamination assessment, which we validate in silico and against minimal residual disease testing. From a systematic review of [Formula: see text] patients with haematological malignancies and sarcomas, we find...]]></summary>
        <author>
            <name>Jonathan Mitchell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical application of tumour-in-normal contamination assessment from whole genome sequencing]]></title>
        <id>pubmed:38238294</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38238294/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240130195039&amp;v=2.18.0"/>
        <updated>2024-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The unexpected contamination of normal samples with tumour cells reduces variant detection sensitivity, compromising downstream analyses in canonical tumour-normal analyses. Leveraging whole-genome sequencing data available at Genomics England, we develop a tool for normal sample contamination assessment, which we validate in silico and against minimal residual disease testing. From a systematic review of [Formula: see text] patients with haematological malignancies and sarcomas, we find...]]></summary>
        <author>
            <name>Jonathan Mitchell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical application of tumour-in-normal contamination assessment from whole genome sequencing]]></title>
        <id>pubmed:38238294</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38238294/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240129195013&amp;v=2.18.0"/>
        <updated>2024-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The unexpected contamination of normal samples with tumour cells reduces variant detection sensitivity, compromising downstream analyses in canonical tumour-normal analyses. Leveraging whole-genome sequencing data available at Genomics England, we develop a tool for normal sample contamination assessment, which we validate in silico and against minimal residual disease testing. From a systematic review of [Formula: see text] patients with haematological malignancies and sarcomas, we find...]]></summary>
        <author>
            <name>Jonathan Mitchell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical application of tumour-in-normal contamination assessment from whole genome sequencing]]></title>
        <id>pubmed:38238294</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38238294/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240128195055&amp;v=2.18.0"/>
        <updated>2024-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The unexpected contamination of normal samples with tumour cells reduces variant detection sensitivity, compromising downstream analyses in canonical tumour-normal analyses. Leveraging whole-genome sequencing data available at Genomics England, we develop a tool for normal sample contamination assessment, which we validate in silico and against minimal residual disease testing. From a systematic review of [Formula: see text] patients with haematological malignancies and sarcomas, we find...]]></summary>
        <author>
            <name>Jonathan Mitchell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical application of tumour-in-normal contamination assessment from whole genome sequencing]]></title>
        <id>pubmed:38238294</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38238294/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240127195322&amp;v=2.18.0"/>
        <updated>2024-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The unexpected contamination of normal samples with tumour cells reduces variant detection sensitivity, compromising downstream analyses in canonical tumour-normal analyses. Leveraging whole-genome sequencing data available at Genomics England, we develop a tool for normal sample contamination assessment, which we validate in silico and against minimal residual disease testing. From a systematic review of [Formula: see text] patients with haematological malignancies and sarcomas, we find...]]></summary>
        <author>
            <name>Jonathan Mitchell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical application of tumour-in-normal contamination assessment from whole genome sequencing]]></title>
        <id>pubmed:38238294</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38238294/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240126194954&amp;v=2.18.0"/>
        <updated>2024-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The unexpected contamination of normal samples with tumour cells reduces variant detection sensitivity, compromising downstream analyses in canonical tumour-normal analyses. Leveraging whole-genome sequencing data available at Genomics England, we develop a tool for normal sample contamination assessment, which we validate in silico and against minimal residual disease testing. From a systematic review of [Formula: see text] patients with haematological malignancies and sarcomas, we find...]]></summary>
        <author>
            <name>Jonathan Mitchell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical application of tumour-in-normal contamination assessment from whole genome sequencing]]></title>
        <id>pubmed:38238294</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38238294/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240125195050&amp;v=2.18.0"/>
        <updated>2024-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The unexpected contamination of normal samples with tumour cells reduces variant detection sensitivity, compromising downstream analyses in canonical tumour-normal analyses. Leveraging whole-genome sequencing data available at Genomics England, we develop a tool for normal sample contamination assessment, which we validate in silico and against minimal residual disease testing. From a systematic review of [Formula: see text] patients with haematological malignancies and sarcomas, we find...]]></summary>
        <author>
            <name>Jonathan Mitchell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical application of tumour-in-normal contamination assessment from whole genome sequencing]]></title>
        <id>pubmed:38238294</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38238294/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240124195506&amp;v=2.18.0"/>
        <updated>2024-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The unexpected contamination of normal samples with tumour cells reduces variant detection sensitivity, compromising downstream analyses in canonical tumour-normal analyses. Leveraging whole-genome sequencing data available at Genomics England, we develop a tool for normal sample contamination assessment, which we validate in silico and against minimal residual disease testing. From a systematic review of [Formula: see text] patients with haematological malignancies and sarcomas, we find...]]></summary>
        <author>
            <name>Jonathan Mitchell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical application of tumour-in-normal contamination assessment from whole genome sequencing]]></title>
        <id>pubmed:38238294</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38238294/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240123195503&amp;v=2.18.0"/>
        <updated>2024-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The unexpected contamination of normal samples with tumour cells reduces variant detection sensitivity, compromising downstream analyses in canonical tumour-normal analyses. Leveraging whole-genome sequencing data available at Genomics England, we develop a tool for normal sample contamination assessment, which we validate in silico and against minimal residual disease testing. From a systematic review of [Formula: see text] patients with haematological malignancies and sarcomas, we find...]]></summary>
        <author>
            <name>Jonathan Mitchell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical application of tumour-in-normal contamination assessment from whole genome sequencing]]></title>
        <id>pubmed:38238294</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38238294/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240122195511&amp;v=2.18.0"/>
        <updated>2024-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The unexpected contamination of normal samples with tumour cells reduces variant detection sensitivity, compromising downstream analyses in canonical tumour-normal analyses. Leveraging whole-genome sequencing data available at Genomics England, we develop a tool for normal sample contamination assessment, which we validate in silico and against minimal residual disease testing. From a systematic review of [Formula: see text] patients with haematological malignancies and sarcomas, we find...]]></summary>
        <author>
            <name>Jonathan Mitchell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical application of tumour-in-normal contamination assessment from whole genome sequencing]]></title>
        <id>pubmed:38238294</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38238294/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240121195630&amp;v=2.18.0"/>
        <updated>2024-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The unexpected contamination of normal samples with tumour cells reduces variant detection sensitivity, compromising downstream analyses in canonical tumour-normal analyses. Leveraging whole-genome sequencing data available at Genomics England, we develop a tool for normal sample contamination assessment, which we validate in silico and against minimal residual disease testing. From a systematic review of [Formula: see text] patients with haematological malignancies and sarcomas, we find...]]></summary>
        <author>
            <name>Jonathan Mitchell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical application of tumour-in-normal contamination assessment from whole genome sequencing]]></title>
        <id>pubmed:38238294</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38238294/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240120195815&amp;v=2.18.0"/>
        <updated>2024-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The unexpected contamination of normal samples with tumour cells reduces variant detection sensitivity, compromising downstream analyses in canonical tumour-normal analyses. Leveraging whole-genome sequencing data available at Genomics England, we develop a tool for normal sample contamination assessment, which we validate in silico and against minimal residual disease testing. From a systematic review of [Formula: see text] patients with haematological malignancies and sarcomas, we find...]]></summary>
        <author>
            <name>Jonathan Mitchell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical application of tumour-in-normal contamination assessment from whole genome sequencing]]></title>
        <id>pubmed:38238294</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38238294/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240119195313&amp;v=2.18.0"/>
        <updated>2024-01-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The unexpected contamination of normal samples with tumour cells reduces variant detection sensitivity, compromising downstream analyses in canonical tumour-normal analyses. Leveraging whole-genome sequencing data available at Genomics England, we develop a tool for normal sample contamination assessment, which we validate in silico and against minimal residual disease testing. From a systematic review of [Formula: see text] patients with haematological malignancies and sarcomas, we find...]]></summary>
        <author>
            <name>Jonathan Mitchell</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Risk Score and All-Cause and Cardiovascular Mortality in Older Adults]]></title>
        <id>pubmed:38231513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38231513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240204195148&amp;v=2.18.0"/>
        <updated>2024-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: In this cohort study, the CHRS was associated with all-cause, HM-related, and cardiovascular disease mortality in older adults with CH and may be useful in shared decision-making to guide clinical management and identify appropriate candidates for clinical trials.]]></summary>
        <author>
            <name>Seyedmohammad Saadatagah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Risk Score and All-Cause and Cardiovascular Mortality in Older Adults]]></title>
        <id>pubmed:38231513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38231513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240203195418&amp;v=2.18.0"/>
        <updated>2024-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: In this cohort study, the CHRS was associated with all-cause, HM-related, and cardiovascular disease mortality in older adults with CH and may be useful in shared decision-making to guide clinical management and identify appropriate candidates for clinical trials.]]></summary>
        <author>
            <name>Seyedmohammad Saadatagah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Risk Score and All-Cause and Cardiovascular Mortality in Older Adults]]></title>
        <id>pubmed:38231513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38231513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240202194939&amp;v=2.18.0"/>
        <updated>2024-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: In this cohort study, the CHRS was associated with all-cause, HM-related, and cardiovascular disease mortality in older adults with CH and may be useful in shared decision-making to guide clinical management and identify appropriate candidates for clinical trials.]]></summary>
        <author>
            <name>Seyedmohammad Saadatagah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Risk Score and All-Cause and Cardiovascular Mortality in Older Adults]]></title>
        <id>pubmed:38231513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38231513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240201195024&amp;v=2.18.0"/>
        <updated>2024-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: In this cohort study, the CHRS was associated with all-cause, HM-related, and cardiovascular disease mortality in older adults with CH and may be useful in shared decision-making to guide clinical management and identify appropriate candidates for clinical trials.]]></summary>
        <author>
            <name>Seyedmohammad Saadatagah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Risk Score and All-Cause and Cardiovascular Mortality in Older Adults]]></title>
        <id>pubmed:38231513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38231513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240131195240&amp;v=2.18.0"/>
        <updated>2024-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: In this cohort study, the CHRS was associated with all-cause, HM-related, and cardiovascular disease mortality in older adults with CH and may be useful in shared decision-making to guide clinical management and identify appropriate candidates for clinical trials.]]></summary>
        <author>
            <name>Seyedmohammad Saadatagah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Risk Score and All-Cause and Cardiovascular Mortality in Older Adults]]></title>
        <id>pubmed:38231513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38231513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240130195039&amp;v=2.18.0"/>
        <updated>2024-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: In this cohort study, the CHRS was associated with all-cause, HM-related, and cardiovascular disease mortality in older adults with CH and may be useful in shared decision-making to guide clinical management and identify appropriate candidates for clinical trials.]]></summary>
        <author>
            <name>Seyedmohammad Saadatagah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Risk Score and All-Cause and Cardiovascular Mortality in Older Adults]]></title>
        <id>pubmed:38231513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38231513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240129195013&amp;v=2.18.0"/>
        <updated>2024-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: In this cohort study, the CHRS was associated with all-cause, HM-related, and cardiovascular disease mortality in older adults with CH and may be useful in shared decision-making to guide clinical management and identify appropriate candidates for clinical trials.]]></summary>
        <author>
            <name>Seyedmohammad Saadatagah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Risk Score and All-Cause and Cardiovascular Mortality in Older Adults]]></title>
        <id>pubmed:38231513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38231513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240128195055&amp;v=2.18.0"/>
        <updated>2024-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: In this cohort study, the CHRS was associated with all-cause, HM-related, and cardiovascular disease mortality in older adults with CH and may be useful in shared decision-making to guide clinical management and identify appropriate candidates for clinical trials.]]></summary>
        <author>
            <name>Seyedmohammad Saadatagah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Risk Score and All-Cause and Cardiovascular Mortality in Older Adults]]></title>
        <id>pubmed:38231513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38231513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240127195322&amp;v=2.18.0"/>
        <updated>2024-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: In this cohort study, the CHRS was associated with all-cause, HM-related, and cardiovascular disease mortality in older adults with CH and may be useful in shared decision-making to guide clinical management and identify appropriate candidates for clinical trials.]]></summary>
        <author>
            <name>Seyedmohammad Saadatagah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Risk Score and All-Cause and Cardiovascular Mortality in Older Adults]]></title>
        <id>pubmed:38231513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38231513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240126194954&amp;v=2.18.0"/>
        <updated>2024-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: In this cohort study, the CHRS was associated with all-cause, HM-related, and cardiovascular disease mortality in older adults with CH and may be useful in shared decision-making to guide clinical management and identify appropriate candidates for clinical trials.]]></summary>
        <author>
            <name>Seyedmohammad Saadatagah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Risk Score and All-Cause and Cardiovascular Mortality in Older Adults]]></title>
        <id>pubmed:38231513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38231513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240125195050&amp;v=2.18.0"/>
        <updated>2024-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: In this cohort study, the CHRS was associated with all-cause, HM-related, and cardiovascular disease mortality in older adults with CH and may be useful in shared decision-making to guide clinical management and identify appropriate candidates for clinical trials.]]></summary>
        <author>
            <name>Seyedmohammad Saadatagah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Risk Score and All-Cause and Cardiovascular Mortality in Older Adults]]></title>
        <id>pubmed:38231513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38231513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240124195506&amp;v=2.18.0"/>
        <updated>2024-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: In this cohort study, the CHRS was associated with all-cause, HM-related, and cardiovascular disease mortality in older adults with CH and may be useful in shared decision-making to guide clinical management and identify appropriate candidates for clinical trials.]]></summary>
        <author>
            <name>Seyedmohammad Saadatagah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Risk Score and All-Cause and Cardiovascular Mortality in Older Adults]]></title>
        <id>pubmed:38231513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38231513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240123195503&amp;v=2.18.0"/>
        <updated>2024-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: In this cohort study, the CHRS was associated with all-cause, HM-related, and cardiovascular disease mortality in older adults with CH and may be useful in shared decision-making to guide clinical management and identify appropriate candidates for clinical trials.]]></summary>
        <author>
            <name>Seyedmohammad Saadatagah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Risk Score and All-Cause and Cardiovascular Mortality in Older Adults]]></title>
        <id>pubmed:38231513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38231513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240122195511&amp;v=2.18.0"/>
        <updated>2024-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: In this cohort study, the CHRS was associated with all-cause, HM-related, and cardiovascular disease mortality in older adults with CH and may be useful in shared decision-making to guide clinical management and identify appropriate candidates for clinical trials.]]></summary>
        <author>
            <name>Seyedmohammad Saadatagah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Risk Score and All-Cause and Cardiovascular Mortality in Older Adults]]></title>
        <id>pubmed:38231513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38231513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240121195630&amp;v=2.18.0"/>
        <updated>2024-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: In this cohort study, the CHRS was associated with all-cause, HM-related, and cardiovascular disease mortality in older adults with CH and may be useful in shared decision-making to guide clinical management and identify appropriate candidates for clinical trials.]]></summary>
        <author>
            <name>Seyedmohammad Saadatagah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Risk Score and All-Cause and Cardiovascular Mortality in Older Adults]]></title>
        <id>pubmed:38231513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38231513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240120195815&amp;v=2.18.0"/>
        <updated>2024-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: In this cohort study, the CHRS was associated with all-cause, HM-related, and cardiovascular disease mortality in older adults with CH and may be useful in shared decision-making to guide clinical management and identify appropriate candidates for clinical trials.]]></summary>
        <author>
            <name>Seyedmohammad Saadatagah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Risk Score and All-Cause and Cardiovascular Mortality in Older Adults]]></title>
        <id>pubmed:38231513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38231513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240119195313&amp;v=2.18.0"/>
        <updated>2024-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: In this cohort study, the CHRS was associated with all-cause, HM-related, and cardiovascular disease mortality in older adults with CH and may be useful in shared decision-making to guide clinical management and identify appropriate candidates for clinical trials.]]></summary>
        <author>
            <name>Seyedmohammad Saadatagah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Risk Score and All-Cause and Cardiovascular Mortality in Older Adults]]></title>
        <id>pubmed:38231513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38231513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240118195421&amp;v=2.18.0"/>
        <updated>2024-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: In this cohort study, the CHRS was associated with all-cause, HM-related, and cardiovascular disease mortality in older adults with CH and may be useful in shared decision-making to guide clinical management and identify appropriate candidates for clinical trials.]]></summary>
        <author>
            <name>Seyedmohammad Saadatagah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Risk Score and All-Cause and Cardiovascular Mortality in Older Adults]]></title>
        <id>pubmed:38231513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38231513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240117195336&amp;v=2.18.0"/>
        <updated>2024-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: In this cohort study, the CHRS was associated with all-cause, HM-related, and cardiovascular disease mortality in older adults with CH and may be useful in shared decision-making to guide clinical management and identify appropriate candidates for clinical trials.]]></summary>
        <author>
            <name>Seyedmohammad Saadatagah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Risk Score and All-Cause and Cardiovascular Mortality in Older Adults]]></title>
        <id>pubmed:38231513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38231513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240206194820&amp;v=2.18.0"/>
        <updated>2024-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: In this cohort study, the CHRS was associated with all-cause, HM-related, and cardiovascular disease mortality in older adults with CH and may be useful in shared decision-making to guide clinical management and identify appropriate candidates for clinical trials.]]></summary>
        <author>
            <name>Seyedmohammad Saadatagah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Risk Score and All-Cause and Cardiovascular Mortality in Older Adults]]></title>
        <id>pubmed:38231513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38231513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240205194943&amp;v=2.18.0"/>
        <updated>2024-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: In this cohort study, the CHRS was associated with all-cause, HM-related, and cardiovascular disease mortality in older adults with CH and may be useful in shared decision-making to guide clinical management and identify appropriate candidates for clinical trials.]]></summary>
        <author>
            <name>Seyedmohammad Saadatagah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Risk Score and All-Cause and Cardiovascular Mortality in Older Adults]]></title>
        <id>pubmed:38231513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38231513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240204195148&amp;v=2.18.0"/>
        <updated>2024-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: In this cohort study, the CHRS was associated with all-cause, HM-related, and cardiovascular disease mortality in older adults with CH and may be useful in shared decision-making to guide clinical management and identify appropriate candidates for clinical trials.]]></summary>
        <author>
            <name>Seyedmohammad Saadatagah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Risk Score and All-Cause and Cardiovascular Mortality in Older Adults]]></title>
        <id>pubmed:38231513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38231513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240203195418&amp;v=2.18.0"/>
        <updated>2024-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: In this cohort study, the CHRS was associated with all-cause, HM-related, and cardiovascular disease mortality in older adults with CH and may be useful in shared decision-making to guide clinical management and identify appropriate candidates for clinical trials.]]></summary>
        <author>
            <name>Seyedmohammad Saadatagah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Risk Score and All-Cause and Cardiovascular Mortality in Older Adults]]></title>
        <id>pubmed:38231513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38231513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240202194939&amp;v=2.18.0"/>
        <updated>2024-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: In this cohort study, the CHRS was associated with all-cause, HM-related, and cardiovascular disease mortality in older adults with CH and may be useful in shared decision-making to guide clinical management and identify appropriate candidates for clinical trials.]]></summary>
        <author>
            <name>Seyedmohammad Saadatagah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Risk Score and All-Cause and Cardiovascular Mortality in Older Adults]]></title>
        <id>pubmed:38231513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38231513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240201195024&amp;v=2.18.0"/>
        <updated>2024-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: In this cohort study, the CHRS was associated with all-cause, HM-related, and cardiovascular disease mortality in older adults with CH and may be useful in shared decision-making to guide clinical management and identify appropriate candidates for clinical trials.]]></summary>
        <author>
            <name>Seyedmohammad Saadatagah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Risk Score and All-Cause and Cardiovascular Mortality in Older Adults]]></title>
        <id>pubmed:38231513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38231513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240131195240&amp;v=2.18.0"/>
        <updated>2024-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: In this cohort study, the CHRS was associated with all-cause, HM-related, and cardiovascular disease mortality in older adults with CH and may be useful in shared decision-making to guide clinical management and identify appropriate candidates for clinical trials.]]></summary>
        <author>
            <name>Seyedmohammad Saadatagah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Risk Score and All-Cause and Cardiovascular Mortality in Older Adults]]></title>
        <id>pubmed:38231513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38231513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240130195039&amp;v=2.18.0"/>
        <updated>2024-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: In this cohort study, the CHRS was associated with all-cause, HM-related, and cardiovascular disease mortality in older adults with CH and may be useful in shared decision-making to guide clinical management and identify appropriate candidates for clinical trials.]]></summary>
        <author>
            <name>Seyedmohammad Saadatagah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Risk Score and All-Cause and Cardiovascular Mortality in Older Adults]]></title>
        <id>pubmed:38231513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38231513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240129195013&amp;v=2.18.0"/>
        <updated>2024-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: In this cohort study, the CHRS was associated with all-cause, HM-related, and cardiovascular disease mortality in older adults with CH and may be useful in shared decision-making to guide clinical management and identify appropriate candidates for clinical trials.]]></summary>
        <author>
            <name>Seyedmohammad Saadatagah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Risk Score and All-Cause and Cardiovascular Mortality in Older Adults]]></title>
        <id>pubmed:38231513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38231513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240128195055&amp;v=2.18.0"/>
        <updated>2024-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: In this cohort study, the CHRS was associated with all-cause, HM-related, and cardiovascular disease mortality in older adults with CH and may be useful in shared decision-making to guide clinical management and identify appropriate candidates for clinical trials.]]></summary>
        <author>
            <name>Seyedmohammad Saadatagah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Risk Score and All-Cause and Cardiovascular Mortality in Older Adults]]></title>
        <id>pubmed:38231513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38231513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240127195322&amp;v=2.18.0"/>
        <updated>2024-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: In this cohort study, the CHRS was associated with all-cause, HM-related, and cardiovascular disease mortality in older adults with CH and may be useful in shared decision-making to guide clinical management and identify appropriate candidates for clinical trials.]]></summary>
        <author>
            <name>Seyedmohammad Saadatagah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Risk Score and All-Cause and Cardiovascular Mortality in Older Adults]]></title>
        <id>pubmed:38231513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38231513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240126194954&amp;v=2.18.0"/>
        <updated>2024-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: In this cohort study, the CHRS was associated with all-cause, HM-related, and cardiovascular disease mortality in older adults with CH and may be useful in shared decision-making to guide clinical management and identify appropriate candidates for clinical trials.]]></summary>
        <author>
            <name>Seyedmohammad Saadatagah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Risk Score and All-Cause and Cardiovascular Mortality in Older Adults]]></title>
        <id>pubmed:38231513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38231513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240125195050&amp;v=2.18.0"/>
        <updated>2024-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: In this cohort study, the CHRS was associated with all-cause, HM-related, and cardiovascular disease mortality in older adults with CH and may be useful in shared decision-making to guide clinical management and identify appropriate candidates for clinical trials.]]></summary>
        <author>
            <name>Seyedmohammad Saadatagah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Risk Score and All-Cause and Cardiovascular Mortality in Older Adults]]></title>
        <id>pubmed:38231513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38231513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240124195506&amp;v=2.18.0"/>
        <updated>2024-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: In this cohort study, the CHRS was associated with all-cause, HM-related, and cardiovascular disease mortality in older adults with CH and may be useful in shared decision-making to guide clinical management and identify appropriate candidates for clinical trials.]]></summary>
        <author>
            <name>Seyedmohammad Saadatagah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Risk Score and All-Cause and Cardiovascular Mortality in Older Adults]]></title>
        <id>pubmed:38231513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38231513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240123195503&amp;v=2.18.0"/>
        <updated>2024-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: In this cohort study, the CHRS was associated with all-cause, HM-related, and cardiovascular disease mortality in older adults with CH and may be useful in shared decision-making to guide clinical management and identify appropriate candidates for clinical trials.]]></summary>
        <author>
            <name>Seyedmohammad Saadatagah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Risk Score and All-Cause and Cardiovascular Mortality in Older Adults]]></title>
        <id>pubmed:38231513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38231513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240122195511&amp;v=2.18.0"/>
        <updated>2024-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: In this cohort study, the CHRS was associated with all-cause, HM-related, and cardiovascular disease mortality in older adults with CH and may be useful in shared decision-making to guide clinical management and identify appropriate candidates for clinical trials.]]></summary>
        <author>
            <name>Seyedmohammad Saadatagah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Risk Score and All-Cause and Cardiovascular Mortality in Older Adults]]></title>
        <id>pubmed:38231513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38231513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240121195630&amp;v=2.18.0"/>
        <updated>2024-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: In this cohort study, the CHRS was associated with all-cause, HM-related, and cardiovascular disease mortality in older adults with CH and may be useful in shared decision-making to guide clinical management and identify appropriate candidates for clinical trials.]]></summary>
        <author>
            <name>Seyedmohammad Saadatagah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Risk Score and All-Cause and Cardiovascular Mortality in Older Adults]]></title>
        <id>pubmed:38231513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38231513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240120195815&amp;v=2.18.0"/>
        <updated>2024-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: In this cohort study, the CHRS was associated with all-cause, HM-related, and cardiovascular disease mortality in older adults with CH and may be useful in shared decision-making to guide clinical management and identify appropriate candidates for clinical trials.]]></summary>
        <author>
            <name>Seyedmohammad Saadatagah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Risk Score and All-Cause and Cardiovascular Mortality in Older Adults]]></title>
        <id>pubmed:38231513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38231513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240119195313&amp;v=2.18.0"/>
        <updated>2024-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: In this cohort study, the CHRS was associated with all-cause, HM-related, and cardiovascular disease mortality in older adults with CH and may be useful in shared decision-making to guide clinical management and identify appropriate candidates for clinical trials.]]></summary>
        <author>
            <name>Seyedmohammad Saadatagah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis Risk Score and All-Cause and Cardiovascular Mortality in Older Adults]]></title>
        <id>pubmed:38231513</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38231513/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240118195420&amp;v=2.18.0"/>
        <updated>2024-01-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS AND RELEVANCE: In this cohort study, the CHRS was associated with all-cause, HM-related, and cardiovascular disease mortality in older adults with CH and may be useful in shared decision-making to guide clinical management and identify appropriate candidates for clinical trials.]]></summary>
        <author>
            <name>Seyedmohammad Saadatagah</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Origin of Clonal Hematopoiesis and Its Implication in Human Diseases]]></title>
        <id>pubmed:38228959</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38228959/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240203195418&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal expansion of hematopoietic cells is first observed in hematological malignancies where all the leukemic cells can be traced back to a single cell carrying oncogenic alterations. Interestingly, expansion of hematopoietic clones with defined genomic alterations, including single nucleotide variants (SNVs), small insertions and deletions (indels), and large structural chromosomal alterations (CAs), is also found in the healthy population. These genomic changes often affect leukemia driver...]]></summary>
        <author>
            <name>Zhen Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Origin of Clonal Hematopoiesis and Its Implication in Human Diseases]]></title>
        <id>pubmed:38228959</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38228959/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240202194939&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal expansion of hematopoietic cells is first observed in hematological malignancies where all the leukemic cells can be traced back to a single cell carrying oncogenic alterations. Interestingly, expansion of hematopoietic clones with defined genomic alterations, including single nucleotide variants (SNVs), small insertions and deletions (indels), and large structural chromosomal alterations (CAs), is also found in the healthy population. These genomic changes often affect leukemia driver...]]></summary>
        <author>
            <name>Zhen Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Origin of Clonal Hematopoiesis and Its Implication in Human Diseases]]></title>
        <id>pubmed:38228959</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38228959/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240201195024&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal expansion of hematopoietic cells is first observed in hematological malignancies where all the leukemic cells can be traced back to a single cell carrying oncogenic alterations. Interestingly, expansion of hematopoietic clones with defined genomic alterations, including single nucleotide variants (SNVs), small insertions and deletions (indels), and large structural chromosomal alterations (CAs), is also found in the healthy population. These genomic changes often affect leukemia driver...]]></summary>
        <author>
            <name>Zhen Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Origin of Clonal Hematopoiesis and Its Implication in Human Diseases]]></title>
        <id>pubmed:38228959</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38228959/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240131195240&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal expansion of hematopoietic cells is first observed in hematological malignancies where all the leukemic cells can be traced back to a single cell carrying oncogenic alterations. Interestingly, expansion of hematopoietic clones with defined genomic alterations, including single nucleotide variants (SNVs), small insertions and deletions (indels), and large structural chromosomal alterations (CAs), is also found in the healthy population. These genomic changes often affect leukemia driver...]]></summary>
        <author>
            <name>Zhen Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Origin of Clonal Hematopoiesis and Its Implication in Human Diseases]]></title>
        <id>pubmed:38228959</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38228959/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240130195039&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal expansion of hematopoietic cells is first observed in hematological malignancies where all the leukemic cells can be traced back to a single cell carrying oncogenic alterations. Interestingly, expansion of hematopoietic clones with defined genomic alterations, including single nucleotide variants (SNVs), small insertions and deletions (indels), and large structural chromosomal alterations (CAs), is also found in the healthy population. These genomic changes often affect leukemia driver...]]></summary>
        <author>
            <name>Zhen Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Coronary Artery Calcification: Current Concepts and Clinical Implications]]></title>
        <id>pubmed:38227718</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38227718/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240130195039&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Coronary artery calcification (CAC) accompanies the development of advanced atherosclerosis. Its role in atherosclerosis holds great interest because the presence and burden of coronary calcification provide direct evidence of the presence and extent of coronary artery disease; furthermore, CAC predicts future events independently of concomitant conventional cardiovascular risk factors and to a greater extent than any other noninvasive biomarker of this disease. Nevertheless, the relationship...]]></summary>
        <author>
            <name>Carlotta Onnis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Origin of Clonal Hematopoiesis and Its Implication in Human Diseases]]></title>
        <id>pubmed:38228959</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38228959/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240129195013&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal expansion of hematopoietic cells is first observed in hematological malignancies where all the leukemic cells can be traced back to a single cell carrying oncogenic alterations. Interestingly, expansion of hematopoietic clones with defined genomic alterations, including single nucleotide variants (SNVs), small insertions and deletions (indels), and large structural chromosomal alterations (CAs), is also found in the healthy population. These genomic changes often affect leukemia driver...]]></summary>
        <author>
            <name>Zhen Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Coronary Artery Calcification: Current Concepts and Clinical Implications]]></title>
        <id>pubmed:38227718</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38227718/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240129195013&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Coronary artery calcification (CAC) accompanies the development of advanced atherosclerosis. Its role in atherosclerosis holds great interest because the presence and burden of coronary calcification provide direct evidence of the presence and extent of coronary artery disease; furthermore, CAC predicts future events independently of concomitant conventional cardiovascular risk factors and to a greater extent than any other noninvasive biomarker of this disease. Nevertheless, the relationship...]]></summary>
        <author>
            <name>Carlotta Onnis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Origin of Clonal Hematopoiesis and Its Implication in Human Diseases]]></title>
        <id>pubmed:38228959</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38228959/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240128195055&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal expansion of hematopoietic cells is first observed in hematological malignancies where all the leukemic cells can be traced back to a single cell carrying oncogenic alterations. Interestingly, expansion of hematopoietic clones with defined genomic alterations, including single nucleotide variants (SNVs), small insertions and deletions (indels), and large structural chromosomal alterations (CAs), is also found in the healthy population. These genomic changes often affect leukemia driver...]]></summary>
        <author>
            <name>Zhen Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Coronary Artery Calcification: Current Concepts and Clinical Implications]]></title>
        <id>pubmed:38227718</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38227718/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240128195055&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Coronary artery calcification (CAC) accompanies the development of advanced atherosclerosis. Its role in atherosclerosis holds great interest because the presence and burden of coronary calcification provide direct evidence of the presence and extent of coronary artery disease; furthermore, CAC predicts future events independently of concomitant conventional cardiovascular risk factors and to a greater extent than any other noninvasive biomarker of this disease. Nevertheless, the relationship...]]></summary>
        <author>
            <name>Carlotta Onnis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal barcoding of endogenous adult hematopoietic stem cells reveals a spectrum of lineage contributions]]></title>
        <id>pubmed:38227649</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38227649/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240128195055&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The hierarchical model of hematopoiesis posits that self-renewing, multipotent hematopoietic stem cells (HSCs) give rise to all blood cell lineages. While this model accounts for hematopoiesis in transplant settings, its applicability to steady-state hematopoiesis remains to be clarified. Here, we used inducible clonal DNA barcoding of endogenous adult HSCs to trace their contribution to major hematopoietic cell lineages in unmanipulated animals. While the majority of barcodes were unique to a...]]></summary>
        <author>
            <name>Jue Feng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Origin of Clonal Hematopoiesis and Its Implication in Human Diseases]]></title>
        <id>pubmed:38228959</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38228959/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240127195322&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal expansion of hematopoietic cells is first observed in hematological malignancies where all the leukemic cells can be traced back to a single cell carrying oncogenic alterations. Interestingly, expansion of hematopoietic clones with defined genomic alterations, including single nucleotide variants (SNVs), small insertions and deletions (indels), and large structural chromosomal alterations (CAs), is also found in the healthy population. These genomic changes often affect leukemia driver...]]></summary>
        <author>
            <name>Zhen Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Coronary Artery Calcification: Current Concepts and Clinical Implications]]></title>
        <id>pubmed:38227718</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38227718/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240127195322&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Coronary artery calcification (CAC) accompanies the development of advanced atherosclerosis. Its role in atherosclerosis holds great interest because the presence and burden of coronary calcification provide direct evidence of the presence and extent of coronary artery disease; furthermore, CAC predicts future events independently of concomitant conventional cardiovascular risk factors and to a greater extent than any other noninvasive biomarker of this disease. Nevertheless, the relationship...]]></summary>
        <author>
            <name>Carlotta Onnis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal barcoding of endogenous adult hematopoietic stem cells reveals a spectrum of lineage contributions]]></title>
        <id>pubmed:38227649</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38227649/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240127195322&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The hierarchical model of hematopoiesis posits that self-renewing, multipotent hematopoietic stem cells (HSCs) give rise to all blood cell lineages. While this model accounts for hematopoiesis in transplant settings, its applicability to steady-state hematopoiesis remains to be clarified. Here, we used inducible clonal DNA barcoding of endogenous adult HSCs to trace their contribution to major hematopoietic cell lineages in unmanipulated animals. While the majority of barcodes were unique to a...]]></summary>
        <author>
            <name>Jue Feng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Origin of Clonal Hematopoiesis and Its Implication in Human Diseases]]></title>
        <id>pubmed:38228959</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38228959/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240126194954&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal expansion of hematopoietic cells is first observed in hematological malignancies where all the leukemic cells can be traced back to a single cell carrying oncogenic alterations. Interestingly, expansion of hematopoietic clones with defined genomic alterations, including single nucleotide variants (SNVs), small insertions and deletions (indels), and large structural chromosomal alterations (CAs), is also found in the healthy population. These genomic changes often affect leukemia driver...]]></summary>
        <author>
            <name>Zhen Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Coronary Artery Calcification: Current Concepts and Clinical Implications]]></title>
        <id>pubmed:38227718</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38227718/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240126194954&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Coronary artery calcification (CAC) accompanies the development of advanced atherosclerosis. Its role in atherosclerosis holds great interest because the presence and burden of coronary calcification provide direct evidence of the presence and extent of coronary artery disease; furthermore, CAC predicts future events independently of concomitant conventional cardiovascular risk factors and to a greater extent than any other noninvasive biomarker of this disease. Nevertheless, the relationship...]]></summary>
        <author>
            <name>Carlotta Onnis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal barcoding of endogenous adult hematopoietic stem cells reveals a spectrum of lineage contributions]]></title>
        <id>pubmed:38227649</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38227649/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240126194954&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The hierarchical model of hematopoiesis posits that self-renewing, multipotent hematopoietic stem cells (HSCs) give rise to all blood cell lineages. While this model accounts for hematopoiesis in transplant settings, its applicability to steady-state hematopoiesis remains to be clarified. Here, we used inducible clonal DNA barcoding of endogenous adult HSCs to trace their contribution to major hematopoietic cell lineages in unmanipulated animals. While the majority of barcodes were unique to a...]]></summary>
        <author>
            <name>Jue Feng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Origin of Clonal Hematopoiesis and Its Implication in Human Diseases]]></title>
        <id>pubmed:38228959</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38228959/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240125195050&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal expansion of hematopoietic cells is first observed in hematological malignancies where all the leukemic cells can be traced back to a single cell carrying oncogenic alterations. Interestingly, expansion of hematopoietic clones with defined genomic alterations, including single nucleotide variants (SNVs), small insertions and deletions (indels), and large structural chromosomal alterations (CAs), is also found in the healthy population. These genomic changes often affect leukemia driver...]]></summary>
        <author>
            <name>Zhen Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Coronary Artery Calcification: Current Concepts and Clinical Implications]]></title>
        <id>pubmed:38227718</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38227718/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240125195050&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Coronary artery calcification (CAC) accompanies the development of advanced atherosclerosis. Its role in atherosclerosis holds great interest because the presence and burden of coronary calcification provide direct evidence of the presence and extent of coronary artery disease; furthermore, CAC predicts future events independently of concomitant conventional cardiovascular risk factors and to a greater extent than any other noninvasive biomarker of this disease. Nevertheless, the relationship...]]></summary>
        <author>
            <name>Carlotta Onnis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal barcoding of endogenous adult hematopoietic stem cells reveals a spectrum of lineage contributions]]></title>
        <id>pubmed:38227649</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38227649/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240125195050&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The hierarchical model of hematopoiesis posits that self-renewing, multipotent hematopoietic stem cells (HSCs) give rise to all blood cell lineages. While this model accounts for hematopoiesis in transplant settings, its applicability to steady-state hematopoiesis remains to be clarified. Here, we used inducible clonal DNA barcoding of endogenous adult HSCs to trace their contribution to major hematopoietic cell lineages in unmanipulated animals. While the majority of barcodes were unique to a...]]></summary>
        <author>
            <name>Jue Feng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Origin of Clonal Hematopoiesis and Its Implication in Human Diseases]]></title>
        <id>pubmed:38228959</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38228959/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240124195506&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal expansion of hematopoietic cells is first observed in hematological malignancies where all the leukemic cells can be traced back to a single cell carrying oncogenic alterations. Interestingly, expansion of hematopoietic clones with defined genomic alterations, including single nucleotide variants (SNVs), small insertions and deletions (indels), and large structural chromosomal alterations (CAs), is also found in the healthy population. These genomic changes often affect leukemia driver...]]></summary>
        <author>
            <name>Zhen Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Coronary Artery Calcification: Current Concepts and Clinical Implications]]></title>
        <id>pubmed:38227718</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38227718/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240124195506&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Coronary artery calcification (CAC) accompanies the development of advanced atherosclerosis. Its role in atherosclerosis holds great interest because the presence and burden of coronary calcification provide direct evidence of the presence and extent of coronary artery disease; furthermore, CAC predicts future events independently of concomitant conventional cardiovascular risk factors and to a greater extent than any other noninvasive biomarker of this disease. Nevertheless, the relationship...]]></summary>
        <author>
            <name>Carlotta Onnis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal barcoding of endogenous adult hematopoietic stem cells reveals a spectrum of lineage contributions]]></title>
        <id>pubmed:38227649</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38227649/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240124195506&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The hierarchical model of hematopoiesis posits that self-renewing, multipotent hematopoietic stem cells (HSCs) give rise to all blood cell lineages. While this model accounts for hematopoiesis in transplant settings, its applicability to steady-state hematopoiesis remains to be clarified. Here, we used inducible clonal DNA barcoding of endogenous adult HSCs to trace their contribution to major hematopoietic cell lineages in unmanipulated animals. While the majority of barcodes were unique to a...]]></summary>
        <author>
            <name>Jue Feng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Origin of Clonal Hematopoiesis and Its Implication in Human Diseases]]></title>
        <id>pubmed:38228959</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38228959/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240123195503&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal expansion of hematopoietic cells is first observed in hematological malignancies where all the leukemic cells can be traced back to a single cell carrying oncogenic alterations. Interestingly, expansion of hematopoietic clones with defined genomic alterations, including single nucleotide variants (SNVs), small insertions and deletions (indels), and large structural chromosomal alterations (CAs), is also found in the healthy population. These genomic changes often affect leukemia driver...]]></summary>
        <author>
            <name>Zhen Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Coronary Artery Calcification: Current Concepts and Clinical Implications]]></title>
        <id>pubmed:38227718</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38227718/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240123195503&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Coronary artery calcification (CAC) accompanies the development of advanced atherosclerosis. Its role in atherosclerosis holds great interest because the presence and burden of coronary calcification provide direct evidence of the presence and extent of coronary artery disease; furthermore, CAC predicts future events independently of concomitant conventional cardiovascular risk factors and to a greater extent than any other noninvasive biomarker of this disease. Nevertheless, the relationship...]]></summary>
        <author>
            <name>Carlotta Onnis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal barcoding of endogenous adult hematopoietic stem cells reveals a spectrum of lineage contributions]]></title>
        <id>pubmed:38227649</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38227649/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240123195503&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The hierarchical model of hematopoiesis posits that self-renewing, multipotent hematopoietic stem cells (HSCs) give rise to all blood cell lineages. While this model accounts for hematopoiesis in transplant settings, its applicability to steady-state hematopoiesis remains to be clarified. Here, we used inducible clonal DNA barcoding of endogenous adult HSCs to trace their contribution to major hematopoietic cell lineages in unmanipulated animals. While the majority of barcodes were unique to a...]]></summary>
        <author>
            <name>Jue Feng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Origin of Clonal Hematopoiesis and Its Implication in Human Diseases]]></title>
        <id>pubmed:38228959</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38228959/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240122195511&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal expansion of hematopoietic cells is first observed in hematological malignancies where all the leukemic cells can be traced back to a single cell carrying oncogenic alterations. Interestingly, expansion of hematopoietic clones with defined genomic alterations, including single nucleotide variants (SNVs), small insertions and deletions (indels), and large structural chromosomal alterations (CAs), is also found in the healthy population. These genomic changes often affect leukemia driver...]]></summary>
        <author>
            <name>Zhen Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Coronary Artery Calcification: Current Concepts and Clinical Implications]]></title>
        <id>pubmed:38227718</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38227718/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240122195511&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Coronary artery calcification (CAC) accompanies the development of advanced atherosclerosis. Its role in atherosclerosis holds great interest because the presence and burden of coronary calcification provide direct evidence of the presence and extent of coronary artery disease; furthermore, CAC predicts future events independently of concomitant conventional cardiovascular risk factors and to a greater extent than any other noninvasive biomarker of this disease. Nevertheless, the relationship...]]></summary>
        <author>
            <name>Carlotta Onnis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal barcoding of endogenous adult hematopoietic stem cells reveals a spectrum of lineage contributions]]></title>
        <id>pubmed:38227649</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38227649/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240122195511&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The hierarchical model of hematopoiesis posits that self-renewing, multipotent hematopoietic stem cells (HSCs) give rise to all blood cell lineages. While this model accounts for hematopoiesis in transplant settings, its applicability to steady-state hematopoiesis remains to be clarified. Here, we used inducible clonal DNA barcoding of endogenous adult HSCs to trace their contribution to major hematopoietic cell lineages in unmanipulated animals. While the majority of barcodes were unique to a...]]></summary>
        <author>
            <name>Jue Feng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Origin of Clonal Hematopoiesis and Its Implication in Human Diseases]]></title>
        <id>pubmed:38228959</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38228959/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240121195630&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal expansion of hematopoietic cells is first observed in hematological malignancies where all the leukemic cells can be traced back to a single cell carrying oncogenic alterations. Interestingly, expansion of hematopoietic clones with defined genomic alterations, including single nucleotide variants (SNVs), small insertions and deletions (indels), and large structural chromosomal alterations (CAs), is also found in the healthy population. These genomic changes often affect leukemia driver...]]></summary>
        <author>
            <name>Zhen Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Coronary Artery Calcification: Current Concepts and Clinical Implications]]></title>
        <id>pubmed:38227718</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38227718/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240121195630&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Coronary artery calcification (CAC) accompanies the development of advanced atherosclerosis. Its role in atherosclerosis holds great interest because the presence and burden of coronary calcification provide direct evidence of the presence and extent of coronary artery disease; furthermore, CAC predicts future events independently of concomitant conventional cardiovascular risk factors and to a greater extent than any other noninvasive biomarker of this disease. Nevertheless, the relationship...]]></summary>
        <author>
            <name>Carlotta Onnis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal barcoding of endogenous adult hematopoietic stem cells reveals a spectrum of lineage contributions]]></title>
        <id>pubmed:38227649</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38227649/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240121195630&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The hierarchical model of hematopoiesis posits that self-renewing, multipotent hematopoietic stem cells (HSCs) give rise to all blood cell lineages. While this model accounts for hematopoiesis in transplant settings, its applicability to steady-state hematopoiesis remains to be clarified. Here, we used inducible clonal DNA barcoding of endogenous adult HSCs to trace their contribution to major hematopoietic cell lineages in unmanipulated animals. While the majority of barcodes were unique to a...]]></summary>
        <author>
            <name>Jue Feng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Origin of Clonal Hematopoiesis and Its Implication in Human Diseases]]></title>
        <id>pubmed:38228959</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38228959/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240120195815&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal expansion of hematopoietic cells is first observed in hematological malignancies where all the leukemic cells can be traced back to a single cell carrying oncogenic alterations. Interestingly, expansion of hematopoietic clones with defined genomic alterations, including single nucleotide variants (SNVs), small insertions and deletions (indels), and large structural chromosomal alterations (CAs), is also found in the healthy population. These genomic changes often affect leukemia driver...]]></summary>
        <author>
            <name>Zhen Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Coronary Artery Calcification: Current Concepts and Clinical Implications]]></title>
        <id>pubmed:38227718</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38227718/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240120195815&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Coronary artery calcification (CAC) accompanies the development of advanced atherosclerosis. Its role in atherosclerosis holds great interest because the presence and burden of coronary calcification provide direct evidence of the presence and extent of coronary artery disease; furthermore, CAC predicts future events independently of concomitant conventional cardiovascular risk factors and to a greater extent than any other noninvasive biomarker of this disease. Nevertheless, the relationship...]]></summary>
        <author>
            <name>Carlotta Onnis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal barcoding of endogenous adult hematopoietic stem cells reveals a spectrum of lineage contributions]]></title>
        <id>pubmed:38227649</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38227649/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240120195815&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The hierarchical model of hematopoiesis posits that self-renewing, multipotent hematopoietic stem cells (HSCs) give rise to all blood cell lineages. While this model accounts for hematopoiesis in transplant settings, its applicability to steady-state hematopoiesis remains to be clarified. Here, we used inducible clonal DNA barcoding of endogenous adult HSCs to trace their contribution to major hematopoietic cell lineages in unmanipulated animals. While the majority of barcodes were unique to a...]]></summary>
        <author>
            <name>Jue Feng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Origin of Clonal Hematopoiesis and Its Implication in Human Diseases]]></title>
        <id>pubmed:38228959</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38228959/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240119195313&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal expansion of hematopoietic cells is first observed in hematological malignancies where all the leukemic cells can be traced back to a single cell carrying oncogenic alterations. Interestingly, expansion of hematopoietic clones with defined genomic alterations, including single nucleotide variants (SNVs), small insertions and deletions (indels), and large structural chromosomal alterations (CAs), is also found in the healthy population. These genomic changes often affect leukemia driver...]]></summary>
        <author>
            <name>Zhen Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Coronary Artery Calcification: Current Concepts and Clinical Implications]]></title>
        <id>pubmed:38227718</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38227718/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240119195313&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Coronary artery calcification (CAC) accompanies the development of advanced atherosclerosis. Its role in atherosclerosis holds great interest because the presence and burden of coronary calcification provide direct evidence of the presence and extent of coronary artery disease; furthermore, CAC predicts future events independently of concomitant conventional cardiovascular risk factors and to a greater extent than any other noninvasive biomarker of this disease. Nevertheless, the relationship...]]></summary>
        <author>
            <name>Carlotta Onnis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal barcoding of endogenous adult hematopoietic stem cells reveals a spectrum of lineage contributions]]></title>
        <id>pubmed:38227649</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38227649/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240119195313&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The hierarchical model of hematopoiesis posits that self-renewing, multipotent hematopoietic stem cells (HSCs) give rise to all blood cell lineages. While this model accounts for hematopoiesis in transplant settings, its applicability to steady-state hematopoiesis remains to be clarified. Here, we used inducible clonal DNA barcoding of endogenous adult HSCs to trace their contribution to major hematopoietic cell lineages in unmanipulated animals. While the majority of barcodes were unique to a...]]></summary>
        <author>
            <name>Jue Feng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Origin of Clonal Hematopoiesis and Its Implication in Human Diseases]]></title>
        <id>pubmed:38228959</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38228959/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240118195421&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal expansion of hematopoietic cells is first observed in hematological malignancies where all the leukemic cells can be traced back to a single cell carrying oncogenic alterations. Interestingly, expansion of hematopoietic clones with defined genomic alterations, including single nucleotide variants (SNVs), small insertions and deletions (indels), and large structural chromosomal alterations (CAs), is also found in the healthy population. These genomic changes often affect leukemia driver...]]></summary>
        <author>
            <name>Zhen Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Coronary Artery Calcification: Current Concepts and Clinical Implications]]></title>
        <id>pubmed:38227718</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38227718/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240118195421&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Coronary artery calcification (CAC) accompanies the development of advanced atherosclerosis. Its role in atherosclerosis holds great interest because the presence and burden of coronary calcification provide direct evidence of the presence and extent of coronary artery disease; furthermore, CAC predicts future events independently of concomitant conventional cardiovascular risk factors and to a greater extent than any other noninvasive biomarker of this disease. Nevertheless, the relationship...]]></summary>
        <author>
            <name>Carlotta Onnis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal barcoding of endogenous adult hematopoietic stem cells reveals a spectrum of lineage contributions]]></title>
        <id>pubmed:38227649</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38227649/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240118195421&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The hierarchical model of hematopoiesis posits that self-renewing, multipotent hematopoietic stem cells (HSCs) give rise to all blood cell lineages. While this model accounts for hematopoiesis in transplant settings, its applicability to steady-state hematopoiesis remains to be clarified. Here, we used inducible clonal DNA barcoding of endogenous adult HSCs to trace their contribution to major hematopoietic cell lineages in unmanipulated animals. While the majority of barcodes were unique to a...]]></summary>
        <author>
            <name>Jue Feng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Origin of Clonal Hematopoiesis and Its Implication in Human Diseases]]></title>
        <id>pubmed:38228959</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38228959/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240117195336&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal expansion of hematopoietic cells is first observed in hematological malignancies where all the leukemic cells can be traced back to a single cell carrying oncogenic alterations. Interestingly, expansion of hematopoietic clones with defined genomic alterations, including single nucleotide variants (SNVs), small insertions and deletions (indels), and large structural chromosomal alterations (CAs), is also found in the healthy population. These genomic changes often affect leukemia driver...]]></summary>
        <author>
            <name>Zhen Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Coronary Artery Calcification: Current Concepts and Clinical Implications]]></title>
        <id>pubmed:38227718</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38227718/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240117195336&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Coronary artery calcification (CAC) accompanies the development of advanced atherosclerosis. Its role in atherosclerosis holds great interest because the presence and burden of coronary calcification provide direct evidence of the presence and extent of coronary artery disease; furthermore, CAC predicts future events independently of concomitant conventional cardiovascular risk factors and to a greater extent than any other noninvasive biomarker of this disease. Nevertheless, the relationship...]]></summary>
        <author>
            <name>Carlotta Onnis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal barcoding of endogenous adult hematopoietic stem cells reveals a spectrum of lineage contributions]]></title>
        <id>pubmed:38227649</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38227649/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240117195336&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The hierarchical model of hematopoiesis posits that self-renewing, multipotent hematopoietic stem cells (HSCs) give rise to all blood cell lineages. While this model accounts for hematopoiesis in transplant settings, its applicability to steady-state hematopoiesis remains to be clarified. Here, we used inducible clonal DNA barcoding of endogenous adult HSCs to trace their contribution to major hematopoietic cell lineages in unmanipulated animals. While the majority of barcodes were unique to a...]]></summary>
        <author>
            <name>Jue Feng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Coronary Artery Calcification: Current Concepts and Clinical Implications]]></title>
        <id>pubmed:38227718</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38227718/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240116195412&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Coronary artery calcification (CAC) accompanies the development of advanced atherosclerosis. Its role in atherosclerosis holds great interest because the presence and burden of coronary calcification provide direct evidence of the presence and extent of coronary artery disease; furthermore, CAC predicts future events independently of concomitant conventional cardiovascular risk factors and to a greater extent than any other noninvasive biomarker of this disease. Nevertheless, the relationship...]]></summary>
        <author>
            <name>Carlotta Onnis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal barcoding of endogenous adult hematopoietic stem cells reveals a spectrum of lineage contributions]]></title>
        <id>pubmed:38227649</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38227649/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240116195412&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The hierarchical model of hematopoiesis posits that self-renewing, multipotent hematopoietic stem cells (HSCs) give rise to all blood cell lineages. While this model accounts for hematopoiesis in transplant settings, its applicability to steady-state hematopoiesis remains to be clarified. Here, we used inducible clonal DNA barcoding of endogenous adult HSCs to trace their contribution to major hematopoietic cell lineages in unmanipulated animals. While the majority of barcodes were unique to a...]]></summary>
        <author>
            <name>Jue Feng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Emerging Targets for Systemic Treatment of Gastric Cancer: HER2 and Beyond]]></title>
        <id>pubmed:38225765</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38225765/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240204195148&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[In recent years, remarkable progress has been made in the molecular profiling of gastric cancer. This progress has led to the development of various molecular classifications to uncover subtype-specific dependencies that can be targeted for therapeutic interventions. Human epidermal growth factor receptor 2 (HER2) is a crucial biomarker for advanced gastric cancer. The recent promising results of novel approaches, including combination therapies or newer potent agents such as antibody-drug...]]></summary>
        <author>
            <name>In-Ho Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Emerging Targets for Systemic Treatment of Gastric Cancer: HER2 and Beyond]]></title>
        <id>pubmed:38225765</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38225765/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240203195418&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[In recent years, remarkable progress has been made in the molecular profiling of gastric cancer. This progress has led to the development of various molecular classifications to uncover subtype-specific dependencies that can be targeted for therapeutic interventions. Human epidermal growth factor receptor 2 (HER2) is a crucial biomarker for advanced gastric cancer. The recent promising results of novel approaches, including combination therapies or newer potent agents such as antibody-drug...]]></summary>
        <author>
            <name>In-Ho Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Emerging Targets for Systemic Treatment of Gastric Cancer: HER2 and Beyond]]></title>
        <id>pubmed:38225765</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38225765/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240202194939&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[In recent years, remarkable progress has been made in the molecular profiling of gastric cancer. This progress has led to the development of various molecular classifications to uncover subtype-specific dependencies that can be targeted for therapeutic interventions. Human epidermal growth factor receptor 2 (HER2) is a crucial biomarker for advanced gastric cancer. The recent promising results of novel approaches, including combination therapies or newer potent agents such as antibody-drug...]]></summary>
        <author>
            <name>In-Ho Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Emerging Targets for Systemic Treatment of Gastric Cancer: HER2 and Beyond]]></title>
        <id>pubmed:38225765</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38225765/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240201195024&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[In recent years, remarkable progress has been made in the molecular profiling of gastric cancer. This progress has led to the development of various molecular classifications to uncover subtype-specific dependencies that can be targeted for therapeutic interventions. Human epidermal growth factor receptor 2 (HER2) is a crucial biomarker for advanced gastric cancer. The recent promising results of novel approaches, including combination therapies or newer potent agents such as antibody-drug...]]></summary>
        <author>
            <name>In-Ho Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Emerging Targets for Systemic Treatment of Gastric Cancer: HER2 and Beyond]]></title>
        <id>pubmed:38225765</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38225765/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240131195240&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[In recent years, remarkable progress has been made in the molecular profiling of gastric cancer. This progress has led to the development of various molecular classifications to uncover subtype-specific dependencies that can be targeted for therapeutic interventions. Human epidermal growth factor receptor 2 (HER2) is a crucial biomarker for advanced gastric cancer. The recent promising results of novel approaches, including combination therapies or newer potent agents such as antibody-drug...]]></summary>
        <author>
            <name>In-Ho Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Emerging Targets for Systemic Treatment of Gastric Cancer: HER2 and Beyond]]></title>
        <id>pubmed:38225765</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38225765/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240130195039&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[In recent years, remarkable progress has been made in the molecular profiling of gastric cancer. This progress has led to the development of various molecular classifications to uncover subtype-specific dependencies that can be targeted for therapeutic interventions. Human epidermal growth factor receptor 2 (HER2) is a crucial biomarker for advanced gastric cancer. The recent promising results of novel approaches, including combination therapies or newer potent agents such as antibody-drug...]]></summary>
        <author>
            <name>In-Ho Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Emerging Targets for Systemic Treatment of Gastric Cancer: HER2 and Beyond]]></title>
        <id>pubmed:38225765</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38225765/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240129195013&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[In recent years, remarkable progress has been made in the molecular profiling of gastric cancer. This progress has led to the development of various molecular classifications to uncover subtype-specific dependencies that can be targeted for therapeutic interventions. Human epidermal growth factor receptor 2 (HER2) is a crucial biomarker for advanced gastric cancer. The recent promising results of novel approaches, including combination therapies or newer potent agents such as antibody-drug...]]></summary>
        <author>
            <name>In-Ho Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Emerging Targets for Systemic Treatment of Gastric Cancer: HER2 and Beyond]]></title>
        <id>pubmed:38225765</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38225765/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240128195055&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[In recent years, remarkable progress has been made in the molecular profiling of gastric cancer. This progress has led to the development of various molecular classifications to uncover subtype-specific dependencies that can be targeted for therapeutic interventions. Human epidermal growth factor receptor 2 (HER2) is a crucial biomarker for advanced gastric cancer. The recent promising results of novel approaches, including combination therapies or newer potent agents such as antibody-drug...]]></summary>
        <author>
            <name>In-Ho Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Emerging Targets for Systemic Treatment of Gastric Cancer: HER2 and Beyond]]></title>
        <id>pubmed:38225765</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38225765/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240127195322&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[In recent years, remarkable progress has been made in the molecular profiling of gastric cancer. This progress has led to the development of various molecular classifications to uncover subtype-specific dependencies that can be targeted for therapeutic interventions. Human epidermal growth factor receptor 2 (HER2) is a crucial biomarker for advanced gastric cancer. The recent promising results of novel approaches, including combination therapies or newer potent agents such as antibody-drug...]]></summary>
        <author>
            <name>In-Ho Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Emerging Targets for Systemic Treatment of Gastric Cancer: HER2 and Beyond]]></title>
        <id>pubmed:38225765</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38225765/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240126194954&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[In recent years, remarkable progress has been made in the molecular profiling of gastric cancer. This progress has led to the development of various molecular classifications to uncover subtype-specific dependencies that can be targeted for therapeutic interventions. Human epidermal growth factor receptor 2 (HER2) is a crucial biomarker for advanced gastric cancer. The recent promising results of novel approaches, including combination therapies or newer potent agents such as antibody-drug...]]></summary>
        <author>
            <name>In-Ho Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Emerging Targets for Systemic Treatment of Gastric Cancer: HER2 and Beyond]]></title>
        <id>pubmed:38225765</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38225765/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240125195050&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[In recent years, remarkable progress has been made in the molecular profiling of gastric cancer. This progress has led to the development of various molecular classifications to uncover subtype-specific dependencies that can be targeted for therapeutic interventions. Human epidermal growth factor receptor 2 (HER2) is a crucial biomarker for advanced gastric cancer. The recent promising results of novel approaches, including combination therapies or newer potent agents such as antibody-drug...]]></summary>
        <author>
            <name>In-Ho Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Emerging Targets for Systemic Treatment of Gastric Cancer: HER2 and Beyond]]></title>
        <id>pubmed:38225765</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38225765/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240124195506&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[In recent years, remarkable progress has been made in the molecular profiling of gastric cancer. This progress has led to the development of various molecular classifications to uncover subtype-specific dependencies that can be targeted for therapeutic interventions. Human epidermal growth factor receptor 2 (HER2) is a crucial biomarker for advanced gastric cancer. The recent promising results of novel approaches, including combination therapies or newer potent agents such as antibody-drug...]]></summary>
        <author>
            <name>In-Ho Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Emerging Targets for Systemic Treatment of Gastric Cancer: HER2 and Beyond]]></title>
        <id>pubmed:38225765</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38225765/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240123195503&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[In recent years, remarkable progress has been made in the molecular profiling of gastric cancer. This progress has led to the development of various molecular classifications to uncover subtype-specific dependencies that can be targeted for therapeutic interventions. Human epidermal growth factor receptor 2 (HER2) is a crucial biomarker for advanced gastric cancer. The recent promising results of novel approaches, including combination therapies or newer potent agents such as antibody-drug...]]></summary>
        <author>
            <name>In-Ho Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Emerging Targets for Systemic Treatment of Gastric Cancer: HER2 and Beyond]]></title>
        <id>pubmed:38225765</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38225765/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240122195511&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[In recent years, remarkable progress has been made in the molecular profiling of gastric cancer. This progress has led to the development of various molecular classifications to uncover subtype-specific dependencies that can be targeted for therapeutic interventions. Human epidermal growth factor receptor 2 (HER2) is a crucial biomarker for advanced gastric cancer. The recent promising results of novel approaches, including combination therapies or newer potent agents such as antibody-drug...]]></summary>
        <author>
            <name>In-Ho Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Emerging Targets for Systemic Treatment of Gastric Cancer: HER2 and Beyond]]></title>
        <id>pubmed:38225765</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38225765/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240121195630&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[In recent years, remarkable progress has been made in the molecular profiling of gastric cancer. This progress has led to the development of various molecular classifications to uncover subtype-specific dependencies that can be targeted for therapeutic interventions. Human epidermal growth factor receptor 2 (HER2) is a crucial biomarker for advanced gastric cancer. The recent promising results of novel approaches, including combination therapies or newer potent agents such as antibody-drug...]]></summary>
        <author>
            <name>In-Ho Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Emerging Targets for Systemic Treatment of Gastric Cancer: HER2 and Beyond]]></title>
        <id>pubmed:38225765</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38225765/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240120195815&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[In recent years, remarkable progress has been made in the molecular profiling of gastric cancer. This progress has led to the development of various molecular classifications to uncover subtype-specific dependencies that can be targeted for therapeutic interventions. Human epidermal growth factor receptor 2 (HER2) is a crucial biomarker for advanced gastric cancer. The recent promising results of novel approaches, including combination therapies or newer potent agents such as antibody-drug...]]></summary>
        <author>
            <name>In-Ho Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Emerging Targets for Systemic Treatment of Gastric Cancer: HER2 and Beyond]]></title>
        <id>pubmed:38225765</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38225765/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240119195313&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[In recent years, remarkable progress has been made in the molecular profiling of gastric cancer. This progress has led to the development of various molecular classifications to uncover subtype-specific dependencies that can be targeted for therapeutic interventions. Human epidermal growth factor receptor 2 (HER2) is a crucial biomarker for advanced gastric cancer. The recent promising results of novel approaches, including combination therapies or newer potent agents such as antibody-drug...]]></summary>
        <author>
            <name>In-Ho Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Emerging Targets for Systemic Treatment of Gastric Cancer: HER2 and Beyond]]></title>
        <id>pubmed:38225765</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38225765/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240118195420&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[In recent years, remarkable progress has been made in the molecular profiling of gastric cancer. This progress has led to the development of various molecular classifications to uncover subtype-specific dependencies that can be targeted for therapeutic interventions. Human epidermal growth factor receptor 2 (HER2) is a crucial biomarker for advanced gastric cancer. The recent promising results of novel approaches, including combination therapies or newer potent agents such as antibody-drug...]]></summary>
        <author>
            <name>In-Ho Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Emerging Targets for Systemic Treatment of Gastric Cancer: HER2 and Beyond]]></title>
        <id>pubmed:38225765</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38225765/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240117195336&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[In recent years, remarkable progress has been made in the molecular profiling of gastric cancer. This progress has led to the development of various molecular classifications to uncover subtype-specific dependencies that can be targeted for therapeutic interventions. Human epidermal growth factor receptor 2 (HER2) is a crucial biomarker for advanced gastric cancer. The recent promising results of novel approaches, including combination therapies or newer potent agents such as antibody-drug...]]></summary>
        <author>
            <name>In-Ho Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Emerging Targets for Systemic Treatment of Gastric Cancer: HER2 and Beyond]]></title>
        <id>pubmed:38225765</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38225765/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240116195412&amp;v=2.18.0"/>
        <updated>2024-01-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[In recent years, remarkable progress has been made in the molecular profiling of gastric cancer. This progress has led to the development of various molecular classifications to uncover subtype-specific dependencies that can be targeted for therapeutic interventions. Human epidermal growth factor receptor 2 (HER2) is a crucial biomarker for advanced gastric cancer. The recent promising results of novel approaches, including combination therapies or newer potent agents such as antibody-drug...]]></summary>
        <author>
            <name>In-Ho Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Driver mutation zygosity is a critical factor in predicting clonal hematopoiesis transformation risk]]></title>
        <id>pubmed:38225345</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38225345/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240125195050&amp;v=2.18.0"/>
        <updated>2024-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) can be caused by either single gene mutations (eg point mutations in JAK2 causing CHIP) or mosaic chromosomal alterations (e.g., loss of heterozygosity at chromosome 9p). CH is associated with a significantly increased risk of hematologic malignancies. However, the absolute rate of transformation on an annualized basis is low. Improved prognostication of transformation risk is urgently needed for routine clinical practice. We hypothesized that the co-occurrence of CHIP...]]></summary>
        <author>
            <name>Ashwin Kishtagari</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Driver mutation zygosity is a critical factor in predicting clonal hematopoiesis transformation risk]]></title>
        <id>pubmed:38225345</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38225345/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240124195506&amp;v=2.18.0"/>
        <updated>2024-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) can be caused by either single gene mutations (eg point mutations in JAK2 causing CHIP) or mosaic chromosomal alterations (e.g., loss of heterozygosity at chromosome 9p). CH is associated with a significantly increased risk of hematologic malignancies. However, the absolute rate of transformation on an annualized basis is low. Improved prognostication of transformation risk is urgently needed for routine clinical practice. We hypothesized that the co-occurrence of CHIP...]]></summary>
        <author>
            <name>Ashwin Kishtagari</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Driver mutation zygosity is a critical factor in predicting clonal hematopoiesis transformation risk]]></title>
        <id>pubmed:38225345</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38225345/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240123195503&amp;v=2.18.0"/>
        <updated>2024-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) can be caused by either single gene mutations (eg point mutations in JAK2 causing CHIP) or mosaic chromosomal alterations (e.g., loss of heterozygosity at chromosome 9p). CH is associated with a significantly increased risk of hematologic malignancies. However, the absolute rate of transformation on an annualized basis is low. Improved prognostication of transformation risk is urgently needed for routine clinical practice. We hypothesized that the co-occurrence of CHIP...]]></summary>
        <author>
            <name>Ashwin Kishtagari</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Driver mutation zygosity is a critical factor in predicting clonal hematopoiesis transformation risk]]></title>
        <id>pubmed:38225345</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38225345/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240122195511&amp;v=2.18.0"/>
        <updated>2024-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) can be caused by either single gene mutations (eg point mutations in JAK2 causing CHIP) or mosaic chromosomal alterations (e.g., loss of heterozygosity at chromosome 9p). CH is associated with a significantly increased risk of hematologic malignancies. However, the absolute rate of transformation on an annualized basis is low. Improved prognostication of transformation risk is urgently needed for routine clinical practice. We hypothesized that the co-occurrence of CHIP...]]></summary>
        <author>
            <name>Ashwin Kishtagari</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Driver mutation zygosity is a critical factor in predicting clonal hematopoiesis transformation risk]]></title>
        <id>pubmed:38225345</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38225345/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240121195630&amp;v=2.18.0"/>
        <updated>2024-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) can be caused by either single gene mutations (eg point mutations in JAK2 causing CHIP) or mosaic chromosomal alterations (e.g., loss of heterozygosity at chromosome 9p). CH is associated with a significantly increased risk of hematologic malignancies. However, the absolute rate of transformation on an annualized basis is low. Improved prognostication of transformation risk is urgently needed for routine clinical practice. We hypothesized that the co-occurrence of CHIP...]]></summary>
        <author>
            <name>Ashwin Kishtagari</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Driver mutation zygosity is a critical factor in predicting clonal hematopoiesis transformation risk]]></title>
        <id>pubmed:38225345</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38225345/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240120195815&amp;v=2.18.0"/>
        <updated>2024-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) can be caused by either single gene mutations (eg point mutations in JAK2 causing CHIP) or mosaic chromosomal alterations (e.g., loss of heterozygosity at chromosome 9p). CH is associated with a significantly increased risk of hematologic malignancies. However, the absolute rate of transformation on an annualized basis is low. Improved prognostication of transformation risk is urgently needed for routine clinical practice. We hypothesized that the co-occurrence of CHIP...]]></summary>
        <author>
            <name>Ashwin Kishtagari</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Driver mutation zygosity is a critical factor in predicting clonal hematopoiesis transformation risk]]></title>
        <id>pubmed:38225345</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38225345/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240119195313&amp;v=2.18.0"/>
        <updated>2024-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) can be caused by either single gene mutations (eg point mutations in JAK2 causing CHIP) or mosaic chromosomal alterations (e.g., loss of heterozygosity at chromosome 9p). CH is associated with a significantly increased risk of hematologic malignancies. However, the absolute rate of transformation on an annualized basis is low. Improved prognostication of transformation risk is urgently needed for routine clinical practice. We hypothesized that the co-occurrence of CHIP...]]></summary>
        <author>
            <name>Ashwin Kishtagari</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Driver mutation zygosity is a critical factor in predicting clonal hematopoiesis transformation risk]]></title>
        <id>pubmed:38225345</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38225345/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240118195421&amp;v=2.18.0"/>
        <updated>2024-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) can be caused by either single gene mutations (eg point mutations in JAK2 causing CHIP) or mosaic chromosomal alterations (e.g., loss of heterozygosity at chromosome 9p). CH is associated with a significantly increased risk of hematologic malignancies. However, the absolute rate of transformation on an annualized basis is low. Improved prognostication of transformation risk is urgently needed for routine clinical practice. We hypothesized that the co-occurrence of CHIP...]]></summary>
        <author>
            <name>Ashwin Kishtagari</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Driver mutation zygosity is a critical factor in predicting clonal hematopoiesis transformation risk]]></title>
        <id>pubmed:38225345</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38225345/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240117195336&amp;v=2.18.0"/>
        <updated>2024-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) can be caused by either single gene mutations (eg point mutations in JAK2 causing CHIP) or mosaic chromosomal alterations (e.g., loss of heterozygosity at chromosome 9p). CH is associated with a significantly increased risk of hematologic malignancies. However, the absolute rate of transformation on an annualized basis is low. Improved prognostication of transformation risk is urgently needed for routine clinical practice. We hypothesized that the co-occurrence of CHIP...]]></summary>
        <author>
            <name>Ashwin Kishtagari</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Driver mutation zygosity is a critical factor in predicting clonal hematopoiesis transformation risk]]></title>
        <id>pubmed:38225345</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38225345/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240116195412&amp;v=2.18.0"/>
        <updated>2024-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) can be caused by either single gene mutations (eg point mutations in JAK2 causing CHIP) or mosaic chromosomal alterations (e.g., loss of heterozygosity at chromosome 9p). CH is associated with a significantly increased risk of hematologic malignancies. However, the absolute rate of transformation on an annualized basis is low. Improved prognostication of transformation risk is urgently needed for routine clinical practice. We hypothesized that the co-occurrence of CHIP...]]></summary>
        <author>
            <name>Ashwin Kishtagari</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Driver mutation zygosity is a critical factor in predicting clonal hematopoiesis transformation risk]]></title>
        <id>pubmed:38225345</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38225345/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240201195024&amp;v=2.18.0"/>
        <updated>2024-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) can be caused by either single gene mutations (eg point mutations in JAK2 causing CHIP) or mosaic chromosomal alterations (e.g., loss of heterozygosity at chromosome 9p). CH is associated with a significantly increased risk of hematologic malignancies. However, the absolute rate of transformation on an annualized basis is low. Improved prognostication of transformation risk is urgently needed for routine clinical practice. We hypothesized that the co-occurrence of CHIP...]]></summary>
        <author>
            <name>Ashwin Kishtagari</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Characterizing chromosomal instability-driven cancer evolution and cell fitness at a glance]]></title>
        <id>pubmed:38224461</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38224461/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240201195024&amp;v=2.18.0"/>
        <updated>2024-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosomal instability (CIN), an increased rate of chromosome segregation errors during mitosis, is a hallmark of cancer cells. CIN leads to karyotype differences between cells and thus large-scale heterogeneity among individual cancer cells; therefore, it plays an important role in cancer evolution. Studying CIN and its consequences is technically challenging, but various technologies have been developed to track karyotype dynamics during tumorigenesis, trace clonal lineages and link genomic...]]></summary>
        <author>
            <name>Andra E Tijhuis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Driver mutation zygosity is a critical factor in predicting clonal hematopoiesis transformation risk]]></title>
        <id>pubmed:38225345</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38225345/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240131195240&amp;v=2.18.0"/>
        <updated>2024-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) can be caused by either single gene mutations (eg point mutations in JAK2 causing CHIP) or mosaic chromosomal alterations (e.g., loss of heterozygosity at chromosome 9p). CH is associated with a significantly increased risk of hematologic malignancies. However, the absolute rate of transformation on an annualized basis is low. Improved prognostication of transformation risk is urgently needed for routine clinical practice. We hypothesized that the co-occurrence of CHIP...]]></summary>
        <author>
            <name>Ashwin Kishtagari</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Characterizing chromosomal instability-driven cancer evolution and cell fitness at a glance]]></title>
        <id>pubmed:38224461</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38224461/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240131195240&amp;v=2.18.0"/>
        <updated>2024-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosomal instability (CIN), an increased rate of chromosome segregation errors during mitosis, is a hallmark of cancer cells. CIN leads to karyotype differences between cells and thus large-scale heterogeneity among individual cancer cells; therefore, it plays an important role in cancer evolution. Studying CIN and its consequences is technically challenging, but various technologies have been developed to track karyotype dynamics during tumorigenesis, trace clonal lineages and link genomic...]]></summary>
        <author>
            <name>Andra E Tijhuis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between Leukemic Evolution and Uncommon Chromosomal Alterations in Pediatric Myelodysplastic Syndrome]]></title>
        <id>pubmed:38223485</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38223485/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240131195240&amp;v=2.18.0"/>
        <updated>2024-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The study of uncommon cytogenetic alterations in pMDS is important to improve the prognosis and guide early indication of HSCT.]]></summary>
        <author>
            <name>Viviane Lamim Lovatel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Driver mutation zygosity is a critical factor in predicting clonal hematopoiesis transformation risk]]></title>
        <id>pubmed:38225345</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38225345/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240130195039&amp;v=2.18.0"/>
        <updated>2024-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) can be caused by either single gene mutations (eg point mutations in JAK2 causing CHIP) or mosaic chromosomal alterations (e.g., loss of heterozygosity at chromosome 9p). CH is associated with a significantly increased risk of hematologic malignancies. However, the absolute rate of transformation on an annualized basis is low. Improved prognostication of transformation risk is urgently needed for routine clinical practice. We hypothesized that the co-occurrence of CHIP...]]></summary>
        <author>
            <name>Ashwin Kishtagari</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Characterizing chromosomal instability-driven cancer evolution and cell fitness at a glance]]></title>
        <id>pubmed:38224461</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38224461/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240130195039&amp;v=2.18.0"/>
        <updated>2024-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosomal instability (CIN), an increased rate of chromosome segregation errors during mitosis, is a hallmark of cancer cells. CIN leads to karyotype differences between cells and thus large-scale heterogeneity among individual cancer cells; therefore, it plays an important role in cancer evolution. Studying CIN and its consequences is technically challenging, but various technologies have been developed to track karyotype dynamics during tumorigenesis, trace clonal lineages and link genomic...]]></summary>
        <author>
            <name>Andra E Tijhuis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between Leukemic Evolution and Uncommon Chromosomal Alterations in Pediatric Myelodysplastic Syndrome]]></title>
        <id>pubmed:38223485</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38223485/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240130195039&amp;v=2.18.0"/>
        <updated>2024-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The study of uncommon cytogenetic alterations in pMDS is important to improve the prognosis and guide early indication of HSCT.]]></summary>
        <author>
            <name>Viviane Lamim Lovatel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Driver mutation zygosity is a critical factor in predicting clonal hematopoiesis transformation risk]]></title>
        <id>pubmed:38225345</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38225345/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240129195013&amp;v=2.18.0"/>
        <updated>2024-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) can be caused by either single gene mutations (eg point mutations in JAK2 causing CHIP) or mosaic chromosomal alterations (e.g., loss of heterozygosity at chromosome 9p). CH is associated with a significantly increased risk of hematologic malignancies. However, the absolute rate of transformation on an annualized basis is low. Improved prognostication of transformation risk is urgently needed for routine clinical practice. We hypothesized that the co-occurrence of CHIP...]]></summary>
        <author>
            <name>Ashwin Kishtagari</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Characterizing chromosomal instability-driven cancer evolution and cell fitness at a glance]]></title>
        <id>pubmed:38224461</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38224461/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240129195013&amp;v=2.18.0"/>
        <updated>2024-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosomal instability (CIN), an increased rate of chromosome segregation errors during mitosis, is a hallmark of cancer cells. CIN leads to karyotype differences between cells and thus large-scale heterogeneity among individual cancer cells; therefore, it plays an important role in cancer evolution. Studying CIN and its consequences is technically challenging, but various technologies have been developed to track karyotype dynamics during tumorigenesis, trace clonal lineages and link genomic...]]></summary>
        <author>
            <name>Andra E Tijhuis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between Leukemic Evolution and Uncommon Chromosomal Alterations in Pediatric Myelodysplastic Syndrome]]></title>
        <id>pubmed:38223485</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38223485/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240129195013&amp;v=2.18.0"/>
        <updated>2024-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The study of uncommon cytogenetic alterations in pMDS is important to improve the prognosis and guide early indication of HSCT.]]></summary>
        <author>
            <name>Viviane Lamim Lovatel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Driver mutation zygosity is a critical factor in predicting clonal hematopoiesis transformation risk]]></title>
        <id>pubmed:38225345</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38225345/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240128195055&amp;v=2.18.0"/>
        <updated>2024-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) can be caused by either single gene mutations (eg point mutations in JAK2 causing CHIP) or mosaic chromosomal alterations (e.g., loss of heterozygosity at chromosome 9p). CH is associated with a significantly increased risk of hematologic malignancies. However, the absolute rate of transformation on an annualized basis is low. Improved prognostication of transformation risk is urgently needed for routine clinical practice. We hypothesized that the co-occurrence of CHIP...]]></summary>
        <author>
            <name>Ashwin Kishtagari</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Characterizing chromosomal instability-driven cancer evolution and cell fitness at a glance]]></title>
        <id>pubmed:38224461</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38224461/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240128195055&amp;v=2.18.0"/>
        <updated>2024-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosomal instability (CIN), an increased rate of chromosome segregation errors during mitosis, is a hallmark of cancer cells. CIN leads to karyotype differences between cells and thus large-scale heterogeneity among individual cancer cells; therefore, it plays an important role in cancer evolution. Studying CIN and its consequences is technically challenging, but various technologies have been developed to track karyotype dynamics during tumorigenesis, trace clonal lineages and link genomic...]]></summary>
        <author>
            <name>Andra E Tijhuis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between Leukemic Evolution and Uncommon Chromosomal Alterations in Pediatric Myelodysplastic Syndrome]]></title>
        <id>pubmed:38223485</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38223485/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240128195055&amp;v=2.18.0"/>
        <updated>2024-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The study of uncommon cytogenetic alterations in pMDS is important to improve the prognosis and guide early indication of HSCT.]]></summary>
        <author>
            <name>Viviane Lamim Lovatel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Driver mutation zygosity is a critical factor in predicting clonal hematopoiesis transformation risk]]></title>
        <id>pubmed:38225345</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38225345/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240127195322&amp;v=2.18.0"/>
        <updated>2024-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) can be caused by either single gene mutations (eg point mutations in JAK2 causing CHIP) or mosaic chromosomal alterations (e.g., loss of heterozygosity at chromosome 9p). CH is associated with a significantly increased risk of hematologic malignancies. However, the absolute rate of transformation on an annualized basis is low. Improved prognostication of transformation risk is urgently needed for routine clinical practice. We hypothesized that the co-occurrence of CHIP...]]></summary>
        <author>
            <name>Ashwin Kishtagari</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Characterizing chromosomal instability-driven cancer evolution and cell fitness at a glance]]></title>
        <id>pubmed:38224461</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38224461/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240127195322&amp;v=2.18.0"/>
        <updated>2024-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosomal instability (CIN), an increased rate of chromosome segregation errors during mitosis, is a hallmark of cancer cells. CIN leads to karyotype differences between cells and thus large-scale heterogeneity among individual cancer cells; therefore, it plays an important role in cancer evolution. Studying CIN and its consequences is technically challenging, but various technologies have been developed to track karyotype dynamics during tumorigenesis, trace clonal lineages and link genomic...]]></summary>
        <author>
            <name>Andra E Tijhuis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between Leukemic Evolution and Uncommon Chromosomal Alterations in Pediatric Myelodysplastic Syndrome]]></title>
        <id>pubmed:38223485</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38223485/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240127195322&amp;v=2.18.0"/>
        <updated>2024-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The study of uncommon cytogenetic alterations in pMDS is important to improve the prognosis and guide early indication of HSCT.]]></summary>
        <author>
            <name>Viviane Lamim Lovatel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Driver mutation zygosity is a critical factor in predicting clonal hematopoiesis transformation risk]]></title>
        <id>pubmed:38225345</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38225345/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240126194954&amp;v=2.18.0"/>
        <updated>2024-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) can be caused by either single gene mutations (eg point mutations in JAK2 causing CHIP) or mosaic chromosomal alterations (e.g., loss of heterozygosity at chromosome 9p). CH is associated with a significantly increased risk of hematologic malignancies. However, the absolute rate of transformation on an annualized basis is low. Improved prognostication of transformation risk is urgently needed for routine clinical practice. We hypothesized that the co-occurrence of CHIP...]]></summary>
        <author>
            <name>Ashwin Kishtagari</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Characterizing chromosomal instability-driven cancer evolution and cell fitness at a glance]]></title>
        <id>pubmed:38224461</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38224461/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240126194954&amp;v=2.18.0"/>
        <updated>2024-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosomal instability (CIN), an increased rate of chromosome segregation errors during mitosis, is a hallmark of cancer cells. CIN leads to karyotype differences between cells and thus large-scale heterogeneity among individual cancer cells; therefore, it plays an important role in cancer evolution. Studying CIN and its consequences is technically challenging, but various technologies have been developed to track karyotype dynamics during tumorigenesis, trace clonal lineages and link genomic...]]></summary>
        <author>
            <name>Andra E Tijhuis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between Leukemic Evolution and Uncommon Chromosomal Alterations in Pediatric Myelodysplastic Syndrome]]></title>
        <id>pubmed:38223485</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38223485/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240126194954&amp;v=2.18.0"/>
        <updated>2024-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The study of uncommon cytogenetic alterations in pMDS is important to improve the prognosis and guide early indication of HSCT.]]></summary>
        <author>
            <name>Viviane Lamim Lovatel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Driver mutation zygosity is a critical factor in predicting clonal hematopoiesis transformation risk]]></title>
        <id>pubmed:38225345</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38225345/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240125195050&amp;v=2.18.0"/>
        <updated>2024-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) can be caused by either single gene mutations (eg point mutations in JAK2 causing CHIP) or mosaic chromosomal alterations (e.g., loss of heterozygosity at chromosome 9p). CH is associated with a significantly increased risk of hematologic malignancies. However, the absolute rate of transformation on an annualized basis is low. Improved prognostication of transformation risk is urgently needed for routine clinical practice. We hypothesized that the co-occurrence of CHIP...]]></summary>
        <author>
            <name>Ashwin Kishtagari</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Characterizing chromosomal instability-driven cancer evolution and cell fitness at a glance]]></title>
        <id>pubmed:38224461</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38224461/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240125195050&amp;v=2.18.0"/>
        <updated>2024-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosomal instability (CIN), an increased rate of chromosome segregation errors during mitosis, is a hallmark of cancer cells. CIN leads to karyotype differences between cells and thus large-scale heterogeneity among individual cancer cells; therefore, it plays an important role in cancer evolution. Studying CIN and its consequences is technically challenging, but various technologies have been developed to track karyotype dynamics during tumorigenesis, trace clonal lineages and link genomic...]]></summary>
        <author>
            <name>Andra E Tijhuis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between Leukemic Evolution and Uncommon Chromosomal Alterations in Pediatric Myelodysplastic Syndrome]]></title>
        <id>pubmed:38223485</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38223485/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240125195050&amp;v=2.18.0"/>
        <updated>2024-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The study of uncommon cytogenetic alterations in pMDS is important to improve the prognosis and guide early indication of HSCT.]]></summary>
        <author>
            <name>Viviane Lamim Lovatel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Driver mutation zygosity is a critical factor in predicting clonal hematopoiesis transformation risk]]></title>
        <id>pubmed:38225345</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38225345/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240124195506&amp;v=2.18.0"/>
        <updated>2024-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) can be caused by either single gene mutations (eg point mutations in JAK2 causing CHIP) or mosaic chromosomal alterations (e.g., loss of heterozygosity at chromosome 9p). CH is associated with a significantly increased risk of hematologic malignancies. However, the absolute rate of transformation on an annualized basis is low. Improved prognostication of transformation risk is urgently needed for routine clinical practice. We hypothesized that the co-occurrence of CHIP...]]></summary>
        <author>
            <name>Ashwin Kishtagari</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Characterizing chromosomal instability-driven cancer evolution and cell fitness at a glance]]></title>
        <id>pubmed:38224461</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38224461/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240124195506&amp;v=2.18.0"/>
        <updated>2024-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosomal instability (CIN), an increased rate of chromosome segregation errors during mitosis, is a hallmark of cancer cells. CIN leads to karyotype differences between cells and thus large-scale heterogeneity among individual cancer cells; therefore, it plays an important role in cancer evolution. Studying CIN and its consequences is technically challenging, but various technologies have been developed to track karyotype dynamics during tumorigenesis, trace clonal lineages and link genomic...]]></summary>
        <author>
            <name>Andra E Tijhuis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between Leukemic Evolution and Uncommon Chromosomal Alterations in Pediatric Myelodysplastic Syndrome]]></title>
        <id>pubmed:38223485</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38223485/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240124195506&amp;v=2.18.0"/>
        <updated>2024-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The study of uncommon cytogenetic alterations in pMDS is important to improve the prognosis and guide early indication of HSCT.]]></summary>
        <author>
            <name>Viviane Lamim Lovatel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Driver mutation zygosity is a critical factor in predicting clonal hematopoiesis transformation risk]]></title>
        <id>pubmed:38225345</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38225345/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240123195503&amp;v=2.18.0"/>
        <updated>2024-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) can be caused by either single gene mutations (eg point mutations in JAK2 causing CHIP) or mosaic chromosomal alterations (e.g., loss of heterozygosity at chromosome 9p). CH is associated with a significantly increased risk of hematologic malignancies. However, the absolute rate of transformation on an annualized basis is low. Improved prognostication of transformation risk is urgently needed for routine clinical practice. We hypothesized that the co-occurrence of CHIP...]]></summary>
        <author>
            <name>Ashwin Kishtagari</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Characterizing chromosomal instability-driven cancer evolution and cell fitness at a glance]]></title>
        <id>pubmed:38224461</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38224461/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240123195503&amp;v=2.18.0"/>
        <updated>2024-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosomal instability (CIN), an increased rate of chromosome segregation errors during mitosis, is a hallmark of cancer cells. CIN leads to karyotype differences between cells and thus large-scale heterogeneity among individual cancer cells; therefore, it plays an important role in cancer evolution. Studying CIN and its consequences is technically challenging, but various technologies have been developed to track karyotype dynamics during tumorigenesis, trace clonal lineages and link genomic...]]></summary>
        <author>
            <name>Andra E Tijhuis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between Leukemic Evolution and Uncommon Chromosomal Alterations in Pediatric Myelodysplastic Syndrome]]></title>
        <id>pubmed:38223485</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38223485/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240123195503&amp;v=2.18.0"/>
        <updated>2024-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The study of uncommon cytogenetic alterations in pMDS is important to improve the prognosis and guide early indication of HSCT.]]></summary>
        <author>
            <name>Viviane Lamim Lovatel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Driver mutation zygosity is a critical factor in predicting clonal hematopoiesis transformation risk]]></title>
        <id>pubmed:38225345</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38225345/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240122195511&amp;v=2.18.0"/>
        <updated>2024-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) can be caused by either single gene mutations (eg point mutations in JAK2 causing CHIP) or mosaic chromosomal alterations (e.g., loss of heterozygosity at chromosome 9p). CH is associated with a significantly increased risk of hematologic malignancies. However, the absolute rate of transformation on an annualized basis is low. Improved prognostication of transformation risk is urgently needed for routine clinical practice. We hypothesized that the co-occurrence of CHIP...]]></summary>
        <author>
            <name>Ashwin Kishtagari</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Characterizing chromosomal instability-driven cancer evolution and cell fitness at a glance]]></title>
        <id>pubmed:38224461</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38224461/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240122195511&amp;v=2.18.0"/>
        <updated>2024-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosomal instability (CIN), an increased rate of chromosome segregation errors during mitosis, is a hallmark of cancer cells. CIN leads to karyotype differences between cells and thus large-scale heterogeneity among individual cancer cells; therefore, it plays an important role in cancer evolution. Studying CIN and its consequences is technically challenging, but various technologies have been developed to track karyotype dynamics during tumorigenesis, trace clonal lineages and link genomic...]]></summary>
        <author>
            <name>Andra E Tijhuis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between Leukemic Evolution and Uncommon Chromosomal Alterations in Pediatric Myelodysplastic Syndrome]]></title>
        <id>pubmed:38223485</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38223485/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240122195511&amp;v=2.18.0"/>
        <updated>2024-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The study of uncommon cytogenetic alterations in pMDS is important to improve the prognosis and guide early indication of HSCT.]]></summary>
        <author>
            <name>Viviane Lamim Lovatel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Driver mutation zygosity is a critical factor in predicting clonal hematopoiesis transformation risk]]></title>
        <id>pubmed:38225345</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38225345/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240121195630&amp;v=2.18.0"/>
        <updated>2024-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) can be caused by either single gene mutations (eg point mutations in JAK2 causing CHIP) or mosaic chromosomal alterations (e.g., loss of heterozygosity at chromosome 9p). CH is associated with a significantly increased risk of hematologic malignancies. However, the absolute rate of transformation on an annualized basis is low. Improved prognostication of transformation risk is urgently needed for routine clinical practice. We hypothesized that the co-occurrence of CHIP...]]></summary>
        <author>
            <name>Ashwin Kishtagari</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Characterizing chromosomal instability-driven cancer evolution and cell fitness at a glance]]></title>
        <id>pubmed:38224461</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38224461/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240121195630&amp;v=2.18.0"/>
        <updated>2024-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosomal instability (CIN), an increased rate of chromosome segregation errors during mitosis, is a hallmark of cancer cells. CIN leads to karyotype differences between cells and thus large-scale heterogeneity among individual cancer cells; therefore, it plays an important role in cancer evolution. Studying CIN and its consequences is technically challenging, but various technologies have been developed to track karyotype dynamics during tumorigenesis, trace clonal lineages and link genomic...]]></summary>
        <author>
            <name>Andra E Tijhuis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between Leukemic Evolution and Uncommon Chromosomal Alterations in Pediatric Myelodysplastic Syndrome]]></title>
        <id>pubmed:38223485</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38223485/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240121195630&amp;v=2.18.0"/>
        <updated>2024-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The study of uncommon cytogenetic alterations in pMDS is important to improve the prognosis and guide early indication of HSCT.]]></summary>
        <author>
            <name>Viviane Lamim Lovatel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Driver mutation zygosity is a critical factor in predicting clonal hematopoiesis transformation risk]]></title>
        <id>pubmed:38225345</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38225345/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240120195815&amp;v=2.18.0"/>
        <updated>2024-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) can be caused by either single gene mutations (eg point mutations in JAK2 causing CHIP) or mosaic chromosomal alterations (e.g., loss of heterozygosity at chromosome 9p). CH is associated with a significantly increased risk of hematologic malignancies. However, the absolute rate of transformation on an annualized basis is low. Improved prognostication of transformation risk is urgently needed for routine clinical practice. We hypothesized that the co-occurrence of CHIP...]]></summary>
        <author>
            <name>Ashwin Kishtagari</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Characterizing chromosomal instability-driven cancer evolution and cell fitness at a glance]]></title>
        <id>pubmed:38224461</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38224461/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240120195815&amp;v=2.18.0"/>
        <updated>2024-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosomal instability (CIN), an increased rate of chromosome segregation errors during mitosis, is a hallmark of cancer cells. CIN leads to karyotype differences between cells and thus large-scale heterogeneity among individual cancer cells; therefore, it plays an important role in cancer evolution. Studying CIN and its consequences is technically challenging, but various technologies have been developed to track karyotype dynamics during tumorigenesis, trace clonal lineages and link genomic...]]></summary>
        <author>
            <name>Andra E Tijhuis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between Leukemic Evolution and Uncommon Chromosomal Alterations in Pediatric Myelodysplastic Syndrome]]></title>
        <id>pubmed:38223485</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38223485/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240120195815&amp;v=2.18.0"/>
        <updated>2024-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The study of uncommon cytogenetic alterations in pMDS is important to improve the prognosis and guide early indication of HSCT.]]></summary>
        <author>
            <name>Viviane Lamim Lovatel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Driver mutation zygosity is a critical factor in predicting clonal hematopoiesis transformation risk]]></title>
        <id>pubmed:38225345</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38225345/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240119195313&amp;v=2.18.0"/>
        <updated>2024-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) can be caused by either single gene mutations (eg point mutations in JAK2 causing CHIP) or mosaic chromosomal alterations (e.g., loss of heterozygosity at chromosome 9p). CH is associated with a significantly increased risk of hematologic malignancies. However, the absolute rate of transformation on an annualized basis is low. Improved prognostication of transformation risk is urgently needed for routine clinical practice. We hypothesized that the co-occurrence of CHIP...]]></summary>
        <author>
            <name>Ashwin Kishtagari</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Characterizing chromosomal instability-driven cancer evolution and cell fitness at a glance]]></title>
        <id>pubmed:38224461</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38224461/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240119195313&amp;v=2.18.0"/>
        <updated>2024-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosomal instability (CIN), an increased rate of chromosome segregation errors during mitosis, is a hallmark of cancer cells. CIN leads to karyotype differences between cells and thus large-scale heterogeneity among individual cancer cells; therefore, it plays an important role in cancer evolution. Studying CIN and its consequences is technically challenging, but various technologies have been developed to track karyotype dynamics during tumorigenesis, trace clonal lineages and link genomic...]]></summary>
        <author>
            <name>Andra E Tijhuis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between Leukemic Evolution and Uncommon Chromosomal Alterations in Pediatric Myelodysplastic Syndrome]]></title>
        <id>pubmed:38223485</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38223485/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240119195313&amp;v=2.18.0"/>
        <updated>2024-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The study of uncommon cytogenetic alterations in pMDS is important to improve the prognosis and guide early indication of HSCT.]]></summary>
        <author>
            <name>Viviane Lamim Lovatel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Driver mutation zygosity is a critical factor in predicting clonal hematopoiesis transformation risk]]></title>
        <id>pubmed:38225345</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38225345/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240118195420&amp;v=2.18.0"/>
        <updated>2024-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) can be caused by either single gene mutations (eg point mutations in JAK2 causing CHIP) or mosaic chromosomal alterations (e.g., loss of heterozygosity at chromosome 9p). CH is associated with a significantly increased risk of hematologic malignancies. However, the absolute rate of transformation on an annualized basis is low. Improved prognostication of transformation risk is urgently needed for routine clinical practice. We hypothesized that the co-occurrence of CHIP...]]></summary>
        <author>
            <name>Ashwin Kishtagari</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Characterizing chromosomal instability-driven cancer evolution and cell fitness at a glance]]></title>
        <id>pubmed:38224461</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38224461/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240118195420&amp;v=2.18.0"/>
        <updated>2024-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosomal instability (CIN), an increased rate of chromosome segregation errors during mitosis, is a hallmark of cancer cells. CIN leads to karyotype differences between cells and thus large-scale heterogeneity among individual cancer cells; therefore, it plays an important role in cancer evolution. Studying CIN and its consequences is technically challenging, but various technologies have been developed to track karyotype dynamics during tumorigenesis, trace clonal lineages and link genomic...]]></summary>
        <author>
            <name>Andra E Tijhuis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between Leukemic Evolution and Uncommon Chromosomal Alterations in Pediatric Myelodysplastic Syndrome]]></title>
        <id>pubmed:38223485</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38223485/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240118195420&amp;v=2.18.0"/>
        <updated>2024-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The study of uncommon cytogenetic alterations in pMDS is important to improve the prognosis and guide early indication of HSCT.]]></summary>
        <author>
            <name>Viviane Lamim Lovatel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Driver mutation zygosity is a critical factor in predicting clonal hematopoiesis transformation risk]]></title>
        <id>pubmed:38225345</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38225345/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240117195336&amp;v=2.18.0"/>
        <updated>2024-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) can be caused by either single gene mutations (eg point mutations in JAK2 causing CHIP) or mosaic chromosomal alterations (e.g., loss of heterozygosity at chromosome 9p). CH is associated with a significantly increased risk of hematologic malignancies. However, the absolute rate of transformation on an annualized basis is low. Improved prognostication of transformation risk is urgently needed for routine clinical practice. We hypothesized that the co-occurrence of CHIP...]]></summary>
        <author>
            <name>Ashwin Kishtagari</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Characterizing chromosomal instability-driven cancer evolution and cell fitness at a glance]]></title>
        <id>pubmed:38224461</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38224461/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240117195336&amp;v=2.18.0"/>
        <updated>2024-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosomal instability (CIN), an increased rate of chromosome segregation errors during mitosis, is a hallmark of cancer cells. CIN leads to karyotype differences between cells and thus large-scale heterogeneity among individual cancer cells; therefore, it plays an important role in cancer evolution. Studying CIN and its consequences is technically challenging, but various technologies have been developed to track karyotype dynamics during tumorigenesis, trace clonal lineages and link genomic...]]></summary>
        <author>
            <name>Andra E Tijhuis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between Leukemic Evolution and Uncommon Chromosomal Alterations in Pediatric Myelodysplastic Syndrome]]></title>
        <id>pubmed:38223485</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38223485/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240117195336&amp;v=2.18.0"/>
        <updated>2024-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The study of uncommon cytogenetic alterations in pMDS is important to improve the prognosis and guide early indication of HSCT.]]></summary>
        <author>
            <name>Viviane Lamim Lovatel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Characterizing chromosomal instability-driven cancer evolution and cell fitness at a glance]]></title>
        <id>pubmed:38224461</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38224461/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240116195412&amp;v=2.18.0"/>
        <updated>2024-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosomal instability (CIN), an increased rate of chromosome segregation errors during mitosis, is a hallmark of cancer cells. CIN leads to karyotype differences between cells and thus large-scale heterogeneity among individual cancer cells; therefore, it plays an important role in cancer evolution. Studying CIN and its consequences is technically challenging, but various technologies have been developed to track karyotype dynamics during tumorigenesis, trace clonal lineages and link genomic...]]></summary>
        <author>
            <name>Andra E Tijhuis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between Leukemic Evolution and Uncommon Chromosomal Alterations in Pediatric Myelodysplastic Syndrome]]></title>
        <id>pubmed:38223485</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38223485/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240116195412&amp;v=2.18.0"/>
        <updated>2024-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The study of uncommon cytogenetic alterations in pMDS is important to improve the prognosis and guide early indication of HSCT.]]></summary>
        <author>
            <name>Viviane Lamim Lovatel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between Leukemic Evolution and Uncommon Chromosomal Alterations in Pediatric Myelodysplastic Syndrome]]></title>
        <id>pubmed:38223485</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38223485/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240115195351&amp;v=2.18.0"/>
        <updated>2024-01-15T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: The study of uncommon cytogenetic alterations in pMDS is important to improve the prognosis and guide early indication of HSCT.]]></summary>
        <author>
            <name>Viviane Lamim Lovatel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Minimizing false positives for CTC identification]]></title>
        <id>pubmed:38220297</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38220297/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240130195039&amp;v=2.18.0"/>
        <updated>2024-01-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Cancer is a leading cause of death worldwide, with metastasis playing a significant role. Circulating Tumour Cells (CTCs) can provide important real-time insights into tumour heterogeneity and clonal evolution, making them an important tool for early diagnosis and patient monitoring. Isolated CTCs are typically identified by immunocytochemistry using positive biomarkers (cytokeratin) and exclusion biomarkers (CD45). However, some white blood cell (WBC) populations can express low...]]></summary>
        <author>
            <name>Adriana Carneiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Minimizing false positives for CTC identification]]></title>
        <id>pubmed:38220297</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38220297/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240129195013&amp;v=2.18.0"/>
        <updated>2024-01-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Cancer is a leading cause of death worldwide, with metastasis playing a significant role. Circulating Tumour Cells (CTCs) can provide important real-time insights into tumour heterogeneity and clonal evolution, making them an important tool for early diagnosis and patient monitoring. Isolated CTCs are typically identified by immunocytochemistry using positive biomarkers (cytokeratin) and exclusion biomarkers (CD45). However, some white blood cell (WBC) populations can express low...]]></summary>
        <author>
            <name>Adriana Carneiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Minimizing false positives for CTC identification]]></title>
        <id>pubmed:38220297</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38220297/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240128195055&amp;v=2.18.0"/>
        <updated>2024-01-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Cancer is a leading cause of death worldwide, with metastasis playing a significant role. Circulating Tumour Cells (CTCs) can provide important real-time insights into tumour heterogeneity and clonal evolution, making them an important tool for early diagnosis and patient monitoring. Isolated CTCs are typically identified by immunocytochemistry using positive biomarkers (cytokeratin) and exclusion biomarkers (CD45). However, some white blood cell (WBC) populations can express low...]]></summary>
        <author>
            <name>Adriana Carneiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Minimizing false positives for CTC identification]]></title>
        <id>pubmed:38220297</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38220297/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240127195322&amp;v=2.18.0"/>
        <updated>2024-01-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Cancer is a leading cause of death worldwide, with metastasis playing a significant role. Circulating Tumour Cells (CTCs) can provide important real-time insights into tumour heterogeneity and clonal evolution, making them an important tool for early diagnosis and patient monitoring. Isolated CTCs are typically identified by immunocytochemistry using positive biomarkers (cytokeratin) and exclusion biomarkers (CD45). However, some white blood cell (WBC) populations can express low...]]></summary>
        <author>
            <name>Adriana Carneiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Minimizing false positives for CTC identification]]></title>
        <id>pubmed:38220297</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38220297/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240126194954&amp;v=2.18.0"/>
        <updated>2024-01-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Cancer is a leading cause of death worldwide, with metastasis playing a significant role. Circulating Tumour Cells (CTCs) can provide important real-time insights into tumour heterogeneity and clonal evolution, making them an important tool for early diagnosis and patient monitoring. Isolated CTCs are typically identified by immunocytochemistry using positive biomarkers (cytokeratin) and exclusion biomarkers (CD45). However, some white blood cell (WBC) populations can express low...]]></summary>
        <author>
            <name>Adriana Carneiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Minimizing false positives for CTC identification]]></title>
        <id>pubmed:38220297</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38220297/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240125195050&amp;v=2.18.0"/>
        <updated>2024-01-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Cancer is a leading cause of death worldwide, with metastasis playing a significant role. Circulating Tumour Cells (CTCs) can provide important real-time insights into tumour heterogeneity and clonal evolution, making them an important tool for early diagnosis and patient monitoring. Isolated CTCs are typically identified by immunocytochemistry using positive biomarkers (cytokeratin) and exclusion biomarkers (CD45). However, some white blood cell (WBC) populations can express low...]]></summary>
        <author>
            <name>Adriana Carneiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Minimizing false positives for CTC identification]]></title>
        <id>pubmed:38220297</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38220297/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240124195506&amp;v=2.18.0"/>
        <updated>2024-01-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Cancer is a leading cause of death worldwide, with metastasis playing a significant role. Circulating Tumour Cells (CTCs) can provide important real-time insights into tumour heterogeneity and clonal evolution, making them an important tool for early diagnosis and patient monitoring. Isolated CTCs are typically identified by immunocytochemistry using positive biomarkers (cytokeratin) and exclusion biomarkers (CD45). However, some white blood cell (WBC) populations can express low...]]></summary>
        <author>
            <name>Adriana Carneiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Minimizing false positives for CTC identification]]></title>
        <id>pubmed:38220297</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38220297/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240123195503&amp;v=2.18.0"/>
        <updated>2024-01-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Cancer is a leading cause of death worldwide, with metastasis playing a significant role. Circulating Tumour Cells (CTCs) can provide important real-time insights into tumour heterogeneity and clonal evolution, making them an important tool for early diagnosis and patient monitoring. Isolated CTCs are typically identified by immunocytochemistry using positive biomarkers (cytokeratin) and exclusion biomarkers (CD45). However, some white blood cell (WBC) populations can express low...]]></summary>
        <author>
            <name>Adriana Carneiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Minimizing false positives for CTC identification]]></title>
        <id>pubmed:38220297</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38220297/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240122195511&amp;v=2.18.0"/>
        <updated>2024-01-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Cancer is a leading cause of death worldwide, with metastasis playing a significant role. Circulating Tumour Cells (CTCs) can provide important real-time insights into tumour heterogeneity and clonal evolution, making them an important tool for early diagnosis and patient monitoring. Isolated CTCs are typically identified by immunocytochemistry using positive biomarkers (cytokeratin) and exclusion biomarkers (CD45). However, some white blood cell (WBC) populations can express low...]]></summary>
        <author>
            <name>Adriana Carneiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Minimizing false positives for CTC identification]]></title>
        <id>pubmed:38220297</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38220297/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240121195630&amp;v=2.18.0"/>
        <updated>2024-01-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Cancer is a leading cause of death worldwide, with metastasis playing a significant role. Circulating Tumour Cells (CTCs) can provide important real-time insights into tumour heterogeneity and clonal evolution, making them an important tool for early diagnosis and patient monitoring. Isolated CTCs are typically identified by immunocytochemistry using positive biomarkers (cytokeratin) and exclusion biomarkers (CD45). However, some white blood cell (WBC) populations can express low...]]></summary>
        <author>
            <name>Adriana Carneiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Minimizing false positives for CTC identification]]></title>
        <id>pubmed:38220297</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38220297/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240120195815&amp;v=2.18.0"/>
        <updated>2024-01-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Cancer is a leading cause of death worldwide, with metastasis playing a significant role. Circulating Tumour Cells (CTCs) can provide important real-time insights into tumour heterogeneity and clonal evolution, making them an important tool for early diagnosis and patient monitoring. Isolated CTCs are typically identified by immunocytochemistry using positive biomarkers (cytokeratin) and exclusion biomarkers (CD45). However, some white blood cell (WBC) populations can express low...]]></summary>
        <author>
            <name>Adriana Carneiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Minimizing false positives for CTC identification]]></title>
        <id>pubmed:38220297</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38220297/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240119195313&amp;v=2.18.0"/>
        <updated>2024-01-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Cancer is a leading cause of death worldwide, with metastasis playing a significant role. Circulating Tumour Cells (CTCs) can provide important real-time insights into tumour heterogeneity and clonal evolution, making them an important tool for early diagnosis and patient monitoring. Isolated CTCs are typically identified by immunocytochemistry using positive biomarkers (cytokeratin) and exclusion biomarkers (CD45). However, some white blood cell (WBC) populations can express low...]]></summary>
        <author>
            <name>Adriana Carneiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Minimizing false positives for CTC identification]]></title>
        <id>pubmed:38220297</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38220297/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240118195420&amp;v=2.18.0"/>
        <updated>2024-01-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Cancer is a leading cause of death worldwide, with metastasis playing a significant role. Circulating Tumour Cells (CTCs) can provide important real-time insights into tumour heterogeneity and clonal evolution, making them an important tool for early diagnosis and patient monitoring. Isolated CTCs are typically identified by immunocytochemistry using positive biomarkers (cytokeratin) and exclusion biomarkers (CD45). However, some white blood cell (WBC) populations can express low...]]></summary>
        <author>
            <name>Adriana Carneiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Minimizing false positives for CTC identification]]></title>
        <id>pubmed:38220297</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38220297/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240117195336&amp;v=2.18.0"/>
        <updated>2024-01-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Cancer is a leading cause of death worldwide, with metastasis playing a significant role. Circulating Tumour Cells (CTCs) can provide important real-time insights into tumour heterogeneity and clonal evolution, making them an important tool for early diagnosis and patient monitoring. Isolated CTCs are typically identified by immunocytochemistry using positive biomarkers (cytokeratin) and exclusion biomarkers (CD45). However, some white blood cell (WBC) populations can express low...]]></summary>
        <author>
            <name>Adriana Carneiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Minimizing false positives for CTC identification]]></title>
        <id>pubmed:38220297</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38220297/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240116195412&amp;v=2.18.0"/>
        <updated>2024-01-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Cancer is a leading cause of death worldwide, with metastasis playing a significant role. Circulating Tumour Cells (CTCs) can provide important real-time insights into tumour heterogeneity and clonal evolution, making them an important tool for early diagnosis and patient monitoring. Isolated CTCs are typically identified by immunocytochemistry using positive biomarkers (cytokeratin) and exclusion biomarkers (CD45). However, some white blood cell (WBC) populations can express low...]]></summary>
        <author>
            <name>Adriana Carneiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Minimizing false positives for CTC identification]]></title>
        <id>pubmed:38220297</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38220297/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240115195351&amp;v=2.18.0"/>
        <updated>2024-01-14T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Cancer is a leading cause of death worldwide, with metastasis playing a significant role. Circulating Tumour Cells (CTCs) can provide important real-time insights into tumour heterogeneity and clonal evolution, making them an important tool for early diagnosis and patient monitoring. Isolated CTCs are typically identified by immunocytochemistry using positive biomarkers (cytokeratin) and exclusion biomarkers (CD45). However, some white blood cell (WBC) populations can express low...]]></summary>
        <author>
            <name>Adriana Carneiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association Between Clonal Hematopoiesis Driver Mutations, Immune Cell Function, and the Vasculometabolic Complications of Obesity]]></title>
        <id>pubmed:38214284</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38214284/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240124195506&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In individuals with overweight or obesity, CHDMs are not associated with vasculometabolic complications, but rather with a lower presence of carotid plaques. CHDMs associate with increased circulating inflammatory markers and leukocyte numbers, but a lower peripheral blood mononuclear cell cytokine production capacity.]]></summary>
        <author>
            <name>Helin Tercan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Renal Extramedullary Hematopoiesis in Mast Cell Leukemia with Bone Marrow Fibrosis]]></title>
        <id>pubmed:38213502</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38213502/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240124195506&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Systemic mastocytosis is defined by the clonal proliferation of abnormal mast cells. The clinical course can range from indolent forms with normal life expectancy to advanced mast cell leukemia with dismal prognosis. An association with other diseases, including myeloproliferative neoplasia, has been described. We present a case of a 75-year patient with a history of cutaneous mastocytosis who was diagnosed with mast cell leukemia more than 9 years ago and did not receive treatment. The patient...]]></summary>
        <author>
            <name>Damian T Rieke</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association Between Clonal Hematopoiesis Driver Mutations, Immune Cell Function, and the Vasculometabolic Complications of Obesity]]></title>
        <id>pubmed:38214284</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38214284/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240123195503&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In individuals with overweight or obesity, CHDMs are not associated with vasculometabolic complications, but rather with a lower presence of carotid plaques. CHDMs associate with increased circulating inflammatory markers and leukocyte numbers, but a lower peripheral blood mononuclear cell cytokine production capacity.]]></summary>
        <author>
            <name>Helin Tercan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Renal Extramedullary Hematopoiesis in Mast Cell Leukemia with Bone Marrow Fibrosis]]></title>
        <id>pubmed:38213502</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38213502/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240123195503&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Systemic mastocytosis is defined by the clonal proliferation of abnormal mast cells. The clinical course can range from indolent forms with normal life expectancy to advanced mast cell leukemia with dismal prognosis. An association with other diseases, including myeloproliferative neoplasia, has been described. We present a case of a 75-year patient with a history of cutaneous mastocytosis who was diagnosed with mast cell leukemia more than 9 years ago and did not receive treatment. The patient...]]></summary>
        <author>
            <name>Damian T Rieke</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association Between Clonal Hematopoiesis Driver Mutations, Immune Cell Function, and the Vasculometabolic Complications of Obesity]]></title>
        <id>pubmed:38214284</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38214284/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240122195511&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In individuals with overweight or obesity, CHDMs are not associated with vasculometabolic complications, but rather with a lower presence of carotid plaques. CHDMs associate with increased circulating inflammatory markers and leukocyte numbers, but a lower peripheral blood mononuclear cell cytokine production capacity.]]></summary>
        <author>
            <name>Helin Tercan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Renal Extramedullary Hematopoiesis in Mast Cell Leukemia with Bone Marrow Fibrosis]]></title>
        <id>pubmed:38213502</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38213502/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240122195511&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Systemic mastocytosis is defined by the clonal proliferation of abnormal mast cells. The clinical course can range from indolent forms with normal life expectancy to advanced mast cell leukemia with dismal prognosis. An association with other diseases, including myeloproliferative neoplasia, has been described. We present a case of a 75-year patient with a history of cutaneous mastocytosis who was diagnosed with mast cell leukemia more than 9 years ago and did not receive treatment. The patient...]]></summary>
        <author>
            <name>Damian T Rieke</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association Between Clonal Hematopoiesis Driver Mutations, Immune Cell Function, and the Vasculometabolic Complications of Obesity]]></title>
        <id>pubmed:38214284</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38214284/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240121195630&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In individuals with overweight or obesity, CHDMs are not associated with vasculometabolic complications, but rather with a lower presence of carotid plaques. CHDMs associate with increased circulating inflammatory markers and leukocyte numbers, but a lower peripheral blood mononuclear cell cytokine production capacity.]]></summary>
        <author>
            <name>Helin Tercan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Renal Extramedullary Hematopoiesis in Mast Cell Leukemia with Bone Marrow Fibrosis]]></title>
        <id>pubmed:38213502</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38213502/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240121195630&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Systemic mastocytosis is defined by the clonal proliferation of abnormal mast cells. The clinical course can range from indolent forms with normal life expectancy to advanced mast cell leukemia with dismal prognosis. An association with other diseases, including myeloproliferative neoplasia, has been described. We present a case of a 75-year patient with a history of cutaneous mastocytosis who was diagnosed with mast cell leukemia more than 9 years ago and did not receive treatment. The patient...]]></summary>
        <author>
            <name>Damian T Rieke</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association Between Clonal Hematopoiesis Driver Mutations, Immune Cell Function, and the Vasculometabolic Complications of Obesity]]></title>
        <id>pubmed:38214284</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38214284/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240120195815&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In individuals with overweight or obesity, CHDMs are not associated with vasculometabolic complications, but rather with a lower presence of carotid plaques. CHDMs associate with increased circulating inflammatory markers and leukocyte numbers, but a lower peripheral blood mononuclear cell cytokine production capacity.]]></summary>
        <author>
            <name>Helin Tercan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Renal Extramedullary Hematopoiesis in Mast Cell Leukemia with Bone Marrow Fibrosis]]></title>
        <id>pubmed:38213502</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38213502/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240120195815&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Systemic mastocytosis is defined by the clonal proliferation of abnormal mast cells. The clinical course can range from indolent forms with normal life expectancy to advanced mast cell leukemia with dismal prognosis. An association with other diseases, including myeloproliferative neoplasia, has been described. We present a case of a 75-year patient with a history of cutaneous mastocytosis who was diagnosed with mast cell leukemia more than 9 years ago and did not receive treatment. The patient...]]></summary>
        <author>
            <name>Damian T Rieke</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association Between Clonal Hematopoiesis Driver Mutations, Immune Cell Function, and the Vasculometabolic Complications of Obesity]]></title>
        <id>pubmed:38214284</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38214284/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240119195313&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In individuals with overweight or obesity, CHDMs are not associated with vasculometabolic complications, but rather with a lower presence of carotid plaques. CHDMs associate with increased circulating inflammatory markers and leukocyte numbers, but a lower peripheral blood mononuclear cell cytokine production capacity.]]></summary>
        <author>
            <name>Helin Tercan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Renal Extramedullary Hematopoiesis in Mast Cell Leukemia with Bone Marrow Fibrosis]]></title>
        <id>pubmed:38213502</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38213502/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240119195313&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Systemic mastocytosis is defined by the clonal proliferation of abnormal mast cells. The clinical course can range from indolent forms with normal life expectancy to advanced mast cell leukemia with dismal prognosis. An association with other diseases, including myeloproliferative neoplasia, has been described. We present a case of a 75-year patient with a history of cutaneous mastocytosis who was diagnosed with mast cell leukemia more than 9 years ago and did not receive treatment. The patient...]]></summary>
        <author>
            <name>Damian T Rieke</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association Between Clonal Hematopoiesis Driver Mutations, Immune Cell Function, and the Vasculometabolic Complications of Obesity]]></title>
        <id>pubmed:38214284</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38214284/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240118195421&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In individuals with overweight or obesity, CHDMs are not associated with vasculometabolic complications, but rather with a lower presence of carotid plaques. CHDMs associate with increased circulating inflammatory markers and leukocyte numbers, but a lower peripheral blood mononuclear cell cytokine production capacity.]]></summary>
        <author>
            <name>Helin Tercan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Renal Extramedullary Hematopoiesis in Mast Cell Leukemia with Bone Marrow Fibrosis]]></title>
        <id>pubmed:38213502</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38213502/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240118195421&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Systemic mastocytosis is defined by the clonal proliferation of abnormal mast cells. The clinical course can range from indolent forms with normal life expectancy to advanced mast cell leukemia with dismal prognosis. An association with other diseases, including myeloproliferative neoplasia, has been described. We present a case of a 75-year patient with a history of cutaneous mastocytosis who was diagnosed with mast cell leukemia more than 9 years ago and did not receive treatment. The patient...]]></summary>
        <author>
            <name>Damian T Rieke</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association Between Clonal Hematopoiesis Driver Mutations, Immune Cell Function, and the Vasculometabolic Complications of Obesity]]></title>
        <id>pubmed:38214284</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38214284/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240117195336&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In individuals with overweight or obesity, CHDMs are not associated with vasculometabolic complications, but rather with a lower presence of carotid plaques. CHDMs associate with increased circulating inflammatory markers and leukocyte numbers, but a lower peripheral blood mononuclear cell cytokine production capacity.]]></summary>
        <author>
            <name>Helin Tercan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Renal Extramedullary Hematopoiesis in Mast Cell Leukemia with Bone Marrow Fibrosis]]></title>
        <id>pubmed:38213502</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38213502/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240117195336&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Systemic mastocytosis is defined by the clonal proliferation of abnormal mast cells. The clinical course can range from indolent forms with normal life expectancy to advanced mast cell leukemia with dismal prognosis. An association with other diseases, including myeloproliferative neoplasia, has been described. We present a case of a 75-year patient with a history of cutaneous mastocytosis who was diagnosed with mast cell leukemia more than 9 years ago and did not receive treatment. The patient...]]></summary>
        <author>
            <name>Damian T Rieke</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association Between Clonal Hematopoiesis Driver Mutations, Immune Cell Function, and the Vasculometabolic Complications of Obesity]]></title>
        <id>pubmed:38214284</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38214284/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240116195412&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In individuals with overweight or obesity, CHDMs are not associated with vasculometabolic complications, but rather with a lower presence of carotid plaques. CHDMs associate with increased circulating inflammatory markers and leukocyte numbers, but a lower peripheral blood mononuclear cell cytokine production capacity.]]></summary>
        <author>
            <name>Helin Tercan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Renal Extramedullary Hematopoiesis in Mast Cell Leukemia with Bone Marrow Fibrosis]]></title>
        <id>pubmed:38213502</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38213502/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240116195412&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Systemic mastocytosis is defined by the clonal proliferation of abnormal mast cells. The clinical course can range from indolent forms with normal life expectancy to advanced mast cell leukemia with dismal prognosis. An association with other diseases, including myeloproliferative neoplasia, has been described. We present a case of a 75-year patient with a history of cutaneous mastocytosis who was diagnosed with mast cell leukemia more than 9 years ago and did not receive treatment. The patient...]]></summary>
        <author>
            <name>Damian T Rieke</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association Between Clonal Hematopoiesis Driver Mutations, Immune Cell Function, and the Vasculometabolic Complications of Obesity]]></title>
        <id>pubmed:38214284</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38214284/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240115195351&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In individuals with overweight or obesity, CHDMs are not associated with vasculometabolic complications, but rather with a lower presence of carotid plaques. CHDMs associate with increased circulating inflammatory markers and leukocyte numbers, but a lower peripheral blood mononuclear cell cytokine production capacity.]]></summary>
        <author>
            <name>Helin Tercan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Renal Extramedullary Hematopoiesis in Mast Cell Leukemia with Bone Marrow Fibrosis]]></title>
        <id>pubmed:38213502</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38213502/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240115195351&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Systemic mastocytosis is defined by the clonal proliferation of abnormal mast cells. The clinical course can range from indolent forms with normal life expectancy to advanced mast cell leukemia with dismal prognosis. An association with other diseases, including myeloproliferative neoplasia, has been described. We present a case of a 75-year patient with a history of cutaneous mastocytosis who was diagnosed with mast cell leukemia more than 9 years ago and did not receive treatment. The patient...]]></summary>
        <author>
            <name>Damian T Rieke</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association Between Clonal Hematopoiesis Driver Mutations, Immune Cell Function, and the Vasculometabolic Complications of Obesity]]></title>
        <id>pubmed:38214284</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38214284/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240114195558&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In individuals with overweight or obesity, CHDMs are not associated with vasculometabolic complications, but rather with a lower presence of carotid plaques. CHDMs associate with increased circulating inflammatory markers and leukocyte numbers, but a lower peripheral blood mononuclear cell cytokine production capacity.]]></summary>
        <author>
            <name>Helin Tercan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Renal Extramedullary Hematopoiesis in Mast Cell Leukemia with Bone Marrow Fibrosis]]></title>
        <id>pubmed:38213502</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38213502/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240114195558&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Systemic mastocytosis is defined by the clonal proliferation of abnormal mast cells. The clinical course can range from indolent forms with normal life expectancy to advanced mast cell leukemia with dismal prognosis. An association with other diseases, including myeloproliferative neoplasia, has been described. We present a case of a 75-year patient with a history of cutaneous mastocytosis who was diagnosed with mast cell leukemia more than 9 years ago and did not receive treatment. The patient...]]></summary>
        <author>
            <name>Damian T Rieke</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association Between Clonal Hematopoiesis Driver Mutations, Immune Cell Function, and the Vasculometabolic Complications of Obesity]]></title>
        <id>pubmed:38214284</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38214284/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240113195804&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In individuals with overweight or obesity, CHDMs are not associated with vasculometabolic complications, but rather with a lower presence of carotid plaques. CHDMs associate with increased circulating inflammatory markers and leukocyte numbers, but a lower peripheral blood mononuclear cell cytokine production capacity.]]></summary>
        <author>
            <name>Helin Tercan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Renal Extramedullary Hematopoiesis in Mast Cell Leukemia with Bone Marrow Fibrosis]]></title>
        <id>pubmed:38213502</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38213502/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240113195804&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Systemic mastocytosis is defined by the clonal proliferation of abnormal mast cells. The clinical course can range from indolent forms with normal life expectancy to advanced mast cell leukemia with dismal prognosis. An association with other diseases, including myeloproliferative neoplasia, has been described. We present a case of a 75-year patient with a history of cutaneous mastocytosis who was diagnosed with mast cell leukemia more than 9 years ago and did not receive treatment. The patient...]]></summary>
        <author>
            <name>Damian T Rieke</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association Between Clonal Hematopoiesis Driver Mutations, Immune Cell Function, and the Vasculometabolic Complications of Obesity]]></title>
        <id>pubmed:38214284</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38214284/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240112195322&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In individuals with overweight or obesity, CHDMs are not associated with vasculometabolic complications, but rather with a lower presence of carotid plaques. CHDMs associate with increased circulating inflammatory markers and leukocyte numbers, but a lower peripheral blood mononuclear cell cytokine production capacity.]]></summary>
        <author>
            <name>Helin Tercan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Renal Extramedullary Hematopoiesis in Mast Cell Leukemia with Bone Marrow Fibrosis]]></title>
        <id>pubmed:38213502</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38213502/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240112195322&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Systemic mastocytosis is defined by the clonal proliferation of abnormal mast cells. The clinical course can range from indolent forms with normal life expectancy to advanced mast cell leukemia with dismal prognosis. An association with other diseases, including myeloproliferative neoplasia, has been described. We present a case of a 75-year patient with a history of cutaneous mastocytosis who was diagnosed with mast cell leukemia more than 9 years ago and did not receive treatment. The patient...]]></summary>
        <author>
            <name>Damian T Rieke</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer]]></title>
        <id>pubmed:38215748</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38215748/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240130195039&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Although immunotherapy with PD-(L)1 blockade is routine for lung cancer, little is known about acquired resistance. Among 1,201 patients with non-small cell lung cancer (NSCLC) treated with PD-(L)1 blockade, acquired resistance is common, occurring in >60% of initial responders. Acquired resistance shows differential expression of inflammation and interferon (IFN) signaling. Relapsed tumors can be separated by upregulated or stable expression of IFN response genes. Upregulation of IFN response...]]></summary>
        <author>
            <name>Danish Memon</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer]]></title>
        <id>pubmed:38215748</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38215748/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240129195013&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Although immunotherapy with PD-(L)1 blockade is routine for lung cancer, little is known about acquired resistance. Among 1,201 patients with non-small cell lung cancer (NSCLC) treated with PD-(L)1 blockade, acquired resistance is common, occurring in >60% of initial responders. Acquired resistance shows differential expression of inflammation and interferon (IFN) signaling. Relapsed tumors can be separated by upregulated or stable expression of IFN response genes. Upregulation of IFN response...]]></summary>
        <author>
            <name>Danish Memon</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer]]></title>
        <id>pubmed:38215748</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38215748/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240128195055&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Although immunotherapy with PD-(L)1 blockade is routine for lung cancer, little is known about acquired resistance. Among 1,201 patients with non-small cell lung cancer (NSCLC) treated with PD-(L)1 blockade, acquired resistance is common, occurring in >60% of initial responders. Acquired resistance shows differential expression of inflammation and interferon (IFN) signaling. Relapsed tumors can be separated by upregulated or stable expression of IFN response genes. Upregulation of IFN response...]]></summary>
        <author>
            <name>Danish Memon</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[From Multiple Myeloma to Acute Myeloid Leukemia: A Case Report of a 61-year-old Woman after 8 Years of Chemotherapy and Immunotherapy]]></title>
        <id>pubmed:38214323</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38214323/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240128195055&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In this course, disease relapses occurred twice, one of which was manifested by a light chain escape (LCE). Moreover, through the course of the disease in this patient, we review the process of clonal evolution that may be relevant.]]></summary>
        <author>
            <name>Xue-Hang Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer]]></title>
        <id>pubmed:38215748</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38215748/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240127195322&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Although immunotherapy with PD-(L)1 blockade is routine for lung cancer, little is known about acquired resistance. Among 1,201 patients with non-small cell lung cancer (NSCLC) treated with PD-(L)1 blockade, acquired resistance is common, occurring in >60% of initial responders. Acquired resistance shows differential expression of inflammation and interferon (IFN) signaling. Relapsed tumors can be separated by upregulated or stable expression of IFN response genes. Upregulation of IFN response...]]></summary>
        <author>
            <name>Danish Memon</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[From Multiple Myeloma to Acute Myeloid Leukemia: A Case Report of a 61-year-old Woman after 8 Years of Chemotherapy and Immunotherapy]]></title>
        <id>pubmed:38214323</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38214323/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240127195322&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In this course, disease relapses occurred twice, one of which was manifested by a light chain escape (LCE). Moreover, through the course of the disease in this patient, we review the process of clonal evolution that may be relevant.]]></summary>
        <author>
            <name>Xue-Hang Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer]]></title>
        <id>pubmed:38215748</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38215748/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240126194954&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Although immunotherapy with PD-(L)1 blockade is routine for lung cancer, little is known about acquired resistance. Among 1,201 patients with non-small cell lung cancer (NSCLC) treated with PD-(L)1 blockade, acquired resistance is common, occurring in >60% of initial responders. Acquired resistance shows differential expression of inflammation and interferon (IFN) signaling. Relapsed tumors can be separated by upregulated or stable expression of IFN response genes. Upregulation of IFN response...]]></summary>
        <author>
            <name>Danish Memon</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[From Multiple Myeloma to Acute Myeloid Leukemia: A Case Report of a 61-year-old Woman after 8 Years of Chemotherapy and Immunotherapy]]></title>
        <id>pubmed:38214323</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38214323/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240126194954&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In this course, disease relapses occurred twice, one of which was manifested by a light chain escape (LCE). Moreover, through the course of the disease in this patient, we review the process of clonal evolution that may be relevant.]]></summary>
        <author>
            <name>Xue-Hang Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer]]></title>
        <id>pubmed:38215748</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38215748/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240125195050&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Although immunotherapy with PD-(L)1 blockade is routine for lung cancer, little is known about acquired resistance. Among 1,201 patients with non-small cell lung cancer (NSCLC) treated with PD-(L)1 blockade, acquired resistance is common, occurring in >60% of initial responders. Acquired resistance shows differential expression of inflammation and interferon (IFN) signaling. Relapsed tumors can be separated by upregulated or stable expression of IFN response genes. Upregulation of IFN response...]]></summary>
        <author>
            <name>Danish Memon</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[From Multiple Myeloma to Acute Myeloid Leukemia: A Case Report of a 61-year-old Woman after 8 Years of Chemotherapy and Immunotherapy]]></title>
        <id>pubmed:38214323</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38214323/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240125195050&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In this course, disease relapses occurred twice, one of which was manifested by a light chain escape (LCE). Moreover, through the course of the disease in this patient, we review the process of clonal evolution that may be relevant.]]></summary>
        <author>
            <name>Xue-Hang Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer]]></title>
        <id>pubmed:38215748</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38215748/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240124195506&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Although immunotherapy with PD-(L)1 blockade is routine for lung cancer, little is known about acquired resistance. Among 1,201 patients with non-small cell lung cancer (NSCLC) treated with PD-(L)1 blockade, acquired resistance is common, occurring in >60% of initial responders. Acquired resistance shows differential expression of inflammation and interferon (IFN) signaling. Relapsed tumors can be separated by upregulated or stable expression of IFN response genes. Upregulation of IFN response...]]></summary>
        <author>
            <name>Danish Memon</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[From Multiple Myeloma to Acute Myeloid Leukemia: A Case Report of a 61-year-old Woman after 8 Years of Chemotherapy and Immunotherapy]]></title>
        <id>pubmed:38214323</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38214323/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240124195506&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In this course, disease relapses occurred twice, one of which was manifested by a light chain escape (LCE). Moreover, through the course of the disease in this patient, we review the process of clonal evolution that may be relevant.]]></summary>
        <author>
            <name>Xue-Hang Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Intratumor heterogeneity: models of malignancy emergence and evolution]]></title>
        <id>pubmed:38213707</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38213707/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240124195506&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer is a complex and heterogeneous disease characterized by the accumulation of genetic alterations that drive uncontrolled cell growth and proliferation. Evolutionary dynamics plays a crucial role in the emergence and development of tumors, shaping the heterogeneity and adaptability of cancer cells. From the perspective of evolutionary theory, tumors are complex ecosystems that evolve through a process of microevolution influenced by genetic mutations, epigenetic changes, tumor...]]></summary>
        <author>
            <name>R A Ivanov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer]]></title>
        <id>pubmed:38215748</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38215748/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240123195503&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Although immunotherapy with PD-(L)1 blockade is routine for lung cancer, little is known about acquired resistance. Among 1,201 patients with non-small cell lung cancer (NSCLC) treated with PD-(L)1 blockade, acquired resistance is common, occurring in >60% of initial responders. Acquired resistance shows differential expression of inflammation and interferon (IFN) signaling. Relapsed tumors can be separated by upregulated or stable expression of IFN response genes. Upregulation of IFN response...]]></summary>
        <author>
            <name>Danish Memon</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[From Multiple Myeloma to Acute Myeloid Leukemia: A Case Report of a 61-year-old Woman after 8 Years of Chemotherapy and Immunotherapy]]></title>
        <id>pubmed:38214323</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38214323/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240123195503&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In this course, disease relapses occurred twice, one of which was manifested by a light chain escape (LCE). Moreover, through the course of the disease in this patient, we review the process of clonal evolution that may be relevant.]]></summary>
        <author>
            <name>Xue-Hang Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Intratumor heterogeneity: models of malignancy emergence and evolution]]></title>
        <id>pubmed:38213707</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38213707/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240123195503&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer is a complex and heterogeneous disease characterized by the accumulation of genetic alterations that drive uncontrolled cell growth and proliferation. Evolutionary dynamics plays a crucial role in the emergence and development of tumors, shaping the heterogeneity and adaptability of cancer cells. From the perspective of evolutionary theory, tumors are complex ecosystems that evolve through a process of microevolution influenced by genetic mutations, epigenetic changes, tumor...]]></summary>
        <author>
            <name>R A Ivanov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer]]></title>
        <id>pubmed:38215748</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38215748/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240122195511&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Although immunotherapy with PD-(L)1 blockade is routine for lung cancer, little is known about acquired resistance. Among 1,201 patients with non-small cell lung cancer (NSCLC) treated with PD-(L)1 blockade, acquired resistance is common, occurring in >60% of initial responders. Acquired resistance shows differential expression of inflammation and interferon (IFN) signaling. Relapsed tumors can be separated by upregulated or stable expression of IFN response genes. Upregulation of IFN response...]]></summary>
        <author>
            <name>Danish Memon</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[From Multiple Myeloma to Acute Myeloid Leukemia: A Case Report of a 61-year-old Woman after 8 Years of Chemotherapy and Immunotherapy]]></title>
        <id>pubmed:38214323</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38214323/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240122195511&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In this course, disease relapses occurred twice, one of which was manifested by a light chain escape (LCE). Moreover, through the course of the disease in this patient, we review the process of clonal evolution that may be relevant.]]></summary>
        <author>
            <name>Xue-Hang Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Intratumor heterogeneity: models of malignancy emergence and evolution]]></title>
        <id>pubmed:38213707</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38213707/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240122195511&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer is a complex and heterogeneous disease characterized by the accumulation of genetic alterations that drive uncontrolled cell growth and proliferation. Evolutionary dynamics plays a crucial role in the emergence and development of tumors, shaping the heterogeneity and adaptability of cancer cells. From the perspective of evolutionary theory, tumors are complex ecosystems that evolve through a process of microevolution influenced by genetic mutations, epigenetic changes, tumor...]]></summary>
        <author>
            <name>R A Ivanov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer]]></title>
        <id>pubmed:38215748</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38215748/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240121195630&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Although immunotherapy with PD-(L)1 blockade is routine for lung cancer, little is known about acquired resistance. Among 1,201 patients with non-small cell lung cancer (NSCLC) treated with PD-(L)1 blockade, acquired resistance is common, occurring in >60% of initial responders. Acquired resistance shows differential expression of inflammation and interferon (IFN) signaling. Relapsed tumors can be separated by upregulated or stable expression of IFN response genes. Upregulation of IFN response...]]></summary>
        <author>
            <name>Danish Memon</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[From Multiple Myeloma to Acute Myeloid Leukemia: A Case Report of a 61-year-old Woman after 8 Years of Chemotherapy and Immunotherapy]]></title>
        <id>pubmed:38214323</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38214323/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240121195630&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In this course, disease relapses occurred twice, one of which was manifested by a light chain escape (LCE). Moreover, through the course of the disease in this patient, we review the process of clonal evolution that may be relevant.]]></summary>
        <author>
            <name>Xue-Hang Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Intratumor heterogeneity: models of malignancy emergence and evolution]]></title>
        <id>pubmed:38213707</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38213707/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240121195630&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer is a complex and heterogeneous disease characterized by the accumulation of genetic alterations that drive uncontrolled cell growth and proliferation. Evolutionary dynamics plays a crucial role in the emergence and development of tumors, shaping the heterogeneity and adaptability of cancer cells. From the perspective of evolutionary theory, tumors are complex ecosystems that evolve through a process of microevolution influenced by genetic mutations, epigenetic changes, tumor...]]></summary>
        <author>
            <name>R A Ivanov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer]]></title>
        <id>pubmed:38215748</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38215748/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240120195815&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Although immunotherapy with PD-(L)1 blockade is routine for lung cancer, little is known about acquired resistance. Among 1,201 patients with non-small cell lung cancer (NSCLC) treated with PD-(L)1 blockade, acquired resistance is common, occurring in >60% of initial responders. Acquired resistance shows differential expression of inflammation and interferon (IFN) signaling. Relapsed tumors can be separated by upregulated or stable expression of IFN response genes. Upregulation of IFN response...]]></summary>
        <author>
            <name>Danish Memon</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[From Multiple Myeloma to Acute Myeloid Leukemia: A Case Report of a 61-year-old Woman after 8 Years of Chemotherapy and Immunotherapy]]></title>
        <id>pubmed:38214323</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38214323/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240120195815&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In this course, disease relapses occurred twice, one of which was manifested by a light chain escape (LCE). Moreover, through the course of the disease in this patient, we review the process of clonal evolution that may be relevant.]]></summary>
        <author>
            <name>Xue-Hang Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Intratumor heterogeneity: models of malignancy emergence and evolution]]></title>
        <id>pubmed:38213707</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38213707/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240120195815&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer is a complex and heterogeneous disease characterized by the accumulation of genetic alterations that drive uncontrolled cell growth and proliferation. Evolutionary dynamics plays a crucial role in the emergence and development of tumors, shaping the heterogeneity and adaptability of cancer cells. From the perspective of evolutionary theory, tumors are complex ecosystems that evolve through a process of microevolution influenced by genetic mutations, epigenetic changes, tumor...]]></summary>
        <author>
            <name>R A Ivanov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer]]></title>
        <id>pubmed:38215748</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38215748/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240119195313&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Although immunotherapy with PD-(L)1 blockade is routine for lung cancer, little is known about acquired resistance. Among 1,201 patients with non-small cell lung cancer (NSCLC) treated with PD-(L)1 blockade, acquired resistance is common, occurring in >60% of initial responders. Acquired resistance shows differential expression of inflammation and interferon (IFN) signaling. Relapsed tumors can be separated by upregulated or stable expression of IFN response genes. Upregulation of IFN response...]]></summary>
        <author>
            <name>Danish Memon</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[From Multiple Myeloma to Acute Myeloid Leukemia: A Case Report of a 61-year-old Woman after 8 Years of Chemotherapy and Immunotherapy]]></title>
        <id>pubmed:38214323</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38214323/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240119195313&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In this course, disease relapses occurred twice, one of which was manifested by a light chain escape (LCE). Moreover, through the course of the disease in this patient, we review the process of clonal evolution that may be relevant.]]></summary>
        <author>
            <name>Xue-Hang Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Intratumor heterogeneity: models of malignancy emergence and evolution]]></title>
        <id>pubmed:38213707</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38213707/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240119195313&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer is a complex and heterogeneous disease characterized by the accumulation of genetic alterations that drive uncontrolled cell growth and proliferation. Evolutionary dynamics plays a crucial role in the emergence and development of tumors, shaping the heterogeneity and adaptability of cancer cells. From the perspective of evolutionary theory, tumors are complex ecosystems that evolve through a process of microevolution influenced by genetic mutations, epigenetic changes, tumor...]]></summary>
        <author>
            <name>R A Ivanov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer]]></title>
        <id>pubmed:38215748</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38215748/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240118195420&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Although immunotherapy with PD-(L)1 blockade is routine for lung cancer, little is known about acquired resistance. Among 1,201 patients with non-small cell lung cancer (NSCLC) treated with PD-(L)1 blockade, acquired resistance is common, occurring in >60% of initial responders. Acquired resistance shows differential expression of inflammation and interferon (IFN) signaling. Relapsed tumors can be separated by upregulated or stable expression of IFN response genes. Upregulation of IFN response...]]></summary>
        <author>
            <name>Danish Memon</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[From Multiple Myeloma to Acute Myeloid Leukemia: A Case Report of a 61-year-old Woman after 8 Years of Chemotherapy and Immunotherapy]]></title>
        <id>pubmed:38214323</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38214323/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240118195420&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In this course, disease relapses occurred twice, one of which was manifested by a light chain escape (LCE). Moreover, through the course of the disease in this patient, we review the process of clonal evolution that may be relevant.]]></summary>
        <author>
            <name>Xue-Hang Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Intratumor heterogeneity: models of malignancy emergence and evolution]]></title>
        <id>pubmed:38213707</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38213707/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240118195420&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer is a complex and heterogeneous disease characterized by the accumulation of genetic alterations that drive uncontrolled cell growth and proliferation. Evolutionary dynamics plays a crucial role in the emergence and development of tumors, shaping the heterogeneity and adaptability of cancer cells. From the perspective of evolutionary theory, tumors are complex ecosystems that evolve through a process of microevolution influenced by genetic mutations, epigenetic changes, tumor...]]></summary>
        <author>
            <name>R A Ivanov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer]]></title>
        <id>pubmed:38215748</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38215748/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240117195336&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Although immunotherapy with PD-(L)1 blockade is routine for lung cancer, little is known about acquired resistance. Among 1,201 patients with non-small cell lung cancer (NSCLC) treated with PD-(L)1 blockade, acquired resistance is common, occurring in >60% of initial responders. Acquired resistance shows differential expression of inflammation and interferon (IFN) signaling. Relapsed tumors can be separated by upregulated or stable expression of IFN response genes. Upregulation of IFN response...]]></summary>
        <author>
            <name>Danish Memon</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[From Multiple Myeloma to Acute Myeloid Leukemia: A Case Report of a 61-year-old Woman after 8 Years of Chemotherapy and Immunotherapy]]></title>
        <id>pubmed:38214323</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38214323/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240117195336&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In this course, disease relapses occurred twice, one of which was manifested by a light chain escape (LCE). Moreover, through the course of the disease in this patient, we review the process of clonal evolution that may be relevant.]]></summary>
        <author>
            <name>Xue-Hang Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Intratumor heterogeneity: models of malignancy emergence and evolution]]></title>
        <id>pubmed:38213707</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38213707/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240117195336&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer is a complex and heterogeneous disease characterized by the accumulation of genetic alterations that drive uncontrolled cell growth and proliferation. Evolutionary dynamics plays a crucial role in the emergence and development of tumors, shaping the heterogeneity and adaptability of cancer cells. From the perspective of evolutionary theory, tumors are complex ecosystems that evolve through a process of microevolution influenced by genetic mutations, epigenetic changes, tumor...]]></summary>
        <author>
            <name>R A Ivanov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer]]></title>
        <id>pubmed:38215748</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38215748/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240116195412&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Although immunotherapy with PD-(L)1 blockade is routine for lung cancer, little is known about acquired resistance. Among 1,201 patients with non-small cell lung cancer (NSCLC) treated with PD-(L)1 blockade, acquired resistance is common, occurring in >60% of initial responders. Acquired resistance shows differential expression of inflammation and interferon (IFN) signaling. Relapsed tumors can be separated by upregulated or stable expression of IFN response genes. Upregulation of IFN response...]]></summary>
        <author>
            <name>Danish Memon</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[From Multiple Myeloma to Acute Myeloid Leukemia: A Case Report of a 61-year-old Woman after 8 Years of Chemotherapy and Immunotherapy]]></title>
        <id>pubmed:38214323</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38214323/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240116195412&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In this course, disease relapses occurred twice, one of which was manifested by a light chain escape (LCE). Moreover, through the course of the disease in this patient, we review the process of clonal evolution that may be relevant.]]></summary>
        <author>
            <name>Xue-Hang Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Intratumor heterogeneity: models of malignancy emergence and evolution]]></title>
        <id>pubmed:38213707</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38213707/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240116195412&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer is a complex and heterogeneous disease characterized by the accumulation of genetic alterations that drive uncontrolled cell growth and proliferation. Evolutionary dynamics plays a crucial role in the emergence and development of tumors, shaping the heterogeneity and adaptability of cancer cells. From the perspective of evolutionary theory, tumors are complex ecosystems that evolve through a process of microevolution influenced by genetic mutations, epigenetic changes, tumor...]]></summary>
        <author>
            <name>R A Ivanov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer]]></title>
        <id>pubmed:38215748</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38215748/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240115195351&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Although immunotherapy with PD-(L)1 blockade is routine for lung cancer, little is known about acquired resistance. Among 1,201 patients with non-small cell lung cancer (NSCLC) treated with PD-(L)1 blockade, acquired resistance is common, occurring in >60% of initial responders. Acquired resistance shows differential expression of inflammation and interferon (IFN) signaling. Relapsed tumors can be separated by upregulated or stable expression of IFN response genes. Upregulation of IFN response...]]></summary>
        <author>
            <name>Danish Memon</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[From Multiple Myeloma to Acute Myeloid Leukemia: A Case Report of a 61-year-old Woman after 8 Years of Chemotherapy and Immunotherapy]]></title>
        <id>pubmed:38214323</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38214323/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240115195351&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In this course, disease relapses occurred twice, one of which was manifested by a light chain escape (LCE). Moreover, through the course of the disease in this patient, we review the process of clonal evolution that may be relevant.]]></summary>
        <author>
            <name>Xue-Hang Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Intratumor heterogeneity: models of malignancy emergence and evolution]]></title>
        <id>pubmed:38213707</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38213707/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240115195351&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer is a complex and heterogeneous disease characterized by the accumulation of genetic alterations that drive uncontrolled cell growth and proliferation. Evolutionary dynamics plays a crucial role in the emergence and development of tumors, shaping the heterogeneity and adaptability of cancer cells. From the perspective of evolutionary theory, tumors are complex ecosystems that evolve through a process of microevolution influenced by genetic mutations, epigenetic changes, tumor...]]></summary>
        <author>
            <name>R A Ivanov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer]]></title>
        <id>pubmed:38215748</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38215748/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240114195558&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Although immunotherapy with PD-(L)1 blockade is routine for lung cancer, little is known about acquired resistance. Among 1,201 patients with non-small cell lung cancer (NSCLC) treated with PD-(L)1 blockade, acquired resistance is common, occurring in >60% of initial responders. Acquired resistance shows differential expression of inflammation and interferon (IFN) signaling. Relapsed tumors can be separated by upregulated or stable expression of IFN response genes. Upregulation of IFN response...]]></summary>
        <author>
            <name>Danish Memon</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Intratumor heterogeneity: models of malignancy emergence and evolution]]></title>
        <id>pubmed:38213707</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38213707/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240114195558&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer is a complex and heterogeneous disease characterized by the accumulation of genetic alterations that drive uncontrolled cell growth and proliferation. Evolutionary dynamics plays a crucial role in the emergence and development of tumors, shaping the heterogeneity and adaptability of cancer cells. From the perspective of evolutionary theory, tumors are complex ecosystems that evolve through a process of microevolution influenced by genetic mutations, epigenetic changes, tumor...]]></summary>
        <author>
            <name>R A Ivanov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer]]></title>
        <id>pubmed:38215748</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38215748/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240113195804&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Although immunotherapy with PD-(L)1 blockade is routine for lung cancer, little is known about acquired resistance. Among 1,201 patients with non-small cell lung cancer (NSCLC) treated with PD-(L)1 blockade, acquired resistance is common, occurring in >60% of initial responders. Acquired resistance shows differential expression of inflammation and interferon (IFN) signaling. Relapsed tumors can be separated by upregulated or stable expression of IFN response genes. Upregulation of IFN response...]]></summary>
        <author>
            <name>Danish Memon</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Intratumor heterogeneity: models of malignancy emergence and evolution]]></title>
        <id>pubmed:38213707</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38213707/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240113195804&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer is a complex and heterogeneous disease characterized by the accumulation of genetic alterations that drive uncontrolled cell growth and proliferation. Evolutionary dynamics plays a crucial role in the emergence and development of tumors, shaping the heterogeneity and adaptability of cancer cells. From the perspective of evolutionary theory, tumors are complex ecosystems that evolve through a process of microevolution influenced by genetic mutations, epigenetic changes, tumor...]]></summary>
        <author>
            <name>R A Ivanov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Intratumor heterogeneity: models of malignancy emergence and evolution]]></title>
        <id>pubmed:38213707</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38213707/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240112195322&amp;v=2.18.0"/>
        <updated>2024-01-12T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer is a complex and heterogeneous disease characterized by the accumulation of genetic alterations that drive uncontrolled cell growth and proliferation. Evolutionary dynamics plays a crucial role in the emergence and development of tumors, shaping the heterogeneity and adaptability of cancer cells. From the perspective of evolutionary theory, tumors are complex ecosystems that evolve through a process of microevolution influenced by genetic mutations, epigenetic changes, tumor...]]></summary>
        <author>
            <name>R A Ivanov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[IL-1 promotes MPN disease initiation by favoring early clonal expansion of JAK2-mutant hematopoietic stem cells]]></title>
        <id>pubmed:38207211</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38207211/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240124195506&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[JAK2-V617F is the most frequent somatic mutation causing myeloproliferative neoplasm (MPN). JAK2-V617F can be found in healthy individuals with clonal hematopoiesis of indeterminate potential (CHIP) with a frequency much higher than the prevalence of MPN. The factors controlling the conversion of JAK2-V617F CHIP to MPN are largely unknown. We hypothesized that IL-1 mediated inflammation can favor this progression. We established an experimental system using bone marrow (BM) transplantations...]]></summary>
        <author>
            <name>Shivam Rai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[IL-1 promotes MPN disease initiation by favoring early clonal expansion of JAK2-mutant hematopoietic stem cells]]></title>
        <id>pubmed:38207211</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38207211/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240123195503&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[JAK2-V617F is the most frequent somatic mutation causing myeloproliferative neoplasm (MPN). JAK2-V617F can be found in healthy individuals with clonal hematopoiesis of indeterminate potential (CHIP) with a frequency much higher than the prevalence of MPN. The factors controlling the conversion of JAK2-V617F CHIP to MPN are largely unknown. We hypothesized that IL-1 mediated inflammation can favor this progression. We established an experimental system using bone marrow (BM) transplantations...]]></summary>
        <author>
            <name>Shivam Rai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[IL-1 promotes MPN disease initiation by favoring early clonal expansion of JAK2-mutant hematopoietic stem cells]]></title>
        <id>pubmed:38207211</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38207211/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240122195511&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[JAK2-V617F is the most frequent somatic mutation causing myeloproliferative neoplasm (MPN). JAK2-V617F can be found in healthy individuals with clonal hematopoiesis of indeterminate potential (CHIP) with a frequency much higher than the prevalence of MPN. The factors controlling the conversion of JAK2-V617F CHIP to MPN are largely unknown. We hypothesized that IL-1 mediated inflammation can favor this progression. We established an experimental system using bone marrow (BM) transplantations...]]></summary>
        <author>
            <name>Shivam Rai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case report of a patient with VEXAS syndrome]]></title>
        <id>pubmed:38206689</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38206689/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240122195511&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[RATIONALE: Hematological malignancies have always been a challenge for scientists because there is a constant need to better define these entities. Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders characterized by ineffective hematopoiesis. Cytogenetics and molecular findings are a prerequisite for these syndromes as they confirm the clonal nature of the disease. However, MDS is often linked to autoimmunity and inflammation as part of its pathogenesis. Recently, VEXAS syndrome...]]></summary>
        <author>
            <name>Ioannis Tsourveloudis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association Between Aortic Valve Sclerosis and Clonal Hematopoiesis of Indeterminate Potential]]></title>
        <id>pubmed:38205526</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38205526/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240122195511&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Participants with AVS more commonly had larger CHIP clones than age- and sex-matched controls. Further studies are warranted to identify causality between AVS and CHIP.]]></summary>
        <author>
            <name>Minkwan Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[IL-1 promotes MPN disease initiation by favoring early clonal expansion of JAK2-mutant hematopoietic stem cells]]></title>
        <id>pubmed:38207211</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38207211/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240121195630&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[JAK2-V617F is the most frequent somatic mutation causing myeloproliferative neoplasm (MPN). JAK2-V617F can be found in healthy individuals with clonal hematopoiesis of indeterminate potential (CHIP) with a frequency much higher than the prevalence of MPN. The factors controlling the conversion of JAK2-V617F CHIP to MPN are largely unknown. We hypothesized that IL-1 mediated inflammation can favor this progression. We established an experimental system using bone marrow (BM) transplantations...]]></summary>
        <author>
            <name>Shivam Rai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case report of a patient with VEXAS syndrome]]></title>
        <id>pubmed:38206689</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38206689/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240121195630&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[RATIONALE: Hematological malignancies have always been a challenge for scientists because there is a constant need to better define these entities. Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders characterized by ineffective hematopoiesis. Cytogenetics and molecular findings are a prerequisite for these syndromes as they confirm the clonal nature of the disease. However, MDS is often linked to autoimmunity and inflammation as part of its pathogenesis. Recently, VEXAS syndrome...]]></summary>
        <author>
            <name>Ioannis Tsourveloudis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association Between Aortic Valve Sclerosis and Clonal Hematopoiesis of Indeterminate Potential]]></title>
        <id>pubmed:38205526</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38205526/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240121195630&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Participants with AVS more commonly had larger CHIP clones than age- and sex-matched controls. Further studies are warranted to identify causality between AVS and CHIP.]]></summary>
        <author>
            <name>Minkwan Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[IL-1 promotes MPN disease initiation by favoring early clonal expansion of JAK2-mutant hematopoietic stem cells]]></title>
        <id>pubmed:38207211</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38207211/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240120195815&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[JAK2-V617F is the most frequent somatic mutation causing myeloproliferative neoplasm (MPN). JAK2-V617F can be found in healthy individuals with clonal hematopoiesis of indeterminate potential (CHIP) with a frequency much higher than the prevalence of MPN. The factors controlling the conversion of JAK2-V617F CHIP to MPN are largely unknown. We hypothesized that IL-1 mediated inflammation can favor this progression. We established an experimental system using bone marrow (BM) transplantations...]]></summary>
        <author>
            <name>Shivam Rai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case report of a patient with VEXAS syndrome]]></title>
        <id>pubmed:38206689</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38206689/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240120195815&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[RATIONALE: Hematological malignancies have always been a challenge for scientists because there is a constant need to better define these entities. Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders characterized by ineffective hematopoiesis. Cytogenetics and molecular findings are a prerequisite for these syndromes as they confirm the clonal nature of the disease. However, MDS is often linked to autoimmunity and inflammation as part of its pathogenesis. Recently, VEXAS syndrome...]]></summary>
        <author>
            <name>Ioannis Tsourveloudis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association Between Aortic Valve Sclerosis and Clonal Hematopoiesis of Indeterminate Potential]]></title>
        <id>pubmed:38205526</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38205526/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240120195815&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Participants with AVS more commonly had larger CHIP clones than age- and sex-matched controls. Further studies are warranted to identify causality between AVS and CHIP.]]></summary>
        <author>
            <name>Minkwan Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[IL-1 promotes MPN disease initiation by favoring early clonal expansion of JAK2-mutant hematopoietic stem cells]]></title>
        <id>pubmed:38207211</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38207211/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240119195313&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[JAK2-V617F is the most frequent somatic mutation causing myeloproliferative neoplasm (MPN). JAK2-V617F can be found in healthy individuals with clonal hematopoiesis of indeterminate potential (CHIP) with a frequency much higher than the prevalence of MPN. The factors controlling the conversion of JAK2-V617F CHIP to MPN are largely unknown. We hypothesized that IL-1 mediated inflammation can favor this progression. We established an experimental system using bone marrow (BM) transplantations...]]></summary>
        <author>
            <name>Shivam Rai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case report of a patient with VEXAS syndrome]]></title>
        <id>pubmed:38206689</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38206689/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240119195313&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[RATIONALE: Hematological malignancies have always been a challenge for scientists because there is a constant need to better define these entities. Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders characterized by ineffective hematopoiesis. Cytogenetics and molecular findings are a prerequisite for these syndromes as they confirm the clonal nature of the disease. However, MDS is often linked to autoimmunity and inflammation as part of its pathogenesis. Recently, VEXAS syndrome...]]></summary>
        <author>
            <name>Ioannis Tsourveloudis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association Between Aortic Valve Sclerosis and Clonal Hematopoiesis of Indeterminate Potential]]></title>
        <id>pubmed:38205526</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38205526/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240119195313&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Participants with AVS more commonly had larger CHIP clones than age- and sex-matched controls. Further studies are warranted to identify causality between AVS and CHIP.]]></summary>
        <author>
            <name>Minkwan Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[IL-1 promotes MPN disease initiation by favoring early clonal expansion of JAK2-mutant hematopoietic stem cells]]></title>
        <id>pubmed:38207211</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38207211/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240118195421&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[JAK2-V617F is the most frequent somatic mutation causing myeloproliferative neoplasm (MPN). JAK2-V617F can be found in healthy individuals with clonal hematopoiesis of indeterminate potential (CHIP) with a frequency much higher than the prevalence of MPN. The factors controlling the conversion of JAK2-V617F CHIP to MPN are largely unknown. We hypothesized that IL-1 mediated inflammation can favor this progression. We established an experimental system using bone marrow (BM) transplantations...]]></summary>
        <author>
            <name>Shivam Rai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case report of a patient with VEXAS syndrome]]></title>
        <id>pubmed:38206689</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38206689/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240118195421&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[RATIONALE: Hematological malignancies have always been a challenge for scientists because there is a constant need to better define these entities. Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders characterized by ineffective hematopoiesis. Cytogenetics and molecular findings are a prerequisite for these syndromes as they confirm the clonal nature of the disease. However, MDS is often linked to autoimmunity and inflammation as part of its pathogenesis. Recently, VEXAS syndrome...]]></summary>
        <author>
            <name>Ioannis Tsourveloudis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association Between Aortic Valve Sclerosis and Clonal Hematopoiesis of Indeterminate Potential]]></title>
        <id>pubmed:38205526</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38205526/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240118195421&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Participants with AVS more commonly had larger CHIP clones than age- and sex-matched controls. Further studies are warranted to identify causality between AVS and CHIP.]]></summary>
        <author>
            <name>Minkwan Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[IL-1 promotes MPN disease initiation by favoring early clonal expansion of JAK2-mutant hematopoietic stem cells]]></title>
        <id>pubmed:38207211</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38207211/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240117195336&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[JAK2-V617F is the most frequent somatic mutation causing myeloproliferative neoplasm (MPN). JAK2-V617F can be found in healthy individuals with clonal hematopoiesis of indeterminate potential (CHIP) with a frequency much higher than the prevalence of MPN. The factors controlling the conversion of JAK2-V617F CHIP to MPN are largely unknown. We hypothesized that IL-1 mediated inflammation can favor this progression. We established an experimental system using bone marrow (BM) transplantations...]]></summary>
        <author>
            <name>Shivam Rai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case report of a patient with VEXAS syndrome]]></title>
        <id>pubmed:38206689</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38206689/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240117195336&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[RATIONALE: Hematological malignancies have always been a challenge for scientists because there is a constant need to better define these entities. Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders characterized by ineffective hematopoiesis. Cytogenetics and molecular findings are a prerequisite for these syndromes as they confirm the clonal nature of the disease. However, MDS is often linked to autoimmunity and inflammation as part of its pathogenesis. Recently, VEXAS syndrome...]]></summary>
        <author>
            <name>Ioannis Tsourveloudis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association Between Aortic Valve Sclerosis and Clonal Hematopoiesis of Indeterminate Potential]]></title>
        <id>pubmed:38205526</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38205526/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240117195336&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Participants with AVS more commonly had larger CHIP clones than age- and sex-matched controls. Further studies are warranted to identify causality between AVS and CHIP.]]></summary>
        <author>
            <name>Minkwan Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[IL-1 promotes MPN disease initiation by favoring early clonal expansion of JAK2-mutant hematopoietic stem cells]]></title>
        <id>pubmed:38207211</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38207211/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240116195412&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[JAK2-V617F is the most frequent somatic mutation causing myeloproliferative neoplasm (MPN). JAK2-V617F can be found in healthy individuals with clonal hematopoiesis of indeterminate potential (CHIP) with a frequency much higher than the prevalence of MPN. The factors controlling the conversion of JAK2-V617F CHIP to MPN are largely unknown. We hypothesized that IL-1 mediated inflammation can favor this progression. We established an experimental system using bone marrow (BM) transplantations...]]></summary>
        <author>
            <name>Shivam Rai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case report of a patient with VEXAS syndrome]]></title>
        <id>pubmed:38206689</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38206689/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240116195412&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[RATIONALE: Hematological malignancies have always been a challenge for scientists because there is a constant need to better define these entities. Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders characterized by ineffective hematopoiesis. Cytogenetics and molecular findings are a prerequisite for these syndromes as they confirm the clonal nature of the disease. However, MDS is often linked to autoimmunity and inflammation as part of its pathogenesis. Recently, VEXAS syndrome...]]></summary>
        <author>
            <name>Ioannis Tsourveloudis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association Between Aortic Valve Sclerosis and Clonal Hematopoiesis of Indeterminate Potential]]></title>
        <id>pubmed:38205526</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38205526/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240116195412&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Participants with AVS more commonly had larger CHIP clones than age- and sex-matched controls. Further studies are warranted to identify causality between AVS and CHIP.]]></summary>
        <author>
            <name>Minkwan Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[IL-1 promotes MPN disease initiation by favoring early clonal expansion of JAK2-mutant hematopoietic stem cells]]></title>
        <id>pubmed:38207211</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38207211/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240115195351&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[JAK2-V617F is the most frequent somatic mutation causing myeloproliferative neoplasm (MPN). JAK2-V617F can be found in healthy individuals with clonal hematopoiesis of indeterminate potential (CHIP) with a frequency much higher than the prevalence of MPN. The factors controlling the conversion of JAK2-V617F CHIP to MPN are largely unknown. We hypothesized that IL-1 mediated inflammation can favor this progression. We established an experimental system using bone marrow (BM) transplantations...]]></summary>
        <author>
            <name>Shivam Rai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case report of a patient with VEXAS syndrome]]></title>
        <id>pubmed:38206689</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38206689/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240115195351&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[RATIONALE: Hematological malignancies have always been a challenge for scientists because there is a constant need to better define these entities. Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders characterized by ineffective hematopoiesis. Cytogenetics and molecular findings are a prerequisite for these syndromes as they confirm the clonal nature of the disease. However, MDS is often linked to autoimmunity and inflammation as part of its pathogenesis. Recently, VEXAS syndrome...]]></summary>
        <author>
            <name>Ioannis Tsourveloudis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association Between Aortic Valve Sclerosis and Clonal Hematopoiesis of Indeterminate Potential]]></title>
        <id>pubmed:38205526</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38205526/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240115195351&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Participants with AVS more commonly had larger CHIP clones than age- and sex-matched controls. Further studies are warranted to identify causality between AVS and CHIP.]]></summary>
        <author>
            <name>Minkwan Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[IL-1 promotes MPN disease initiation by favoring early clonal expansion of JAK2-mutant hematopoietic stem cells]]></title>
        <id>pubmed:38207211</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38207211/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240114195558&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[JAK2-V617F is the most frequent somatic mutation causing myeloproliferative neoplasm (MPN). JAK2-V617F can be found in healthy individuals with clonal hematopoiesis of indeterminate potential (CHIP) with a frequency much higher than the prevalence of MPN. The factors controlling the conversion of JAK2-V617F CHIP to MPN are largely unknown. We hypothesized that IL-1 mediated inflammation can favor this progression. We established an experimental system using bone marrow (BM) transplantations...]]></summary>
        <author>
            <name>Shivam Rai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case report of a patient with VEXAS syndrome]]></title>
        <id>pubmed:38206689</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38206689/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240114195558&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[RATIONALE: Hematological malignancies have always been a challenge for scientists because there is a constant need to better define these entities. Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders characterized by ineffective hematopoiesis. Cytogenetics and molecular findings are a prerequisite for these syndromes as they confirm the clonal nature of the disease. However, MDS is often linked to autoimmunity and inflammation as part of its pathogenesis. Recently, VEXAS syndrome...]]></summary>
        <author>
            <name>Ioannis Tsourveloudis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association Between Aortic Valve Sclerosis and Clonal Hematopoiesis of Indeterminate Potential]]></title>
        <id>pubmed:38205526</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38205526/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240114195558&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Participants with AVS more commonly had larger CHIP clones than age- and sex-matched controls. Further studies are warranted to identify causality between AVS and CHIP.]]></summary>
        <author>
            <name>Minkwan Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[IL-1 promotes MPN disease initiation by favoring early clonal expansion of JAK2-mutant hematopoietic stem cells]]></title>
        <id>pubmed:38207211</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38207211/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240113195804&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[JAK2-V617F is the most frequent somatic mutation causing myeloproliferative neoplasm (MPN). JAK2-V617F can be found in healthy individuals with clonal hematopoiesis of indeterminate potential (CHIP) with a frequency much higher than the prevalence of MPN. The factors controlling the conversion of JAK2-V617F CHIP to MPN are largely unknown. We hypothesized that IL-1 mediated inflammation can favor this progression. We established an experimental system using bone marrow (BM) transplantations...]]></summary>
        <author>
            <name>Shivam Rai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case report of a patient with VEXAS syndrome]]></title>
        <id>pubmed:38206689</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38206689/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240113195804&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[RATIONALE: Hematological malignancies have always been a challenge for scientists because there is a constant need to better define these entities. Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders characterized by ineffective hematopoiesis. Cytogenetics and molecular findings are a prerequisite for these syndromes as they confirm the clonal nature of the disease. However, MDS is often linked to autoimmunity and inflammation as part of its pathogenesis. Recently, VEXAS syndrome...]]></summary>
        <author>
            <name>Ioannis Tsourveloudis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association Between Aortic Valve Sclerosis and Clonal Hematopoiesis of Indeterminate Potential]]></title>
        <id>pubmed:38205526</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38205526/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240113195804&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Participants with AVS more commonly had larger CHIP clones than age- and sex-matched controls. Further studies are warranted to identify causality between AVS and CHIP.]]></summary>
        <author>
            <name>Minkwan Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[IL-1 promotes MPN disease initiation by favoring early clonal expansion of JAK2-mutant hematopoietic stem cells]]></title>
        <id>pubmed:38207211</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38207211/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240112195322&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[JAK2-V617F is the most frequent somatic mutation causing myeloproliferative neoplasm (MPN). JAK2-V617F can be found in healthy individuals with clonal hematopoiesis of indeterminate potential (CHIP) with a frequency much higher than the prevalence of MPN. The factors controlling the conversion of JAK2-V617F CHIP to MPN are largely unknown. We hypothesized that IL-1 mediated inflammation can favor this progression. We established an experimental system using bone marrow (BM) transplantations...]]></summary>
        <author>
            <name>Shivam Rai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case report of a patient with VEXAS syndrome]]></title>
        <id>pubmed:38206689</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38206689/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240112195322&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[RATIONALE: Hematological malignancies have always been a challenge for scientists because there is a constant need to better define these entities. Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders characterized by ineffective hematopoiesis. Cytogenetics and molecular findings are a prerequisite for these syndromes as they confirm the clonal nature of the disease. However, MDS is often linked to autoimmunity and inflammation as part of its pathogenesis. Recently, VEXAS syndrome...]]></summary>
        <author>
            <name>Ioannis Tsourveloudis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association Between Aortic Valve Sclerosis and Clonal Hematopoiesis of Indeterminate Potential]]></title>
        <id>pubmed:38205526</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38205526/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240112195322&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Participants with AVS more commonly had larger CHIP clones than age- and sex-matched controls. Further studies are warranted to identify causality between AVS and CHIP.]]></summary>
        <author>
            <name>Minkwan Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[IL-1 promotes MPN disease initiation by favoring early clonal expansion of JAK2-mutant hematopoietic stem cells]]></title>
        <id>pubmed:38207211</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38207211/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240111195444&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[JAK2-V617F is the most frequent somatic mutation causing myeloproliferative neoplasm (MPN). JAK2-V617F can be found in healthy individuals with clonal hematopoiesis of indeterminate potential (CHIP) with a frequency much higher than the prevalence of MPN. The factors controlling the conversion of JAK2-V617F CHIP to MPN are largely unknown. We hypothesized that IL-1 mediated inflammation can favor this progression. We established an experimental system using bone marrow (BM) transplantations...]]></summary>
        <author>
            <name>Shivam Rai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case report of a patient with VEXAS syndrome]]></title>
        <id>pubmed:38206689</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38206689/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240111195444&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[RATIONALE: Hematological malignancies have always been a challenge for scientists because there is a constant need to better define these entities. Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders characterized by ineffective hematopoiesis. Cytogenetics and molecular findings are a prerequisite for these syndromes as they confirm the clonal nature of the disease. However, MDS is often linked to autoimmunity and inflammation as part of its pathogenesis. Recently, VEXAS syndrome...]]></summary>
        <author>
            <name>Ioannis Tsourveloudis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association Between Aortic Valve Sclerosis and Clonal Hematopoiesis of Indeterminate Potential]]></title>
        <id>pubmed:38205526</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38205526/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240111195444&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Participants with AVS more commonly had larger CHIP clones than age- and sex-matched controls. Further studies are warranted to identify causality between AVS and CHIP.]]></summary>
        <author>
            <name>Minkwan Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline gene fusions across species reveal the chromosomal instability regions and cancer susceptibility]]></title>
        <id>pubmed:38205119</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38205119/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240122195511&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The canine transmissible venereal tumor (CTVT) is a clonal cell-mediated cancer with a long evolutionary history and extensive karyotype rearrangements in its genome. However, little is known about its genetic similarity to human tumors. Here, using multi-omics data we identified 11 germline gene fusions (GGFs) in CTVT, which showed higher genetic susceptibility than others. Additionally, we illustrate a mechanism of a complex gene fusion of three gene segments (HSD17B4-DMXL1-TNFAIP8) that we...]]></summary>
        <author>
            <name>Bo-Wen Zhou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Real-World Concordance between Germline and Tumour <em>BRCA1/2</em> Status in Epithelial Ovarian Cancer]]></title>
        <id>pubmed:38201604</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38201604/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240122195511&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients diagnosed with epithelial ovarian cancer may undergo reflex tumour BRCA1/2 testing followed by germline BRCA1/2 testing in patients with a positive tumour test result. This testing model relies on tumour BRCA1/2 tests being able to detect all types of pathogenic variant. We analysed germline and tumour BRCA1/2 test results from patients treated for epithelial ovarian cancer at our specialist oncological referral centre. Tumour BRCA1/2 testing was performed using the next-generation...]]></summary>
        <author>
            <name>Robert D Morgan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline gene fusions across species reveal the chromosomal instability regions and cancer susceptibility]]></title>
        <id>pubmed:38205119</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38205119/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240121195630&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The canine transmissible venereal tumor (CTVT) is a clonal cell-mediated cancer with a long evolutionary history and extensive karyotype rearrangements in its genome. However, little is known about its genetic similarity to human tumors. Here, using multi-omics data we identified 11 germline gene fusions (GGFs) in CTVT, which showed higher genetic susceptibility than others. Additionally, we illustrate a mechanism of a complex gene fusion of three gene segments (HSD17B4-DMXL1-TNFAIP8) that we...]]></summary>
        <author>
            <name>Bo-Wen Zhou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Real-World Concordance between Germline and Tumour <em>BRCA1/2</em> Status in Epithelial Ovarian Cancer]]></title>
        <id>pubmed:38201604</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38201604/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240121195630&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients diagnosed with epithelial ovarian cancer may undergo reflex tumour BRCA1/2 testing followed by germline BRCA1/2 testing in patients with a positive tumour test result. This testing model relies on tumour BRCA1/2 tests being able to detect all types of pathogenic variant. We analysed germline and tumour BRCA1/2 test results from patients treated for epithelial ovarian cancer at our specialist oncological referral centre. Tumour BRCA1/2 testing was performed using the next-generation...]]></summary>
        <author>
            <name>Robert D Morgan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Promising and Minimally Invasive Biomarkers: Targeting Melanoma]]></title>
        <id>pubmed:38201222</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38201222/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240121195630&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The therapeutic landscape of malignant melanoma has been radically reformed in recent years, with novel treatments emerging in both the field of cancer immunotherapy and signalling pathway inhibition. Large-scale tumour genomic characterization has accurately classified malignant melanoma into four different genomic subtypes so far. Despite this, only somatic mutations in BRAF oncogene, as assessed in tumour biopsies, has so far become a validated predictive biomarker of treatment with small...]]></summary>
        <author>
            <name>Pavlina Spiliopoulou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline gene fusions across species reveal the chromosomal instability regions and cancer susceptibility]]></title>
        <id>pubmed:38205119</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38205119/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240120195815&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The canine transmissible venereal tumor (CTVT) is a clonal cell-mediated cancer with a long evolutionary history and extensive karyotype rearrangements in its genome. However, little is known about its genetic similarity to human tumors. Here, using multi-omics data we identified 11 germline gene fusions (GGFs) in CTVT, which showed higher genetic susceptibility than others. Additionally, we illustrate a mechanism of a complex gene fusion of three gene segments (HSD17B4-DMXL1-TNFAIP8) that we...]]></summary>
        <author>
            <name>Bo-Wen Zhou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Real-World Concordance between Germline and Tumour <em>BRCA1/2</em> Status in Epithelial Ovarian Cancer]]></title>
        <id>pubmed:38201604</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38201604/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240120195815&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients diagnosed with epithelial ovarian cancer may undergo reflex tumour BRCA1/2 testing followed by germline BRCA1/2 testing in patients with a positive tumour test result. This testing model relies on tumour BRCA1/2 tests being able to detect all types of pathogenic variant. We analysed germline and tumour BRCA1/2 test results from patients treated for epithelial ovarian cancer at our specialist oncological referral centre. Tumour BRCA1/2 testing was performed using the next-generation...]]></summary>
        <author>
            <name>Robert D Morgan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Promising and Minimally Invasive Biomarkers: Targeting Melanoma]]></title>
        <id>pubmed:38201222</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38201222/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240120195815&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The therapeutic landscape of malignant melanoma has been radically reformed in recent years, with novel treatments emerging in both the field of cancer immunotherapy and signalling pathway inhibition. Large-scale tumour genomic characterization has accurately classified malignant melanoma into four different genomic subtypes so far. Despite this, only somatic mutations in BRAF oncogene, as assessed in tumour biopsies, has so far become a validated predictive biomarker of treatment with small...]]></summary>
        <author>
            <name>Pavlina Spiliopoulou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline gene fusions across species reveal the chromosomal instability regions and cancer susceptibility]]></title>
        <id>pubmed:38205119</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38205119/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240119195313&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The canine transmissible venereal tumor (CTVT) is a clonal cell-mediated cancer with a long evolutionary history and extensive karyotype rearrangements in its genome. However, little is known about its genetic similarity to human tumors. Here, using multi-omics data we identified 11 germline gene fusions (GGFs) in CTVT, which showed higher genetic susceptibility than others. Additionally, we illustrate a mechanism of a complex gene fusion of three gene segments (HSD17B4-DMXL1-TNFAIP8) that we...]]></summary>
        <author>
            <name>Bo-Wen Zhou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Real-World Concordance between Germline and Tumour <em>BRCA1/2</em> Status in Epithelial Ovarian Cancer]]></title>
        <id>pubmed:38201604</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38201604/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240119195313&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients diagnosed with epithelial ovarian cancer may undergo reflex tumour BRCA1/2 testing followed by germline BRCA1/2 testing in patients with a positive tumour test result. This testing model relies on tumour BRCA1/2 tests being able to detect all types of pathogenic variant. We analysed germline and tumour BRCA1/2 test results from patients treated for epithelial ovarian cancer at our specialist oncological referral centre. Tumour BRCA1/2 testing was performed using the next-generation...]]></summary>
        <author>
            <name>Robert D Morgan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Promising and Minimally Invasive Biomarkers: Targeting Melanoma]]></title>
        <id>pubmed:38201222</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38201222/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240119195313&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The therapeutic landscape of malignant melanoma has been radically reformed in recent years, with novel treatments emerging in both the field of cancer immunotherapy and signalling pathway inhibition. Large-scale tumour genomic characterization has accurately classified malignant melanoma into four different genomic subtypes so far. Despite this, only somatic mutations in BRAF oncogene, as assessed in tumour biopsies, has so far become a validated predictive biomarker of treatment with small...]]></summary>
        <author>
            <name>Pavlina Spiliopoulou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline gene fusions across species reveal the chromosomal instability regions and cancer susceptibility]]></title>
        <id>pubmed:38205119</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38205119/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240118195420&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The canine transmissible venereal tumor (CTVT) is a clonal cell-mediated cancer with a long evolutionary history and extensive karyotype rearrangements in its genome. However, little is known about its genetic similarity to human tumors. Here, using multi-omics data we identified 11 germline gene fusions (GGFs) in CTVT, which showed higher genetic susceptibility than others. Additionally, we illustrate a mechanism of a complex gene fusion of three gene segments (HSD17B4-DMXL1-TNFAIP8) that we...]]></summary>
        <author>
            <name>Bo-Wen Zhou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Real-World Concordance between Germline and Tumour <em>BRCA1/2</em> Status in Epithelial Ovarian Cancer]]></title>
        <id>pubmed:38201604</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38201604/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240118195420&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients diagnosed with epithelial ovarian cancer may undergo reflex tumour BRCA1/2 testing followed by germline BRCA1/2 testing in patients with a positive tumour test result. This testing model relies on tumour BRCA1/2 tests being able to detect all types of pathogenic variant. We analysed germline and tumour BRCA1/2 test results from patients treated for epithelial ovarian cancer at our specialist oncological referral centre. Tumour BRCA1/2 testing was performed using the next-generation...]]></summary>
        <author>
            <name>Robert D Morgan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Promising and Minimally Invasive Biomarkers: Targeting Melanoma]]></title>
        <id>pubmed:38201222</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38201222/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240118195420&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The therapeutic landscape of malignant melanoma has been radically reformed in recent years, with novel treatments emerging in both the field of cancer immunotherapy and signalling pathway inhibition. Large-scale tumour genomic characterization has accurately classified malignant melanoma into four different genomic subtypes so far. Despite this, only somatic mutations in BRAF oncogene, as assessed in tumour biopsies, has so far become a validated predictive biomarker of treatment with small...]]></summary>
        <author>
            <name>Pavlina Spiliopoulou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline gene fusions across species reveal the chromosomal instability regions and cancer susceptibility]]></title>
        <id>pubmed:38205119</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38205119/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240117195336&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The canine transmissible venereal tumor (CTVT) is a clonal cell-mediated cancer with a long evolutionary history and extensive karyotype rearrangements in its genome. However, little is known about its genetic similarity to human tumors. Here, using multi-omics data we identified 11 germline gene fusions (GGFs) in CTVT, which showed higher genetic susceptibility than others. Additionally, we illustrate a mechanism of a complex gene fusion of three gene segments (HSD17B4-DMXL1-TNFAIP8) that we...]]></summary>
        <author>
            <name>Bo-Wen Zhou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Real-World Concordance between Germline and Tumour <em>BRCA1/2</em> Status in Epithelial Ovarian Cancer]]></title>
        <id>pubmed:38201604</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38201604/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240117195336&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients diagnosed with epithelial ovarian cancer may undergo reflex tumour BRCA1/2 testing followed by germline BRCA1/2 testing in patients with a positive tumour test result. This testing model relies on tumour BRCA1/2 tests being able to detect all types of pathogenic variant. We analysed germline and tumour BRCA1/2 test results from patients treated for epithelial ovarian cancer at our specialist oncological referral centre. Tumour BRCA1/2 testing was performed using the next-generation...]]></summary>
        <author>
            <name>Robert D Morgan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Promising and Minimally Invasive Biomarkers: Targeting Melanoma]]></title>
        <id>pubmed:38201222</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38201222/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240117195336&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The therapeutic landscape of malignant melanoma has been radically reformed in recent years, with novel treatments emerging in both the field of cancer immunotherapy and signalling pathway inhibition. Large-scale tumour genomic characterization has accurately classified malignant melanoma into four different genomic subtypes so far. Despite this, only somatic mutations in BRAF oncogene, as assessed in tumour biopsies, has so far become a validated predictive biomarker of treatment with small...]]></summary>
        <author>
            <name>Pavlina Spiliopoulou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline gene fusions across species reveal the chromosomal instability regions and cancer susceptibility]]></title>
        <id>pubmed:38205119</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38205119/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240116195412&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The canine transmissible venereal tumor (CTVT) is a clonal cell-mediated cancer with a long evolutionary history and extensive karyotype rearrangements in its genome. However, little is known about its genetic similarity to human tumors. Here, using multi-omics data we identified 11 germline gene fusions (GGFs) in CTVT, which showed higher genetic susceptibility than others. Additionally, we illustrate a mechanism of a complex gene fusion of three gene segments (HSD17B4-DMXL1-TNFAIP8) that we...]]></summary>
        <author>
            <name>Bo-Wen Zhou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Real-World Concordance between Germline and Tumour <em>BRCA1/2</em> Status in Epithelial Ovarian Cancer]]></title>
        <id>pubmed:38201604</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38201604/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240116195412&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients diagnosed with epithelial ovarian cancer may undergo reflex tumour BRCA1/2 testing followed by germline BRCA1/2 testing in patients with a positive tumour test result. This testing model relies on tumour BRCA1/2 tests being able to detect all types of pathogenic variant. We analysed germline and tumour BRCA1/2 test results from patients treated for epithelial ovarian cancer at our specialist oncological referral centre. Tumour BRCA1/2 testing was performed using the next-generation...]]></summary>
        <author>
            <name>Robert D Morgan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Promising and Minimally Invasive Biomarkers: Targeting Melanoma]]></title>
        <id>pubmed:38201222</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38201222/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240116195412&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The therapeutic landscape of malignant melanoma has been radically reformed in recent years, with novel treatments emerging in both the field of cancer immunotherapy and signalling pathway inhibition. Large-scale tumour genomic characterization has accurately classified malignant melanoma into four different genomic subtypes so far. Despite this, only somatic mutations in BRAF oncogene, as assessed in tumour biopsies, has so far become a validated predictive biomarker of treatment with small...]]></summary>
        <author>
            <name>Pavlina Spiliopoulou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline gene fusions across species reveal the chromosomal instability regions and cancer susceptibility]]></title>
        <id>pubmed:38205119</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38205119/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240115195351&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The canine transmissible venereal tumor (CTVT) is a clonal cell-mediated cancer with a long evolutionary history and extensive karyotype rearrangements in its genome. However, little is known about its genetic similarity to human tumors. Here, using multi-omics data we identified 11 germline gene fusions (GGFs) in CTVT, which showed higher genetic susceptibility than others. Additionally, we illustrate a mechanism of a complex gene fusion of three gene segments (HSD17B4-DMXL1-TNFAIP8) that we...]]></summary>
        <author>
            <name>Bo-Wen Zhou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Real-World Concordance between Germline and Tumour <em>BRCA1/2</em> Status in Epithelial Ovarian Cancer]]></title>
        <id>pubmed:38201604</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38201604/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240115195351&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients diagnosed with epithelial ovarian cancer may undergo reflex tumour BRCA1/2 testing followed by germline BRCA1/2 testing in patients with a positive tumour test result. This testing model relies on tumour BRCA1/2 tests being able to detect all types of pathogenic variant. We analysed germline and tumour BRCA1/2 test results from patients treated for epithelial ovarian cancer at our specialist oncological referral centre. Tumour BRCA1/2 testing was performed using the next-generation...]]></summary>
        <author>
            <name>Robert D Morgan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Promising and Minimally Invasive Biomarkers: Targeting Melanoma]]></title>
        <id>pubmed:38201222</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38201222/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240115195351&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The therapeutic landscape of malignant melanoma has been radically reformed in recent years, with novel treatments emerging in both the field of cancer immunotherapy and signalling pathway inhibition. Large-scale tumour genomic characterization has accurately classified malignant melanoma into four different genomic subtypes so far. Despite this, only somatic mutations in BRAF oncogene, as assessed in tumour biopsies, has so far become a validated predictive biomarker of treatment with small...]]></summary>
        <author>
            <name>Pavlina Spiliopoulou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline gene fusions across species reveal the chromosomal instability regions and cancer susceptibility]]></title>
        <id>pubmed:38205119</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38205119/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240114195558&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The canine transmissible venereal tumor (CTVT) is a clonal cell-mediated cancer with a long evolutionary history and extensive karyotype rearrangements in its genome. However, little is known about its genetic similarity to human tumors. Here, using multi-omics data we identified 11 germline gene fusions (GGFs) in CTVT, which showed higher genetic susceptibility than others. Additionally, we illustrate a mechanism of a complex gene fusion of three gene segments (HSD17B4-DMXL1-TNFAIP8) that we...]]></summary>
        <author>
            <name>Bo-Wen Zhou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Real-World Concordance between Germline and Tumour <em>BRCA1/2</em> Status in Epithelial Ovarian Cancer]]></title>
        <id>pubmed:38201604</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38201604/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240114195558&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients diagnosed with epithelial ovarian cancer may undergo reflex tumour BRCA1/2 testing followed by germline BRCA1/2 testing in patients with a positive tumour test result. This testing model relies on tumour BRCA1/2 tests being able to detect all types of pathogenic variant. We analysed germline and tumour BRCA1/2 test results from patients treated for epithelial ovarian cancer at our specialist oncological referral centre. Tumour BRCA1/2 testing was performed using the next-generation...]]></summary>
        <author>
            <name>Robert D Morgan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Promising and Minimally Invasive Biomarkers: Targeting Melanoma]]></title>
        <id>pubmed:38201222</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38201222/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240114195558&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The therapeutic landscape of malignant melanoma has been radically reformed in recent years, with novel treatments emerging in both the field of cancer immunotherapy and signalling pathway inhibition. Large-scale tumour genomic characterization has accurately classified malignant melanoma into four different genomic subtypes so far. Despite this, only somatic mutations in BRAF oncogene, as assessed in tumour biopsies, has so far become a validated predictive biomarker of treatment with small...]]></summary>
        <author>
            <name>Pavlina Spiliopoulou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline gene fusions across species reveal the chromosomal instability regions and cancer susceptibility]]></title>
        <id>pubmed:38205119</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38205119/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240113195804&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The canine transmissible venereal tumor (CTVT) is a clonal cell-mediated cancer with a long evolutionary history and extensive karyotype rearrangements in its genome. However, little is known about its genetic similarity to human tumors. Here, using multi-omics data we identified 11 germline gene fusions (GGFs) in CTVT, which showed higher genetic susceptibility than others. Additionally, we illustrate a mechanism of a complex gene fusion of three gene segments (HSD17B4-DMXL1-TNFAIP8) that we...]]></summary>
        <author>
            <name>Bo-Wen Zhou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Real-World Concordance between Germline and Tumour <em>BRCA1/2</em> Status in Epithelial Ovarian Cancer]]></title>
        <id>pubmed:38201604</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38201604/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240113195804&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients diagnosed with epithelial ovarian cancer may undergo reflex tumour BRCA1/2 testing followed by germline BRCA1/2 testing in patients with a positive tumour test result. This testing model relies on tumour BRCA1/2 tests being able to detect all types of pathogenic variant. We analysed germline and tumour BRCA1/2 test results from patients treated for epithelial ovarian cancer at our specialist oncological referral centre. Tumour BRCA1/2 testing was performed using the next-generation...]]></summary>
        <author>
            <name>Robert D Morgan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Promising and Minimally Invasive Biomarkers: Targeting Melanoma]]></title>
        <id>pubmed:38201222</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38201222/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240113195804&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The therapeutic landscape of malignant melanoma has been radically reformed in recent years, with novel treatments emerging in both the field of cancer immunotherapy and signalling pathway inhibition. Large-scale tumour genomic characterization has accurately classified malignant melanoma into four different genomic subtypes so far. Despite this, only somatic mutations in BRAF oncogene, as assessed in tumour biopsies, has so far become a validated predictive biomarker of treatment with small...]]></summary>
        <author>
            <name>Pavlina Spiliopoulou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline gene fusions across species reveal the chromosomal instability regions and cancer susceptibility]]></title>
        <id>pubmed:38205119</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38205119/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240112195322&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The canine transmissible venereal tumor (CTVT) is a clonal cell-mediated cancer with a long evolutionary history and extensive karyotype rearrangements in its genome. However, little is known about its genetic similarity to human tumors. Here, using multi-omics data we identified 11 germline gene fusions (GGFs) in CTVT, which showed higher genetic susceptibility than others. Additionally, we illustrate a mechanism of a complex gene fusion of three gene segments (HSD17B4-DMXL1-TNFAIP8) that we...]]></summary>
        <author>
            <name>Bo-Wen Zhou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Real-World Concordance between Germline and Tumour <em>BRCA1/2</em> Status in Epithelial Ovarian Cancer]]></title>
        <id>pubmed:38201604</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38201604/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240112195322&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients diagnosed with epithelial ovarian cancer may undergo reflex tumour BRCA1/2 testing followed by germline BRCA1/2 testing in patients with a positive tumour test result. This testing model relies on tumour BRCA1/2 tests being able to detect all types of pathogenic variant. We analysed germline and tumour BRCA1/2 test results from patients treated for epithelial ovarian cancer at our specialist oncological referral centre. Tumour BRCA1/2 testing was performed using the next-generation...]]></summary>
        <author>
            <name>Robert D Morgan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Promising and Minimally Invasive Biomarkers: Targeting Melanoma]]></title>
        <id>pubmed:38201222</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38201222/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240112195322&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The therapeutic landscape of malignant melanoma has been radically reformed in recent years, with novel treatments emerging in both the field of cancer immunotherapy and signalling pathway inhibition. Large-scale tumour genomic characterization has accurately classified malignant melanoma into four different genomic subtypes so far. Despite this, only somatic mutations in BRAF oncogene, as assessed in tumour biopsies, has so far become a validated predictive biomarker of treatment with small...]]></summary>
        <author>
            <name>Pavlina Spiliopoulou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline gene fusions across species reveal the chromosomal instability regions and cancer susceptibility]]></title>
        <id>pubmed:38205119</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38205119/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240111195444&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The canine transmissible venereal tumor (CTVT) is a clonal cell-mediated cancer with a long evolutionary history and extensive karyotype rearrangements in its genome. However, little is known about its genetic similarity to human tumors. Here, using multi-omics data we identified 11 germline gene fusions (GGFs) in CTVT, which showed higher genetic susceptibility than others. Additionally, we illustrate a mechanism of a complex gene fusion of three gene segments (HSD17B4-DMXL1-TNFAIP8) that we...]]></summary>
        <author>
            <name>Bo-Wen Zhou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Real-World Concordance between Germline and Tumour <em>BRCA1/2</em> Status in Epithelial Ovarian Cancer]]></title>
        <id>pubmed:38201604</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38201604/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240111195444&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Patients diagnosed with epithelial ovarian cancer may undergo reflex tumour BRCA1/2 testing followed by germline BRCA1/2 testing in patients with a positive tumour test result. This testing model relies on tumour BRCA1/2 tests being able to detect all types of pathogenic variant. We analysed germline and tumour BRCA1/2 test results from patients treated for epithelial ovarian cancer at our specialist oncological referral centre. Tumour BRCA1/2 testing was performed using the next-generation...]]></summary>
        <author>
            <name>Robert D Morgan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Promising and Minimally Invasive Biomarkers: Targeting Melanoma]]></title>
        <id>pubmed:38201222</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38201222/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240111195444&amp;v=2.18.0"/>
        <updated>2024-01-11T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The therapeutic landscape of malignant melanoma has been radically reformed in recent years, with novel treatments emerging in both the field of cancer immunotherapy and signalling pathway inhibition. Large-scale tumour genomic characterization has accurately classified malignant melanoma into four different genomic subtypes so far. Despite this, only somatic mutations in BRAF oncogene, as assessed in tumour biopsies, has so far become a validated predictive biomarker of treatment with small...]]></summary>
        <author>
            <name>Pavlina Spiliopoulou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[High-sensitivity analysis of clonal hematopoiesis reveals increased clonal complexity of potential-driver mutations in severe COVID-19 patients]]></title>
        <id>pubmed:38198467</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38198467/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240122195511&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Whether Clonal Hematopoiesis (CH) represents a risk factor for severity of the COVID-19 disease remains a controversial issue. We report the first high- sensitivity analysis of CH in COVID-19 patients (threshold of detection at 0.5% vs 1 or 2% in previous studies). We analyzed 24 patients admitted to ICU for COVID-19 (COV-ICU) and 19 controls, including healthy subjects and asymptomatic SARS-CoV2-positive individuals. Despite the significantly higher numbers of CH mutations identified (80%...]]></summary>
        <author>
            <name>Chiara Ronchini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Somatic and Germline Variants and Coronary Heart Disease in a Chinese Population]]></title>
        <id>pubmed:38198131</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38198131/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240122195511&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This study revealed that elevated CHD risk attributed to CHIP was nonnegligible even for small clones. Inflammation genes involved in CHD could aggravate or abrogate CHIP-related CHD risk.]]></summary>
        <author>
            <name>Kun Zhao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[High-sensitivity analysis of clonal hematopoiesis reveals increased clonal complexity of potential-driver mutations in severe COVID-19 patients]]></title>
        <id>pubmed:38198467</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38198467/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240121195630&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Whether Clonal Hematopoiesis (CH) represents a risk factor for severity of the COVID-19 disease remains a controversial issue. We report the first high- sensitivity analysis of CH in COVID-19 patients (threshold of detection at 0.5% vs 1 or 2% in previous studies). We analyzed 24 patients admitted to ICU for COVID-19 (COV-ICU) and 19 controls, including healthy subjects and asymptomatic SARS-CoV2-positive individuals. Despite the significantly higher numbers of CH mutations identified (80%...]]></summary>
        <author>
            <name>Chiara Ronchini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Somatic and Germline Variants and Coronary Heart Disease in a Chinese Population]]></title>
        <id>pubmed:38198131</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38198131/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240121195630&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This study revealed that elevated CHD risk attributed to CHIP was nonnegligible even for small clones. Inflammation genes involved in CHD could aggravate or abrogate CHIP-related CHD risk.]]></summary>
        <author>
            <name>Kun Zhao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[High-sensitivity analysis of clonal hematopoiesis reveals increased clonal complexity of potential-driver mutations in severe COVID-19 patients]]></title>
        <id>pubmed:38198467</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38198467/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240120195815&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Whether Clonal Hematopoiesis (CH) represents a risk factor for severity of the COVID-19 disease remains a controversial issue. We report the first high- sensitivity analysis of CH in COVID-19 patients (threshold of detection at 0.5% vs 1 or 2% in previous studies). We analyzed 24 patients admitted to ICU for COVID-19 (COV-ICU) and 19 controls, including healthy subjects and asymptomatic SARS-CoV2-positive individuals. Despite the significantly higher numbers of CH mutations identified (80%...]]></summary>
        <author>
            <name>Chiara Ronchini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Somatic and Germline Variants and Coronary Heart Disease in a Chinese Population]]></title>
        <id>pubmed:38198131</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38198131/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240120195815&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This study revealed that elevated CHD risk attributed to CHIP was nonnegligible even for small clones. Inflammation genes involved in CHD could aggravate or abrogate CHIP-related CHD risk.]]></summary>
        <author>
            <name>Kun Zhao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Risk Factors for Clonal Hematopoiesis of Indeterminate Potential in People with HIV: a report from the REPRIEVE Trial]]></title>
        <id>pubmed:38197863</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38197863/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240120195815&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of Indeterminate Potential (CHIP), the clonal expansion of myeloid cells with leukemogenic mutations, results in increased coronary artery disease (CAD) risk. CHIP is more prevalent among people with HIV (PWH) but the risk factors are unknown. CHIP was identified among PWH in REPRIEVE (Randomized Trial to Prevent Vascular Events in HIV) using whole exome sequencing (WES). Logistic regression was used to associate sociodemographic factors and HIV-specific factors with CHIP...]]></summary>
        <author>
            <name>Romit Bhattacharya</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[High-sensitivity analysis of clonal hematopoiesis reveals increased clonal complexity of potential-driver mutations in severe COVID-19 patients]]></title>
        <id>pubmed:38198467</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38198467/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240119195313&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Whether Clonal Hematopoiesis (CH) represents a risk factor for severity of the COVID-19 disease remains a controversial issue. We report the first high- sensitivity analysis of CH in COVID-19 patients (threshold of detection at 0.5% vs 1 or 2% in previous studies). We analyzed 24 patients admitted to ICU for COVID-19 (COV-ICU) and 19 controls, including healthy subjects and asymptomatic SARS-CoV2-positive individuals. Despite the significantly higher numbers of CH mutations identified (80%...]]></summary>
        <author>
            <name>Chiara Ronchini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Somatic and Germline Variants and Coronary Heart Disease in a Chinese Population]]></title>
        <id>pubmed:38198131</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38198131/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240119195313&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This study revealed that elevated CHD risk attributed to CHIP was nonnegligible even for small clones. Inflammation genes involved in CHD could aggravate or abrogate CHIP-related CHD risk.]]></summary>
        <author>
            <name>Kun Zhao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Risk Factors for Clonal Hematopoiesis of Indeterminate Potential in People with HIV: a report from the REPRIEVE Trial]]></title>
        <id>pubmed:38197863</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38197863/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240119195313&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of Indeterminate Potential (CHIP), the clonal expansion of myeloid cells with leukemogenic mutations, results in increased coronary artery disease (CAD) risk. CHIP is more prevalent among people with HIV (PWH) but the risk factors are unknown. CHIP was identified among PWH in REPRIEVE (Randomized Trial to Prevent Vascular Events in HIV) using whole exome sequencing (WES). Logistic regression was used to associate sociodemographic factors and HIV-specific factors with CHIP...]]></summary>
        <author>
            <name>Romit Bhattacharya</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[High-sensitivity analysis of clonal hematopoiesis reveals increased clonal complexity of potential-driver mutations in severe COVID-19 patients]]></title>
        <id>pubmed:38198467</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38198467/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240118195421&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Whether Clonal Hematopoiesis (CH) represents a risk factor for severity of the COVID-19 disease remains a controversial issue. We report the first high- sensitivity analysis of CH in COVID-19 patients (threshold of detection at 0.5% vs 1 or 2% in previous studies). We analyzed 24 patients admitted to ICU for COVID-19 (COV-ICU) and 19 controls, including healthy subjects and asymptomatic SARS-CoV2-positive individuals. Despite the significantly higher numbers of CH mutations identified (80%...]]></summary>
        <author>
            <name>Chiara Ronchini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Somatic and Germline Variants and Coronary Heart Disease in a Chinese Population]]></title>
        <id>pubmed:38198131</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38198131/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240118195421&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This study revealed that elevated CHD risk attributed to CHIP was nonnegligible even for small clones. Inflammation genes involved in CHD could aggravate or abrogate CHIP-related CHD risk.]]></summary>
        <author>
            <name>Kun Zhao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Risk Factors for Clonal Hematopoiesis of Indeterminate Potential in People with HIV: a report from the REPRIEVE Trial]]></title>
        <id>pubmed:38197863</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38197863/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240118195421&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of Indeterminate Potential (CHIP), the clonal expansion of myeloid cells with leukemogenic mutations, results in increased coronary artery disease (CAD) risk. CHIP is more prevalent among people with HIV (PWH) but the risk factors are unknown. CHIP was identified among PWH in REPRIEVE (Randomized Trial to Prevent Vascular Events in HIV) using whole exome sequencing (WES). Logistic regression was used to associate sociodemographic factors and HIV-specific factors with CHIP...]]></summary>
        <author>
            <name>Romit Bhattacharya</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[High-sensitivity analysis of clonal hematopoiesis reveals increased clonal complexity of potential-driver mutations in severe COVID-19 patients]]></title>
        <id>pubmed:38198467</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38198467/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240117195336&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Whether Clonal Hematopoiesis (CH) represents a risk factor for severity of the COVID-19 disease remains a controversial issue. We report the first high- sensitivity analysis of CH in COVID-19 patients (threshold of detection at 0.5% vs 1 or 2% in previous studies). We analyzed 24 patients admitted to ICU for COVID-19 (COV-ICU) and 19 controls, including healthy subjects and asymptomatic SARS-CoV2-positive individuals. Despite the significantly higher numbers of CH mutations identified (80%...]]></summary>
        <author>
            <name>Chiara Ronchini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Somatic and Germline Variants and Coronary Heart Disease in a Chinese Population]]></title>
        <id>pubmed:38198131</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38198131/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240117195336&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This study revealed that elevated CHD risk attributed to CHIP was nonnegligible even for small clones. Inflammation genes involved in CHD could aggravate or abrogate CHIP-related CHD risk.]]></summary>
        <author>
            <name>Kun Zhao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Risk Factors for Clonal Hematopoiesis of Indeterminate Potential in People with HIV: a report from the REPRIEVE Trial]]></title>
        <id>pubmed:38197863</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38197863/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240117195336&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of Indeterminate Potential (CHIP), the clonal expansion of myeloid cells with leukemogenic mutations, results in increased coronary artery disease (CAD) risk. CHIP is more prevalent among people with HIV (PWH) but the risk factors are unknown. CHIP was identified among PWH in REPRIEVE (Randomized Trial to Prevent Vascular Events in HIV) using whole exome sequencing (WES). Logistic regression was used to associate sociodemographic factors and HIV-specific factors with CHIP...]]></summary>
        <author>
            <name>Romit Bhattacharya</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[High-sensitivity analysis of clonal hematopoiesis reveals increased clonal complexity of potential-driver mutations in severe COVID-19 patients]]></title>
        <id>pubmed:38198467</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38198467/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240116195412&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Whether Clonal Hematopoiesis (CH) represents a risk factor for severity of the COVID-19 disease remains a controversial issue. We report the first high- sensitivity analysis of CH in COVID-19 patients (threshold of detection at 0.5% vs 1 or 2% in previous studies). We analyzed 24 patients admitted to ICU for COVID-19 (COV-ICU) and 19 controls, including healthy subjects and asymptomatic SARS-CoV2-positive individuals. Despite the significantly higher numbers of CH mutations identified (80%...]]></summary>
        <author>
            <name>Chiara Ronchini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Somatic and Germline Variants and Coronary Heart Disease in a Chinese Population]]></title>
        <id>pubmed:38198131</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38198131/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240116195412&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This study revealed that elevated CHD risk attributed to CHIP was nonnegligible even for small clones. Inflammation genes involved in CHD could aggravate or abrogate CHIP-related CHD risk.]]></summary>
        <author>
            <name>Kun Zhao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Risk Factors for Clonal Hematopoiesis of Indeterminate Potential in People with HIV: a report from the REPRIEVE Trial]]></title>
        <id>pubmed:38197863</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38197863/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240116195412&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of Indeterminate Potential (CHIP), the clonal expansion of myeloid cells with leukemogenic mutations, results in increased coronary artery disease (CAD) risk. CHIP is more prevalent among people with HIV (PWH) but the risk factors are unknown. CHIP was identified among PWH in REPRIEVE (Randomized Trial to Prevent Vascular Events in HIV) using whole exome sequencing (WES). Logistic regression was used to associate sociodemographic factors and HIV-specific factors with CHIP...]]></summary>
        <author>
            <name>Romit Bhattacharya</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[High-sensitivity analysis of clonal hematopoiesis reveals increased clonal complexity of potential-driver mutations in severe COVID-19 patients]]></title>
        <id>pubmed:38198467</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38198467/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240115195351&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Whether Clonal Hematopoiesis (CH) represents a risk factor for severity of the COVID-19 disease remains a controversial issue. We report the first high- sensitivity analysis of CH in COVID-19 patients (threshold of detection at 0.5% vs 1 or 2% in previous studies). We analyzed 24 patients admitted to ICU for COVID-19 (COV-ICU) and 19 controls, including healthy subjects and asymptomatic SARS-CoV2-positive individuals. Despite the significantly higher numbers of CH mutations identified (80%...]]></summary>
        <author>
            <name>Chiara Ronchini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Somatic and Germline Variants and Coronary Heart Disease in a Chinese Population]]></title>
        <id>pubmed:38198131</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38198131/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240115195351&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This study revealed that elevated CHD risk attributed to CHIP was nonnegligible even for small clones. Inflammation genes involved in CHD could aggravate or abrogate CHIP-related CHD risk.]]></summary>
        <author>
            <name>Kun Zhao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Risk Factors for Clonal Hematopoiesis of Indeterminate Potential in People with HIV: a report from the REPRIEVE Trial]]></title>
        <id>pubmed:38197863</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38197863/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240115195351&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of Indeterminate Potential (CHIP), the clonal expansion of myeloid cells with leukemogenic mutations, results in increased coronary artery disease (CAD) risk. CHIP is more prevalent among people with HIV (PWH) but the risk factors are unknown. CHIP was identified among PWH in REPRIEVE (Randomized Trial to Prevent Vascular Events in HIV) using whole exome sequencing (WES). Logistic regression was used to associate sociodemographic factors and HIV-specific factors with CHIP...]]></summary>
        <author>
            <name>Romit Bhattacharya</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[High-sensitivity analysis of clonal hematopoiesis reveals increased clonal complexity of potential-driver mutations in severe COVID-19 patients]]></title>
        <id>pubmed:38198467</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38198467/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240114195558&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Whether Clonal Hematopoiesis (CH) represents a risk factor for severity of the COVID-19 disease remains a controversial issue. We report the first high- sensitivity analysis of CH in COVID-19 patients (threshold of detection at 0.5% vs 1 or 2% in previous studies). We analyzed 24 patients admitted to ICU for COVID-19 (COV-ICU) and 19 controls, including healthy subjects and asymptomatic SARS-CoV2-positive individuals. Despite the significantly higher numbers of CH mutations identified (80%...]]></summary>
        <author>
            <name>Chiara Ronchini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Somatic and Germline Variants and Coronary Heart Disease in a Chinese Population]]></title>
        <id>pubmed:38198131</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38198131/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240114195558&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This study revealed that elevated CHD risk attributed to CHIP was nonnegligible even for small clones. Inflammation genes involved in CHD could aggravate or abrogate CHIP-related CHD risk.]]></summary>
        <author>
            <name>Kun Zhao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Risk Factors for Clonal Hematopoiesis of Indeterminate Potential in People with HIV: a report from the REPRIEVE Trial]]></title>
        <id>pubmed:38197863</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38197863/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240114195558&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of Indeterminate Potential (CHIP), the clonal expansion of myeloid cells with leukemogenic mutations, results in increased coronary artery disease (CAD) risk. CHIP is more prevalent among people with HIV (PWH) but the risk factors are unknown. CHIP was identified among PWH in REPRIEVE (Randomized Trial to Prevent Vascular Events in HIV) using whole exome sequencing (WES). Logistic regression was used to associate sociodemographic factors and HIV-specific factors with CHIP...]]></summary>
        <author>
            <name>Romit Bhattacharya</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[High-sensitivity analysis of clonal hematopoiesis reveals increased clonal complexity of potential-driver mutations in severe COVID-19 patients]]></title>
        <id>pubmed:38198467</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38198467/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240113195804&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Whether Clonal Hematopoiesis (CH) represents a risk factor for severity of the COVID-19 disease remains a controversial issue. We report the first high- sensitivity analysis of CH in COVID-19 patients (threshold of detection at 0.5% vs 1 or 2% in previous studies). We analyzed 24 patients admitted to ICU for COVID-19 (COV-ICU) and 19 controls, including healthy subjects and asymptomatic SARS-CoV2-positive individuals. Despite the significantly higher numbers of CH mutations identified (80%...]]></summary>
        <author>
            <name>Chiara Ronchini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Somatic and Germline Variants and Coronary Heart Disease in a Chinese Population]]></title>
        <id>pubmed:38198131</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38198131/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240113195804&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This study revealed that elevated CHD risk attributed to CHIP was nonnegligible even for small clones. Inflammation genes involved in CHD could aggravate or abrogate CHIP-related CHD risk.]]></summary>
        <author>
            <name>Kun Zhao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Risk Factors for Clonal Hematopoiesis of Indeterminate Potential in People with HIV: a report from the REPRIEVE Trial]]></title>
        <id>pubmed:38197863</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38197863/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240113195804&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of Indeterminate Potential (CHIP), the clonal expansion of myeloid cells with leukemogenic mutations, results in increased coronary artery disease (CAD) risk. CHIP is more prevalent among people with HIV (PWH) but the risk factors are unknown. CHIP was identified among PWH in REPRIEVE (Randomized Trial to Prevent Vascular Events in HIV) using whole exome sequencing (WES). Logistic regression was used to associate sociodemographic factors and HIV-specific factors with CHIP...]]></summary>
        <author>
            <name>Romit Bhattacharya</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[High-sensitivity analysis of clonal hematopoiesis reveals increased clonal complexity of potential-driver mutations in severe COVID-19 patients]]></title>
        <id>pubmed:38198467</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38198467/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240112195322&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Whether Clonal Hematopoiesis (CH) represents a risk factor for severity of the COVID-19 disease remains a controversial issue. We report the first high- sensitivity analysis of CH in COVID-19 patients (threshold of detection at 0.5% vs 1 or 2% in previous studies). We analyzed 24 patients admitted to ICU for COVID-19 (COV-ICU) and 19 controls, including healthy subjects and asymptomatic SARS-CoV2-positive individuals. Despite the significantly higher numbers of CH mutations identified (80%...]]></summary>
        <author>
            <name>Chiara Ronchini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Somatic and Germline Variants and Coronary Heart Disease in a Chinese Population]]></title>
        <id>pubmed:38198131</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38198131/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240112195322&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This study revealed that elevated CHD risk attributed to CHIP was nonnegligible even for small clones. Inflammation genes involved in CHD could aggravate or abrogate CHIP-related CHD risk.]]></summary>
        <author>
            <name>Kun Zhao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Risk Factors for Clonal Hematopoiesis of Indeterminate Potential in People with HIV: a report from the REPRIEVE Trial]]></title>
        <id>pubmed:38197863</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38197863/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240112195322&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of Indeterminate Potential (CHIP), the clonal expansion of myeloid cells with leukemogenic mutations, results in increased coronary artery disease (CAD) risk. CHIP is more prevalent among people with HIV (PWH) but the risk factors are unknown. CHIP was identified among PWH in REPRIEVE (Randomized Trial to Prevent Vascular Events in HIV) using whole exome sequencing (WES). Logistic regression was used to associate sociodemographic factors and HIV-specific factors with CHIP...]]></summary>
        <author>
            <name>Romit Bhattacharya</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[High-sensitivity analysis of clonal hematopoiesis reveals increased clonal complexity of potential-driver mutations in severe COVID-19 patients]]></title>
        <id>pubmed:38198467</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38198467/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240111195444&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Whether Clonal Hematopoiesis (CH) represents a risk factor for severity of the COVID-19 disease remains a controversial issue. We report the first high- sensitivity analysis of CH in COVID-19 patients (threshold of detection at 0.5% vs 1 or 2% in previous studies). We analyzed 24 patients admitted to ICU for COVID-19 (COV-ICU) and 19 controls, including healthy subjects and asymptomatic SARS-CoV2-positive individuals. Despite the significantly higher numbers of CH mutations identified (80%...]]></summary>
        <author>
            <name>Chiara Ronchini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Somatic and Germline Variants and Coronary Heart Disease in a Chinese Population]]></title>
        <id>pubmed:38198131</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38198131/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240111195444&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This study revealed that elevated CHD risk attributed to CHIP was nonnegligible even for small clones. Inflammation genes involved in CHD could aggravate or abrogate CHIP-related CHD risk.]]></summary>
        <author>
            <name>Kun Zhao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Risk Factors for Clonal Hematopoiesis of Indeterminate Potential in People with HIV: a report from the REPRIEVE Trial]]></title>
        <id>pubmed:38197863</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38197863/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240111195444&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of Indeterminate Potential (CHIP), the clonal expansion of myeloid cells with leukemogenic mutations, results in increased coronary artery disease (CAD) risk. CHIP is more prevalent among people with HIV (PWH) but the risk factors are unknown. CHIP was identified among PWH in REPRIEVE (Randomized Trial to Prevent Vascular Events in HIV) using whole exome sequencing (WES). Logistic regression was used to associate sociodemographic factors and HIV-specific factors with CHIP...]]></summary>
        <author>
            <name>Romit Bhattacharya</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[High-sensitivity analysis of clonal hematopoiesis reveals increased clonal complexity of potential-driver mutations in severe COVID-19 patients]]></title>
        <id>pubmed:38198467</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38198467/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240110195405&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Whether Clonal Hematopoiesis (CH) represents a risk factor for severity of the COVID-19 disease remains a controversial issue. We report the first high- sensitivity analysis of CH in COVID-19 patients (threshold of detection at 0.5% vs 1 or 2% in previous studies). We analyzed 24 patients admitted to ICU for COVID-19 (COV-ICU) and 19 controls, including healthy subjects and asymptomatic SARS-CoV2-positive individuals. Despite the significantly higher numbers of CH mutations identified (80%...]]></summary>
        <author>
            <name>Chiara Ronchini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Somatic and Germline Variants and Coronary Heart Disease in a Chinese Population]]></title>
        <id>pubmed:38198131</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38198131/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240110195405&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This study revealed that elevated CHD risk attributed to CHIP was nonnegligible even for small clones. Inflammation genes involved in CHD could aggravate or abrogate CHIP-related CHD risk.]]></summary>
        <author>
            <name>Kun Zhao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Risk Factors for Clonal Hematopoiesis of Indeterminate Potential in People with HIV: a report from the REPRIEVE Trial]]></title>
        <id>pubmed:38197863</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38197863/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240110195405&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of Indeterminate Potential (CHIP), the clonal expansion of myeloid cells with leukemogenic mutations, results in increased coronary artery disease (CAD) risk. CHIP is more prevalent among people with HIV (PWH) but the risk factors are unknown. CHIP was identified among PWH in REPRIEVE (Randomized Trial to Prevent Vascular Events in HIV) using whole exome sequencing (WES). Logistic regression was used to associate sociodemographic factors and HIV-specific factors with CHIP...]]></summary>
        <author>
            <name>Romit Bhattacharya</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cell cycle gene alterations associate with a redistribution of mutation risk across chromosomal domains in human cancers]]></title>
        <id>pubmed:38200245</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38200245/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240121195630&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in human cells exhibit increased burden in heterochromatic, late DNA replication time (RT) chromosomal domains, with variation in mutation rates between tissues mirroring variation in heterochromatin and RT. We observed that regional mutation risk further varies between individual tumors in a manner independent of cell type, identifying three signatures of domain-scale mutagenesis in >4,000 tumor genomes. The major signature reflects remodeling of heterochromatin and of the RT program...]]></summary>
        <author>
            <name>Marina Salvadores</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cell cycle gene alterations associate with a redistribution of mutation risk across chromosomal domains in human cancers]]></title>
        <id>pubmed:38200245</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38200245/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240120195815&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in human cells exhibit increased burden in heterochromatic, late DNA replication time (RT) chromosomal domains, with variation in mutation rates between tissues mirroring variation in heterochromatin and RT. We observed that regional mutation risk further varies between individual tumors in a manner independent of cell type, identifying three signatures of domain-scale mutagenesis in >4,000 tumor genomes. The major signature reflects remodeling of heterochromatin and of the RT program...]]></summary>
        <author>
            <name>Marina Salvadores</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cell cycle gene alterations associate with a redistribution of mutation risk across chromosomal domains in human cancers]]></title>
        <id>pubmed:38200245</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38200245/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240119195313&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in human cells exhibit increased burden in heterochromatic, late DNA replication time (RT) chromosomal domains, with variation in mutation rates between tissues mirroring variation in heterochromatin and RT. We observed that regional mutation risk further varies between individual tumors in a manner independent of cell type, identifying three signatures of domain-scale mutagenesis in >4,000 tumor genomes. The major signature reflects remodeling of heterochromatin and of the RT program...]]></summary>
        <author>
            <name>Marina Salvadores</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiomics profiling reveals the benefits of gamma-delta () T lymphocytes for improving the tumor microenvironment, immunotherapy efficacy and prognosis in cervical cancer]]></title>
        <id>pubmed:38199610</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38199610/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240119195313&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS:  T cells play a beneficial role in antitumor immunity in cervical cancer. The abundance of  T cells in cervical cancerous tissue is associated with higher response rates to immunotherapy.]]></summary>
        <author>
            <name>Junyi Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cell cycle gene alterations associate with a redistribution of mutation risk across chromosomal domains in human cancers]]></title>
        <id>pubmed:38200245</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38200245/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240118195420&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in human cells exhibit increased burden in heterochromatic, late DNA replication time (RT) chromosomal domains, with variation in mutation rates between tissues mirroring variation in heterochromatin and RT. We observed that regional mutation risk further varies between individual tumors in a manner independent of cell type, identifying three signatures of domain-scale mutagenesis in >4,000 tumor genomes. The major signature reflects remodeling of heterochromatin and of the RT program...]]></summary>
        <author>
            <name>Marina Salvadores</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiomics profiling reveals the benefits of gamma-delta () T lymphocytes for improving the tumor microenvironment, immunotherapy efficacy and prognosis in cervical cancer]]></title>
        <id>pubmed:38199610</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38199610/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240118195420&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS:  T cells play a beneficial role in antitumor immunity in cervical cancer. The abundance of  T cells in cervical cancerous tissue is associated with higher response rates to immunotherapy.]]></summary>
        <author>
            <name>Junyi Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[High-sensitivity analysis of clonal hematopoiesis reveals increased clonal complexity of potential-driver mutations in severe COVID-19 patients]]></title>
        <id>pubmed:38198467</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38198467/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240118195420&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Whether Clonal Hematopoiesis (CH) represents a risk factor for severity of the COVID-19 disease remains a controversial issue. We report the first high- sensitivity analysis of CH in COVID-19 patients (threshold of detection at 0.5% vs 1 or 2% in previous studies). We analyzed 24 patients admitted to ICU for COVID-19 (COV-ICU) and 19 controls, including healthy subjects and asymptomatic SARS-CoV2-positive individuals. Despite the significantly higher numbers of CH mutations identified (80%...]]></summary>
        <author>
            <name>Chiara Ronchini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cell cycle gene alterations associate with a redistribution of mutation risk across chromosomal domains in human cancers]]></title>
        <id>pubmed:38200245</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38200245/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240117195336&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in human cells exhibit increased burden in heterochromatic, late DNA replication time (RT) chromosomal domains, with variation in mutation rates between tissues mirroring variation in heterochromatin and RT. We observed that regional mutation risk further varies between individual tumors in a manner independent of cell type, identifying three signatures of domain-scale mutagenesis in >4,000 tumor genomes. The major signature reflects remodeling of heterochromatin and of the RT program...]]></summary>
        <author>
            <name>Marina Salvadores</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiomics profiling reveals the benefits of gamma-delta () T lymphocytes for improving the tumor microenvironment, immunotherapy efficacy and prognosis in cervical cancer]]></title>
        <id>pubmed:38199610</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38199610/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240117195336&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS:  T cells play a beneficial role in antitumor immunity in cervical cancer. The abundance of  T cells in cervical cancerous tissue is associated with higher response rates to immunotherapy.]]></summary>
        <author>
            <name>Junyi Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[High-sensitivity analysis of clonal hematopoiesis reveals increased clonal complexity of potential-driver mutations in severe COVID-19 patients]]></title>
        <id>pubmed:38198467</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38198467/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240117195336&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Whether Clonal Hematopoiesis (CH) represents a risk factor for severity of the COVID-19 disease remains a controversial issue. We report the first high- sensitivity analysis of CH in COVID-19 patients (threshold of detection at 0.5% vs 1 or 2% in previous studies). We analyzed 24 patients admitted to ICU for COVID-19 (COV-ICU) and 19 controls, including healthy subjects and asymptomatic SARS-CoV2-positive individuals. Despite the significantly higher numbers of CH mutations identified (80%...]]></summary>
        <author>
            <name>Chiara Ronchini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cell cycle gene alterations associate with a redistribution of mutation risk across chromosomal domains in human cancers]]></title>
        <id>pubmed:38200245</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38200245/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240116195412&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in human cells exhibit increased burden in heterochromatic, late DNA replication time (RT) chromosomal domains, with variation in mutation rates between tissues mirroring variation in heterochromatin and RT. We observed that regional mutation risk further varies between individual tumors in a manner independent of cell type, identifying three signatures of domain-scale mutagenesis in >4,000 tumor genomes. The major signature reflects remodeling of heterochromatin and of the RT program...]]></summary>
        <author>
            <name>Marina Salvadores</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiomics profiling reveals the benefits of gamma-delta () T lymphocytes for improving the tumor microenvironment, immunotherapy efficacy and prognosis in cervical cancer]]></title>
        <id>pubmed:38199610</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38199610/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240116195412&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS:  T cells play a beneficial role in antitumor immunity in cervical cancer. The abundance of  T cells in cervical cancerous tissue is associated with higher response rates to immunotherapy.]]></summary>
        <author>
            <name>Junyi Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[High-sensitivity analysis of clonal hematopoiesis reveals increased clonal complexity of potential-driver mutations in severe COVID-19 patients]]></title>
        <id>pubmed:38198467</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38198467/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240116195412&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Whether Clonal Hematopoiesis (CH) represents a risk factor for severity of the COVID-19 disease remains a controversial issue. We report the first high- sensitivity analysis of CH in COVID-19 patients (threshold of detection at 0.5% vs 1 or 2% in previous studies). We analyzed 24 patients admitted to ICU for COVID-19 (COV-ICU) and 19 controls, including healthy subjects and asymptomatic SARS-CoV2-positive individuals. Despite the significantly higher numbers of CH mutations identified (80%...]]></summary>
        <author>
            <name>Chiara Ronchini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cell cycle gene alterations associate with a redistribution of mutation risk across chromosomal domains in human cancers]]></title>
        <id>pubmed:38200245</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38200245/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240115195351&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in human cells exhibit increased burden in heterochromatic, late DNA replication time (RT) chromosomal domains, with variation in mutation rates between tissues mirroring variation in heterochromatin and RT. We observed that regional mutation risk further varies between individual tumors in a manner independent of cell type, identifying three signatures of domain-scale mutagenesis in >4,000 tumor genomes. The major signature reflects remodeling of heterochromatin and of the RT program...]]></summary>
        <author>
            <name>Marina Salvadores</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiomics profiling reveals the benefits of gamma-delta () T lymphocytes for improving the tumor microenvironment, immunotherapy efficacy and prognosis in cervical cancer]]></title>
        <id>pubmed:38199610</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38199610/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240115195351&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS:  T cells play a beneficial role in antitumor immunity in cervical cancer. The abundance of  T cells in cervical cancerous tissue is associated with higher response rates to immunotherapy.]]></summary>
        <author>
            <name>Junyi Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[High-sensitivity analysis of clonal hematopoiesis reveals increased clonal complexity of potential-driver mutations in severe COVID-19 patients]]></title>
        <id>pubmed:38198467</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38198467/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240115195351&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Whether Clonal Hematopoiesis (CH) represents a risk factor for severity of the COVID-19 disease remains a controversial issue. We report the first high- sensitivity analysis of CH in COVID-19 patients (threshold of detection at 0.5% vs 1 or 2% in previous studies). We analyzed 24 patients admitted to ICU for COVID-19 (COV-ICU) and 19 controls, including healthy subjects and asymptomatic SARS-CoV2-positive individuals. Despite the significantly higher numbers of CH mutations identified (80%...]]></summary>
        <author>
            <name>Chiara Ronchini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cell cycle gene alterations associate with a redistribution of mutation risk across chromosomal domains in human cancers]]></title>
        <id>pubmed:38200245</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38200245/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240114195558&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in human cells exhibit increased burden in heterochromatic, late DNA replication time (RT) chromosomal domains, with variation in mutation rates between tissues mirroring variation in heterochromatin and RT. We observed that regional mutation risk further varies between individual tumors in a manner independent of cell type, identifying three signatures of domain-scale mutagenesis in >4,000 tumor genomes. The major signature reflects remodeling of heterochromatin and of the RT program...]]></summary>
        <author>
            <name>Marina Salvadores</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiomics profiling reveals the benefits of gamma-delta () T lymphocytes for improving the tumor microenvironment, immunotherapy efficacy and prognosis in cervical cancer]]></title>
        <id>pubmed:38199610</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38199610/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240114195558&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS:  T cells play a beneficial role in antitumor immunity in cervical cancer. The abundance of  T cells in cervical cancerous tissue is associated with higher response rates to immunotherapy.]]></summary>
        <author>
            <name>Junyi Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[High-sensitivity analysis of clonal hematopoiesis reveals increased clonal complexity of potential-driver mutations in severe COVID-19 patients]]></title>
        <id>pubmed:38198467</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38198467/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240114195558&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Whether Clonal Hematopoiesis (CH) represents a risk factor for severity of the COVID-19 disease remains a controversial issue. We report the first high- sensitivity analysis of CH in COVID-19 patients (threshold of detection at 0.5% vs 1 or 2% in previous studies). We analyzed 24 patients admitted to ICU for COVID-19 (COV-ICU) and 19 controls, including healthy subjects and asymptomatic SARS-CoV2-positive individuals. Despite the significantly higher numbers of CH mutations identified (80%...]]></summary>
        <author>
            <name>Chiara Ronchini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cell cycle gene alterations associate with a redistribution of mutation risk across chromosomal domains in human cancers]]></title>
        <id>pubmed:38200245</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38200245/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240113195804&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in human cells exhibit increased burden in heterochromatic, late DNA replication time (RT) chromosomal domains, with variation in mutation rates between tissues mirroring variation in heterochromatin and RT. We observed that regional mutation risk further varies between individual tumors in a manner independent of cell type, identifying three signatures of domain-scale mutagenesis in >4,000 tumor genomes. The major signature reflects remodeling of heterochromatin and of the RT program...]]></summary>
        <author>
            <name>Marina Salvadores</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiomics profiling reveals the benefits of gamma-delta () T lymphocytes for improving the tumor microenvironment, immunotherapy efficacy and prognosis in cervical cancer]]></title>
        <id>pubmed:38199610</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38199610/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240113195804&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS:  T cells play a beneficial role in antitumor immunity in cervical cancer. The abundance of  T cells in cervical cancerous tissue is associated with higher response rates to immunotherapy.]]></summary>
        <author>
            <name>Junyi Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[High-sensitivity analysis of clonal hematopoiesis reveals increased clonal complexity of potential-driver mutations in severe COVID-19 patients]]></title>
        <id>pubmed:38198467</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38198467/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240113195804&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Whether Clonal Hematopoiesis (CH) represents a risk factor for severity of the COVID-19 disease remains a controversial issue. We report the first high- sensitivity analysis of CH in COVID-19 patients (threshold of detection at 0.5% vs 1 or 2% in previous studies). We analyzed 24 patients admitted to ICU for COVID-19 (COV-ICU) and 19 controls, including healthy subjects and asymptomatic SARS-CoV2-positive individuals. Despite the significantly higher numbers of CH mutations identified (80%...]]></summary>
        <author>
            <name>Chiara Ronchini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cell cycle gene alterations associate with a redistribution of mutation risk across chromosomal domains in human cancers]]></title>
        <id>pubmed:38200245</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38200245/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240112195322&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in human cells exhibit increased burden in heterochromatic, late DNA replication time (RT) chromosomal domains, with variation in mutation rates between tissues mirroring variation in heterochromatin and RT. We observed that regional mutation risk further varies between individual tumors in a manner independent of cell type, identifying three signatures of domain-scale mutagenesis in >4,000 tumor genomes. The major signature reflects remodeling of heterochromatin and of the RT program...]]></summary>
        <author>
            <name>Marina Salvadores</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiomics profiling reveals the benefits of gamma-delta () T lymphocytes for improving the tumor microenvironment, immunotherapy efficacy and prognosis in cervical cancer]]></title>
        <id>pubmed:38199610</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38199610/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240112195322&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS:  T cells play a beneficial role in antitumor immunity in cervical cancer. The abundance of  T cells in cervical cancerous tissue is associated with higher response rates to immunotherapy.]]></summary>
        <author>
            <name>Junyi Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[High-sensitivity analysis of clonal hematopoiesis reveals increased clonal complexity of potential-driver mutations in severe COVID-19 patients]]></title>
        <id>pubmed:38198467</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38198467/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240112195322&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Whether Clonal Hematopoiesis (CH) represents a risk factor for severity of the COVID-19 disease remains a controversial issue. We report the first high- sensitivity analysis of CH in COVID-19 patients (threshold of detection at 0.5% vs 1 or 2% in previous studies). We analyzed 24 patients admitted to ICU for COVID-19 (COV-ICU) and 19 controls, including healthy subjects and asymptomatic SARS-CoV2-positive individuals. Despite the significantly higher numbers of CH mutations identified (80%...]]></summary>
        <author>
            <name>Chiara Ronchini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cell cycle gene alterations associate with a redistribution of mutation risk across chromosomal domains in human cancers]]></title>
        <id>pubmed:38200245</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38200245/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240111195444&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in human cells exhibit increased burden in heterochromatic, late DNA replication time (RT) chromosomal domains, with variation in mutation rates between tissues mirroring variation in heterochromatin and RT. We observed that regional mutation risk further varies between individual tumors in a manner independent of cell type, identifying three signatures of domain-scale mutagenesis in >4,000 tumor genomes. The major signature reflects remodeling of heterochromatin and of the RT program...]]></summary>
        <author>
            <name>Marina Salvadores</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiomics profiling reveals the benefits of gamma-delta () T lymphocytes for improving the tumor microenvironment, immunotherapy efficacy and prognosis in cervical cancer]]></title>
        <id>pubmed:38199610</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38199610/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240111195444&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS:  T cells play a beneficial role in antitumor immunity in cervical cancer. The abundance of  T cells in cervical cancerous tissue is associated with higher response rates to immunotherapy.]]></summary>
        <author>
            <name>Junyi Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[High-sensitivity analysis of clonal hematopoiesis reveals increased clonal complexity of potential-driver mutations in severe COVID-19 patients]]></title>
        <id>pubmed:38198467</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38198467/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240111195444&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Whether Clonal Hematopoiesis (CH) represents a risk factor for severity of the COVID-19 disease remains a controversial issue. We report the first high- sensitivity analysis of CH in COVID-19 patients (threshold of detection at 0.5% vs 1 or 2% in previous studies). We analyzed 24 patients admitted to ICU for COVID-19 (COV-ICU) and 19 controls, including healthy subjects and asymptomatic SARS-CoV2-positive individuals. Despite the significantly higher numbers of CH mutations identified (80%...]]></summary>
        <author>
            <name>Chiara Ronchini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[High-sensitivity analysis of clonal hematopoiesis reveals increased clonal complexity of potential-driver mutations in severe COVID-19 patients]]></title>
        <id>pubmed:38198467</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38198467/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240110195405&amp;v=2.18.0"/>
        <updated>2024-01-10T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Whether Clonal Hematopoiesis (CH) represents a risk factor for severity of the COVID-19 disease remains a controversial issue. We report the first high- sensitivity analysis of CH in COVID-19 patients (threshold of detection at 0.5% vs 1 or 2% in previous studies). We analyzed 24 patients admitted to ICU for COVID-19 (COV-ICU) and 19 controls, including healthy subjects and asymptomatic SARS-CoV2-positive individuals. Despite the significantly higher numbers of CH mutations identified (80%...]]></summary>
        <author>
            <name>Chiara Ronchini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone marrow macrophages are involved in the ineffective hematopoiesis of myelodysplastic syndromes]]></title>
        <id>pubmed:38192063</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38192063/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240119195313&amp;v=2.18.0"/>
        <updated>2024-01-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a group of heterogeneous myeloid clonal disorders characterized by ineffective hematopoiesis. Accumulating evidence has shown that macrophages (Ms) are important components in the regulation of tumor progression and hematopoietic stem cells (HSCs). However, the roles of bone marrow (BM) Ms in regulating normal and malignant hematopoiesis in different clinical stages of MDS are largely unknown. Age-paired patients with lower-risk MDS (N = 15), higher-risk MDS...]]></summary>
        <author>
            <name>Tong Xing</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone marrow macrophages are involved in the ineffective hematopoiesis of myelodysplastic syndromes]]></title>
        <id>pubmed:38192063</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38192063/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240118195421&amp;v=2.18.0"/>
        <updated>2024-01-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a group of heterogeneous myeloid clonal disorders characterized by ineffective hematopoiesis. Accumulating evidence has shown that macrophages (Ms) are important components in the regulation of tumor progression and hematopoietic stem cells (HSCs). However, the roles of bone marrow (BM) Ms in regulating normal and malignant hematopoiesis in different clinical stages of MDS are largely unknown. Age-paired patients with lower-risk MDS (N = 15), higher-risk MDS...]]></summary>
        <author>
            <name>Tong Xing</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone marrow macrophages are involved in the ineffective hematopoiesis of myelodysplastic syndromes]]></title>
        <id>pubmed:38192063</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38192063/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240117195336&amp;v=2.18.0"/>
        <updated>2024-01-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a group of heterogeneous myeloid clonal disorders characterized by ineffective hematopoiesis. Accumulating evidence has shown that macrophages (Ms) are important components in the regulation of tumor progression and hematopoietic stem cells (HSCs). However, the roles of bone marrow (BM) Ms in regulating normal and malignant hematopoiesis in different clinical stages of MDS are largely unknown. Age-paired patients with lower-risk MDS (N = 15), higher-risk MDS...]]></summary>
        <author>
            <name>Tong Xing</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone marrow macrophages are involved in the ineffective hematopoiesis of myelodysplastic syndromes]]></title>
        <id>pubmed:38192063</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38192063/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240116195412&amp;v=2.18.0"/>
        <updated>2024-01-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a group of heterogeneous myeloid clonal disorders characterized by ineffective hematopoiesis. Accumulating evidence has shown that macrophages (Ms) are important components in the regulation of tumor progression and hematopoietic stem cells (HSCs). However, the roles of bone marrow (BM) Ms in regulating normal and malignant hematopoiesis in different clinical stages of MDS are largely unknown. Age-paired patients with lower-risk MDS (N = 15), higher-risk MDS...]]></summary>
        <author>
            <name>Tong Xing</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone marrow macrophages are involved in the ineffective hematopoiesis of myelodysplastic syndromes]]></title>
        <id>pubmed:38192063</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38192063/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240115195351&amp;v=2.18.0"/>
        <updated>2024-01-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a group of heterogeneous myeloid clonal disorders characterized by ineffective hematopoiesis. Accumulating evidence has shown that macrophages (Ms) are important components in the regulation of tumor progression and hematopoietic stem cells (HSCs). However, the roles of bone marrow (BM) Ms in regulating normal and malignant hematopoiesis in different clinical stages of MDS are largely unknown. Age-paired patients with lower-risk MDS (N = 15), higher-risk MDS...]]></summary>
        <author>
            <name>Tong Xing</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone marrow macrophages are involved in the ineffective hematopoiesis of myelodysplastic syndromes]]></title>
        <id>pubmed:38192063</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38192063/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240114195558&amp;v=2.18.0"/>
        <updated>2024-01-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a group of heterogeneous myeloid clonal disorders characterized by ineffective hematopoiesis. Accumulating evidence has shown that macrophages (Ms) are important components in the regulation of tumor progression and hematopoietic stem cells (HSCs). However, the roles of bone marrow (BM) Ms in regulating normal and malignant hematopoiesis in different clinical stages of MDS are largely unknown. Age-paired patients with lower-risk MDS (N = 15), higher-risk MDS...]]></summary>
        <author>
            <name>Tong Xing</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone marrow macrophages are involved in the ineffective hematopoiesis of myelodysplastic syndromes]]></title>
        <id>pubmed:38192063</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38192063/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240113195804&amp;v=2.18.0"/>
        <updated>2024-01-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a group of heterogeneous myeloid clonal disorders characterized by ineffective hematopoiesis. Accumulating evidence has shown that macrophages (Ms) are important components in the regulation of tumor progression and hematopoietic stem cells (HSCs). However, the roles of bone marrow (BM) Ms in regulating normal and malignant hematopoiesis in different clinical stages of MDS are largely unknown. Age-paired patients with lower-risk MDS (N = 15), higher-risk MDS...]]></summary>
        <author>
            <name>Tong Xing</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone marrow macrophages are involved in the ineffective hematopoiesis of myelodysplastic syndromes]]></title>
        <id>pubmed:38192063</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38192063/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240112195322&amp;v=2.18.0"/>
        <updated>2024-01-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a group of heterogeneous myeloid clonal disorders characterized by ineffective hematopoiesis. Accumulating evidence has shown that macrophages (Ms) are important components in the regulation of tumor progression and hematopoietic stem cells (HSCs). However, the roles of bone marrow (BM) Ms in regulating normal and malignant hematopoiesis in different clinical stages of MDS are largely unknown. Age-paired patients with lower-risk MDS (N = 15), higher-risk MDS...]]></summary>
        <author>
            <name>Tong Xing</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone marrow macrophages are involved in the ineffective hematopoiesis of myelodysplastic syndromes]]></title>
        <id>pubmed:38192063</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38192063/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240111195444&amp;v=2.18.0"/>
        <updated>2024-01-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a group of heterogeneous myeloid clonal disorders characterized by ineffective hematopoiesis. Accumulating evidence has shown that macrophages (Ms) are important components in the regulation of tumor progression and hematopoietic stem cells (HSCs). However, the roles of bone marrow (BM) Ms in regulating normal and malignant hematopoiesis in different clinical stages of MDS are largely unknown. Age-paired patients with lower-risk MDS (N = 15), higher-risk MDS...]]></summary>
        <author>
            <name>Tong Xing</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone marrow macrophages are involved in the ineffective hematopoiesis of myelodysplastic syndromes]]></title>
        <id>pubmed:38192063</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38192063/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240110195405&amp;v=2.18.0"/>
        <updated>2024-01-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a group of heterogeneous myeloid clonal disorders characterized by ineffective hematopoiesis. Accumulating evidence has shown that macrophages (Ms) are important components in the regulation of tumor progression and hematopoietic stem cells (HSCs). However, the roles of bone marrow (BM) Ms in regulating normal and malignant hematopoiesis in different clinical stages of MDS are largely unknown. Age-paired patients with lower-risk MDS (N = 15), higher-risk MDS...]]></summary>
        <author>
            <name>Tong Xing</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone marrow macrophages are involved in the ineffective hematopoiesis of myelodysplastic syndromes]]></title>
        <id>pubmed:38192063</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38192063/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240109195408&amp;v=2.18.0"/>
        <updated>2024-01-09T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a group of heterogeneous myeloid clonal disorders characterized by ineffective hematopoiesis. Accumulating evidence has shown that macrophages (Ms) are important components in the regulation of tumor progression and hematopoietic stem cells (HSCs). However, the roles of bone marrow (BM) Ms in regulating normal and malignant hematopoiesis in different clinical stages of MDS are largely unknown. Age-paired patients with lower-risk MDS (N = 15), higher-risk MDS...]]></summary>
        <author>
            <name>Tong Xing</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence, Dynamics, and Prognostic Role of Clonal Hematopoiesis of Indeterminate Potential in Patients With Breast Cancer]]></title>
        <id>pubmed:38190580</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38190580/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240117195336&amp;v=2.18.0"/>
        <updated>2024-01-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CHIP is frequent in patients with breast cancer. In this study, CT did not lead to emergence of new CHIP, and most patients had low risk of developing t-MN. This finding is reassuring, given long life expectancy of patients with eBC and the association of CHIP with morbidity and mortality. However, TP53-mutant CH with VAF 0.005 emerged with CT, which carries high risk of t-MN. Evolution of these small clones and their clinical significance warrant further investigation.]]></summary>
        <author>
            <name>Stefania Morganti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence, Dynamics, and Prognostic Role of Clonal Hematopoiesis of Indeterminate Potential in Patients With Breast Cancer]]></title>
        <id>pubmed:38190580</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38190580/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240116195412&amp;v=2.18.0"/>
        <updated>2024-01-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CHIP is frequent in patients with breast cancer. In this study, CT did not lead to emergence of new CHIP, and most patients had low risk of developing t-MN. This finding is reassuring, given long life expectancy of patients with eBC and the association of CHIP with morbidity and mortality. However, TP53-mutant CH with VAF 0.005 emerged with CT, which carries high risk of t-MN. Evolution of these small clones and their clinical significance warrant further investigation.]]></summary>
        <author>
            <name>Stefania Morganti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence, Dynamics, and Prognostic Role of Clonal Hematopoiesis of Indeterminate Potential in Patients With Breast Cancer]]></title>
        <id>pubmed:38190580</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38190580/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240115195351&amp;v=2.18.0"/>
        <updated>2024-01-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CHIP is frequent in patients with breast cancer. In this study, CT did not lead to emergence of new CHIP, and most patients had low risk of developing t-MN. This finding is reassuring, given long life expectancy of patients with eBC and the association of CHIP with morbidity and mortality. However, TP53-mutant CH with VAF 0.005 emerged with CT, which carries high risk of t-MN. Evolution of these small clones and their clinical significance warrant further investigation.]]></summary>
        <author>
            <name>Stefania Morganti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence, Dynamics, and Prognostic Role of Clonal Hematopoiesis of Indeterminate Potential in Patients With Breast Cancer]]></title>
        <id>pubmed:38190580</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38190580/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240114195558&amp;v=2.18.0"/>
        <updated>2024-01-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CHIP is frequent in patients with breast cancer. In this study, CT did not lead to emergence of new CHIP, and most patients had low risk of developing t-MN. This finding is reassuring, given long life expectancy of patients with eBC and the association of CHIP with morbidity and mortality. However, TP53-mutant CH with VAF 0.005 emerged with CT, which carries high risk of t-MN. Evolution of these small clones and their clinical significance warrant further investigation.]]></summary>
        <author>
            <name>Stefania Morganti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence, Dynamics, and Prognostic Role of Clonal Hematopoiesis of Indeterminate Potential in Patients With Breast Cancer]]></title>
        <id>pubmed:38190580</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38190580/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240113195804&amp;v=2.18.0"/>
        <updated>2024-01-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CHIP is frequent in patients with breast cancer. In this study, CT did not lead to emergence of new CHIP, and most patients had low risk of developing t-MN. This finding is reassuring, given long life expectancy of patients with eBC and the association of CHIP with morbidity and mortality. However, TP53-mutant CH with VAF 0.005 emerged with CT, which carries high risk of t-MN. Evolution of these small clones and their clinical significance warrant further investigation.]]></summary>
        <author>
            <name>Stefania Morganti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence, Dynamics, and Prognostic Role of Clonal Hematopoiesis of Indeterminate Potential in Patients With Breast Cancer]]></title>
        <id>pubmed:38190580</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38190580/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240112195322&amp;v=2.18.0"/>
        <updated>2024-01-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CHIP is frequent in patients with breast cancer. In this study, CT did not lead to emergence of new CHIP, and most patients had low risk of developing t-MN. This finding is reassuring, given long life expectancy of patients with eBC and the association of CHIP with morbidity and mortality. However, TP53-mutant CH with VAF 0.005 emerged with CT, which carries high risk of t-MN. Evolution of these small clones and their clinical significance warrant further investigation.]]></summary>
        <author>
            <name>Stefania Morganti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence, Dynamics, and Prognostic Role of Clonal Hematopoiesis of Indeterminate Potential in Patients With Breast Cancer]]></title>
        <id>pubmed:38190580</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38190580/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240111195444&amp;v=2.18.0"/>
        <updated>2024-01-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CHIP is frequent in patients with breast cancer. In this study, CT did not lead to emergence of new CHIP, and most patients had low risk of developing t-MN. This finding is reassuring, given long life expectancy of patients with eBC and the association of CHIP with morbidity and mortality. However, TP53-mutant CH with VAF 0.005 emerged with CT, which carries high risk of t-MN. Evolution of these small clones and their clinical significance warrant further investigation.]]></summary>
        <author>
            <name>Stefania Morganti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence, Dynamics, and Prognostic Role of Clonal Hematopoiesis of Indeterminate Potential in Patients With Breast Cancer]]></title>
        <id>pubmed:38190580</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38190580/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240110195405&amp;v=2.18.0"/>
        <updated>2024-01-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CHIP is frequent in patients with breast cancer. In this study, CT did not lead to emergence of new CHIP, and most patients had low risk of developing t-MN. This finding is reassuring, given long life expectancy of patients with eBC and the association of CHIP with morbidity and mortality. However, TP53-mutant CH with VAF 0.005 emerged with CT, which carries high risk of t-MN. Evolution of these small clones and their clinical significance warrant further investigation.]]></summary>
        <author>
            <name>Stefania Morganti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence, Dynamics, and Prognostic Role of Clonal Hematopoiesis of Indeterminate Potential in Patients With Breast Cancer]]></title>
        <id>pubmed:38190580</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38190580/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240109195408&amp;v=2.18.0"/>
        <updated>2024-01-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CHIP is frequent in patients with breast cancer. In this study, CT did not lead to emergence of new CHIP, and most patients had low risk of developing t-MN. This finding is reassuring, given long life expectancy of patients with eBC and the association of CHIP with morbidity and mortality. However, TP53-mutant CH with VAF 0.005 emerged with CT, which carries high risk of t-MN. Evolution of these small clones and their clinical significance warrant further investigation.]]></summary>
        <author>
            <name>Stefania Morganti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence, Dynamics, and Prognostic Role of Clonal Hematopoiesis of Indeterminate Potential in Patients With Breast Cancer]]></title>
        <id>pubmed:38190580</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38190580/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240108195354&amp;v=2.18.0"/>
        <updated>2024-01-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CHIP is frequent in patients with breast cancer. In this study, CT did not lead to emergence of new CHIP, and most patients had low risk of developing t-MN. This finding is reassuring, given long life expectancy of patients with eBC and the association of CHIP with morbidity and mortality. However, TP53-mutant CH with VAF 0.005 emerged with CT, which carries high risk of t-MN. Evolution of these small clones and their clinical significance warrant further investigation.]]></summary>
        <author>
            <name>Stefania Morganti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence, Dynamics, and Prognostic Role of Clonal Hematopoiesis of Indeterminate Potential in Patients With Breast Cancer]]></title>
        <id>pubmed:38190580</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38190580/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240117195336&amp;v=2.18.0"/>
        <updated>2024-01-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CHIP is frequent in patients with breast cancer. In this study, CT did not lead to emergence of new CHIP, and most patients had low risk of developing t-MN. This finding is reassuring, given long life expectancy of patients with eBC and the association of CHIP with morbidity and mortality. However, TP53-mutant CH with VAF 0.005 emerged with CT, which carries high risk of t-MN. Evolution of these small clones and their clinical significance warrant further investigation.]]></summary>
        <author>
            <name>Stefania Morganti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence, Dynamics, and Prognostic Role of Clonal Hematopoiesis of Indeterminate Potential in Patients With Breast Cancer]]></title>
        <id>pubmed:38190580</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38190580/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240116195412&amp;v=2.18.0"/>
        <updated>2024-01-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CHIP is frequent in patients with breast cancer. In this study, CT did not lead to emergence of new CHIP, and most patients had low risk of developing t-MN. This finding is reassuring, given long life expectancy of patients with eBC and the association of CHIP with morbidity and mortality. However, TP53-mutant CH with VAF 0.005 emerged with CT, which carries high risk of t-MN. Evolution of these small clones and their clinical significance warrant further investigation.]]></summary>
        <author>
            <name>Stefania Morganti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence, Dynamics, and Prognostic Role of Clonal Hematopoiesis of Indeterminate Potential in Patients With Breast Cancer]]></title>
        <id>pubmed:38190580</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38190580/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240115195351&amp;v=2.18.0"/>
        <updated>2024-01-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CHIP is frequent in patients with breast cancer. In this study, CT did not lead to emergence of new CHIP, and most patients had low risk of developing t-MN. This finding is reassuring, given long life expectancy of patients with eBC and the association of CHIP with morbidity and mortality. However, TP53-mutant CH with VAF 0.005 emerged with CT, which carries high risk of t-MN. Evolution of these small clones and their clinical significance warrant further investigation.]]></summary>
        <author>
            <name>Stefania Morganti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence, Dynamics, and Prognostic Role of Clonal Hematopoiesis of Indeterminate Potential in Patients With Breast Cancer]]></title>
        <id>pubmed:38190580</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38190580/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240114195558&amp;v=2.18.0"/>
        <updated>2024-01-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CHIP is frequent in patients with breast cancer. In this study, CT did not lead to emergence of new CHIP, and most patients had low risk of developing t-MN. This finding is reassuring, given long life expectancy of patients with eBC and the association of CHIP with morbidity and mortality. However, TP53-mutant CH with VAF 0.005 emerged with CT, which carries high risk of t-MN. Evolution of these small clones and their clinical significance warrant further investigation.]]></summary>
        <author>
            <name>Stefania Morganti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence, Dynamics, and Prognostic Role of Clonal Hematopoiesis of Indeterminate Potential in Patients With Breast Cancer]]></title>
        <id>pubmed:38190580</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38190580/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240113195804&amp;v=2.18.0"/>
        <updated>2024-01-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CHIP is frequent in patients with breast cancer. In this study, CT did not lead to emergence of new CHIP, and most patients had low risk of developing t-MN. This finding is reassuring, given long life expectancy of patients with eBC and the association of CHIP with morbidity and mortality. However, TP53-mutant CH with VAF 0.005 emerged with CT, which carries high risk of t-MN. Evolution of these small clones and their clinical significance warrant further investigation.]]></summary>
        <author>
            <name>Stefania Morganti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence, Dynamics, and Prognostic Role of Clonal Hematopoiesis of Indeterminate Potential in Patients With Breast Cancer]]></title>
        <id>pubmed:38190580</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38190580/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240112195322&amp;v=2.18.0"/>
        <updated>2024-01-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CHIP is frequent in patients with breast cancer. In this study, CT did not lead to emergence of new CHIP, and most patients had low risk of developing t-MN. This finding is reassuring, given long life expectancy of patients with eBC and the association of CHIP with morbidity and mortality. However, TP53-mutant CH with VAF 0.005 emerged with CT, which carries high risk of t-MN. Evolution of these small clones and their clinical significance warrant further investigation.]]></summary>
        <author>
            <name>Stefania Morganti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence, Dynamics, and Prognostic Role of Clonal Hematopoiesis of Indeterminate Potential in Patients With Breast Cancer]]></title>
        <id>pubmed:38190580</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38190580/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240111195444&amp;v=2.18.0"/>
        <updated>2024-01-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CHIP is frequent in patients with breast cancer. In this study, CT did not lead to emergence of new CHIP, and most patients had low risk of developing t-MN. This finding is reassuring, given long life expectancy of patients with eBC and the association of CHIP with morbidity and mortality. However, TP53-mutant CH with VAF 0.005 emerged with CT, which carries high risk of t-MN. Evolution of these small clones and their clinical significance warrant further investigation.]]></summary>
        <author>
            <name>Stefania Morganti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence, Dynamics, and Prognostic Role of Clonal Hematopoiesis of Indeterminate Potential in Patients With Breast Cancer]]></title>
        <id>pubmed:38190580</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38190580/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240110195405&amp;v=2.18.0"/>
        <updated>2024-01-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CHIP is frequent in patients with breast cancer. In this study, CT did not lead to emergence of new CHIP, and most patients had low risk of developing t-MN. This finding is reassuring, given long life expectancy of patients with eBC and the association of CHIP with morbidity and mortality. However, TP53-mutant CH with VAF 0.005 emerged with CT, which carries high risk of t-MN. Evolution of these small clones and their clinical significance warrant further investigation.]]></summary>
        <author>
            <name>Stefania Morganti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence, Dynamics, and Prognostic Role of Clonal Hematopoiesis of Indeterminate Potential in Patients With Breast Cancer]]></title>
        <id>pubmed:38190580</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38190580/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240109195408&amp;v=2.18.0"/>
        <updated>2024-01-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CHIP is frequent in patients with breast cancer. In this study, CT did not lead to emergence of new CHIP, and most patients had low risk of developing t-MN. This finding is reassuring, given long life expectancy of patients with eBC and the association of CHIP with morbidity and mortality. However, TP53-mutant CH with VAF 0.005 emerged with CT, which carries high risk of t-MN. Evolution of these small clones and their clinical significance warrant further investigation.]]></summary>
        <author>
            <name>Stefania Morganti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence, Dynamics, and Prognostic Role of Clonal Hematopoiesis of Indeterminate Potential in Patients With Breast Cancer]]></title>
        <id>pubmed:38190580</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38190580/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240108195354&amp;v=2.18.0"/>
        <updated>2024-01-08T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CHIP is frequent in patients with breast cancer. In this study, CT did not lead to emergence of new CHIP, and most patients had low risk of developing t-MN. This finding is reassuring, given long life expectancy of patients with eBC and the association of CHIP with morbidity and mortality. However, TP53-mutant CH with VAF 0.005 emerged with CT, which carries high risk of t-MN. Evolution of these small clones and their clinical significance warrant further investigation.]]></summary>
        <author>
            <name>Stefania Morganti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolving perspectives in reverse cardio-oncology: A review of current status, pathophysiological insights, and future directives]]></title>
        <id>pubmed:38184129</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38184129/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240116195412&amp;v=2.18.0"/>
        <updated>2024-01-06T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiovascular disease (CVD) and cancer are leading causes of mortality worldwide, traditionally linked through adverse effects of cancer therapies on cardiovascular health. However, reverse cardio-oncology, a burgeoning field, shifts this perspective to examine how cardiovascular diseases influence the onset and progression of cancer. This novel approach has revealed a higher likelihood of cancer development in patients with pre-existing cardiovascular conditions, attributed to shared risk...]]></summary>
        <author>
            <name>Shahzeb Imran</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolving perspectives in reverse cardio-oncology: A review of current status, pathophysiological insights, and future directives]]></title>
        <id>pubmed:38184129</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38184129/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240115195351&amp;v=2.18.0"/>
        <updated>2024-01-06T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiovascular disease (CVD) and cancer are leading causes of mortality worldwide, traditionally linked through adverse effects of cancer therapies on cardiovascular health. However, reverse cardio-oncology, a burgeoning field, shifts this perspective to examine how cardiovascular diseases influence the onset and progression of cancer. This novel approach has revealed a higher likelihood of cancer development in patients with pre-existing cardiovascular conditions, attributed to shared risk...]]></summary>
        <author>
            <name>Shahzeb Imran</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolving perspectives in reverse cardio-oncology: A review of current status, pathophysiological insights, and future directives]]></title>
        <id>pubmed:38184129</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38184129/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240114195558&amp;v=2.18.0"/>
        <updated>2024-01-06T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiovascular disease (CVD) and cancer are leading causes of mortality worldwide, traditionally linked through adverse effects of cancer therapies on cardiovascular health. However, reverse cardio-oncology, a burgeoning field, shifts this perspective to examine how cardiovascular diseases influence the onset and progression of cancer. This novel approach has revealed a higher likelihood of cancer development in patients with pre-existing cardiovascular conditions, attributed to shared risk...]]></summary>
        <author>
            <name>Shahzeb Imran</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolving perspectives in reverse cardio-oncology: A review of current status, pathophysiological insights, and future directives]]></title>
        <id>pubmed:38184129</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38184129/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240113195804&amp;v=2.18.0"/>
        <updated>2024-01-06T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiovascular disease (CVD) and cancer are leading causes of mortality worldwide, traditionally linked through adverse effects of cancer therapies on cardiovascular health. However, reverse cardio-oncology, a burgeoning field, shifts this perspective to examine how cardiovascular diseases influence the onset and progression of cancer. This novel approach has revealed a higher likelihood of cancer development in patients with pre-existing cardiovascular conditions, attributed to shared risk...]]></summary>
        <author>
            <name>Shahzeb Imran</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolving perspectives in reverse cardio-oncology: A review of current status, pathophysiological insights, and future directives]]></title>
        <id>pubmed:38184129</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38184129/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240112195322&amp;v=2.18.0"/>
        <updated>2024-01-06T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiovascular disease (CVD) and cancer are leading causes of mortality worldwide, traditionally linked through adverse effects of cancer therapies on cardiovascular health. However, reverse cardio-oncology, a burgeoning field, shifts this perspective to examine how cardiovascular diseases influence the onset and progression of cancer. This novel approach has revealed a higher likelihood of cancer development in patients with pre-existing cardiovascular conditions, attributed to shared risk...]]></summary>
        <author>
            <name>Shahzeb Imran</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolving perspectives in reverse cardio-oncology: A review of current status, pathophysiological insights, and future directives]]></title>
        <id>pubmed:38184129</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38184129/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240111195444&amp;v=2.18.0"/>
        <updated>2024-01-06T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiovascular disease (CVD) and cancer are leading causes of mortality worldwide, traditionally linked through adverse effects of cancer therapies on cardiovascular health. However, reverse cardio-oncology, a burgeoning field, shifts this perspective to examine how cardiovascular diseases influence the onset and progression of cancer. This novel approach has revealed a higher likelihood of cancer development in patients with pre-existing cardiovascular conditions, attributed to shared risk...]]></summary>
        <author>
            <name>Shahzeb Imran</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolving perspectives in reverse cardio-oncology: A review of current status, pathophysiological insights, and future directives]]></title>
        <id>pubmed:38184129</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38184129/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240110195405&amp;v=2.18.0"/>
        <updated>2024-01-06T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiovascular disease (CVD) and cancer are leading causes of mortality worldwide, traditionally linked through adverse effects of cancer therapies on cardiovascular health. However, reverse cardio-oncology, a burgeoning field, shifts this perspective to examine how cardiovascular diseases influence the onset and progression of cancer. This novel approach has revealed a higher likelihood of cancer development in patients with pre-existing cardiovascular conditions, attributed to shared risk...]]></summary>
        <author>
            <name>Shahzeb Imran</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolving perspectives in reverse cardio-oncology: A review of current status, pathophysiological insights, and future directives]]></title>
        <id>pubmed:38184129</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38184129/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240109195408&amp;v=2.18.0"/>
        <updated>2024-01-06T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiovascular disease (CVD) and cancer are leading causes of mortality worldwide, traditionally linked through adverse effects of cancer therapies on cardiovascular health. However, reverse cardio-oncology, a burgeoning field, shifts this perspective to examine how cardiovascular diseases influence the onset and progression of cancer. This novel approach has revealed a higher likelihood of cancer development in patients with pre-existing cardiovascular conditions, attributed to shared risk...]]></summary>
        <author>
            <name>Shahzeb Imran</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolving perspectives in reverse cardio-oncology: A review of current status, pathophysiological insights, and future directives]]></title>
        <id>pubmed:38184129</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38184129/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240108195354&amp;v=2.18.0"/>
        <updated>2024-01-06T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiovascular disease (CVD) and cancer are leading causes of mortality worldwide, traditionally linked through adverse effects of cancer therapies on cardiovascular health. However, reverse cardio-oncology, a burgeoning field, shifts this perspective to examine how cardiovascular diseases influence the onset and progression of cancer. This novel approach has revealed a higher likelihood of cancer development in patients with pre-existing cardiovascular conditions, attributed to shared risk...]]></summary>
        <author>
            <name>Shahzeb Imran</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolving Perspectives in Reverse Cardio-Oncology: A Review of Current Status, Pathophysiological Insights, and Future Directives]]></title>
        <id>pubmed:38184129</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38184129/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240107195432&amp;v=2.18.0"/>
        <updated>2024-01-06T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiovascular disease (CVD) and cancer are leading causes of mortality worldwide, traditionally linked through adverse effects of cancer therapies on cardiovascular health. However, reverse cardio-oncology, a burgeoning field, shifts this perspective to examine how cardiovascular diseases influence the onset and progression of cancer. This novel approach has revealed a higher likelihood of cancer development in patients with pre-existing cardiovascular conditions, attributed to shared risk...]]></summary>
        <author>
            <name>Shahzeb Imran</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tumour-based Mutational Profiles Predict Visceral Metastasis Outcome and Early Death in Prostate Cancer Patients]]></title>
        <id>pubmed:38182487</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38182487/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240116195412&amp;v=2.18.0"/>
        <updated>2024-01-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Mutations in the TP53 gene and genes (APC/CTNNB1) related to the Wnt pathway are associated with metastatic visceral dissemination and early death. These genomic alterations could be considered as markers to identify prostate cancer patients at a high risk of life-threatening disease who might benefit from more intensified treatment or new targeted therapies.]]></summary>
        <author>
            <name>Olivier Cussenot</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tumour-based Mutational Profiles Predict Visceral Metastasis Outcome and Early Death in Prostate Cancer Patients]]></title>
        <id>pubmed:38182487</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38182487/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240115195351&amp;v=2.18.0"/>
        <updated>2024-01-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Mutations in the TP53 gene and genes (APC/CTNNB1) related to the Wnt pathway are associated with metastatic visceral dissemination and early death. These genomic alterations could be considered as markers to identify prostate cancer patients at a high risk of life-threatening disease who might benefit from more intensified treatment or new targeted therapies.]]></summary>
        <author>
            <name>Olivier Cussenot</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tumour-based Mutational Profiles Predict Visceral Metastasis Outcome and Early Death in Prostate Cancer Patients]]></title>
        <id>pubmed:38182487</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38182487/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240114195558&amp;v=2.18.0"/>
        <updated>2024-01-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Mutations in the TP53 gene and genes (APC/CTNNB1) related to the Wnt pathway are associated with metastatic visceral dissemination and early death. These genomic alterations could be considered as markers to identify prostate cancer patients at a high risk of life-threatening disease who might benefit from more intensified treatment or new targeted therapies.]]></summary>
        <author>
            <name>Olivier Cussenot</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tumour-based Mutational Profiles Predict Visceral Metastasis Outcome and Early Death in Prostate Cancer Patients]]></title>
        <id>pubmed:38182487</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38182487/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240113195804&amp;v=2.18.0"/>
        <updated>2024-01-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Mutations in the TP53 gene and genes (APC/CTNNB1) related to the Wnt pathway are associated with metastatic visceral dissemination and early death. These genomic alterations could be considered as markers to identify prostate cancer patients at a high risk of life-threatening disease who might benefit from more intensified treatment or new targeted therapies.]]></summary>
        <author>
            <name>Olivier Cussenot</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tumour-based Mutational Profiles Predict Visceral Metastasis Outcome and Early Death in Prostate Cancer Patients]]></title>
        <id>pubmed:38182487</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38182487/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240112195322&amp;v=2.18.0"/>
        <updated>2024-01-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Mutations in the TP53 gene and genes (APC/CTNNB1) related to the Wnt pathway are associated with metastatic visceral dissemination and early death. These genomic alterations could be considered as markers to identify prostate cancer patients at a high risk of life-threatening disease who might benefit from more intensified treatment or new targeted therapies.]]></summary>
        <author>
            <name>Olivier Cussenot</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tumour-based Mutational Profiles Predict Visceral Metastasis Outcome and Early Death in Prostate Cancer Patients]]></title>
        <id>pubmed:38182487</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38182487/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240111195444&amp;v=2.18.0"/>
        <updated>2024-01-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Mutations in the TP53 gene and genes (APC/CTNNB1) related to the Wnt pathway are associated with metastatic visceral dissemination and early death. These genomic alterations could be considered as markers to identify prostate cancer patients at a high risk of life-threatening disease who might benefit from more intensified treatment or new targeted therapies.]]></summary>
        <author>
            <name>Olivier Cussenot</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tumour-based Mutational Profiles Predict Visceral Metastasis Outcome and Early Death in Prostate Cancer Patients]]></title>
        <id>pubmed:38182487</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38182487/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240110195405&amp;v=2.18.0"/>
        <updated>2024-01-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Mutations in the TP53 gene and genes (APC/CTNNB1) related to the Wnt pathway are associated with metastatic visceral dissemination and early death. These genomic alterations could be considered as markers to identify prostate cancer patients at a high risk of life-threatening disease who might benefit from more intensified treatment or new targeted therapies.]]></summary>
        <author>
            <name>Olivier Cussenot</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tumour-based Mutational Profiles Predict Visceral Metastasis Outcome and Early Death in Prostate Cancer Patients]]></title>
        <id>pubmed:38182487</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38182487/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240109195408&amp;v=2.18.0"/>
        <updated>2024-01-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Mutations in the TP53 gene and genes (APC/CTNNB1) related to the Wnt pathway are associated with metastatic visceral dissemination and early death. These genomic alterations could be considered as markers to identify prostate cancer patients at a high risk of life-threatening disease who might benefit from more intensified treatment or new targeted therapies.]]></summary>
        <author>
            <name>Olivier Cussenot</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tumour-based Mutational Profiles Predict Visceral Metastasis Outcome and Early Death in Prostate Cancer Patients]]></title>
        <id>pubmed:38182487</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38182487/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240108195354&amp;v=2.18.0"/>
        <updated>2024-01-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Mutations in the TP53 gene and genes (APC/CTNNB1) related to the Wnt pathway are associated with metastatic visceral dissemination and early death. These genomic alterations could be considered as markers to identify prostate cancer patients at a high risk of life-threatening disease who might benefit from more intensified treatment or new targeted therapies.]]></summary>
        <author>
            <name>Olivier Cussenot</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tumour-based Mutational Profiles Predict Visceral Metastasis Outcome and Early Death in Prostate Cancer Patients]]></title>
        <id>pubmed:38182487</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38182487/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240107195431&amp;v=2.18.0"/>
        <updated>2024-01-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Mutations in the TP53 gene and genes (APC/CTNNB1) related to the Wnt pathway are associated with metastatic visceral dissemination and early death. These genomic alterations could be considered as markers to identify prostate cancer patients at a high risk of life-threatening disease who might benefit from more intensified treatment or new targeted therapies.]]></summary>
        <author>
            <name>Olivier Cussenot</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tumour-based Mutational Profiles Predict Visceral Metastasis Outcome and Early Death in Prostate Cancer Patients]]></title>
        <id>pubmed:38182487</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38182487/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240106195750&amp;v=2.18.0"/>
        <updated>2024-01-05T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Mutations in the TP53 gene and genes (APC/CTNNB1) related to the Wnt pathway are associated with metastatic visceral dissemination and early death. These genomic alterations could be considered as markers to identify prostate cancer patients at a high risk of life-threatening disease who might benefit from more intensified treatment or new targeted therapies.]]></summary>
        <author>
            <name>Olivier Cussenot</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[B-lymphoblastic leukemia/lymphoma with MYC and BCL2 gene rearrangements shows evidence for clonal evolution and mitotic recombination]]></title>
        <id>pubmed:38175445</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38175445/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240115195351&amp;v=2.18.0"/>
        <updated>2024-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: A clonal evolution model involving multiple chromosomal translocations and mitotic recombination is postulated to account for the karyotype, FISH, and microarray results but leaves unresolved the exact order of the evolutionary changes.]]></summary>
        <author>
            <name>Steven A Schichman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiparameter flow cytometry and ClonoSEQ correlation to evaluate precursor B-lymphoblastic leukemia measurable residual disease]]></title>
        <id>pubmed:38175444</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38175444/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240115195351&amp;v=2.18.0"/>
        <updated>2024-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Measurable residual disease (MRD) detection for precursor B-lymphoblastic leukemia (B-ALL) has become the standard of care. However, the testing methodology has not been standardized. We aim to correlate COG multiparameter flow cytometry (MFC) and ClonoSEQ techniques to assess the test characteristics, to study abnormal immunophenotype for B-ALL MRD, and to observe B-ALL clonal evolution and the impact of blinatumomab therapy on MFC testing. MFC and molecular reports were retrieved from...]]></summary>
        <author>
            <name>Nouran Momen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[B-lymphoblastic leukemia/lymphoma with MYC and BCL2 gene rearrangements shows evidence for clonal evolution and mitotic recombination]]></title>
        <id>pubmed:38175445</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38175445/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240114195558&amp;v=2.18.0"/>
        <updated>2024-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: A clonal evolution model involving multiple chromosomal translocations and mitotic recombination is postulated to account for the karyotype, FISH, and microarray results but leaves unresolved the exact order of the evolutionary changes.]]></summary>
        <author>
            <name>Steven A Schichman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiparameter flow cytometry and ClonoSEQ correlation to evaluate precursor B-lymphoblastic leukemia measurable residual disease]]></title>
        <id>pubmed:38175444</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38175444/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240114195558&amp;v=2.18.0"/>
        <updated>2024-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Measurable residual disease (MRD) detection for precursor B-lymphoblastic leukemia (B-ALL) has become the standard of care. However, the testing methodology has not been standardized. We aim to correlate COG multiparameter flow cytometry (MFC) and ClonoSEQ techniques to assess the test characteristics, to study abnormal immunophenotype for B-ALL MRD, and to observe B-ALL clonal evolution and the impact of blinatumomab therapy on MFC testing. MFC and molecular reports were retrieved from...]]></summary>
        <author>
            <name>Nouran Momen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[B-lymphoblastic leukemia/lymphoma with MYC and BCL2 gene rearrangements shows evidence for clonal evolution and mitotic recombination]]></title>
        <id>pubmed:38175445</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38175445/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240113195804&amp;v=2.18.0"/>
        <updated>2024-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: A clonal evolution model involving multiple chromosomal translocations and mitotic recombination is postulated to account for the karyotype, FISH, and microarray results but leaves unresolved the exact order of the evolutionary changes.]]></summary>
        <author>
            <name>Steven A Schichman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiparameter flow cytometry and ClonoSEQ correlation to evaluate precursor B-lymphoblastic leukemia measurable residual disease]]></title>
        <id>pubmed:38175444</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38175444/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240113195804&amp;v=2.18.0"/>
        <updated>2024-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Measurable residual disease (MRD) detection for precursor B-lymphoblastic leukemia (B-ALL) has become the standard of care. However, the testing methodology has not been standardized. We aim to correlate COG multiparameter flow cytometry (MFC) and ClonoSEQ techniques to assess the test characteristics, to study abnormal immunophenotype for B-ALL MRD, and to observe B-ALL clonal evolution and the impact of blinatumomab therapy on MFC testing. MFC and molecular reports were retrieved from...]]></summary>
        <author>
            <name>Nouran Momen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[B-lymphoblastic leukemia/lymphoma with MYC and BCL2 gene rearrangements shows evidence for clonal evolution and mitotic recombination]]></title>
        <id>pubmed:38175445</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38175445/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240112195322&amp;v=2.18.0"/>
        <updated>2024-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: A clonal evolution model involving multiple chromosomal translocations and mitotic recombination is postulated to account for the karyotype, FISH, and microarray results but leaves unresolved the exact order of the evolutionary changes.]]></summary>
        <author>
            <name>Steven A Schichman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiparameter flow cytometry and ClonoSEQ correlation to evaluate precursor B-lymphoblastic leukemia measurable residual disease]]></title>
        <id>pubmed:38175444</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38175444/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240112195322&amp;v=2.18.0"/>
        <updated>2024-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Measurable residual disease (MRD) detection for precursor B-lymphoblastic leukemia (B-ALL) has become the standard of care. However, the testing methodology has not been standardized. We aim to correlate COG multiparameter flow cytometry (MFC) and ClonoSEQ techniques to assess the test characteristics, to study abnormal immunophenotype for B-ALL MRD, and to observe B-ALL clonal evolution and the impact of blinatumomab therapy on MFC testing. MFC and molecular reports were retrieved from...]]></summary>
        <author>
            <name>Nouran Momen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[B-lymphoblastic leukemia/lymphoma with MYC and BCL2 gene rearrangements shows evidence for clonal evolution and mitotic recombination]]></title>
        <id>pubmed:38175445</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38175445/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240111195444&amp;v=2.18.0"/>
        <updated>2024-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: A clonal evolution model involving multiple chromosomal translocations and mitotic recombination is postulated to account for the karyotype, FISH, and microarray results but leaves unresolved the exact order of the evolutionary changes.]]></summary>
        <author>
            <name>Steven A Schichman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiparameter flow cytometry and ClonoSEQ correlation to evaluate precursor B-lymphoblastic leukemia measurable residual disease]]></title>
        <id>pubmed:38175444</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38175444/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240111195444&amp;v=2.18.0"/>
        <updated>2024-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Measurable residual disease (MRD) detection for precursor B-lymphoblastic leukemia (B-ALL) has become the standard of care. However, the testing methodology has not been standardized. We aim to correlate COG multiparameter flow cytometry (MFC) and ClonoSEQ techniques to assess the test characteristics, to study abnormal immunophenotype for B-ALL MRD, and to observe B-ALL clonal evolution and the impact of blinatumomab therapy on MFC testing. MFC and molecular reports were retrieved from...]]></summary>
        <author>
            <name>Nouran Momen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[B-lymphoblastic leukemia/lymphoma with MYC and BCL2 gene rearrangements shows evidence for clonal evolution and mitotic recombination]]></title>
        <id>pubmed:38175445</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38175445/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240110195405&amp;v=2.18.0"/>
        <updated>2024-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: A clonal evolution model involving multiple chromosomal translocations and mitotic recombination is postulated to account for the karyotype, FISH, and microarray results but leaves unresolved the exact order of the evolutionary changes.]]></summary>
        <author>
            <name>Steven A Schichman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiparameter flow cytometry and ClonoSEQ correlation to evaluate precursor B-lymphoblastic leukemia measurable residual disease]]></title>
        <id>pubmed:38175444</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38175444/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240110195405&amp;v=2.18.0"/>
        <updated>2024-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Measurable residual disease (MRD) detection for precursor B-lymphoblastic leukemia (B-ALL) has become the standard of care. However, the testing methodology has not been standardized. We aim to correlate COG multiparameter flow cytometry (MFC) and ClonoSEQ techniques to assess the test characteristics, to study abnormal immunophenotype for B-ALL MRD, and to observe B-ALL clonal evolution and the impact of blinatumomab therapy on MFC testing. MFC and molecular reports were retrieved from...]]></summary>
        <author>
            <name>Nouran Momen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[B-lymphoblastic leukemia/lymphoma with MYC and BCL2 gene rearrangements shows evidence for clonal evolution and mitotic recombination]]></title>
        <id>pubmed:38175445</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38175445/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240109195408&amp;v=2.18.0"/>
        <updated>2024-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: A clonal evolution model involving multiple chromosomal translocations and mitotic recombination is postulated to account for the karyotype, FISH, and microarray results but leaves unresolved the exact order of the evolutionary changes.]]></summary>
        <author>
            <name>Steven A Schichman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiparameter flow cytometry and ClonoSEQ correlation to evaluate precursor B-lymphoblastic leukemia measurable residual disease]]></title>
        <id>pubmed:38175444</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38175444/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240109195408&amp;v=2.18.0"/>
        <updated>2024-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Measurable residual disease (MRD) detection for precursor B-lymphoblastic leukemia (B-ALL) has become the standard of care. However, the testing methodology has not been standardized. We aim to correlate COG multiparameter flow cytometry (MFC) and ClonoSEQ techniques to assess the test characteristics, to study abnormal immunophenotype for B-ALL MRD, and to observe B-ALL clonal evolution and the impact of blinatumomab therapy on MFC testing. MFC and molecular reports were retrieved from...]]></summary>
        <author>
            <name>Nouran Momen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[B-lymphoblastic leukemia/lymphoma with MYC and BCL2 gene rearrangements shows evidence for clonal evolution and mitotic recombination]]></title>
        <id>pubmed:38175445</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38175445/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240108195354&amp;v=2.18.0"/>
        <updated>2024-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: A clonal evolution model involving multiple chromosomal translocations and mitotic recombination is postulated to account for the karyotype, FISH, and microarray results but leaves unresolved the exact order of the evolutionary changes.]]></summary>
        <author>
            <name>Steven A Schichman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiparameter flow cytometry and ClonoSEQ correlation to evaluate precursor B-lymphoblastic leukemia measurable residual disease]]></title>
        <id>pubmed:38175444</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38175444/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240108195354&amp;v=2.18.0"/>
        <updated>2024-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Measurable residual disease (MRD) detection for precursor B-lymphoblastic leukemia (B-ALL) has become the standard of care. However, the testing methodology has not been standardized. We aim to correlate COG multiparameter flow cytometry (MFC) and ClonoSEQ techniques to assess the test characteristics, to study abnormal immunophenotype for B-ALL MRD, and to observe B-ALL clonal evolution and the impact of blinatumomab therapy on MFC testing. MFC and molecular reports were retrieved from...]]></summary>
        <author>
            <name>Nouran Momen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[B-lymphoblastic leukemia/lymphoma with MYC and BCL2 gene rearrangements shows evidence for clonal evolution and mitotic recombination]]></title>
        <id>pubmed:38175445</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38175445/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240107195431&amp;v=2.18.0"/>
        <updated>2024-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: A clonal evolution model involving multiple chromosomal translocations and mitotic recombination is postulated to account for the karyotype, FISH, and microarray results but leaves unresolved the exact order of the evolutionary changes.]]></summary>
        <author>
            <name>Steven A Schichman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiparameter flow cytometry and ClonoSEQ correlation to evaluate precursor B-lymphoblastic leukemia measurable residual disease]]></title>
        <id>pubmed:38175444</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38175444/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240107195431&amp;v=2.18.0"/>
        <updated>2024-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Measurable residual disease (MRD) detection for precursor B-lymphoblastic leukemia (B-ALL) has become the standard of care. However, the testing methodology has not been standardized. We aim to correlate COG multiparameter flow cytometry (MFC) and ClonoSEQ techniques to assess the test characteristics, to study abnormal immunophenotype for B-ALL MRD, and to observe B-ALL clonal evolution and the impact of blinatumomab therapy on MFC testing. MFC and molecular reports were retrieved from...]]></summary>
        <author>
            <name>Nouran Momen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[B-lymphoblastic leukemia/lymphoma with MYC and BCL2 gene rearrangements shows evidence for clonal evolution and mitotic recombination]]></title>
        <id>pubmed:38175445</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38175445/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240106195750&amp;v=2.18.0"/>
        <updated>2024-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: A clonal evolution model involving multiple chromosomal translocations and mitotic recombination is postulated to account for the karyotype, FISH, and microarray results but leaves unresolved the exact order of the evolutionary changes.]]></summary>
        <author>
            <name>Steven A Schichman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiparameter flow cytometry and ClonoSEQ correlation to evaluate precursor B-lymphoblastic leukemia measurable residual disease]]></title>
        <id>pubmed:38175444</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38175444/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240106195750&amp;v=2.18.0"/>
        <updated>2024-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Measurable residual disease (MRD) detection for precursor B-lymphoblastic leukemia (B-ALL) has become the standard of care. However, the testing methodology has not been standardized. We aim to correlate COG multiparameter flow cytometry (MFC) and ClonoSEQ techniques to assess the test characteristics, to study abnormal immunophenotype for B-ALL MRD, and to observe B-ALL clonal evolution and the impact of blinatumomab therapy on MFC testing. MFC and molecular reports were retrieved from...]]></summary>
        <author>
            <name>Nouran Momen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[B-lymphoblastic leukemia/lymphoma with MYC and BCL2 gene rearrangements shows evidence for clonal evolution and mitotic recombination]]></title>
        <id>pubmed:38175445</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38175445/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240105195208&amp;v=2.18.0"/>
        <updated>2024-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: A clonal evolution model involving multiple chromosomal translocations and mitotic recombination is postulated to account for the karyotype, FISH, and microarray results but leaves unresolved the exact order of the evolutionary changes.]]></summary>
        <author>
            <name>Steven A Schichman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Multiparameter flow cytometry and ClonoSEQ correlation to evaluate precursor B-lymphoblastic leukemia measurable residual disease]]></title>
        <id>pubmed:38175444</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38175444/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240105195208&amp;v=2.18.0"/>
        <updated>2024-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Measurable residual disease (MRD) detection for precursor B-lymphoblastic leukemia (B-ALL) has become the standard of care. However, the testing methodology has not been standardized. We aim to correlate COG multiparameter flow cytometry (MFC) and ClonoSEQ techniques to assess the test characteristics, to study abnormal immunophenotype for B-ALL MRD, and to observe B-ALL clonal evolution and the impact of blinatumomab therapy on MFC testing. MFC and molecular reports were retrieved from...]]></summary>
        <author>
            <name>Nouran Momen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[B-lymphoblastic leukemia/lymphoma with MYC and BCL2 gene rearrangements shows evidence for clonal evolution and mitotic recombination]]></title>
        <id>pubmed:38175445</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38175445/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240104195307&amp;v=2.18.0"/>
        <updated>2024-01-04T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: A clonal evolution model involving multiple chromosomal translocations and mitotic recombination is postulated to account for the karyotype, FISH, and microarray results but leaves unresolved the exact order of the evolutionary changes.]]></summary>
        <author>
            <name>Steven A Schichman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Radon Exposure, Clonal Hematopoiesis, and Stroke Susceptibility in the Women's Health Initiative]]></title>
        <id>pubmed:38170948</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38170948/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240116195412&amp;v=2.18.0"/>
        <updated>2024-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND AND OBJECTIVES: Studies suggest that clonal hematopoiesis of indeterminate potential (CHIP) may increase risk of hematologic malignancy and cardiovascular disease, including stroke. However, few studies have investigated plausible environmental risk factors for CHIP such as radon, despite the climate-related increases in and documented infrequency of testing for this common indoor air pollutant.The purpose of this study was to estimate the risk of CHIP related to radon, an established...]]></summary>
        <author>
            <name>Kurtis M Anthony</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Radon Exposure, Clonal Hematopoiesis, and Stroke Susceptibility in the Women's Health Initiative]]></title>
        <id>pubmed:38170948</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38170948/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240115195351&amp;v=2.18.0"/>
        <updated>2024-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND AND OBJECTIVES: Studies suggest that clonal hematopoiesis of indeterminate potential (CHIP) may increase risk of hematologic malignancy and cardiovascular disease, including stroke. However, few studies have investigated plausible environmental risk factors for CHIP such as radon, despite the climate-related increases in and documented infrequency of testing for this common indoor air pollutant.The purpose of this study was to estimate the risk of CHIP related to radon, an established...]]></summary>
        <author>
            <name>Kurtis M Anthony</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lower-Risk Myelodysplastic Syndrome (MDS) Patients Exhibit Diminished Proteasome Proteolytic Activity and High Intracellular Reactive Oxygen Species (ROS) Levels]]></title>
        <id>pubmed:38169896</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38169896/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240115195351&amp;v=2.18.0"/>
        <updated>2024-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) constitute a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis and an elevated risk of transformation to acute myeloid leukemia (AML). Available disease-modifying treatment approaches are limited. The ineffectiveness of proteasome inhibitors (PIs) in MDS patients is currently investigated, although it is unclear whether they rapidly develop resistance to PIs or whether proteasome proteolytic activity (PPA)...]]></summary>
        <author>
            <name>Kalliopi Zafeiropoulou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Identification of Clonal Hematopoiesis Driver Mutations through In Silico Saturation Mutagenesis]]></title>
        <id>pubmed:38168256</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38168256/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240115195351&amp;v=2.18.0"/>
        <updated>2024-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is a phenomenon of clonal expansion of hematopoietic stem cells driven by somatic mutations affecting certain genes. Recently, CH has been linked to the development of a number of hematologic malignancies, cardiovascular diseases and other conditions. Although the most frequently mutated CH driver genes have been identified, a systematic landscape of the mutations capable of initiating this phenomenon is still lacking. Here, we train high-quality machine-learning models...]]></summary>
        <author>
            <name>Santiago Demajo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Radon Exposure, Clonal Hematopoiesis, and Stroke Susceptibility in the Women's Health Initiative]]></title>
        <id>pubmed:38170948</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38170948/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240114195558&amp;v=2.18.0"/>
        <updated>2024-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND AND OBJECTIVES: Studies suggest that clonal hematopoiesis of indeterminate potential (CHIP) may increase risk of hematologic malignancy and cardiovascular disease, including stroke. However, few studies have investigated plausible environmental risk factors for CHIP such as radon, despite the climate-related increases in and documented infrequency of testing for this common indoor air pollutant.The purpose of this study was to estimate the risk of CHIP related to radon, an established...]]></summary>
        <author>
            <name>Kurtis M Anthony</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lower-Risk Myelodysplastic Syndrome (MDS) Patients Exhibit Diminished Proteasome Proteolytic Activity and High Intracellular Reactive Oxygen Species (ROS) Levels]]></title>
        <id>pubmed:38169896</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38169896/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240114195558&amp;v=2.18.0"/>
        <updated>2024-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) constitute a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis and an elevated risk of transformation to acute myeloid leukemia (AML). Available disease-modifying treatment approaches are limited. The ineffectiveness of proteasome inhibitors (PIs) in MDS patients is currently investigated, although it is unclear whether they rapidly develop resistance to PIs or whether proteasome proteolytic activity (PPA)...]]></summary>
        <author>
            <name>Kalliopi Zafeiropoulou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Identification of Clonal Hematopoiesis Driver Mutations through In Silico Saturation Mutagenesis]]></title>
        <id>pubmed:38168256</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38168256/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240114195558&amp;v=2.18.0"/>
        <updated>2024-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is a phenomenon of clonal expansion of hematopoietic stem cells driven by somatic mutations affecting certain genes. Recently, CH has been linked to the development of a number of hematologic malignancies, cardiovascular diseases and other conditions. Although the most frequently mutated CH driver genes have been identified, a systematic landscape of the mutations capable of initiating this phenomenon is still lacking. Here, we train high-quality machine-learning models...]]></summary>
        <author>
            <name>Santiago Demajo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Radon Exposure, Clonal Hematopoiesis, and Stroke Susceptibility in the Women's Health Initiative]]></title>
        <id>pubmed:38170948</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38170948/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240113195804&amp;v=2.18.0"/>
        <updated>2024-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND AND OBJECTIVES: Studies suggest that clonal hematopoiesis of indeterminate potential (CHIP) may increase risk of hematologic malignancy and cardiovascular disease, including stroke. However, few studies have investigated plausible environmental risk factors for CHIP such as radon, despite the climate-related increases in and documented infrequency of testing for this common indoor air pollutant.The purpose of this study was to estimate the risk of CHIP related to radon, an established...]]></summary>
        <author>
            <name>Kurtis M Anthony</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lower-Risk Myelodysplastic Syndrome (MDS) Patients Exhibit Diminished Proteasome Proteolytic Activity and High Intracellular Reactive Oxygen Species (ROS) Levels]]></title>
        <id>pubmed:38169896</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38169896/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240113195804&amp;v=2.18.0"/>
        <updated>2024-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) constitute a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis and an elevated risk of transformation to acute myeloid leukemia (AML). Available disease-modifying treatment approaches are limited. The ineffectiveness of proteasome inhibitors (PIs) in MDS patients is currently investigated, although it is unclear whether they rapidly develop resistance to PIs or whether proteasome proteolytic activity (PPA)...]]></summary>
        <author>
            <name>Kalliopi Zafeiropoulou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Identification of Clonal Hematopoiesis Driver Mutations through In Silico Saturation Mutagenesis]]></title>
        <id>pubmed:38168256</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38168256/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240113195804&amp;v=2.18.0"/>
        <updated>2024-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is a phenomenon of clonal expansion of hematopoietic stem cells driven by somatic mutations affecting certain genes. Recently, CH has been linked to the development of a number of hematologic malignancies, cardiovascular diseases and other conditions. Although the most frequently mutated CH driver genes have been identified, a systematic landscape of the mutations capable of initiating this phenomenon is still lacking. Here, we train high-quality machine-learning models...]]></summary>
        <author>
            <name>Santiago Demajo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Radon Exposure, Clonal Hematopoiesis, and Stroke Susceptibility in the Women's Health Initiative]]></title>
        <id>pubmed:38170948</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38170948/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240112195322&amp;v=2.18.0"/>
        <updated>2024-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND AND OBJECTIVES: Studies suggest that clonal hematopoiesis of indeterminate potential (CHIP) may increase risk of hematologic malignancy and cardiovascular disease, including stroke. However, few studies have investigated plausible environmental risk factors for CHIP such as radon, despite the climate-related increases in and documented infrequency of testing for this common indoor air pollutant.The purpose of this study was to estimate the risk of CHIP related to radon, an established...]]></summary>
        <author>
            <name>Kurtis M Anthony</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lower-Risk Myelodysplastic Syndrome (MDS) Patients Exhibit Diminished Proteasome Proteolytic Activity and High Intracellular Reactive Oxygen Species (ROS) Levels]]></title>
        <id>pubmed:38169896</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38169896/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240112195322&amp;v=2.18.0"/>
        <updated>2024-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) constitute a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis and an elevated risk of transformation to acute myeloid leukemia (AML). Available disease-modifying treatment approaches are limited. The ineffectiveness of proteasome inhibitors (PIs) in MDS patients is currently investigated, although it is unclear whether they rapidly develop resistance to PIs or whether proteasome proteolytic activity (PPA)...]]></summary>
        <author>
            <name>Kalliopi Zafeiropoulou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Identification of Clonal Hematopoiesis Driver Mutations through In Silico Saturation Mutagenesis]]></title>
        <id>pubmed:38168256</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38168256/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240112195322&amp;v=2.18.0"/>
        <updated>2024-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is a phenomenon of clonal expansion of hematopoietic stem cells driven by somatic mutations affecting certain genes. Recently, CH has been linked to the development of a number of hematologic malignancies, cardiovascular diseases and other conditions. Although the most frequently mutated CH driver genes have been identified, a systematic landscape of the mutations capable of initiating this phenomenon is still lacking. Here, we train high-quality machine-learning models...]]></summary>
        <author>
            <name>Santiago Demajo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Radon Exposure, Clonal Hematopoiesis, and Stroke Susceptibility in the Women's Health Initiative]]></title>
        <id>pubmed:38170948</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38170948/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240111195444&amp;v=2.18.0"/>
        <updated>2024-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND AND OBJECTIVES: Studies suggest that clonal hematopoiesis of indeterminate potential (CHIP) may increase risk of hematologic malignancy and cardiovascular disease, including stroke. However, few studies have investigated plausible environmental risk factors for CHIP such as radon, despite the climate-related increases in and documented infrequency of testing for this common indoor air pollutant.The purpose of this study was to estimate the risk of CHIP related to radon, an established...]]></summary>
        <author>
            <name>Kurtis M Anthony</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lower-Risk Myelodysplastic Syndrome (MDS) Patients Exhibit Diminished Proteasome Proteolytic Activity and High Intracellular Reactive Oxygen Species (ROS) Levels]]></title>
        <id>pubmed:38169896</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38169896/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240111195444&amp;v=2.18.0"/>
        <updated>2024-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) constitute a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis and an elevated risk of transformation to acute myeloid leukemia (AML). Available disease-modifying treatment approaches are limited. The ineffectiveness of proteasome inhibitors (PIs) in MDS patients is currently investigated, although it is unclear whether they rapidly develop resistance to PIs or whether proteasome proteolytic activity (PPA)...]]></summary>
        <author>
            <name>Kalliopi Zafeiropoulou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Identification of Clonal Hematopoiesis Driver Mutations through In Silico Saturation Mutagenesis]]></title>
        <id>pubmed:38168256</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38168256/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240111195444&amp;v=2.18.0"/>
        <updated>2024-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is a phenomenon of clonal expansion of hematopoietic stem cells driven by somatic mutations affecting certain genes. Recently, CH has been linked to the development of a number of hematologic malignancies, cardiovascular diseases and other conditions. Although the most frequently mutated CH driver genes have been identified, a systematic landscape of the mutations capable of initiating this phenomenon is still lacking. Here, we train high-quality machine-learning models...]]></summary>
        <author>
            <name>Santiago Demajo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Radon Exposure, Clonal Hematopoiesis, and Stroke Susceptibility in the Women's Health Initiative]]></title>
        <id>pubmed:38170948</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38170948/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240110195405&amp;v=2.18.0"/>
        <updated>2024-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND AND OBJECTIVES: Studies suggest that clonal hematopoiesis of indeterminate potential (CHIP) may increase risk of hematologic malignancy and cardiovascular disease, including stroke. However, few studies have investigated plausible environmental risk factors for CHIP such as radon, despite the climate-related increases in and documented infrequency of testing for this common indoor air pollutant.The purpose of this study was to estimate the risk of CHIP related to radon, an established...]]></summary>
        <author>
            <name>Kurtis M Anthony</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lower-Risk Myelodysplastic Syndrome (MDS) Patients Exhibit Diminished Proteasome Proteolytic Activity and High Intracellular Reactive Oxygen Species (ROS) Levels]]></title>
        <id>pubmed:38169896</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38169896/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240110195405&amp;v=2.18.0"/>
        <updated>2024-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) constitute a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis and an elevated risk of transformation to acute myeloid leukemia (AML). Available disease-modifying treatment approaches are limited. The ineffectiveness of proteasome inhibitors (PIs) in MDS patients is currently investigated, although it is unclear whether they rapidly develop resistance to PIs or whether proteasome proteolytic activity (PPA)...]]></summary>
        <author>
            <name>Kalliopi Zafeiropoulou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Identification of Clonal Hematopoiesis Driver Mutations through In Silico Saturation Mutagenesis]]></title>
        <id>pubmed:38168256</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38168256/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240110195405&amp;v=2.18.0"/>
        <updated>2024-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is a phenomenon of clonal expansion of hematopoietic stem cells driven by somatic mutations affecting certain genes. Recently, CH has been linked to the development of a number of hematologic malignancies, cardiovascular diseases and other conditions. Although the most frequently mutated CH driver genes have been identified, a systematic landscape of the mutations capable of initiating this phenomenon is still lacking. Here, we train high-quality machine-learning models...]]></summary>
        <author>
            <name>Santiago Demajo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Radon Exposure, Clonal Hematopoiesis, and Stroke Susceptibility in the Women's Health Initiative]]></title>
        <id>pubmed:38170948</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38170948/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240109195408&amp;v=2.18.0"/>
        <updated>2024-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND AND OBJECTIVES: Studies suggest that clonal hematopoiesis of indeterminate potential (CHIP) may increase risk of hematologic malignancy and cardiovascular disease, including stroke. However, few studies have investigated plausible environmental risk factors for CHIP such as radon, despite the climate-related increases in and documented infrequency of testing for this common indoor air pollutant.The purpose of this study was to estimate the risk of CHIP related to radon, an established...]]></summary>
        <author>
            <name>Kurtis M Anthony</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lower-Risk Myelodysplastic Syndrome (MDS) Patients Exhibit Diminished Proteasome Proteolytic Activity and High Intracellular Reactive Oxygen Species (ROS) Levels]]></title>
        <id>pubmed:38169896</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38169896/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240109195408&amp;v=2.18.0"/>
        <updated>2024-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) constitute a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis and an elevated risk of transformation to acute myeloid leukemia (AML). Available disease-modifying treatment approaches are limited. The ineffectiveness of proteasome inhibitors (PIs) in MDS patients is currently investigated, although it is unclear whether they rapidly develop resistance to PIs or whether proteasome proteolytic activity (PPA)...]]></summary>
        <author>
            <name>Kalliopi Zafeiropoulou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Identification of Clonal Hematopoiesis Driver Mutations through In Silico Saturation Mutagenesis]]></title>
        <id>pubmed:38168256</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38168256/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240109195408&amp;v=2.18.0"/>
        <updated>2024-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is a phenomenon of clonal expansion of hematopoietic stem cells driven by somatic mutations affecting certain genes. Recently, CH has been linked to the development of a number of hematologic malignancies, cardiovascular diseases and other conditions. Although the most frequently mutated CH driver genes have been identified, a systematic landscape of the mutations capable of initiating this phenomenon is still lacking. Here, we train high-quality machine-learning models...]]></summary>
        <author>
            <name>Santiago Demajo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Radon Exposure, Clonal Hematopoiesis, and Stroke Susceptibility in the Women's Health Initiative]]></title>
        <id>pubmed:38170948</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38170948/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240108195354&amp;v=2.18.0"/>
        <updated>2024-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND AND OBJECTIVES: Studies suggest that clonal hematopoiesis of indeterminate potential (CHIP) may increase risk of hematologic malignancy and cardiovascular disease, including stroke. However, few studies have investigated plausible environmental risk factors for CHIP such as radon, despite the climate-related increases in and documented infrequency of testing for this common indoor air pollutant.The purpose of this study was to estimate the risk of CHIP related to radon, an established...]]></summary>
        <author>
            <name>Kurtis M Anthony</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lower-Risk Myelodysplastic Syndrome (MDS) Patients Exhibit Diminished Proteasome Proteolytic Activity and High Intracellular Reactive Oxygen Species (ROS) Levels]]></title>
        <id>pubmed:38169896</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38169896/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240108195354&amp;v=2.18.0"/>
        <updated>2024-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) constitute a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis and an elevated risk of transformation to acute myeloid leukemia (AML). Available disease-modifying treatment approaches are limited. The ineffectiveness of proteasome inhibitors (PIs) in MDS patients is currently investigated, although it is unclear whether they rapidly develop resistance to PIs or whether proteasome proteolytic activity (PPA)...]]></summary>
        <author>
            <name>Kalliopi Zafeiropoulou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Identification of Clonal Hematopoiesis Driver Mutations through In Silico Saturation Mutagenesis]]></title>
        <id>pubmed:38168256</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38168256/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240108195354&amp;v=2.18.0"/>
        <updated>2024-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is a phenomenon of clonal expansion of hematopoietic stem cells driven by somatic mutations affecting certain genes. Recently, CH has been linked to the development of a number of hematologic malignancies, cardiovascular diseases and other conditions. Although the most frequently mutated CH driver genes have been identified, a systematic landscape of the mutations capable of initiating this phenomenon is still lacking. Here, we train high-quality machine-learning models...]]></summary>
        <author>
            <name>Santiago Demajo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Radon Exposure, Clonal Hematopoiesis, and Stroke Susceptibility in the Women's Health Initiative]]></title>
        <id>pubmed:38170948</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38170948/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240107195432&amp;v=2.18.0"/>
        <updated>2024-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND AND OBJECTIVES: Studies suggest that clonal hematopoiesis of indeterminate potential (CHIP) may increase risk of hematologic malignancy and cardiovascular disease, including stroke. However, few studies have investigated plausible environmental risk factors for CHIP such as radon, despite the climate-related increases in and documented infrequency of testing for this common indoor air pollutant.The purpose of this study was to estimate the risk of CHIP related to radon, an established...]]></summary>
        <author>
            <name>Kurtis M Anthony</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lower-Risk Myelodysplastic Syndrome (MDS) Patients Exhibit Diminished Proteasome Proteolytic Activity and High Intracellular Reactive Oxygen Species (ROS) Levels]]></title>
        <id>pubmed:38169896</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38169896/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240107195432&amp;v=2.18.0"/>
        <updated>2024-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) constitute a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis and an elevated risk of transformation to acute myeloid leukemia (AML). Available disease-modifying treatment approaches are limited. The ineffectiveness of proteasome inhibitors (PIs) in MDS patients is currently investigated, although it is unclear whether they rapidly develop resistance to PIs or whether proteasome proteolytic activity (PPA)...]]></summary>
        <author>
            <name>Kalliopi Zafeiropoulou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Identification of Clonal Hematopoiesis Driver Mutations through In Silico Saturation Mutagenesis]]></title>
        <id>pubmed:38168256</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38168256/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240107195432&amp;v=2.18.0"/>
        <updated>2024-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is a phenomenon of clonal expansion of hematopoietic stem cells driven by somatic mutations affecting certain genes. Recently, CH has been linked to the development of a number of hematologic malignancies, cardiovascular diseases and other conditions. Although the most frequently mutated CH driver genes have been identified, a systematic landscape of the mutations capable of initiating this phenomenon is still lacking. Here, we train high-quality machine-learning models...]]></summary>
        <author>
            <name>Santiago Demajo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Radon Exposure, Clonal Hematopoiesis, and Stroke Susceptibility in the Women's Health Initiative]]></title>
        <id>pubmed:38170948</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38170948/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240106195750&amp;v=2.18.0"/>
        <updated>2024-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND AND OBJECTIVES: Studies suggest that clonal hematopoiesis of indeterminate potential (CHIP) may increase risk of hematologic malignancy and cardiovascular disease, including stroke. However, few studies have investigated plausible environmental risk factors for CHIP such as radon, despite the climate-related increases in and documented infrequency of testing for this common indoor air pollutant.The purpose of this study was to estimate the risk of CHIP related to radon, an established...]]></summary>
        <author>
            <name>Kurtis M Anthony</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lower-Risk Myelodysplastic Syndrome (MDS) Patients Exhibit Diminished Proteasome Proteolytic Activity and High Intracellular Reactive Oxygen Species (ROS) Levels]]></title>
        <id>pubmed:38169896</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38169896/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240106195750&amp;v=2.18.0"/>
        <updated>2024-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) constitute a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis and an elevated risk of transformation to acute myeloid leukemia (AML). Available disease-modifying treatment approaches are limited. The ineffectiveness of proteasome inhibitors (PIs) in MDS patients is currently investigated, although it is unclear whether they rapidly develop resistance to PIs or whether proteasome proteolytic activity (PPA)...]]></summary>
        <author>
            <name>Kalliopi Zafeiropoulou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Identification of Clonal Hematopoiesis Driver Mutations through In Silico Saturation Mutagenesis]]></title>
        <id>pubmed:38168256</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38168256/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240106195750&amp;v=2.18.0"/>
        <updated>2024-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is a phenomenon of clonal expansion of hematopoietic stem cells driven by somatic mutations affecting certain genes. Recently, CH has been linked to the development of a number of hematologic malignancies, cardiovascular diseases and other conditions. Although the most frequently mutated CH driver genes have been identified, a systematic landscape of the mutations capable of initiating this phenomenon is still lacking. Here, we train high-quality machine-learning models...]]></summary>
        <author>
            <name>Santiago Demajo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Radon Exposure, Clonal Hematopoiesis, and Stroke Susceptibility in the Women's Health Initiative]]></title>
        <id>pubmed:38170948</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38170948/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240105195208&amp;v=2.18.0"/>
        <updated>2024-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND AND OBJECTIVES: Studies suggest that clonal hematopoiesis of indeterminate potential (CHIP) may increase risk of hematologic malignancy and cardiovascular disease, including stroke. However, few studies have investigated plausible environmental risk factors for CHIP such as radon, despite the climate-related increases in and documented infrequency of testing for this common indoor air pollutant.The purpose of this study was to estimate the risk of CHIP related to radon, an established...]]></summary>
        <author>
            <name>Kurtis M Anthony</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lower-Risk Myelodysplastic Syndrome (MDS) Patients Exhibit Diminished Proteasome Proteolytic Activity and High Intracellular Reactive Oxygen Species (ROS) Levels]]></title>
        <id>pubmed:38169896</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38169896/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240105195208&amp;v=2.18.0"/>
        <updated>2024-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) constitute a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis and an elevated risk of transformation to acute myeloid leukemia (AML). Available disease-modifying treatment approaches are limited. The ineffectiveness of proteasome inhibitors (PIs) in MDS patients is currently investigated, although it is unclear whether they rapidly develop resistance to PIs or whether proteasome proteolytic activity (PPA)...]]></summary>
        <author>
            <name>Kalliopi Zafeiropoulou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Identification of Clonal Hematopoiesis Driver Mutations through In Silico Saturation Mutagenesis]]></title>
        <id>pubmed:38168256</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38168256/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240105195208&amp;v=2.18.0"/>
        <updated>2024-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is a phenomenon of clonal expansion of hematopoietic stem cells driven by somatic mutations affecting certain genes. Recently, CH has been linked to the development of a number of hematologic malignancies, cardiovascular diseases and other conditions. Although the most frequently mutated CH driver genes have been identified, a systematic landscape of the mutations capable of initiating this phenomenon is still lacking. Here, we train high-quality machine-learning models...]]></summary>
        <author>
            <name>Santiago Demajo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Radon Exposure, Clonal Hematopoiesis, and Stroke Susceptibility in the Women's Health Initiative]]></title>
        <id>pubmed:38170948</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38170948/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240104195306&amp;v=2.18.0"/>
        <updated>2024-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND AND OBJECTIVES: Studies suggest that clonal hematopoiesis of indeterminate potential (CHIP) may increase risk of hematologic malignancy and cardiovascular disease, including stroke. However, few studies have investigated plausible environmental risk factors for CHIP such as radon, despite the climate-related increases in and documented infrequency of testing for this common indoor air pollutant.The purpose of this study was to estimate the risk of CHIP related to radon, an established...]]></summary>
        <author>
            <name>Kurtis M Anthony</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Lower-Risk Myelodysplastic Syndrome (MDS) Patients Exhibit Diminished Proteasome Proteolytic Activity and High Intracellular Reactive Oxygen Species (ROS) Levels]]></title>
        <id>pubmed:38169896</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38169896/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240104195306&amp;v=2.18.0"/>
        <updated>2024-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) constitute a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis and an elevated risk of transformation to acute myeloid leukemia (AML). Available disease-modifying treatment approaches are limited. The ineffectiveness of proteasome inhibitors (PIs) in MDS patients is currently investigated, although it is unclear whether they rapidly develop resistance to PIs or whether proteasome proteolytic activity (PPA)...]]></summary>
        <author>
            <name>Kalliopi Zafeiropoulou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Identification of Clonal Hematopoiesis Driver Mutations through In Silico Saturation Mutagenesis]]></title>
        <id>pubmed:38168256</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38168256/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240104195306&amp;v=2.18.0"/>
        <updated>2024-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is a phenomenon of clonal expansion of hematopoietic stem cells driven by somatic mutations affecting certain genes. Recently, CH has been linked to the development of a number of hematologic malignancies, cardiovascular diseases and other conditions. Although the most frequently mutated CH driver genes have been identified, a systematic landscape of the mutations capable of initiating this phenomenon is still lacking. Here, we train high-quality machine-learning models...]]></summary>
        <author>
            <name>Santiago Demajo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The ALT pathway generates telomere fusions that can be detected in the blood of cancer patients]]></title>
        <id>pubmed:38167290</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38167290/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240114195558&amp;v=2.18.0"/>
        <updated>2024-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Telomere fusions (TFs) can trigger the accumulation of oncogenic alterations leading to malignant transformation and drug resistance. Despite their relevance in tumour evolution, our understanding of the patterns and consequences of TFs in human cancers remains limited. Here, we characterize the rates and spectrum of somatic TFs across >30 cancer types using whole-genome sequencing data. TFs are pervasive in human tumours with rates varying markedly across and within cancer types. In addition to...]]></summary>
        <author>
            <name>Francesc Muyas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The ALT pathway generates telomere fusions that can be detected in the blood of cancer patients]]></title>
        <id>pubmed:38167290</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38167290/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240113195804&amp;v=2.18.0"/>
        <updated>2024-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Telomere fusions (TFs) can trigger the accumulation of oncogenic alterations leading to malignant transformation and drug resistance. Despite their relevance in tumour evolution, our understanding of the patterns and consequences of TFs in human cancers remains limited. Here, we characterize the rates and spectrum of somatic TFs across >30 cancer types using whole-genome sequencing data. TFs are pervasive in human tumours with rates varying markedly across and within cancer types. In addition to...]]></summary>
        <author>
            <name>Francesc Muyas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The ALT pathway generates telomere fusions that can be detected in the blood of cancer patients]]></title>
        <id>pubmed:38167290</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38167290/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240112195322&amp;v=2.18.0"/>
        <updated>2024-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Telomere fusions (TFs) can trigger the accumulation of oncogenic alterations leading to malignant transformation and drug resistance. Despite their relevance in tumour evolution, our understanding of the patterns and consequences of TFs in human cancers remains limited. Here, we characterize the rates and spectrum of somatic TFs across >30 cancer types using whole-genome sequencing data. TFs are pervasive in human tumours with rates varying markedly across and within cancer types. In addition to...]]></summary>
        <author>
            <name>Francesc Muyas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The ALT pathway generates telomere fusions that can be detected in the blood of cancer patients]]></title>
        <id>pubmed:38167290</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38167290/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240111195444&amp;v=2.18.0"/>
        <updated>2024-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Telomere fusions (TFs) can trigger the accumulation of oncogenic alterations leading to malignant transformation and drug resistance. Despite their relevance in tumour evolution, our understanding of the patterns and consequences of TFs in human cancers remains limited. Here, we characterize the rates and spectrum of somatic TFs across >30 cancer types using whole-genome sequencing data. TFs are pervasive in human tumours with rates varying markedly across and within cancer types. In addition to...]]></summary>
        <author>
            <name>Francesc Muyas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The ALT pathway generates telomere fusions that can be detected in the blood of cancer patients]]></title>
        <id>pubmed:38167290</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38167290/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240110195405&amp;v=2.18.0"/>
        <updated>2024-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Telomere fusions (TFs) can trigger the accumulation of oncogenic alterations leading to malignant transformation and drug resistance. Despite their relevance in tumour evolution, our understanding of the patterns and consequences of TFs in human cancers remains limited. Here, we characterize the rates and spectrum of somatic TFs across >30 cancer types using whole-genome sequencing data. TFs are pervasive in human tumours with rates varying markedly across and within cancer types. In addition to...]]></summary>
        <author>
            <name>Francesc Muyas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The ALT pathway generates telomere fusions that can be detected in the blood of cancer patients]]></title>
        <id>pubmed:38167290</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38167290/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240109195408&amp;v=2.18.0"/>
        <updated>2024-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Telomere fusions (TFs) can trigger the accumulation of oncogenic alterations leading to malignant transformation and drug resistance. Despite their relevance in tumour evolution, our understanding of the patterns and consequences of TFs in human cancers remains limited. Here, we characterize the rates and spectrum of somatic TFs across >30 cancer types using whole-genome sequencing data. TFs are pervasive in human tumours with rates varying markedly across and within cancer types. In addition to...]]></summary>
        <author>
            <name>Francesc Muyas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The ALT pathway generates telomere fusions that can be detected in the blood of cancer patients]]></title>
        <id>pubmed:38167290</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38167290/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240108195354&amp;v=2.18.0"/>
        <updated>2024-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Telomere fusions (TFs) can trigger the accumulation of oncogenic alterations leading to malignant transformation and drug resistance. Despite their relevance in tumour evolution, our understanding of the patterns and consequences of TFs in human cancers remains limited. Here, we characterize the rates and spectrum of somatic TFs across >30 cancer types using whole-genome sequencing data. TFs are pervasive in human tumours with rates varying markedly across and within cancer types. In addition to...]]></summary>
        <author>
            <name>Francesc Muyas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The ALT pathway generates telomere fusions that can be detected in the blood of cancer patients]]></title>
        <id>pubmed:38167290</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38167290/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240107195431&amp;v=2.18.0"/>
        <updated>2024-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Telomere fusions (TFs) can trigger the accumulation of oncogenic alterations leading to malignant transformation and drug resistance. Despite their relevance in tumour evolution, our understanding of the patterns and consequences of TFs in human cancers remains limited. Here, we characterize the rates and spectrum of somatic TFs across >30 cancer types using whole-genome sequencing data. TFs are pervasive in human tumours with rates varying markedly across and within cancer types. In addition to...]]></summary>
        <author>
            <name>Francesc Muyas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The ALT pathway generates telomere fusions that can be detected in the blood of cancer patients]]></title>
        <id>pubmed:38167290</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38167290/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240106195750&amp;v=2.18.0"/>
        <updated>2024-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Telomere fusions (TFs) can trigger the accumulation of oncogenic alterations leading to malignant transformation and drug resistance. Despite their relevance in tumour evolution, our understanding of the patterns and consequences of TFs in human cancers remains limited. Here, we characterize the rates and spectrum of somatic TFs across >30 cancer types using whole-genome sequencing data. TFs are pervasive in human tumours with rates varying markedly across and within cancer types. In addition to...]]></summary>
        <author>
            <name>Francesc Muyas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The ALT pathway generates telomere fusions that can be detected in the blood of cancer patients]]></title>
        <id>pubmed:38167290</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38167290/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240105195208&amp;v=2.18.0"/>
        <updated>2024-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Telomere fusions (TFs) can trigger the accumulation of oncogenic alterations leading to malignant transformation and drug resistance. Despite their relevance in tumour evolution, our understanding of the patterns and consequences of TFs in human cancers remains limited. Here, we characterize the rates and spectrum of somatic TFs across >30 cancer types using whole-genome sequencing data. TFs are pervasive in human tumours with rates varying markedly across and within cancer types. In addition to...]]></summary>
        <author>
            <name>Francesc Muyas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The ALT pathway generates telomere fusions that can be detected in the blood of cancer patients]]></title>
        <id>pubmed:38167290</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38167290/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240104195307&amp;v=2.18.0"/>
        <updated>2024-01-03T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Telomere fusions (TFs) can trigger the accumulation of oncogenic alterations leading to malignant transformation and drug resistance. Despite their relevance in tumour evolution, our understanding of the patterns and consequences of TFs in human cancers remains limited. Here, we characterize the rates and spectrum of somatic TFs across >30 cancer types using whole-genome sequencing data. TFs are pervasive in human tumours with rates varying markedly across and within cancer types. In addition to...]]></summary>
        <author>
            <name>Francesc Muyas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular and clinical aspects relevant for counseling individuals with clonal hematopoiesis of indeterminate potential]]></title>
        <id>pubmed:38162500</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38162500/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240115195351&amp;v=2.18.0"/>
        <updated>2024-01-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) has fascinated the medical community for some time. Discovered about a decade ago, this phenomenon links age-related alterations in hematopoiesis not only to the later development of hematological malignancies but also to an increased risk of early-onset cardiovascular disease and some other disorders. CHIP is detected in the blood and is characterized by clonally expanded somatic mutations in cancer-associated genes, predisposing to the...]]></summary>
        <author>
            <name>Anna Maria Cacic</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular and clinical aspects relevant for counseling individuals with clonal hematopoiesis of indeterminate potential]]></title>
        <id>pubmed:38162500</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38162500/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240114195558&amp;v=2.18.0"/>
        <updated>2024-01-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) has fascinated the medical community for some time. Discovered about a decade ago, this phenomenon links age-related alterations in hematopoiesis not only to the later development of hematological malignancies but also to an increased risk of early-onset cardiovascular disease and some other disorders. CHIP is detected in the blood and is characterized by clonally expanded somatic mutations in cancer-associated genes, predisposing to the...]]></summary>
        <author>
            <name>Anna Maria Cacic</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular and clinical aspects relevant for counseling individuals with clonal hematopoiesis of indeterminate potential]]></title>
        <id>pubmed:38162500</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38162500/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240113195804&amp;v=2.18.0"/>
        <updated>2024-01-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) has fascinated the medical community for some time. Discovered about a decade ago, this phenomenon links age-related alterations in hematopoiesis not only to the later development of hematological malignancies but also to an increased risk of early-onset cardiovascular disease and some other disorders. CHIP is detected in the blood and is characterized by clonally expanded somatic mutations in cancer-associated genes, predisposing to the...]]></summary>
        <author>
            <name>Anna Maria Cacic</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular and clinical aspects relevant for counseling individuals with clonal hematopoiesis of indeterminate potential]]></title>
        <id>pubmed:38162500</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38162500/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240112195322&amp;v=2.18.0"/>
        <updated>2024-01-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) has fascinated the medical community for some time. Discovered about a decade ago, this phenomenon links age-related alterations in hematopoiesis not only to the later development of hematological malignancies but also to an increased risk of early-onset cardiovascular disease and some other disorders. CHIP is detected in the blood and is characterized by clonally expanded somatic mutations in cancer-associated genes, predisposing to the...]]></summary>
        <author>
            <name>Anna Maria Cacic</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular and clinical aspects relevant for counseling individuals with clonal hematopoiesis of indeterminate potential]]></title>
        <id>pubmed:38162500</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38162500/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240111195444&amp;v=2.18.0"/>
        <updated>2024-01-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) has fascinated the medical community for some time. Discovered about a decade ago, this phenomenon links age-related alterations in hematopoiesis not only to the later development of hematological malignancies but also to an increased risk of early-onset cardiovascular disease and some other disorders. CHIP is detected in the blood and is characterized by clonally expanded somatic mutations in cancer-associated genes, predisposing to the...]]></summary>
        <author>
            <name>Anna Maria Cacic</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular and clinical aspects relevant for counseling individuals with clonal hematopoiesis of indeterminate potential]]></title>
        <id>pubmed:38162500</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38162500/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240110195405&amp;v=2.18.0"/>
        <updated>2024-01-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) has fascinated the medical community for some time. Discovered about a decade ago, this phenomenon links age-related alterations in hematopoiesis not only to the later development of hematological malignancies but also to an increased risk of early-onset cardiovascular disease and some other disorders. CHIP is detected in the blood and is characterized by clonally expanded somatic mutations in cancer-associated genes, predisposing to the...]]></summary>
        <author>
            <name>Anna Maria Cacic</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular and clinical aspects relevant for counseling individuals with clonal hematopoiesis of indeterminate potential]]></title>
        <id>pubmed:38162500</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38162500/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240109195408&amp;v=2.18.0"/>
        <updated>2024-01-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) has fascinated the medical community for some time. Discovered about a decade ago, this phenomenon links age-related alterations in hematopoiesis not only to the later development of hematological malignancies but also to an increased risk of early-onset cardiovascular disease and some other disorders. CHIP is detected in the blood and is characterized by clonally expanded somatic mutations in cancer-associated genes, predisposing to the...]]></summary>
        <author>
            <name>Anna Maria Cacic</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular and clinical aspects relevant for counseling individuals with clonal hematopoiesis of indeterminate potential]]></title>
        <id>pubmed:38162500</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38162500/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240108195354&amp;v=2.18.0"/>
        <updated>2024-01-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) has fascinated the medical community for some time. Discovered about a decade ago, this phenomenon links age-related alterations in hematopoiesis not only to the later development of hematological malignancies but also to an increased risk of early-onset cardiovascular disease and some other disorders. CHIP is detected in the blood and is characterized by clonally expanded somatic mutations in cancer-associated genes, predisposing to the...]]></summary>
        <author>
            <name>Anna Maria Cacic</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular and clinical aspects relevant for counseling individuals with clonal hematopoiesis of indeterminate potential]]></title>
        <id>pubmed:38162500</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38162500/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240107195432&amp;v=2.18.0"/>
        <updated>2024-01-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) has fascinated the medical community for some time. Discovered about a decade ago, this phenomenon links age-related alterations in hematopoiesis not only to the later development of hematological malignancies but also to an increased risk of early-onset cardiovascular disease and some other disorders. CHIP is detected in the blood and is characterized by clonally expanded somatic mutations in cancer-associated genes, predisposing to the...]]></summary>
        <author>
            <name>Anna Maria Cacic</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular and clinical aspects relevant for counseling individuals with clonal hematopoiesis of indeterminate potential]]></title>
        <id>pubmed:38162500</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38162500/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240106195750&amp;v=2.18.0"/>
        <updated>2024-01-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) has fascinated the medical community for some time. Discovered about a decade ago, this phenomenon links age-related alterations in hematopoiesis not only to the later development of hematological malignancies but also to an increased risk of early-onset cardiovascular disease and some other disorders. CHIP is detected in the blood and is characterized by clonally expanded somatic mutations in cancer-associated genes, predisposing to the...]]></summary>
        <author>
            <name>Anna Maria Cacic</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular and clinical aspects relevant for counseling individuals with clonal hematopoiesis of indeterminate potential]]></title>
        <id>pubmed:38162500</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38162500/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240105195208&amp;v=2.18.0"/>
        <updated>2024-01-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) has fascinated the medical community for some time. Discovered about a decade ago, this phenomenon links age-related alterations in hematopoiesis not only to the later development of hematological malignancies but also to an increased risk of early-onset cardiovascular disease and some other disorders. CHIP is detected in the blood and is characterized by clonally expanded somatic mutations in cancer-associated genes, predisposing to the...]]></summary>
        <author>
            <name>Anna Maria Cacic</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular and clinical aspects relevant for counseling individuals with clonal hematopoiesis of indeterminate potential]]></title>
        <id>pubmed:38162500</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38162500/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240104195306&amp;v=2.18.0"/>
        <updated>2024-01-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) has fascinated the medical community for some time. Discovered about a decade ago, this phenomenon links age-related alterations in hematopoiesis not only to the later development of hematological malignancies but also to an increased risk of early-onset cardiovascular disease and some other disorders. CHIP is detected in the blood and is characterized by clonally expanded somatic mutations in cancer-associated genes, predisposing to the...]]></summary>
        <author>
            <name>Anna Maria Cacic</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular and clinical aspects relevant for counseling individuals with clonal hematopoiesis of indeterminate potential]]></title>
        <id>pubmed:38162500</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38162500/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240103195259&amp;v=2.18.0"/>
        <updated>2024-01-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) has fascinated the medical community for some time. Discovered about a decade ago, this phenomenon links age-related alterations in hematopoiesis not only to the later development of hematological malignancies but also to an increased risk of early-onset cardiovascular disease and some other disorders. CHIP is detected in the blood and is characterized by clonally expanded somatic mutations in cancer-associated genes, predisposing to the...]]></summary>
        <author>
            <name>Anna Maria Cacic</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular and clinical aspects relevant for counseling individuals with clonal hematopoiesis of indeterminate potential]]></title>
        <id>pubmed:38162500</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38162500/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240102195247&amp;v=2.18.0"/>
        <updated>2024-01-01T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) has fascinated the medical community for some time. Discovered about a decade ago, this phenomenon links age-related alterations in hematopoiesis not only to the later development of hematological malignancies but also to an increased risk of early-onset cardiovascular disease and some other disorders. CHIP is detected in the blood and is characterized by clonally expanded somatic mutations in cancer-associated genes, predisposing to the...]]></summary>
        <author>
            <name>Anna Maria Cacic</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammation and the pathogenesis of atherosclerosis]]></title>
        <id>pubmed:38157682</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38157682/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240111195444&amp;v=2.18.0"/>
        <updated>2023-12-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The notion that inflammation contributes to atherosclerosis has now gained considerable currency. Inflammation participates in atherosclerosis inception, progression, and thrombotic complications. Induced expression of endothelial leukocyte adhesion molecules and chemoattractant cytokines recruit blood cells to the arterial intima. Lesions can contain virtually every type of leukocyte. Monocytes mature into macrophages and imbibe lipids becoming foam cells, a hallmark of the atherosclerotic...]]></summary>
        <author>
            <name>Peter Libby</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammation and the pathogenesis of atherosclerosis]]></title>
        <id>pubmed:38157682</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38157682/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240110195405&amp;v=2.18.0"/>
        <updated>2023-12-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The notion that inflammation contributes to atherosclerosis has now gained considerable currency. Inflammation participates in atherosclerosis inception, progression, and thrombotic complications. Induced expression of endothelial leukocyte adhesion molecules and chemoattractant cytokines recruit blood cells to the arterial intima. Lesions can contain virtually every type of leukocyte. Monocytes mature into macrophages and imbibe lipids becoming foam cells, a hallmark of the atherosclerotic...]]></summary>
        <author>
            <name>Peter Libby</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammation and the pathogenesis of atherosclerosis]]></title>
        <id>pubmed:38157682</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38157682/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240109195408&amp;v=2.18.0"/>
        <updated>2023-12-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The notion that inflammation contributes to atherosclerosis has now gained considerable currency. Inflammation participates in atherosclerosis inception, progression, and thrombotic complications. Induced expression of endothelial leukocyte adhesion molecules and chemoattractant cytokines recruit blood cells to the arterial intima. Lesions can contain virtually every type of leukocyte. Monocytes mature into macrophages and imbibe lipids becoming foam cells, a hallmark of the atherosclerotic...]]></summary>
        <author>
            <name>Peter Libby</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammation and the pathogenesis of atherosclerosis]]></title>
        <id>pubmed:38157682</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38157682/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240108195354&amp;v=2.18.0"/>
        <updated>2023-12-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The notion that inflammation contributes to atherosclerosis has now gained considerable currency. Inflammation participates in atherosclerosis inception, progression, and thrombotic complications. Induced expression of endothelial leukocyte adhesion molecules and chemoattractant cytokines recruit blood cells to the arterial intima. Lesions can contain virtually every type of leukocyte. Monocytes mature into macrophages and imbibe lipids becoming foam cells, a hallmark of the atherosclerotic...]]></summary>
        <author>
            <name>Peter Libby</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammation and the pathogenesis of atherosclerosis]]></title>
        <id>pubmed:38157682</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38157682/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240107195432&amp;v=2.18.0"/>
        <updated>2023-12-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The notion that inflammation contributes to atherosclerosis has now gained considerable currency. Inflammation participates in atherosclerosis inception, progression, and thrombotic complications. Induced expression of endothelial leukocyte adhesion molecules and chemoattractant cytokines recruit blood cells to the arterial intima. Lesions can contain virtually every type of leukocyte. Monocytes mature into macrophages and imbibe lipids becoming foam cells, a hallmark of the atherosclerotic...]]></summary>
        <author>
            <name>Peter Libby</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammation and the pathogenesis of atherosclerosis]]></title>
        <id>pubmed:38157682</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38157682/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240106195750&amp;v=2.18.0"/>
        <updated>2023-12-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The notion that inflammation contributes to atherosclerosis has now gained considerable currency. Inflammation participates in atherosclerosis inception, progression, and thrombotic complications. Induced expression of endothelial leukocyte adhesion molecules and chemoattractant cytokines recruit blood cells to the arterial intima. Lesions can contain virtually every type of leukocyte. Monocytes mature into macrophages and imbibe lipids becoming foam cells, a hallmark of the atherosclerotic...]]></summary>
        <author>
            <name>Peter Libby</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammation and the pathogenesis of atherosclerosis]]></title>
        <id>pubmed:38157682</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38157682/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240105195208&amp;v=2.18.0"/>
        <updated>2023-12-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The notion that inflammation contributes to atherosclerosis has now gained considerable currency. Inflammation participates in atherosclerosis inception, progression, and thrombotic complications. Induced expression of endothelial leukocyte adhesion molecules and chemoattractant cytokines recruit blood cells to the arterial intima. Lesions can contain virtually every type of leukocyte. Monocytes mature into macrophages and imbibe lipids becoming foam cells, a hallmark of the atherosclerotic...]]></summary>
        <author>
            <name>Peter Libby</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammation and the pathogenesis of atherosclerosis]]></title>
        <id>pubmed:38157682</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38157682/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240104195306&amp;v=2.18.0"/>
        <updated>2023-12-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The notion that inflammation contributes to atherosclerosis has now gained considerable currency. Inflammation participates in atherosclerosis inception, progression, and thrombotic complications. Induced expression of endothelial leukocyte adhesion molecules and chemoattractant cytokines recruit blood cells to the arterial intima. Lesions can contain virtually every type of leukocyte. Monocytes mature into macrophages and imbibe lipids becoming foam cells, a hallmark of the atherosclerotic...]]></summary>
        <author>
            <name>Peter Libby</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammation and the pathogenesis of atherosclerosis]]></title>
        <id>pubmed:38157682</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38157682/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240103195259&amp;v=2.18.0"/>
        <updated>2023-12-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The notion that inflammation contributes to atherosclerosis has now gained considerable currency. Inflammation participates in atherosclerosis inception, progression, and thrombotic complications. Induced expression of endothelial leukocyte adhesion molecules and chemoattractant cytokines recruit blood cells to the arterial intima. Lesions can contain virtually every type of leukocyte. Monocytes mature into macrophages and imbibe lipids becoming foam cells, a hallmark of the atherosclerotic...]]></summary>
        <author>
            <name>Peter Libby</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammation and the pathogenesis of atherosclerosis]]></title>
        <id>pubmed:38157682</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38157682/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240102195247&amp;v=2.18.0"/>
        <updated>2023-12-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The notion that inflammation contributes to atherosclerosis has now gained considerable currency. Inflammation participates in atherosclerosis inception, progression, and thrombotic complications. Induced expression of endothelial leukocyte adhesion molecules and chemoattractant cytokines recruit blood cells to the arterial intima. Lesions can contain virtually every type of leukocyte. Monocytes mature into macrophages and imbibe lipids becoming foam cells, a hallmark of the atherosclerotic...]]></summary>
        <author>
            <name>Peter Libby</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Relapses in early-stage follicular lymphoma frequently develop via a divergent evolution from their clonally related precursor cells]]></title>
        <id>pubmed:38156368</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38156368/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240114195558&amp;v=2.18.0"/>
        <updated>2023-12-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Follicular lymphoma (FL) develops through a stepwise acquisition of cooperative genetic changes with t(14;18)(q32;q21)/IGH::BCL2 occurring early at the pre-B stage of B-cell development. Patients with FL typically show an indolent clinical course, remitting and relapsing with the eventual development of resistance to treatments. Interestingly, the majority of transformed FL do not progress directly from FL but originate from their clonally related lymphoma precursor (CLP) cells. To examine...]]></summary>
        <author>
            <name>Jasmine Makker</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Relapses in early-stage follicular lymphoma frequently develop via a divergent evolution from their clonally related precursor cells]]></title>
        <id>pubmed:38156368</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38156368/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240113195804&amp;v=2.18.0"/>
        <updated>2023-12-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Follicular lymphoma (FL) develops through a stepwise acquisition of cooperative genetic changes with t(14;18)(q32;q21)/IGH::BCL2 occurring early at the pre-B stage of B-cell development. Patients with FL typically show an indolent clinical course, remitting and relapsing with the eventual development of resistance to treatments. Interestingly, the majority of transformed FL do not progress directly from FL but originate from their clonally related lymphoma precursor (CLP) cells. To examine...]]></summary>
        <author>
            <name>Jasmine Makker</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Relapses in early-stage follicular lymphoma frequently develop via a divergent evolution from their clonally related precursor cells]]></title>
        <id>pubmed:38156368</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38156368/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240112195322&amp;v=2.18.0"/>
        <updated>2023-12-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Follicular lymphoma (FL) develops through a stepwise acquisition of cooperative genetic changes with t(14;18)(q32;q21)/IGH::BCL2 occurring early at the pre-B stage of B-cell development. Patients with FL typically show an indolent clinical course, remitting and relapsing with the eventual development of resistance to treatments. Interestingly, the majority of transformed FL do not progress directly from FL but originate from their clonally related lymphoma precursor (CLP) cells. To examine...]]></summary>
        <author>
            <name>Jasmine Makker</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Relapses in early-stage follicular lymphoma frequently develop via a divergent evolution from their clonally related precursor cells]]></title>
        <id>pubmed:38156368</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38156368/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240111195444&amp;v=2.18.0"/>
        <updated>2023-12-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Follicular lymphoma (FL) develops through a stepwise acquisition of cooperative genetic changes with t(14;18)(q32;q21)/IGH::BCL2 occurring early at the pre-B stage of B-cell development. Patients with FL typically show an indolent clinical course, remitting and relapsing with the eventual development of resistance to treatments. Interestingly, the majority of transformed FL do not progress directly from FL but originate from their clonally related lymphoma precursor (CLP) cells. To examine...]]></summary>
        <author>
            <name>Jasmine Makker</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Relapses in early-stage follicular lymphoma frequently develop via a divergent evolution from their clonally related precursor cells]]></title>
        <id>pubmed:38156368</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38156368/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240110195405&amp;v=2.18.0"/>
        <updated>2023-12-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Follicular lymphoma (FL) develops through a stepwise acquisition of cooperative genetic changes with t(14;18)(q32;q21)/IGH::BCL2 occurring early at the pre-B stage of B-cell development. Patients with FL typically show an indolent clinical course, remitting and relapsing with the eventual development of resistance to treatments. Interestingly, the majority of transformed FL do not progress directly from FL but originate from their clonally related lymphoma precursor (CLP) cells. To examine...]]></summary>
        <author>
            <name>Jasmine Makker</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Relapses in early-stage follicular lymphoma frequently develop via a divergent evolution from their clonally related precursor cells]]></title>
        <id>pubmed:38156368</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38156368/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240109195408&amp;v=2.18.0"/>
        <updated>2023-12-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Follicular lymphoma (FL) develops through a stepwise acquisition of cooperative genetic changes with t(14;18)(q32;q21)/IGH::BCL2 occurring early at the pre-B stage of B-cell development. Patients with FL typically show an indolent clinical course, remitting and relapsing with the eventual development of resistance to treatments. Interestingly, the majority of transformed FL do not progress directly from FL but originate from their clonally related lymphoma precursor (CLP) cells. To examine...]]></summary>
        <author>
            <name>Jasmine Makker</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Relapses in early-stage follicular lymphoma frequently develop via a divergent evolution from their clonally related precursor cells]]></title>
        <id>pubmed:38156368</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38156368/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240108195354&amp;v=2.18.0"/>
        <updated>2023-12-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Follicular lymphoma (FL) develops through a stepwise acquisition of cooperative genetic changes with t(14;18)(q32;q21)/IGH::BCL2 occurring early at the pre-B stage of B-cell development. Patients with FL typically show an indolent clinical course, remitting and relapsing with the eventual development of resistance to treatments. Interestingly, the majority of transformed FL do not progress directly from FL but originate from their clonally related lymphoma precursor (CLP) cells. To examine...]]></summary>
        <author>
            <name>Jasmine Makker</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Relapses in early-stage follicular lymphoma frequently develop via a divergent evolution from their clonally related precursor cells]]></title>
        <id>pubmed:38156368</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38156368/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240107195431&amp;v=2.18.0"/>
        <updated>2023-12-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Follicular lymphoma (FL) develops through a stepwise acquisition of cooperative genetic changes with t(14;18)(q32;q21)/IGH::BCL2 occurring early at the pre-B stage of B-cell development. Patients with FL typically show an indolent clinical course, remitting and relapsing with the eventual development of resistance to treatments. Interestingly, the majority of transformed FL do not progress directly from FL but originate from their clonally related lymphoma precursor (CLP) cells. To examine...]]></summary>
        <author>
            <name>Jasmine Makker</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Relapses in early-stage follicular lymphoma frequently develop via a divergent evolution from their clonally related precursor cells]]></title>
        <id>pubmed:38156368</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38156368/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240106195750&amp;v=2.18.0"/>
        <updated>2023-12-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Follicular lymphoma (FL) develops through a stepwise acquisition of cooperative genetic changes with t(14;18)(q32;q21)/IGH::BCL2 occurring early at the pre-B stage of B-cell development. Patients with FL typically show an indolent clinical course, remitting and relapsing with the eventual development of resistance to treatments. Interestingly, the majority of transformed FL do not progress directly from FL but originate from their clonally related lymphoma precursor (CLP) cells. To examine...]]></summary>
        <author>
            <name>Jasmine Makker</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Relapses in early-stage follicular lymphoma frequently develop via a divergent evolution from their clonally related precursor cells]]></title>
        <id>pubmed:38156368</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38156368/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240105195208&amp;v=2.18.0"/>
        <updated>2023-12-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Follicular lymphoma (FL) develops through a stepwise acquisition of cooperative genetic changes with t(14;18)(q32;q21)/IGH::BCL2 occurring early at the pre-B stage of B-cell development. Patients with FL typically show an indolent clinical course, remitting and relapsing with the eventual development of resistance to treatments. Interestingly, the majority of transformed FL do not progress directly from FL but originate from their clonally related lymphoma precursor (CLP) cells. To examine...]]></summary>
        <author>
            <name>Jasmine Makker</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Relapses in early-stage follicular lymphoma frequently develop via a divergent evolution from their clonally related precursor cells]]></title>
        <id>pubmed:38156368</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38156368/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240104195307&amp;v=2.18.0"/>
        <updated>2023-12-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Follicular lymphoma (FL) develops through a stepwise acquisition of cooperative genetic changes with t(14;18)(q32;q21)/IGH::BCL2 occurring early at the pre-B stage of B-cell development. Patients with FL typically show an indolent clinical course, remitting and relapsing with the eventual development of resistance to treatments. Interestingly, the majority of transformed FL do not progress directly from FL but originate from their clonally related lymphoma precursor (CLP) cells. To examine...]]></summary>
        <author>
            <name>Jasmine Makker</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Relapses in early-stage follicular lymphoma frequently develop via a divergent evolution from their clonally related precursor cells]]></title>
        <id>pubmed:38156368</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38156368/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240103195303&amp;v=2.18.0"/>
        <updated>2023-12-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Follicular lymphoma (FL) develops through a stepwise acquisition of cooperative genetic changes with t(14;18)(q32;q21)/IGH::BCL2 occurring early at the pre-B stage of B-cell development. Patients with FL typically show an indolent clinical course, remitting and relapsing with the eventual development of resistance to treatments. Interestingly, the majority of transformed FL do not progress directly from FL but originate from their clonally related lymphoma precursor (CLP) cells. To examine...]]></summary>
        <author>
            <name>Jasmine Makker</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Relapses in early-stage follicular lymphoma frequently develop via a divergent evolution from their clonally related precursor cells]]></title>
        <id>pubmed:38156368</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38156368/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240102195247&amp;v=2.18.0"/>
        <updated>2023-12-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Follicular lymphoma (FL) develops through a stepwise acquisition of cooperative genetic changes with t(14;18)(q32;q21)/IGH::BCL2 occurring early at the pre-B stage of B-cell development. Patients with FL typically show an indolent clinical course, remitting and relapsing with the eventual development of resistance to treatments. Interestingly, the majority of transformed FL do not progress directly from FL but originate from their clonally related lymphoma precursor (CLP) cells. To examine...]]></summary>
        <author>
            <name>Jasmine Makker</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Relapses in early-stage follicular lymphoma frequently develop via a divergent evolution from their clonally related precursor cells]]></title>
        <id>pubmed:38156368</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38156368/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240101195419&amp;v=2.18.0"/>
        <updated>2023-12-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Follicular lymphoma (FL) develops through a stepwise acquisition of cooperative genetic changes with t(14;18)(q32;q21)/IGH::BCL2 occurring early at the pre-B stage of B-cell development. Patients with FL typically show an indolent clinical course, remitting and relapsing with the eventual development of resistance to treatments. Interestingly, the majority of transformed FL do not progress directly from FL but originate from their clonally related lymphoma precursor (CLP) cells. To examine...]]></summary>
        <author>
            <name>Jasmine Makker</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Relapses in early-stage follicular lymphoma frequently develop via a divergent evolution from their clonally related precursor cells]]></title>
        <id>pubmed:38156368</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38156368/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231231195742&amp;v=2.18.0"/>
        <updated>2023-12-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Follicular lymphoma (FL) develops through a stepwise acquisition of cooperative genetic changes with t(14;18)(q32;q21)/IGH::BCL2 occurring early at the pre-B stage of B-cell development. Patients with FL typically show an indolent clinical course, remitting and relapsing with the eventual development of resistance to treatments. Interestingly, the majority of transformed FL do not progress directly from FL but originate from their clonally related lymphoma precursor (CLP) cells. To examine...]]></summary>
        <author>
            <name>Jasmine Makker</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Relapses in early-stage follicular lymphoma frequently develop via a divergent evolution from their clonally related precursor cells]]></title>
        <id>pubmed:38156368</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38156368/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231230195628&amp;v=2.18.0"/>
        <updated>2023-12-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Follicular lymphoma (FL) develops through a stepwise acquisition of cooperative genetic changes with t(14;18)(q32;q21)/IGH::BCL2 occurring early at the pre-B stage of B-cell development. Patients with FL typically show an indolent clinical course, remitting and relapsing with the eventual development of resistance to treatments. Interestingly, the majority of transformed FL do not progress directly from FL but originate from their clonally related lymphoma precursor (CLP) cells. To examine...]]></summary>
        <author>
            <name>Jasmine Makker</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Relapses in early-stage follicular lymphoma frequently develop via a divergent evolution from their clonally related precursor cells]]></title>
        <id>pubmed:38156368</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38156368/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231229195054&amp;v=2.18.0"/>
        <updated>2023-12-29T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Follicular lymphoma (FL) develops through a stepwise acquisition of cooperative genetic changes with t(14;18)(q32;q21)/IGH::BCL2 occurring early at the pre-B stage of B-cell development. Patients with FL typically show an indolent clinical course, remitting and relapsing with the eventual development of resistance to treatments. Interestingly, the majority of transformed FL do not progress directly from FL but originate from their clonally related lymphoma precursor (CLP) cells. To examine...]]></summary>
        <author>
            <name>Jasmine Makker</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute lymphoblastic leukemia with myeloid mutations is a high-risk disease associated with clonal hematopoiesis]]></title>
        <id>pubmed:38150184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38150184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240111195444&amp;v=2.18.0"/>
        <updated>2023-12-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid neoplasms arise from pre-existing clonal hematopoiesis (CH), however the role of CH in pathogenesis of ALL is unknown. We found that 18% of adult ALL cases harbored TP53, and 16% had myeloid CH-associated gene mutations. ALL with myeloid mutations (MyM) had distinct genetic and clinical characteristics, associated with inferior survival. By using single cell proteogenomic analysis, we demonstrated that myeloid mutations were present years before the diagnosis of ALL, and a subset of...]]></summary>
        <author>
            <name>Caner Saygin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute lymphoblastic leukemia with myeloid mutations is a high-risk disease associated with clonal hematopoiesis]]></title>
        <id>pubmed:38150184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38150184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240110195405&amp;v=2.18.0"/>
        <updated>2023-12-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid neoplasms arise from pre-existing clonal hematopoiesis (CH), however the role of CH in pathogenesis of ALL is unknown. We found that 18% of adult ALL cases harbored TP53, and 16% had myeloid CH-associated gene mutations. ALL with myeloid mutations (MyM) had distinct genetic and clinical characteristics, associated with inferior survival. By using single cell proteogenomic analysis, we demonstrated that myeloid mutations were present years before the diagnosis of ALL, and a subset of...]]></summary>
        <author>
            <name>Caner Saygin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Incipient clonal hematopoiesis is accelerated following CD30.CAR-T therapy]]></title>
        <id>pubmed:38149948</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38149948/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240110195405&amp;v=2.18.0"/>
        <updated>2023-12-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chimeric antigen receptor (CAR) T-cells are an emerging therapy for refractory lymphomas. Clonal hematopoiesis (CH), the preferential outgrowth of mutated bone marrow progenitors, is enriched in lymphoma patients receiving CAR-T cells. CAR-T therapy requires conditioning chemotherapy and often induces systemic inflammatory reactions, both of which have been shown to promote expansion of CH clones. Thus, we hypothesized that pre-existing CH clones could expand during CAR-T cell treatment. We...]]></summary>
        <author>
            <name>Chiraag D Kapadia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute lymphoblastic leukemia with myeloid mutations is a high-risk disease associated with clonal hematopoiesis]]></title>
        <id>pubmed:38150184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38150184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240109195408&amp;v=2.18.0"/>
        <updated>2023-12-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid neoplasms arise from pre-existing clonal hematopoiesis (CH), however the role of CH in pathogenesis of ALL is unknown. We found that 18% of adult ALL cases harbored TP53, and 16% had myeloid CH-associated gene mutations. ALL with myeloid mutations (MyM) had distinct genetic and clinical characteristics, associated with inferior survival. By using single cell proteogenomic analysis, we demonstrated that myeloid mutations were present years before the diagnosis of ALL, and a subset of...]]></summary>
        <author>
            <name>Caner Saygin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Incipient clonal hematopoiesis is accelerated following CD30.CAR-T therapy]]></title>
        <id>pubmed:38149948</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38149948/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240109195408&amp;v=2.18.0"/>
        <updated>2023-12-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chimeric antigen receptor (CAR) T-cells are an emerging therapy for refractory lymphomas. Clonal hematopoiesis (CH), the preferential outgrowth of mutated bone marrow progenitors, is enriched in lymphoma patients receiving CAR-T cells. CAR-T therapy requires conditioning chemotherapy and often induces systemic inflammatory reactions, both of which have been shown to promote expansion of CH clones. Thus, we hypothesized that pre-existing CH clones could expand during CAR-T cell treatment. We...]]></summary>
        <author>
            <name>Chiraag D Kapadia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute lymphoblastic leukemia with myeloid mutations is a high-risk disease associated with clonal hematopoiesis]]></title>
        <id>pubmed:38150184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38150184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240108195354&amp;v=2.18.0"/>
        <updated>2023-12-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid neoplasms arise from pre-existing clonal hematopoiesis (CH), however the role of CH in pathogenesis of ALL is unknown. We found that 18% of adult ALL cases harbored TP53, and 16% had myeloid CH-associated gene mutations. ALL with myeloid mutations (MyM) had distinct genetic and clinical characteristics, associated with inferior survival. By using single cell proteogenomic analysis, we demonstrated that myeloid mutations were present years before the diagnosis of ALL, and a subset of...]]></summary>
        <author>
            <name>Caner Saygin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Incipient clonal hematopoiesis is accelerated following CD30.CAR-T therapy]]></title>
        <id>pubmed:38149948</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38149948/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240108195354&amp;v=2.18.0"/>
        <updated>2023-12-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chimeric antigen receptor (CAR) T-cells are an emerging therapy for refractory lymphomas. Clonal hematopoiesis (CH), the preferential outgrowth of mutated bone marrow progenitors, is enriched in lymphoma patients receiving CAR-T cells. CAR-T therapy requires conditioning chemotherapy and often induces systemic inflammatory reactions, both of which have been shown to promote expansion of CH clones. Thus, we hypothesized that pre-existing CH clones could expand during CAR-T cell treatment. We...]]></summary>
        <author>
            <name>Chiraag D Kapadia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute lymphoblastic leukemia with myeloid mutations is a high-risk disease associated with clonal hematopoiesis]]></title>
        <id>pubmed:38150184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38150184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240107195432&amp;v=2.18.0"/>
        <updated>2023-12-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid neoplasms arise from pre-existing clonal hematopoiesis (CH), however the role of CH in pathogenesis of ALL is unknown. We found that 18% of adult ALL cases harbored TP53, and 16% had myeloid CH-associated gene mutations. ALL with myeloid mutations (MyM) had distinct genetic and clinical characteristics, associated with inferior survival. By using single cell proteogenomic analysis, we demonstrated that myeloid mutations were present years before the diagnosis of ALL, and a subset of...]]></summary>
        <author>
            <name>Caner Saygin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Incipient clonal hematopoiesis is accelerated following CD30.CAR-T therapy]]></title>
        <id>pubmed:38149948</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38149948/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240107195432&amp;v=2.18.0"/>
        <updated>2023-12-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chimeric antigen receptor (CAR) T-cells are an emerging therapy for refractory lymphomas. Clonal hematopoiesis (CH), the preferential outgrowth of mutated bone marrow progenitors, is enriched in lymphoma patients receiving CAR-T cells. CAR-T therapy requires conditioning chemotherapy and often induces systemic inflammatory reactions, both of which have been shown to promote expansion of CH clones. Thus, we hypothesized that pre-existing CH clones could expand during CAR-T cell treatment. We...]]></summary>
        <author>
            <name>Chiraag D Kapadia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute lymphoblastic leukemia with myeloid mutations is a high-risk disease associated with clonal hematopoiesis]]></title>
        <id>pubmed:38150184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38150184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240106195750&amp;v=2.18.0"/>
        <updated>2023-12-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid neoplasms arise from pre-existing clonal hematopoiesis (CH), however the role of CH in pathogenesis of ALL is unknown. We found that 18% of adult ALL cases harbored TP53, and 16% had myeloid CH-associated gene mutations. ALL with myeloid mutations (MyM) had distinct genetic and clinical characteristics, associated with inferior survival. By using single cell proteogenomic analysis, we demonstrated that myeloid mutations were present years before the diagnosis of ALL, and a subset of...]]></summary>
        <author>
            <name>Caner Saygin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Incipient clonal hematopoiesis is accelerated following CD30.CAR-T therapy]]></title>
        <id>pubmed:38149948</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38149948/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240106195750&amp;v=2.18.0"/>
        <updated>2023-12-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chimeric antigen receptor (CAR) T-cells are an emerging therapy for refractory lymphomas. Clonal hematopoiesis (CH), the preferential outgrowth of mutated bone marrow progenitors, is enriched in lymphoma patients receiving CAR-T cells. CAR-T therapy requires conditioning chemotherapy and often induces systemic inflammatory reactions, both of which have been shown to promote expansion of CH clones. Thus, we hypothesized that pre-existing CH clones could expand during CAR-T cell treatment. We...]]></summary>
        <author>
            <name>Chiraag D Kapadia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute lymphoblastic leukemia with myeloid mutations is a high-risk disease associated with clonal hematopoiesis]]></title>
        <id>pubmed:38150184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38150184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240105195208&amp;v=2.18.0"/>
        <updated>2023-12-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid neoplasms arise from pre-existing clonal hematopoiesis (CH), however the role of CH in pathogenesis of ALL is unknown. We found that 18% of adult ALL cases harbored TP53, and 16% had myeloid CH-associated gene mutations. ALL with myeloid mutations (MyM) had distinct genetic and clinical characteristics, associated with inferior survival. By using single cell proteogenomic analysis, we demonstrated that myeloid mutations were present years before the diagnosis of ALL, and a subset of...]]></summary>
        <author>
            <name>Caner Saygin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Incipient clonal hematopoiesis is accelerated following CD30.CAR-T therapy]]></title>
        <id>pubmed:38149948</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38149948/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240105195208&amp;v=2.18.0"/>
        <updated>2023-12-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chimeric antigen receptor (CAR) T-cells are an emerging therapy for refractory lymphomas. Clonal hematopoiesis (CH), the preferential outgrowth of mutated bone marrow progenitors, is enriched in lymphoma patients receiving CAR-T cells. CAR-T therapy requires conditioning chemotherapy and often induces systemic inflammatory reactions, both of which have been shown to promote expansion of CH clones. Thus, we hypothesized that pre-existing CH clones could expand during CAR-T cell treatment. We...]]></summary>
        <author>
            <name>Chiraag D Kapadia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute lymphoblastic leukemia with myeloid mutations is a high-risk disease associated with clonal hematopoiesis]]></title>
        <id>pubmed:38150184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38150184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240104195306&amp;v=2.18.0"/>
        <updated>2023-12-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid neoplasms arise from pre-existing clonal hematopoiesis (CH), however the role of CH in pathogenesis of ALL is unknown. We found that 18% of adult ALL cases harbored TP53, and 16% had myeloid CH-associated gene mutations. ALL with myeloid mutations (MyM) had distinct genetic and clinical characteristics, associated with inferior survival. By using single cell proteogenomic analysis, we demonstrated that myeloid mutations were present years before the diagnosis of ALL, and a subset of...]]></summary>
        <author>
            <name>Caner Saygin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Incipient clonal hematopoiesis is accelerated following CD30.CAR-T therapy]]></title>
        <id>pubmed:38149948</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38149948/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240104195306&amp;v=2.18.0"/>
        <updated>2023-12-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chimeric antigen receptor (CAR) T-cells are an emerging therapy for refractory lymphomas. Clonal hematopoiesis (CH), the preferential outgrowth of mutated bone marrow progenitors, is enriched in lymphoma patients receiving CAR-T cells. CAR-T therapy requires conditioning chemotherapy and often induces systemic inflammatory reactions, both of which have been shown to promote expansion of CH clones. Thus, we hypothesized that pre-existing CH clones could expand during CAR-T cell treatment. We...]]></summary>
        <author>
            <name>Chiraag D Kapadia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute lymphoblastic leukemia with myeloid mutations is a high-risk disease associated with clonal hematopoiesis]]></title>
        <id>pubmed:38150184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38150184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240103195259&amp;v=2.18.0"/>
        <updated>2023-12-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid neoplasms arise from pre-existing clonal hematopoiesis (CH), however the role of CH in pathogenesis of ALL is unknown. We found that 18% of adult ALL cases harbored TP53, and 16% had myeloid CH-associated gene mutations. ALL with myeloid mutations (MyM) had distinct genetic and clinical characteristics, associated with inferior survival. By using single cell proteogenomic analysis, we demonstrated that myeloid mutations were present years before the diagnosis of ALL, and a subset of...]]></summary>
        <author>
            <name>Caner Saygin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Incipient clonal hematopoiesis is accelerated following CD30.CAR-T therapy]]></title>
        <id>pubmed:38149948</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38149948/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240103195259&amp;v=2.18.0"/>
        <updated>2023-12-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chimeric antigen receptor (CAR) T-cells are an emerging therapy for refractory lymphomas. Clonal hematopoiesis (CH), the preferential outgrowth of mutated bone marrow progenitors, is enriched in lymphoma patients receiving CAR-T cells. CAR-T therapy requires conditioning chemotherapy and often induces systemic inflammatory reactions, both of which have been shown to promote expansion of CH clones. Thus, we hypothesized that pre-existing CH clones could expand during CAR-T cell treatment. We...]]></summary>
        <author>
            <name>Chiraag D Kapadia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute lymphoblastic leukemia with myeloid mutations is a high-risk disease associated with clonal hematopoiesis]]></title>
        <id>pubmed:38150184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38150184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240102195247&amp;v=2.18.0"/>
        <updated>2023-12-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid neoplasms arise from pre-existing clonal hematopoiesis (CH), however the role of CH in pathogenesis of ALL is unknown. We found that 18% of adult ALL cases harbored TP53, and 16% had myeloid CH-associated gene mutations. ALL with myeloid mutations (MyM) had distinct genetic and clinical characteristics, associated with inferior survival. By using single cell proteogenomic analysis, we demonstrated that myeloid mutations were present years before the diagnosis of ALL, and a subset of...]]></summary>
        <author>
            <name>Caner Saygin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Incipient clonal hematopoiesis is accelerated following CD30.CAR-T therapy]]></title>
        <id>pubmed:38149948</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38149948/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240102195247&amp;v=2.18.0"/>
        <updated>2023-12-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chimeric antigen receptor (CAR) T-cells are an emerging therapy for refractory lymphomas. Clonal hematopoiesis (CH), the preferential outgrowth of mutated bone marrow progenitors, is enriched in lymphoma patients receiving CAR-T cells. CAR-T therapy requires conditioning chemotherapy and often induces systemic inflammatory reactions, both of which have been shown to promote expansion of CH clones. Thus, we hypothesized that pre-existing CH clones could expand during CAR-T cell treatment. We...]]></summary>
        <author>
            <name>Chiraag D Kapadia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute lymphoblastic leukemia with myeloid mutations is a high-risk disease associated with clonal hematopoiesis]]></title>
        <id>pubmed:38150184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38150184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240101195419&amp;v=2.18.0"/>
        <updated>2023-12-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid neoplasms arise from pre-existing clonal hematopoiesis (CH), however the role of CH in pathogenesis of ALL is unknown. We found that 18% of adult ALL cases harbored TP53, and 16% had myeloid CH-associated gene mutations. ALL with myeloid mutations (MyM) had distinct genetic and clinical characteristics, associated with inferior survival. By using single cell proteogenomic analysis, we demonstrated that myeloid mutations were present years before the diagnosis of ALL, and a subset of...]]></summary>
        <author>
            <name>Caner Saygin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Incipient clonal hematopoiesis is accelerated following CD30.CAR-T therapy]]></title>
        <id>pubmed:38149948</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38149948/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240101195419&amp;v=2.18.0"/>
        <updated>2023-12-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chimeric antigen receptor (CAR) T-cells are an emerging therapy for refractory lymphomas. Clonal hematopoiesis (CH), the preferential outgrowth of mutated bone marrow progenitors, is enriched in lymphoma patients receiving CAR-T cells. CAR-T therapy requires conditioning chemotherapy and often induces systemic inflammatory reactions, both of which have been shown to promote expansion of CH clones. Thus, we hypothesized that pre-existing CH clones could expand during CAR-T cell treatment. We...]]></summary>
        <author>
            <name>Chiraag D Kapadia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute lymphoblastic leukemia with myeloid mutations is a high-risk disease associated with clonal hematopoiesis]]></title>
        <id>pubmed:38150184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38150184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231231195742&amp;v=2.18.0"/>
        <updated>2023-12-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid neoplasms arise from pre-existing clonal hematopoiesis (CH), however the role of CH in pathogenesis of ALL is unknown. We found that 18% of adult ALL cases harbored TP53, and 16% had myeloid CH-associated gene mutations. ALL with myeloid mutations (MyM) had distinct genetic and clinical characteristics, associated with inferior survival. By using single cell proteogenomic analysis, we demonstrated that myeloid mutations were present years before the diagnosis of ALL, and a subset of...]]></summary>
        <author>
            <name>Caner Saygin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Incipient clonal hematopoiesis is accelerated following CD30.CAR-T therapy]]></title>
        <id>pubmed:38149948</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38149948/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231231195742&amp;v=2.18.0"/>
        <updated>2023-12-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chimeric antigen receptor (CAR) T-cells are an emerging therapy for refractory lymphomas. Clonal hematopoiesis (CH), the preferential outgrowth of mutated bone marrow progenitors, is enriched in lymphoma patients receiving CAR-T cells. CAR-T therapy requires conditioning chemotherapy and often induces systemic inflammatory reactions, both of which have been shown to promote expansion of CH clones. Thus, we hypothesized that pre-existing CH clones could expand during CAR-T cell treatment. We...]]></summary>
        <author>
            <name>Chiraag D Kapadia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute lymphoblastic leukemia with myeloid mutations is a high-risk disease associated with clonal hematopoiesis]]></title>
        <id>pubmed:38150184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38150184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231230195628&amp;v=2.18.0"/>
        <updated>2023-12-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid neoplasms arise from pre-existing clonal hematopoiesis (CH), however the role of CH in pathogenesis of ALL is unknown. We found that 18% of adult ALL cases harbored TP53, and 16% had myeloid CH-associated gene mutations. ALL with myeloid mutations (MyM) had distinct genetic and clinical characteristics, associated with inferior survival. By using single cell proteogenomic analysis, we demonstrated that myeloid mutations were present years before the diagnosis of ALL, and a subset of...]]></summary>
        <author>
            <name>Caner Saygin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Incipient clonal hematopoiesis is accelerated following CD30.CAR-T therapy]]></title>
        <id>pubmed:38149948</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38149948/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231230195628&amp;v=2.18.0"/>
        <updated>2023-12-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chimeric antigen receptor (CAR) T-cells are an emerging therapy for refractory lymphomas. Clonal hematopoiesis (CH), the preferential outgrowth of mutated bone marrow progenitors, is enriched in lymphoma patients receiving CAR-T cells. CAR-T therapy requires conditioning chemotherapy and often induces systemic inflammatory reactions, both of which have been shown to promote expansion of CH clones. Thus, we hypothesized that pre-existing CH clones could expand during CAR-T cell treatment. We...]]></summary>
        <author>
            <name>Chiraag D Kapadia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute lymphoblastic leukemia with myeloid mutations is a high-risk disease associated with clonal hematopoiesis]]></title>
        <id>pubmed:38150184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38150184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231229195054&amp;v=2.18.0"/>
        <updated>2023-12-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid neoplasms arise from pre-existing clonal hematopoiesis (CH), however the role of CH in pathogenesis of ALL is unknown. We found that 18% of adult ALL cases harbored TP53, and 16% had myeloid CH-associated gene mutations. ALL with myeloid mutations (MyM) had distinct genetic and clinical characteristics, associated with inferior survival. By using single cell proteogenomic analysis, we demonstrated that myeloid mutations were present years before the diagnosis of ALL, and a subset of...]]></summary>
        <author>
            <name>Caner Saygin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Incipient clonal hematopoiesis is accelerated following CD30.CAR-T therapy]]></title>
        <id>pubmed:38149948</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38149948/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231229195054&amp;v=2.18.0"/>
        <updated>2023-12-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chimeric antigen receptor (CAR) T-cells are an emerging therapy for refractory lymphomas. Clonal hematopoiesis (CH), the preferential outgrowth of mutated bone marrow progenitors, is enriched in lymphoma patients receiving CAR-T cells. CAR-T therapy requires conditioning chemotherapy and often induces systemic inflammatory reactions, both of which have been shown to promote expansion of CH clones. Thus, we hypothesized that pre-existing CH clones could expand during CAR-T cell treatment. We...]]></summary>
        <author>
            <name>Chiraag D Kapadia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute lymphoblastic leukemia with myeloid mutations is a high-risk disease associated with clonal hematopoiesis]]></title>
        <id>pubmed:38150184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38150184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231228194204&amp;v=2.18.0"/>
        <updated>2023-12-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid neoplasms arise from pre-existing clonal hematopoiesis (CH), however the role of CH in pathogenesis of ALL is unknown. We found that 18% of adult ALL cases harbored TP53, and 16% had myeloid CH-associated gene mutations. ALL with myeloid mutations (MyM) had distinct genetic and clinical characteristics, associated with inferior survival. By using single cell proteogenomic analysis, we demonstrated that myeloid mutations were present years before the diagnosis of ALL, and a subset of...]]></summary>
        <author>
            <name>Caner Saygin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Incipient clonal hematopoiesis is accelerated following CD30.CAR-T therapy]]></title>
        <id>pubmed:38149948</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38149948/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231228194204&amp;v=2.18.0"/>
        <updated>2023-12-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chimeric antigen receptor (CAR) T-cells are an emerging therapy for refractory lymphomas. Clonal hematopoiesis (CH), the preferential outgrowth of mutated bone marrow progenitors, is enriched in lymphoma patients receiving CAR-T cells. CAR-T therapy requires conditioning chemotherapy and often induces systemic inflammatory reactions, both of which have been shown to promote expansion of CH clones. Thus, we hypothesized that pre-existing CH clones could expand during CAR-T cell treatment. We...]]></summary>
        <author>
            <name>Chiraag D Kapadia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute lymphoblastic leukemia with myeloid mutations is a high-risk disease associated with clonal hematopoiesis]]></title>
        <id>pubmed:38150184</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38150184/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231227195056&amp;v=2.18.0"/>
        <updated>2023-12-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid neoplasms arise from pre-existing clonal hematopoiesis (CH), however the role of CH in pathogenesis of ALL is unknown. We found that 18% of adult ALL cases harbored TP53, and 16% had myeloid CH-associated gene mutations. ALL with myeloid mutations (MyM) had distinct genetic and clinical characteristics, associated with inferior survival. By using single cell proteogenomic analysis, we demonstrated that myeloid mutations were present years before the diagnosis of ALL, and a subset of...]]></summary>
        <author>
            <name>Caner Saygin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Incipient clonal hematopoiesis is accelerated following CD30.CAR-T therapy]]></title>
        <id>pubmed:38149948</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38149948/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231227195056&amp;v=2.18.0"/>
        <updated>2023-12-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chimeric antigen receptor (CAR) T-cells are an emerging therapy for refractory lymphomas. Clonal hematopoiesis (CH), the preferential outgrowth of mutated bone marrow progenitors, is enriched in lymphoma patients receiving CAR-T cells. CAR-T therapy requires conditioning chemotherapy and often induces systemic inflammatory reactions, both of which have been shown to promote expansion of CH clones. Thus, we hypothesized that pre-existing CH clones could expand during CAR-T cell treatment. We...]]></summary>
        <author>
            <name>Chiraag D Kapadia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring the intratumoral heterogeneity of DNA ploidy in prostate cancer]]></title>
        <id>pubmed:38148577</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38148577/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240114195558&amp;v=2.18.0"/>
        <updated>2023-12-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this proof-of-concept study, we demonstrate the feasibility to predict the DNA ploidy status of distinct populations within one tumor by H&E morphology. Future studies are needed to further investigate the clonal relationship between the diploid and the aneuploid subpopulation and test the hypothesis that the aneuploid population is derived from the diploid one. Finally, our analyses pointed to an enrichment of the stemness-associated marker ALDH1A1 in diploid populations, which...]]></summary>
        <author>
            <name>Tatjana Vlajnic</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring the intratumoral heterogeneity of DNA ploidy in prostate cancer]]></title>
        <id>pubmed:38148577</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38148577/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240113195804&amp;v=2.18.0"/>
        <updated>2023-12-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this proof-of-concept study, we demonstrate the feasibility to predict the DNA ploidy status of distinct populations within one tumor by H&E morphology. Future studies are needed to further investigate the clonal relationship between the diploid and the aneuploid subpopulation and test the hypothesis that the aneuploid population is derived from the diploid one. Finally, our analyses pointed to an enrichment of the stemness-associated marker ALDH1A1 in diploid populations, which...]]></summary>
        <author>
            <name>Tatjana Vlajnic</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring the intratumoral heterogeneity of DNA ploidy in prostate cancer]]></title>
        <id>pubmed:38148577</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38148577/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240112195322&amp;v=2.18.0"/>
        <updated>2023-12-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this proof-of-concept study, we demonstrate the feasibility to predict the DNA ploidy status of distinct populations within one tumor by H&E morphology. Future studies are needed to further investigate the clonal relationship between the diploid and the aneuploid subpopulation and test the hypothesis that the aneuploid population is derived from the diploid one. Finally, our analyses pointed to an enrichment of the stemness-associated marker ALDH1A1 in diploid populations, which...]]></summary>
        <author>
            <name>Tatjana Vlajnic</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring the intratumoral heterogeneity of DNA ploidy in prostate cancer]]></title>
        <id>pubmed:38148577</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38148577/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240111195444&amp;v=2.18.0"/>
        <updated>2023-12-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this proof-of-concept study, we demonstrate the feasibility to predict the DNA ploidy status of distinct populations within one tumor by H&E morphology. Future studies are needed to further investigate the clonal relationship between the diploid and the aneuploid subpopulation and test the hypothesis that the aneuploid population is derived from the diploid one. Finally, our analyses pointed to an enrichment of the stemness-associated marker ALDH1A1 in diploid populations, which...]]></summary>
        <author>
            <name>Tatjana Vlajnic</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring the intratumoral heterogeneity of DNA ploidy in prostate cancer]]></title>
        <id>pubmed:38148577</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38148577/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240110195405&amp;v=2.18.0"/>
        <updated>2023-12-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this proof-of-concept study, we demonstrate the feasibility to predict the DNA ploidy status of distinct populations within one tumor by H&E morphology. Future studies are needed to further investigate the clonal relationship between the diploid and the aneuploid subpopulation and test the hypothesis that the aneuploid population is derived from the diploid one. Finally, our analyses pointed to an enrichment of the stemness-associated marker ALDH1A1 in diploid populations, which...]]></summary>
        <author>
            <name>Tatjana Vlajnic</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring the intratumoral heterogeneity of DNA ploidy in prostate cancer]]></title>
        <id>pubmed:38148577</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38148577/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240109195408&amp;v=2.18.0"/>
        <updated>2023-12-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this proof-of-concept study, we demonstrate the feasibility to predict the DNA ploidy status of distinct populations within one tumor by H&E morphology. Future studies are needed to further investigate the clonal relationship between the diploid and the aneuploid subpopulation and test the hypothesis that the aneuploid population is derived from the diploid one. Finally, our analyses pointed to an enrichment of the stemness-associated marker ALDH1A1 in diploid populations, which...]]></summary>
        <author>
            <name>Tatjana Vlajnic</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring the intratumoral heterogeneity of DNA ploidy in prostate cancer]]></title>
        <id>pubmed:38148577</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38148577/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240108195354&amp;v=2.18.0"/>
        <updated>2023-12-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this proof-of-concept study, we demonstrate the feasibility to predict the DNA ploidy status of distinct populations within one tumor by H&E morphology. Future studies are needed to further investigate the clonal relationship between the diploid and the aneuploid subpopulation and test the hypothesis that the aneuploid population is derived from the diploid one. Finally, our analyses pointed to an enrichment of the stemness-associated marker ALDH1A1 in diploid populations, which...]]></summary>
        <author>
            <name>Tatjana Vlajnic</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring the intratumoral heterogeneity of DNA ploidy in prostate cancer]]></title>
        <id>pubmed:38148577</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38148577/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240107195431&amp;v=2.18.0"/>
        <updated>2023-12-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this proof-of-concept study, we demonstrate the feasibility to predict the DNA ploidy status of distinct populations within one tumor by H&E morphology. Future studies are needed to further investigate the clonal relationship between the diploid and the aneuploid subpopulation and test the hypothesis that the aneuploid population is derived from the diploid one. Finally, our analyses pointed to an enrichment of the stemness-associated marker ALDH1A1 in diploid populations, which...]]></summary>
        <author>
            <name>Tatjana Vlajnic</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring the intratumoral heterogeneity of DNA ploidy in prostate cancer]]></title>
        <id>pubmed:38148577</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38148577/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240106195750&amp;v=2.18.0"/>
        <updated>2023-12-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this proof-of-concept study, we demonstrate the feasibility to predict the DNA ploidy status of distinct populations within one tumor by H&E morphology. Future studies are needed to further investigate the clonal relationship between the diploid and the aneuploid subpopulation and test the hypothesis that the aneuploid population is derived from the diploid one. Finally, our analyses pointed to an enrichment of the stemness-associated marker ALDH1A1 in diploid populations, which...]]></summary>
        <author>
            <name>Tatjana Vlajnic</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring the intratumoral heterogeneity of DNA ploidy in prostate cancer]]></title>
        <id>pubmed:38148577</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38148577/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240105195208&amp;v=2.18.0"/>
        <updated>2023-12-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this proof-of-concept study, we demonstrate the feasibility to predict the DNA ploidy status of distinct populations within one tumor by H&E morphology. Future studies are needed to further investigate the clonal relationship between the diploid and the aneuploid subpopulation and test the hypothesis that the aneuploid population is derived from the diploid one. Finally, our analyses pointed to an enrichment of the stemness-associated marker ALDH1A1 in diploid populations, which...]]></summary>
        <author>
            <name>Tatjana Vlajnic</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring the intratumoral heterogeneity of DNA ploidy in prostate cancer]]></title>
        <id>pubmed:38148577</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38148577/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240104195307&amp;v=2.18.0"/>
        <updated>2023-12-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this proof-of-concept study, we demonstrate the feasibility to predict the DNA ploidy status of distinct populations within one tumor by H&E morphology. Future studies are needed to further investigate the clonal relationship between the diploid and the aneuploid subpopulation and test the hypothesis that the aneuploid population is derived from the diploid one. Finally, our analyses pointed to an enrichment of the stemness-associated marker ALDH1A1 in diploid populations, which...]]></summary>
        <author>
            <name>Tatjana Vlajnic</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring the intratumoral heterogeneity of DNA ploidy in prostate cancer]]></title>
        <id>pubmed:38148577</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38148577/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240103195303&amp;v=2.18.0"/>
        <updated>2023-12-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this proof-of-concept study, we demonstrate the feasibility to predict the DNA ploidy status of distinct populations within one tumor by H&E morphology. Future studies are needed to further investigate the clonal relationship between the diploid and the aneuploid subpopulation and test the hypothesis that the aneuploid population is derived from the diploid one. Finally, our analyses pointed to an enrichment of the stemness-associated marker ALDH1A1 in diploid populations, which...]]></summary>
        <author>
            <name>Tatjana Vlajnic</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring the intratumoral heterogeneity of DNA ploidy in prostate cancer]]></title>
        <id>pubmed:38148577</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38148577/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240102195247&amp;v=2.18.0"/>
        <updated>2023-12-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this proof-of-concept study, we demonstrate the feasibility to predict the DNA ploidy status of distinct populations within one tumor by H&E morphology. Future studies are needed to further investigate the clonal relationship between the diploid and the aneuploid subpopulation and test the hypothesis that the aneuploid population is derived from the diploid one. Finally, our analyses pointed to an enrichment of the stemness-associated marker ALDH1A1 in diploid populations, which...]]></summary>
        <author>
            <name>Tatjana Vlajnic</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring the intratumoral heterogeneity of DNA ploidy in prostate cancer]]></title>
        <id>pubmed:38148577</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38148577/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240101195419&amp;v=2.18.0"/>
        <updated>2023-12-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this proof-of-concept study, we demonstrate the feasibility to predict the DNA ploidy status of distinct populations within one tumor by H&E morphology. Future studies are needed to further investigate the clonal relationship between the diploid and the aneuploid subpopulation and test the hypothesis that the aneuploid population is derived from the diploid one. Finally, our analyses pointed to an enrichment of the stemness-associated marker ALDH1A1 in diploid populations, which...]]></summary>
        <author>
            <name>Tatjana Vlajnic</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring the intratumoral heterogeneity of DNA ploidy in prostate cancer]]></title>
        <id>pubmed:38148577</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38148577/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231231195742&amp;v=2.18.0"/>
        <updated>2023-12-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this proof-of-concept study, we demonstrate the feasibility to predict the DNA ploidy status of distinct populations within one tumor by H&E morphology. Future studies are needed to further investigate the clonal relationship between the diploid and the aneuploid subpopulation and test the hypothesis that the aneuploid population is derived from the diploid one. Finally, our analyses pointed to an enrichment of the stemness-associated marker ALDH1A1 in diploid populations, which...]]></summary>
        <author>
            <name>Tatjana Vlajnic</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring the intratumoral heterogeneity of DNA ploidy in prostate cancer]]></title>
        <id>pubmed:38148577</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38148577/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231230195628&amp;v=2.18.0"/>
        <updated>2023-12-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this proof-of-concept study, we demonstrate the feasibility to predict the DNA ploidy status of distinct populations within one tumor by H&E morphology. Future studies are needed to further investigate the clonal relationship between the diploid and the aneuploid subpopulation and test the hypothesis that the aneuploid population is derived from the diploid one. Finally, our analyses pointed to an enrichment of the stemness-associated marker ALDH1A1 in diploid populations, which...]]></summary>
        <author>
            <name>Tatjana Vlajnic</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring the intratumoral heterogeneity of DNA ploidy in prostate cancer]]></title>
        <id>pubmed:38148577</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38148577/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231229195054&amp;v=2.18.0"/>
        <updated>2023-12-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this proof-of-concept study, we demonstrate the feasibility to predict the DNA ploidy status of distinct populations within one tumor by H&E morphology. Future studies are needed to further investigate the clonal relationship between the diploid and the aneuploid subpopulation and test the hypothesis that the aneuploid population is derived from the diploid one. Finally, our analyses pointed to an enrichment of the stemness-associated marker ALDH1A1 in diploid populations, which...]]></summary>
        <author>
            <name>Tatjana Vlajnic</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring the intratumoral heterogeneity of DNA ploidy in prostate cancer]]></title>
        <id>pubmed:38148577</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38148577/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231228194204&amp;v=2.18.0"/>
        <updated>2023-12-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this proof-of-concept study, we demonstrate the feasibility to predict the DNA ploidy status of distinct populations within one tumor by H&E morphology. Future studies are needed to further investigate the clonal relationship between the diploid and the aneuploid subpopulation and test the hypothesis that the aneuploid population is derived from the diploid one. Finally, our analyses pointed to an enrichment of the stemness-associated marker ALDH1A1 in diploid populations, which...]]></summary>
        <author>
            <name>Tatjana Vlajnic</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring the intratumoral heterogeneity of DNA ploidy in prostate cancer]]></title>
        <id>pubmed:38148577</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38148577/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231227195056&amp;v=2.18.0"/>
        <updated>2023-12-27T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: In this proof-of-concept study, we demonstrate the feasibility to predict the DNA ploidy status of distinct populations within one tumor by H&E morphology. Future studies are needed to further investigate the clonal relationship between the diploid and the aneuploid subpopulation and test the hypothesis that the aneuploid population is derived from the diploid one. Finally, our analyses pointed to an enrichment of the stemness-associated marker ALDH1A1 in diploid populations, which...]]></summary>
        <author>
            <name>Tatjana Vlajnic</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[High risk and silent clonal hematopoietic genotypes in patients with non-hematologic cancer]]></title>
        <id>pubmed:38147626</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38147626/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240110195405&amp;v=2.18.0"/>
        <updated>2023-12-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) identified by somatic gene variants with variant allele fraction (VAF) >= 2% is associated with an increased risk of hematologic malignancy. However, CH defined by a broader set of genotypes and lower VAFs is ubiquitous in older individuals. To improve our understanding of the relationship between CH genotype and risk of hematologic malignancy we analyzed data from 42,714 patients who underwent blood sequencing as a normal comparator for non-hematologic tumor testing...]]></summary>
        <author>
            <name>Aaron James Stonestrom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[High risk and silent clonal hematopoietic genotypes in patients with non-hematologic cancer]]></title>
        <id>pubmed:38147626</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38147626/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240109195408&amp;v=2.18.0"/>
        <updated>2023-12-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) identified by somatic gene variants with variant allele fraction (VAF) >= 2% is associated with an increased risk of hematologic malignancy. However, CH defined by a broader set of genotypes and lower VAFs is ubiquitous in older individuals. To improve our understanding of the relationship between CH genotype and risk of hematologic malignancy we analyzed data from 42,714 patients who underwent blood sequencing as a normal comparator for non-hematologic tumor testing...]]></summary>
        <author>
            <name>Aaron James Stonestrom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[High risk and silent clonal hematopoietic genotypes in patients with non-hematologic cancer]]></title>
        <id>pubmed:38147626</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38147626/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240108195354&amp;v=2.18.0"/>
        <updated>2023-12-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) identified by somatic gene variants with variant allele fraction (VAF) >= 2% is associated with an increased risk of hematologic malignancy. However, CH defined by a broader set of genotypes and lower VAFs is ubiquitous in older individuals. To improve our understanding of the relationship between CH genotype and risk of hematologic malignancy we analyzed data from 42,714 patients who underwent blood sequencing as a normal comparator for non-hematologic tumor testing...]]></summary>
        <author>
            <name>Aaron James Stonestrom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[High risk and silent clonal hematopoietic genotypes in patients with non-hematologic cancer]]></title>
        <id>pubmed:38147626</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38147626/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240107195432&amp;v=2.18.0"/>
        <updated>2023-12-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) identified by somatic gene variants with variant allele fraction (VAF) >= 2% is associated with an increased risk of hematologic malignancy. However, CH defined by a broader set of genotypes and lower VAFs is ubiquitous in older individuals. To improve our understanding of the relationship between CH genotype and risk of hematologic malignancy we analyzed data from 42,714 patients who underwent blood sequencing as a normal comparator for non-hematologic tumor testing...]]></summary>
        <author>
            <name>Aaron James Stonestrom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[High risk and silent clonal hematopoietic genotypes in patients with non-hematologic cancer]]></title>
        <id>pubmed:38147626</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38147626/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240106195750&amp;v=2.18.0"/>
        <updated>2023-12-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) identified by somatic gene variants with variant allele fraction (VAF) >= 2% is associated with an increased risk of hematologic malignancy. However, CH defined by a broader set of genotypes and lower VAFs is ubiquitous in older individuals. To improve our understanding of the relationship between CH genotype and risk of hematologic malignancy we analyzed data from 42,714 patients who underwent blood sequencing as a normal comparator for non-hematologic tumor testing...]]></summary>
        <author>
            <name>Aaron James Stonestrom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[High risk and silent clonal hematopoietic genotypes in patients with non-hematologic cancer]]></title>
        <id>pubmed:38147626</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38147626/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240105195208&amp;v=2.18.0"/>
        <updated>2023-12-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) identified by somatic gene variants with variant allele fraction (VAF) >= 2% is associated with an increased risk of hematologic malignancy. However, CH defined by a broader set of genotypes and lower VAFs is ubiquitous in older individuals. To improve our understanding of the relationship between CH genotype and risk of hematologic malignancy we analyzed data from 42,714 patients who underwent blood sequencing as a normal comparator for non-hematologic tumor testing...]]></summary>
        <author>
            <name>Aaron James Stonestrom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[High risk and silent clonal hematopoietic genotypes in patients with non-hematologic cancer]]></title>
        <id>pubmed:38147626</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38147626/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240104195306&amp;v=2.18.0"/>
        <updated>2023-12-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) identified by somatic gene variants with variant allele fraction (VAF) >= 2% is associated with an increased risk of hematologic malignancy. However, CH defined by a broader set of genotypes and lower VAFs is ubiquitous in older individuals. To improve our understanding of the relationship between CH genotype and risk of hematologic malignancy we analyzed data from 42,714 patients who underwent blood sequencing as a normal comparator for non-hematologic tumor testing...]]></summary>
        <author>
            <name>Aaron James Stonestrom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[High risk and silent clonal hematopoietic genotypes in patients with non-hematologic cancer]]></title>
        <id>pubmed:38147626</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38147626/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240103195259&amp;v=2.18.0"/>
        <updated>2023-12-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) identified by somatic gene variants with variant allele fraction (VAF) >= 2% is associated with an increased risk of hematologic malignancy. However, CH defined by a broader set of genotypes and lower VAFs is ubiquitous in older individuals. To improve our understanding of the relationship between CH genotype and risk of hematologic malignancy we analyzed data from 42,714 patients who underwent blood sequencing as a normal comparator for non-hematologic tumor testing...]]></summary>
        <author>
            <name>Aaron James Stonestrom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[High risk and silent clonal hematopoietic genotypes in patients with non-hematologic cancer]]></title>
        <id>pubmed:38147626</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38147626/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240102195247&amp;v=2.18.0"/>
        <updated>2023-12-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) identified by somatic gene variants with variant allele fraction (VAF) >= 2% is associated with an increased risk of hematologic malignancy. However, CH defined by a broader set of genotypes and lower VAFs is ubiquitous in older individuals. To improve our understanding of the relationship between CH genotype and risk of hematologic malignancy we analyzed data from 42,714 patients who underwent blood sequencing as a normal comparator for non-hematologic tumor testing...]]></summary>
        <author>
            <name>Aaron James Stonestrom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[High risk and silent clonal hematopoietic genotypes in patients with non-hematologic cancer]]></title>
        <id>pubmed:38147626</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38147626/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240101195419&amp;v=2.18.0"/>
        <updated>2023-12-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) identified by somatic gene variants with variant allele fraction (VAF) >= 2% is associated with an increased risk of hematologic malignancy. However, CH defined by a broader set of genotypes and lower VAFs is ubiquitous in older individuals. To improve our understanding of the relationship between CH genotype and risk of hematologic malignancy we analyzed data from 42,714 patients who underwent blood sequencing as a normal comparator for non-hematologic tumor testing...]]></summary>
        <author>
            <name>Aaron James Stonestrom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[High risk and silent clonal hematopoietic genotypes in patients with non-hematologic cancer]]></title>
        <id>pubmed:38147626</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38147626/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231231195742&amp;v=2.18.0"/>
        <updated>2023-12-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) identified by somatic gene variants with variant allele fraction (VAF) >= 2% is associated with an increased risk of hematologic malignancy. However, CH defined by a broader set of genotypes and lower VAFs is ubiquitous in older individuals. To improve our understanding of the relationship between CH genotype and risk of hematologic malignancy we analyzed data from 42,714 patients who underwent blood sequencing as a normal comparator for non-hematologic tumor testing...]]></summary>
        <author>
            <name>Aaron James Stonestrom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[High risk and silent clonal hematopoietic genotypes in patients with non-hematologic cancer]]></title>
        <id>pubmed:38147626</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38147626/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231230195628&amp;v=2.18.0"/>
        <updated>2023-12-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) identified by somatic gene variants with variant allele fraction (VAF) >= 2% is associated with an increased risk of hematologic malignancy. However, CH defined by a broader set of genotypes and lower VAFs is ubiquitous in older individuals. To improve our understanding of the relationship between CH genotype and risk of hematologic malignancy we analyzed data from 42,714 patients who underwent blood sequencing as a normal comparator for non-hematologic tumor testing...]]></summary>
        <author>
            <name>Aaron James Stonestrom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[High risk and silent clonal hematopoietic genotypes in patients with non-hematologic cancer]]></title>
        <id>pubmed:38147626</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38147626/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231229195054&amp;v=2.18.0"/>
        <updated>2023-12-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) identified by somatic gene variants with variant allele fraction (VAF) >= 2% is associated with an increased risk of hematologic malignancy. However, CH defined by a broader set of genotypes and lower VAFs is ubiquitous in older individuals. To improve our understanding of the relationship between CH genotype and risk of hematologic malignancy we analyzed data from 42,714 patients who underwent blood sequencing as a normal comparator for non-hematologic tumor testing...]]></summary>
        <author>
            <name>Aaron James Stonestrom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[High risk and silent clonal hematopoietic genotypes in patients with non-hematologic cancer]]></title>
        <id>pubmed:38147626</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38147626/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231228194204&amp;v=2.18.0"/>
        <updated>2023-12-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) identified by somatic gene variants with variant allele fraction (VAF) >= 2% is associated with an increased risk of hematologic malignancy. However, CH defined by a broader set of genotypes and lower VAFs is ubiquitous in older individuals. To improve our understanding of the relationship between CH genotype and risk of hematologic malignancy we analyzed data from 42,714 patients who underwent blood sequencing as a normal comparator for non-hematologic tumor testing...]]></summary>
        <author>
            <name>Aaron James Stonestrom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[High risk and silent clonal hematopoietic genotypes in patients with non-hematologic cancer]]></title>
        <id>pubmed:38147626</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38147626/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231227195056&amp;v=2.18.0"/>
        <updated>2023-12-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) identified by somatic gene variants with variant allele fraction (VAF) >= 2% is associated with an increased risk of hematologic malignancy. However, CH defined by a broader set of genotypes and lower VAFs is ubiquitous in older individuals. To improve our understanding of the relationship between CH genotype and risk of hematologic malignancy we analyzed data from 42,714 patients who underwent blood sequencing as a normal comparator for non-hematologic tumor testing...]]></summary>
        <author>
            <name>Aaron James Stonestrom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[High risk and silent clonal hematopoietic genotypes in patients with non-hematologic cancer]]></title>
        <id>pubmed:38147626</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38147626/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231226195107&amp;v=2.18.0"/>
        <updated>2023-12-26T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) identified by somatic gene variants with variant allele fraction (VAF) >= 2% is associated with an increased risk of hematologic malignancy. However, CH defined by a broader set of genotypes and lower VAFs is ubiquitous in older individuals. To improve our understanding of the relationship between CH genotype and risk of hematologic malignancy we analyzed data from 42,714 patients who underwent blood sequencing as a normal comparator for non-hematologic tumor testing...]]></summary>
        <author>
            <name>Aaron James Stonestrom</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Jak2V617F clonal hematopoiesis promotes arterial thrombosis via platelet activation and cross-talk]]></title>
        <id>pubmed:38142422</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38142422/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240110195405&amp;v=2.18.0"/>
        <updated>2023-12-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[JAK2V617F (JAK2VF) clonal hematopoiesis (CH) has been associated with atherothrombotic cardiovascular disease (CVD). We assessed the impact of Jak2VF CH on arterial thrombosis and explored the underlying mechanisms. A meta-analysis of three large cohort studies confirmed the association of JAK2VF with CVD, and with platelet counts and adjusted mean platelet volume (MPV). In mice, 20% or 1.5% Jak2VF CH accelerated arterial thrombosis and increased platelet activation. Megakaryocytes in Jak2VF CH...]]></summary>
        <author>
            <name>Wenli Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Jak2V617F clonal hematopoiesis promotes arterial thrombosis via platelet activation and cross-talk]]></title>
        <id>pubmed:38142422</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38142422/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240109195408&amp;v=2.18.0"/>
        <updated>2023-12-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[JAK2V617F (JAK2VF) clonal hematopoiesis (CH) has been associated with atherothrombotic cardiovascular disease (CVD). We assessed the impact of Jak2VF CH on arterial thrombosis and explored the underlying mechanisms. A meta-analysis of three large cohort studies confirmed the association of JAK2VF with CVD, and with platelet counts and adjusted mean platelet volume (MPV). In mice, 20% or 1.5% Jak2VF CH accelerated arterial thrombosis and increased platelet activation. Megakaryocytes in Jak2VF CH...]]></summary>
        <author>
            <name>Wenli Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Jak2V617F clonal hematopoiesis promotes arterial thrombosis via platelet activation and cross-talk]]></title>
        <id>pubmed:38142422</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38142422/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240108195354&amp;v=2.18.0"/>
        <updated>2023-12-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[JAK2V617F (JAK2VF) clonal hematopoiesis (CH) has been associated with atherothrombotic cardiovascular disease (CVD). We assessed the impact of Jak2VF CH on arterial thrombosis and explored the underlying mechanisms. A meta-analysis of three large cohort studies confirmed the association of JAK2VF with CVD, and with platelet counts and adjusted mean platelet volume (MPV). In mice, 20% or 1.5% Jak2VF CH accelerated arterial thrombosis and increased platelet activation. Megakaryocytes in Jak2VF CH...]]></summary>
        <author>
            <name>Wenli Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Jak2V617F clonal hematopoiesis promotes arterial thrombosis via platelet activation and cross-talk]]></title>
        <id>pubmed:38142422</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38142422/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240107195432&amp;v=2.18.0"/>
        <updated>2023-12-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[JAK2V617F (JAK2VF) clonal hematopoiesis (CH) has been associated with atherothrombotic cardiovascular disease (CVD). We assessed the impact of Jak2VF CH on arterial thrombosis and explored the underlying mechanisms. A meta-analysis of three large cohort studies confirmed the association of JAK2VF with CVD, and with platelet counts and adjusted mean platelet volume (MPV). In mice, 20% or 1.5% Jak2VF CH accelerated arterial thrombosis and increased platelet activation. Megakaryocytes in Jak2VF CH...]]></summary>
        <author>
            <name>Wenli Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Jak2V617F clonal hematopoiesis promotes arterial thrombosis via platelet activation and cross-talk]]></title>
        <id>pubmed:38142422</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38142422/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240106195750&amp;v=2.18.0"/>
        <updated>2023-12-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[JAK2V617F (JAK2VF) clonal hematopoiesis (CH) has been associated with atherothrombotic cardiovascular disease (CVD). We assessed the impact of Jak2VF CH on arterial thrombosis and explored the underlying mechanisms. A meta-analysis of three large cohort studies confirmed the association of JAK2VF with CVD, and with platelet counts and adjusted mean platelet volume (MPV). In mice, 20% or 1.5% Jak2VF CH accelerated arterial thrombosis and increased platelet activation. Megakaryocytes in Jak2VF CH...]]></summary>
        <author>
            <name>Wenli Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Jak2V617F clonal hematopoiesis promotes arterial thrombosis via platelet activation and cross-talk]]></title>
        <id>pubmed:38142422</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38142422/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240105195208&amp;v=2.18.0"/>
        <updated>2023-12-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[JAK2V617F (JAK2VF) clonal hematopoiesis (CH) has been associated with atherothrombotic cardiovascular disease (CVD). We assessed the impact of Jak2VF CH on arterial thrombosis and explored the underlying mechanisms. A meta-analysis of three large cohort studies confirmed the association of JAK2VF with CVD, and with platelet counts and adjusted mean platelet volume (MPV). In mice, 20% or 1.5% Jak2VF CH accelerated arterial thrombosis and increased platelet activation. Megakaryocytes in Jak2VF CH...]]></summary>
        <author>
            <name>Wenli Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Jak2V617F clonal hematopoiesis promotes arterial thrombosis via platelet activation and cross-talk]]></title>
        <id>pubmed:38142422</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38142422/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240104195306&amp;v=2.18.0"/>
        <updated>2023-12-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[JAK2V617F (JAK2VF) clonal hematopoiesis (CH) has been associated with atherothrombotic cardiovascular disease (CVD). We assessed the impact of Jak2VF CH on arterial thrombosis and explored the underlying mechanisms. A meta-analysis of three large cohort studies confirmed the association of JAK2VF with CVD, and with platelet counts and adjusted mean platelet volume (MPV). In mice, 20% or 1.5% Jak2VF CH accelerated arterial thrombosis and increased platelet activation. Megakaryocytes in Jak2VF CH...]]></summary>
        <author>
            <name>Wenli Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Jak2V617F clonal hematopoiesis promotes arterial thrombosis via platelet activation and cross-talk]]></title>
        <id>pubmed:38142422</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38142422/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240103195259&amp;v=2.18.0"/>
        <updated>2023-12-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[JAK2V617F (JAK2VF) clonal hematopoiesis (CH) has been associated with atherothrombotic cardiovascular disease (CVD). We assessed the impact of Jak2VF CH on arterial thrombosis and explored the underlying mechanisms. A meta-analysis of three large cohort studies confirmed the association of JAK2VF with CVD, and with platelet counts and adjusted mean platelet volume (MPV). In mice, 20% or 1.5% Jak2VF CH accelerated arterial thrombosis and increased platelet activation. Megakaryocytes in Jak2VF CH...]]></summary>
        <author>
            <name>Wenli Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Jak2V617F clonal hematopoiesis promotes arterial thrombosis via platelet activation and cross-talk]]></title>
        <id>pubmed:38142422</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38142422/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240102195247&amp;v=2.18.0"/>
        <updated>2023-12-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[JAK2V617F (JAK2VF) clonal hematopoiesis (CH) has been associated with atherothrombotic cardiovascular disease (CVD). We assessed the impact of Jak2VF CH on arterial thrombosis and explored the underlying mechanisms. A meta-analysis of three large cohort studies confirmed the association of JAK2VF with CVD, and with platelet counts and adjusted mean platelet volume (MPV). In mice, 20% or 1.5% Jak2VF CH accelerated arterial thrombosis and increased platelet activation. Megakaryocytes in Jak2VF CH...]]></summary>
        <author>
            <name>Wenli Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Jak2V617F clonal hematopoiesis promotes arterial thrombosis via platelet activation and cross-talk]]></title>
        <id>pubmed:38142422</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38142422/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240101195419&amp;v=2.18.0"/>
        <updated>2023-12-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[JAK2V617F (JAK2VF) clonal hematopoiesis (CH) has been associated with atherothrombotic cardiovascular disease (CVD). We assessed the impact of Jak2VF CH on arterial thrombosis and explored the underlying mechanisms. A meta-analysis of three large cohort studies confirmed the association of JAK2VF with CVD, and with platelet counts and adjusted mean platelet volume (MPV). In mice, 20% or 1.5% Jak2VF CH accelerated arterial thrombosis and increased platelet activation. Megakaryocytes in Jak2VF CH...]]></summary>
        <author>
            <name>Wenli Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Jak2V617F clonal hematopoiesis promotes arterial thrombosis via platelet activation and cross-talk]]></title>
        <id>pubmed:38142422</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38142422/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231231195742&amp;v=2.18.0"/>
        <updated>2023-12-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[JAK2V617F (JAK2VF) clonal hematopoiesis (CH) has been associated with atherothrombotic cardiovascular disease (CVD). We assessed the impact of Jak2VF CH on arterial thrombosis and explored the underlying mechanisms. A meta-analysis of three large cohort studies confirmed the association of JAK2VF with CVD, and with platelet counts and adjusted mean platelet volume (MPV). In mice, 20% or 1.5% Jak2VF CH accelerated arterial thrombosis and increased platelet activation. Megakaryocytes in Jak2VF CH...]]></summary>
        <author>
            <name>Wenli Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Jak2V617F clonal hematopoiesis promotes arterial thrombosis via platelet activation and cross-talk]]></title>
        <id>pubmed:38142422</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38142422/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231230195628&amp;v=2.18.0"/>
        <updated>2023-12-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[JAK2V617F (JAK2VF) clonal hematopoiesis (CH) has been associated with atherothrombotic cardiovascular disease (CVD). We assessed the impact of Jak2VF CH on arterial thrombosis and explored the underlying mechanisms. A meta-analysis of three large cohort studies confirmed the association of JAK2VF with CVD, and with platelet counts and adjusted mean platelet volume (MPV). In mice, 20% or 1.5% Jak2VF CH accelerated arterial thrombosis and increased platelet activation. Megakaryocytes in Jak2VF CH...]]></summary>
        <author>
            <name>Wenli Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Jak2V617F clonal hematopoiesis promotes arterial thrombosis via platelet activation and cross-talk]]></title>
        <id>pubmed:38142422</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38142422/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231229195054&amp;v=2.18.0"/>
        <updated>2023-12-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[JAK2V617F (JAK2VF) clonal hematopoiesis (CH) has been associated with atherothrombotic cardiovascular disease (CVD). We assessed the impact of Jak2VF CH on arterial thrombosis and explored the underlying mechanisms. A meta-analysis of three large cohort studies confirmed the association of JAK2VF with CVD, and with platelet counts and adjusted mean platelet volume (MPV). In mice, 20% or 1.5% Jak2VF CH accelerated arterial thrombosis and increased platelet activation. Megakaryocytes in Jak2VF CH...]]></summary>
        <author>
            <name>Wenli Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Jak2V617F clonal hematopoiesis promotes arterial thrombosis via platelet activation and cross-talk]]></title>
        <id>pubmed:38142422</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38142422/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231228194204&amp;v=2.18.0"/>
        <updated>2023-12-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[JAK2V617F (JAK2VF) clonal hematopoiesis (CH) has been associated with atherothrombotic cardiovascular disease (CVD). We assessed the impact of Jak2VF CH on arterial thrombosis and explored the underlying mechanisms. A meta-analysis of three large cohort studies confirmed the association of JAK2VF with CVD, and with platelet counts and adjusted mean platelet volume (MPV). In mice, 20% or 1.5% Jak2VF CH accelerated arterial thrombosis and increased platelet activation. Megakaryocytes in Jak2VF CH...]]></summary>
        <author>
            <name>Wenli Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Jak2V617F clonal hematopoiesis promotes arterial thrombosis via platelet activation and cross-talk]]></title>
        <id>pubmed:38142422</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38142422/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231227195056&amp;v=2.18.0"/>
        <updated>2023-12-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[JAK2V617F (JAK2VF) clonal hematopoiesis (CH) has been associated with atherothrombotic cardiovascular disease (CVD). We assessed the impact of Jak2VF CH on arterial thrombosis and explored the underlying mechanisms. A meta-analysis of three large cohort studies confirmed the association of JAK2VF with CVD, and with platelet counts and adjusted mean platelet volume (MPV). In mice, 20% or 1.5% Jak2VF CH accelerated arterial thrombosis and increased platelet activation. Megakaryocytes in Jak2VF CH...]]></summary>
        <author>
            <name>Wenli Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Jak2V617F clonal hematopoiesis promotes arterial thrombosis via platelet activation and cross-talk]]></title>
        <id>pubmed:38142422</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38142422/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231226195107&amp;v=2.18.0"/>
        <updated>2023-12-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[JAK2V617F (JAK2VF) clonal hematopoiesis (CH) has been associated with atherothrombotic cardiovascular disease (CVD). We assessed the impact of Jak2VF CH on arterial thrombosis and explored the underlying mechanisms. A meta-analysis of three large cohort studies confirmed the association of JAK2VF with CVD, and with platelet counts and adjusted mean platelet volume (MPV). In mice, 20% or 1.5% Jak2VF CH accelerated arterial thrombosis and increased platelet activation. Megakaryocytes in Jak2VF CH...]]></summary>
        <author>
            <name>Wenli Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Jak2V617F clonal hematopoiesis promotes arterial thrombosis via platelet activation and cross-talk]]></title>
        <id>pubmed:38142422</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38142422/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231225195059&amp;v=2.18.0"/>
        <updated>2023-12-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[JAK2V617F (JAK2VF) clonal hematopoiesis (CH) has been associated with atherothrombotic cardiovascular disease (CVD). We assessed the impact of Jak2VF CH on arterial thrombosis and explored the underlying mechanisms. A meta-analysis of three large cohort studies confirmed the association of JAK2VF with CVD, and with platelet counts and adjusted mean platelet volume (MPV). In mice, 20% or 1.5% Jak2VF CH accelerated arterial thrombosis and increased platelet activation. Megakaryocytes in Jak2VF CH...]]></summary>
        <author>
            <name>Wenli Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Jak2V617F clonal hematopoiesis promotes arterial thrombosis via platelet activation and cross-talk]]></title>
        <id>pubmed:38142422</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38142422/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231224195316&amp;v=2.18.0"/>
        <updated>2023-12-24T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[JAK2V617F (JAK2VF) clonal hematopoiesis (CH) has been associated with atherothrombotic cardiovascular disease (CVD). We assessed the impact of Jak2VF CH on arterial thrombosis and explored the underlying mechanisms. A meta-analysis of three large cohort studies confirmed the association of JAK2VF with CVD, and with platelet counts and adjusted mean platelet volume (MPV). In mice, 20% or 1.5% Jak2VF CH accelerated arterial thrombosis and increased platelet activation. Megakaryocytes in Jak2VF CH...]]></summary>
        <author>
            <name>Wenli Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploiting Synthetic Lethality between Germline BRCA1 Haploinsufficiency and PARP Inhibition in JAK2V617F-Positive Myeloproliferative Neoplasms]]></title>
        <id>pubmed:38139386</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38139386/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240109195408&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are rare hematologic disorders characterized by clonal hematopoiesis. Familial clustering is observed in a subset of cases, with a notable proportion exhibiting heterozygous germline mutations in DNA double-strand break repair genes (e.g., BRCA1). We investigated the therapeutic potential of targeting BRCA1 haploinsufficiency alongside the JAK2V617F driver mutation. We assessed the efficacy of combining the PARP inhibitor olaparib with interferon-alpha (IFN)...]]></summary>
        <author>
            <name>Max Bermes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cells in Atherosclerosis: Focus on Cellular Senescence from Basic Science to Clinical Practice]]></title>
        <id>pubmed:38138958</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38138958/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240109195408&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is a major risk factor of atherosclerosis through different complex pathways including replicative cellular senescence and age-related clonal hematopoiesis. In addition to aging, extracellular stress factors, such as mechanical and oxidative stress, can induce cellular senescence, defined as premature cellular senescence. Senescent cells can accumulate within atherosclerotic plaques over time and contribute to plaque instability. This review summarizes the role of cellular senescence in...]]></summary>
        <author>
            <name>Andrea gnes Molnr</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Long Telomeric Repeat-Containing RNA (TERRA): Biological Functions and Challenges in Vascular Aging and Disease]]></title>
        <id>pubmed:38137431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38137431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240109195408&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Telomere dysfunction is implicated in vascular aging and shorter leucocyte telomeres are associated with an increased risk of atherosclerosis, myocardial infarction, and heart failure. Another pathophysiological mechanism that explains the causal relationship between telomere shortening and atherosclerosis development focuses on the clonal hematopoiesis of indeterminate potential (CHIP), which represents a new and independent risk factor in atherosclerotic cardiovascular diseases. Since telomere...]]></summary>
        <author>
            <name>Paola Canale</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploiting Synthetic Lethality between Germline BRCA1 Haploinsufficiency and PARP Inhibition in JAK2V617F-Positive Myeloproliferative Neoplasms]]></title>
        <id>pubmed:38139386</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38139386/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240108195354&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are rare hematologic disorders characterized by clonal hematopoiesis. Familial clustering is observed in a subset of cases, with a notable proportion exhibiting heterozygous germline mutations in DNA double-strand break repair genes (e.g., BRCA1). We investigated the therapeutic potential of targeting BRCA1 haploinsufficiency alongside the JAK2V617F driver mutation. We assessed the efficacy of combining the PARP inhibitor olaparib with interferon-alpha (IFN)...]]></summary>
        <author>
            <name>Max Bermes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cells in Atherosclerosis: Focus on Cellular Senescence from Basic Science to Clinical Practice]]></title>
        <id>pubmed:38138958</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38138958/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240108195354&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is a major risk factor of atherosclerosis through different complex pathways including replicative cellular senescence and age-related clonal hematopoiesis. In addition to aging, extracellular stress factors, such as mechanical and oxidative stress, can induce cellular senescence, defined as premature cellular senescence. Senescent cells can accumulate within atherosclerotic plaques over time and contribute to plaque instability. This review summarizes the role of cellular senescence in...]]></summary>
        <author>
            <name>Andrea gnes Molnr</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Long Telomeric Repeat-Containing RNA (TERRA): Biological Functions and Challenges in Vascular Aging and Disease]]></title>
        <id>pubmed:38137431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38137431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240108195354&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Telomere dysfunction is implicated in vascular aging and shorter leucocyte telomeres are associated with an increased risk of atherosclerosis, myocardial infarction, and heart failure. Another pathophysiological mechanism that explains the causal relationship between telomere shortening and atherosclerosis development focuses on the clonal hematopoiesis of indeterminate potential (CHIP), which represents a new and independent risk factor in atherosclerotic cardiovascular diseases. Since telomere...]]></summary>
        <author>
            <name>Paola Canale</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploiting Synthetic Lethality between Germline BRCA1 Haploinsufficiency and PARP Inhibition in JAK2V617F-Positive Myeloproliferative Neoplasms]]></title>
        <id>pubmed:38139386</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38139386/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240107195432&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are rare hematologic disorders characterized by clonal hematopoiesis. Familial clustering is observed in a subset of cases, with a notable proportion exhibiting heterozygous germline mutations in DNA double-strand break repair genes (e.g., BRCA1). We investigated the therapeutic potential of targeting BRCA1 haploinsufficiency alongside the JAK2V617F driver mutation. We assessed the efficacy of combining the PARP inhibitor olaparib with interferon-alpha (IFN)...]]></summary>
        <author>
            <name>Max Bermes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cells in Atherosclerosis: Focus on Cellular Senescence from Basic Science to Clinical Practice]]></title>
        <id>pubmed:38138958</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38138958/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240107195432&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is a major risk factor of atherosclerosis through different complex pathways including replicative cellular senescence and age-related clonal hematopoiesis. In addition to aging, extracellular stress factors, such as mechanical and oxidative stress, can induce cellular senescence, defined as premature cellular senescence. Senescent cells can accumulate within atherosclerotic plaques over time and contribute to plaque instability. This review summarizes the role of cellular senescence in...]]></summary>
        <author>
            <name>Andrea gnes Molnr</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Long Telomeric Repeat-Containing RNA (TERRA): Biological Functions and Challenges in Vascular Aging and Disease]]></title>
        <id>pubmed:38137431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38137431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240107195432&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Telomere dysfunction is implicated in vascular aging and shorter leucocyte telomeres are associated with an increased risk of atherosclerosis, myocardial infarction, and heart failure. Another pathophysiological mechanism that explains the causal relationship between telomere shortening and atherosclerosis development focuses on the clonal hematopoiesis of indeterminate potential (CHIP), which represents a new and independent risk factor in atherosclerotic cardiovascular diseases. Since telomere...]]></summary>
        <author>
            <name>Paola Canale</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploiting Synthetic Lethality between Germline BRCA1 Haploinsufficiency and PARP Inhibition in JAK2V617F-Positive Myeloproliferative Neoplasms]]></title>
        <id>pubmed:38139386</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38139386/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240106195750&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are rare hematologic disorders characterized by clonal hematopoiesis. Familial clustering is observed in a subset of cases, with a notable proportion exhibiting heterozygous germline mutations in DNA double-strand break repair genes (e.g., BRCA1). We investigated the therapeutic potential of targeting BRCA1 haploinsufficiency alongside the JAK2V617F driver mutation. We assessed the efficacy of combining the PARP inhibitor olaparib with interferon-alpha (IFN)...]]></summary>
        <author>
            <name>Max Bermes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cells in Atherosclerosis: Focus on Cellular Senescence from Basic Science to Clinical Practice]]></title>
        <id>pubmed:38138958</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38138958/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240106195750&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is a major risk factor of atherosclerosis through different complex pathways including replicative cellular senescence and age-related clonal hematopoiesis. In addition to aging, extracellular stress factors, such as mechanical and oxidative stress, can induce cellular senescence, defined as premature cellular senescence. Senescent cells can accumulate within atherosclerotic plaques over time and contribute to plaque instability. This review summarizes the role of cellular senescence in...]]></summary>
        <author>
            <name>Andrea gnes Molnr</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Long Telomeric Repeat-Containing RNA (TERRA): Biological Functions and Challenges in Vascular Aging and Disease]]></title>
        <id>pubmed:38137431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38137431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240106195750&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Telomere dysfunction is implicated in vascular aging and shorter leucocyte telomeres are associated with an increased risk of atherosclerosis, myocardial infarction, and heart failure. Another pathophysiological mechanism that explains the causal relationship between telomere shortening and atherosclerosis development focuses on the clonal hematopoiesis of indeterminate potential (CHIP), which represents a new and independent risk factor in atherosclerotic cardiovascular diseases. Since telomere...]]></summary>
        <author>
            <name>Paola Canale</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploiting Synthetic Lethality between Germline BRCA1 Haploinsufficiency and PARP Inhibition in JAK2V617F-Positive Myeloproliferative Neoplasms]]></title>
        <id>pubmed:38139386</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38139386/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240105195208&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are rare hematologic disorders characterized by clonal hematopoiesis. Familial clustering is observed in a subset of cases, with a notable proportion exhibiting heterozygous germline mutations in DNA double-strand break repair genes (e.g., BRCA1). We investigated the therapeutic potential of targeting BRCA1 haploinsufficiency alongside the JAK2V617F driver mutation. We assessed the efficacy of combining the PARP inhibitor olaparib with interferon-alpha (IFN)...]]></summary>
        <author>
            <name>Max Bermes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cells in Atherosclerosis: Focus on Cellular Senescence from Basic Science to Clinical Practice]]></title>
        <id>pubmed:38138958</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38138958/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240105195208&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is a major risk factor of atherosclerosis through different complex pathways including replicative cellular senescence and age-related clonal hematopoiesis. In addition to aging, extracellular stress factors, such as mechanical and oxidative stress, can induce cellular senescence, defined as premature cellular senescence. Senescent cells can accumulate within atherosclerotic plaques over time and contribute to plaque instability. This review summarizes the role of cellular senescence in...]]></summary>
        <author>
            <name>Andrea gnes Molnr</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Long Telomeric Repeat-Containing RNA (TERRA): Biological Functions and Challenges in Vascular Aging and Disease]]></title>
        <id>pubmed:38137431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38137431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240105195208&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Telomere dysfunction is implicated in vascular aging and shorter leucocyte telomeres are associated with an increased risk of atherosclerosis, myocardial infarction, and heart failure. Another pathophysiological mechanism that explains the causal relationship between telomere shortening and atherosclerosis development focuses on the clonal hematopoiesis of indeterminate potential (CHIP), which represents a new and independent risk factor in atherosclerotic cardiovascular diseases. Since telomere...]]></summary>
        <author>
            <name>Paola Canale</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploiting Synthetic Lethality between Germline BRCA1 Haploinsufficiency and PARP Inhibition in JAK2V617F-Positive Myeloproliferative Neoplasms]]></title>
        <id>pubmed:38139386</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38139386/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240104195306&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are rare hematologic disorders characterized by clonal hematopoiesis. Familial clustering is observed in a subset of cases, with a notable proportion exhibiting heterozygous germline mutations in DNA double-strand break repair genes (e.g., BRCA1). We investigated the therapeutic potential of targeting BRCA1 haploinsufficiency alongside the JAK2V617F driver mutation. We assessed the efficacy of combining the PARP inhibitor olaparib with interferon-alpha (IFN)...]]></summary>
        <author>
            <name>Max Bermes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cells in Atherosclerosis: Focus on Cellular Senescence from Basic Science to Clinical Practice]]></title>
        <id>pubmed:38138958</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38138958/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240104195306&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is a major risk factor of atherosclerosis through different complex pathways including replicative cellular senescence and age-related clonal hematopoiesis. In addition to aging, extracellular stress factors, such as mechanical and oxidative stress, can induce cellular senescence, defined as premature cellular senescence. Senescent cells can accumulate within atherosclerotic plaques over time and contribute to plaque instability. This review summarizes the role of cellular senescence in...]]></summary>
        <author>
            <name>Andrea gnes Molnr</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Long Telomeric Repeat-Containing RNA (TERRA): Biological Functions and Challenges in Vascular Aging and Disease]]></title>
        <id>pubmed:38137431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38137431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240104195306&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Telomere dysfunction is implicated in vascular aging and shorter leucocyte telomeres are associated with an increased risk of atherosclerosis, myocardial infarction, and heart failure. Another pathophysiological mechanism that explains the causal relationship between telomere shortening and atherosclerosis development focuses on the clonal hematopoiesis of indeterminate potential (CHIP), which represents a new and independent risk factor in atherosclerotic cardiovascular diseases. Since telomere...]]></summary>
        <author>
            <name>Paola Canale</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploiting Synthetic Lethality between Germline BRCA1 Haploinsufficiency and PARP Inhibition in JAK2V617F-Positive Myeloproliferative Neoplasms]]></title>
        <id>pubmed:38139386</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38139386/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240103195259&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are rare hematologic disorders characterized by clonal hematopoiesis. Familial clustering is observed in a subset of cases, with a notable proportion exhibiting heterozygous germline mutations in DNA double-strand break repair genes (e.g., BRCA1). We investigated the therapeutic potential of targeting BRCA1 haploinsufficiency alongside the JAK2V617F driver mutation. We assessed the efficacy of combining the PARP inhibitor olaparib with interferon-alpha (IFN)...]]></summary>
        <author>
            <name>Max Bermes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cells in Atherosclerosis: Focus on Cellular Senescence from Basic Science to Clinical Practice]]></title>
        <id>pubmed:38138958</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38138958/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240103195259&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is a major risk factor of atherosclerosis through different complex pathways including replicative cellular senescence and age-related clonal hematopoiesis. In addition to aging, extracellular stress factors, such as mechanical and oxidative stress, can induce cellular senescence, defined as premature cellular senescence. Senescent cells can accumulate within atherosclerotic plaques over time and contribute to plaque instability. This review summarizes the role of cellular senescence in...]]></summary>
        <author>
            <name>Andrea gnes Molnr</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Long Telomeric Repeat-Containing RNA (TERRA): Biological Functions and Challenges in Vascular Aging and Disease]]></title>
        <id>pubmed:38137431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38137431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240103195259&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Telomere dysfunction is implicated in vascular aging and shorter leucocyte telomeres are associated with an increased risk of atherosclerosis, myocardial infarction, and heart failure. Another pathophysiological mechanism that explains the causal relationship between telomere shortening and atherosclerosis development focuses on the clonal hematopoiesis of indeterminate potential (CHIP), which represents a new and independent risk factor in atherosclerotic cardiovascular diseases. Since telomere...]]></summary>
        <author>
            <name>Paola Canale</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploiting Synthetic Lethality between Germline BRCA1 Haploinsufficiency and PARP Inhibition in JAK2V617F-Positive Myeloproliferative Neoplasms]]></title>
        <id>pubmed:38139386</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38139386/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240102195247&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are rare hematologic disorders characterized by clonal hematopoiesis. Familial clustering is observed in a subset of cases, with a notable proportion exhibiting heterozygous germline mutations in DNA double-strand break repair genes (e.g., BRCA1). We investigated the therapeutic potential of targeting BRCA1 haploinsufficiency alongside the JAK2V617F driver mutation. We assessed the efficacy of combining the PARP inhibitor olaparib with interferon-alpha (IFN)...]]></summary>
        <author>
            <name>Max Bermes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cells in Atherosclerosis: Focus on Cellular Senescence from Basic Science to Clinical Practice]]></title>
        <id>pubmed:38138958</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38138958/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240102195247&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is a major risk factor of atherosclerosis through different complex pathways including replicative cellular senescence and age-related clonal hematopoiesis. In addition to aging, extracellular stress factors, such as mechanical and oxidative stress, can induce cellular senescence, defined as premature cellular senescence. Senescent cells can accumulate within atherosclerotic plaques over time and contribute to plaque instability. This review summarizes the role of cellular senescence in...]]></summary>
        <author>
            <name>Andrea gnes Molnr</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Long Telomeric Repeat-Containing RNA (TERRA): Biological Functions and Challenges in Vascular Aging and Disease]]></title>
        <id>pubmed:38137431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38137431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240102195247&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Telomere dysfunction is implicated in vascular aging and shorter leucocyte telomeres are associated with an increased risk of atherosclerosis, myocardial infarction, and heart failure. Another pathophysiological mechanism that explains the causal relationship between telomere shortening and atherosclerosis development focuses on the clonal hematopoiesis of indeterminate potential (CHIP), which represents a new and independent risk factor in atherosclerotic cardiovascular diseases. Since telomere...]]></summary>
        <author>
            <name>Paola Canale</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploiting Synthetic Lethality between Germline BRCA1 Haploinsufficiency and PARP Inhibition in JAK2V617F-Positive Myeloproliferative Neoplasms]]></title>
        <id>pubmed:38139386</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38139386/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240101195419&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are rare hematologic disorders characterized by clonal hematopoiesis. Familial clustering is observed in a subset of cases, with a notable proportion exhibiting heterozygous germline mutations in DNA double-strand break repair genes (e.g., BRCA1). We investigated the therapeutic potential of targeting BRCA1 haploinsufficiency alongside the JAK2V617F driver mutation. We assessed the efficacy of combining the PARP inhibitor olaparib with interferon-alpha (IFN)...]]></summary>
        <author>
            <name>Max Bermes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cells in Atherosclerosis: Focus on Cellular Senescence from Basic Science to Clinical Practice]]></title>
        <id>pubmed:38138958</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38138958/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240101195419&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is a major risk factor of atherosclerosis through different complex pathways including replicative cellular senescence and age-related clonal hematopoiesis. In addition to aging, extracellular stress factors, such as mechanical and oxidative stress, can induce cellular senescence, defined as premature cellular senescence. Senescent cells can accumulate within atherosclerotic plaques over time and contribute to plaque instability. This review summarizes the role of cellular senescence in...]]></summary>
        <author>
            <name>Andrea gnes Molnr</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Long Telomeric Repeat-Containing RNA (TERRA): Biological Functions and Challenges in Vascular Aging and Disease]]></title>
        <id>pubmed:38137431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38137431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240101195419&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Telomere dysfunction is implicated in vascular aging and shorter leucocyte telomeres are associated with an increased risk of atherosclerosis, myocardial infarction, and heart failure. Another pathophysiological mechanism that explains the causal relationship between telomere shortening and atherosclerosis development focuses on the clonal hematopoiesis of indeterminate potential (CHIP), which represents a new and independent risk factor in atherosclerotic cardiovascular diseases. Since telomere...]]></summary>
        <author>
            <name>Paola Canale</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploiting Synthetic Lethality between Germline BRCA1 Haploinsufficiency and PARP Inhibition in JAK2V617F-Positive Myeloproliferative Neoplasms]]></title>
        <id>pubmed:38139386</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38139386/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231231195742&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are rare hematologic disorders characterized by clonal hematopoiesis. Familial clustering is observed in a subset of cases, with a notable proportion exhibiting heterozygous germline mutations in DNA double-strand break repair genes (e.g., BRCA1). We investigated the therapeutic potential of targeting BRCA1 haploinsufficiency alongside the JAK2V617F driver mutation. We assessed the efficacy of combining the PARP inhibitor olaparib with interferon-alpha (IFN)...]]></summary>
        <author>
            <name>Max Bermes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cells in Atherosclerosis: Focus on Cellular Senescence from Basic Science to Clinical Practice]]></title>
        <id>pubmed:38138958</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38138958/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231231195742&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is a major risk factor of atherosclerosis through different complex pathways including replicative cellular senescence and age-related clonal hematopoiesis. In addition to aging, extracellular stress factors, such as mechanical and oxidative stress, can induce cellular senescence, defined as premature cellular senescence. Senescent cells can accumulate within atherosclerotic plaques over time and contribute to plaque instability. This review summarizes the role of cellular senescence in...]]></summary>
        <author>
            <name>Andrea gnes Molnr</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Long Telomeric Repeat-Containing RNA (TERRA): Biological Functions and Challenges in Vascular Aging and Disease]]></title>
        <id>pubmed:38137431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38137431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231231195742&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Telomere dysfunction is implicated in vascular aging and shorter leucocyte telomeres are associated with an increased risk of atherosclerosis, myocardial infarction, and heart failure. Another pathophysiological mechanism that explains the causal relationship between telomere shortening and atherosclerosis development focuses on the clonal hematopoiesis of indeterminate potential (CHIP), which represents a new and independent risk factor in atherosclerotic cardiovascular diseases. Since telomere...]]></summary>
        <author>
            <name>Paola Canale</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploiting Synthetic Lethality between Germline BRCA1 Haploinsufficiency and PARP Inhibition in JAK2V617F-Positive Myeloproliferative Neoplasms]]></title>
        <id>pubmed:38139386</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38139386/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231230195628&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are rare hematologic disorders characterized by clonal hematopoiesis. Familial clustering is observed in a subset of cases, with a notable proportion exhibiting heterozygous germline mutations in DNA double-strand break repair genes (e.g., BRCA1). We investigated the therapeutic potential of targeting BRCA1 haploinsufficiency alongside the JAK2V617F driver mutation. We assessed the efficacy of combining the PARP inhibitor olaparib with interferon-alpha (IFN)...]]></summary>
        <author>
            <name>Max Bermes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cells in Atherosclerosis: Focus on Cellular Senescence from Basic Science to Clinical Practice]]></title>
        <id>pubmed:38138958</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38138958/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231230195628&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is a major risk factor of atherosclerosis through different complex pathways including replicative cellular senescence and age-related clonal hematopoiesis. In addition to aging, extracellular stress factors, such as mechanical and oxidative stress, can induce cellular senescence, defined as premature cellular senescence. Senescent cells can accumulate within atherosclerotic plaques over time and contribute to plaque instability. This review summarizes the role of cellular senescence in...]]></summary>
        <author>
            <name>Andrea gnes Molnr</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Long Telomeric Repeat-Containing RNA (TERRA): Biological Functions and Challenges in Vascular Aging and Disease]]></title>
        <id>pubmed:38137431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38137431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231230195628&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Telomere dysfunction is implicated in vascular aging and shorter leucocyte telomeres are associated with an increased risk of atherosclerosis, myocardial infarction, and heart failure. Another pathophysiological mechanism that explains the causal relationship between telomere shortening and atherosclerosis development focuses on the clonal hematopoiesis of indeterminate potential (CHIP), which represents a new and independent risk factor in atherosclerotic cardiovascular diseases. Since telomere...]]></summary>
        <author>
            <name>Paola Canale</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploiting Synthetic Lethality between Germline BRCA1 Haploinsufficiency and PARP Inhibition in JAK2V617F-Positive Myeloproliferative Neoplasms]]></title>
        <id>pubmed:38139386</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38139386/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231229195054&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are rare hematologic disorders characterized by clonal hematopoiesis. Familial clustering is observed in a subset of cases, with a notable proportion exhibiting heterozygous germline mutations in DNA double-strand break repair genes (e.g., BRCA1). We investigated the therapeutic potential of targeting BRCA1 haploinsufficiency alongside the JAK2V617F driver mutation. We assessed the efficacy of combining the PARP inhibitor olaparib with interferon-alpha (IFN)...]]></summary>
        <author>
            <name>Max Bermes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cells in Atherosclerosis: Focus on Cellular Senescence from Basic Science to Clinical Practice]]></title>
        <id>pubmed:38138958</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38138958/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231229195054&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is a major risk factor of atherosclerosis through different complex pathways including replicative cellular senescence and age-related clonal hematopoiesis. In addition to aging, extracellular stress factors, such as mechanical and oxidative stress, can induce cellular senescence, defined as premature cellular senescence. Senescent cells can accumulate within atherosclerotic plaques over time and contribute to plaque instability. This review summarizes the role of cellular senescence in...]]></summary>
        <author>
            <name>Andrea gnes Molnr</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Long Telomeric Repeat-Containing RNA (TERRA): Biological Functions and Challenges in Vascular Aging and Disease]]></title>
        <id>pubmed:38137431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38137431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231229195054&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Telomere dysfunction is implicated in vascular aging and shorter leucocyte telomeres are associated with an increased risk of atherosclerosis, myocardial infarction, and heart failure. Another pathophysiological mechanism that explains the causal relationship between telomere shortening and atherosclerosis development focuses on the clonal hematopoiesis of indeterminate potential (CHIP), which represents a new and independent risk factor in atherosclerotic cardiovascular diseases. Since telomere...]]></summary>
        <author>
            <name>Paola Canale</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploiting Synthetic Lethality between Germline BRCA1 Haploinsufficiency and PARP Inhibition in JAK2V617F-Positive Myeloproliferative Neoplasms]]></title>
        <id>pubmed:38139386</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38139386/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231228194204&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are rare hematologic disorders characterized by clonal hematopoiesis. Familial clustering is observed in a subset of cases, with a notable proportion exhibiting heterozygous germline mutations in DNA double-strand break repair genes (e.g., BRCA1). We investigated the therapeutic potential of targeting BRCA1 haploinsufficiency alongside the JAK2V617F driver mutation. We assessed the efficacy of combining the PARP inhibitor olaparib with interferon-alpha (IFN)...]]></summary>
        <author>
            <name>Max Bermes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cells in Atherosclerosis: Focus on Cellular Senescence from Basic Science to Clinical Practice]]></title>
        <id>pubmed:38138958</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38138958/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231228194204&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is a major risk factor of atherosclerosis through different complex pathways including replicative cellular senescence and age-related clonal hematopoiesis. In addition to aging, extracellular stress factors, such as mechanical and oxidative stress, can induce cellular senescence, defined as premature cellular senescence. Senescent cells can accumulate within atherosclerotic plaques over time and contribute to plaque instability. This review summarizes the role of cellular senescence in...]]></summary>
        <author>
            <name>Andrea gnes Molnr</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Long Telomeric Repeat-Containing RNA (TERRA): Biological Functions and Challenges in Vascular Aging and Disease]]></title>
        <id>pubmed:38137431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38137431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231228194204&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Telomere dysfunction is implicated in vascular aging and shorter leucocyte telomeres are associated with an increased risk of atherosclerosis, myocardial infarction, and heart failure. Another pathophysiological mechanism that explains the causal relationship between telomere shortening and atherosclerosis development focuses on the clonal hematopoiesis of indeterminate potential (CHIP), which represents a new and independent risk factor in atherosclerotic cardiovascular diseases. Since telomere...]]></summary>
        <author>
            <name>Paola Canale</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploiting Synthetic Lethality between Germline BRCA1 Haploinsufficiency and PARP Inhibition in JAK2V617F-Positive Myeloproliferative Neoplasms]]></title>
        <id>pubmed:38139386</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38139386/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231227195056&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are rare hematologic disorders characterized by clonal hematopoiesis. Familial clustering is observed in a subset of cases, with a notable proportion exhibiting heterozygous germline mutations in DNA double-strand break repair genes (e.g., BRCA1). We investigated the therapeutic potential of targeting BRCA1 haploinsufficiency alongside the JAK2V617F driver mutation. We assessed the efficacy of combining the PARP inhibitor olaparib with interferon-alpha (IFN)...]]></summary>
        <author>
            <name>Max Bermes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cells in Atherosclerosis: Focus on Cellular Senescence from Basic Science to Clinical Practice]]></title>
        <id>pubmed:38138958</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38138958/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231227195056&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is a major risk factor of atherosclerosis through different complex pathways including replicative cellular senescence and age-related clonal hematopoiesis. In addition to aging, extracellular stress factors, such as mechanical and oxidative stress, can induce cellular senescence, defined as premature cellular senescence. Senescent cells can accumulate within atherosclerotic plaques over time and contribute to plaque instability. This review summarizes the role of cellular senescence in...]]></summary>
        <author>
            <name>Andrea gnes Molnr</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Long Telomeric Repeat-Containing RNA (TERRA): Biological Functions and Challenges in Vascular Aging and Disease]]></title>
        <id>pubmed:38137431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38137431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231227195056&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Telomere dysfunction is implicated in vascular aging and shorter leucocyte telomeres are associated with an increased risk of atherosclerosis, myocardial infarction, and heart failure. Another pathophysiological mechanism that explains the causal relationship between telomere shortening and atherosclerosis development focuses on the clonal hematopoiesis of indeterminate potential (CHIP), which represents a new and independent risk factor in atherosclerotic cardiovascular diseases. Since telomere...]]></summary>
        <author>
            <name>Paola Canale</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploiting Synthetic Lethality between Germline BRCA1 Haploinsufficiency and PARP Inhibition in JAK2V617F-Positive Myeloproliferative Neoplasms]]></title>
        <id>pubmed:38139386</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38139386/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231226195107&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are rare hematologic disorders characterized by clonal hematopoiesis. Familial clustering is observed in a subset of cases, with a notable proportion exhibiting heterozygous germline mutations in DNA double-strand break repair genes (e.g., BRCA1). We investigated the therapeutic potential of targeting BRCA1 haploinsufficiency alongside the JAK2V617F driver mutation. We assessed the efficacy of combining the PARP inhibitor olaparib with interferon-alpha (IFN)...]]></summary>
        <author>
            <name>Max Bermes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cells in Atherosclerosis: Focus on Cellular Senescence from Basic Science to Clinical Practice]]></title>
        <id>pubmed:38138958</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38138958/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231226195107&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is a major risk factor of atherosclerosis through different complex pathways including replicative cellular senescence and age-related clonal hematopoiesis. In addition to aging, extracellular stress factors, such as mechanical and oxidative stress, can induce cellular senescence, defined as premature cellular senescence. Senescent cells can accumulate within atherosclerotic plaques over time and contribute to plaque instability. This review summarizes the role of cellular senescence in...]]></summary>
        <author>
            <name>Andrea gnes Molnr</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Long Telomeric Repeat-Containing RNA (TERRA): Biological Functions and Challenges in Vascular Aging and Disease]]></title>
        <id>pubmed:38137431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38137431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231226195107&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Telomere dysfunction is implicated in vascular aging and shorter leucocyte telomeres are associated with an increased risk of atherosclerosis, myocardial infarction, and heart failure. Another pathophysiological mechanism that explains the causal relationship between telomere shortening and atherosclerosis development focuses on the clonal hematopoiesis of indeterminate potential (CHIP), which represents a new and independent risk factor in atherosclerotic cardiovascular diseases. Since telomere...]]></summary>
        <author>
            <name>Paola Canale</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploiting Synthetic Lethality between Germline BRCA1 Haploinsufficiency and PARP Inhibition in JAK2V617F-Positive Myeloproliferative Neoplasms]]></title>
        <id>pubmed:38139386</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38139386/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231225195059&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are rare hematologic disorders characterized by clonal hematopoiesis. Familial clustering is observed in a subset of cases, with a notable proportion exhibiting heterozygous germline mutations in DNA double-strand break repair genes (e.g., BRCA1). We investigated the therapeutic potential of targeting BRCA1 haploinsufficiency alongside the JAK2V617F driver mutation. We assessed the efficacy of combining the PARP inhibitor olaparib with interferon-alpha (IFN)...]]></summary>
        <author>
            <name>Max Bermes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cells in Atherosclerosis: Focus on Cellular Senescence from Basic Science to Clinical Practice]]></title>
        <id>pubmed:38138958</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38138958/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231225195059&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is a major risk factor of atherosclerosis through different complex pathways including replicative cellular senescence and age-related clonal hematopoiesis. In addition to aging, extracellular stress factors, such as mechanical and oxidative stress, can induce cellular senescence, defined as premature cellular senescence. Senescent cells can accumulate within atherosclerotic plaques over time and contribute to plaque instability. This review summarizes the role of cellular senescence in...]]></summary>
        <author>
            <name>Andrea gnes Molnr</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Long Telomeric Repeat-Containing RNA (TERRA): Biological Functions and Challenges in Vascular Aging and Disease]]></title>
        <id>pubmed:38137431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38137431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231225195059&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Telomere dysfunction is implicated in vascular aging and shorter leucocyte telomeres are associated with an increased risk of atherosclerosis, myocardial infarction, and heart failure. Another pathophysiological mechanism that explains the causal relationship between telomere shortening and atherosclerosis development focuses on the clonal hematopoiesis of indeterminate potential (CHIP), which represents a new and independent risk factor in atherosclerotic cardiovascular diseases. Since telomere...]]></summary>
        <author>
            <name>Paola Canale</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploiting Synthetic Lethality between Germline BRCA1 Haploinsufficiency and PARP Inhibition in JAK2V617F-Positive Myeloproliferative Neoplasms]]></title>
        <id>pubmed:38139386</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38139386/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231224195316&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are rare hematologic disorders characterized by clonal hematopoiesis. Familial clustering is observed in a subset of cases, with a notable proportion exhibiting heterozygous germline mutations in DNA double-strand break repair genes (e.g., BRCA1). We investigated the therapeutic potential of targeting BRCA1 haploinsufficiency alongside the JAK2V617F driver mutation. We assessed the efficacy of combining the PARP inhibitor olaparib with interferon-alpha (IFN)...]]></summary>
        <author>
            <name>Max Bermes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cells in Atherosclerosis: Focus on Cellular Senescence from Basic Science to Clinical Practice]]></title>
        <id>pubmed:38138958</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38138958/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231224195316&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is a major risk factor of atherosclerosis through different complex pathways including replicative cellular senescence and age-related clonal hematopoiesis. In addition to aging, extracellular stress factors, such as mechanical and oxidative stress, can induce cellular senescence, defined as premature cellular senescence. Senescent cells can accumulate within atherosclerotic plaques over time and contribute to plaque instability. This review summarizes the role of cellular senescence in...]]></summary>
        <author>
            <name>Andrea gnes Molnr</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Long Telomeric Repeat-Containing RNA (TERRA): Biological Functions and Challenges in Vascular Aging and Disease]]></title>
        <id>pubmed:38137431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38137431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231224195316&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Telomere dysfunction is implicated in vascular aging and shorter leucocyte telomeres are associated with an increased risk of atherosclerosis, myocardial infarction, and heart failure. Another pathophysiological mechanism that explains the causal relationship between telomere shortening and atherosclerosis development focuses on the clonal hematopoiesis of indeterminate potential (CHIP), which represents a new and independent risk factor in atherosclerotic cardiovascular diseases. Since telomere...]]></summary>
        <author>
            <name>Paola Canale</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploiting Synthetic Lethality between Germline BRCA1 Haploinsufficiency and PARP Inhibition in JAK2V617F-Positive Myeloproliferative Neoplasms]]></title>
        <id>pubmed:38139386</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38139386/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231223195542&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are rare hematologic disorders characterized by clonal hematopoiesis. Familial clustering is observed in a subset of cases, with a notable proportion exhibiting heterozygous germline mutations in DNA double-strand break repair genes (e.g., BRCA1). We investigated the therapeutic potential of targeting BRCA1 haploinsufficiency alongside the JAK2V617F driver mutation. We assessed the efficacy of combining the PARP inhibitor olaparib with interferon-alpha (IFN)...]]></summary>
        <author>
            <name>Max Bermes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cells in Atherosclerosis: Focus on Cellular Senescence from Basic Science to Clinical Practice]]></title>
        <id>pubmed:38138958</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38138958/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231223195542&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Aging is a major risk factor of atherosclerosis through different complex pathways including replicative cellular senescence and age-related clonal hematopoiesis. In addition to aging, extracellular stress factors, such as mechanical and oxidative stress, can induce cellular senescence, defined as premature cellular senescence. Senescent cells can accumulate within atherosclerotic plaques over time and contribute to plaque instability. This review summarizes the role of cellular senescence in...]]></summary>
        <author>
            <name>Andrea gnes Molnr</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Long Telomeric Repeat-Containing RNA (TERRA): Biological Functions and Challenges in Vascular Aging and Disease]]></title>
        <id>pubmed:38137431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38137431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231223195542&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Telomere dysfunction is implicated in vascular aging and shorter leucocyte telomeres are associated with an increased risk of atherosclerosis, myocardial infarction, and heart failure. Another pathophysiological mechanism that explains the causal relationship between telomere shortening and atherosclerosis development focuses on the clonal hematopoiesis of indeterminate potential (CHIP), which represents a new and independent risk factor in atherosclerotic cardiovascular diseases. Since telomere...]]></summary>
        <author>
            <name>Paola Canale</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early Evolution in Cancer: A Mathematical Support for Pathological and Genomic Evidence in Clear Cell Renal Cell Carcinoma]]></title>
        <id>pubmed:38136439</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38136439/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240112195322&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clear cell renal cell carcinoma (CCRCC) is an aggressive form of cancer and a paradigmatic example of intratumor heterogeneity (ITH). The hawk-dove game is a mathematical tool designed to analyze competition in biological systems. Using this game, the study reported here analyzes the early phase of CCRCC development, comparing clonal fitness in homogeneous (linear evolutionary) and highly heterogeneous (branching evolutionary) models. Fitness in the analysis is a measure of tumor aggressiveness....]]></summary>
        <author>
            <name>Annick Laruelle</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early Evolution in Cancer: A Mathematical Support for Pathological and Genomic Evidence in Clear Cell Renal Cell Carcinoma]]></title>
        <id>pubmed:38136439</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38136439/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240111195444&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clear cell renal cell carcinoma (CCRCC) is an aggressive form of cancer and a paradigmatic example of intratumor heterogeneity (ITH). The hawk-dove game is a mathematical tool designed to analyze competition in biological systems. Using this game, the study reported here analyzes the early phase of CCRCC development, comparing clonal fitness in homogeneous (linear evolutionary) and highly heterogeneous (branching evolutionary) models. Fitness in the analysis is a measure of tumor aggressiveness....]]></summary>
        <author>
            <name>Annick Laruelle</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early Evolution in Cancer: A Mathematical Support for Pathological and Genomic Evidence in Clear Cell Renal Cell Carcinoma]]></title>
        <id>pubmed:38136439</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38136439/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240110195405&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clear cell renal cell carcinoma (CCRCC) is an aggressive form of cancer and a paradigmatic example of intratumor heterogeneity (ITH). The hawk-dove game is a mathematical tool designed to analyze competition in biological systems. Using this game, the study reported here analyzes the early phase of CCRCC development, comparing clonal fitness in homogeneous (linear evolutionary) and highly heterogeneous (branching evolutionary) models. Fitness in the analysis is a measure of tumor aggressiveness....]]></summary>
        <author>
            <name>Annick Laruelle</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early Evolution in Cancer: A Mathematical Support for Pathological and Genomic Evidence in Clear Cell Renal Cell Carcinoma]]></title>
        <id>pubmed:38136439</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38136439/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240109195408&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clear cell renal cell carcinoma (CCRCC) is an aggressive form of cancer and a paradigmatic example of intratumor heterogeneity (ITH). The hawk-dove game is a mathematical tool designed to analyze competition in biological systems. Using this game, the study reported here analyzes the early phase of CCRCC development, comparing clonal fitness in homogeneous (linear evolutionary) and highly heterogeneous (branching evolutionary) models. Fitness in the analysis is a measure of tumor aggressiveness....]]></summary>
        <author>
            <name>Annick Laruelle</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early Evolution in Cancer: A Mathematical Support for Pathological and Genomic Evidence in Clear Cell Renal Cell Carcinoma]]></title>
        <id>pubmed:38136439</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38136439/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240108195354&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clear cell renal cell carcinoma (CCRCC) is an aggressive form of cancer and a paradigmatic example of intratumor heterogeneity (ITH). The hawk-dove game is a mathematical tool designed to analyze competition in biological systems. Using this game, the study reported here analyzes the early phase of CCRCC development, comparing clonal fitness in homogeneous (linear evolutionary) and highly heterogeneous (branching evolutionary) models. Fitness in the analysis is a measure of tumor aggressiveness....]]></summary>
        <author>
            <name>Annick Laruelle</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early Evolution in Cancer: A Mathematical Support for Pathological and Genomic Evidence in Clear Cell Renal Cell Carcinoma]]></title>
        <id>pubmed:38136439</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38136439/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240107195431&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clear cell renal cell carcinoma (CCRCC) is an aggressive form of cancer and a paradigmatic example of intratumor heterogeneity (ITH). The hawk-dove game is a mathematical tool designed to analyze competition in biological systems. Using this game, the study reported here analyzes the early phase of CCRCC development, comparing clonal fitness in homogeneous (linear evolutionary) and highly heterogeneous (branching evolutionary) models. Fitness in the analysis is a measure of tumor aggressiveness....]]></summary>
        <author>
            <name>Annick Laruelle</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early Evolution in Cancer: A Mathematical Support for Pathological and Genomic Evidence in Clear Cell Renal Cell Carcinoma]]></title>
        <id>pubmed:38136439</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38136439/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240106195750&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clear cell renal cell carcinoma (CCRCC) is an aggressive form of cancer and a paradigmatic example of intratumor heterogeneity (ITH). The hawk-dove game is a mathematical tool designed to analyze competition in biological systems. Using this game, the study reported here analyzes the early phase of CCRCC development, comparing clonal fitness in homogeneous (linear evolutionary) and highly heterogeneous (branching evolutionary) models. Fitness in the analysis is a measure of tumor aggressiveness....]]></summary>
        <author>
            <name>Annick Laruelle</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early Evolution in Cancer: A Mathematical Support for Pathological and Genomic Evidence in Clear Cell Renal Cell Carcinoma]]></title>
        <id>pubmed:38136439</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38136439/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240105195208&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clear cell renal cell carcinoma (CCRCC) is an aggressive form of cancer and a paradigmatic example of intratumor heterogeneity (ITH). The hawk-dove game is a mathematical tool designed to analyze competition in biological systems. Using this game, the study reported here analyzes the early phase of CCRCC development, comparing clonal fitness in homogeneous (linear evolutionary) and highly heterogeneous (branching evolutionary) models. Fitness in the analysis is a measure of tumor aggressiveness....]]></summary>
        <author>
            <name>Annick Laruelle</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early Evolution in Cancer: A Mathematical Support for Pathological and Genomic Evidence in Clear Cell Renal Cell Carcinoma]]></title>
        <id>pubmed:38136439</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38136439/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240104195307&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clear cell renal cell carcinoma (CCRCC) is an aggressive form of cancer and a paradigmatic example of intratumor heterogeneity (ITH). The hawk-dove game is a mathematical tool designed to analyze competition in biological systems. Using this game, the study reported here analyzes the early phase of CCRCC development, comparing clonal fitness in homogeneous (linear evolutionary) and highly heterogeneous (branching evolutionary) models. Fitness in the analysis is a measure of tumor aggressiveness....]]></summary>
        <author>
            <name>Annick Laruelle</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early Evolution in Cancer: A Mathematical Support for Pathological and Genomic Evidence in Clear Cell Renal Cell Carcinoma]]></title>
        <id>pubmed:38136439</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38136439/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240103195303&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clear cell renal cell carcinoma (CCRCC) is an aggressive form of cancer and a paradigmatic example of intratumor heterogeneity (ITH). The hawk-dove game is a mathematical tool designed to analyze competition in biological systems. Using this game, the study reported here analyzes the early phase of CCRCC development, comparing clonal fitness in homogeneous (linear evolutionary) and highly heterogeneous (branching evolutionary) models. Fitness in the analysis is a measure of tumor aggressiveness....]]></summary>
        <author>
            <name>Annick Laruelle</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early Evolution in Cancer: A Mathematical Support for Pathological and Genomic Evidence in Clear Cell Renal Cell Carcinoma]]></title>
        <id>pubmed:38136439</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38136439/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240102195247&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clear cell renal cell carcinoma (CCRCC) is an aggressive form of cancer and a paradigmatic example of intratumor heterogeneity (ITH). The hawk-dove game is a mathematical tool designed to analyze competition in biological systems. Using this game, the study reported here analyzes the early phase of CCRCC development, comparing clonal fitness in homogeneous (linear evolutionary) and highly heterogeneous (branching evolutionary) models. Fitness in the analysis is a measure of tumor aggressiveness....]]></summary>
        <author>
            <name>Annick Laruelle</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early Evolution in Cancer: A Mathematical Support for Pathological and Genomic Evidence in Clear Cell Renal Cell Carcinoma]]></title>
        <id>pubmed:38136439</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38136439/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240101195419&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clear cell renal cell carcinoma (CCRCC) is an aggressive form of cancer and a paradigmatic example of intratumor heterogeneity (ITH). The hawk-dove game is a mathematical tool designed to analyze competition in biological systems. Using this game, the study reported here analyzes the early phase of CCRCC development, comparing clonal fitness in homogeneous (linear evolutionary) and highly heterogeneous (branching evolutionary) models. Fitness in the analysis is a measure of tumor aggressiveness....]]></summary>
        <author>
            <name>Annick Laruelle</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early Evolution in Cancer: A Mathematical Support for Pathological and Genomic Evidence in Clear Cell Renal Cell Carcinoma]]></title>
        <id>pubmed:38136439</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38136439/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231231195742&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clear cell renal cell carcinoma (CCRCC) is an aggressive form of cancer and a paradigmatic example of intratumor heterogeneity (ITH). The hawk-dove game is a mathematical tool designed to analyze competition in biological systems. Using this game, the study reported here analyzes the early phase of CCRCC development, comparing clonal fitness in homogeneous (linear evolutionary) and highly heterogeneous (branching evolutionary) models. Fitness in the analysis is a measure of tumor aggressiveness....]]></summary>
        <author>
            <name>Annick Laruelle</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early Evolution in Cancer: A Mathematical Support for Pathological and Genomic Evidence in Clear Cell Renal Cell Carcinoma]]></title>
        <id>pubmed:38136439</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38136439/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231230195628&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clear cell renal cell carcinoma (CCRCC) is an aggressive form of cancer and a paradigmatic example of intratumor heterogeneity (ITH). The hawk-dove game is a mathematical tool designed to analyze competition in biological systems. Using this game, the study reported here analyzes the early phase of CCRCC development, comparing clonal fitness in homogeneous (linear evolutionary) and highly heterogeneous (branching evolutionary) models. Fitness in the analysis is a measure of tumor aggressiveness....]]></summary>
        <author>
            <name>Annick Laruelle</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early Evolution in Cancer: A Mathematical Support for Pathological and Genomic Evidence in Clear Cell Renal Cell Carcinoma]]></title>
        <id>pubmed:38136439</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38136439/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231229195054&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clear cell renal cell carcinoma (CCRCC) is an aggressive form of cancer and a paradigmatic example of intratumor heterogeneity (ITH). The hawk-dove game is a mathematical tool designed to analyze competition in biological systems. Using this game, the study reported here analyzes the early phase of CCRCC development, comparing clonal fitness in homogeneous (linear evolutionary) and highly heterogeneous (branching evolutionary) models. Fitness in the analysis is a measure of tumor aggressiveness....]]></summary>
        <author>
            <name>Annick Laruelle</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early Evolution in Cancer: A Mathematical Support for Pathological and Genomic Evidence in Clear Cell Renal Cell Carcinoma]]></title>
        <id>pubmed:38136439</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38136439/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231228194204&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clear cell renal cell carcinoma (CCRCC) is an aggressive form of cancer and a paradigmatic example of intratumor heterogeneity (ITH). The hawk-dove game is a mathematical tool designed to analyze competition in biological systems. Using this game, the study reported here analyzes the early phase of CCRCC development, comparing clonal fitness in homogeneous (linear evolutionary) and highly heterogeneous (branching evolutionary) models. Fitness in the analysis is a measure of tumor aggressiveness....]]></summary>
        <author>
            <name>Annick Laruelle</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early Evolution in Cancer: A Mathematical Support for Pathological and Genomic Evidence in Clear Cell Renal Cell Carcinoma]]></title>
        <id>pubmed:38136439</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38136439/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231227195056&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clear cell renal cell carcinoma (CCRCC) is an aggressive form of cancer and a paradigmatic example of intratumor heterogeneity (ITH). The hawk-dove game is a mathematical tool designed to analyze competition in biological systems. Using this game, the study reported here analyzes the early phase of CCRCC development, comparing clonal fitness in homogeneous (linear evolutionary) and highly heterogeneous (branching evolutionary) models. Fitness in the analysis is a measure of tumor aggressiveness....]]></summary>
        <author>
            <name>Annick Laruelle</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early Evolution in Cancer: A Mathematical Support for Pathological and Genomic Evidence in Clear Cell Renal Cell Carcinoma]]></title>
        <id>pubmed:38136439</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38136439/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231226195107&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clear cell renal cell carcinoma (CCRCC) is an aggressive form of cancer and a paradigmatic example of intratumor heterogeneity (ITH). The hawk-dove game is a mathematical tool designed to analyze competition in biological systems. Using this game, the study reported here analyzes the early phase of CCRCC development, comparing clonal fitness in homogeneous (linear evolutionary) and highly heterogeneous (branching evolutionary) models. Fitness in the analysis is a measure of tumor aggressiveness....]]></summary>
        <author>
            <name>Annick Laruelle</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early Evolution in Cancer: A Mathematical Support for Pathological and Genomic Evidence in Clear Cell Renal Cell Carcinoma]]></title>
        <id>pubmed:38136439</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38136439/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231225195059&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clear cell renal cell carcinoma (CCRCC) is an aggressive form of cancer and a paradigmatic example of intratumor heterogeneity (ITH). The hawk-dove game is a mathematical tool designed to analyze competition in biological systems. Using this game, the study reported here analyzes the early phase of CCRCC development, comparing clonal fitness in homogeneous (linear evolutionary) and highly heterogeneous (branching evolutionary) models. Fitness in the analysis is a measure of tumor aggressiveness....]]></summary>
        <author>
            <name>Annick Laruelle</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early Evolution in Cancer: A Mathematical Support for Pathological and Genomic Evidence in Clear Cell Renal Cell Carcinoma]]></title>
        <id>pubmed:38136439</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38136439/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231224195316&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clear cell renal cell carcinoma (CCRCC) is an aggressive form of cancer and a paradigmatic example of intratumor heterogeneity (ITH). The hawk-dove game is a mathematical tool designed to analyze competition in biological systems. Using this game, the study reported here analyzes the early phase of CCRCC development, comparing clonal fitness in homogeneous (linear evolutionary) and highly heterogeneous (branching evolutionary) models. Fitness in the analysis is a measure of tumor aggressiveness....]]></summary>
        <author>
            <name>Annick Laruelle</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Early Evolution in Cancer: A Mathematical Support for Pathological and Genomic Evidence in Clear Cell Renal Cell Carcinoma]]></title>
        <id>pubmed:38136439</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38136439/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231223195542&amp;v=2.18.0"/>
        <updated>2023-12-23T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clear cell renal cell carcinoma (CCRCC) is an aggressive form of cancer and a paradigmatic example of intratumor heterogeneity (ITH). The hawk-dove game is a mathematical tool designed to analyze competition in biological systems. Using this game, the study reported here analyzes the early phase of CCRCC development, comparing clonal fitness in homogeneous (linear evolutionary) and highly heterogeneous (branching evolutionary) models. Fitness in the analysis is a measure of tumor aggressiveness....]]></summary>
        <author>
            <name>Annick Laruelle</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Age-related micro-environmental changes as drivers of clonal hematopoiesis]]></title>
        <id>pubmed:38133628</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38133628/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240108195354&amp;v=2.18.0"/>
        <updated>2023-12-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Both aging and reduced diversity at the hematopoietic stem cells (HSCs) level are ubiquitous. What remains unclear is why some individuals develop clonal hematopoiesis (CH), and why does CH due to specific mutations occur in specific individuals. Much like aging, reduced diversity of HSCs is a complex phenotype shaped by numerous factors (germline & environment). The purpose of the current review is to discuss the role of two other age-related ubiquitous processes that might...]]></summary>
        <author>
            <name>Tal Bacharach</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Age-related micro-environmental changes as drivers of clonal hematopoiesis]]></title>
        <id>pubmed:38133628</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38133628/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240107195432&amp;v=2.18.0"/>
        <updated>2023-12-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Both aging and reduced diversity at the hematopoietic stem cells (HSCs) level are ubiquitous. What remains unclear is why some individuals develop clonal hematopoiesis (CH), and why does CH due to specific mutations occur in specific individuals. Much like aging, reduced diversity of HSCs is a complex phenotype shaped by numerous factors (germline & environment). The purpose of the current review is to discuss the role of two other age-related ubiquitous processes that might...]]></summary>
        <author>
            <name>Tal Bacharach</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Low-Frequency <em>PPM1D</em> Gene Mutations Affect Treatment Response to CD19-Targeted CAR T-Cell Therapy in Large B-Cell Lymphoma]]></title>
        <id>pubmed:38132396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38132396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240107195432&amp;v=2.18.0"/>
        <updated>2023-12-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chimeric antigen receptor T (CAR T)-cell therapy has become a standard treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). Mutations in the PPM1D gene, a frequent driver alteration in clonal hematopoiesis (CH), lead to a gain of function of PPM1D/Wip1 phosphatase, impairing p53-dependent G1 checkpoint and promoting cell proliferation. The presence of PPM1D mutations has been correlated with reduced response to standard chemotherapy in lymphoma...]]></summary>
        <author>
            <name>Katja Seipel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Age-related micro-environmental changes as drivers of clonal hematopoiesis]]></title>
        <id>pubmed:38133628</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38133628/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240106195750&amp;v=2.18.0"/>
        <updated>2023-12-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Both aging and reduced diversity at the hematopoietic stem cells (HSCs) level are ubiquitous. What remains unclear is why some individuals develop clonal hematopoiesis (CH), and why does CH due to specific mutations occur in specific individuals. Much like aging, reduced diversity of HSCs is a complex phenotype shaped by numerous factors (germline & environment). The purpose of the current review is to discuss the role of two other age-related ubiquitous processes that might...]]></summary>
        <author>
            <name>Tal Bacharach</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Low-Frequency <em>PPM1D</em> Gene Mutations Affect Treatment Response to CD19-Targeted CAR T-Cell Therapy in Large B-Cell Lymphoma]]></title>
        <id>pubmed:38132396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38132396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240106195750&amp;v=2.18.0"/>
        <updated>2023-12-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chimeric antigen receptor T (CAR T)-cell therapy has become a standard treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). Mutations in the PPM1D gene, a frequent driver alteration in clonal hematopoiesis (CH), lead to a gain of function of PPM1D/Wip1 phosphatase, impairing p53-dependent G1 checkpoint and promoting cell proliferation. The presence of PPM1D mutations has been correlated with reduced response to standard chemotherapy in lymphoma...]]></summary>
        <author>
            <name>Katja Seipel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Biomarkers of aging through the life course: A Recent Literature Update]]></title>
        <id>pubmed:38130910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38130910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240106195750&amp;v=2.18.0"/>
        <updated>2023-12-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: The development of biomarkers of aging has greatly advanced epidemiological studies of aging processes. However, much debate remains on the timing of aging onset and the causal relevance of these biomarkers. In this review, we discuss the most recent biomarkers of aging that have been applied across the life course.]]></summary>
        <author>
            <name>Abigail Gaylord</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Age-related micro-environmental changes as drivers of clonal hematopoiesis]]></title>
        <id>pubmed:38133628</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38133628/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240105195208&amp;v=2.18.0"/>
        <updated>2023-12-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Both aging and reduced diversity at the hematopoietic stem cells (HSCs) level are ubiquitous. What remains unclear is why some individuals develop clonal hematopoiesis (CH), and why does CH due to specific mutations occur in specific individuals. Much like aging, reduced diversity of HSCs is a complex phenotype shaped by numerous factors (germline & environment). The purpose of the current review is to discuss the role of two other age-related ubiquitous processes that might...]]></summary>
        <author>
            <name>Tal Bacharach</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Low-Frequency <em>PPM1D</em> Gene Mutations Affect Treatment Response to CD19-Targeted CAR T-Cell Therapy in Large B-Cell Lymphoma]]></title>
        <id>pubmed:38132396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38132396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240105195208&amp;v=2.18.0"/>
        <updated>2023-12-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chimeric antigen receptor T (CAR T)-cell therapy has become a standard treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). Mutations in the PPM1D gene, a frequent driver alteration in clonal hematopoiesis (CH), lead to a gain of function of PPM1D/Wip1 phosphatase, impairing p53-dependent G1 checkpoint and promoting cell proliferation. The presence of PPM1D mutations has been correlated with reduced response to standard chemotherapy in lymphoma...]]></summary>
        <author>
            <name>Katja Seipel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Biomarkers of aging through the life course: A Recent Literature Update]]></title>
        <id>pubmed:38130910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38130910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240105195208&amp;v=2.18.0"/>
        <updated>2023-12-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: The development of biomarkers of aging has greatly advanced epidemiological studies of aging processes. However, much debate remains on the timing of aging onset and the causal relevance of these biomarkers. In this review, we discuss the most recent biomarkers of aging that have been applied across the life course.]]></summary>
        <author>
            <name>Abigail Gaylord</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Age-related micro-environmental changes as drivers of clonal hematopoiesis]]></title>
        <id>pubmed:38133628</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38133628/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240104195306&amp;v=2.18.0"/>
        <updated>2023-12-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Both aging and reduced diversity at the hematopoietic stem cells (HSCs) level are ubiquitous. What remains unclear is why some individuals develop clonal hematopoiesis (CH), and why does CH due to specific mutations occur in specific individuals. Much like aging, reduced diversity of HSCs is a complex phenotype shaped by numerous factors (germline & environment). The purpose of the current review is to discuss the role of two other age-related ubiquitous processes that might...]]></summary>
        <author>
            <name>Tal Bacharach</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Low-Frequency <em>PPM1D</em> Gene Mutations Affect Treatment Response to CD19-Targeted CAR T-Cell Therapy in Large B-Cell Lymphoma]]></title>
        <id>pubmed:38132396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38132396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240104195306&amp;v=2.18.0"/>
        <updated>2023-12-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chimeric antigen receptor T (CAR T)-cell therapy has become a standard treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). Mutations in the PPM1D gene, a frequent driver alteration in clonal hematopoiesis (CH), lead to a gain of function of PPM1D/Wip1 phosphatase, impairing p53-dependent G1 checkpoint and promoting cell proliferation. The presence of PPM1D mutations has been correlated with reduced response to standard chemotherapy in lymphoma...]]></summary>
        <author>
            <name>Katja Seipel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Biomarkers of aging through the life course: A Recent Literature Update]]></title>
        <id>pubmed:38130910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38130910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240104195306&amp;v=2.18.0"/>
        <updated>2023-12-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: The development of biomarkers of aging has greatly advanced epidemiological studies of aging processes. However, much debate remains on the timing of aging onset and the causal relevance of these biomarkers. In this review, we discuss the most recent biomarkers of aging that have been applied across the life course.]]></summary>
        <author>
            <name>Abigail Gaylord</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Age-related micro-environmental changes as drivers of clonal hematopoiesis]]></title>
        <id>pubmed:38133628</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38133628/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240103195259&amp;v=2.18.0"/>
        <updated>2023-12-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Both aging and reduced diversity at the hematopoietic stem cells (HSCs) level are ubiquitous. What remains unclear is why some individuals develop clonal hematopoiesis (CH), and why does CH due to specific mutations occur in specific individuals. Much like aging, reduced diversity of HSCs is a complex phenotype shaped by numerous factors (germline & environment). The purpose of the current review is to discuss the role of two other age-related ubiquitous processes that might...]]></summary>
        <author>
            <name>Tal Bacharach</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Low-Frequency <em>PPM1D</em> Gene Mutations Affect Treatment Response to CD19-Targeted CAR T-Cell Therapy in Large B-Cell Lymphoma]]></title>
        <id>pubmed:38132396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38132396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240103195259&amp;v=2.18.0"/>
        <updated>2023-12-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chimeric antigen receptor T (CAR T)-cell therapy has become a standard treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). Mutations in the PPM1D gene, a frequent driver alteration in clonal hematopoiesis (CH), lead to a gain of function of PPM1D/Wip1 phosphatase, impairing p53-dependent G1 checkpoint and promoting cell proliferation. The presence of PPM1D mutations has been correlated with reduced response to standard chemotherapy in lymphoma...]]></summary>
        <author>
            <name>Katja Seipel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Biomarkers of aging through the life course: A Recent Literature Update]]></title>
        <id>pubmed:38130910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38130910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240103195259&amp;v=2.18.0"/>
        <updated>2023-12-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: The development of biomarkers of aging has greatly advanced epidemiological studies of aging processes. However, much debate remains on the timing of aging onset and the causal relevance of these biomarkers. In this review, we discuss the most recent biomarkers of aging that have been applied across the life course.]]></summary>
        <author>
            <name>Abigail Gaylord</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Age-related micro-environmental changes as drivers of clonal hematopoiesis]]></title>
        <id>pubmed:38133628</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38133628/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240102195247&amp;v=2.18.0"/>
        <updated>2023-12-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Both aging and reduced diversity at the hematopoietic stem cells (HSCs) level are ubiquitous. What remains unclear is why some individuals develop clonal hematopoiesis (CH), and why does CH due to specific mutations occur in specific individuals. Much like aging, reduced diversity of HSCs is a complex phenotype shaped by numerous factors (germline & environment). The purpose of the current review is to discuss the role of two other age-related ubiquitous processes that might...]]></summary>
        <author>
            <name>Tal Bacharach</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Low-Frequency <em>PPM1D</em> Gene Mutations Affect Treatment Response to CD19-Targeted CAR T-Cell Therapy in Large B-Cell Lymphoma]]></title>
        <id>pubmed:38132396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38132396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240102195247&amp;v=2.18.0"/>
        <updated>2023-12-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chimeric antigen receptor T (CAR T)-cell therapy has become a standard treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). Mutations in the PPM1D gene, a frequent driver alteration in clonal hematopoiesis (CH), lead to a gain of function of PPM1D/Wip1 phosphatase, impairing p53-dependent G1 checkpoint and promoting cell proliferation. The presence of PPM1D mutations has been correlated with reduced response to standard chemotherapy in lymphoma...]]></summary>
        <author>
            <name>Katja Seipel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Biomarkers of aging through the life course: A Recent Literature Update]]></title>
        <id>pubmed:38130910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38130910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240102195247&amp;v=2.18.0"/>
        <updated>2023-12-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: The development of biomarkers of aging has greatly advanced epidemiological studies of aging processes. However, much debate remains on the timing of aging onset and the causal relevance of these biomarkers. In this review, we discuss the most recent biomarkers of aging that have been applied across the life course.]]></summary>
        <author>
            <name>Abigail Gaylord</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Age-related micro-environmental changes as drivers of clonal hematopoiesis]]></title>
        <id>pubmed:38133628</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38133628/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240101195419&amp;v=2.18.0"/>
        <updated>2023-12-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Both aging and reduced diversity at the hematopoietic stem cells (HSCs) level are ubiquitous. What remains unclear is why some individuals develop clonal hematopoiesis (CH), and why does CH due to specific mutations occur in specific individuals. Much like aging, reduced diversity of HSCs is a complex phenotype shaped by numerous factors (germline & environment). The purpose of the current review is to discuss the role of two other age-related ubiquitous processes that might...]]></summary>
        <author>
            <name>Tal Bacharach</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Low-Frequency <em>PPM1D</em> Gene Mutations Affect Treatment Response to CD19-Targeted CAR T-Cell Therapy in Large B-Cell Lymphoma]]></title>
        <id>pubmed:38132396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38132396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240101195419&amp;v=2.18.0"/>
        <updated>2023-12-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chimeric antigen receptor T (CAR T)-cell therapy has become a standard treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). Mutations in the PPM1D gene, a frequent driver alteration in clonal hematopoiesis (CH), lead to a gain of function of PPM1D/Wip1 phosphatase, impairing p53-dependent G1 checkpoint and promoting cell proliferation. The presence of PPM1D mutations has been correlated with reduced response to standard chemotherapy in lymphoma...]]></summary>
        <author>
            <name>Katja Seipel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Biomarkers of aging through the life course: A Recent Literature Update]]></title>
        <id>pubmed:38130910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38130910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240101195419&amp;v=2.18.0"/>
        <updated>2023-12-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: The development of biomarkers of aging has greatly advanced epidemiological studies of aging processes. However, much debate remains on the timing of aging onset and the causal relevance of these biomarkers. In this review, we discuss the most recent biomarkers of aging that have been applied across the life course.]]></summary>
        <author>
            <name>Abigail Gaylord</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Age-related micro-environmental changes as drivers of clonal hematopoiesis]]></title>
        <id>pubmed:38133628</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38133628/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231231195742&amp;v=2.18.0"/>
        <updated>2023-12-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Both aging and reduced diversity at the hematopoietic stem cells (HSCs) level are ubiquitous. What remains unclear is why some individuals develop clonal hematopoiesis (CH), and why does CH due to specific mutations occur in specific individuals. Much like aging, reduced diversity of HSCs is a complex phenotype shaped by numerous factors (germline & environment). The purpose of the current review is to discuss the role of two other age-related ubiquitous processes that might...]]></summary>
        <author>
            <name>Tal Bacharach</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Low-Frequency <em>PPM1D</em> Gene Mutations Affect Treatment Response to CD19-Targeted CAR T-Cell Therapy in Large B-Cell Lymphoma]]></title>
        <id>pubmed:38132396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38132396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231231195742&amp;v=2.18.0"/>
        <updated>2023-12-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chimeric antigen receptor T (CAR T)-cell therapy has become a standard treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). Mutations in the PPM1D gene, a frequent driver alteration in clonal hematopoiesis (CH), lead to a gain of function of PPM1D/Wip1 phosphatase, impairing p53-dependent G1 checkpoint and promoting cell proliferation. The presence of PPM1D mutations has been correlated with reduced response to standard chemotherapy in lymphoma...]]></summary>
        <author>
            <name>Katja Seipel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Biomarkers of aging through the life course: A Recent Literature Update]]></title>
        <id>pubmed:38130910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38130910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231231195742&amp;v=2.18.0"/>
        <updated>2023-12-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: The development of biomarkers of aging has greatly advanced epidemiological studies of aging processes. However, much debate remains on the timing of aging onset and the causal relevance of these biomarkers. In this review, we discuss the most recent biomarkers of aging that have been applied across the life course.]]></summary>
        <author>
            <name>Abigail Gaylord</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Age-related micro-environmental changes as drivers of clonal hematopoiesis]]></title>
        <id>pubmed:38133628</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38133628/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231230195628&amp;v=2.18.0"/>
        <updated>2023-12-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Both aging and reduced diversity at the hematopoietic stem cells (HSCs) level are ubiquitous. What remains unclear is why some individuals develop clonal hematopoiesis (CH), and why does CH due to specific mutations occur in specific individuals. Much like aging, reduced diversity of HSCs is a complex phenotype shaped by numerous factors (germline & environment). The purpose of the current review is to discuss the role of two other age-related ubiquitous processes that might...]]></summary>
        <author>
            <name>Tal Bacharach</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Low-Frequency <em>PPM1D</em> Gene Mutations Affect Treatment Response to CD19-Targeted CAR T-Cell Therapy in Large B-Cell Lymphoma]]></title>
        <id>pubmed:38132396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38132396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231230195628&amp;v=2.18.0"/>
        <updated>2023-12-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chimeric antigen receptor T (CAR T)-cell therapy has become a standard treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). Mutations in the PPM1D gene, a frequent driver alteration in clonal hematopoiesis (CH), lead to a gain of function of PPM1D/Wip1 phosphatase, impairing p53-dependent G1 checkpoint and promoting cell proliferation. The presence of PPM1D mutations has been correlated with reduced response to standard chemotherapy in lymphoma...]]></summary>
        <author>
            <name>Katja Seipel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Biomarkers of aging through the life course: A Recent Literature Update]]></title>
        <id>pubmed:38130910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38130910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231230195628&amp;v=2.18.0"/>
        <updated>2023-12-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: The development of biomarkers of aging has greatly advanced epidemiological studies of aging processes. However, much debate remains on the timing of aging onset and the causal relevance of these biomarkers. In this review, we discuss the most recent biomarkers of aging that have been applied across the life course.]]></summary>
        <author>
            <name>Abigail Gaylord</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Age-related micro-environmental changes as drivers of clonal hematopoiesis]]></title>
        <id>pubmed:38133628</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38133628/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231229195054&amp;v=2.18.0"/>
        <updated>2023-12-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Both aging and reduced diversity at the hematopoietic stem cells (HSCs) level are ubiquitous. What remains unclear is why some individuals develop clonal hematopoiesis (CH), and why does CH due to specific mutations occur in specific individuals. Much like aging, reduced diversity of HSCs is a complex phenotype shaped by numerous factors (germline & environment). The purpose of the current review is to discuss the role of two other age-related ubiquitous processes that might...]]></summary>
        <author>
            <name>Tal Bacharach</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Low-Frequency <em>PPM1D</em> Gene Mutations Affect Treatment Response to CD19-Targeted CAR T-Cell Therapy in Large B-Cell Lymphoma]]></title>
        <id>pubmed:38132396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38132396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231229195054&amp;v=2.18.0"/>
        <updated>2023-12-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chimeric antigen receptor T (CAR T)-cell therapy has become a standard treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). Mutations in the PPM1D gene, a frequent driver alteration in clonal hematopoiesis (CH), lead to a gain of function of PPM1D/Wip1 phosphatase, impairing p53-dependent G1 checkpoint and promoting cell proliferation. The presence of PPM1D mutations has been correlated with reduced response to standard chemotherapy in lymphoma...]]></summary>
        <author>
            <name>Katja Seipel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Biomarkers of aging through the life course: A Recent Literature Update]]></title>
        <id>pubmed:38130910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38130910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231229195054&amp;v=2.18.0"/>
        <updated>2023-12-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: The development of biomarkers of aging has greatly advanced epidemiological studies of aging processes. However, much debate remains on the timing of aging onset and the causal relevance of these biomarkers. In this review, we discuss the most recent biomarkers of aging that have been applied across the life course.]]></summary>
        <author>
            <name>Abigail Gaylord</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Age-related micro-environmental changes as drivers of clonal hematopoiesis]]></title>
        <id>pubmed:38133628</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38133628/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231228194204&amp;v=2.18.0"/>
        <updated>2023-12-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Both aging and reduced diversity at the hematopoietic stem cells (HSCs) level are ubiquitous. What remains unclear is why some individuals develop clonal hematopoiesis (CH), and why does CH due to specific mutations occur in specific individuals. Much like aging, reduced diversity of HSCs is a complex phenotype shaped by numerous factors (germline & environment). The purpose of the current review is to discuss the role of two other age-related ubiquitous processes that might...]]></summary>
        <author>
            <name>Tal Bacharach</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Low-Frequency <em>PPM1D</em> Gene Mutations Affect Treatment Response to CD19-Targeted CAR T-Cell Therapy in Large B-Cell Lymphoma]]></title>
        <id>pubmed:38132396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38132396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231228194204&amp;v=2.18.0"/>
        <updated>2023-12-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chimeric antigen receptor T (CAR T)-cell therapy has become a standard treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). Mutations in the PPM1D gene, a frequent driver alteration in clonal hematopoiesis (CH), lead to a gain of function of PPM1D/Wip1 phosphatase, impairing p53-dependent G1 checkpoint and promoting cell proliferation. The presence of PPM1D mutations has been correlated with reduced response to standard chemotherapy in lymphoma...]]></summary>
        <author>
            <name>Katja Seipel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Biomarkers of aging through the life course: A Recent Literature Update]]></title>
        <id>pubmed:38130910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38130910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231228194204&amp;v=2.18.0"/>
        <updated>2023-12-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: The development of biomarkers of aging has greatly advanced epidemiological studies of aging processes. However, much debate remains on the timing of aging onset and the causal relevance of these biomarkers. In this review, we discuss the most recent biomarkers of aging that have been applied across the life course.]]></summary>
        <author>
            <name>Abigail Gaylord</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Age-related micro-environmental changes as drivers of clonal hematopoiesis]]></title>
        <id>pubmed:38133628</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38133628/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231227195056&amp;v=2.18.0"/>
        <updated>2023-12-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Both aging and reduced diversity at the hematopoietic stem cells (HSCs) level are ubiquitous. What remains unclear is why some individuals develop clonal hematopoiesis (CH), and why does CH due to specific mutations occur in specific individuals. Much like aging, reduced diversity of HSCs is a complex phenotype shaped by numerous factors (germline & environment). The purpose of the current review is to discuss the role of two other age-related ubiquitous processes that might...]]></summary>
        <author>
            <name>Tal Bacharach</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Low-Frequency <em>PPM1D</em> Gene Mutations Affect Treatment Response to CD19-Targeted CAR T-Cell Therapy in Large B-Cell Lymphoma]]></title>
        <id>pubmed:38132396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38132396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231227195056&amp;v=2.18.0"/>
        <updated>2023-12-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chimeric antigen receptor T (CAR T)-cell therapy has become a standard treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). Mutations in the PPM1D gene, a frequent driver alteration in clonal hematopoiesis (CH), lead to a gain of function of PPM1D/Wip1 phosphatase, impairing p53-dependent G1 checkpoint and promoting cell proliferation. The presence of PPM1D mutations has been correlated with reduced response to standard chemotherapy in lymphoma...]]></summary>
        <author>
            <name>Katja Seipel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Biomarkers of aging through the life course: A Recent Literature Update]]></title>
        <id>pubmed:38130910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38130910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231227195056&amp;v=2.18.0"/>
        <updated>2023-12-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: The development of biomarkers of aging has greatly advanced epidemiological studies of aging processes. However, much debate remains on the timing of aging onset and the causal relevance of these biomarkers. In this review, we discuss the most recent biomarkers of aging that have been applied across the life course.]]></summary>
        <author>
            <name>Abigail Gaylord</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Age-related micro-environmental changes as drivers of clonal hematopoiesis]]></title>
        <id>pubmed:38133628</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38133628/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231226195107&amp;v=2.18.0"/>
        <updated>2023-12-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Both aging and reduced diversity at the hematopoietic stem cells (HSCs) level are ubiquitous. What remains unclear is why some individuals develop clonal hematopoiesis (CH), and why does CH due to specific mutations occur in specific individuals. Much like aging, reduced diversity of HSCs is a complex phenotype shaped by numerous factors (germline & environment). The purpose of the current review is to discuss the role of two other age-related ubiquitous processes that might...]]></summary>
        <author>
            <name>Tal Bacharach</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Low-Frequency <em>PPM1D</em> Gene Mutations Affect Treatment Response to CD19-Targeted CAR T-Cell Therapy in Large B-Cell Lymphoma]]></title>
        <id>pubmed:38132396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38132396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231226195107&amp;v=2.18.0"/>
        <updated>2023-12-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chimeric antigen receptor T (CAR T)-cell therapy has become a standard treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). Mutations in the PPM1D gene, a frequent driver alteration in clonal hematopoiesis (CH), lead to a gain of function of PPM1D/Wip1 phosphatase, impairing p53-dependent G1 checkpoint and promoting cell proliferation. The presence of PPM1D mutations has been correlated with reduced response to standard chemotherapy in lymphoma...]]></summary>
        <author>
            <name>Katja Seipel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Biomarkers of aging through the life course: A Recent Literature Update]]></title>
        <id>pubmed:38130910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38130910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231226195107&amp;v=2.18.0"/>
        <updated>2023-12-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: The development of biomarkers of aging has greatly advanced epidemiological studies of aging processes. However, much debate remains on the timing of aging onset and the causal relevance of these biomarkers. In this review, we discuss the most recent biomarkers of aging that have been applied across the life course.]]></summary>
        <author>
            <name>Abigail Gaylord</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Age-related micro-environmental changes as drivers of clonal hematopoiesis]]></title>
        <id>pubmed:38133628</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38133628/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231225195059&amp;v=2.18.0"/>
        <updated>2023-12-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Both aging and reduced diversity at the hematopoietic stem cells (HSCs) level are ubiquitous. What remains unclear is why some individuals develop clonal hematopoiesis (CH), and why does CH due to specific mutations occur in specific individuals. Much like aging, reduced diversity of HSCs is a complex phenotype shaped by numerous factors (germline & environment). The purpose of the current review is to discuss the role of two other age-related ubiquitous processes that might...]]></summary>
        <author>
            <name>Tal Bacharach</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Low-Frequency <em>PPM1D</em> Gene Mutations Affect Treatment Response to CD19-Targeted CAR T-Cell Therapy in Large B-Cell Lymphoma]]></title>
        <id>pubmed:38132396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38132396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231225195059&amp;v=2.18.0"/>
        <updated>2023-12-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chimeric antigen receptor T (CAR T)-cell therapy has become a standard treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). Mutations in the PPM1D gene, a frequent driver alteration in clonal hematopoiesis (CH), lead to a gain of function of PPM1D/Wip1 phosphatase, impairing p53-dependent G1 checkpoint and promoting cell proliferation. The presence of PPM1D mutations has been correlated with reduced response to standard chemotherapy in lymphoma...]]></summary>
        <author>
            <name>Katja Seipel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Biomarkers of aging through the life course: A Recent Literature Update]]></title>
        <id>pubmed:38130910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38130910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231225195059&amp;v=2.18.0"/>
        <updated>2023-12-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: The development of biomarkers of aging has greatly advanced epidemiological studies of aging processes. However, much debate remains on the timing of aging onset and the causal relevance of these biomarkers. In this review, we discuss the most recent biomarkers of aging that have been applied across the life course.]]></summary>
        <author>
            <name>Abigail Gaylord</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Age-related micro-environmental changes as drivers of clonal hematopoiesis]]></title>
        <id>pubmed:38133628</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38133628/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231224195316&amp;v=2.18.0"/>
        <updated>2023-12-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Both aging and reduced diversity at the hematopoietic stem cells (HSCs) level are ubiquitous. What remains unclear is why some individuals develop clonal hematopoiesis (CH), and why does CH due to specific mutations occur in specific individuals. Much like aging, reduced diversity of HSCs is a complex phenotype shaped by numerous factors (germline & environment). The purpose of the current review is to discuss the role of two other age-related ubiquitous processes that might...]]></summary>
        <author>
            <name>Tal Bacharach</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Low-Frequency <em>PPM1D</em> Gene Mutations Affect Treatment Response to CD19-Targeted CAR T-Cell Therapy in Large B-Cell Lymphoma]]></title>
        <id>pubmed:38132396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38132396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231224195316&amp;v=2.18.0"/>
        <updated>2023-12-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chimeric antigen receptor T (CAR T)-cell therapy has become a standard treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). Mutations in the PPM1D gene, a frequent driver alteration in clonal hematopoiesis (CH), lead to a gain of function of PPM1D/Wip1 phosphatase, impairing p53-dependent G1 checkpoint and promoting cell proliferation. The presence of PPM1D mutations has been correlated with reduced response to standard chemotherapy in lymphoma...]]></summary>
        <author>
            <name>Katja Seipel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Biomarkers of aging through the life course: A Recent Literature Update]]></title>
        <id>pubmed:38130910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38130910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231224195316&amp;v=2.18.0"/>
        <updated>2023-12-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: The development of biomarkers of aging has greatly advanced epidemiological studies of aging processes. However, much debate remains on the timing of aging onset and the causal relevance of these biomarkers. In this review, we discuss the most recent biomarkers of aging that have been applied across the life course.]]></summary>
        <author>
            <name>Abigail Gaylord</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Age-related micro-environmental changes as drivers of clonal hematopoiesis]]></title>
        <id>pubmed:38133628</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38133628/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231223195542&amp;v=2.18.0"/>
        <updated>2023-12-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Both aging and reduced diversity at the hematopoietic stem cells (HSCs) level are ubiquitous. What remains unclear is why some individuals develop clonal hematopoiesis (CH), and why does CH due to specific mutations occur in specific individuals. Much like aging, reduced diversity of HSCs is a complex phenotype shaped by numerous factors (germline & environment). The purpose of the current review is to discuss the role of two other age-related ubiquitous processes that might...]]></summary>
        <author>
            <name>Tal Bacharach</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Low-Frequency <em>PPM1D</em> Gene Mutations Affect Treatment Response to CD19-Targeted CAR T-Cell Therapy in Large B-Cell Lymphoma]]></title>
        <id>pubmed:38132396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38132396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231223195542&amp;v=2.18.0"/>
        <updated>2023-12-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chimeric antigen receptor T (CAR T)-cell therapy has become a standard treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). Mutations in the PPM1D gene, a frequent driver alteration in clonal hematopoiesis (CH), lead to a gain of function of PPM1D/Wip1 phosphatase, impairing p53-dependent G1 checkpoint and promoting cell proliferation. The presence of PPM1D mutations has been correlated with reduced response to standard chemotherapy in lymphoma...]]></summary>
        <author>
            <name>Katja Seipel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Biomarkers of aging through the life course: A Recent Literature Update]]></title>
        <id>pubmed:38130910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38130910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231223195542&amp;v=2.18.0"/>
        <updated>2023-12-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: The development of biomarkers of aging has greatly advanced epidemiological studies of aging processes. However, much debate remains on the timing of aging onset and the causal relevance of these biomarkers. In this review, we discuss the most recent biomarkers of aging that have been applied across the life course.]]></summary>
        <author>
            <name>Abigail Gaylord</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Age-related micro-environmental changes as drivers of clonal hematopoiesis]]></title>
        <id>pubmed:38133628</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38133628/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231222195013&amp;v=2.18.0"/>
        <updated>2023-12-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Both aging and reduced diversity at the hematopoietic stem cells (HSCs) level are ubiquitous. What remains unclear is why some individuals develop clonal hematopoiesis (CH), and why does CH due to specific mutations occur in specific individuals. Much like aging, reduced diversity of HSCs is a complex phenotype shaped by numerous factors (germline & environment). The purpose of the current review is to discuss the role of two other age-related ubiquitous processes that might...]]></summary>
        <author>
            <name>Tal Bacharach</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Low-Frequency <em>PPM1D</em> Gene Mutations Affect Treatment Response to CD19-Targeted CAR T-Cell Therapy in Large B-Cell Lymphoma]]></title>
        <id>pubmed:38132396</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38132396/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231222195013&amp;v=2.18.0"/>
        <updated>2023-12-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chimeric antigen receptor T (CAR T)-cell therapy has become a standard treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). Mutations in the PPM1D gene, a frequent driver alteration in clonal hematopoiesis (CH), lead to a gain of function of PPM1D/Wip1 phosphatase, impairing p53-dependent G1 checkpoint and promoting cell proliferation. The presence of PPM1D mutations has been correlated with reduced response to standard chemotherapy in lymphoma...]]></summary>
        <author>
            <name>Katja Seipel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Biomarkers of aging through the life course: A Recent Literature Update]]></title>
        <id>pubmed:38130910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38130910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231222195013&amp;v=2.18.0"/>
        <updated>2023-12-22T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: The development of biomarkers of aging has greatly advanced epidemiological studies of aging processes. However, much debate remains on the timing of aging onset and the causal relevance of these biomarkers. In this review, we discuss the most recent biomarkers of aging that have been applied across the life course.]]></summary>
        <author>
            <name>Abigail Gaylord</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploratory analysis of the cervix tumoral HPV antigen-specific T-cell repertoire during chemoradiation and after brachytherapy]]></title>
        <id>pubmed:38129211</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38129211/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240111195444&amp;v=2.18.0"/>
        <updated>2023-12-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CRT and brachytherapy alters the cervical cancer microenvironment to facilitate the expansion of specific T-cell populations, which may contribute to treatment efficacy.]]></summary>
        <author>
            <name>Gohar S Manzar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploratory analysis of the cervix tumoral HPV antigen-specific T-cell repertoire during chemoradiation and after brachytherapy]]></title>
        <id>pubmed:38129211</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38129211/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240110195405&amp;v=2.18.0"/>
        <updated>2023-12-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CRT and brachytherapy alters the cervical cancer microenvironment to facilitate the expansion of specific T-cell populations, which may contribute to treatment efficacy.]]></summary>
        <author>
            <name>Gohar S Manzar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploratory analysis of the cervix tumoral HPV antigen-specific T-cell repertoire during chemoradiation and after brachytherapy]]></title>
        <id>pubmed:38129211</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38129211/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240109195408&amp;v=2.18.0"/>
        <updated>2023-12-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CRT and brachytherapy alters the cervical cancer microenvironment to facilitate the expansion of specific T-cell populations, which may contribute to treatment efficacy.]]></summary>
        <author>
            <name>Gohar S Manzar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploratory analysis of the cervix tumoral HPV antigen-specific T-cell repertoire during chemoradiation and after brachytherapy]]></title>
        <id>pubmed:38129211</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38129211/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240108195354&amp;v=2.18.0"/>
        <updated>2023-12-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CRT and brachytherapy alters the cervical cancer microenvironment to facilitate the expansion of specific T-cell populations, which may contribute to treatment efficacy.]]></summary>
        <author>
            <name>Gohar S Manzar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploratory analysis of the cervix tumoral HPV antigen-specific T-cell repertoire during chemoradiation and after brachytherapy]]></title>
        <id>pubmed:38129211</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38129211/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240107195431&amp;v=2.18.0"/>
        <updated>2023-12-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CRT and brachytherapy alters the cervical cancer microenvironment to facilitate the expansion of specific T-cell populations, which may contribute to treatment efficacy.]]></summary>
        <author>
            <name>Gohar S Manzar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploratory analysis of the cervix tumoral HPV antigen-specific T-cell repertoire during chemoradiation and after brachytherapy]]></title>
        <id>pubmed:38129211</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38129211/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240106195750&amp;v=2.18.0"/>
        <updated>2023-12-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CRT and brachytherapy alters the cervical cancer microenvironment to facilitate the expansion of specific T-cell populations, which may contribute to treatment efficacy.]]></summary>
        <author>
            <name>Gohar S Manzar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploratory analysis of the cervix tumoral HPV antigen-specific T-cell repertoire during chemoradiation and after brachytherapy]]></title>
        <id>pubmed:38129211</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38129211/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240105195208&amp;v=2.18.0"/>
        <updated>2023-12-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CRT and brachytherapy alters the cervical cancer microenvironment to facilitate the expansion of specific T-cell populations, which may contribute to treatment efficacy.]]></summary>
        <author>
            <name>Gohar S Manzar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploratory analysis of the cervix tumoral HPV antigen-specific T-cell repertoire during chemoradiation and after brachytherapy]]></title>
        <id>pubmed:38129211</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38129211/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240104195307&amp;v=2.18.0"/>
        <updated>2023-12-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CRT and brachytherapy alters the cervical cancer microenvironment to facilitate the expansion of specific T-cell populations, which may contribute to treatment efficacy.]]></summary>
        <author>
            <name>Gohar S Manzar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploratory analysis of the cervix tumoral HPV antigen-specific T-cell repertoire during chemoradiation and after brachytherapy]]></title>
        <id>pubmed:38129211</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38129211/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240103195303&amp;v=2.18.0"/>
        <updated>2023-12-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CRT and brachytherapy alters the cervical cancer microenvironment to facilitate the expansion of specific T-cell populations, which may contribute to treatment efficacy.]]></summary>
        <author>
            <name>Gohar S Manzar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploratory analysis of the cervix tumoral HPV antigen-specific T-cell repertoire during chemoradiation and after brachytherapy]]></title>
        <id>pubmed:38129211</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38129211/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240102195247&amp;v=2.18.0"/>
        <updated>2023-12-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CRT and brachytherapy alters the cervical cancer microenvironment to facilitate the expansion of specific T-cell populations, which may contribute to treatment efficacy.]]></summary>
        <author>
            <name>Gohar S Manzar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploratory analysis of the cervix tumoral HPV antigen-specific T-cell repertoire during chemoradiation and after brachytherapy]]></title>
        <id>pubmed:38129211</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38129211/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240101195419&amp;v=2.18.0"/>
        <updated>2023-12-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CRT and brachytherapy alters the cervical cancer microenvironment to facilitate the expansion of specific T-cell populations, which may contribute to treatment efficacy.]]></summary>
        <author>
            <name>Gohar S Manzar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploratory analysis of the cervix tumoral HPV antigen-specific T-cell repertoire during chemoradiation and after brachytherapy]]></title>
        <id>pubmed:38129211</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38129211/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231231195742&amp;v=2.18.0"/>
        <updated>2023-12-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CRT and brachytherapy alters the cervical cancer microenvironment to facilitate the expansion of specific T-cell populations, which may contribute to treatment efficacy.]]></summary>
        <author>
            <name>Gohar S Manzar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploratory analysis of the cervix tumoral HPV antigen-specific T-cell repertoire during chemoradiation and after brachytherapy]]></title>
        <id>pubmed:38129211</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38129211/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231230195628&amp;v=2.18.0"/>
        <updated>2023-12-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CRT and brachytherapy alters the cervical cancer microenvironment to facilitate the expansion of specific T-cell populations, which may contribute to treatment efficacy.]]></summary>
        <author>
            <name>Gohar S Manzar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploratory analysis of the cervix tumoral HPV antigen-specific T-cell repertoire during chemoradiation and after brachytherapy]]></title>
        <id>pubmed:38129211</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38129211/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231229195054&amp;v=2.18.0"/>
        <updated>2023-12-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CRT and brachytherapy alters the cervical cancer microenvironment to facilitate the expansion of specific T-cell populations, which may contribute to treatment efficacy.]]></summary>
        <author>
            <name>Gohar S Manzar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploratory analysis of the cervix tumoral HPV antigen-specific T-cell repertoire during chemoradiation and after brachytherapy]]></title>
        <id>pubmed:38129211</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38129211/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231228194204&amp;v=2.18.0"/>
        <updated>2023-12-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CRT and brachytherapy alters the cervical cancer microenvironment to facilitate the expansion of specific T-cell populations, which may contribute to treatment efficacy.]]></summary>
        <author>
            <name>Gohar S Manzar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploratory analysis of the cervix tumoral HPV antigen-specific T-cell repertoire during chemoradiation and after brachytherapy]]></title>
        <id>pubmed:38129211</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38129211/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231227195056&amp;v=2.18.0"/>
        <updated>2023-12-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CRT and brachytherapy alters the cervical cancer microenvironment to facilitate the expansion of specific T-cell populations, which may contribute to treatment efficacy.]]></summary>
        <author>
            <name>Gohar S Manzar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploratory analysis of the cervix tumoral HPV antigen-specific T-cell repertoire during chemoradiation and after brachytherapy]]></title>
        <id>pubmed:38129211</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38129211/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231226195107&amp;v=2.18.0"/>
        <updated>2023-12-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CRT and brachytherapy alters the cervical cancer microenvironment to facilitate the expansion of specific T-cell populations, which may contribute to treatment efficacy.]]></summary>
        <author>
            <name>Gohar S Manzar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploratory analysis of the cervix tumoral HPV antigen-specific T-cell repertoire during chemoradiation and after brachytherapy]]></title>
        <id>pubmed:38129211</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38129211/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231225195059&amp;v=2.18.0"/>
        <updated>2023-12-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CRT and brachytherapy alters the cervical cancer microenvironment to facilitate the expansion of specific T-cell populations, which may contribute to treatment efficacy.]]></summary>
        <author>
            <name>Gohar S Manzar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploratory analysis of the cervix tumoral HPV antigen-specific T-cell repertoire during chemoradiation and after brachytherapy]]></title>
        <id>pubmed:38129211</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38129211/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231224195316&amp;v=2.18.0"/>
        <updated>2023-12-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CRT and brachytherapy alters the cervical cancer microenvironment to facilitate the expansion of specific T-cell populations, which may contribute to treatment efficacy.]]></summary>
        <author>
            <name>Gohar S Manzar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploratory analysis of the cervix tumoral HPV antigen-specific T-cell repertoire during chemoradiation and after brachytherapy]]></title>
        <id>pubmed:38129211</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38129211/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231223195542&amp;v=2.18.0"/>
        <updated>2023-12-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CRT and brachytherapy alters the cervical cancer microenvironment to facilitate the expansion of specific T-cell populations, which may contribute to treatment efficacy.]]></summary>
        <author>
            <name>Gohar S Manzar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploratory analysis of the cervix tumoral HPV antigen-specific T-cell repertoire during chemoradiation and after brachytherapy]]></title>
        <id>pubmed:38129211</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38129211/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231222195013&amp;v=2.18.0"/>
        <updated>2023-12-21T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CRT and brachytherapy alters the cervical cancer microenvironment to facilitate the expansion of specific T-cell populations, which may contribute to treatment efficacy.]]></summary>
        <author>
            <name>Gohar S Manzar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential in Chronic Thromboembolic Pulmonary Hypertension: A Multicenter Study]]></title>
        <id>pubmed:38116660</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38116660/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240103195259&amp;v=2.18.0"/>
        <updated>2023-12-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This is the first study to show that CHIP mutations occurred in 9.4% of patients with CTEPH are associated with a severe inflammatory state and confer a poorer prognosis in long-term follow-up.]]></summary>
        <author>
            <name>Chao Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential in Chronic Thromboembolic Pulmonary Hypertension: A Multicenter Study]]></title>
        <id>pubmed:38116660</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38116660/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240102195247&amp;v=2.18.0"/>
        <updated>2023-12-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This is the first study to show that CHIP mutations occurred in 9.4% of patients with CTEPH are associated with a severe inflammatory state and confer a poorer prognosis in long-term follow-up.]]></summary>
        <author>
            <name>Chao Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential in Chronic Thromboembolic Pulmonary Hypertension: A Multicenter Study]]></title>
        <id>pubmed:38116660</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38116660/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240101195419&amp;v=2.18.0"/>
        <updated>2023-12-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This is the first study to show that CHIP mutations occurred in 9.4% of patients with CTEPH are associated with a severe inflammatory state and confer a poorer prognosis in long-term follow-up.]]></summary>
        <author>
            <name>Chao Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential in Chronic Thromboembolic Pulmonary Hypertension: A Multicenter Study]]></title>
        <id>pubmed:38116660</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38116660/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231231195742&amp;v=2.18.0"/>
        <updated>2023-12-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This is the first study to show that CHIP mutations occurred in 9.4% of patients with CTEPH are associated with a severe inflammatory state and confer a poorer prognosis in long-term follow-up.]]></summary>
        <author>
            <name>Chao Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential in Chronic Thromboembolic Pulmonary Hypertension: A Multicenter Study]]></title>
        <id>pubmed:38116660</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38116660/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231230195628&amp;v=2.18.0"/>
        <updated>2023-12-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This is the first study to show that CHIP mutations occurred in 9.4% of patients with CTEPH are associated with a severe inflammatory state and confer a poorer prognosis in long-term follow-up.]]></summary>
        <author>
            <name>Chao Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential in Chronic Thromboembolic Pulmonary Hypertension: A Multicenter Study]]></title>
        <id>pubmed:38116660</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38116660/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231229195054&amp;v=2.18.0"/>
        <updated>2023-12-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This is the first study to show that CHIP mutations occurred in 9.4% of patients with CTEPH are associated with a severe inflammatory state and confer a poorer prognosis in long-term follow-up.]]></summary>
        <author>
            <name>Chao Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential in Chronic Thromboembolic Pulmonary Hypertension: A Multicenter Study]]></title>
        <id>pubmed:38116660</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38116660/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231228194204&amp;v=2.18.0"/>
        <updated>2023-12-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This is the first study to show that CHIP mutations occurred in 9.4% of patients with CTEPH are associated with a severe inflammatory state and confer a poorer prognosis in long-term follow-up.]]></summary>
        <author>
            <name>Chao Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential in Chronic Thromboembolic Pulmonary Hypertension: A Multicenter Study]]></title>
        <id>pubmed:38116660</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38116660/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231227195056&amp;v=2.18.0"/>
        <updated>2023-12-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This is the first study to show that CHIP mutations occurred in 9.4% of patients with CTEPH are associated with a severe inflammatory state and confer a poorer prognosis in long-term follow-up.]]></summary>
        <author>
            <name>Chao Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential in Chronic Thromboembolic Pulmonary Hypertension: A Multicenter Study]]></title>
        <id>pubmed:38116660</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38116660/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231226195107&amp;v=2.18.0"/>
        <updated>2023-12-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This is the first study to show that CHIP mutations occurred in 9.4% of patients with CTEPH are associated with a severe inflammatory state and confer a poorer prognosis in long-term follow-up.]]></summary>
        <author>
            <name>Chao Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential in Chronic Thromboembolic Pulmonary Hypertension: A Multicenter Study]]></title>
        <id>pubmed:38116660</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38116660/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231225195059&amp;v=2.18.0"/>
        <updated>2023-12-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This is the first study to show that CHIP mutations occurred in 9.4% of patients with CTEPH are associated with a severe inflammatory state and confer a poorer prognosis in long-term follow-up.]]></summary>
        <author>
            <name>Chao Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential in Chronic Thromboembolic Pulmonary Hypertension: A Multicenter Study]]></title>
        <id>pubmed:38116660</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38116660/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231224195316&amp;v=2.18.0"/>
        <updated>2023-12-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This is the first study to show that CHIP mutations occurred in 9.4% of patients with CTEPH are associated with a severe inflammatory state and confer a poorer prognosis in long-term follow-up.]]></summary>
        <author>
            <name>Chao Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential in Chronic Thromboembolic Pulmonary Hypertension: A Multicenter Study]]></title>
        <id>pubmed:38116660</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38116660/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231223195542&amp;v=2.18.0"/>
        <updated>2023-12-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This is the first study to show that CHIP mutations occurred in 9.4% of patients with CTEPH are associated with a severe inflammatory state and confer a poorer prognosis in long-term follow-up.]]></summary>
        <author>
            <name>Chao Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential in Chronic Thromboembolic Pulmonary Hypertension: A Multicenter Study]]></title>
        <id>pubmed:38116660</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38116660/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231222195013&amp;v=2.18.0"/>
        <updated>2023-12-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This is the first study to show that CHIP mutations occurred in 9.4% of patients with CTEPH are associated with a severe inflammatory state and confer a poorer prognosis in long-term follow-up.]]></summary>
        <author>
            <name>Chao Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential in Chronic Thromboembolic Pulmonary Hypertension: A Multicenter Study]]></title>
        <id>pubmed:38116660</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38116660/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231221195154&amp;v=2.18.0"/>
        <updated>2023-12-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This is the first study to show that CHIP mutations occurred in 9.4% of patients with CTEPH are associated with a severe inflammatory state and confer a poorer prognosis in long-term follow-up.]]></summary>
        <author>
            <name>Chao Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential in Chronic Thromboembolic Pulmonary Hypertension: A Multicenter Study]]></title>
        <id>pubmed:38116660</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38116660/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231220195219&amp;v=2.18.0"/>
        <updated>2023-12-20T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This is the first study to show that CHIP mutations occurred in 9.4% of patients with CTEPH are associated with a severe inflammatory state and confer a poorer prognosis in long-term follow-up.]]></summary>
        <author>
            <name>Chao Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Ten-Eleven-Translocation Genes in Cancer]]></title>
        <id>pubmed:38113007</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38113007/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240103195259&amp;v=2.18.0"/>
        <updated>2023-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The Ten-Eleven-Translocation (TET) family of genes, including TET1, TET2, and TET3, play critical roles in the oxidation of 5-methylcytosine marks in both DNA and RNA, thereby regulating the epigenome and epitranscriptome in cells. These genes are frequently mutated in both hematopoietic malignancies and in solid cancers. TET2, in particular, is one of the most frequently mutated genes in clonal hematopoiesis in the general population, which impacts both the transformation of hematopoietic...]]></summary>
        <author>
            <name>Yadong Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Ten-Eleven-Translocation Genes in Cancer]]></title>
        <id>pubmed:38113007</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38113007/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240102195247&amp;v=2.18.0"/>
        <updated>2023-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The Ten-Eleven-Translocation (TET) family of genes, including TET1, TET2, and TET3, play critical roles in the oxidation of 5-methylcytosine marks in both DNA and RNA, thereby regulating the epigenome and epitranscriptome in cells. These genes are frequently mutated in both hematopoietic malignancies and in solid cancers. TET2, in particular, is one of the most frequently mutated genes in clonal hematopoiesis in the general population, which impacts both the transformation of hematopoietic...]]></summary>
        <author>
            <name>Yadong Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Ten-Eleven-Translocation Genes in Cancer]]></title>
        <id>pubmed:38113007</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38113007/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240101195419&amp;v=2.18.0"/>
        <updated>2023-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The Ten-Eleven-Translocation (TET) family of genes, including TET1, TET2, and TET3, play critical roles in the oxidation of 5-methylcytosine marks in both DNA and RNA, thereby regulating the epigenome and epitranscriptome in cells. These genes are frequently mutated in both hematopoietic malignancies and in solid cancers. TET2, in particular, is one of the most frequently mutated genes in clonal hematopoiesis in the general population, which impacts both the transformation of hematopoietic...]]></summary>
        <author>
            <name>Yadong Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Ten-Eleven-Translocation Genes in Cancer]]></title>
        <id>pubmed:38113007</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38113007/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231231195742&amp;v=2.18.0"/>
        <updated>2023-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The Ten-Eleven-Translocation (TET) family of genes, including TET1, TET2, and TET3, play critical roles in the oxidation of 5-methylcytosine marks in both DNA and RNA, thereby regulating the epigenome and epitranscriptome in cells. These genes are frequently mutated in both hematopoietic malignancies and in solid cancers. TET2, in particular, is one of the most frequently mutated genes in clonal hematopoiesis in the general population, which impacts both the transformation of hematopoietic...]]></summary>
        <author>
            <name>Yadong Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Ten-Eleven-Translocation Genes in Cancer]]></title>
        <id>pubmed:38113007</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38113007/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231230195628&amp;v=2.18.0"/>
        <updated>2023-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The Ten-Eleven-Translocation (TET) family of genes, including TET1, TET2, and TET3, play critical roles in the oxidation of 5-methylcytosine marks in both DNA and RNA, thereby regulating the epigenome and epitranscriptome in cells. These genes are frequently mutated in both hematopoietic malignancies and in solid cancers. TET2, in particular, is one of the most frequently mutated genes in clonal hematopoiesis in the general population, which impacts both the transformation of hematopoietic...]]></summary>
        <author>
            <name>Yadong Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Ten-Eleven-Translocation Genes in Cancer]]></title>
        <id>pubmed:38113007</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38113007/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231229195054&amp;v=2.18.0"/>
        <updated>2023-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The Ten-Eleven-Translocation (TET) family of genes, including TET1, TET2, and TET3, play critical roles in the oxidation of 5-methylcytosine marks in both DNA and RNA, thereby regulating the epigenome and epitranscriptome in cells. These genes are frequently mutated in both hematopoietic malignancies and in solid cancers. TET2, in particular, is one of the most frequently mutated genes in clonal hematopoiesis in the general population, which impacts both the transformation of hematopoietic...]]></summary>
        <author>
            <name>Yadong Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Ten-Eleven-Translocation Genes in Cancer]]></title>
        <id>pubmed:38113007</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38113007/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231228194204&amp;v=2.18.0"/>
        <updated>2023-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The Ten-Eleven-Translocation (TET) family of genes, including TET1, TET2, and TET3, play critical roles in the oxidation of 5-methylcytosine marks in both DNA and RNA, thereby regulating the epigenome and epitranscriptome in cells. These genes are frequently mutated in both hematopoietic malignancies and in solid cancers. TET2, in particular, is one of the most frequently mutated genes in clonal hematopoiesis in the general population, which impacts both the transformation of hematopoietic...]]></summary>
        <author>
            <name>Yadong Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Ten-Eleven-Translocation Genes in Cancer]]></title>
        <id>pubmed:38113007</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38113007/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231227195056&amp;v=2.18.0"/>
        <updated>2023-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The Ten-Eleven-Translocation (TET) family of genes, including TET1, TET2, and TET3, play critical roles in the oxidation of 5-methylcytosine marks in both DNA and RNA, thereby regulating the epigenome and epitranscriptome in cells. These genes are frequently mutated in both hematopoietic malignancies and in solid cancers. TET2, in particular, is one of the most frequently mutated genes in clonal hematopoiesis in the general population, which impacts both the transformation of hematopoietic...]]></summary>
        <author>
            <name>Yadong Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Ten-Eleven-Translocation Genes in Cancer]]></title>
        <id>pubmed:38113007</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38113007/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231226195107&amp;v=2.18.0"/>
        <updated>2023-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The Ten-Eleven-Translocation (TET) family of genes, including TET1, TET2, and TET3, play critical roles in the oxidation of 5-methylcytosine marks in both DNA and RNA, thereby regulating the epigenome and epitranscriptome in cells. These genes are frequently mutated in both hematopoietic malignancies and in solid cancers. TET2, in particular, is one of the most frequently mutated genes in clonal hematopoiesis in the general population, which impacts both the transformation of hematopoietic...]]></summary>
        <author>
            <name>Yadong Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Ten-Eleven-Translocation Genes in Cancer]]></title>
        <id>pubmed:38113007</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38113007/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231225195059&amp;v=2.18.0"/>
        <updated>2023-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The Ten-Eleven-Translocation (TET) family of genes, including TET1, TET2, and TET3, play critical roles in the oxidation of 5-methylcytosine marks in both DNA and RNA, thereby regulating the epigenome and epitranscriptome in cells. These genes are frequently mutated in both hematopoietic malignancies and in solid cancers. TET2, in particular, is one of the most frequently mutated genes in clonal hematopoiesis in the general population, which impacts both the transformation of hematopoietic...]]></summary>
        <author>
            <name>Yadong Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Ten-Eleven-Translocation Genes in Cancer]]></title>
        <id>pubmed:38113007</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38113007/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231224195316&amp;v=2.18.0"/>
        <updated>2023-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The Ten-Eleven-Translocation (TET) family of genes, including TET1, TET2, and TET3, play critical roles in the oxidation of 5-methylcytosine marks in both DNA and RNA, thereby regulating the epigenome and epitranscriptome in cells. These genes are frequently mutated in both hematopoietic malignancies and in solid cancers. TET2, in particular, is one of the most frequently mutated genes in clonal hematopoiesis in the general population, which impacts both the transformation of hematopoietic...]]></summary>
        <author>
            <name>Yadong Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Ten-Eleven-Translocation Genes in Cancer]]></title>
        <id>pubmed:38113007</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38113007/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231223195542&amp;v=2.18.0"/>
        <updated>2023-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The Ten-Eleven-Translocation (TET) family of genes, including TET1, TET2, and TET3, play critical roles in the oxidation of 5-methylcytosine marks in both DNA and RNA, thereby regulating the epigenome and epitranscriptome in cells. These genes are frequently mutated in both hematopoietic malignancies and in solid cancers. TET2, in particular, is one of the most frequently mutated genes in clonal hematopoiesis in the general population, which impacts both the transformation of hematopoietic...]]></summary>
        <author>
            <name>Yadong Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Ten-Eleven-Translocation Genes in Cancer]]></title>
        <id>pubmed:38113007</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38113007/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231222195013&amp;v=2.18.0"/>
        <updated>2023-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The Ten-Eleven-Translocation (TET) family of genes, including TET1, TET2, and TET3, play critical roles in the oxidation of 5-methylcytosine marks in both DNA and RNA, thereby regulating the epigenome and epitranscriptome in cells. These genes are frequently mutated in both hematopoietic malignancies and in solid cancers. TET2, in particular, is one of the most frequently mutated genes in clonal hematopoiesis in the general population, which impacts both the transformation of hematopoietic...]]></summary>
        <author>
            <name>Yadong Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Ten-Eleven-Translocation Genes in Cancer]]></title>
        <id>pubmed:38113007</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38113007/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231221195154&amp;v=2.18.0"/>
        <updated>2023-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The Ten-Eleven-Translocation (TET) family of genes, including TET1, TET2, and TET3, play critical roles in the oxidation of 5-methylcytosine marks in both DNA and RNA, thereby regulating the epigenome and epitranscriptome in cells. These genes are frequently mutated in both hematopoietic malignancies and in solid cancers. TET2, in particular, is one of the most frequently mutated genes in clonal hematopoiesis in the general population, which impacts both the transformation of hematopoietic...]]></summary>
        <author>
            <name>Yadong Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Ten-Eleven-Translocation Genes in Cancer]]></title>
        <id>pubmed:38113007</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38113007/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231220195219&amp;v=2.18.0"/>
        <updated>2023-12-19T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[The Ten-Eleven-Translocation (TET) family of genes, including TET1, TET2, and TET3, play critical roles in the oxidation of 5-methylcytosine marks in both DNA and RNA, thereby regulating the epigenome and epitranscriptome in cells. These genes are frequently mutated in both hematopoietic malignancies and in solid cancers. TET2, in particular, is one of the most frequently mutated genes in clonal hematopoiesis in the general population, which impacts both the transformation of hematopoietic...]]></summary>
        <author>
            <name>Yadong Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Sc-TUSV-ext: Single-cell clonal lineage inference from single nucleotide variants (SNV), copy number alterations (CNA) and structural variants (SV)]]></title>
        <id>pubmed:38106049</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38106049/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240110195405&amp;v=2.18.0"/>
        <updated>2023-12-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal lineage inference ("tumor phylogenetics") has become a crucial tool for making sense of somatic evolution processes that underlie cancer development and are increasingly recognized as part of normal tissue growth and aging. The inference of clonal lineage trees from single cell sequence data offers particular promise for revealing processes of somatic evolution in unprecedented detail. However, most such tools are based on fairly restrictive models of the types of mutation events observed...]]></summary>
        <author>
            <name>Nishat Anjum Bristy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolvability of cancer-associated genes under APOBEC3A/B selection]]></title>
        <id>pubmed:38106028</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38106028/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240110195405&amp;v=2.18.0"/>
        <updated>2023-12-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolvability is an emergent hallmark of cancer that depends on intra-tumor heterogeneity and, ultimately, genetic variation. Mutations generated by APOBEC3 cytidine deaminases can contribute to genetic variation and the consequences of APOBEC activation differ depending on the stage of cancer, with the most significant impact observed during the early stages. However, how APOBEC activity shapes evolutionary patterns of genes in the host genome and differential impacts on cancer-associated and...]]></summary>
        <author>
            <name>Joon-Hyun Song</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Sc-TUSV-ext: Single-cell clonal lineage inference from single nucleotide variants (SNV), copy number alterations (CNA) and structural variants (SV)]]></title>
        <id>pubmed:38106049</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38106049/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240109195408&amp;v=2.18.0"/>
        <updated>2023-12-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal lineage inference ("tumor phylogenetics") has become a crucial tool for making sense of somatic evolution processes that underlie cancer development and are increasingly recognized as part of normal tissue growth and aging. The inference of clonal lineage trees from single cell sequence data offers particular promise for revealing processes of somatic evolution in unprecedented detail. However, most such tools are based on fairly restrictive models of the types of mutation events observed...]]></summary>
        <author>
            <name>Nishat Anjum Bristy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolvability of cancer-associated genes under APOBEC3A/B selection]]></title>
        <id>pubmed:38106028</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38106028/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240109195408&amp;v=2.18.0"/>
        <updated>2023-12-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolvability is an emergent hallmark of cancer that depends on intra-tumor heterogeneity and, ultimately, genetic variation. Mutations generated by APOBEC3 cytidine deaminases can contribute to genetic variation and the consequences of APOBEC activation differ depending on the stage of cancer, with the most significant impact observed during the early stages. However, how APOBEC activity shapes evolutionary patterns of genes in the host genome and differential impacts on cancer-associated and...]]></summary>
        <author>
            <name>Joon-Hyun Song</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Sc-TUSV-ext: Single-cell clonal lineage inference from single nucleotide variants (SNV), copy number alterations (CNA) and structural variants (SV)]]></title>
        <id>pubmed:38106049</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38106049/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240108195354&amp;v=2.18.0"/>
        <updated>2023-12-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal lineage inference ("tumor phylogenetics") has become a crucial tool for making sense of somatic evolution processes that underlie cancer development and are increasingly recognized as part of normal tissue growth and aging. The inference of clonal lineage trees from single cell sequence data offers particular promise for revealing processes of somatic evolution in unprecedented detail. However, most such tools are based on fairly restrictive models of the types of mutation events observed...]]></summary>
        <author>
            <name>Nishat Anjum Bristy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolvability of cancer-associated genes under APOBEC3A/B selection]]></title>
        <id>pubmed:38106028</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38106028/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240108195354&amp;v=2.18.0"/>
        <updated>2023-12-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolvability is an emergent hallmark of cancer that depends on intra-tumor heterogeneity and, ultimately, genetic variation. Mutations generated by APOBEC3 cytidine deaminases can contribute to genetic variation and the consequences of APOBEC activation differ depending on the stage of cancer, with the most significant impact observed during the early stages. However, how APOBEC activity shapes evolutionary patterns of genes in the host genome and differential impacts on cancer-associated and...]]></summary>
        <author>
            <name>Joon-Hyun Song</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Sc-TUSV-ext: Single-cell clonal lineage inference from single nucleotide variants (SNV), copy number alterations (CNA) and structural variants (SV)]]></title>
        <id>pubmed:38106049</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38106049/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240107195431&amp;v=2.18.0"/>
        <updated>2023-12-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal lineage inference ("tumor phylogenetics") has become a crucial tool for making sense of somatic evolution processes that underlie cancer development and are increasingly recognized as part of normal tissue growth and aging. The inference of clonal lineage trees from single cell sequence data offers particular promise for revealing processes of somatic evolution in unprecedented detail. However, most such tools are based on fairly restrictive models of the types of mutation events observed...]]></summary>
        <author>
            <name>Nishat Anjum Bristy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolvability of cancer-associated genes under APOBEC3A/B selection]]></title>
        <id>pubmed:38106028</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38106028/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240107195431&amp;v=2.18.0"/>
        <updated>2023-12-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolvability is an emergent hallmark of cancer that depends on intra-tumor heterogeneity and, ultimately, genetic variation. Mutations generated by APOBEC3 cytidine deaminases can contribute to genetic variation and the consequences of APOBEC activation differ depending on the stage of cancer, with the most significant impact observed during the early stages. However, how APOBEC activity shapes evolutionary patterns of genes in the host genome and differential impacts on cancer-associated and...]]></summary>
        <author>
            <name>Joon-Hyun Song</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Sc-TUSV-ext: Single-cell clonal lineage inference from single nucleotide variants (SNV), copy number alterations (CNA) and structural variants (SV)]]></title>
        <id>pubmed:38106049</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38106049/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240106195750&amp;v=2.18.0"/>
        <updated>2023-12-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal lineage inference ("tumor phylogenetics") has become a crucial tool for making sense of somatic evolution processes that underlie cancer development and are increasingly recognized as part of normal tissue growth and aging. The inference of clonal lineage trees from single cell sequence data offers particular promise for revealing processes of somatic evolution in unprecedented detail. However, most such tools are based on fairly restrictive models of the types of mutation events observed...]]></summary>
        <author>
            <name>Nishat Anjum Bristy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolvability of cancer-associated genes under APOBEC3A/B selection]]></title>
        <id>pubmed:38106028</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38106028/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240106195750&amp;v=2.18.0"/>
        <updated>2023-12-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolvability is an emergent hallmark of cancer that depends on intra-tumor heterogeneity and, ultimately, genetic variation. Mutations generated by APOBEC3 cytidine deaminases can contribute to genetic variation and the consequences of APOBEC activation differ depending on the stage of cancer, with the most significant impact observed during the early stages. However, how APOBEC activity shapes evolutionary patterns of genes in the host genome and differential impacts on cancer-associated and...]]></summary>
        <author>
            <name>Joon-Hyun Song</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Sc-TUSV-ext: Single-cell clonal lineage inference from single nucleotide variants (SNV), copy number alterations (CNA) and structural variants (SV)]]></title>
        <id>pubmed:38106049</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38106049/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240105195208&amp;v=2.18.0"/>
        <updated>2023-12-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal lineage inference ("tumor phylogenetics") has become a crucial tool for making sense of somatic evolution processes that underlie cancer development and are increasingly recognized as part of normal tissue growth and aging. The inference of clonal lineage trees from single cell sequence data offers particular promise for revealing processes of somatic evolution in unprecedented detail. However, most such tools are based on fairly restrictive models of the types of mutation events observed...]]></summary>
        <author>
            <name>Nishat Anjum Bristy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolvability of cancer-associated genes under APOBEC3A/B selection]]></title>
        <id>pubmed:38106028</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38106028/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240105195208&amp;v=2.18.0"/>
        <updated>2023-12-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolvability is an emergent hallmark of cancer that depends on intra-tumor heterogeneity and, ultimately, genetic variation. Mutations generated by APOBEC3 cytidine deaminases can contribute to genetic variation and the consequences of APOBEC activation differ depending on the stage of cancer, with the most significant impact observed during the early stages. However, how APOBEC activity shapes evolutionary patterns of genes in the host genome and differential impacts on cancer-associated and...]]></summary>
        <author>
            <name>Joon-Hyun Song</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Sc-TUSV-ext: Single-cell clonal lineage inference from single nucleotide variants (SNV), copy number alterations (CNA) and structural variants (SV)]]></title>
        <id>pubmed:38106049</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38106049/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240104195307&amp;v=2.18.0"/>
        <updated>2023-12-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal lineage inference ("tumor phylogenetics") has become a crucial tool for making sense of somatic evolution processes that underlie cancer development and are increasingly recognized as part of normal tissue growth and aging. The inference of clonal lineage trees from single cell sequence data offers particular promise for revealing processes of somatic evolution in unprecedented detail. However, most such tools are based on fairly restrictive models of the types of mutation events observed...]]></summary>
        <author>
            <name>Nishat Anjum Bristy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolvability of cancer-associated genes under APOBEC3A/B selection]]></title>
        <id>pubmed:38106028</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38106028/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240104195307&amp;v=2.18.0"/>
        <updated>2023-12-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolvability is an emergent hallmark of cancer that depends on intra-tumor heterogeneity and, ultimately, genetic variation. Mutations generated by APOBEC3 cytidine deaminases can contribute to genetic variation and the consequences of APOBEC activation differ depending on the stage of cancer, with the most significant impact observed during the early stages. However, how APOBEC activity shapes evolutionary patterns of genes in the host genome and differential impacts on cancer-associated and...]]></summary>
        <author>
            <name>Joon-Hyun Song</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Sc-TUSV-ext: Single-cell clonal lineage inference from single nucleotide variants (SNV), copy number alterations (CNA) and structural variants (SV)]]></title>
        <id>pubmed:38106049</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38106049/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240103195303&amp;v=2.18.0"/>
        <updated>2023-12-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal lineage inference ("tumor phylogenetics") has become a crucial tool for making sense of somatic evolution processes that underlie cancer development and are increasingly recognized as part of normal tissue growth and aging. The inference of clonal lineage trees from single cell sequence data offers particular promise for revealing processes of somatic evolution in unprecedented detail. However, most such tools are based on fairly restrictive models of the types of mutation events observed...]]></summary>
        <author>
            <name>Nishat Anjum Bristy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolvability of cancer-associated genes under APOBEC3A/B selection]]></title>
        <id>pubmed:38106028</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38106028/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240103195303&amp;v=2.18.0"/>
        <updated>2023-12-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolvability is an emergent hallmark of cancer that depends on intra-tumor heterogeneity and, ultimately, genetic variation. Mutations generated by APOBEC3 cytidine deaminases can contribute to genetic variation and the consequences of APOBEC activation differ depending on the stage of cancer, with the most significant impact observed during the early stages. However, how APOBEC activity shapes evolutionary patterns of genes in the host genome and differential impacts on cancer-associated and...]]></summary>
        <author>
            <name>Joon-Hyun Song</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Sc-TUSV-ext: Single-cell clonal lineage inference from single nucleotide variants (SNV), copy number alterations (CNA) and structural variants (SV)]]></title>
        <id>pubmed:38106049</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38106049/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240102195247&amp;v=2.18.0"/>
        <updated>2023-12-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal lineage inference ("tumor phylogenetics") has become a crucial tool for making sense of somatic evolution processes that underlie cancer development and are increasingly recognized as part of normal tissue growth and aging. The inference of clonal lineage trees from single cell sequence data offers particular promise for revealing processes of somatic evolution in unprecedented detail. However, most such tools are based on fairly restrictive models of the types of mutation events observed...]]></summary>
        <author>
            <name>Nishat Anjum Bristy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolvability of cancer-associated genes under APOBEC3A/B selection]]></title>
        <id>pubmed:38106028</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38106028/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240102195247&amp;v=2.18.0"/>
        <updated>2023-12-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolvability is an emergent hallmark of cancer that depends on intra-tumor heterogeneity and, ultimately, genetic variation. Mutations generated by APOBEC3 cytidine deaminases can contribute to genetic variation and the consequences of APOBEC activation differ depending on the stage of cancer, with the most significant impact observed during the early stages. However, how APOBEC activity shapes evolutionary patterns of genes in the host genome and differential impacts on cancer-associated and...]]></summary>
        <author>
            <name>Joon-Hyun Song</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Sc-TUSV-ext: Single-cell clonal lineage inference from single nucleotide variants (SNV), copy number alterations (CNA) and structural variants (SV)]]></title>
        <id>pubmed:38106049</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38106049/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240101195419&amp;v=2.18.0"/>
        <updated>2023-12-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal lineage inference ("tumor phylogenetics") has become a crucial tool for making sense of somatic evolution processes that underlie cancer development and are increasingly recognized as part of normal tissue growth and aging. The inference of clonal lineage trees from single cell sequence data offers particular promise for revealing processes of somatic evolution in unprecedented detail. However, most such tools are based on fairly restrictive models of the types of mutation events observed...]]></summary>
        <author>
            <name>Nishat Anjum Bristy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolvability of cancer-associated genes under APOBEC3A/B selection]]></title>
        <id>pubmed:38106028</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38106028/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240101195419&amp;v=2.18.0"/>
        <updated>2023-12-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolvability is an emergent hallmark of cancer that depends on intra-tumor heterogeneity and, ultimately, genetic variation. Mutations generated by APOBEC3 cytidine deaminases can contribute to genetic variation and the consequences of APOBEC activation differ depending on the stage of cancer, with the most significant impact observed during the early stages. However, how APOBEC activity shapes evolutionary patterns of genes in the host genome and differential impacts on cancer-associated and...]]></summary>
        <author>
            <name>Joon-Hyun Song</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Sc-TUSV-ext: Single-cell clonal lineage inference from single nucleotide variants (SNV), copy number alterations (CNA) and structural variants (SV)]]></title>
        <id>pubmed:38106049</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38106049/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231231195742&amp;v=2.18.0"/>
        <updated>2023-12-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal lineage inference ("tumor phylogenetics") has become a crucial tool for making sense of somatic evolution processes that underlie cancer development and are increasingly recognized as part of normal tissue growth and aging. The inference of clonal lineage trees from single cell sequence data offers particular promise for revealing processes of somatic evolution in unprecedented detail. However, most such tools are based on fairly restrictive models of the types of mutation events observed...]]></summary>
        <author>
            <name>Nishat Anjum Bristy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolvability of cancer-associated genes under APOBEC3A/B selection]]></title>
        <id>pubmed:38106028</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38106028/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231231195742&amp;v=2.18.0"/>
        <updated>2023-12-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolvability is an emergent hallmark of cancer that depends on intra-tumor heterogeneity and, ultimately, genetic variation. Mutations generated by APOBEC3 cytidine deaminases can contribute to genetic variation and the consequences of APOBEC activation differ depending on the stage of cancer, with the most significant impact observed during the early stages. However, how APOBEC activity shapes evolutionary patterns of genes in the host genome and differential impacts on cancer-associated and...]]></summary>
        <author>
            <name>Joon-Hyun Song</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Sc-TUSV-ext: Single-cell clonal lineage inference from single nucleotide variants (SNV), copy number alterations (CNA) and structural variants (SV)]]></title>
        <id>pubmed:38106049</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38106049/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231230195628&amp;v=2.18.0"/>
        <updated>2023-12-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal lineage inference ("tumor phylogenetics") has become a crucial tool for making sense of somatic evolution processes that underlie cancer development and are increasingly recognized as part of normal tissue growth and aging. The inference of clonal lineage trees from single cell sequence data offers particular promise for revealing processes of somatic evolution in unprecedented detail. However, most such tools are based on fairly restrictive models of the types of mutation events observed...]]></summary>
        <author>
            <name>Nishat Anjum Bristy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolvability of cancer-associated genes under APOBEC3A/B selection]]></title>
        <id>pubmed:38106028</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38106028/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231230195628&amp;v=2.18.0"/>
        <updated>2023-12-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolvability is an emergent hallmark of cancer that depends on intra-tumor heterogeneity and, ultimately, genetic variation. Mutations generated by APOBEC3 cytidine deaminases can contribute to genetic variation and the consequences of APOBEC activation differ depending on the stage of cancer, with the most significant impact observed during the early stages. However, how APOBEC activity shapes evolutionary patterns of genes in the host genome and differential impacts on cancer-associated and...]]></summary>
        <author>
            <name>Joon-Hyun Song</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Sc-TUSV-ext: Single-cell clonal lineage inference from single nucleotide variants (SNV), copy number alterations (CNA) and structural variants (SV)]]></title>
        <id>pubmed:38106049</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38106049/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231229195054&amp;v=2.18.0"/>
        <updated>2023-12-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal lineage inference ("tumor phylogenetics") has become a crucial tool for making sense of somatic evolution processes that underlie cancer development and are increasingly recognized as part of normal tissue growth and aging. The inference of clonal lineage trees from single cell sequence data offers particular promise for revealing processes of somatic evolution in unprecedented detail. However, most such tools are based on fairly restrictive models of the types of mutation events observed...]]></summary>
        <author>
            <name>Nishat Anjum Bristy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolvability of cancer-associated genes under APOBEC3A/B selection]]></title>
        <id>pubmed:38106028</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38106028/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231229195054&amp;v=2.18.0"/>
        <updated>2023-12-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolvability is an emergent hallmark of cancer that depends on intra-tumor heterogeneity and, ultimately, genetic variation. Mutations generated by APOBEC3 cytidine deaminases can contribute to genetic variation and the consequences of APOBEC activation differ depending on the stage of cancer, with the most significant impact observed during the early stages. However, how APOBEC activity shapes evolutionary patterns of genes in the host genome and differential impacts on cancer-associated and...]]></summary>
        <author>
            <name>Joon-Hyun Song</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Sc-TUSV-ext: Single-cell clonal lineage inference from single nucleotide variants (SNV), copy number alterations (CNA) and structural variants (SV)]]></title>
        <id>pubmed:38106049</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38106049/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231228194204&amp;v=2.18.0"/>
        <updated>2023-12-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal lineage inference ("tumor phylogenetics") has become a crucial tool for making sense of somatic evolution processes that underlie cancer development and are increasingly recognized as part of normal tissue growth and aging. The inference of clonal lineage trees from single cell sequence data offers particular promise for revealing processes of somatic evolution in unprecedented detail. However, most such tools are based on fairly restrictive models of the types of mutation events observed...]]></summary>
        <author>
            <name>Nishat Anjum Bristy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolvability of cancer-associated genes under APOBEC3A/B selection]]></title>
        <id>pubmed:38106028</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38106028/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231228194204&amp;v=2.18.0"/>
        <updated>2023-12-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolvability is an emergent hallmark of cancer that depends on intra-tumor heterogeneity and, ultimately, genetic variation. Mutations generated by APOBEC3 cytidine deaminases can contribute to genetic variation and the consequences of APOBEC activation differ depending on the stage of cancer, with the most significant impact observed during the early stages. However, how APOBEC activity shapes evolutionary patterns of genes in the host genome and differential impacts on cancer-associated and...]]></summary>
        <author>
            <name>Joon-Hyun Song</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Sc-TUSV-ext: Single-cell clonal lineage inference from single nucleotide variants (SNV), copy number alterations (CNA) and structural variants (SV)]]></title>
        <id>pubmed:38106049</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38106049/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231227195056&amp;v=2.18.0"/>
        <updated>2023-12-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal lineage inference ("tumor phylogenetics") has become a crucial tool for making sense of somatic evolution processes that underlie cancer development and are increasingly recognized as part of normal tissue growth and aging. The inference of clonal lineage trees from single cell sequence data offers particular promise for revealing processes of somatic evolution in unprecedented detail. However, most such tools are based on fairly restrictive models of the types of mutation events observed...]]></summary>
        <author>
            <name>Nishat Anjum Bristy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolvability of cancer-associated genes under APOBEC3A/B selection]]></title>
        <id>pubmed:38106028</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38106028/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231227195056&amp;v=2.18.0"/>
        <updated>2023-12-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolvability is an emergent hallmark of cancer that depends on intra-tumor heterogeneity and, ultimately, genetic variation. Mutations generated by APOBEC3 cytidine deaminases can contribute to genetic variation and the consequences of APOBEC activation differ depending on the stage of cancer, with the most significant impact observed during the early stages. However, how APOBEC activity shapes evolutionary patterns of genes in the host genome and differential impacts on cancer-associated and...]]></summary>
        <author>
            <name>Joon-Hyun Song</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Sc-TUSV-ext: Single-cell clonal lineage inference from single nucleotide variants (SNV), copy number alterations (CNA) and structural variants (SV)]]></title>
        <id>pubmed:38106049</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38106049/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231226195107&amp;v=2.18.0"/>
        <updated>2023-12-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal lineage inference ("tumor phylogenetics") has become a crucial tool for making sense of somatic evolution processes that underlie cancer development and are increasingly recognized as part of normal tissue growth and aging. The inference of clonal lineage trees from single cell sequence data offers particular promise for revealing processes of somatic evolution in unprecedented detail. However, most such tools are based on fairly restrictive models of the types of mutation events observed...]]></summary>
        <author>
            <name>Nishat Anjum Bristy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolvability of cancer-associated genes under APOBEC3A/B selection]]></title>
        <id>pubmed:38106028</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38106028/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231226195107&amp;v=2.18.0"/>
        <updated>2023-12-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolvability is an emergent hallmark of cancer that depends on intra-tumor heterogeneity and, ultimately, genetic variation. Mutations generated by APOBEC3 cytidine deaminases can contribute to genetic variation and the consequences of APOBEC activation differ depending on the stage of cancer, with the most significant impact observed during the early stages. However, how APOBEC activity shapes evolutionary patterns of genes in the host genome and differential impacts on cancer-associated and...]]></summary>
        <author>
            <name>Joon-Hyun Song</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Sc-TUSV-ext: Single-cell clonal lineage inference from single nucleotide variants (SNV), copy number alterations (CNA) and structural variants (SV)]]></title>
        <id>pubmed:38106049</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38106049/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231225195059&amp;v=2.18.0"/>
        <updated>2023-12-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal lineage inference ("tumor phylogenetics") has become a crucial tool for making sense of somatic evolution processes that underlie cancer development and are increasingly recognized as part of normal tissue growth and aging. The inference of clonal lineage trees from single cell sequence data offers particular promise for revealing processes of somatic evolution in unprecedented detail. However, most such tools are based on fairly restrictive models of the types of mutation events observed...]]></summary>
        <author>
            <name>Nishat Anjum Bristy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolvability of cancer-associated genes under APOBEC3A/B selection]]></title>
        <id>pubmed:38106028</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38106028/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231225195059&amp;v=2.18.0"/>
        <updated>2023-12-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolvability is an emergent hallmark of cancer that depends on intra-tumor heterogeneity and, ultimately, genetic variation. Mutations generated by APOBEC3 cytidine deaminases can contribute to genetic variation and the consequences of APOBEC activation differ depending on the stage of cancer, with the most significant impact observed during the early stages. However, how APOBEC activity shapes evolutionary patterns of genes in the host genome and differential impacts on cancer-associated and...]]></summary>
        <author>
            <name>Joon-Hyun Song</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Sc-TUSV-ext: Single-cell clonal lineage inference from single nucleotide variants (SNV), copy number alterations (CNA) and structural variants (SV)]]></title>
        <id>pubmed:38106049</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38106049/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231224195316&amp;v=2.18.0"/>
        <updated>2023-12-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal lineage inference ("tumor phylogenetics") has become a crucial tool for making sense of somatic evolution processes that underlie cancer development and are increasingly recognized as part of normal tissue growth and aging. The inference of clonal lineage trees from single cell sequence data offers particular promise for revealing processes of somatic evolution in unprecedented detail. However, most such tools are based on fairly restrictive models of the types of mutation events observed...]]></summary>
        <author>
            <name>Nishat Anjum Bristy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolvability of cancer-associated genes under APOBEC3A/B selection]]></title>
        <id>pubmed:38106028</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38106028/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231224195316&amp;v=2.18.0"/>
        <updated>2023-12-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolvability is an emergent hallmark of cancer that depends on intra-tumor heterogeneity and, ultimately, genetic variation. Mutations generated by APOBEC3 cytidine deaminases can contribute to genetic variation and the consequences of APOBEC activation differ depending on the stage of cancer, with the most significant impact observed during the early stages. However, how APOBEC activity shapes evolutionary patterns of genes in the host genome and differential impacts on cancer-associated and...]]></summary>
        <author>
            <name>Joon-Hyun Song</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Sc-TUSV-ext: Single-cell clonal lineage inference from single nucleotide variants (SNV), copy number alterations (CNA) and structural variants (SV)]]></title>
        <id>pubmed:38106049</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38106049/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231223195542&amp;v=2.18.0"/>
        <updated>2023-12-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal lineage inference ("tumor phylogenetics") has become a crucial tool for making sense of somatic evolution processes that underlie cancer development and are increasingly recognized as part of normal tissue growth and aging. The inference of clonal lineage trees from single cell sequence data offers particular promise for revealing processes of somatic evolution in unprecedented detail. However, most such tools are based on fairly restrictive models of the types of mutation events observed...]]></summary>
        <author>
            <name>Nishat Anjum Bristy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolvability of cancer-associated genes under APOBEC3A/B selection]]></title>
        <id>pubmed:38106028</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38106028/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231223195542&amp;v=2.18.0"/>
        <updated>2023-12-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolvability is an emergent hallmark of cancer that depends on intra-tumor heterogeneity and, ultimately, genetic variation. Mutations generated by APOBEC3 cytidine deaminases can contribute to genetic variation and the consequences of APOBEC activation differ depending on the stage of cancer, with the most significant impact observed during the early stages. However, how APOBEC activity shapes evolutionary patterns of genes in the host genome and differential impacts on cancer-associated and...]]></summary>
        <author>
            <name>Joon-Hyun Song</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Sc-TUSV-ext: Single-cell clonal lineage inference from single nucleotide variants (SNV), copy number alterations (CNA) and structural variants (SV)]]></title>
        <id>pubmed:38106049</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38106049/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231222195013&amp;v=2.18.0"/>
        <updated>2023-12-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal lineage inference ("tumor phylogenetics") has become a crucial tool for making sense of somatic evolution processes that underlie cancer development and are increasingly recognized as part of normal tissue growth and aging. The inference of clonal lineage trees from single cell sequence data offers particular promise for revealing processes of somatic evolution in unprecedented detail. However, most such tools are based on fairly restrictive models of the types of mutation events observed...]]></summary>
        <author>
            <name>Nishat Anjum Bristy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolvability of cancer-associated genes under APOBEC3A/B selection]]></title>
        <id>pubmed:38106028</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38106028/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231222195013&amp;v=2.18.0"/>
        <updated>2023-12-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolvability is an emergent hallmark of cancer that depends on intra-tumor heterogeneity and, ultimately, genetic variation. Mutations generated by APOBEC3 cytidine deaminases can contribute to genetic variation and the consequences of APOBEC activation differ depending on the stage of cancer, with the most significant impact observed during the early stages. However, how APOBEC activity shapes evolutionary patterns of genes in the host genome and differential impacts on cancer-associated and...]]></summary>
        <author>
            <name>Joon-Hyun Song</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Sc-TUSV-ext: Single-cell clonal lineage inference from single nucleotide variants (SNV), copy number alterations (CNA) and structural variants (SV)]]></title>
        <id>pubmed:38106049</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38106049/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231221195154&amp;v=2.18.0"/>
        <updated>2023-12-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal lineage inference ("tumor phylogenetics") has become a crucial tool for making sense of somatic evolution processes that underlie cancer development and are increasingly recognized as part of normal tissue growth and aging. The inference of clonal lineage trees from single cell sequence data offers particular promise for revealing processes of somatic evolution in unprecedented detail. However, most such tools are based on fairly restrictive models of the types of mutation events observed...]]></summary>
        <author>
            <name>Nishat Anjum Bristy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolvability of cancer-associated genes under APOBEC3A/B selection]]></title>
        <id>pubmed:38106028</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38106028/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231221195154&amp;v=2.18.0"/>
        <updated>2023-12-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolvability is an emergent hallmark of cancer that depends on intra-tumor heterogeneity and, ultimately, genetic variation. Mutations generated by APOBEC3 cytidine deaminases can contribute to genetic variation and the consequences of APOBEC activation differ depending on the stage of cancer, with the most significant impact observed during the early stages. However, how APOBEC activity shapes evolutionary patterns of genes in the host genome and differential impacts on cancer-associated and...]]></summary>
        <author>
            <name>Joon-Hyun Song</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Sc-TUSV-ext: Single-cell clonal lineage inference from single nucleotide variants (SNV), copy number alterations (CNA) and structural variants (SV)]]></title>
        <id>pubmed:38106049</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38106049/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231220195218&amp;v=2.18.0"/>
        <updated>2023-12-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal lineage inference ("tumor phylogenetics") has become a crucial tool for making sense of somatic evolution processes that underlie cancer development and are increasingly recognized as part of normal tissue growth and aging. The inference of clonal lineage trees from single cell sequence data offers particular promise for revealing processes of somatic evolution in unprecedented detail. However, most such tools are based on fairly restrictive models of the types of mutation events observed...]]></summary>
        <author>
            <name>Nishat Anjum Bristy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolvability of cancer-associated genes under APOBEC3A/B selection]]></title>
        <id>pubmed:38106028</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38106028/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231220195218&amp;v=2.18.0"/>
        <updated>2023-12-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolvability is an emergent hallmark of cancer that depends on intra-tumor heterogeneity and, ultimately, genetic variation. Mutations generated by APOBEC3 cytidine deaminases can contribute to genetic variation and the consequences of APOBEC activation differ depending on the stage of cancer, with the most significant impact observed during the early stages. However, how APOBEC activity shapes evolutionary patterns of genes in the host genome and differential impacts on cancer-associated and...]]></summary>
        <author>
            <name>Joon-Hyun Song</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Sc-TUSV-ext: Single-cell clonal lineage inference from single nucleotide variants (SNV), copy number alterations (CNA) and structural variants (SV)]]></title>
        <id>pubmed:38106049</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38106049/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231219194249&amp;v=2.18.0"/>
        <updated>2023-12-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal lineage inference ("tumor phylogenetics") has become a crucial tool for making sense of somatic evolution processes that underlie cancer development and are increasingly recognized as part of normal tissue growth and aging. The inference of clonal lineage trees from single cell sequence data offers particular promise for revealing processes of somatic evolution in unprecedented detail. However, most such tools are based on fairly restrictive models of the types of mutation events observed...]]></summary>
        <author>
            <name>Nishat Anjum Bristy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolvability of cancer-associated genes under APOBEC3A/B selection]]></title>
        <id>pubmed:38106028</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38106028/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231219194249&amp;v=2.18.0"/>
        <updated>2023-12-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolvability is an emergent hallmark of cancer that depends on intra-tumor heterogeneity and, ultimately, genetic variation. Mutations generated by APOBEC3 cytidine deaminases can contribute to genetic variation and the consequences of APOBEC activation differ depending on the stage of cancer, with the most significant impact observed during the early stages. However, how APOBEC activity shapes evolutionary patterns of genes in the host genome and differential impacts on cancer-associated and...]]></summary>
        <author>
            <name>Joon-Hyun Song</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Sc-TUSV-ext: Single-cell clonal lineage inference from single nucleotide variants (SNV), copy number alterations (CNA) and structural variants (SV)]]></title>
        <id>pubmed:38106049</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38106049/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231218195330&amp;v=2.18.0"/>
        <updated>2023-12-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal lineage inference ("tumor phylogenetics") has become a crucial tool for making sense of somatic evolution processes that underlie cancer development and are increasingly recognized as part of normal tissue growth and aging. The inference of clonal lineage trees from single cell sequence data offers particular promise for revealing processes of somatic evolution in unprecedented detail. However, most such tools are based on fairly restrictive models of the types of mutation events observed...]]></summary>
        <author>
            <name>Nishat Anjum Bristy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolvability of cancer-associated genes under APOBEC3A/B selection]]></title>
        <id>pubmed:38106028</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38106028/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231218195330&amp;v=2.18.0"/>
        <updated>2023-12-18T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Evolvability is an emergent hallmark of cancer that depends on intra-tumor heterogeneity and, ultimately, genetic variation. Mutations generated by APOBEC3 cytidine deaminases can contribute to genetic variation and the consequences of APOBEC activation differ depending on the stage of cancer, with the most significant impact observed during the early stages. However, how APOBEC activity shapes evolutionary patterns of genes in the host genome and differential impacts on cancer-associated and...]]></summary>
        <author>
            <name>Joon-Hyun Song</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Uveal melanoma modeling in mice and zebrafish]]></title>
        <id>pubmed:38104908</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38104908/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240110195405&amp;v=2.18.0"/>
        <updated>2023-12-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Despite extensive research and refined therapeutic options, the survival for metastasized uveal melanoma (UM) patients has not improved significantly. UM, a malignant tumor originating from melanocytes in the uveal tract, can be asymptomatic and small tumors may be detected only during routine ophthalmic exams; making early detection and treatment difficult. UM is the result of a number of characteristic somatic alterations which are associated with prognosis. Although UM morphology and biology...]]></summary>
        <author>
            <name>Quincy C C van den Bosch</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Uveal melanoma modeling in mice and zebrafish]]></title>
        <id>pubmed:38104908</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38104908/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240109195408&amp;v=2.18.0"/>
        <updated>2023-12-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Despite extensive research and refined therapeutic options, the survival for metastasized uveal melanoma (UM) patients has not improved significantly. UM, a malignant tumor originating from melanocytes in the uveal tract, can be asymptomatic and small tumors may be detected only during routine ophthalmic exams; making early detection and treatment difficult. UM is the result of a number of characteristic somatic alterations which are associated with prognosis. Although UM morphology and biology...]]></summary>
        <author>
            <name>Quincy C C van den Bosch</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Uveal melanoma modeling in mice and zebrafish]]></title>
        <id>pubmed:38104908</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38104908/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240108195354&amp;v=2.18.0"/>
        <updated>2023-12-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Despite extensive research and refined therapeutic options, the survival for metastasized uveal melanoma (UM) patients has not improved significantly. UM, a malignant tumor originating from melanocytes in the uveal tract, can be asymptomatic and small tumors may be detected only during routine ophthalmic exams; making early detection and treatment difficult. UM is the result of a number of characteristic somatic alterations which are associated with prognosis. Although UM morphology and biology...]]></summary>
        <author>
            <name>Quincy C C van den Bosch</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Uveal melanoma modeling in mice and zebrafish]]></title>
        <id>pubmed:38104908</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38104908/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240107195431&amp;v=2.18.0"/>
        <updated>2023-12-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Despite extensive research and refined therapeutic options, the survival for metastasized uveal melanoma (UM) patients has not improved significantly. UM, a malignant tumor originating from melanocytes in the uveal tract, can be asymptomatic and small tumors may be detected only during routine ophthalmic exams; making early detection and treatment difficult. UM is the result of a number of characteristic somatic alterations which are associated with prognosis. Although UM morphology and biology...]]></summary>
        <author>
            <name>Quincy C C van den Bosch</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Uveal melanoma modeling in mice and zebrafish]]></title>
        <id>pubmed:38104908</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38104908/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240106195750&amp;v=2.18.0"/>
        <updated>2023-12-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Despite extensive research and refined therapeutic options, the survival for metastasized uveal melanoma (UM) patients has not improved significantly. UM, a malignant tumor originating from melanocytes in the uveal tract, can be asymptomatic and small tumors may be detected only during routine ophthalmic exams; making early detection and treatment difficult. UM is the result of a number of characteristic somatic alterations which are associated with prognosis. Although UM morphology and biology...]]></summary>
        <author>
            <name>Quincy C C van den Bosch</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Uveal melanoma modeling in mice and zebrafish]]></title>
        <id>pubmed:38104908</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38104908/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240105195208&amp;v=2.18.0"/>
        <updated>2023-12-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Despite extensive research and refined therapeutic options, the survival for metastasized uveal melanoma (UM) patients has not improved significantly. UM, a malignant tumor originating from melanocytes in the uveal tract, can be asymptomatic and small tumors may be detected only during routine ophthalmic exams; making early detection and treatment difficult. UM is the result of a number of characteristic somatic alterations which are associated with prognosis. Although UM morphology and biology...]]></summary>
        <author>
            <name>Quincy C C van den Bosch</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Uveal melanoma modeling in mice and zebrafish]]></title>
        <id>pubmed:38104908</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38104908/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240104195307&amp;v=2.18.0"/>
        <updated>2023-12-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Despite extensive research and refined therapeutic options, the survival for metastasized uveal melanoma (UM) patients has not improved significantly. UM, a malignant tumor originating from melanocytes in the uveal tract, can be asymptomatic and small tumors may be detected only during routine ophthalmic exams; making early detection and treatment difficult. UM is the result of a number of characteristic somatic alterations which are associated with prognosis. Although UM morphology and biology...]]></summary>
        <author>
            <name>Quincy C C van den Bosch</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Uveal melanoma modeling in mice and zebrafish]]></title>
        <id>pubmed:38104908</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38104908/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240103195303&amp;v=2.18.0"/>
        <updated>2023-12-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Despite extensive research and refined therapeutic options, the survival for metastasized uveal melanoma (UM) patients has not improved significantly. UM, a malignant tumor originating from melanocytes in the uveal tract, can be asymptomatic and small tumors may be detected only during routine ophthalmic exams; making early detection and treatment difficult. UM is the result of a number of characteristic somatic alterations which are associated with prognosis. Although UM morphology and biology...]]></summary>
        <author>
            <name>Quincy C C van den Bosch</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Uveal melanoma modeling in mice and zebrafish]]></title>
        <id>pubmed:38104908</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38104908/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240102195247&amp;v=2.18.0"/>
        <updated>2023-12-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Despite extensive research and refined therapeutic options, the survival for metastasized uveal melanoma (UM) patients has not improved significantly. UM, a malignant tumor originating from melanocytes in the uveal tract, can be asymptomatic and small tumors may be detected only during routine ophthalmic exams; making early detection and treatment difficult. UM is the result of a number of characteristic somatic alterations which are associated with prognosis. Although UM morphology and biology...]]></summary>
        <author>
            <name>Quincy C C van den Bosch</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Uveal melanoma modeling in mice and zebrafish]]></title>
        <id>pubmed:38104908</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38104908/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20240101195419&amp;v=2.18.0"/>
        <updated>2023-12-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Despite extensive research and refined therapeutic options, the survival for metastasized uveal melanoma (UM) patients has not improved significantly. UM, a malignant tumor originating from melanocytes in the uveal tract, can be asymptomatic and small tumors may be detected only during routine ophthalmic exams; making early detection and treatment difficult. UM is the result of a number of characteristic somatic alterations which are associated with prognosis. Although UM morphology and biology...]]></summary>
        <author>
            <name>Quincy C C van den Bosch</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Uveal melanoma modeling in mice and zebrafish]]></title>
        <id>pubmed:38104908</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38104908/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231231195742&amp;v=2.18.0"/>
        <updated>2023-12-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Despite extensive research and refined therapeutic options, the survival for metastasized uveal melanoma (UM) patients has not improved significantly. UM, a malignant tumor originating from melanocytes in the uveal tract, can be asymptomatic and small tumors may be detected only during routine ophthalmic exams; making early detection and treatment difficult. UM is the result of a number of characteristic somatic alterations which are associated with prognosis. Although UM morphology and biology...]]></summary>
        <author>
            <name>Quincy C C van den Bosch</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Uveal melanoma modeling in mice and zebrafish]]></title>
        <id>pubmed:38104908</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38104908/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231230195628&amp;v=2.18.0"/>
        <updated>2023-12-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Despite extensive research and refined therapeutic options, the survival for metastasized uveal melanoma (UM) patients has not improved significantly. UM, a malignant tumor originating from melanocytes in the uveal tract, can be asymptomatic and small tumors may be detected only during routine ophthalmic exams; making early detection and treatment difficult. UM is the result of a number of characteristic somatic alterations which are associated with prognosis. Although UM morphology and biology...]]></summary>
        <author>
            <name>Quincy C C van den Bosch</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Uveal melanoma modeling in mice and zebrafish]]></title>
        <id>pubmed:38104908</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38104908/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231229195054&amp;v=2.18.0"/>
        <updated>2023-12-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Despite extensive research and refined therapeutic options, the survival for metastasized uveal melanoma (UM) patients has not improved significantly. UM, a malignant tumor originating from melanocytes in the uveal tract, can be asymptomatic and small tumors may be detected only during routine ophthalmic exams; making early detection and treatment difficult. UM is the result of a number of characteristic somatic alterations which are associated with prognosis. Although UM morphology and biology...]]></summary>
        <author>
            <name>Quincy C C van den Bosch</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Uveal melanoma modeling in mice and zebrafish]]></title>
        <id>pubmed:38104908</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38104908/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231228194204&amp;v=2.18.0"/>
        <updated>2023-12-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Despite extensive research and refined therapeutic options, the survival for metastasized uveal melanoma (UM) patients has not improved significantly. UM, a malignant tumor originating from melanocytes in the uveal tract, can be asymptomatic and small tumors may be detected only during routine ophthalmic exams; making early detection and treatment difficult. UM is the result of a number of characteristic somatic alterations which are associated with prognosis. Although UM morphology and biology...]]></summary>
        <author>
            <name>Quincy C C van den Bosch</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Uveal melanoma modeling in mice and zebrafish]]></title>
        <id>pubmed:38104908</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38104908/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231227195056&amp;v=2.18.0"/>
        <updated>2023-12-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Despite extensive research and refined therapeutic options, the survival for metastasized uveal melanoma (UM) patients has not improved significantly. UM, a malignant tumor originating from melanocytes in the uveal tract, can be asymptomatic and small tumors may be detected only during routine ophthalmic exams; making early detection and treatment difficult. UM is the result of a number of characteristic somatic alterations which are associated with prognosis. Although UM morphology and biology...]]></summary>
        <author>
            <name>Quincy C C van den Bosch</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Uveal melanoma modeling in mice and zebrafish]]></title>
        <id>pubmed:38104908</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38104908/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231226195107&amp;v=2.18.0"/>
        <updated>2023-12-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Despite extensive research and refined therapeutic options, the survival for metastasized uveal melanoma (UM) patients has not improved significantly. UM, a malignant tumor originating from melanocytes in the uveal tract, can be asymptomatic and small tumors may be detected only during routine ophthalmic exams; making early detection and treatment difficult. UM is the result of a number of characteristic somatic alterations which are associated with prognosis. Although UM morphology and biology...]]></summary>
        <author>
            <name>Quincy C C van den Bosch</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Uveal melanoma modeling in mice and zebrafish]]></title>
        <id>pubmed:38104908</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38104908/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231225195059&amp;v=2.18.0"/>
        <updated>2023-12-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Despite extensive research and refined therapeutic options, the survival for metastasized uveal melanoma (UM) patients has not improved significantly. UM, a malignant tumor originating from melanocytes in the uveal tract, can be asymptomatic and small tumors may be detected only during routine ophthalmic exams; making early detection and treatment difficult. UM is the result of a number of characteristic somatic alterations which are associated with prognosis. Although UM morphology and biology...]]></summary>
        <author>
            <name>Quincy C C van den Bosch</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Uveal melanoma modeling in mice and zebrafish]]></title>
        <id>pubmed:38104908</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38104908/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231224195316&amp;v=2.18.0"/>
        <updated>2023-12-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Despite extensive research and refined therapeutic options, the survival for metastasized uveal melanoma (UM) patients has not improved significantly. UM, a malignant tumor originating from melanocytes in the uveal tract, can be asymptomatic and small tumors may be detected only during routine ophthalmic exams; making early detection and treatment difficult. UM is the result of a number of characteristic somatic alterations which are associated with prognosis. Although UM morphology and biology...]]></summary>
        <author>
            <name>Quincy C C van den Bosch</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Uveal melanoma modeling in mice and zebrafish]]></title>
        <id>pubmed:38104908</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38104908/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231223195542&amp;v=2.18.0"/>
        <updated>2023-12-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Despite extensive research and refined therapeutic options, the survival for metastasized uveal melanoma (UM) patients has not improved significantly. UM, a malignant tumor originating from melanocytes in the uveal tract, can be asymptomatic and small tumors may be detected only during routine ophthalmic exams; making early detection and treatment difficult. UM is the result of a number of characteristic somatic alterations which are associated with prognosis. Although UM morphology and biology...]]></summary>
        <author>
            <name>Quincy C C van den Bosch</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Uveal melanoma modeling in mice and zebrafish]]></title>
        <id>pubmed:38104908</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38104908/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231222195013&amp;v=2.18.0"/>
        <updated>2023-12-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Despite extensive research and refined therapeutic options, the survival for metastasized uveal melanoma (UM) patients has not improved significantly. UM, a malignant tumor originating from melanocytes in the uveal tract, can be asymptomatic and small tumors may be detected only during routine ophthalmic exams; making early detection and treatment difficult. UM is the result of a number of characteristic somatic alterations which are associated with prognosis. Although UM morphology and biology...]]></summary>
        <author>
            <name>Quincy C C van den Bosch</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Uveal melanoma modeling in mice and zebrafish]]></title>
        <id>pubmed:38104908</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38104908/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231221195154&amp;v=2.18.0"/>
        <updated>2023-12-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Despite extensive research and refined therapeutic options, the survival for metastasized uveal melanoma (UM) patients has not improved significantly. UM, a malignant tumor originating from melanocytes in the uveal tract, can be asymptomatic and small tumors may be detected only during routine ophthalmic exams; making early detection and treatment difficult. UM is the result of a number of characteristic somatic alterations which are associated with prognosis. Although UM morphology and biology...]]></summary>
        <author>
            <name>Quincy C C van den Bosch</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Uveal melanoma modeling in mice and zebrafish]]></title>
        <id>pubmed:38104908</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38104908/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231220195218&amp;v=2.18.0"/>
        <updated>2023-12-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Despite extensive research and refined therapeutic options, the survival for metastasized uveal melanoma (UM) patients has not improved significantly. UM, a malignant tumor originating from melanocytes in the uveal tract, can be asymptomatic and small tumors may be detected only during routine ophthalmic exams; making early detection and treatment difficult. UM is the result of a number of characteristic somatic alterations which are associated with prognosis. Although UM morphology and biology...]]></summary>
        <author>
            <name>Quincy C C van den Bosch</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Uveal melanoma modeling in mice and zebrafish]]></title>
        <id>pubmed:38104908</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38104908/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231219194249&amp;v=2.18.0"/>
        <updated>2023-12-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Despite extensive research and refined therapeutic options, the survival for metastasized uveal melanoma (UM) patients has not improved significantly. UM, a malignant tumor originating from melanocytes in the uveal tract, can be asymptomatic and small tumors may be detected only during routine ophthalmic exams; making early detection and treatment difficult. UM is the result of a number of characteristic somatic alterations which are associated with prognosis. Although UM morphology and biology...]]></summary>
        <author>
            <name>Quincy C C van den Bosch</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Uveal melanoma modeling in mice and zebrafish]]></title>
        <id>pubmed:38104908</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38104908/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231218195330&amp;v=2.18.0"/>
        <updated>2023-12-17T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[Despite extensive research and refined therapeutic options, the survival for metastasized uveal melanoma (UM) patients has not improved significantly. UM, a malignant tumor originating from melanocytes in the uveal tract, can be asymptomatic and small tumors may be detected only during routine ophthalmic exams; making early detection and treatment difficult. UM is the result of a number of characteristic somatic alterations which are associated with prognosis. Although UM morphology and biology...]]></summary>
        <author>
            <name>Quincy C C van den Bosch</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between clonal hematopoiesis-related gene mutations and unfavorable functional outcome in patients with large-artery atherosclerotic stroke]]></title>
        <id>pubmed:38104193</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38104193/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240103195259&amp;v=2.18.0"/>
        <updated>2023-12-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CHIP is associated with unfavorable functional outcomes in patients with LAA stroke and hyper-inflammation. Genetic IL-6 signaling inhibition might attenuate the risk of unfavorable functional outcomes in CHIP carriers, especially in LAA stroke patients.]]></summary>
        <author>
            <name>Xin Qiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between clonal hematopoiesis-related gene mutations and unfavorable functional outcome in patients with large-artery atherosclerotic stroke]]></title>
        <id>pubmed:38104193</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38104193/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240102195247&amp;v=2.18.0"/>
        <updated>2023-12-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CHIP is associated with unfavorable functional outcomes in patients with LAA stroke and hyper-inflammation. Genetic IL-6 signaling inhibition might attenuate the risk of unfavorable functional outcomes in CHIP carriers, especially in LAA stroke patients.]]></summary>
        <author>
            <name>Xin Qiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between clonal hematopoiesis-related gene mutations and unfavorable functional outcome in patients with large-artery atherosclerotic stroke]]></title>
        <id>pubmed:38104193</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38104193/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20240101195419&amp;v=2.18.0"/>
        <updated>2023-12-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CHIP is associated with unfavorable functional outcomes in patients with LAA stroke and hyper-inflammation. Genetic IL-6 signaling inhibition might attenuate the risk of unfavorable functional outcomes in CHIP carriers, especially in LAA stroke patients.]]></summary>
        <author>
            <name>Xin Qiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between clonal hematopoiesis-related gene mutations and unfavorable functional outcome in patients with large-artery atherosclerotic stroke]]></title>
        <id>pubmed:38104193</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38104193/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231231195742&amp;v=2.18.0"/>
        <updated>2023-12-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CHIP is associated with unfavorable functional outcomes in patients with LAA stroke and hyper-inflammation. Genetic IL-6 signaling inhibition might attenuate the risk of unfavorable functional outcomes in CHIP carriers, especially in LAA stroke patients.]]></summary>
        <author>
            <name>Xin Qiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between clonal hematopoiesis-related gene mutations and unfavorable functional outcome in patients with large-artery atherosclerotic stroke]]></title>
        <id>pubmed:38104193</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38104193/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231230195628&amp;v=2.18.0"/>
        <updated>2023-12-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CHIP is associated with unfavorable functional outcomes in patients with LAA stroke and hyper-inflammation. Genetic IL-6 signaling inhibition might attenuate the risk of unfavorable functional outcomes in CHIP carriers, especially in LAA stroke patients.]]></summary>
        <author>
            <name>Xin Qiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between clonal hematopoiesis-related gene mutations and unfavorable functional outcome in patients with large-artery atherosclerotic stroke]]></title>
        <id>pubmed:38104193</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38104193/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231229195054&amp;v=2.18.0"/>
        <updated>2023-12-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CHIP is associated with unfavorable functional outcomes in patients with LAA stroke and hyper-inflammation. Genetic IL-6 signaling inhibition might attenuate the risk of unfavorable functional outcomes in CHIP carriers, especially in LAA stroke patients.]]></summary>
        <author>
            <name>Xin Qiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between clonal hematopoiesis-related gene mutations and unfavorable functional outcome in patients with large-artery atherosclerotic stroke]]></title>
        <id>pubmed:38104193</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38104193/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231228194204&amp;v=2.18.0"/>
        <updated>2023-12-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CHIP is associated with unfavorable functional outcomes in patients with LAA stroke and hyper-inflammation. Genetic IL-6 signaling inhibition might attenuate the risk of unfavorable functional outcomes in CHIP carriers, especially in LAA stroke patients.]]></summary>
        <author>
            <name>Xin Qiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between clonal hematopoiesis-related gene mutations and unfavorable functional outcome in patients with large-artery atherosclerotic stroke]]></title>
        <id>pubmed:38104193</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38104193/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231227195056&amp;v=2.18.0"/>
        <updated>2023-12-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CHIP is associated with unfavorable functional outcomes in patients with LAA stroke and hyper-inflammation. Genetic IL-6 signaling inhibition might attenuate the risk of unfavorable functional outcomes in CHIP carriers, especially in LAA stroke patients.]]></summary>
        <author>
            <name>Xin Qiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between clonal hematopoiesis-related gene mutations and unfavorable functional outcome in patients with large-artery atherosclerotic stroke]]></title>
        <id>pubmed:38104193</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38104193/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231226195107&amp;v=2.18.0"/>
        <updated>2023-12-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CHIP is associated with unfavorable functional outcomes in patients with LAA stroke and hyper-inflammation. Genetic IL-6 signaling inhibition might attenuate the risk of unfavorable functional outcomes in CHIP carriers, especially in LAA stroke patients.]]></summary>
        <author>
            <name>Xin Qiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between clonal hematopoiesis-related gene mutations and unfavorable functional outcome in patients with large-artery atherosclerotic stroke]]></title>
        <id>pubmed:38104193</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38104193/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231225195059&amp;v=2.18.0"/>
        <updated>2023-12-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CHIP is associated with unfavorable functional outcomes in patients with LAA stroke and hyper-inflammation. Genetic IL-6 signaling inhibition might attenuate the risk of unfavorable functional outcomes in CHIP carriers, especially in LAA stroke patients.]]></summary>
        <author>
            <name>Xin Qiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between clonal hematopoiesis-related gene mutations and unfavorable functional outcome in patients with large-artery atherosclerotic stroke]]></title>
        <id>pubmed:38104193</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38104193/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231224195316&amp;v=2.18.0"/>
        <updated>2023-12-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CHIP is associated with unfavorable functional outcomes in patients with LAA stroke and hyper-inflammation. Genetic IL-6 signaling inhibition might attenuate the risk of unfavorable functional outcomes in CHIP carriers, especially in LAA stroke patients.]]></summary>
        <author>
            <name>Xin Qiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between clonal hematopoiesis-related gene mutations and unfavorable functional outcome in patients with large-artery atherosclerotic stroke]]></title>
        <id>pubmed:38104193</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38104193/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231223195542&amp;v=2.18.0"/>
        <updated>2023-12-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CHIP is associated with unfavorable functional outcomes in patients with LAA stroke and hyper-inflammation. Genetic IL-6 signaling inhibition might attenuate the risk of unfavorable functional outcomes in CHIP carriers, especially in LAA stroke patients.]]></summary>
        <author>
            <name>Xin Qiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between clonal hematopoiesis-related gene mutations and unfavorable functional outcome in patients with large-artery atherosclerotic stroke]]></title>
        <id>pubmed:38104193</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38104193/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231222195013&amp;v=2.18.0"/>
        <updated>2023-12-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CHIP is associated with unfavorable functional outcomes in patients with LAA stroke and hyper-inflammation. Genetic IL-6 signaling inhibition might attenuate the risk of unfavorable functional outcomes in CHIP carriers, especially in LAA stroke patients.]]></summary>
        <author>
            <name>Xin Qiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between clonal hematopoiesis-related gene mutations and unfavorable functional outcome in patients with large-artery atherosclerotic stroke]]></title>
        <id>pubmed:38104193</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38104193/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231221195154&amp;v=2.18.0"/>
        <updated>2023-12-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CHIP is associated with unfavorable functional outcomes in patients with LAA stroke and hyper-inflammation. Genetic IL-6 signaling inhibition might attenuate the risk of unfavorable functional outcomes in CHIP carriers, especially in LAA stroke patients.]]></summary>
        <author>
            <name>Xin Qiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between clonal hematopoiesis-related gene mutations and unfavorable functional outcome in patients with large-artery atherosclerotic stroke]]></title>
        <id>pubmed:38104193</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38104193/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231220195219&amp;v=2.18.0"/>
        <updated>2023-12-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CHIP is associated with unfavorable functional outcomes in patients with LAA stroke and hyper-inflammation. Genetic IL-6 signaling inhibition might attenuate the risk of unfavorable functional outcomes in CHIP carriers, especially in LAA stroke patients.]]></summary>
        <author>
            <name>Xin Qiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between clonal hematopoiesis-related gene mutations and unfavorable functional outcome in patients with large-artery atherosclerotic stroke]]></title>
        <id>pubmed:38104193</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38104193/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231219194249&amp;v=2.18.0"/>
        <updated>2023-12-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CHIP is associated with unfavorable functional outcomes in patients with LAA stroke and hyper-inflammation. Genetic IL-6 signaling inhibition might attenuate the risk of unfavorable functional outcomes in CHIP carriers, especially in LAA stroke patients.]]></summary>
        <author>
            <name>Xin Qiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between clonal hematopoiesis-related gene mutations and unfavorable functional outcome in patients with large-artery atherosclerotic stroke]]></title>
        <id>pubmed:38104193</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38104193/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231218195330&amp;v=2.18.0"/>
        <updated>2023-12-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CHIP is associated with unfavorable functional outcomes in patients with LAA stroke and hyper-inflammation. Genetic IL-6 signaling inhibition might attenuate the risk of unfavorable functional outcomes in CHIP carriers, especially in LAA stroke patients.]]></summary>
        <author>
            <name>Xin Qiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between clonal hematopoiesis-related gene mutations and unfavorable functional outcome in patients with large-artery atherosclerotic stroke]]></title>
        <id>pubmed:38104193</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/38104193/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231217195410&amp;v=2.18.0"/>
        <updated>2023-12-16T11:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CHIP is associated with unfavorable functional outcomes in patients with LAA stroke and hyper-inflammation. Genetic IL-6 signaling inhibition might attenuate the risk of unfavorable functional outcomes in CHIP carriers, especially in LAA stroke patients.]]></summary>
        <author>
            <name>Xin Qiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Nodal interferon exposure drives tumour-specific tolerance]]></title>
        <id>72a3a11d39c217b1a80cbb551444e6f6</id>
        <link href="https://twitter.com/NatureRevCancer/status/1533878403463405569"/>
        <updated>2022-06-06T18:28:04.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Nodal interferon exposure drives tumour-specific tolerance https://t.co/FT4NeBcFTg pic.twitter.com/NRHkVDUsOr
 NatureReviewsCancer (@NatureRevCancer) June 6, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@VIBConferences: #Cancer #immunotherapy has become a crucial pillar of anticancer therapy. 19 leading researchers at #ImmunoOnco22 will give new insights into the immune response to tumors and tackle unresolved questions.Registration Deadline: Thursday 2 June. Read more]]></title>
        <id>bb6bc242bcbc356c4a38db850e74d812</id>
        <link href="https://twitter.com/VIBConferences/status/1531132720952266752"/>
        <updated>2022-05-30T04:37:42.000Z</updated>
        <summary type="html"><![CDATA[#Cancer #immunotherapy has become a crucial pillar of anticancer therapy. 19 leading researchers at #ImmunoOnco22 will give new insights into the immune response to tumors and tackle unresolved questions.
Registration Deadline: Thursday 2 June. Read more https://t.co/cc0HC5cj6W pic.twitter.com/u8LFuzBbsV
 VIB Conferences (@VIBConferences) May 30, 2022]]></summary>
        <author>
            <name>@VIBConferences</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Nonsense-mediated RNA decay: an emerging modulator of malignancy]]></title>
        <id>ed6c996dc1a718afb523de6229a53131</id>
        <link href="https://twitter.com/NatureRevCancer/status/1530198403686072320"/>
        <updated>2022-05-27T14:45:03.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Nonsense-mediated RNA decay: an emerging modulator of malignancy https://t.co/wjuHplkpof pic.twitter.com/1SoKYhRsPO
 NatureReviewsCancer (@NatureRevCancer) May 27, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: Our June issue, out NOW! With articles on #therapyresistance, #senescence & targeting CDK4 & CDK6 in #cancer! Plus, a Comment on cancer mRNA vaccines as well as the launch of our new Tools of the Trade articles #NRCToT. So much content ]]></title>
        <id>d15a3a4b24853812d7fa21fd56de5815</id>
        <link href="https://twitter.com/NatureRevCancer/status/1530174481313972224"/>
        <updated>2022-05-27T13:10:00.000Z</updated>
        <summary type="html"><![CDATA[Our June issue, out NOW! With articles on #therapyresistance, #senescence & targeting CDK4 & CDK6 in #cancer! Plus, a Comment on cancer mRNA vaccines as well as the launch of our new Tools of the Trade articles #NRCToT. So much content 
 https://t.co/Fo6XRWV3OZ@natrescancer pic.twitter.com/rbxRPqLV6g
 NatureReviewsCancer (@NatureRevCancer) May 27, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@UlrikeHarjes: This Review by @MarcusDGon @cantleylab is part of the @NatureRevCancer series on #Diet & #SystemicMetabolism in cancer:  do love this topic in general plus I am handling research at @NatureMedicine now.. get in touch if you have something of interest]]></title>
        <id>fe13755a2693ea65459e5e21df097d2a</id>
        <link href="https://twitter.com/UlrikeHarjes/status/1529747629936193537"/>
        <updated>2022-05-26T08:53:50.000Z</updated>
        <summary type="html"><![CDATA[This Review by @MarcusDGon @cantleylab is part of the @NatureRevCancer series on #Diet & #SystemicMetabolism in cancer: https://t.co/p3Y2cdNhco
I do love this topic in general plus I am handling research at @NatureMedicine now.. get in touch if you have something of interest https://t.co/qWH2dTv8j9
 Ulrike Harjes (@UlrikeHarjes) May 26, 2022]]></summary>
        <author>
            <name>@UlrikeHarjes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Developing dietary interventions as therapy for cancer]]></title>
        <id>9ba5279424b31b0122a4ae20c18e6d03</id>
        <link href="https://twitter.com/NatureRevCancer/status/1529516411059437568"/>
        <updated>2022-05-25T17:35:04.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Developing dietary interventions as therapy for cancer https://t.co/ijuqctk1wJ pic.twitter.com/KHPpMKnCFa
 NatureReviewsCancer (@NatureRevCancer) May 25, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Digging for treasures in the tumour interactome]]></title>
        <id>611d40f2e6ea2796b028bebda41a86dd</id>
        <link href="https://twitter.com/NatureRevCancer/status/1526928478490095616"/>
        <updated>2022-05-18T14:11:32.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Digging for treasures in the tumour interactome https://t.co/NhHYAwUgLE
 NatureReviewsCancer (@NatureRevCancer) May 18, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: As part of our overall commitment to diversity, equity and inclusion at Springer Nature, wed like to better understand what DEI means within the global research community. Take the survey here]]></title>
        <id>9590a971b00448cd312078183965b21d</id>
        <link href="https://twitter.com/NatureRevCancer/status/1526560254091313156"/>
        <updated>2022-05-17T13:48:21.000Z</updated>
        <summary type="html"><![CDATA[As part of our overall commitment to diversity, equity and inclusion at Springer Nature, wed like to better understand what DEI means within the global research community. Take the survey here https://t.co/03yLiUxFTq
 NatureReviewsCancer (@NatureRevCancer) May 17, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: Newsflash! We have a new article type in the journal - Tools of the Trade #NRCToT   where we hope to enable more #ECRs to interact with the editorial team & have a bigger voice in our content. For more info, check out the Editorial ]]></title>
        <id>aa38ff4245b93e964773f191844ddc7a</id>
        <link href="https://twitter.com/NatureRevCancer/status/1524772831904509953"/>
        <updated>2022-05-12T15:25:46.000Z</updated>
        <summary type="html"><![CDATA[Newsflash! We have a new article type in the journal - Tools of the Trade #NRCToT   where we hope to enable more #ECRs to interact with the editorial team & have a bigger voice in our content. For more info, check out the Editorial  https://t.co/VbyoUJmTRJ
 NatureReviewsCancer (@NatureRevCancer) May 12, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Tools for the next generation]]></title>
        <id>65aca76b9f794aaa668d84ad32dca4a0</id>
        <link href="https://twitter.com/NatureRevCancer/status/1524068259712036864"/>
        <updated>2022-05-10T16:46:03.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Tools for the next generation https://t.co/lEzTPFYDf5
 NatureReviewsCancer (@NatureRevCancer) May 10, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Hunting down rare drug-tolerant cycling cells with Watermelon]]></title>
        <id>afa9b6784b4ccc7c05ed4efd26ddfb2d</id>
        <link href="https://twitter.com/NatureRevCancer/status/1524022709386190856"/>
        <updated>2022-05-10T13:45:03.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Hunting down rare drug-tolerant cycling cells with Watermelon https://t.co/XXT0c9SAYX
 NatureReviewsCancer (@NatureRevCancer) May 10, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@VarunVenkatara2: Very happy that our latest Perspective is now online @NatureRevCancer ! We discuss implications of malignant, multicellular networks and potential therapeutic strategies how to disconnect them. Thanks to everyone involved ! #CancerNeuroscience #TumorMicrotubes #neurotwitter]]></title>
        <id>43e2d5ccebc9030f737d656f47ac9d98</id>
        <link href="https://twitter.com/VarunVenkatara2/status/1520050291986604033"/>
        <updated>2022-04-29T14:40:05.000Z</updated>
        <summary type="html"><![CDATA[Very happy that our latest Perspective is now online @NatureRevCancer ! We discuss implications of malignant, multicellular networks and potential therapeutic strategies how to disconnect them. Thanks to everyone involved ! #CancerNeuroscience #TumorMicrotubes #neurotwitter https://t.co/S55cKTGNFd
 Varun Venkataramani (@VarunVenkatara2) April 29, 2022]]></summary>
        <author>
            <name>@VarunVenkatara2</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! An inhospitable site]]></title>
        <id>9f6b8644378881f4c2e6b6833c93fc2f</id>
        <link href="https://twitter.com/NatureRevCancer/status/1520020349068316673"/>
        <updated>2022-04-29T12:41:06.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! An inhospitable site https://t.co/0dvqIKCWxh pic.twitter.com/PtY8J9Fz7r
 NatureReviewsCancer (@NatureRevCancer) April 29, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Disconnecting multicellular networks in brain tumours]]></title>
        <id>f6d91efcd60dae769e2722585bdfa8df</id>
        <link href="https://twitter.com/NatureRevCancer/status/1520020340201598978"/>
        <updated>2022-04-29T12:41:04.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Disconnecting multicellular networks in brain tumours https://t.co/LJrzy8bRma pic.twitter.com/CO7BnooP0r
 NatureReviewsCancer (@NatureRevCancer) April 29, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: Our May issue, out NOW! With Reviews on #CRISPR in cancer biology & #therapy, ROS in tumour development & progression, and cancer #proteogenomics, and Comments on esophageal cancer research in Eastern Africa and on Critical Race Theory.]]></title>
        <id>76e3b436bc8e43ad21366a80c120e395</id>
        <link href="https://twitter.com/NatureRevCancer/status/1519678964364623872"/>
        <updated>2022-04-28T14:04:34.000Z</updated>
        <summary type="html"><![CDATA[Our May issue, out NOW! With Reviews on #CRISPR in cancer biology & #therapy, ROS in tumour development & progression, and cancer #proteogenomics, and Comments on esophageal cancer research in Eastern Africa and on Critical Race Theory.
 https://t.co/vQwHFJhpwv@natrescancer pic.twitter.com/6kYgjRYhdT
 NatureReviewsCancer (@NatureRevCancer) April 28, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@tmurraystewart: Our latest publication on #polyamines is online!@HopkinsMedicine]]></title>
        <id>fdf224ea293cdf039086d16e5699a59a</id>
        <link href="https://twitter.com/tmurraystewart/status/1519413460978704384"/>
        <updated>2022-04-27T20:29:33.000Z</updated>
        <summary type="html"><![CDATA[Our latest publication on #polyamines is online!@HopkinsMedicine https://t.co/ehRGgN1w9R
 Tracy Murray Stewart (@tmurraystewart) April 27, 2022]]></summary>
        <author>
            <name>@tmurraystewart</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Polyamines in cancer: integrating organismal metabolism and antitumour immunity]]></title>
        <id>4f43226ec4dc8e531ff6e64a9c5ab8e6</id>
        <link href="https://twitter.com/NatureRevCancer/status/1519381375874265088"/>
        <updated>2022-04-27T18:22:03.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Polyamines in cancer: integrating organismal metabolism and antitumour immunity https://t.co/YCJX1hRQLO pic.twitter.com/zRUCRNXyxH
 NatureReviewsCancer (@NatureRevCancer) April 27, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW #ResearchHighlight! Lv, Liu, Mo & co demonstrate that in pancreatic #PDAC cells, gasdermin E transports YBX1 to the nucleus, which promotes mucin expression, thereby providing tumour cells with a barrier against digestive enzymes.]]></title>
        <id>a44ed79b9f76aad377b9272fb392f553</id>
        <link href="https://twitter.com/NatureRevCancer/status/1519317944995569664"/>
        <updated>2022-04-27T14:10:00.000Z</updated>
        <summary type="html"><![CDATA[NEW #ResearchHighlight! Lv, Liu, Mo & co demonstrate that in pancreatic #PDAC cells, gasdermin E transports YBX1 to the nucleus, which promotes mucin expression, thereby providing tumour cells with a barrier against digestive enzymes.
 https://t.co/JTUhX0DHQ1@natrescancer pic.twitter.com/2PdCmsDu2p
 NatureReviewsCancer (@NatureRevCancer) April 27, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: In the April issue of @NatureRevCancer | Comment, Reimagining cancer research with art, by @CancerSciArtist, Stefani Shoreibah & @tdanino  @natrescancer @Columbia]]></title>
        <id>06ff7641d8f5fcc0dff91f835ac3bbc1</id>
        <link href="https://twitter.com/NatureRevCancer/status/1518967636561956865"/>
        <updated>2022-04-26T14:58:00.000Z</updated>
        <summary type="html"><![CDATA[In the April issue of @NatureRevCancer | Comment, Reimagining cancer research with art, by @CancerSciArtist, Stefani Shoreibah & @tdanino
 https://t.co/GeTVCMJQsp @natrescancer
 @Columbia pic.twitter.com/ZXW6A0Fe0c
 NatureReviewsCancer (@NatureRevCancer) April 26, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Tracking dormant disseminated tumour cells]]></title>
        <id>96b2ddff4eb269cf343213c6a1b1ce95</id>
        <link href="https://twitter.com/NatureRevCancer/status/1518563607440621569"/>
        <updated>2022-04-25T12:12:32.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Tracking dormant disseminated tumour cells https://t.co/kSXyWAvCxF
 NatureReviewsCancer (@NatureRevCancer) April 25, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
</feed>